<SEC-DOCUMENT>0001193125-24-165712.txt : 20240621
<SEC-HEADER>0001193125-24-165712.hdr.sgml : 20240621
<ACCEPTANCE-DATETIME>20240621162328
ACCESSION NUMBER:		0001193125-24-165712
CONFORMED SUBMISSION TYPE:	DEF 14A
PUBLIC DOCUMENT COUNT:		7
CONFORMED PERIOD OF REPORT:	20240806
FILED AS OF DATE:		20240621
DATE AS OF CHANGE:		20240621

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Wave Life Sciences Ltd.
		CENTRAL INDEX KEY:			0001631574
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			U0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DEF 14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37627
		FILM NUMBER:		241060748

	BUSINESS ADDRESS:	
		STREET 1:		7 STRAITS VIEW
		STREET 2:		#12-00, MARINA ONE EAST TOWER
		CITY:			SINGAPORE
		STATE:			U0
		ZIP:			018936
		BUSINESS PHONE:		617-949-2900

	MAIL ADDRESS:	
		STREET 1:		733 CONCORD AVENUE
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02138

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	WAVE Life Sciences Ltd.
		DATE OF NAME CHANGE:	20170516

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Wave Life Sciences Ltd.
		DATE OF NAME CHANGE:	20151106

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Wave Life Sciences LTD.
		DATE OF NAME CHANGE:	20151106
</SEC-HEADER>
<DOCUMENT>
<TYPE>DEF 14A
<SEQUENCE>1
<FILENAME>d802241ddef14a.htm
<DESCRIPTION>DEF 14A
<TEXT>
<HTML><HEAD>
<TITLE>DEF 14A</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>WASHINGTON, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE 14A
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Proxy Statement Pursuant to Section&nbsp;14(a) of the </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>(Amendment No. ) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Filed by the
Registrant&#8194;&nbsp;&#9746; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Filed by a Party other than the Registrant&#8194;&nbsp;&#9744; </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Preliminary Proxy Statement </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Confidential, for Use of the Commission Only (as permitted by Rule
<FONT STYLE="white-space:nowrap">14a-6(e)(2))</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9746;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Definitive Proxy Statement </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Definitive Additional Materials </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Soliciting Material Under <FONT STYLE="white-space:nowrap">&#167;240.14a-12</FONT> </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>WAVE LIFE SCIENCES LTD. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Name of Registrant as Specified In Its Charter) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Name of Person(s) Filing Proxy Statement, if other than the Registrant) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Payment of Filing Fee (Check all boxes that apply): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9746;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">No fee required. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Fee previously paid with preliminary materials. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules
<FONT STYLE="white-space:nowrap">14a-6(i)(1)</FONT> and <FONT STYLE="white-space:nowrap">0-11.</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>WAVE LIFE SCIENCES LTD. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Incorporated in the Republic of Singapore) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Company Registration Number 201218209G) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTICE OF 2024 ANNUAL GENERAL MEETING OF SHAREHOLDERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>TIME</B>: 11:30 a.m., Eastern Time </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>DATE</B>:
August&nbsp;6, 2024 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PLACE</B>: Wave Life Sciences Ltd., 733 Concord Avenue, Cambridge, MA 02138 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To Our Shareholders: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You are cordially invited to attend the
2024 Annual General Meeting of Shareholders of Wave Life Sciences Ltd. to be held at 11:30 a.m., Eastern Time, on Tuesday, August&nbsp;6, 2024 at 733 Concord Avenue, Cambridge, MA&nbsp;02138. In this Notice, we refer to the 2024 Annual General
Meeting of Shareholders as the &#147;2024 AGM&#148; and we refer to Wave Life Sciences Ltd. as &#147;Wave,&#148; the &#147;Company,&#148; &#147;we,&#148; &#147;us&#148; and &#147;our.&#148; Details regarding the 2024 AGM, the business to be
conducted at the 2024 AGM, and information about Wave Life Sciences Ltd. that you should consider when you vote your shares are described in the attached proxy statement. Shareholders should note that we may be required or it may be advisable to
change our meeting arrangements for the 2024 AGM on short notice. Shareholders should refer to Wave&#146;s website at https://ir.wavelifesciences.com/ and/or its announcements for the latest updates on the status of the 2024 AGM. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The 2024 AGM will be held for the following purposes: </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>As Special Business </U></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.&#8194;&#8201;&#8194;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">(a) To elect Paul B. Bolno, M.D., MBA to serve on the Board of Directors; </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>(Ordinary Resolution 1(a)) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To elect Mark H.N. Corrigan, M.D. to serve on the Board of Directors; </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>(Ordinary Resolution 1(b)) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To elect Christian Henry to serve on the Board of Directors; </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>(Ordinary Resolution 1(c)) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To elect Peter Kolchinsky, Ph.D. to serve on the Board of Directors; </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>(Ordinary Resolution 1(d)) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To elect Adrian Rawcliffe to serve on the Board of Directors; </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>(Ordinary Resolution 1(e)) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To elect Ken Takanashi to serve on the Board of Directors; </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>(Ordinary Resolution 1(f)) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(g)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To elect Aik Na Tan to serve on the Board of Directors; </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>(Ordinary Resolution 1(g)) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(h)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To elect Gregory L. Verdine, Ph.D. to serve on the Board of Directors; </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>(Ordinary Resolution 1(h)) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To elect Heidi L. Wagner, J.D. to serve on the Board of Directors; </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>(Ordinary Resolution 1(i)) </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>As Ordinary Business </U></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To approve the <FONT STYLE="white-space:nowrap">re-appointment</FONT> of KPMG LLP to serve as our independent
registered public accounting firm and independent Singapore auditor for the year ending December&nbsp;31, 2024, and to authorize the Audit Committee of the Board of Directors to fix KPMG LLP&#146;s remuneration for services provided through the date
of our 2025 Annual General Meeting of Shareholders; </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>(Ordinary Resolution 2) </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To approve our payment of cash and equity-based compensation to
<FONT STYLE="white-space:nowrap">non-employee</FONT> directors for service on the Board of Directors and its committees, in the manner and on the basis as set forth under &#147;Proposal 3: <FONT STYLE="white-space:nowrap">Non-Employee</FONT>
Directors&#146; Compensation&#148; in the attached proxy statement; </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>(Ordinary Resolution 3) </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>As Special Business </U></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To approve a proposed amendment to our 2021 Equity Incentive Plan, as amended, to increase the total number of
ordinary shares available for issuance under the 2021 Equity Incentive Plan, as amended, by 5,000,000 ordinary shares in the manner and on the basis as set forth under &#147;Proposal 4: Approval of an Amendment to the 2021 Equity Incentive Plan, as
amended&#148; in the attached proxy statement; </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>(Ordinary Resolution 4) </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Pursuant to the provisions of Section&nbsp;161 of the Companies Act 1967 of Singapore (the &#147;Singapore
Companies Act&#148;), and also subject to the provisions of the Singapore Companies Act and our Constitution, authority be, and hereby is, given to our Board of Directors: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">allot and issue ordinary shares in our capital; and/or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">make or grant offers, agreements, options or other instruments (including the grant of awards or options
pursuant to our equity-based incentive plans and agreements in effect from time to time) that might or would require ordinary shares to be allotted and issued, whether such allotment or issuance would occur during or after the expiration of this
authority (including but not limited to, the creation and issuance of warrants, rights, units, purchase contracts, debentures or other instruments (including debt instruments) convertible into or exercisable for ordinary shares),
</P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">at any time to and/or with such persons and upon such terms and conditions, for such purposes and for consideration as
our directors may in their sole discretion deem fit, and with such rights or restrictions as our directors may think fit to impose and as are set forth in our Constitution; and </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">to allot and issue ordinary shares in our capital pursuant to any offer, agreement, option or other agreement
made, granted or authorized by our directors while this resolution was in effect, regardless of whether the authority conferred by this resolution may have ceased to be in effect at the time of the allotment and issuance, </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">and that such authority, if approved by our shareholders, shall continue in effect until the earlier of the conclusion of our 2025 Annual
General Meeting of Shareholders or the expiration of the period within which our 2025 Annual General Meeting of Shareholders is required by law to be held; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>(Ordinary Resolution 5) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">6.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To approve, on a <FONT STYLE="white-space:nowrap">non-binding,</FONT> advisory basis only, the compensation of
our named executive officers: </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;RESOLVED, on a <FONT STYLE="white-space:nowrap">non-binding,</FONT> advisory basis
only, that the compensation paid to the named executive officers of the Company, as disclosed pursuant to the compensation disclosure rules of the U.S. Securities and Exchange Commission, including the compensation tables and the related material
disclosed in this proxy statement, is hereby APPROVED.&#148; </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">This <FONT STYLE="white-space:nowrap">non-binding</FONT> advisory resolution is being
proposed to shareholders as required pursuant to the requirements of Section&nbsp;14A of the Securities Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;). The shareholders&#146; vote on this proposal is solely advisory and <FONT
STYLE="white-space:nowrap">non-binding</FONT> in nature, will have no legal effect for purposes of Singapore law and will not be enforceable against our Company or our Board of Directors; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><FONT STYLE="white-space:nowrap">(Non-Binding</FONT> Advisory Resolution 6) </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">7.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To transact such other business as may properly come before the 2024 AGM and all adjournments or postponements
thereof. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Board of Directors recommends the approval of each of the first six proposals. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">All of the above proposals should be read in conjunction with the attached proxy statement, which sets out the specific parameters of the
proposals. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Each of the matters to be voted on at the 2024 AGM (other than Proposal 6, which is the only
<FONT STYLE="white-space:nowrap">non-binding</FONT> advisory resolution) may be passed by ordinary resolution pursuant to our Constitution. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Notes About the Annual General Meeting of Shareholders </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Eligibility to Vote at 2024 AGM</I>. The Board of Directors has fixed the close of business on June&nbsp;5, 2024 as the record date for determining those
shareholders who will be entitled to receive copies of this Notice and the attached proxy statement. As of June&nbsp;5, 2024, we had 122,475,119 ordinary shares issued and outstanding. However, under Singapore law, only registered holders of our
ordinary shares (i.e., persons whose names appear on the Register of Members of the Company maintained in accordance with Section&nbsp;190 of the Singapore Companies Act), or &#147;shareholders of record,&#148; on the date of the 2024 AGM,
August&nbsp;6, 2024, will be entitled to vote at the 2024 AGM. If you have sold or transferred any of your ordinary shares after June&nbsp;5, 2024 and prior to the 2024 AGM, you should immediately forward this Notice and the attached proxy statement
and proxy card to the purchaser or transferee of such shares, or to the bank, broker or agent through whom the sale of such shares was effected, for onward transmission to the purchaser or transferee. If you hold shares other than in registered form
as a shareholder of record, and instead hold your shares as, or through, a participant in DTC (i.e., in &#147;street name&#148;), we understand that in order for your vote to be counted at the 2024 AGM, you must also have been a holder of shares on
the date of the 2024 AGM, August&nbsp;6, 2024. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Proxies</I>. All shareholders of record as of the date of the 2024 AGM are cordially invited to attend
the 2024 AGM or appoint a proxy to attend and vote in their place (referred to as a &#147;legal proxy&#148;). A legal proxy need not also be a shareholder of record. <B>Whether or not you plan to attend the 2024 AGM, we urge you to vote and submit
your proxy card by mail in order to ensure the presence of a quorum.</B> A proxy card must be received by Vote Processing, c/o Broadridge, 51 Mercedes Way, Edgewood, NY 11717 not less than 48 hours before the time appointed for holding the 2024 AGM
or within such other time as may be required by the Singapore Companies Act. Completion and submission of the proxy card shall not preclude a shareholder of record from attending and voting at the 2024 AGM. Any appointment of a legal proxy or
proxies will be revoked if a shareholder of record attends and votes in person at the 2024 AGM, and in such event, we reserve the right to refuse to admit any person or persons appointed under the instrument of proxy or proxies to the meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the avoidance of doubt, the reference to &#147;proxy&#148; in this Notice does not mean a &#147;legal proxy&#148; entitled under Singapore law to attend
and vote on behalf of a shareholder of record. The reference to &#147;soliciting your proxy&#148; means that a shareholder of record may appoint the persons identified on the proxy card as such shareholder&#146;s legal proxies to vote in accordance
with such shareholder&#146;s instructions given via proxy or to authorize such persons to vote freely. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Beneficial or &#147;Street Name&#148;
Holders</I>. If your shares are held in &#147;street name&#148; (i.e., in the name of a bank, broker or other shareholder of record), you will receive instructions from the shareholder of record. You must follow the instructions of the shareholder
of record in order for your shares to be voted. If your shares are not registered in </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
your own name and you plan to vote your shares in person at the 2024 AGM, you should contact your broker or agent to obtain a legal proxy or broker&#146;s proxy card and bring it to the 2024 AGM
in order to vote as a legal proxy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Singapore Audited Accounts</I>. At the 2024 AGM, our shareholders will have the opportunity to discuss and ask
questions regarding our Singapore audited accounts for the fiscal year ended December&nbsp;31, 2023, together with the directors&#146; statement and independent auditors&#146; report thereon, in compliance with the laws of Singapore. Shareholder
approval of our Singapore audited accounts is not being sought by the attached proxy statement and will not be sought at the 2024 AGM. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Meeting
Arrangements.</I> Shareholders should note that we may be required or it may be advisable to change our meeting arrangements for the 2024 AGM on short notice. Shareholders should refer to our website at https://ir.wavelifesciences.com/ and/or our
announcements for the latest updates on the status of the 2024 AGM. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">When you have finished reading the attached proxy statement, you are urged to vote in
accordance with the instructions set forth in the proxy statement. We encourage you to vote by proxy so that your shares will be represented and voted at the 2024 AGM, whether or not you can attend. Thank you for your continued support of Wave Life
Sciences Ltd. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="46%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="5%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="46%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD ???? 1 VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD ???? 1 VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">BY ORDER OF THE BOARD OF DIRECTORS</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD ???? 1 VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD ???? 1 VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">


<IMG SRC="g802241g00r01.jpg" ALT="LOGO" STYLE="width:2.00455in;height:0.604546in;">
</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">June&nbsp;21, 2024</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD ???? 1 VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Paul B. Bolno, M.D., MBA</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD ???? 1 VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD ???? 1 VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">President, Chief Executive Officer and Director</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U><A NAME="toc"></A>TABLE OF CONTENTS </U></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="94%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD ???? 1 VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>PAGE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom802241_1">Cautionary Note Regarding Forward-Looking Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom802241_2">Important Information About the Annual General Meeting of Shareholders and
 Voting</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom802241_3">Security Ownership of Certain Beneficial Owners and
Management</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom802241_4">Management and Corporate Governance</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom802241_5">Executive Officer and Director Compensation</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom802241_6">Pay Versus Performance</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom802241_7">Equity Compensation Plan Information</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom802241_8">Report of Audit Committee</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom802241_9">Certain Relationships and Related Person Transactions</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom802241_10">Proposal 1: Election of Directors</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom802241_11">Proposal 2: Independent Registered Public Accounting Firm and Independent
 Singapore Auditor and Auditor Remuneration</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom802241_12">Proposal 3: <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors&#146;
 Compensation</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom802241_13">Proposal 4: Approval of an Amendment to the 2021 Equity Incentive Plan, as
amended</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom802241_14">Proposal 5: Ordinary Share Allotments and Issuances</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom802241_15">Proposal 6: <FONT STYLE="white-space:nowrap">Non-Binding</FONT> Advisory Resolution
 on Approval of Executive Compensation as Disclosed in this Proxy Statement</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom802241_16">Code of Business Conduct and Ethics</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">62</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom802241_17">Other Matters</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">62</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom802241_18">Shareholder Proposals and Nominations For Director</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">62</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Appendices</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom802241_19">Appendix A &#151; Singapore Statutory Financial Statements for the year ended
December&nbsp;31, 2023</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">A-1</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom802241_20">Appendix B &#151; 2021 Equity Incentive Plan, as amended</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">B-1</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">i </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>IMPORTANT NOTICE REGARDING THE AVAILABILITY OF PROXY MATERIALS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FOR THE ANNUAL GENERAL MEETING OF SHAREHOLDERS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TO BE HELD ON AUGUST&nbsp;6, 2024 </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>The
Notice, this proxy statement and our 2023 annual report to shareholders are available for viewing, printing and downloading at&nbsp;www.proxyvote.com. You can elect to receive distributions of our proxy statements and annual reports to shareholders
for future annual general meetings by electronic delivery. For specific instructions on making such an election, please refer to the instructions on the proxy card or voting instruction form. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At no charge, we are providing each person from whom a proxy is solicited a copy of, and access to, our Annual Report on Form
<FONT STYLE="white-space:nowrap">10-K</FONT> for the fiscal year ended December&nbsp;31, 2023, as amended (our &#147;2023 <FONT STYLE="white-space:nowrap">Form&nbsp;10-K&#148;).</FONT> Additionally, you can find a copy of our 2023 Form <FONT
STYLE="white-space:nowrap">10-K</FONT> on the website of the U.S. Securities and Exchange Commission (the &#147;SEC&#148;), at www.sec.gov, or in the &#147;Investors&#148; section of our website at http://ir.wavelifesciences.com/ under the heading
&#147;SEC Filings.&#148; You may also obtain a printed copy of our 2023 <FONT STYLE="white-space:nowrap">Form&nbsp;10-K,</FONT> free of charge, from us by sending a written request to Investor Relations, Wave Life Sciences Ltd., 733 Concord Avenue,
Cambridge, MA 02138 or by email to&nbsp;InvestorRelations@wavelifesci.com. Exhibits to our 2023 <FONT STYLE="white-space:nowrap">Form&nbsp;10-K</FONT> will be provided upon written request and payment of an appropriate processing fee. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The information provided on our website (www.wavelifesciences.com) is referenced in this proxy statement&nbsp;for information purposes only. The information
on our website shall not be deemed to be a part of or incorporated by reference into this proxy statement or any other filings we make with the SEC or any solicitation of proxies by us. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ii </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>WAVE LIFE SCIENCES LTD. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>733 CONCORD AVENUE </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CAMBRIDGE, MA 02138 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PROXY STATEMENT FOR THE WAVE LIFE SCIENCES LTD. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2024 ANNUAL GENERAL MEETING OF SHAREHOLDERS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TO BE HELD ON AUGUST&nbsp;6, 2024 </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This
proxy statement, along with the accompanying Notice of 2024 Annual General Meeting of Shareholders (the &#147;Notice&#148;), contains information about the 2024 Annual General Meeting of Shareholders of Wave Life Sciences Ltd. (including any
adjournments or postponements thereof), which we refer to in this proxy statement as the &#147;2024 AGM.&#148; We are holding the 2024 AGM at 11:30 a.m., Eastern Time, on Tuesday, August&nbsp;6, 2024, at 733 Concord Avenue, Cambridge, MA 02138.
Shareholders should note that we may be required or it may be advisable to change our meeting arrangements for the 2024 AGM on short notice. Shareholders should refer to Wave&#146;s website at https://ir.wavelifesciences.com/ and/or its
announcements for the latest updates on the status of the 2024 AGM. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In this proxy statement, we refer to Wave Life Sciences Ltd. as &#147;Wave,&#148; the
&#147;Company,&#148; &#147;we,&#148; &#147;us&#148; and &#147;our.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This proxy statement relates to the solicitation of proxies by our Board of
Directors for use at the 2024 AGM. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On or about June&nbsp;21, 2024, we intend to begin sending this proxy statement, the Notice and the enclosed proxy
card to shareholders of record as of June&nbsp;5, 2024. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Although not part of this proxy statement, we are also sending, along with this proxy statement,
our 2023 annual report to shareholders, which includes our financial statements for the fiscal year ended December&nbsp;31, 2023. Except as otherwise stated herein, all monetary amounts in this proxy statement have been presented in U.S. dollars.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom802241_1"></A>CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This proxy statement contains &#147;forward-looking statements&#148; within the meaning of the Private Securities Litigation Reform Act of 1995. These
forward-looking statements concern, among other things, expectations about our clinical trials and <FONT STYLE="white-space:nowrap">pre-clinical</FONT> activities and programs, regulatory submissions, collaborations, the anticipated benefits of our
therapeutic candidates, our financial and operating results, and our future performance and our ability to implement our strategy. These statements involve risks, uncertainties and assumptions and are based on the current estimates and assumptions
of the management of the Company as of the date of the proxy statement and are subject to uncertainty and changes. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Important factors that could cause
actual results to differ materially from those indicated by such forward-looking statements include, among others, those set forth under the heading &#147;Risk Factors&#148; contained in our
<FONT STYLE="white-space:nowrap">2023&nbsp;Form&nbsp;10-K,</FONT> as well as any updates to those risk factors filed from time to time in our periodic and current reports filed with the U.S. Securities and Exchange Commission. All information in
this proxy statement is as of the date of this proxy statement and the Company undertakes no duty to update this information unless required by law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom802241_2"></A>IMPORTANT INFORMATION ABOUT THE </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ANNUAL GENERAL MEETING OF SHAREHOLDERS AND VOTING </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Why is the Company Soliciting My Proxy? </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Board of
Directors of Wave Life Sciences Ltd. (the &#147;Board&#148;) is soliciting your proxy to vote at the 2024 Annual General Meeting of Shareholders (the &#147;2024 AGM&#148;) to be held at 733 Concord Avenue, Cambridge, MA 02138 on Tuesday,
August&nbsp;6, 2024, at 11:30 a.m., Eastern Time, and any adjournments or postponements of the 2024 AGM. Shareholders should note that we may be required or it may be advisable to change our meeting arrangements for the 2024 AGM on short notice.
This proxy statement, along with the Notice, summarizes the purposes of the meeting and the information you need to know to vote at the 2024 AGM. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have
made available to you on the Internet or have sent you this proxy statement, the Notice, the proxy card, and our 2023 annual report to shareholders because you owned ordinary shares of Wave Life Sciences Ltd. on the record date for determining those
shareholders who will be entitled to receive copies of the Notice and this proxy statement. We intend to begin distributing the proxy materials to shareholders on or about June&nbsp;21, 2024. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the avoidance of doubt, the reference to &#147;proxy&#148; in this proxy statement does not mean a &#147;legal proxy&#148; entitled under Singapore law to
attend and vote on behalf of a shareholder of record. The reference to &#147;soliciting your proxy&#148; means that a shareholder of record may appoint the persons identified on the proxy card as such shareholder&#146;s legal proxy to vote in
accordance with such shareholder&#146;s instructions given via proxy or to authorize such persons to vote freely. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Who Can Vote? </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Board has fixed the close of business on June&nbsp;5, 2024 as the record date for determining those shareholders who will be entitled to receive copies of
the Notice and this proxy statement. As of June&nbsp;5, 2024, we had 122,475,119 ordinary shares issued and outstanding. However, under Singapore law, only registered holders of our ordinary shares, or &#147;shareholders of record,&#148; on the date
of the 2024 AGM, August&nbsp;6, 2024, will be entitled to vote at the 2024 AGM. If you have sold or transferred any of your ordinary shares after the record date of June&nbsp;5, 2024 and prior to the 2024 AGM, you should immediately forward the
Notice, this proxy statement and the proxy card to the purchaser or transferee of such shares, or to the bank, broker or agent through whom the sale of such shares was effected, for onward transmission to the purchaser or transferee. If you hold
shares other than in registered form as a shareholder of record, and instead hold your shares as, or through, a participant in DTC (i.e., in &#147;street name&#148;), we understand that in order for your vote to be counted at the 2024 AGM, you must
also have been a holder of shares on the date of the 2024 AGM, August&nbsp;6, 2024. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All shareholders of record as of the date of the 2024 AGM are
cordially invited to attend the 2024 AGM or appoint a legal proxy to attend and vote in their place. A legal proxy need not also be a shareholder of record. <B>Whether or not you plan to attend the 2024 AGM, we urge you to vote and submit your proxy
card by mail in order to ensure the presence of a quorum. </B>A proxy card must be received by Vote Processing, c/o Broadridge, 51 Mercedes Way, Edgewood, NY 11717 not less than 48 hours before the time appointed for holding the 2024 AGM or within
such other time as may be required by the Singapore Companies Act. Completion and submission of the proxy card shall not preclude a shareholder of record from attending and voting at the 2024 AGM. Any appointment of a legal proxy or proxies will be
revoked if a shareholder of record attends and votes in person at the 2024 AGM, and in such event, we reserve the right to refuse to admit any person or persons appointed under the instrument of proxy or proxies to the meeting. Shareholders of
record may change or revoke their legal proxies at any time before their shares are voted at the 2024 AGM. For instructions on how to change or revoke your legal proxy, see &#147;May I Change or Revoke My Proxy?&#148; below. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>How Many Votes Do I Have? </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each ordinary share that you own or represent as a legal proxy entitles you to one vote at the 2024 AGM. The Series A preferred shares of the Company are not
entitled to vote on any of the matters being proposed at the 2024 AGM. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>How Do I Vote? </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If you are not planning to attend the 2024 AGM, we urge you to vote by proxy. All shares represented by valid proxies that we receive through this
solicitation, and that are not revoked, will be voted in accordance with your instructions on the proxy card. You may specify whether your shares should be voted for, against or abstain for each nominee for director, and whether your shares should
be voted for, against or abstain with respect to each of the other proposals. If you properly submit a proxy card without giving specific voting instructions, your shares will be voted in accordance with the Board&#146;s recommendations as noted
below, except as described under &#147;Will My Shares be Voted if I Do Not Vote or Provide Voting Instructions?&#148; Voting by proxy will not affect your right to attend the 2024 AGM. If you are a shareholder of record such that your shares are
registered directly in your name through our transfer agent, Computershare Trust Company, N.A., or you have share certificates registered in your name, you may vote: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>By mail.</B> If you received a proxy card by mail, you can vote by mail by completing, signing, dating and
returning the proxy card as instructed on the card. If you sign the proxy card but do not specify how you want your shares voted, they will be voted in accordance with the Board&#146;s recommendations as noted below. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>In person at the meeting.</B> If you attend the meeting, you may vote by completing a ballot, which will be
available at the meeting. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A proxy card must be received by Vote Processing, c/o Broadridge, 51 Mercedes Way, Edgewood, NY&nbsp;11717
not less than 48 hours before the time appointed for holding the 2024 AGM or within such other time as may be required by the Singapore Companies Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If
your shares are held in &#147;street name&#148; (i.e., in the name of a bank, broker or other shareholder of record), you will receive instructions from the shareholder of record. You must follow the instructions of the shareholder of record in
order for your shares to be voted. If your shares are not registered in your own name and you plan to vote your shares in person at the 2024 AGM, you should contact your broker or agent to obtain a legal proxy or broker&#146;s proxy card and bring
it to the 2024 AGM in order to vote. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>How Does the Board of Directors Recommend That I Vote on the Proposals? </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Board of Directors recommends that you vote as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<B><U>FOR</U></B>&#148; each of the resolutions for the election of the nominees for director;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<B><U>FOR</U></B>&#148; the approval of the <FONT STYLE="white-space:nowrap">re-appointment</FONT> of KPMG
LLP as our independent registered public accounting firm and independent Singapore auditor for the year ending December&nbsp;31, 2024, and the authorization of the Audit Committee of the Board of Directors to fix KPMG LLP&#146;s remuneration for
services provided through the date of our 2025 Annual General Meeting of Shareholders; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<B><U>FOR</U></B>&#148; the approval of cash and equity-based compensation to be paid to the <FONT
STYLE="white-space:nowrap">non-employee</FONT> members of the Board of Directors for service on the Board of Directors and its committees, as described under &#147;Proposal 3: <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors&#146;
Compensation&#148;; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<B><U>FOR</U></B>&#148; the approval of an increase in the total number of ordinary shares available for
issuance under the 2021 Equity Incentive Plan, as amended; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<B><U>FOR</U></B>&#148; the authorization of the Board of Directors to allot and issue ordinary shares of
the Company; and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;<B><U>FOR</U></B>&#148; the <FONT STYLE="white-space:nowrap">non-binding</FONT> advisory resolution on
compensation of our named executive officers, as disclosed in this proxy statement. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If any other matter is presented at the 2024 AGM,
your proxy card provides that your shares will be voted by the proxy holder listed in the proxy card in accordance with the proxy holder&#146;s judgment. At the time this proxy statement was first made available, we knew of no matters that needed to
be acted on at the 2024 AGM, other than those discussed in this proxy statement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>May I Change or Revoke My Proxy? </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If you give us your proxy, you may change or revoke it at any time before or at the 2024 AGM in any one of the following ways: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if you received a proxy card, by signing and submitting a new proxy card with a date later than your previously
delivered proxy card, which must be received by Vote Processing, c/o Broadridge, 51&nbsp;Mercedes Way, Edgewood, NY 11717 not less than 48 hours before the time appointed for holding the 2024 AGM or within such other time as may be required by the
Singapore Companies Act; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">by attending and voting at the 2024 AGM in person. Any appointment of a legal proxy or proxies will be revoked if
a shareholder of record attends and votes in person at the 2024 AGM. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Your most current vote is the one that will be counted. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>What if I Receive More Than One Proxy Card? </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You may
receive more than one proxy card if you hold any of our ordinary shares in more than one account, which may be in registered form or held in street name. Please vote in the manner described above under &#147;How Do I Vote?&#148; for each account to
ensure that all of your shares are voted. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Will My Shares be Voted if I Do Not Vote or Provide Voting Instructions? </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If your shares are registered in your name or if you have share certificates, they will not be counted if you do not vote as described above under &#147;How Do
I Vote?&#148;. If your shares are held in street name and you do not provide voting instructions to the bank, broker or other nominee that holds your shares as described above, the bank, broker or other nominee that holds your shares has the
authority to vote your unvoted shares without receiving instructions from you on Proposal 2:<B> </B>the approval of the <FONT STYLE="white-space:nowrap">re-appointment</FONT> of KPMG LLP as our independent registered public accounting firm and
independent Singapore auditor and the authorization of KPMG&#146;s remuneration. We encourage you to provide voting instructions to your bank, broker or other nominee to ensure your shares will be voted at the 2024 AGM and in the manner you desire.
A &#147;broker <FONT STYLE="white-space:nowrap">non-vote&#148;</FONT> will occur if your broker cannot vote your shares on a particular matter because it has not received instructions from you and does not have discretionary voting authority on that
matter or because your broker chooses not to vote on a matter for which it does have discretionary voting authority. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>What Vote is Required to Approve Each Proposal and How are Votes Counted? </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Proposal 1: Elect Directors</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Each nominee for director who receives the affirmative vote of a majority of the votes cast by the holders of ordinary shares voting either in person or by proxy at the 2024 AGM will be elected to serve until the next annual general
meeting of shareholders (meaning the number of shares voted &#147;for&#148; a nominee must exceed the number of shares voted &#147;against&#148; such nominee).</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD ???? 1 VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">You may vote either &#147;for&#148; or &#147;against&#148; each of the nominees, or you may &#147;abstain&#148; from voting for one or more nominees. If you &#147;abstain&#148; from voting with respect to one or more nominees, your
vote will have no effect on the election of such nominees. Brokerage firms do not have authority to vote customers&#146; unvoted shares held by the firms in street name with respect to this proposal. As a result, any shares not voted by a customer
will be treated as a broker <FONT STYLE="white-space:nowrap">non-vote.</FONT> Such broker <FONT STYLE="white-space:nowrap">non-votes</FONT> will have no effect on the results of this vote.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B><FONT STYLE="white-space:nowrap">Proposal&nbsp;2:&nbsp;Approve&nbsp;the&nbsp;Re-Appointment</FONT> of Independent Registered Public Accounting Firm and Independent Singapore Auditor and Authorize the Auditor&#146;s
Remuneration</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">The affirmative vote of a majority of the votes cast by holders of ordinary shares voting in person or by proxy at the 2024 AGM is required to approve the <FONT STYLE="white-space:nowrap">re-appointment</FONT> of KPMG LLP as our
independent registered public accounting firm and our independent Singapore auditor and to authorize the Audit Committee to fix the auditor&#146;s remuneration (meaning the number of shares voted &#147;for&#148; the proposal must exceed the number
of shares voted &#147;against&#148; the proposal).</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD ???? 1 VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">You may vote either &#147;for&#148; or &#147;against&#148; or &#147;abstain&#148; from voting on this proposal. Abstentions will have no effect on the results of this vote. Brokerage firms have authority to vote customers&#146;
unvoted shares held by the firms in street name on this proposal. If a broker does not exercise this authority, such broker <FONT STYLE="white-space:nowrap">non-votes</FONT> will have no effect on the results of this vote.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Proposal 3: Approve the <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors&#146; Compensation</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">The affirmative vote of a majority of the votes cast by holders of ordinary shares voting in person or by proxy at the 2024 AGM is required to approve the <FONT STYLE="white-space:nowrap">non-employee</FONT> directors&#146;
compensation policy (meaning the number of shares voted &#147;for&#148; the proposal must exceed the number of shares voted &#147;against&#148; the proposal).</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD ???? 1 VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">You may vote either &#147;for&#148; or &#147;against&#148; or &#147;abstain&#148; from voting on this proposal. Abstentions will have no effect on the results of this vote. Brokerage firms do not have authority to vote
customers&#146; unvoted shares held by the firms in street name with respect to this proposal. As a result, any shares not voted by a customer will be treated as a broker <FONT STYLE="white-space:nowrap">non-vote.</FONT> Such broker <FONT
STYLE="white-space:nowrap">non-votes</FONT> will have no effect on the results of this vote.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Proposal 4: Approve an Amendment to the 2021 Equity Incentive Plan, as amended</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">The affirmative vote of a majority of the votes cast by holders of ordinary shares voting in person or by proxy at the 2024 AGM is required to approve an amendment to the 2021 Equity Incentive Plan, as amended, to increase the total
number of ordinary shares available for issuance under the 2021 Equity Incentive Plan, as amended, by 5,000,000 ordinary shares (meaning the number of shares voted &#147;for&#148; the proposal must exceed the number of shares voted
&#147;against&#148; the proposal).</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD ???? 1 VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">You may vote either &#147;for&#148; or &#147;against&#148; or &#147;abstain&#148; from voting on this proposal. Abstentions will have no effect on the results of this vote. Brokerage firms do not have authority to vote
customers&#146; unvoted shares held by the firms in street name with respect to this proposal. As a result, any shares not voted by a customer will be treated as a broker <FONT STYLE="white-space:nowrap">non-vote.</FONT> Such broker <FONT
STYLE="white-space:nowrap">non-votes</FONT> will have no effect on the results of this vote.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Proposal 5: Authorize the Board to Allot and Issue Ordinary Shares of the Company</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">The affirmative vote of a majority of the votes cast by holders of ordinary shares voting in person or by proxy at the 2024 AGM is required to authorize the Board to allot and issue ordinary shares of the Company (meaning the number
of shares voted &#147;for&#148; the proposal must exceed the number of shares voted &#147;against&#148; the proposal).</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD ???? 1 VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">You may vote either &#147;for&#148; or &#147;against&#148; or &#147;abstain&#148; from voting on this proposal. Abstentions will have no effect on the results of this vote. Brokerage firms do not have authority to vote
customers&#146; unvoted shares held by the firms in street name with respect to this proposal. As a result, any shares not voted by a customer will be treated as a broker <FONT STYLE="white-space:nowrap">non-vote.</FONT> Such broker <FONT
STYLE="white-space:nowrap">non-votes</FONT> will have no effect on the results of this vote.</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Proposal 6: Approve a <FONT STYLE="white-space:nowrap">Non-Binding</FONT> Advisory Resolution on the Compensation of our Named Executive Officers</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">This <FONT STYLE="white-space:nowrap">non-binding</FONT> advisory resolution is being proposed to shareholders as required pursuant to Section&nbsp;14A of the Exchange Act. The shareholders&#146; vote on this proposal is solely
advisory and <FONT STYLE="white-space:nowrap">non-binding</FONT> in nature, will have no legal effect for purposes of Singapore law and will not be enforceable against our Company or our Board. For the avoidance of doubt, this is not an Ordinary
Resolution.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD ???? 1 VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">The affirmative vote of a majority of the votes cast by holders of ordinary shares voting in person or by proxy at the 2024 AGM is required to approve, on a <FONT STYLE="white-space:nowrap">non-binding,</FONT> advisory basis only,
the compensation of our named executive officers, as described in this proxy statement (meaning the number of shares voted &#147;for&#148; the proposal must exceed the number of shares voted &#147;against&#148; the proposal).</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD ???? 1 VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">You may vote either &#147;for&#148; or &#147;against&#148; or &#147;abstain&#148; from voting on this proposal. Abstentions will have no effect on the results of this vote. Brokerage firms do not have authority to vote
customers&#146; unvoted shares held by the firms in street name with respect to this proposal. As a result, any shares not voted by a customer will be treated as a broker <FONT STYLE="white-space:nowrap">non-vote.</FONT> Such broker <FONT
STYLE="white-space:nowrap">non-votes</FONT> will have no effect on the results of this vote.</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Where Can I Find the Voting Results of the 2024 AGM? </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The preliminary voting results will be announced at the 2024 AGM, and we will publish preliminary results, or final results if available, in a Current Report
on Form <FONT STYLE="white-space:nowrap">8-K</FONT> within four business days after the 2024 AGM. If final results are unavailable at the time we file the Form <FONT STYLE="white-space:nowrap">8-K,</FONT> then we will file an amended report on Form <FONT
STYLE="white-space:nowrap">8-K</FONT> to disclose the final voting results within four business days after the final voting results are known. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>What
Are the Costs of Soliciting these Proxies? </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will pay all of the costs of soliciting these proxies. Our directors and employees may solicit proxies
in person or by telephone or email. We will pay these employees and directors no additional compensation for these services. We will ask banks, brokers and other institutions, nominees and fiduciaries to forward these proxy materials to their
principals and to obtain authority to execute proxies. We will then reimburse them for their expenses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have engaged Innisfree to act as our proxy
solicitor in connection with the proposals to be acted upon at our 2024 AGM. Pursuant to our agreement with our proxy solicitor, our proxy solicitor will, among other things, provide advice regarding proxy solicitation issues and solicit proxies
from our shareholders on our behalf in connection with the 2024 AGM. For these services, we will pay a fee of approximately $25,000 plus expenses. <B>If</B><B></B><B>&nbsp;you have any questions or require any assistance, you may contact Innisfree
using a dedicated toll-free number at <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">877-717-3898</FONT></FONT></B>. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>What Constitutes a Quorum for the 2024 AGM? </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In order to hold the meeting, there must be a quorum. The presence, in person or by proxy, of at least two shareholders holding in aggregate at least a
majority of all issued and outstanding ordinary shares entitled to vote at the 2024 AGM is necessary to constitute a quorum at the 2024 AGM. Votes of shareholders of record who are present in person or represented by proxy at the 2024 AGM,
abstentions and broker <FONT STYLE="white-space:nowrap">non-votes</FONT> are counted for purposes of determining whether a quorum exists. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Attending
the 2024 AGM </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The 2024 AGM will be held at 11:30 a.m., Eastern Time, on Tuesday, August&nbsp;6, 2024 at 733 Concord Avenue, Cambridge, MA 02138. When
you arrive, signs will direct you to the appropriate meeting rooms. You need not attend the 2024 AGM in person in order to vote, provided that your proxy is present to represent your&nbsp;vote. Shareholders should note that we may be required or it
may be advisable to change our meeting arrangements for the 2024 AGM on short notice. Shareholders should refer to our website at https://ir.wavelifesciences.com/ and/or our announcements for the latest updates on the status of the 2024 AGM. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Singapore Statutory Financial Statements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Singapore
audited accounts for the fiscal year ended December&nbsp;31, 2023, prepared in conformity with the provisions of the laws of Singapore, and the accompanying directors&#146; statement and the independent auditors&#146; report thereon are required
under Singapore law and our Constitution to be provided to shareholders for discussion at the 2024 AGM. We refer to such materials herein collectively as the &#147;Singapore Statutory Financial Statements.&#148; The Singapore Statutory Financial
Statements are provided as <U>Appendix A</U> to this proxy statement solely to satisfy this requirement. At the 2024 AGM, our shareholders will have the opportunity to discuss and ask questions regarding the Singapore Statutory Financial Statements.
Shareholder approval of the Singapore Statutory Financial Statements is not being sought by this proxy statement for the 2024 AGM and will not be sought at the 2024 AGM. The Singapore Statutory Financial Statements shall not be deemed to be
&#147;soliciting material&#148; or to be &#147;filed&#148; with the SEC nor shall such information be incorporated by reference into any filings under the Securities Act of 1933, as amended, or under the Exchange Act, or be subject to the
liabilities of Section&nbsp;18 of the Exchange Act, except to the extent that we specifically incorporate this information by reference into any such filing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom802241_3"></A>SECURITY OWNERSHIP OF </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTAIN BENEFICIAL OWNERS AND MANAGEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table sets forth certain information with respect to the beneficial ownership of our ordinary shares as of June&nbsp;5, 2024 for (i)&nbsp;the
executive officers named in the Summary Compensation Table appearing elsewhere in this proxy statement, (ii)&nbsp;each of our directors, (iii)&nbsp;all of our current directors and executive officers as a group, and (iv)&nbsp;each shareholder known
by us to own beneficially more than 5% of our ordinary shares.&nbsp;Beneficial ownership is determined in accordance with the rules of the SEC and includes voting or investment power with respect to the securities.&nbsp;We deem ordinary shares that
may be acquired by an individual or group within 60 days after June&nbsp;5, 2024 pursuant to the exercise of options, the vesting of restricted share unit awards, the exercise of <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants, or the
conversion of our outstanding Series A preferred shares into ordinary shares to be outstanding for the purpose of computing the percentage ownership of such individual or group, but such shares are not deemed to be outstanding for the purpose of
computing the percentage ownership of any other person shown in the table.&nbsp;Except as indicated in footnotes to this table, we believe that the shareholders named in this table have sole voting and investment power with respect to all ordinary
shares shown to be beneficially owned by them based on information provided to us by these shareholders.&nbsp;Percentage ownership is based on 122,475,119 ordinary shares outstanding as of June&nbsp;5, 2024. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Ordinary&nbsp;Shares<BR>Beneficially&nbsp;Owned</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percent</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>5% Beneficial Owners</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">RA Capital Management, L.P.<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25,424,665</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19.60</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">GSK plc<SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13,983,761</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shin Nippon Biomedical Laboratories,
Ltd.<SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,606,408</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Maverick Capital, Ltd.<SUP STYLE="font-size:75%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,447,804</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">M28 Capital Management LP<SUP STYLE="font-size:75%; vertical-align:top">(5)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,373,413</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Directors and Named Executive Officers</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Paul B. Bolno, M.D., MBA<SUP STYLE="font-size:75%; vertical-align:top">(6)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,103,287</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chandra Vargeese, Ph.D.<SUP STYLE="font-size:75%; vertical-align:top">(7)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">769,722</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kyle Moran, CFA<SUP STYLE="font-size:75%; vertical-align:top">(8)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">419,386</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mark H. N. Corrigan, M.D.<SUP STYLE="font-size:75%; vertical-align:top">(9)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">118,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Christian Henry<SUP STYLE="font-size:75%; vertical-align:top">(9)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">129,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Peter Kolchinsky, Ph.D.<SUP STYLE="font-size:75%; vertical-align:top">(10)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25,424,665</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19.60</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adrian Rawcliffe<SUP STYLE="font-size:75%; vertical-align:top">(9)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">129,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ken Takanashi<SUP STYLE="font-size:75%; vertical-align:top">(11)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,735,408</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Heidi L. Wagner, J.D.<SUP STYLE="font-size:75%; vertical-align:top">(9)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">118,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gregory L. Verdine, Ph.D.<SUP STYLE="font-size:75%; vertical-align:top">(12)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">558,597</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Aik Na Tan<SUP STYLE="font-size:75%; vertical-align:top">(9)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">105,576</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>All current directors and executive officers as a group (12&nbsp;individuals)<SUP
STYLE="font-size:75%; vertical-align:top">(13)</SUP></I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">40,116,170</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Represents less than 1% of ordinary shares outstanding on June&nbsp;5, 2024. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Based on information reported by RA Capital Management, L.P. (&#147;RA Capital&#148;) on Form 4/A filed with
the SEC on January&nbsp;17, 2024 and on Schedule 13D/A filed with the SEC on June&nbsp;21, 2022. Consists of (i) 18,202,009 ordinary shares held by RA Capital Healthcare Fund, L.P. (the &#147;Fund&#148;), (ii) 129,000 ordinary shares underlying
options exercisable within 60 days after June&nbsp;5, 2024 held by Dr.&nbsp;Peter Kolchinsky, a member of our Board, and (iii) 7,093,656 ordinary shares that the Fund beneficially owns based on the right to acquire upon exercise of <FONT
STYLE="white-space:nowrap">pre-funded</FONT> warrants. RA Capital Healthcare Fund GP, LLC is the general partner of the Fund. The general partner of RA Capital is RA Capital Management GP, LLC, of which Dr.&nbsp;Kolchinsky and Mr.&nbsp;Rajeev Shah
are the controlling persons. RA Capital serves as investment adviser for the Fund and may be deemed a beneficial owner of any securities of the Company held by the Fund. The </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
Fund has delegated to RA Capital the sole power to vote and the sole power to dispose of all securities held in the Fund&#146;s portfolio, including the ordinary shares held by the Fund. Because
the Fund has divested itself of voting and investment power over the reported securities it holds and may not revoke that delegation on less than 61 days&#146; notice, the Fund disclaims beneficial ownership of the securities it holds for purposes
of Section&nbsp;13(d) of the Exchange Act. As managers of RA Capital, Dr.&nbsp;Kolchinsky and Mr.&nbsp;Shah may be deemed beneficial owners, for purposes of Section&nbsp;13(d) of the Exchange Act, of any securities of the Company beneficially owned
by RA Capital. RA Capital, Dr.&nbsp;Kolchinsky, and Mr.&nbsp;Shah disclaim beneficial ownership of securities reported herein. The address for RA Capital is 200 Berkeley Street, 18<SUP STYLE="font-size:75%; vertical-align:top">th</SUP> Floor,
Boston, MA 02116. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Based on information reported by GSK plc on Schedule 13G filed with the SEC on February&nbsp;6, 2024. Consists
of ordinary shares held of record by Glaxo Group Limited, a wholly-owned subsidiary of GSK plc. The address of GSK plc is 980 Great West Road, Brentford, Middlesex TW8 9GS, England. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Based on information reported by Shin Nippon Biomedical Laboratories, Ltd. (&#147;SNBL&#148;) on Schedule 13D/A
filed with the SEC on August&nbsp;12, 2022. Consists of (i) 1,697,467 ordinary shares held by SNBL; (ii) 4,007,593 ordinary shares held by SNBL USA, Ltd. (&#147;SNBL USA&#148;); (iii) 1,801,348 ordinary shares underlying immediately convertible
Series A preferred shares held by SNBL; and (iv) 2,100,000 ordinary shares underlying immediately convertible Series A preferred shares held by SNBL USA. The Series A preferred shares can be converted at any time on a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">one-for-one</FONT></FONT> basis into ordinary shares at the discretion of the holder. Ken Takanashi, a member of our Board, is an executive officer of SNBL and an executive officer
and director of SNBL USA. SNBL and Mr.&nbsp;Takanashi share voting and dispositive power with respect to such shares and may be deemed to beneficially own such shares. The address of SNBL is
<FONT STYLE="white-space:nowrap">2438&nbsp;Miyanoura-cho,</FONT> Kagoshima City, <FONT STYLE="white-space:nowrap">Kagoshima&nbsp;891-1394,&nbsp;Japan;</FONT> the address of SNBL USA is 2333 Seaway Boulevard, Everett, WA 98203; and the address of
Mr.&nbsp;Takanashi is St. Luke&#146;s Tower <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">28F,&nbsp;8-1,Akashi-cho,</FONT></FONT>
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Chuo-ku,&nbsp;Tokyo&nbsp;104-0044,</FONT></FONT> Japan. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Based on information reported by Maverick Capital, Ltd., Maverick Capital Management, LLC and
Lee&nbsp;S.&nbsp;Ainslee III on Schedule 13G/A filed with the SEC on February&nbsp;14, 2024. Maverick Capital, Ltd. is an investment adviser registered under Section&nbsp;203 of the Investment Advisers Act of 1940 and, as such, may be deemed to have
beneficial ownership of the ordinary shares reported herein through the investment discretion it exercises over its clients&#146; accounts. Maverick Capital Management, LLC is the General Partner of Maverick Capital, Ltd. Mr.&nbsp;Ainslie is the
manager of Maverick Capital Management, LLC. The principal business address of (i)&nbsp;Maverick Capital, Ltd. and Maverick Capital Management, LLC is 1900 N. Pearl Street, 20<SUP STYLE="font-size:75%; vertical-align:top">th</SUP> Floor, Dallas,
Texas, 75201, and (ii)&nbsp;Mr.&nbsp;Ainslie is 360 South Rosemary Ave., Suite 1440, West Palm Beach, Florida 33401. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Based on information reported on Schedule 13G/A filed with the SEC on February&nbsp;12, 2024 by (i)&nbsp;M28
Capital Management LP (&#147;M28 Capital&#148;) with respect to the ordinary shares held by M28 Capital Master Fund LP (the&nbsp;&#147;M28 Fund&#148;) to which it acts as investment manager; and (ii)&nbsp;Marc Elia, the Chief Investment Officer of
M28 Capital and Managing Member of M28 Capital Management GP LLC, the general partner of M28 Capital (&#147;<U>Mr.Elia</U>&#148;, together with M28 Capital and M28 Capital Management GP, LLC, the &#147;M28 Parties&#148;), with respect to the
ordinary shares held by the M28 Funds. The address of the M28 Parties is 700&nbsp;Canal Street, 2<SUP STYLE="font-size:75%; vertical-align:top">nd</SUP> Floor, Stamford, CT, 06902. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of (i) 407,425 ordinary shares held by Dr. Bolno and (ii) 1,695,862 ordinary shares underlying options
exercisable within 60 days of June&nbsp;5, 2024 held by Dr. Bolno. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of (i) 96,346 ordinary shares held by Dr. Vargeese and (ii) 673,376 ordinary shares underlying options
exercisable within 60 days of June&nbsp;5, 2024 held by Dr. Vargeese. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(8)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of (i) 17,146 ordinary shares held by Mr.&nbsp;Moran and (ii) 402,240 ordinary shares underlying
options exercisable within 60 days of June&nbsp;5, 2024 held by Mr.&nbsp;Moran. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(9)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of ordinary shares underlying options exercisable within 60 days of June&nbsp;5, 2024.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(10)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">See Footnote (1)&nbsp;above. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(11)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">See Footnote (3) above. Also consists of 129,000 ordinary shares underlying options exercisable within
60&nbsp;days of June&nbsp;5, 2024 held by Mr. Takanashi. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(12)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of (i) 30,000 ordinary shares held by Dr. Verdine and (ii) 528,597 ordinary shares underlying options
exercisable within 60 days of June&nbsp;5, 2024 held by Dr. Verdine. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(13)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of (i) 4,583,466 ordinary shares underlying options exercisable within 60 days of June&nbsp;5, 2024,
held by our current directors and executive officers, (ii) 24,537,700 outstanding ordinary shares beneficially owned by our current directors and executive officers and entities affiliated with certain of our directors, (iii) 3,901,348 Series A
preferred shares, which can be converted at any time on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">one-for-one</FONT></FONT> basis into ordinary shares at the discretion of the holder, held by entities affiliated with one of
our directors, and (iv)&nbsp;exercisable <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants to purchase 7,093,656 ordinary shares, held by an entity affiliated with one of our directors. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom802241_4"></A>MANAGEMENT AND CORPORATE GOVERNANCE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Board of Directors </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to our Constitution, there
is no maximum number of directors that may hold office at any time. Our Board of Directors (our &#147;Board&#148;) currently consists of nine members and each of our directors is elected annually. Our Constitution requires that each of our directors
retire at each annual general meeting of our shareholders, and each retiring director is then eligible for <FONT STYLE="white-space:nowrap">re-election.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On June&nbsp;5, 2024, our Board accepted the recommendation of the Nominating and Corporate Governance Committee and voted to nominate Paul B. Bolno, M.D.,
MBA, Mark H.N. Corrigan, M.D., Christian Henry, Peter Kolchinsky, Ph.D., Adrian Rawcliffe, Ken Takanashi, Aik Na Tan, Gregory L. Verdine, Ph.D., and Heidi&nbsp;L. Wagner, J.D., each currently a director of the Company, for election at the 2024 AGM.
If each such nominee is elected, he or she will serve on our Board until our 2025 Annual General Meeting of Shareholders and until their successor has been elected and qualified. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the Singapore Companies Act and our Constitution, our Board must have at least one director who is ordinarily resident in Singapore. Ms.&nbsp;Tan
is currently our Singapore resident director. Due to the Singapore Companies Act requirement that we have at least one director who is ordinarily resident in Singapore in office at all times, the sole resident director cannot resign or step down
unless there is at least one other resident director. In the event that Ms.&nbsp;Tan is not elected at the 2024 AGM, she will continue in office after the 2024 AGM as a member of our Board until her qualifying successor (<I>i.e.</I>, a Singapore
resident director) is appointed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Set forth below are the names of our directors, their ages as of June&nbsp;5, 2024, their offices in the Company, if
any, their principal occupations or employment for at least the past five years, the length of their tenure as directors and the names of other public companies in which they hold or have held directorships during the past five years. In addition,
information about the specific experience, qualifications, attributes or skills that led to our Board&#146;s conclusion at the time of filing of this proxy statement that each person listed below should serve as a director is set forth below. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="40%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="50%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Age</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Position/Title</B></P></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Paul B. Bolno, M.D., MBA</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>President,&nbsp;Chief&nbsp;Executive&nbsp;Officer&nbsp;and&nbsp;Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Christian Henry</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">56</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Chair of the Board</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mark H.N. Corrigan, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">66</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Peter&nbsp;Kolchinsky,&nbsp;Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Director</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adrian Rawcliffe</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ken Takanashi</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Director</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Aik Na Tan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">53</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gregory&nbsp;L.&nbsp;Verdine,&nbsp;Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">64</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Director</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Heidi L. Wagner, J.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Director</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Paul B. Bolno, M.D.</I></B><B>, </B><B><I>MBA</I></B> has served as our President and Chief Executive Officer since
December 2013 and as a director since April 2014. Since May 2020, Dr.&nbsp;Bolno has served as Chairman of the Scientific Advisory Group for the Nucleic Acid Therapy Accelerator (NATA) in the United Kingdom. From June 2020 through March 2024,
Dr.&nbsp;Bolno served on the board of directors of SQZ Biotechnologies, a publicly-traded life sciences company that was acquired by STEMCELL Technologies Canada Acquisitions, Inc. in March 2024. Prior to joining us, he served at GlaxoSmithKline plc
from 2009 to 2013 in various roles, including Vice President, Worldwide Business Development&#151;Head of Asia BD and Investments, Head of Global Neuroscience BD, a director of Glaxo Welcome Manufacturing, Pte. Ltd. in Singapore and Vice President,
Business Development for the Oncology Business Unit, where he helped establish GlaxoSmithKline&#146;s global oncology business and served as a member of the Oncology Executive Team, Oncology Commercial Board and Cancer Research Executive Team. Prior
to GlaxoSmithKline, he served as director of Research at Two River LLC, a health care private </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
equity firm from 2004 to 2009. Dr.&nbsp;Bolno earned a medical degree from <FONT STYLE="white-space:nowrap">MCP-Hahnemann</FONT> School of Medicine and an M.B.A. from Drexel University. He was a
general surgery resident and cardiothoracic surgery postdoctoral research fellow at Drexel University College of Medicine. We believe that Dr.&nbsp;Bolno&#146;s experience serving as our President and Chief Executive Officer since 2013, his medical
degree and clinical training in cardiothoracic surgery, his business degree and experience evaluating life sciences companies in healthcare private equity, and his extensive business development and operating experience working in various roles at
one of the world&#146;s largest global healthcare companies qualify him to serve on our Board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Christian Henry </I></B>has served as a director
since November 2016, and as Chairman of our Board since October 2017. Mr.&nbsp;Henry currently serves as the President and Chief Executive Officer of Pacific Biosciences, a publicly traded life sciences company, a position he has held since
September 2020, and has also served on its board of directors since 2018. Mr.&nbsp;Henry has served on the board of directors of Ginkgo Bioworks, a publicly-traded synthetic biology company, since 2016, and previously served on the board of
directors CM Life Sciences III Inc., a publicly-traded special purpose acquisition company, from April 2021 through December 2021. Mr.&nbsp;Henry served as Executive Vice President&nbsp;&amp; Chief Commercial Officer of Illumina, Inc. from 2015
through January 2017, and previously served as Senior Vice President&nbsp;&amp; Chief Commercial Officer from 2014 to 2015, Senior Vice President&nbsp;&amp; General Manager Genomic Solutions from 2012 to 2014, Senior Vice President, Chief Financial
Officer&nbsp;&amp; General Manager Life Sciences from 2010 to 2012, Senior Vice President, Corporate Development&nbsp;&amp; Chief Financial Officer from 2009 to 2010, Senior Vice President&nbsp;&amp; Chief Financial Officer from 2007 to 2009, and
Vice President&nbsp;&amp; Chief Financial Officer from 2005 to 2006. Prior to joining Illumina, Inc., Mr.&nbsp;Henry served as the Chief Financial Officer of Tickets.com, Inc. from 2003 to 2005. From 1999 to 2003, Mr.&nbsp;Henry served as Vice
President, Finance&nbsp;&amp; Corporate Controller of Affymetrix, Inc. (acquired by Thermo Fisher Scientific in 2016). In 1997, Mr.&nbsp;Henry joined Nektar Therapeutics (formerly Inhale Therapeutic Systems, Inc.), as Corporate Controller, and later
as its Chief Accounting Officer from 1997 to 1999. In 1996, Mr.&nbsp;Henry served as General Accounting Manager of Sugen, Inc. Mr.&nbsp;Henry began his career in 1992 at Ernst&nbsp;&amp; Young LLP, where he was a Senior Accountant through 1996.
Mr.&nbsp;Henry earned his B.A. in biochemistry and cell biology from the University of California, San Diego, and his M.B.A., with a concentration in finance, from the University of California, Irvine. We believe he is qualified to serve on our
Board and as our Chairman because of his proven strengths in corporate strategy, finance and operations, along with his extensive experience leading various functions at one of the largest and most innovative genetic healthcare companies, and his
experience as a board member, board committee member and chief executive officer of publicly-traded life sciences companies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Mark H. N. Corrigan,
M.D.</I></B> has served as a director since September 2019. Since June 2021, Dr.&nbsp;Corrigan has served as a member of the board of directors of Nabriva Therapeutics plc, a publicly traded commercial-stage biopharmaceutical company, and previously
served on its board of directors from June 2017 to May 2020. Dr.&nbsp;Corrigan also currently serves as chairman of the board of directors of Elios Therapeutics, LLC, a privately-held development-stage immuno-oncology company, and on the board of
directors and as president of Silver Creek Pharmaceuticals, Inc., a privately-held clinical-stage biotechnology company. Dr.&nbsp;Corrigan served as the Chief Executive Officer of Correvio Pharma Corp. (&#147;Correvio&#148;), from March 2019 to May
2020. Prior to joining Correvio, Dr.&nbsp;Corrigan was President of Research and Development at Tremeau Pharmaceuticals (of which he is also a <FONT STYLE="white-space:nowrap">co-founder)</FONT> from 2016 to March 2019. Dr.&nbsp;Corrigan served as
President and Chief Executive Officer of Zalicus, Inc. (formerly CombinatoRx) from 2010 to 2014. Prior to that time, from 2003 to 2009, Dr.&nbsp;Corrigan held the role of Executive Vice President, Research and Development at Sepracor Inc. From 2000
to 2003, Dr.&nbsp;Corrigan served as Group Vice President, Clinical Research&nbsp;&amp; Experimental Medicine at Pharmacia Corporation. Prior to this, Dr.&nbsp;Corrigan held various roles at The Upjohn Company, The University of North Carolina, and
the National Institute of Mental Health Center for Psychoneuroendocrinology in Adults and Children at Dorthea Dix Hospital. Dr.&nbsp;Corrigan previously served as a member of the board of directors of Avanir Pharmaceuticals, Inc., CoLucid
Pharmaceuticals, Inc., Correvio Pharma Corp., and Cubist Pharmaceuticals, Inc. Dr.&nbsp;Corrigan holds an M.D. from the University of Virginia and received specialty training in psychiatry at Maine Medical Center and Cornell University. He received
a Bachelor of Arts in Psychology from the University of Virginia. We believe he is qualified to serve on our Board because of his extensive </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
experience working with clinical-stage, publicly-traded biopharmaceutical companies as a board member, board committee member and chief executive officer, his medical degree and clinical training
in psychiatry, and his clinical and regulatory expertise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Peter Kolchinsky, Ph.D.</I></B> has served as a director since January 2015.
Dr.&nbsp;Kolchinsky is a founder and Managing Partner of RA Capital, a multi-stage investment manager which is dedicated to evidence-based investing in healthcare and life science companies that are developing drugs, medical devices, diagnostics,
services and research tools, where he has worked since 2001. RA Capital is the investment manager of RA Capital Healthcare Fund, L.P. Dr.&nbsp;Kolchinsky has served as a member of the board of directors of ARS Pharmaceuticals Inc., a publicly-traded
biopharmaceutical company, since November 2022, in addition to serving as a member of the board of directors of a number of privately-held companies. Dr.&nbsp;Kolchinsky previously served as a member of the board of directors of Forma Therapeutics
Holdings, Inc., from December 2019 through October 2022, Dicerna Pharmaceuticals, Inc., from July 2013 to December 2019, Icosavax, Inc. from July 2021 to December 2023, and Synthorx, Inc., from May 2018 to January 2020, all of which were
publicly-traded biopharmaceutical companies. Dr.&nbsp;Kolchinsky also leads RA Capital&#146;s engagement and publishing efforts, which aim to make a positive social impact and spark collaboration among healthcare stakeholders, including patients,
physicians, researchers, policymakers, and industry. He served on the Board of Global Science and Technology for the National Academy of Sciences from 2009 to 2012, is the author of &#147;The Great American Drug Deal&#148; and &#147;The
Entrepreneur&#146;s Guide to a Biotech Startup&#148;, and frequently writes and speaks on the future of biotechnology innovation. Dr.&nbsp;Kolchinsky earned his Ph.D. in virology from Harvard University and earned his bachelor&#146;s degree in
Biology from Cornell University. We believe he is qualified to serve on our Board because of his scientific acumen, his strong reputation as a thought leader in the life sciences industry, his extensive experience investing in and forming, building
and growing life sciences companies and mentoring their management teams, as well as his experience as an institutional investor and his experience serving as a board member, board committee member, and board observer of various publicly-traded and
privately-held healthcare and life science companies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Adrian Rawcliffe</I></B> has served as a director since February 2017. Since September 2019,
Mr.&nbsp;Rawcliffe has served as the Chief Executive Officer and on the board of directors of Adaptimmune Therapeutics plc. (&#147;Adaptimmune&#148;), a publicly traded clinical-stage biopharmaceutical company. Mr.&nbsp;Rawcliffe also serves on the
board of directors of Adaptimmune Ltd., a privately-held company and subsidiary of Adaptimmune. From 2015 to September 2019, he served as Adaptimmune&#146;s Chief Financial Officer. Prior to joining Adaptimmune, Mr.&nbsp;Rawcliffe served in various
roles at GlaxoSmithKline plc, including Senior Vice President Finance, North America Pharmaceuticals and Global Franchises from 2011 to 2015; Senior Vice President, Worldwide Business Development and R&amp;D Finance from 2006 to 2011; Vice
President, Worldwide Business Development Transactions and Ventures from 2003 to 2005; and Vice President, Deal Structuring from 2001 to 2003. From 2005 to 2006, Mr.&nbsp;Rawcliffe served as the President and Managing Partner of SR One Ltd.
Mr.&nbsp;Rawcliffe began his career as a supervisor at Coopers&nbsp;&amp; Lybrand (now PricewaterhouseCoopers) from 1993 to 1997. Mr.&nbsp;Rawcliffe received his B.Sc. in Natural Sciences from the University of Durham, England. Mr.&nbsp;Rawcliffe
also received Chartered Accountancy training through The Institute of Chartered Accountants in England and Wales (ICAEW). We believe he is qualified to serve on our Board because of his global operating and business leadership experience working in
the biopharmaceutical industry, his experience as a board member, board committee member, chief financial officer and chief executive officer of publicly-traded biotechnology companies, and his extensive operating and corporate development
experience working in various roles at one of the world&#146;s largest global healthcare companies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Ken Takanashi</I></B> has served as a director
since July 2012. Since 2002, Mr.&nbsp;Takanashi has served in various executive management and director roles at SNBL and its affiliates and currently serves as its Executive Vice President, Representative Director. Mr.&nbsp;Takanashi was the Chief
Financial Officer of SNBL USA, Ltd., a subsidiary of Shin Nippon Biomedical Laboratories, from 2012 to 2014. Since 2016, Mr.&nbsp;Takanashi has also served on the board of directors of Satsuma Pharmaceuticals, Inc., a biopharmaceutical company that
was previously publicly-traded and became a privately-held company and wholly-owned subsidiary of SNBL on June&nbsp;8, 2023. Mr.&nbsp;Takanashi also serves as a member of the board of directors of TMS Co., Ltd., a
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
biopharmaceutical company listed on the Tokyo Stock Exchange, since March 2022.&nbsp;Mr.&nbsp;Takanashi earned an M.B.A. from the University of Warwick and received his bachelor&#146;s degree
from the University of Tokyo and is a Chartered Public Accountant. We believe he is qualified to serve on our Board because of his extensive experience leading global research and development organizations in the biopharmaceutical industry, his
experience forming, building and taking life sciences companies public, his experience serving as a board member and board committee member of various publicly-traded life sciences companies, his long-standing history with Wave, his close
familiarity with our Japanese operations, and his business, financial and accounting credentials. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Aik Na Tan </I></B>has served as a director since
August 2020<I>.</I><B> </B>Ms.&nbsp;Tan currently serves as Senior Vice-President (Administration) at Nanyang Technological University, Singapore (NTU), a position she has held since January 2020. From when she joined NTU in August 2016 to December
2017, she served as NTU&#146;s Chief Financial Officer. She also served as NTU&#146;s Chief Administrative Officer from April 2017 to December 2017 and as NTU&#146;s Vice-President (Administration) from January 2018 to December 2019. Prior to
joining NTU, Ms.&nbsp;Tan served as Global Finance Transformation Leader&nbsp;&amp; Managing Director of the Chemours Company Singapore Pte Ltd, a <FONT STYLE="white-space:nowrap">spin-off</FONT> from DuPont, from 2015 to 2016. From 1994 to 2015,
Ms.&nbsp;Tan held numerous global and regional leadership roles at DuPont in accounting, corporate treasury, six sigma, financial systems, supply chain, operations, financial and strategic planning, including various positions at DuPont Company
(Singapore) Pte Ltd, most recently serving as the Chief Financial Officer of DuPont Titanium Technologies from November 2011 to February 2015. Ms.&nbsp;Tan began her professional career as a tax assistant at Price Waterhouse. Ms.&nbsp;Tan holds a
Bachelor of Accountancy degree from the Nanyang Technological University, Singapore, and is a member of the Institute of Singapore Chartered Accountants. We believe she is qualified to serve on our Board because of her extensive experience as a
chief financial officer and chief administrative officer, her broad operations experience working in Singapore corporations, her experience working on boards of directors and committees thereof, as well as her business, financial and accounting
credentials. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Gregory L. Verdine, Ph.D.</I></B> is one of our founders and has served as a director since July 2013. He was our President, Chief
Executive Officer and Chief Scientific Officer from our inception through December 2013 and served as Chairman of our Board from July 2013 through September 2017. Since 1989, Dr.&nbsp;Verdine has served as the Erving Professor of Chemistry in the
Department of Stem Cell and Regenerative Biology and the Department of Chemistry and Chemical Biology at Harvard University and Harvard Medical School; he is now Erving Professor of Chemistry, Emeritus. Dr.&nbsp;Verdine <FONT
STYLE="white-space:nowrap">co-founded</FONT> the <FONT STYLE="white-space:nowrap">non-profit</FONT> Gloucester Marine Genomics Institute and Gloucester Biotechnology Academy in 2013 and served as the Founding President until 2016. He is the <FONT
STYLE="white-space:nowrap">co-founder</FONT> of Fog Pharmaceuticals Inc., a privately-held company, and served as President and Chief Executive Officer of the company from October 2015 to June 2023 and Vice Chairman of the Board of Directors from
June 2023 to June 2024. He is also President and Chief Executive Officer and serves on the board of directors of LifeMine Therapeutics Inc., a privately-held company. He is also the founder of Warp Drive Bio (merged with Revolution Medicines, Inc.
(Nasdaq: RVMD)) and served in various roles, from Chief Scientific Officer to Chief Executive Officer, from the company&#146;s inception in 2012 until April 2016. Dr.&nbsp;Verdine founded Enanta Pharmaceuticals and served as a member of its board of
directors from 1990 through its initial public offering in 2013. He has served as a Venture Partner at WuXi Healthcare Ventures, AppleTree Ventures, TPG Biotech and Third Rock Ventures, and he is currently a Venture Partner at Andreessen Horowitz.
He has served on the Board of Scientific Counselors of the National Cancer Institute, and on the Board of Scientific Consultants of the Memorial Sloan Kettering Cancer Center, and was a Senior Advisor to Shin Nippon Biomedical Laboratories Ltd,
Hofmann La Roche, Pfizer and Merck. Dr.&nbsp;Verdine is also a <FONT STYLE="white-space:nowrap">co-founder</FONT> of Eleven Biotherapeutics, Tokai Therapeutics, Aileron Therapeutics, and Gloucester Pharmaceuticals (acquired by Celgene in 2010). He
has also served as a director of the Chemical Biology Initiative and the Program in Cancer Chemical Biology at the Dana-Farber Cancer Institute. Dr.&nbsp;Verdine received his Ph.D. in Chemistry from Columbia University and completed postdoctoral
work in Molecular Biology at the Massachusetts Institute of Technology and Harvard Medical School. We believe he is qualified to serve on our Board because of his expertise and deep knowledge of our technology as one of our <FONT
STYLE="white-space:nowrap">co-founders,</FONT> his vast expertise in new modality therapeutics, including as a <FONT STYLE="white-space:nowrap">co-inventor</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of the core Wave Life Sciences stereochemistry technology and leading expert in the field of stereopure oligonucleotide therapeutics, and his long track record of founding, advising and leading
multiple successful biopharmaceutical companies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Heidi L. Wagner, J.D.</I></B> has served as a director since September 2019. Ms.&nbsp;Wagner
currently serves as Global Head of Government Affairs at ElevateBio, LLC, a privately-held biopharmaceutical company, a position she has held since March 2023. Ms.&nbsp;Wagner also serves as a member of the Board of Directors for the University of
Colorado Foundation. Ms.&nbsp;Wagner served as Senior Vice President, Government Affairs and Policy at Global Blood Therapeutics, Inc., from 2018 through January 2021. Prior to joining Global Blood Therapeutics, Ms.&nbsp;Wagner served as Senior Vice
President, Global Governmental Affairs and a member of the Executive Committee at Alexion Pharmaceuticals, Inc. from 2012 to 2018, and as Vice President, Global Government Affairs from 2009 to 2012. Ms.&nbsp;Wagner held the role of Senior Director
of Government Affairs at Genentech, Inc. from 2000 to 2009, and as Director, Government Affairs from 1998 to 1999. Prior to that time, she served as Health Policy Director and Consultant at Healthcare Leadership Council, and in various roles at
Epstein Becker&nbsp;&amp; Green and Groom&nbsp;&amp; Nordberg, and the U.S. House of Representatives. Ms.&nbsp;Wagner currently serves as a member of the board of directors of the American Kidney Fund, as a Trustee of the University of Colorado
Foundation, and as an advisory board member of the University of Colorado, College of Media, Communication and Information. From 2015 to 2018, she also served as a member of the board of directors of the European Confederation of Pharmaceutical
Entrepreneurs. Ms.&nbsp;Wagner earned a J.D. from George Mason University School of Law and received a Bachelor of Science in Journalism and Mass Communication from the University of Colorado. We believe she is qualified to serve on our Board
because of her enterprise leadership experience and her extensive experience as a government affairs executive driving strategy for government policy, pricing, reimbursement and patient access for various biopharmaceutical companies, including
leading the pricing and reimbursement strategy, and implementing the global compliance programs for leading rare disease biopharmaceutical organizations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Director Independence </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Board believes that
independence is one important component of a high-functioning board capable of objective decision-making that represents the long-term interests of our shareholders and the Company. Since our initial public offering in 2015, our Board has enhanced
its independence by replacing two previous directors &#151; a founder and a representative of an investor &#151; with five directors who are independent and not affiliated with any of our principal shareholders. We further enhanced our Board&#146;s
independent leadership by appointing Christian Henry as our independent Chair. Our Board is committed to ensuring that its members reflect an appropriate level of independence in conjunction with the combination of qualifications, qualities and
skills required to exercise its duties and responsibilities and serve the best interests of the Company and our shareholders. In accordance with our Corporate Governance Guidelines and Nasdaq rules, we hold executive sessions of our independent
directors in conjunction with our regularly scheduled board meetings and otherwise as appropriate. In addition, our Compensation Committee meets in executive session with no members of management present, as necessary or appropriate, to address
various compensation matters, including deliberations regarding our Chief Executive Officer&#146;s performance and compensation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Board has reviewed
the materiality of any relationship that each of our directors has with the Company, either directly or indirectly. Based upon this review, our Board has determined that the following members of the Board are &#147;independent directors&#148; as
defined by the Nasdaq Stock Market: Mses. Tan and Wagner, Drs. Kolchinsky and Corrigan, and Messrs. Henry, Rawcliffe and Takanashi. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Board believes
that our directors should limit the number of other public company boards on which they serve so that they are able to devote adequate time to their duties to Wave, including preparing for and attending our board meetings. Our Corporate Governance
Guidelines indicate that our directors should advise the Chair of the Board and the Chair of the Nominating and Corporate Governance Committee before accepting an invitation to serve on other publicly-traded company boards, and that any such service
shall comply with our conflict of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
interest policies. Our Nominating and Corporate Governance Committee has reviewed our directors&#146; current commitments and determined that such commitments are consistent with our guidelines.
Our Corporate Governance Guidelines are publicly available on our website at http://ir.wavelifesciences.com/ under the heading &#147;Corporate Governance.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Committees of the Board of Directors and Meetings </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Meeting Attendance </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the fiscal year ended
December&nbsp;31, 2023, our Board held five meetings, and the various committees of the Board met a total of 17 times. No director attended fewer than 75% of the total number of meetings of the Board and of committees of the Board on which such
director served during 2023. The Board has adopted a policy under which our directors make reasonable efforts to attend our annual general meetings of shareholders. As a Singapore company, we are required to prepare annual Singapore statutory
audited financial statements (our &#147;second annual audit&#148;) and to deliver them to our shareholders in connection with our annual general meetings of shareholders. Our second annual audit can only be conducted following our first annual
audit, which requires our preparation and filing of annual U.S. generally accepted accounting principles (GAAP) audited consolidated financial statements with the SEC. As a result, these multiple audits do not allow us to schedule our quarterly
board meetings at the same time as our annual general meetings of shareholders and we typically hold our annual general meetings during the summertime. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Audit Committee </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Audit Committee held seven
meetings during the fiscal year ended December&nbsp;31, 2023. Our Audit Committee currently has four members: Mr.&nbsp;Rawcliffe (Chair), Dr.&nbsp;Corrigan, Mr.&nbsp;Henry, and Ms.&nbsp;Tan. Our Audit Committee&#146;s role and responsibilities are
set forth in the Audit Committee&#146;s written charter and include the responsibility to retain and terminate the services of our independent registered public accounting firm. In addition, the Audit Committee&#146;s enumerated role and
responsibilities include the review of annual financial statements and oversight of data privacy and cybersecurity matters, consideration of matters relating to accounting policy and internal controls, and review of the scope of annual audits. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Corrigan, Messrs. Henry and Rawcliffe, and Ms.&nbsp;Tan satisfy the current independence standards promulgated by the SEC and by the Nasdaq Stock
Market, as such standards apply specifically to members of audit committees. The Board has determined that each member of the Audit Committee meets the financial literacy requirements of the Nasdaq Stock Market Rules and that each of
Messrs.&nbsp;Henry and Rawcliffe and Ms.&nbsp;Tan qualifies as an &#147;audit committee financial expert,&#148; as the SEC has defined that term in Item&nbsp;407 of <FONT STYLE="white-space:nowrap">Regulation&nbsp;S-K.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Audit Committee&#146;s written charter is publicly available on our website at www.wavelifesciences.com. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Compensation Committee </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Compensation Committee
met four times during the fiscal year ended December&nbsp;31, 2023. The Compensation Committee currently has three members: Mr.&nbsp;Henry (Chair), Mr.&nbsp;Rawcliffe, and Ms.&nbsp;Wagner. Our Compensation Committee&#146;s role and responsibilities
are set forth in the Compensation Committee&#146;s written charter and include reviewing, approving and making recommendations regarding our compensation policies, practices and procedures to ensure that legal and fiduciary responsibilities of the
Board are carried out and that such policies, practices and procedures contribute to our success. Our Compensation Committee also administers our 2021 Equity Incentive Plan, as amended (the &#147;2021 Plan&#148;), our 2014 Equity Incentive Plan, as
amended (the &#147;2014 Plan&#148;), and our 2019 Employee Share Purchase Plan (the &#147;2019 ESPP&#148;). The Compensation Committee is responsible for determining the compensation of our executive officers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each member of the Compensation Committee qualifies as independent under the definition promulgated by the Nasdaq Stock Market. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Compensation Committee&#146;s written charter is publicly available on our website at
www.wavelifesciences.com. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Nominating and Corporate Governance Committee </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Nominating and Corporate Governance Committee met two times during the fiscal year ended December&nbsp;31, 2023. The Nominating and Corporate Governance
Committee currently has three members: Ms.&nbsp;Wagner (Chair), Mr.&nbsp;Takanashi and Dr.&nbsp;Corrigan. The Nominating and Corporate Governance Committee&#146;s role and responsibilities are set forth in the Nominating and Corporate Governance
Committee&#146;s written charter and include evaluating and making recommendations to the full Board as to the size and composition of the Board and its committees, evaluating and making recommendations as to potential candidates, evaluating current
Board members&#146; performance, overseeing our environmental, social and governance (&#147;ESG&#148;) strategy, initiatives and policies and overseeing our practices related to human capital management and diversity, equity and inclusion
(&#147;DEI&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each member of the Nominating and Corporate Governance Committee qualifies as independent under the definition promulgated by the
Nasdaq Stock Market. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Nominating and Corporate Governance Committee is responsible for identifying individuals qualified to serve as directors on our
Board, consistent with criteria approved by the Board, and recommending the persons to be nominated for election as directors, except where we are legally required by contract, law or otherwise to provide third parties with the right to nominate.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The process followed by the Nominating and Corporate Governance Committee to identify and evaluate director candidates includes making requests to Board
members and others for recommendations, holding meetings from time to time to evaluate biographical information and reviewing background material relating to potential candidates and interviews of selected candidates by members of the committee and
the Board. The Nominating and Corporate Governance Committee is also authorized by its charter to retain search firms to identify director candidates. The qualifications, qualities and skills that the committee believes must be met by a
committee-recommended nominee for a position on our Board are as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Nominees should have a reputation for integrity, honesty and adherence to high ethical standards.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Nominees should have demonstrated business acumen, experience and ability to exercise sound judgments in matters
that relate to our current and long-term objectives and should be willing and able to contribute positively to our decision-making process. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Nominees should have a commitment to understand Wave and our industry and to regularly attend and participate in
meetings of the Board and its committees. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Nominees should have the interest and ability to understand the sometimes conflicting interests of our various
constituencies, which include shareholders, employees, customers, governmental units, creditors and the general public, and to act in the interests of all shareholders. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Nominees should not have, nor appear to have, a conflict of interest that would impair the nominee&#146;s ability
to represent the interests of all of our shareholders and to fulfill the responsibilities of a director. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Nominees shall not be discriminated against on the basis of race, religion, national origin, sex, sexual
orientation, disability or any other basis proscribed by law. Diversity on our Board is highly valued and is actively considered in the nomination process as well as in the Board&#146;s annual performance evaluation. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Nominees should generally be able to serve for at least five years before reaching the age of 70.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Nominating and Corporate Governance Committee considers issues of diversity among its members in identifying and considering
nominees for director, and strives where appropriate to achieve a diverse balance of backgrounds, perspectives, experience, age, gender, ethnicity and country of citizenship on the Board and its </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
committees. The value of many forms of diversity is reflected on our Board, and we believe that our current Board represents diversity of thought, background and experience, as well as diversity
of personal characteristics such as gender, ethnicity and age. The Board and management seek out highly qualified women and minority candidates, as well as candidates with diverse backgrounds, skills and experiences as part of each search they
conduct for qualified directors and executive officers, respectively. Our Board currently includes two directors who identify as women and two directors who identify as racially diverse. The Nominating and Corporate Governance Committee&#146;s
written charter and our Corporate Governance Guidelines, which set forth our nominee requirements, are publicly available on our website at www.wavelifesciences.com. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Research and Development Committee </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Research
and Development Committee met four times during the fiscal year ended December&nbsp;31, 2023. The Research and Development Committee currently has three members: Drs. Corrigan (Chair), Kolchinsky and Verdine. Our Research and Development
Committee&#146;s role and responsibilities are set forth in the Research and Development Committee&#146;s written charter and generally include assisting us in evaluating research, development and technology (&#147;R&amp;D&#148;) issues and
decisions; reviewing and providing feedback to our R&amp;D management on our current and planned R&amp;D programs and initiatives; serving as a sounding board for our R&amp;D organization on research and development matters; and identifying and
discussing with the Board significant emerging scientific and clinical issues and trends. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Board Diversity Matrix </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following Board Diversity Matrix presents our Board diversity statistics in accordance with Nasdaq Rule&nbsp;5606, as self-disclosed by our directors.
While the Board satisfies the minimum objectives of Nasdaq Rule&nbsp;5605(f)(2) by having at least one director who identifies as female and at least one director who identifies as a member of an Underrepresented Minority (as defined by Nasdaq
Rules), the Nominating and Corporate Governance Committee will continue to consider the diversity of our Board in its selection of director nominees<I>.</I> </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" COLSPAN="8" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Board Diversity Matrix (As of June&nbsp;5,
2024)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" COLSPAN="8" NOWRAP STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Total Number of Directors</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" COLSPAN="8" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>9</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD ???? 1 VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Female</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Male</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Gender:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Directors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Number of Directors Who Identify in Any of the Categories Below:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Asian</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">White</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We prioritize opportunities for the appointment of qualified candidates to increase diversity on our Board. Since 2019, our
Board began and continues to seek and evaluate directors who satisfy Nasdaq and SEC independence requirements and increase diversity, including with respect to gender, racial and ethnic diversity, among our directors. Our efforts have resulted in
increasing gender diversity on our Board with the addition of Mses. Tan and Wagner, who have served on our Board since August 2020 and September 2019, respectively, each of whom brings significant leadership expertise to our Board. Importantly,
Ms.&nbsp;Wagner also serves as Chair of our Nominating and Corporate Governance Committee. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Procedures by which Shareholders may Nominate Directors
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Nominating and Corporate Governance Committee shall review and evaluate information available to it regarding candidates proposed by shareholders
and shall apply the same criteria, and shall follow substantially the same process in considering them, as it does in considering other candidates. The factors generally considered </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
by the Nominating and Corporate Governance Committee are set out in our Corporate Governance Guidelines, which are publicly available on our website at http://ir.wavelifesciences.com/ under the
heading &#147;Corporate Governance.&#148; If a shareholder wishes to nominate a candidate to be considered by the Nominating and Corporate Governance Committee for election as a director at our 2025 Annual General Meeting of Shareholders, it must
give timely notice of the nomination in writing to our General Counsel not less than 45 days prior to the date that is one year following the date on which we first mail our proxy statement relating to our 2024 AGM. All shareholder proposals should
be marked for the attention of General Counsel, Wave Life Sciences Ltd., 733&nbsp;Concord Avenue, Cambridge, MA 02138. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Familial Relationships </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There are no familial relationships between any of our executive officers and directors. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Board Leadership Structure and Role in Risk Oversight </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The positions of Chair of the Board and Chief Executive Officer of Wave are presently separate. We believe that separating these positions allows our Chief
Executive Officer to focus on our <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> business operations and strategy, while allowing our Chair of the Board to lead the Board in its fundamental role of
providing advice to, and independent oversight of, management. Our Board recognizes the time, effort and energy that the Chief Executive Officer is required to devote to their position in the current business environment, as well as the commitment
required to serve as our Chair, particularly as the Board&#146;s oversight responsibilities continue to grow. Our Board also believes that this structure ensures a greater role for the independent directors in the oversight of Wave and active
participation of the independent directors in setting agendas and establishing priorities and procedures for the work of our Board. The Board retains the authority to modify this leadership structure as and when appropriate to best address our
unique circumstances at any given time and to serve the best interests of our shareholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Board oversees the risk management activities designed
and implemented by our management and considers specific risks, including, for example, risks associated with our strategic plan, business operations, and capital structure. Our Board executes its oversight responsibility for risk management both
directly and through delegating oversight of certain of these risks to its committees. The committees oversee and regularly report to our Board with respect to the risks delegated to them or when a matter rises to the level of a material or
enterprise level risk. In addition, our Board receives regular reports from members of our management team and other personnel that include assessments and potential mitigation of the risks and exposures involved with their respective areas of
responsibility. Some examples of these risks include matters relating to our operations, research and development efforts, clinical trials, manufacturing capabilities, financial position and liquidity, and our communications strategy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Board delegates to the Audit Committee oversight of certain aspects of our risk management process. Specifically, the Audit Committee receives regular
reports from members of senior management on areas of material risk to us, including operational, financial, legal, regulatory, strategic and reputational risks, and risks related to IT, data privacy and cyber security. Our Compensation Committee
assists the Board in fulfilling its oversight responsibilities with respect to the management of risks arising from our executive compensation policies, practices and goal setting, including whether such policies balance risk and reward
appropriately, align with shareholder interests, and are consistent with best practices. Our Nominating and Corporate Governance Committee assists the Board in fulfilling its oversight responsibilities with respect to the management of risks
associated with Board organization, membership and structure, succession planning for our directors and executive officers, corporate governance and human capital practices. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Environmental, Social and Governance Practices </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As we
continue our work to build a world-class organization unlocking the broad potential of RNA medicines to transform human health, we remain focused on our environmental, social and governance (&#147;ESG&#148;) practices and
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
identifying risks related thereto. We are committed to strengthening our initiatives that support our employees&#146; success, patient advocacy and community outreach efforts, best practices for
corporate governance, and implementing environmental sustainability initiatives. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Environmental Stewardship:</B> We recognize the importance of taking
measures to reduce our environmental footprint and to be good corporate citizens. As we continue to expand our operations, we have implemented certain projects to track our environmental impact, and where feasible, have taken measures to increase
our sustainability efforts. Some of our efforts include our commitment to reduce, reuse or recycle where possible and appropriate; energy efficient projects to lower energy use within our office areas and laboratories; composting in our Lexington
facility, and having processes in place that send over 95% of hazardous waste to an energy conversion center. Our Green Team, a cross-functional group of employees, is actively working to build awareness of environmental concerns and create
opportunities for employees to participate in environmentally-focused initiatives, including educational and volunteer events. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Social Factors and
Supporting Our Workforce:</B> Our approach to how we recruit, develop, retain and manage our talent is driven by our values statement: Making an impact through innovation, inclusion, and inspiration. Our values are at the core of who we are as an
organization, and what drive us to reimagine possible for science, for medicine, and for human health. Critical to achieving our strategic imperatives is our ability to build and retain an exceptional team in which each member plays a unique and
important role. We were recently recognized by the Boston Business Journal and won the distinction of being one of the 2024 &#147;Best Places to Work&#148;, which underscores our employees&#146; recognition of our collective focus, resilience, and
commitment to our mission. We also value DEI and social responsibility, with the goal of fostering a strong sense of belonging and contributing, while being empowered to make a real difference. This commitment is company-wide. Our Nominating and
Corporate Governance Committee oversees our strategies and policies related to our people and DEI initiatives, in addition to those for our ESG initiatives. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We recognize that maintaining an engaged and high-performing workforce who share a connection with the communities we serve is critical to our success.
Comradery and cohesion are key to our collective corporate identity, and are integral facets of our human capital strategy. Whether it is coming together throughout the year to connect at our town halls or participating in local walks for the
patient communities for whom we work, we take a team and human connections-based approach to our work. We are inspired by the communities we serve, the opportunities to engage and learn from individuals and their families, and the possibilities of
what we can achieve together. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We understand that in order to drive innovation, we must continuously improve our people strategies and find ways to foster
engagement and growth within our organization. To this end, below are some of our initiatives: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Employee Engagement</U>: Having an engaged and
dedicated workforce is essential for us to achieve our goals. It is also more apparent than ever that we set our employees up for success and continue to cultivate their engagement with Wave. We conduct surveys as a means of engaging with employees
and gaining their insights. We use the data and input as a tool for improving our human resources management going forward. Engagement is also directly correlated to the interactions our employees have with each other and their teams. We also have a
cross-functional team dedicated to organizing activities, such as themed social gatherings, charity and volunteer opportunities, and health and wellness events, which enrich our culture and bring employees together. We also work to ensure that we
are deeply aligned with our corporate goals as a company, that functional goals are clear and transparent, and that employees understand how their work contributes to the company&#146;s success. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Professional Development Programs and Opportunities</U>: Employees are our most valuable resource, and we focus on providing them with opportunities so
that they can continue to grow and excel in their functions and our company. Professional development of our employees drives engagement and allows us to leverage opportunities to grow and promote key talent from within our organization. We
encourage individual development planning and leadership and management development programs for our employees, including our Building Coaching </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Leaders program that is a learning series designed to build strong coaching capabilities and strengthen a manager&#146;s engagement with their teams, and our Management Essentials Program that is
focused on building the leadership skillset of first-time managers and rising leaders. Through development planning, we strive for employees at all levels to focus on strengthening the skills required in their current role and potentially their next
role. We conduct annual performance reviews for all employees, but, as importantly, we are focused on building a culture of continuous coaching, feedback and open communication between managers and their direct reports throughout the entire year. We
provide managers and employees with training on how to conduct effective forward-looking performance conversations and to set effective goals that are specific, measurable, attainable, relevant and timebound (SMART). We provide our employees with
unlimited access to LinkedIn Learning to advance their professional development, interests, and goals. We also provide company-wide leadership and development opportunities through the Wave Learning Series, which was developed to build awareness of
all functional areas, special areas of interest or importance, timely subject matters and to expand knowledge of industry trends and other matters of interest and relevance within the biopharmaceutical industry. The Wave Learning Series is conducted
through company-wide presentations by employees at various levels, providing opportunities for development and cross-functional exposure for our employees. We also offer all full-time employees the option to participate in our Education Assistance
Program, where we reimburse employees for tuition and eligible expenses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Environmental Health and Safety</U>: Compliance with environmental, health
and safety (&#147;EH&amp;S&#148;) laws and regulations forms the basis of the EH&amp;S policy and programs we have in place, which include occupational health and safety measures that apply to all of our employees, contractors and visitors. These
programs detail the proactive, risk-based approach that we take to prevent workplace injuries and protect the health and safety of our employees and the communities around us. In addition, we engage independent third parties to regularly evaluate
and audit our compliance with EH&amp;S laws and regulations. We foster a culture that strives to embed safety into all aspects of our operations, which includes implementing design safeguards for our employees and patients. Our EH&amp;S management
system engages all levels of the organization to monitor and track the effectiveness of our programs, ensure EH&amp;S compliance, respond to incidents and manage corrective actions to reinforce safeguards. Our training programs provide training to
our employees that is commensurate with their level of risk exposure and are designed to ensure that employees have the knowledge and equipment available to mitigate risk. Our cross-functional Safety Committee meets monthly to discuss any concerns
and ways to improve our EH&amp;S programs. Employees are also required to report any incidents, no matter how small, and are encouraged to voice any health or safety concerns to management or a member of our EH&amp;S team. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Health and Well-Being</U>: We believe that the overall well-being of our employees and ensuring that their basic health and wellness needs are met is
fundamental for us to achieve success as a company. We understand that a key part of our ongoing efforts to prioritize wellness initiatives includes providing our employees with access to mental health, behavioral health, and/or substance abuse
services through our medical plans. We provide an Employee Assistance Program as a cost-free benefit, which is available to help employees and their household members to confidentially manage everyday life, arising work challenges, stress, and other
personal issues, by providing consultation, referrals, and resources, along with ongoing webinars on various work-life, mental health, and wellness topics for employees. We prioritize providing mental health resources for our employees, while
creating forums for dialogue. In addition, we understand that workplace flexibility is an important component to our employees&#146; well-being. Prioritizing employee safety while achieving our goals has provided us with a greater appreciation for
workplace flexibility, which keeps our employees engaged and motivated, while also creating a sense of trust throughout our organization. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Diversity,
Equity and Inclusion (&#147;DEI&#148;)</U>: Our commitment to maintaining a <FONT STYLE="white-space:nowrap">top-performing</FONT> company means investing in and creating ongoing opportunities for employee development in a diverse and inclusive
workplace. We believe that a diverse and inclusive workforce positively impacts our performance, fosters innovation and inspires us to achieve greater results. We provide equal employment opportunities without regard to race, color, religion,
gender, sexual orientation, national origin, age, disability, veteran status or genetics, among other personal characteristics. Our DEI Steering Group leads various initiatives to help us maintain a diverse,
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
equitable, culturally competent and supportive environment for all of our employees and other stakeholders. In addition to this, our intentional focus on DEI helps ensure that we continue to
cultivate the next generation of experienced, diverse leaders and managers necessary to execute on our mission and plans for ambitious growth. As of December&nbsp;31, 2023, women made up approximately 53% of our global workforce and constitute
approximately 55% of senior management (defined as vice president level and above). As of December&nbsp;31, 2023, racially diverse employees (those self-identifying as Black or African American, Hispanic or Latino, Asian, or being of two or more
races) make up approximately 37% of our global workforce and approximately 24% of senior management (defined as vice president level and above) (14% of our employees did not provide us with this information). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Some of the DEI initiatives at Wave include <FONT STYLE="white-space:nowrap">DEI-focused</FONT> training, educational and awareness building events, social
hours celebrating various cultural themes, and our summer internship program with Project Onramp, which is an organization working to bridge the opportunity gap for Massachusetts-based college students in under-served and minority communities.
Additionally, we encourage the formation of Employee Resource Groups and currently have three &#150; Women+ of Wave, Black Employee Network, and LGBTQIA+ &#150; with more likely to be added. We also have a supplier diversity program that identifies
and classifies our suppliers, encouraging the use of a more diversified supply base. We believe that having a diverse group of suppliers will allow us to effectively meet the needs of our organization while expanding our pool of suppliers to create
more competitive business opportunities, and ultimately creating positive social impact by generating economic opportunities for those in our community who may be disadvantaged. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Patient Advocacy and Community Engagement</U>: Our community engagement activities are focused on seeking to better understand the lived experience of
people impacted by rare and prevalent diseases and identifying opportunities to support these communities. We believe that listening to, learning from, and partnering with individuals impacted by the diseases we hope to address, including families
and caregivers, connects us more deeply to our mission and enhances our ability to discover and develop meaningful therapies. Through collaboration with patient communities and advocacy organizations, including participation in community-focused
conferences and events, we aim to incorporate community voices and perspectives into every aspect of our work. Insights from the community inform the design and execution of our clinical trials, shape our corporate culture, and drive activities and
initiatives that are intended to make a positive impact on people&#146;s lives. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Employee volunteering is another important component of our community
engagement initiatives. We partner with advocacy and service organizations to provide opportunities for employees to contribute directly to our local communities, including through our Wave Service Day and holiday giving drives. By participating in
a broad range of volunteer activities, our employees donate time and resources to support individuals and families in our community and beyond. We also recognize that external factors and current events, including systems and policies, impact our
employees, as well as the communities with which we are connected. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Rewards and Recognition</U>: We have a multi-tiered awards program, including <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">peer-to-peer</FONT></FONT> recognition, which our employees use to recognize and reward one another for their contributions and achievements, taking into consideration the combination of
employees who best exemplify our values and the achievement of results. We believe that providing a rewards program not only increases engagement and performance, but meaningfully recognizes those employees who go above and beyond to positively
impact our company and culture. In addition, we offer a team rewards and recognition program to provide another opportunity to recognize and reward collaborative teamwork. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Compensation, Equity and Benefits (Total Rewards)</U>: Compensation programs are one of the most powerful tools available to companies to attract, retain
and motivate employees, as well as align their interests with those of shareholders. We have developed a broad-based compensation program that is designed to attract, retain and motivate our employees, while driving sustainable long-term value
creation. We seek to deliver performance-driven, market competitive reward opportunities commensurate with company and individual performance. All of our employees receive competitive base salaries, cash bonus eligibility, new hire equity grants and
annual </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
long-term incentive grants eligibility, in addition to our comprehensive benefits package. We believe that providing employees with an ownership interest in Wave through grants of equity awards
further strengthens the level of employee engagement. In addition, our 2019 ESPP provides our U.S. employees with an opportunity to purchase our ordinary shares at a 15% discount to the market price. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Offering a highly competitive, industry-leading benefits package is another integral piece of our total rewards package and differentiated employee value
proposition. Notably, we provide our employees with access to choice and offer employees a very progressive health insurance package, with no premiums. We also offer a 401(k) plan with matching contributions for all eligible employees. We provide
innovative solutions that are key to attracting, engaging and motivating employees, including (i)&nbsp;our excellent benefits and compensation programs and strategies; (ii)&nbsp;our employee well-being approach and strategy; (iii)&nbsp;our health
plan; and (iv)&nbsp;internal communications and education around our total rewards strategy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Cybersecurity and Data Protection</U>: As an
organization, we understand that we share a collective stake in protecting our company against cybersecurity threats and breaches. Robust data protection practices, including responsible stewardship of our intellectual property and the secure
processing, storage, maintenance and transmission of critical information by us and other third parties with whom we do business is vital to our operations and business strategy. Accordingly, we take preventative measures to safeguard our employees
and sensitive business information, and have measures in place that are designed to detect and respond to any potential security incidents or breaches of privacy. Throughout the year, we conduct security training programs and training modules for
our employees. We also have systems in place at our facilities to mitigate disruptions to our network and communications systems. To further strengthen our data protection practices, we regularly conduct business continuity and disaster recovery
testing. For additional information, please refer to Item 1C of our 2023 Form <FONT STYLE="white-space:nowrap">10-K.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Governance, Ethics, and
Compliance</B>: Our Board is committed to robust corporate governance practices, risk oversight, shareholder rights, diversity, equity and inclusion, corporate sustainability, ethics and compliance in order to protect the long-term interests of our
Company, employees, shareholders and the patients we serve. Our Board adheres to our Corporate Governance Guidelines, which present a framework for good corporate governance practices, including responsible oversight and management of the Company,
effective controls and processes, compliance with SEC and Nasdaq Stock Market rules and regulations, maintaining an engaged board of directors and a board structure that recognizes the importance of diversity, appropriate compensation practices, and
succession planning, among other matters. In addition, our Code of Business Conduct and Ethics sets forth channels through which employees may anonymously report suspected violations and express concerns regarding compliance with our Code of
Business Conduct and Ethics or other policies of the Company. Any supervisor that receives such a report is required to immediately inform the Chair of our Audit Committee, our Chief Executive Officer or our Chief Financial Officer. A copy of the
Corporate Governance Guidelines and our Code of Business Conduct and Ethics is publicly available on our website at www.wavelifesciences.com. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will
continue to evolve and strengthen our human capital strategies, increase our environmental efforts, maintain and continue to improve our corporate governance practices, and anticipate reporting on other corporate sustainability measures over time.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Hedging and Pledging Policies </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We maintain a policy
that, among other things, prohibits all officers, including our executive officers, directors and employees from engaging in &#147;hedging&#148; transactions with respect to our ordinary shares. This includes short sales, hedging of share ownership
positions, transactions in straddles, collars or other similar risk reduction or hedging devices, and transactions involving derivative securities relating to our ordinary shares. In addition, they are also prohibited from pledging our securities.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Clawback Policy </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On October&nbsp;2, 2023, our Board adopted a Clawback Policy to comply with the new clawback rules and listing standards promulgated by the SEC and Nasdaq
Stock Market, respectively. The Clawback Policy generally provides that we will seek to recover, in the event of a required accounting restatement, excess incentive compensation received by covered officers where that compensation is based on
erroneously reported financial information, regardless of fault or misconduct. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Shareholder Communications to the Board </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Generally, shareholders who have questions or concerns or who wish to address questions regarding our business directly with the Board, or any individual
director, should direct their questions in writing to InvestorRelations@wavelifesci.com. Communications will be distributed to the Board, or to any individual director or directors as appropriate, depending on the facts and circumstances outlined in
the communications. Items that are unrelated to the duties and responsibilities of the Board may be excluded, such as junk mail and mass mailings, resumes and other forms of job inquiries, surveys and solicitations or advertisements. In addition,
any material that is unduly hostile, threatening, or illegal in nature may be excluded, provided that any communication that is filtered out will be made available to any outside director upon request. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Executive Officers </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Set forth below is information as of
June&nbsp;5, 2024 regarding our executive officers who are not also directors. We have employment agreements with our executive officers and all of our executive officers are <FONT STYLE="white-space:nowrap">at-will</FONT> employees. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="31%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="63%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Age</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Title</B></P></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Christopher Francis, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">46</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Senior Vice President, Corporate Development, Head of Emerging Areas</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kyle Moran, CFA</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">54</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Chief Financial Officer</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chandra Vargeese, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">63</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Chief Technology Officer, Head of Platform Discovery Sciences</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Christopher Francis, Ph.D.</I></B> has served as our Senior Vice President, Corporate Development, Head of Emerging
Areas since May 2017. During the period January 2017 to May 2017, Dr.&nbsp;Francis served as our Senior Vice President, Corporate Development&nbsp;&amp; Portfolio Management. Prior to that, Dr.&nbsp;Francis served as our Vice President, Head of
Business Development since April 2014. Prior to joining us, Dr.&nbsp;Francis held senior operational, strategic and business development roles within GlaxoSmithKline Oncology from 2009 to 2014 and was a member of the team that established
GlaxoSmithKline&#146;s Rare Disease Unit. Before GlaxoSmithKline, Dr.&nbsp;Francis was a health care private equity associate at Two River LLC from 2008 to 2009. He began his career in pharmaceutical pricing and reimbursement consulting at IMS
Health. Dr.&nbsp;Francis earned undergraduate and graduate degrees in Biochemistry and Molecular Biology from the University of Melbourne and was a doctoral research associate at the University of Cambridge. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Kyle Moran, CFA</I></B> has served as our Chief Financial Officer since December 2020. Prior to this appointment, Mr.&nbsp;Moran served as our Vice
President, Head of Finance from July 2014 to August 2016; Vice President, Technical Operations from August 2016 to December 2017; Senior Vice President, Technical Operations, from December 2017 to November 2018; Senior Vice President, Operations and
Business Analytics from November 2018 to January 2020; and most recently as Senior Vice President, Finance and Operations from January 2020 through his promotion to Chief Financial Officer in December 2020. Prior to joining us, Mr.&nbsp;Moran served
as Chief Financial Officer and Chief Operating Officer of Veroha, Inc., an information assurance software company focused on electronic notary solutions, from 2010 to 2014. He was also a founding partner of Context Financial Services, LLC, a
boutique consulting firm that provided interim <FONT STYLE="white-space:nowrap">CFO-services</FONT> to <FONT STYLE="white-space:nowrap">start-up</FONT> and middle market companies undergoing rapid expansion or needing expert financial counsel and
worked there from 2006 to 2014. In addition, Mr.&nbsp;Moran held senior operational and financial roles at leading global financial services firms, including Zurich Scudder Investments, JPMorgan Chase and Putnam Investments. Mr.&nbsp;Moran holds a
bachelor&#146;s </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
degree in Economics from Boston College and attended the Lemberg Master&#146;s Program in International Economics and Finance at Brandeis University. Mr.&nbsp;Moran is a Chartered Financial
Analyst. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Chandra Vargeese, Ph.D.</I></B> has served as our Chief Technology Officer, Head of Platform Discovery Sciences since May 2020. During the
period of August 2014 to April 2020, Dr.&nbsp;Vargeese served as Senior Vice President, Head of Drug Discovery. Before joining us, Dr.&nbsp;Vargeese served as Novartis&#146; Executive Director and Head of RNA Chemistry and Delivery, a position she
held from 2008 to 2014. Prior to joining Novartis, Dr.&nbsp;Vargeese led siRNA delivery in the RNA Therapeutics division at Merck&nbsp;&amp; Co., where she served as Senior Director and Head of RNA Chemistry and Delivery. Dr.&nbsp;Vargeese joined
Merck through its acquisition of Sirna Therapeutics (&#147;Sirna&#148;), where she was Vice President of Chemistry. Before Sirna, Dr.&nbsp;Vargeese served as Associate Director of Chemistry at NeXstar Pharmaceuticals and is the <FONT
STYLE="white-space:nowrap">co-inventor</FONT> of Macugen (pegaptanib), an approved therapy for treating wet <FONT STYLE="white-space:nowrap">Age-Related</FONT> Macular Degeneration (AMD). Dr.&nbsp;Vargeese earned a Ph.D. in Organic Chemistry at the
Indian Institute of Science, Bangalore, India and completed post-doctoral work at the University of Rhode Island. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom802241_5"></A>EXECUTIVE OFFICER AND DIRECTOR COMPENSATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Executive Officer Compensation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are a &#147;smaller
reporting company&#148; under Item 10 of Regulation <FONT STYLE="white-space:nowrap">S-K</FONT> promulgated under the Exchange Act, and the following compensation disclosure is intended to comply with the requirements applicable to smaller reporting
companies. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Summary Compensation Table </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following
table shows the total compensation paid or accrued during the last two fiscal years ended December&nbsp;31, 2023 and 2022 for (i)&nbsp;our President and Chief Executive Officer, and (ii)&nbsp;our two next most highly compensated executive officers,
who earned more than $100,000 during the fiscal year ended December&nbsp;31, 2023 and were serving as executive officers as of such date. Collectively, these three individuals are our named executive officers (&#147;NEOs&#148;) for purposes of this
proxy statement. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="52%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Name and Principal Position</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Salary<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Awards<BR>($)<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">Non-Equity</FONT><BR>Incentive&nbsp;Plan<BR>Compensation<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>All Other<BR>Compensation<BR>($)<SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total&nbsp;($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Paul&nbsp;B.&nbsp;Bolno,&nbsp;M.D., MBA</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2023</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">636,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,744,529</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">475,700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17,671</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,874,300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>President and Chief Executive Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2022</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">617,900</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,565,220</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">461,900</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22,977</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,667,997</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chandra Vargeese, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2023</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">473,340</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,051,535</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">245,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13,464</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,783,339</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Chief Technology Officer, Head of Platform Discovery Sciences</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">2022</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">459,540</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">521,740</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">237,800</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">12,714</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">1,231,794</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kyle Moran, CFA</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2023</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">471,300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">970,730</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">243,900</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,142</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,697,072</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Chief Financial Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2022</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">439,875</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">470,923</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">227,600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,392</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,148,790</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Amounts represent the aggregate grant date fair value for the option awards identified, computed in accordance
with FASB ASC Topic 718. A discussion of the assumptions used in determining grant date fair value may be found in Note 7 to the financial statements included in our 2023 Form <FONT STYLE="white-space:nowrap">10-K.</FONT> </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">For 2023, the amounts include 401(k) matching contributions of $9,900 made to each of Drs. Bolno and Vargeese
and Mr.&nbsp;Moran, as well as the value of annual premiums paid by us with respect to a life insurance policy for the benefit of each of the NEOs. For 2023, the amount for Dr.&nbsp;Bolno also includes reimbursement of commuting expenses of $5,606
and the related tax gross up of $1,355. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Narrative to Summary Compensation Table </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Compensation Committee creates the policies that govern base salary, annual cash performance-based incentives, our long-term incentive program and other
compensation and benefits for our NEOs. Our Compensation Committee reviews and discusses our executive officers&#146; proposed compensation with the Chief Executive Officer for all executives other than the Chief Executive Officer. The Chief
Executive Officer&#146;s compensation is determined solely by the Compensation Committee without the Chief Executive Officer present for the discussions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In determining executive officer compensation, our Compensation Committee, with the assistance of its independent compensation consultant, Aon&#146;s Human
Capital Solutions practice, a division of Aon plc (formerly known as Radford) and an independent executive compensation consulting firm, evaluates the market competitiveness of compensation for each of our NEOs in order to guide target compensation
decisions for the coming year. Our Compensation Committee references a peer group of publicly-traded companies in the biopharmaceutical industry for purposes of gathering data to compare with our existing executive compensation levels and practices
and as context for future compensation decisions. Our Compensation Committee reviews and updates the compensation peer group each year, as appropriate, to include companies that the Compensation Committee believes are competitors for executive
talent and that are similar to us in terms of their stage of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
development, therapeutic focus, market capitalization, number of employees, structure, financial profile and geographic proximity to the Cambridge biotech cluster, as applicable. We also
recognize that it is unlikely for companies to align equally on all factors, so we consider companies that meet a majority of the criteria. Due to the nature of our business, we compete for executive talent with many companies much larger than we
are. Our Compensation Committee considers peer group and other industry compensation data and the recommendations of our compensation consultant when making decisions related to executive compensation, ultimately giving consideration to the
competitiveness of our compensation program, internal perceptions of equity and individual performance and role. Our Compensation Committee finds comparative data from our peer group to be useful in setting and adjusting executive compensation, but
it does not target our programs or any particular element of compensation to be at or within a particular percentile or range compared to our peers. Our Compensation Committee uses the peer group data primarily to ensure that our executive
compensation program and its constituent elements are and remain competitive in relation to our peers, and applies judgment and discretion in establishing targeted compensation levels taking into account not only competitive market data but also the
experience of the executive, scope of responsibility, critical skill sets and expertise. Our Compensation Committee retains flexibility to structure compensation based on good governance practices, our objectives of building our company and creating
value for our shareholders, and, most importantly, discovering, developing, and delivering life-changing treatments for people battling devastating diseases. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Base Salaries </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Annual base salary is designed to
provide a competitive fixed rate of pay, recognizing different levels of responsibility and performance. Actual salaries reflect the judgment and consideration of numerous factors by the Compensation Committee. These factors include the NEO&#146;s
experience, importance of position, expected future contributions, performance, comparative survey data, internal pay equity, scope of responsibilities, expertise, the criticality of the NEO&#146;s position within the Company, the other elements of
compensation received by the NEO, and the NEO&#146;s compensation in comparison to similarly situated executive officers at comparable companies in our peer group. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Annual Cash Incentive Program </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our executive
officers are eligible to receive annual cash incentive awards, with the target bonus opportunity for 2023 determined as a percentage of their base salary. At the beginning of 2023, our Board approved ambitious corporate goals and objectives that our
Compensation Committee then used to design our annual cash incentive program for 2023. Under this program, the Compensation Committee determined that the corporate goals would apply uniformly to all of our executive officers. Our 2023 corporate
goals that were set by our Board to determine our 2023 corporate performance, plus our additional achievements that proved to be helpful or important to our operations during 2023, are set forth below: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Executed our <FONT STYLE="white-space:nowrap">WVE-006</FONT> development strategy on time and on budget by
initiating dosing in the first RNA editing clinical trial for AATD, thereby advancing our strategic collaboration with GSK by earning a $20&nbsp;million cash milestone payment and enabling potential achievement of proof of mechanism and additional
milestones in 2024; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Executed <FONT STYLE="white-space:nowrap">WVE-N531</FONT> development strategy on time and on budget by
initiating dosing in Part B of the <FONT STYLE="white-space:nowrap">FORWARD-53</FONT> study to enable evaluation of dystrophin protein restoration data after 24 weeks in 2024, followed by evaluation at 48 weeks of dosing thereafter;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Demonstrated uptake of <FONT STYLE="white-space:nowrap">WVE-N531</FONT> in satellite cells from clinical
biopsies, indicating that <FONT STYLE="white-space:nowrap">WVE-N531</FONT> is being delivered to cells important for tissue regeneration; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Leveraged our strategic collaboration with GSK by selecting INHBE to become our first wholly owned Wave
collaboration program; designed and identified lead candidates for this program and accelerated development of program to enter clinic in 2025; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Designed INHBE program to incorporate our next generation GalNAc-small interfering RNA (siRNA)&nbsp;format to
silence the INHBE (Inhibin &szlig;E) gene through RNA knockdown with a goal of inducing lipolysis <FONT STYLE="white-space:nowrap">(fat-burning)</FONT> while preserving muscle mass to restore and maintain a healthy metabolic profile;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Advanced our strategic collaboration with GSK by initiating all requested target validation programs and
conducting associated research activities on time or ahead of schedule; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Completed enrollment in our 30 mg multi-dose cohort of <FONT STYLE="white-space:nowrap">SELECT-HD</FONT> to
enable availability of clinical data for decision making on our <FONT STYLE="white-space:nowrap">WVE-003</FONT> program on track for the second quarter of 2024; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Advanced our strategic collaboration with Takeda by achieving a $7&nbsp;million cash milestone payment pertaining
to positive results from a <FONT STYLE="white-space:nowrap">non-clinical</FONT> study of <FONT STYLE="white-space:nowrap">WVE-003</FONT> in <FONT STYLE="white-space:nowrap">non-human</FONT> primates, which showed significant tissue exposure levels
of <FONT STYLE="white-space:nowrap">WVE-003</FONT> in deep brain regions, including striatum, and bolstered our existing datasets that confirm the ability of our oligonucleotides to distribute to areas of the CNS important for HD;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Built and utilized proprietary &#147;edit-verse,&#148; powered by genetic datasets and deep learning models and
designed to identify new targets for all of our modalities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Bolstered publication strategy with seven manuscripts published, five more submitted and 25 oral presentations
provided in 2023; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Raised approximately $115&nbsp;million from our December 2023 public offering, thereby extending our cash runway
into the fourth quarter of 2025; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Maintained low employee turnover and added key, diverse talent broadly throughout the organization; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Actively managed spend and delivered our 2023 corporate goals within our 2023 budget. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based on our Board&#146;s assessment and consideration of the relative weighting and importance of our goals, our Board determined that we achieved 115% of
our 2023 corporate goals. The Compensation Committee then determined that bonuses for 2023 performance be paid to our NEOs based on these results. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Long-Term Incentive Compensation </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We view
long-term incentive compensation in the form of equity awards as a critical element of our executive compensation program. Our program is designed to reward demonstrated leadership and performance, align our executive officers&#146; interests with
those of our shareholders through sustained, long-term value creation while retaining and motivating our executive officers for future performance. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>2024 Long-Term Incentive Program </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In 2024, the long-term
incentive component of the compensation of our NEOs consisted solely of share options. These share options were granted to each of our NEOs by our Compensation Committee on February&nbsp;5, 2024, at an exercise price of $3.87 per share, and vest
over a&nbsp;four-year&nbsp;term, with 25% vesting on February&nbsp;5, 2025, and the remainder vesting quarterly thereafter. The Compensation Committee determined to grant share options to best align employees, including NEOs, with investors&#146;
interests to build long-term shareholder value in Wave. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>2023 Long-Term Incentive Program </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In 2023, the long-term incentive component of the compensation of our NEOs consisted solely of share options. These share options were granted to each of our
NEOs by our Compensation Committee on February&nbsp;17, 2023, at an exercise price of $4.75 per share, and vest over a&nbsp;four-year&nbsp;term, with 25% vesting on February&nbsp;17, 2024, and the remainder vesting quarterly thereafter. The
Compensation Committee determined to grant share options to best align employees, including NEOs, with investors&#146; interests to build long-term shareholder value in Wave. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Employment Agreements with Our Named Executive Officers </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Paul B. Bolno, M.D., MBA </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In May 2020, we entered
into an amended and restated employment agreement with Dr.&nbsp;Bolno, pursuant to which he serves as our President and Chief Executive Officer. The employment agreement amends and restates the prior employment arrangement between us and
Dr.&nbsp;Bolno. As of January&nbsp;1, 2023, Dr.&nbsp;Bolno&#146;s annual base salary was $636,400 and the Compensation Committee established his annual target bonus percentage at 65% of his annual base salary, with the actual amount to be paid
determined based on the achievement of annual performance milestones defined by our Board in its sole discretion. Effective January&nbsp;1, 2024, the Compensation Committee approved an increase of Dr.&nbsp;Bolno&#146;s annual base salary to
$655,500. In February 2024, in recognition of his 2023 performance supporting the achievement of our corporate goals, as discussed below, the Compensation Committee authorized a cash bonus for Dr.&nbsp;Bolno of $475,700 that was equal to 115% of his
2023 target bonus. In addition, in February 2024, the Compensation Committee approved an award to Dr.&nbsp;Bolno of an option to purchase 1,008,600 of our ordinary shares under our 2021 Plan as a 2024 long-term incentive plan (&#147;2024 LTIP&#148;)
award, with such options vesting over a four-year period, with 25% vesting on the first anniversary of the date of grant and the remainder vesting quarterly thereafter. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to Dr.&nbsp;Bolno&#146;s employment agreement, if we terminate his employment without cause or if he terminates his employment for good reason,
Dr.&nbsp;Bolno will be entitled to receive continued payment of his then-current annual base salary for 18 months following termination; continued payment of health insurance premiums at our then-normal rate of contribution until the earlier of 18
months following termination or until he commences new employment; and the payment of a separation bonus equal to his then annual target bonus opportunity prorated through the termination date. In addition, if a change of control occurs and within
one year following the change of control Dr.&nbsp;Bolno is terminated without cause or if Dr.&nbsp;Bolno terminates his employment for good reason, he will be entitled to receive a lump sum cash payment equal to 18 months of his then-current annual
base salary; continued payment of health insurance premiums at our then-normal rate of contribution until the earlier of 18 months following termination or until he commences new employment; and the payment of a separation bonus equal to his then
annual target bonus opportunity. Pursuant to applicable equity agreements with Dr.&nbsp;Bolno, all unvested shares underlying outstanding options and RSUs that were granted to him on or after January&nbsp;1, 2018 will become fully vested upon his
termination without cause or for good reason within 12&nbsp;months following a change of control. Receipt of the severance and change of control benefits described above is subject to execution of a release of claims against us and compliance with
certain restrictive covenants following the termination of his employment. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Chandra Vargeese, Ph.D. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In May 2020, we entered into an amended and restated employment agreement with Dr.&nbsp;Vargeese, pursuant to which she serves as our Chief Technology Officer,
Head of Platform Discovery Sciences. The employment agreement amends and restates the prior employment arrangement between us and Dr.&nbsp;Vargeese. As of January&nbsp;1, 2023, Dr.&nbsp;Vargeese&#146;s annual base salary was $473,340, and the
Compensation Committee established her annual target bonus percentage at 45% of her annual base salary, with the actual amount to be paid determined based on the achievement of annual performance milestones defined by our Board in its sole
discretion. Effective January&nbsp;1, 2024, the Compensation Committee approved an increase of Dr.&nbsp;Vargeese&#146;s annual base salary to $487,540. In February 2024, in recognition of her 2023 performance supporting the achievement of our
corporate goals, as discussed below, the Compensation Committee authorized a cash bonus for Dr.&nbsp;Vargeese of $245,000 that was equal to 115% of her 2023 target bonus. In addition, in February 2024, the Compensation Committee approved an award to
Dr.&nbsp;Vargeese of an option to purchase 361,700 of our ordinary shares under our 2021 Plan as a 2024 LTIP award, with such options vesting over a four-year period, with 25% vesting on the first anniversary of the date of grant and the remainder
vesting quarterly thereafter. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to Dr.&nbsp;Vargeese&#146;s employment agreement, if we terminate her employment without cause or if she
terminates her employment for good reason, Dr.&nbsp;Vargeese will be entitled to receive continued payment of her </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
then-current annual base salary for 12 months following termination; continued payment of health insurance premiums at our then-normal rate of contribution until the earlier of 12 months
following termination or until she commences new employment; and the payment of a separation bonus equal to her then annual target bonus opportunity prorated through the termination date. In addition, if a change of control occurs and within one
year following the change of control Dr.&nbsp;Vargeese is terminated without cause or if Dr.&nbsp;Vargeese terminates her employment for good reason, she will be entitled to receive a lump sum cash payment equal to 12 months of her then-current
annual base salary; continued payment of health insurance premiums at our then-normal rate of contribution until the earlier of 12 months following termination or until she commences new employment; and the payment of a separation bonus equal to her
then annual target bonus opportunity. Pursuant to applicable equity agreements with Dr.&nbsp;Vargeese, all unvested shares underlying outstanding options and RSUs that were granted to her on or after January&nbsp;1, 2018 will become fully vested
upon her termination without cause or for good reason within 12 months following a change of control. Receipt of the severance and change of control benefits described above is subject to execution of a release of claims against us and compliance
with certain restrictive covenants following the termination of her employment. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Kyle Moran, CFA </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In January 2021, we entered into an amended and restated employment agreement with Mr.&nbsp;Moran, pursuant to which he serves as our Chief Financial Officer.
The employment agreement amends and restates the prior employment arrangement between us and Mr.&nbsp;Moran. As of January&nbsp;1, 2023, Mr.&nbsp;Moran&#146;s annual base salary was $471,300, and the Compensation Committee established his annual
target bonus percentage at 45% of his annual base salary, with the actual amount to be paid determined based on the achievement of annual performance milestones defined by our Board in its sole discretion. Effective January&nbsp;1, 2024, the
Compensation Committee approved an increase of Mr.&nbsp;Moran&#146;s annual base salary to $497,200. In February 2024, in recognition of his 2023 performance supporting the achievement of our corporate goals, as discussed below, the Compensation
Committee authorized a cash bonus for Mr.&nbsp;Moran of $243,900 that was equal to 115% of his 2023 target bonus. In addition, in February 2024, the Compensation Committee approved an award to Mr.&nbsp;Moran of an option to purchase 371,500 of our
ordinary shares under our 2021 Plan as a 2024 LTIP award, with such options vesting over a four-year period, with 25% vesting on the first anniversary of the date of grant and the remainder vesting quarterly thereafter. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to Mr.&nbsp;Moran&#146;s employment agreement, if we terminate his employment without cause or if he terminates his employment for good reason,
Mr.&nbsp;Moran will be entitled to receive continued payment of his then-current annual base salary for 12 months following termination; continued payment of health insurance premiums at our then-normal rate of contribution until the earlier of 12
months following termination or until he commences new employment; and the payment of a separation bonus equal to his then annual target bonus opportunity prorated through the termination date. In addition, if a change of control occurs and within
one year following the change of control Mr.&nbsp;Moran is terminated without cause or if Mr.&nbsp;Moran terminates his employment for good reason, he will be entitled to receive a lump sum cash payment equal to 12 months of his then-current annual
base salary; continued payment of health insurance premiums at our then-normal rate of contribution until the earlier of 12 months following termination or until he commences new employment; and the payment of a separation bonus equal to his then
annual target bonus opportunity. Pursuant to applicable equity agreements with Mr.&nbsp;Moran, all unvested shares underlying outstanding options and RSUs that were granted to him on or after January&nbsp;1, 2018 will become fully vested upon his
termination without cause or for good reason within 12 months following a change of control. Receipt of the severance and change of control benefits described above is subject to execution of a release of claims against us and compliance with
certain restrictive covenants following the termination of his employment. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Other Provisions Applicable to Named Executive Officers </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, as a condition of their employment, each of our NEOs has entered into a <FONT STYLE="white-space:nowrap">non-competition</FONT> and <FONT
STYLE="white-space:nowrap">non-solicitation</FONT> agreement pursuant to which he or she has agreed not to compete with us for a period of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
12&nbsp;months following the termination of their employment with us. All agreements generally provide for <FONT STYLE="white-space:nowrap">at-will</FONT> employment and that our NEOs are
eligible to participate in employee benefit plans of general applicability to other senior executives, which we maintain from time to time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For purposes
of change of control benefits included in the Company&#146;s employment agreements with its NEOs, change of control is defined as follows: (A)&nbsp;a merger or consolidation of the Company whether or not approved by the Board, other than a merger or
consolidation which would result in the voting securities of the Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity or the
parent of such corporation) more than 50% of the total voting power represented by the voting securities of the Company or such surviving entity&nbsp;or parent of such corporation, as the case may be, outstanding immediately after such merger or
consolidation; or (B)&nbsp;the sale or disposition by the Company of all or substantially all of the Company&#146;s assets in a transaction requiring shareholder approval. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>401(k) Plan </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We maintain a defined contribution
401(k) plan that is intended to qualify under Section&nbsp;401(k) of the Internal Revenue Code of 1986, as amended (the &#147;Code&#148;). In general, all of our U.S. employees, including our NEOs, are eligible to participate in the 401(k) plan.
Under the 401(k) plan, employees may elect to reduce their current compensation by up to the statutorily prescribed annual limit, which was equal to $22,500 in 2023, and to have the amount of such reduction contributed to the 401(k) plan. In
addition, employees who turn age 50 before the end of the 2023 calendar year may also defer up to an additional $7,500. We currently match 50% of an employee&#146;s 401(k) contributions up to a maximum of 6% of the participant&#146;s includable
compensation. Matching contributions are 100% vested upon completion of one year of service with the Company. Matching contributions made to each of our NEOs are included in the &#147;Summary Compensation Table&#148; above. We do not provide defined
benefit retirement plans, post-retirement health coverage, or any other supplemental retiree benefits for our NEOs. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2021 Plan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our 2021 Plan was most recently amended on August&nbsp;1, 2023, following receipt of shareholder approval at our 2023 Annual General Meeting (&#147;2023
AGM&#148;) to authorize an additional 6,500,000 ordinary shares, for an aggregate of 17,950,000 ordinary shares, for the granting of incentive options, <FONT STYLE="white-space:nowrap">non-qualified</FONT> options (&#147;NQSOs&#148;), share
appreciation rights and restricted share unit awards to eligible employees and directors of the Company. The 2021 Plan serves as the successor to our 2014 Plan, such that outstanding awards granted under the 2014 Plan continue to be governed by the
terms of the 2014 Plan, but no awards may be issued under the 2014 Plan after August&nbsp;10, 2021. Any outstanding awards under the 2014 Plan that are forfeited, cancelled or otherwise terminated (other than by exercise or withheld by the Company
to satisfy any tax withholding obligation) on or after August&nbsp;10, 2021 may be reissued under the 2021 Plan and any shares subject to an award that is canceled, forfeited or expires prior to exercise or realization, either in full or in part,
under the 2021 Plan will again become available for issuance under the 2021 Plan. However, shares subject to an award under the 2021 Plan will not again be made available for issuance or delivery under the 2021 Plan if such shares are
(a)&nbsp;shares tendered in payment of an option; (b)&nbsp;shares delivered or withheld by us to satisfy any tax withholding obligation; or (c)&nbsp;shares covered by a share-settled share appreciation right or other awards that were not issued upon
the settlement of the award. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In Proposal 4, we are asking our shareholders to increase the total number of ordinary shares available for issuance under
our 2021 Plan by an additional 5,000,000 ordinary shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we are acquired, our Board or Compensation Committee will with respect to share options and
share appreciation rights: (i)&nbsp;make appropriate provision for the continuation of the share option or share appreciation right by substituting on an equitable basis for the ordinary shares then subject to such share option or share
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
appreciation right either the consideration payable with respect to the outstanding ordinary shares in connection with the corporate transaction or securities of any successor or acquiring
entity; (ii)&nbsp;cancel or arrange for the cancellation of the share options or share appreciation rights, to the extent not vested or exercised prior to the effective time of the transaction, in exchange for a payment in cash or ordinary shares as
determined by our Board, in an amount equal to the amount by which the then fair market value of the ordinary shares subject to such vested share option or share appreciation right exceeds the exercise price; or (iii)&nbsp;after giving holders an
opportunity to exercise to the extent vested their outstanding share options or share appreciation rights, terminate any or all unexercised share options and share appreciation rights at such time as the Board deems appropriate. If we are acquired,
with respect to outstanding restricted share unit awards, our Board or Compensation Committee shall make appropriate provision for the continuation of such restricted awards on the same terms and conditions by substituting on an equitable basis for
the ordinary shares then subject to such restricted awards either the consideration payable with respect to the outstanding ordinary shares in connection with the transaction or securities of any successor or acquiring entity. In lieu of the
foregoing, if we are acquired, our Board may provide that, upon consummation of the acquisition, each outstanding restricted award shall be terminated in exchange for payment of an amount equal to the consideration payable upon consummation of such
transaction to a holder of the number of ordinary shares comprising such restricted award to the extent then vested. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Outstanding Equity Awards at 2023
Fiscal <FONT STYLE="white-space:nowrap">Year-End</FONT> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table shows grants of options and unvested restricted share unit awards
outstanding on the last day of the fiscal year ended December&nbsp;31, 2023 to each of the NEOs. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>

<TD WIDTH="28%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD ???? 1 VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" ???? 1 VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option Awards</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Share Awards</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Grant<BR>Date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Securities<BR>Underlying<BR>Unexercised<BR>Options (#)<BR>Exercisable</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of<BR>Securities<BR>Underlying<BR>Unexercised<BR>Options&nbsp;(#)<BR>Unexercisable</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Exercise<BR>Price&nbsp;($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Expiration<BR>Date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of<BR>Shares&nbsp;or<BR>Share&nbsp;Units<BR>That&nbsp;Have<BR>Not&nbsp;Vested<BR>(#)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Market<BR>Value&nbsp;of<BR>Shares&nbsp;or<BR>Share<BR>Units<BR>That&nbsp;
Have<BR>Not<BR>Vested<BR>($)<SUP STYLE="font-size:75%; vertical-align:top">(5)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Equity<BR>Incentive<BR>Plan</B><br><B>Awards:</B><br><B>Number&nbsp;of<BR>Unearned<BR>Shares,<BR>Units&nbsp;or<BR>Other<BR>Rights<BR>That&nbsp;
Have<BR>Not<BR>Vested<BR>(#)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Equity<BR>Incentive<BR>Plan</B><br><B>Awards:</B><br><B>Market or<BR>Payout<BR>Value of<BR>Unearned<BR>Shares,<BR>Units
or<BR>Other&nbsp;Rights<BR>That<BR>Have Not<BR>Vested&nbsp;($)<SUP STYLE="font-size:75%; vertical-align:top">(5)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Paul B. Bolno, M.D., MBA</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3/10/2015</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">219,025</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3/10/2025</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD ???? 1 VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6/16/2016</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">236,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18.79</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6/16/2026</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD ???? 1 VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1/25/2017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">72,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29.05</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1/25/2027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD ???? 1 VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1/23/2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">109,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">40.05</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1/23/2028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD ???? 1 VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3/3/2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">63,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8.17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3/3/2030</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD ???? 1 VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2/1/2021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">200,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10.48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2/1/2031</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD ???? 1 VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1/1/2022</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">262,500</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">337,500</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1/1/2032</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD ???? 1 VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7/25/2022</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">90,000</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">90,000</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.83</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7/25/2032</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD ???? 1 VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2/17/2023</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">771,000</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4.75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2/17/2033</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD ???? 1 VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">92,500</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(4)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">467,125</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Chandra Vargeese, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3/10/2015</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">205,964</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3/10/2025</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD ???? 1 VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6/16/2016</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">49,600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18.79</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6/16/2026</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD ???? 1 VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1/25/2017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29.05</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1/25/2027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD ???? 1 VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1/23/2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">35,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">40.05</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1/23/2028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD ???? 1 VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3/3/2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">36,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8.17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3/3/2030</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD ???? 1 VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2/1/2021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">50,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10.48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2/1/2031</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD ???? 1 VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1/1/2022</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">87,500</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">112,500</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1/1/2032</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD ???? 1 VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7/25/2022</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30,000</TD>
<TD NOWRAP VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30,000</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.83</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7/25/2032</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD ???? 1 VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2/17/2023</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">295,400</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4.75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2/17/2033</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD ???? 1 VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">50,000</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(4)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">252,5000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>

<TD WIDTH="30%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD ???? 1 VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" ???? 1 VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option Awards</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Share Awards</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Grant<BR>Date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Securities<BR>Underlying<BR>Unexercised<BR>Options (#)<BR>Exercisable</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of<BR>Securities<BR>Underlying<BR>Unexercised<BR>Options&nbsp;(#)<BR>Unexercisable</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Exercise<BR>Price&nbsp;($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Expiration<BR>Date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of<BR>Shares&nbsp;or<BR>Share&nbsp;Units<BR>That&nbsp;Have<BR>Not&nbsp;Vested<BR>(#)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Market<BR>Value&nbsp;of<BR>Shares&nbsp;or<BR>Share<BR>Units<BR>That&nbsp;
Have<BR>Not<BR>Vested<BR>($)<SUP STYLE="font-size:75%; vertical-align:top">(5)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Equity<BR>Incentive<BR>Plan</B><br><B>Awards:</B><br><B>Number&nbsp;of<BR>Unearned<BR>Shares,<BR>Units&nbsp;or<BR>Other<BR>Rights<BR>That&nbsp;
Have<BR>Not<BR>Vested<BR>(#)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Equity<BR>Incentive<BR>Plan</B><br><B>Awards:</B><br><B>Market or<BR>Payout<BR>Value of<BR>Unearned<BR>Shares,<BR>Units
or<BR>Other&nbsp;Rights<BR>That<BR>Have Not<BR>Vested&nbsp;($)<SUP STYLE="font-size:75%; vertical-align:top">(5)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman">Kyle Moran, CFA</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3/10/2015</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3/10/2025</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD ???? 1 VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6/16/2016</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21,647</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18.79</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6/16/2026</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD ???? 1 VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1/23/2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">40.05</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1/23/2028</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD ???? 1 VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3/3/2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">36,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8.17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3/3/2030</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD ???? 1 VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2/1/2021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">50,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10.48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2/1/2031</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD ???? 1 VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1/1/2022</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">76,562</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">98,438</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1/1/2032</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD ???? 1 VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7/25/2022</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30,000</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.83</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7/25/2032</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD ???? 1 VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2/17/2023</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">272,700</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4.75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2/17/2033</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD ???? 1 VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,000</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(4)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">75,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">25% vested on January&nbsp;1, 2023 and the remainder vests in equal quarterly installments over the following
12&nbsp;quarters, subject to such officer&#146;s continued service with us on each such vesting date. The award shall become fully vested upon termination without cause or for good reason within 12 months following a change of control.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">50% vested on July&nbsp;25, 2023 and the remaining 50% vests on July&nbsp;25, 2024, subject to such
officer&#146;s continued service with us on each such vesting date. The award shall become fully vested upon termination without cause or for good reason within 12 months following a change of control. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">25% vests on February&nbsp;17, 2024 and the remainder vests in equal quarterly installments over the following
12 quarters, subject to such officer&#146;s continued service with us on each such vesting date. The award shall become fully vested upon termination without cause or for good reason within 12 months following a change of control.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">On May&nbsp;4, 2022, 50% of the 2019 performance-based RSUs vested upon the achievement of the PN chemistry
milestone and of the shares listed, if prior to March&nbsp;7, 2029 the regulatory approval milestone is achieved, 80% of the unvested performance-based RSUs will be earned and vest, and if the commercial sale milestone is achieved, 20% of the
unvested 2019 performance-based RSUs will be earned and vest. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The market value of the 2019 Performance-Based RSUs is based on the closing price of our ordinary shares of
$5.05 per share at December&nbsp;31, 2023. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Director Compensation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table shows the total compensation paid or accrued during the fiscal year ended December&nbsp;31, 2023 to each of our <FONT
STYLE="white-space:nowrap">non-employee</FONT> directors.&nbsp;Directors who are also employees are not compensated for their service on our Board. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="37%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fees&nbsp;Earned&nbsp;or<BR>Paid&nbsp;in&nbsp;Cash&nbsp;($)<SUP STYLE="font-size:75%; vertical-align:top">&nbsp;(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option&nbsp;Awards&nbsp;($)<SUP STYLE="font-size:75%; vertical-align:top">&nbsp;(2)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>All Other<BR>Compensation&nbsp;($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total&nbsp;($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Christian Henry</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">99,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">123,237</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">222,237</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mark H. N. Corrigan, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">71,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">123,237</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">194,737</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Peter Kolchinsky, Ph.D.(3)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">47,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">123,237</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">170,737</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adrian Rawcliffe</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">65,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">123,237</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">188,737</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ken Takanashi</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">47,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">123,237</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">170,737</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Aik Na Tan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">49,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">123,237</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">172,237</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gregory L. Verdine, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">47,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">123,237</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">170,737</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Heidi L. Wagner, J.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">62,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">123,237</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">185,737</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Amounts represent fees earned during 2023 under our 2023 <FONT STYLE="white-space:nowrap">Non-Employee</FONT>
Director Compensation Policy. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Amount represents the aggregate grant date fair value for the option awards granted in 2023 to our <FONT
STYLE="white-space:nowrap">non-employee</FONT> directors, computed in accordance with FASB ASC Topic 718. A discussion of the assumptions used in determining grant date fair value may be found in Note 7 to the financial statements included in our
2023 Form <FONT STYLE="white-space:nowrap">10-K.</FONT> </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Pursuant to the terms of the RA Capital Healthcare Fund, L.P. governing documents, Dr.&nbsp;Kolchinsky is
required to remit to RA Capital both the cash and the equity compensation, and RA Capital and not Dr.&nbsp;Kolchinsky individually is the beneficial owner of such compensation. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table shows the aggregate number of shares subject to options held by each of our <FONT STYLE="white-space:nowrap">non-employee</FONT> directors
as of December&nbsp;31, 2023: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="83%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Aggregate<BR>Number&nbsp;of<BR>Shares<BR>Subject&nbsp;to<BR>Options</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Christian Henry</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">129,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mark H. N. Corrigan, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">118,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Peter Kolchinsky, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">129,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adrian Rawcliffe</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">129,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ken Takanashi</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">129,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Aik Na Tan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">108,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gregory L. Verdine, Ph.D.(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">558,869</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Heidi Wagner</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">118,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In October 2022, the Compensation Committee granted Dr.&nbsp;Verdine a
<FONT STYLE="white-space:nowrap">non-qualified</FONT> share option for 163,467 ordinary shares as form of payment under his consulting agreement for the service period of October&nbsp;1, 2022 through December&nbsp;31, 2024, the vesting of which is
subject to Dr.&nbsp;Verdine&#146;s continued service under the consulting agreement. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2023
<FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director Compensation Policy </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At our 2023 AGM, our shareholders approved our 2023 <FONT
STYLE="white-space:nowrap">Non-Employee</FONT> Director Compensation Policy, under which our <FONT STYLE="white-space:nowrap">non-employee</FONT> directors are compensated for their service as directors, including as members of the various
committees of our Board on which they serve, for the Board service period that commenced on the date of our 2023 AGM and runs through the date of our 2024 AGM. The terms of the 2023 <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director
Compensation Policy are as follows: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(A) <U>Cash Compensation</U>: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I><U>Board of Director</U></I>s: Annual cash compensation of $40,000 to each
<FONT STYLE="white-space:nowrap">non-employee</FONT> director, other than the Chair of the Board, and cash compensation of $75,000 to the <FONT STYLE="white-space:nowrap">non-employee</FONT> Chair of the Board. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I><U>Audit Committee</U></I>: Additional annual cash compensation of $18,000 to the Chair of the Audit Committee
and $9,000 to each member of the Audit Committee other than the Chair. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I><U>Compensation Committee</U></I>: Additional annual cash compensation of $15,000 to the Chair of the
Compensation Committee and $7,500 to each member of the Compensation Committee other than the Chair. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I><U>Nominating and Corporate Governance Committee</U></I>: Additional annual cash compensation of $15,000 to
the Chair of the Nominating and Corporate Governance Committee and $7,500 to each member of the Nominating and Corporate Governance Committee other than the Chair. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I><U>Research and Development Committee</U></I>: Additional annual cash compensation of $15,000 to the Chair of
the Research and Development Committee and $7,500 to each member of the Research and Development Committee other than the Chair. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I><U>Proration</U></I>: Additional pro rata cash compensation of the annual cash compensation amounts set forth
above shall be made, as applicable, to (i)&nbsp;any director who ceases to be a director, Chair of the Board or member or chair of any committee of the Board and (ii)&nbsp;any new <FONT STYLE="white-space:nowrap">non-employee</FONT> director who is
appointed by the Board, any independent director who is appointed to the position of Chair of the Board or chair of any such committee of the Board or any independent director who is appointed to serve on any such committee of the Board, for their
services rendered as a director and/or committee member, for the portion of the year in which such director so served. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(B) <U>Equity Compensation</U>: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I><U>Initial Equity Grant</U></I>: <FONT STYLE="white-space:nowrap">One-time</FONT> equity grant upon initial
appointment or election to the Board of an option to purchase 90,000 ordinary shares, which shall vest as to 12.5% of the shares on a quarterly basis during the <FONT STYLE="white-space:nowrap">two-year</FONT> period following the grant date.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I><U>Refresh Equity Grant</U></I>: Each <FONT STYLE="white-space:nowrap">non-employee</FONT> director whose
initial equity grant has an expiration date within twelve months following the 2023 AGM shall be granted an option to purchase 90,000 ordinary shares, which shall vest as to 12.5% of the shares on a quarterly basis during the <FONT
STYLE="white-space:nowrap">two-year</FONT> period following the grant date. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I><U>Annual Equity Grant</U></I><I>:</I> Annual equity grant of an option to purchase 45,000 ordinary shares,
which shall vest as to 100% of the shares on the earlier of the 2024 AGM or the first anniversary of the grant date. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I><U>Limitation on Equity Grants</U></I>: A <FONT STYLE="white-space:nowrap">non-employee</FONT> director shall
be eligible to receive only one type of option grant at the 2023 AGM, which shall be an initial equity grant, a refresh equity grant, or an annual equity grant, in each case as described above. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">37 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom802241_6"></A>PAY VERSUS PERFORMANCE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In accordance with rules adopted by the U.S. Securities and Exchange Commission pursuant to the Dodd-Frank Wall Street Reform and Consumer Protection Act of
2010, we provide the following disclosure regarding executive compensation for our principal executive officer (&#147;PEO&#148;) and <FONT STYLE="white-space:nowrap">Non-PEO</FONT> NEOs and Company performance for the fiscal years listed below. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="17%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Year</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Summary<BR>Compensation<BR>Table Total<BR>for PEO&sup1;</B><br><B>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Compensation<BR>Actually Paid<BR>to PEO<SUP STYLE="font-size:75%; vertical-align:top">1,2,3</SUP></B><br><B>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Average<BR>Summary<BR>Compensation<BR>Table Total<BR>for <FONT STYLE="white-space:nowrap">Non-PEO</FONT><BR>NEOs<SUP
STYLE="font-size:75%; vertical-align:top">1</SUP><BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Average<BR>Compensation<BR>Actually Paid<BR>to
<FONT STYLE="white-space:nowrap">Non-PEO</FONT><BR>NEOs<SUP STYLE="font-size:75%; vertical-align:top">1,2,3</SUP></B><br><B>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Value of<BR>Initial<BR>Fixed $100<BR>Investment<BR>based on:<BR>TSR ($)<SUP STYLE="font-size:75%; vertical-align:top">4</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Net</B><br><B>Income<BR>($&nbsp;Millions)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,874,300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,219,787</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,740,206</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,235,657</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">64.17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(57.5</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,667,997</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,079,613</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,190,292</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,247,169</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">88.95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(161.8</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,892,610</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,265,141</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,530,003</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">519,760</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">39.90</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(122.2</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Paul B. Bolno, M.D., MBA was our PEO for each year presented. The individuals comprising the <FONT
STYLE="white-space:nowrap">Non-PEO</FONT> NEOs for each year presented are listed below. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="34%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="30%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>2021</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>2022</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>2023</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">Michael Panzara, M.D., MPH</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Kyle Moran, CFA</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Kyle Moran, CFA</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">Chandra Vargeese, Ph.D.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Chandra Vargeese, Ph.D.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Chandra Vargeese, Ph.D.</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The amounts shown for Compensation Actually Paid have been calculated in accordance with Item 402(v) of
Regulation <FONT STYLE="white-space:nowrap">S-K</FONT> and do not reflect compensation actually earned, realized, or received by the Company&#146;s NEOs. These amounts reflect the Summary Compensation Table Total with certain adjustments as
described in footnote 3 below. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Compensation Actually Paid reflects the exclusions and inclusions of certain amounts for the PEO and the <FONT
STYLE="white-space:nowrap">Non-PEO</FONT> NEOs as set forth below. Equity values are calculated in accordance with FASB ASC Topic 718. Amounts in the Exclusion of Stock Awards and Option Awards column are the totals from the Stock Awards and Option
Awards columns set forth in the Summary Compensation Table. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="23%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Year</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Summary<BR>Compensation&nbsp;Table<BR>Total for PEO<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Exclusion of Stock<BR>Awards&nbsp;and&nbsp;Option<BR>Awards for PEO<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Inclusion&nbsp;of&nbsp;Equity<BR>Values for PEO<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Compensation<BR>Actually&nbsp;Paid&nbsp;to&nbsp;PEO<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,874,300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,744,529</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,090,016</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,219,787</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="21%"></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Year</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Average Summary<BR>Compensation&nbsp;Table<BR>Total for <FONT STYLE="white-space:nowrap">Non-PEO</FONT><BR>NEOs<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Average&nbsp;Exclusion&nbsp;of<BR>Stock Awards and<BR>Option Awards for<BR><FONT STYLE="white-space:nowrap">Non-PEO</FONT> NEOs<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Average&nbsp;Inclusion&nbsp;of<BR>Equity Values for<BR><FONT STYLE="white-space:nowrap">Non-PEO</FONT> NEOs<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Average<BR>Compensation<BR><FONT STYLE="white-space:nowrap">Actually&nbsp;Paid&nbsp;to&nbsp;Non-</FONT></B><br><B>PEO NEOs<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,740,206</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,011,133</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">506,584</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,235,657</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">38 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The amounts in the Inclusion of Equity Values in the tables above are derived from the amounts set forth in
the following tables: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Year</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">Year-End</FONT><BR>Fair Value<BR>of Equity<BR>Awards<BR>Granted<BR>During&nbsp;Year<BR>That<BR>Remained<BR>Unvested
as<BR>of Last Day<BR>of Year for<BR>PEO<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change in<BR>Fair Value<BR>from Last<BR>Day&nbsp;of&nbsp;Prior<BR>Year to Last<BR>Day of Year<BR>of Unvested<BR>Equity<BR>Awards for<BR>PEO<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">Vesting-Date</FONT><BR>Fair Value<BR>of Equity<BR>Awards<BR>Granted<BR>During Year<BR>that Vested<BR>During Year<BR>for
PEO<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change in<BR>Fair Value<BR>from Last<BR>Day&nbsp;of&nbsp;Prior<BR>Year to<BR>Vesting&nbsp;Date<BR>of Unvested<BR>Equity<BR>Awards that<BR>Vested<BR>During
Year<BR>for PEO<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fair&nbsp;Value<BR>at&nbsp;Last&nbsp;Day<BR>of Prior<BR>Year of<BR>Equity<BR>Awards<BR>Forfeited<BR>During&nbsp;Year<BR>for PEO<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total-</B><br><B>Inclusion&nbsp;of<BR>Equity<BR>Values for<BR>PEO<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">2023</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,004,235</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(951,279</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(962,940</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,090,016</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Year</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Average<BR><FONT STYLE="white-space:nowrap">Year-End</FONT><BR>Fair Value<BR>of
Equity<BR>Awards<BR>Granted<BR>During&nbsp;Year<BR>That<BR>Remained<BR>Unvested as<BR>of Last Day<BR>of Year for<BR><FONT STYLE="white-space:nowrap">Non-PEO</FONT><BR>NEOs<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Average<BR>Change in<BR>Fair Value<BR>from Last<BR>Day of<BR>Prior Year<BR>to Last<BR>Day&nbsp;of&nbsp;Year<BR>of Unvested<BR>Equity<BR>Awards for<BR><FONT
STYLE="white-space:nowrap">Non-PEO</FONT><BR>NEOs<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Average<BR><FONT STYLE="white-space:nowrap">Vesting-Date</FONT><BR>Fair Value<BR>of Equity<BR>Awards<BR>Granted<BR>During Year<BR>that Vested<BR>During
Year<BR><FONT STYLE="white-space:nowrap">for&nbsp;Non-</FONT></B><br><B>PEO NEOs<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Average<BR>Change in<BR>Fair&nbsp;Value<BR>from Last<BR>Day&nbsp;of&nbsp;Prior<BR>Year to<BR>Vesting&nbsp;Date<BR>of&nbsp;Unvested<BR>Equity<BR>Awards
that<BR>Vested<BR>During Year<BR><FONT STYLE="white-space:nowrap">for&nbsp;Non-</FONT></B><br><B>PEO NEOs<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Average&nbsp;Fair<BR>Value at<BR>Last Day of<BR>Prior Year<BR>of Equity<BR>Awards<BR>Forfeited<BR>During
Year<BR><FONT STYLE="white-space:nowrap">for&nbsp;Non-</FONT></B><br><B>PEO NEOs<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total-<BR>Average<BR>Inclusion&nbsp;of<BR>Equity<BR>Values for<BR><FONT STYLE="white-space:nowrap">Non-PEO</FONT><BR>NEOs<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">2023</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,106,813</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(307,780</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(292,449</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">506,584</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Assumes $100 was invested in the Company for the period starting December&nbsp;31, 2020, through the end of the
listed year. Historical stock performance is not necessarily indicative of future stock performance. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">39 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Relationship Between PEO and <FONT STYLE="white-space:nowrap">Non-PEO</FONT> NEO Compensation Actually
Paid and Company Total Shareholder Return (&#147;TSR&#148;) </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following chart sets forth the relationship between Compensation Actually Paid to our
PEO, the average of Compensation Actually Paid to our <FONT STYLE="white-space:nowrap">Non-PEO</FONT> NEOs, and the Company&#146;s cumulative TSR over the three most recently completed fiscal years. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g802241g00r41.jpg" ALT="LOGO" STYLE="width:6.1835in;height:3.36258in;">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">40 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Relationship Between PEO and <FONT STYLE="white-space:nowrap">Non-PEO</FONT> NEO Compensation Actually
Paid and Net Income </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following chart sets forth the relationship between Compensation Actually Paid to our PEO, the average of Compensation
Actually Paid to our <FONT STYLE="white-space:nowrap">Non-PEO</FONT> NEOs, and the Company&#146;s Net Income during the three most recently completed fiscal years. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g802241g00r42.jpg" ALT="LOGO" STYLE="width:6.18258in;height:3.36437in;">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">41 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom802241_7"></A>EQUITY COMPENSATION PLAN INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table provides certain information with respect to our 2021 Plan and 2014 Plan (together, the &#147;Equity Compensation Plans&#148;) in effect
as of December&nbsp;31, 2023. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="14%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Plan Category</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of&nbsp;Securities<BR>to be Issued upon<BR>Exercise of<BR>Outstanding&nbsp;Options,<BR>Warrants&nbsp;and&nbsp;Rights</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted-Average<BR>Exercise Price of<BR>Outstanding<BR>Options,&nbsp;Warrants<BR>and Rights</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Securities<BR>Remaining<BR>Available&nbsp;for&nbsp;Future<BR>Issuance under<BR>Equity<BR>Compensation&nbsp;Plans</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Equity compensation plans approved by security holders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,712,142</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6.57</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,591,505</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Equity compensation plans not approved by security holders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">33,125</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(4)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8.95</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:75%; vertical-align:top">(5)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,745,267</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6.58</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,591,505</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of options to purchase 14,074,585 of our ordinary shares outstanding under the Equity Compensation
Plans, 294,681 of our ordinary shares subject to performance-based RSUs outstanding under the Equity Compensation Plans, and 342,876 of our ordinary shares subject to time-based RSUs outstanding under the Equity Compensation Plans, in each case as
of December&nbsp;31, 2023. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Reflects the weighted average exercise price of the options to purchase 14,074,585 of our ordinary shares
outstanding under the Equity Compensation Plans, as of December&nbsp;31, 2023. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of 8,101,005 of our ordinary shares available for future grants under the Equity Compensation Plans,
as well as 2,490,500 of our ordinary shares that remain available for sale under the 2019 ESPP, in each case as of December&nbsp;31, 2023. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of options to purchase 33,125 of our ordinary shares granted outside of the Equity Compensation Plans
in accordance with Nasdaq Listing Rule 5635(c)(4), outstanding as of December&nbsp;31, 2023. The options have an exercise price of $8.95 per share, the closing price on the grant date, and vests over four years with 25% vesting on December&nbsp;1,
2021 and the remainder vesting in equal quarterly installments over the following three years. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Reflects the weighted average exercise price of the options to purchase 33,125 of our ordinary shares granted
in accordance with Nasdaq Listing Rule 5635(c)(4), outstanding as of December&nbsp;31, 2023. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">42 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom802241_8"></A>REPORT OF AUDIT COMMITTEE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Audit Committee of the Board of Directors has furnished the following report: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Audit Committee assists the Board in overseeing and monitoring the integrity of our financial reporting&nbsp;process, compliance with legal and regulatory
requirements, the quality of internal and external audit processes, and related person transaction policies and procedures. The committee&#146;s role and responsibilities are&nbsp;set forth in the Audit Committee charter adopted by the Board, which
is available on our website at www.wavelifesciences.com. The Audit Committee reviews and reassesses its charter annually and recommends any changes to the Board for approval. The Audit Committee is responsible for overseeing our overall financial
reporting process, for establishing and maintaining adequate internal control over financial reporting, and for the appointment, compensation, retention and oversight of the work of KPMG LLP. In fulfilling its responsibilities for the financial
statements for the fiscal year ended December&nbsp;31, 2023, the Audit Committee took the following actions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Reviewed and discussed the audited financial statements for the fiscal year ended December&nbsp;31, 2023 with
management and KPMG LLP, our independent registered public accounting firm and independent Singapore auditor; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Discussed with KPMG LLP the matters required to be discussed by the applicable requirements of the Public Company
Accounting Oversight Board (&#147;PCAOB&#148;) and the SEC; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Received written disclosures and the letter from KPMG LLP regarding its independence as required by applicable
requirements of the PCAOB regarding KPMG LLP communications with the Audit Committee and the Audit Committee further discussed with KPMG LLP their independence. The Audit Committee also considered the status of pending litigation, taxation matters
and other areas of oversight relating to the financial reporting and audit process that the committee determined appropriate. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based on
the Audit Committee&#146;s review of the audited financial statements and discussions with management and KPMG LLP, the Audit Committee recommended to the Board that the audited financial statements be included in our Annual Report on Form <FONT
STYLE="white-space:nowrap">10-K</FONT> for the fiscal year ended December&nbsp;31, 2023 for filing with the SEC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:55%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B>Members of the Audit Committee</B> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:55%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Adrian Rawcliffe, Chair </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:55%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Christian Henry </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:55%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Mark H.N. Corrigan, M.D. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:55%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Aik Na Tan </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">43 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom802241_9"></A>CERTAIN RELATIONSHIPS AND RELATED PERSON TRANSACTIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following includes a summary of transactions since January&nbsp;1, 2022 to which we have been a party, in which the amount involved in the transaction
exceeded the lesser of $120,000 or one percent of the average of our total assets at December&nbsp;31, 2023 and 2022, and in which any of our directors, executive officers or beneficial owners of more than 5% of our ordinary shares, or any member of
the immediate family of any of the foregoing persons had or will have a direct or indirect material interest, other than equity and other compensation, termination, change in control and other arrangements, which are described under, &#147;Executive
Officer and Director Compensation.&#148; We refer to such transactions as &#147;related party transactions&#148; or &#147;related person transactions&#148; and such persons as &#147;related parties&#148; or &#147;related persons.&#148; With the
approval of our Board, we have engaged in the related party transactions described below. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Indemnification Agreements with Officers and Directors
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have entered into deeds of indemnity with our directors and our executive officers.&nbsp;These agreements will require us to indemnify these
individuals to the fullest extent permitted under Singapore law against liabilities that may arise by reason of their service to us as a result of any proceeding against them as to which they could be indemnified.&nbsp;These indemnification rights
shall not be exclusive of any other right which an indemnified person may have or hereafter acquire under any statute, provision of our Constitution, agreement, vote of shareholders or disinterested directors or otherwise if he or she is
subsequently found to have been negligent or otherwise have breached their trust or fiduciary duties or to be in default thereof, or where the Singapore courts have declined to grant relief. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Participation in Our Underwritten Offerings </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On
June&nbsp;16, 2022, we closed an underwritten offering (the &#147;June 2022 Offering&#148;) of (i) 25,464,483 ordinary shares at an offering price of $2.15 per share and <FONT STYLE="white-space:nowrap">(ii)&nbsp;pre-funded</FONT> warrants (the <FONT
STYLE="white-space:nowrap">&#147;pre-funded</FONT> warrants&#148;) to purchase up to 7,093,656 ordinary shares at an offering price of $2.1499 per <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant, which represents the per share offering
price for the ordinary shares less the $0.0001 per share exercise price for each <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant. As part of the June 2022 Offering, RA Capital Healthcare Fund, L.P., an affiliate of RA Capital, purchased
9,480,052 ordinary shares at the offering price of $2.15 per share and <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants to purchase up to 7,093,656 ordinary shares at the offering price of $2.1499 per
<FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant. Peter Kolchinsky, Ph.D., a member of our Board, is the Managing Partner of RA Capital. In addition, as part of the June 2022 Offering, SNBL, one of our principal shareholders, purchased
3,720,930 ordinary shares at the offering price of $2.15 per share. Ken Takanashi, a member of our Board, is an executive officer of SNBL and an executive officer and director of SNBL USA. On December&nbsp;7, 2023, we closed an underwritten offering
(the &#147;December 2023 Offering&#148;) of ordinary shares. As part of the December 2023 Offering, RA Capital purchased 1,000,000 ordinary shares at the offering price of $5.00 per share. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Consulting Agreement with Gregory&nbsp;L. Verdine, Ph.D. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Gregory&nbsp;L. Verdine, Ph.D., a member of our Board, entered into a consulting agreement with Wave Life Sciences USA, Inc. (&#147;Wave USA&#148;), our wholly
owned subsidiary, dated as of April&nbsp;1, 2012, pursuant to which Dr.&nbsp;Verdine serves as a scientific advisor. The consulting agreement does not have a specified term and may be terminated by either party upon 14 days&#146; prior written
notice. Wave USA paid Dr.&nbsp;Verdine $12,500 per month pursuant to the consulting agreement and, in January 2022 through September 2022, Dr.&nbsp;Verdine was paid $112,500 under this agreement. In October 2022, the Compensation Committee approved
a grant to Dr.&nbsp;Verdine of a <FONT STYLE="white-space:nowrap">non-qualified</FONT> share option for 163,467 ordinary shares in lieu of cash payment under this consulting agreement for the service period of October&nbsp;1, 2022 through
December&nbsp;31, 2024 and vests in equal monthly installments over that period, subject to Dr.&nbsp;Verdine&#146;s continued service under the consulting agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">44 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Agreements with GSK and its Affiliate </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December&nbsp;13, 2022, Wave Life Sciences USA, Inc. and Wave Life Sciences UK Limited, two of our direct, wholly-owned subsidiaries entered into a
Collaboration and License Agreement (the &#147;GSK Collaboration Agreement&#148;) with GlaxoSmithKline Intellectual Property (No. 3) (&#147;GSK&#148;), which became effective on January&nbsp;27, 2023. Pursuant to the GSK Collaboration Agreement, we
and GSK have agreed to collaborate on the research, development, and commercialization of oligonucleotide therapeutics, including a global exclusive license to <FONT STYLE="white-space:nowrap">WVE-006.</FONT> The discovery collaboration has an
initial four-year research term and combines our proprietary discovery and drug development platform, PRISM<SUP STYLE="font-size:75%; vertical-align:top">TM</SUP>, with GSK&#146;s unique insights from human genetics and its global development and
commercial capabilities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the terms of the GSK Collaboration Agreement, we received an upfront payment of $170.0&nbsp;million, which included a cash
payment of $120.0&nbsp;million and a $50.0&nbsp;million equity investment. With respect to the $50.0&nbsp;million equity investment, on December&nbsp;13, 2022, we entered into a Share Purchase Agreement (the &#147;GSK Share Purchase Agreement&#148;)
with Glaxo Group Limited (&#147;GGL&#148;), an affiliate of GSK, pursuant to which we sold 10,683,761 of our ordinary shares to GGL (the &#147;GSK Shares&#148;) at a purchase price of $4.68 per share. In connection with the GSK Share Purchase
Agreement, GGL and we agreed upon certain rights and restrictions as set forth in the Investor Agreement, dated as of January&nbsp;26, 2023 (the &#147;GSK Investor Agreement&#148;). Under the GSK Investor Agreement, during the <FONT
STYLE="white-space:nowrap">30-month</FONT> period after the date of the GSK Investor Agreement, GGL and its affiliates will be bound by certain &#147;standstill&#148; provisions. The GSK Shares are subject to a
<FONT STYLE="white-space:nowrap">lock-up</FONT> restriction, such that GGL will not, and will also cause its affiliates not to, without our prior approval, sell, transfer or otherwise dispose of the GSK Shares during the <FONT
STYLE="white-space:nowrap">30-month</FONT> period after the effective date of the GSK Investor Agreement. For a certain period following the expiration of the <FONT STYLE="white-space:nowrap">lock-up</FONT> period, subject to certain conditions and
limitations, we agreed to provide certain demand registration rights to GGL in order to register all or a portion of the GSK Shares purchased by GGL. We also provided GGL with certain &#147;piggyback&#148; registration rights for a certain period
following the expiration of the <FONT STYLE="white-space:nowrap">lock-up</FONT> period, subject to certain conditions and limitations, such that when we propose to register our ordinary shares for our account, GGL will have the right to include some
or all of the GSK Shares in such registration. The GSK Investor Agreement also contains other customary terms and conditions of the parties with respect to the registration of GSK Shares. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contract Research Services Provided by SNBL </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In April
2023, we engaged SNBL to provide approximately $2.8&nbsp;million in certain <FONT STYLE="white-space:nowrap">non-human</FONT> primates (NHPs) contract research services to us. During the year ended December&nbsp;31, 2023, we paid SNBL
$1.4&nbsp;million for a portion of these services. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Related Person Transaction Policy </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Board has adopted a written related person transaction policy that requires future transactions between us and any director, executive officer, holder of
5% or more of any class of our capital stock or any member of the immediate family of, or entities affiliated with, any of them, or any other related persons, as defined in Item 404 of Regulation <FONT STYLE="white-space:nowrap">S-K,</FONT> or their
affiliates, in which the amount involved is equal to or greater than $120,000, be approved in advance by our Audit Committee, or if Audit Committee approval would be inappropriate, by another independent body of our Board. In approving or rejecting
such proposed related person transaction, the committee is to consider all available information deemed relevant by the committee, including, but not limited to, the extent of the related person&#146;s interest in the transaction and whether the
transaction is on terms no less favorable to us than terms we could have generally obtained from an unaffiliated third party under the same or similar circumstances. The committee approves only those transactions that, in light of known
circumstances, are deemed to be in our best interests. In the event that any member of the committee is not a disinterested person with respect to the related person transaction under review, that member is excluded from the review and approval or
rejection of such related person transaction; provided, however, that such committee member may be counted in determining the presence of a quorum at the meeting of the committee at which such transaction is
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">45 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
considered. If we become aware of an existing related person transaction which has not been approved under the policy, the matter will be referred to the committee. The committee evaluates all
options available, including ratification, revision or termination of such transaction. In the event that management determines that it is impractical or undesirable to wait until a meeting of the committee to consummate a related person
transaction, the chair of the committee may approve such transaction in accordance with the related person transaction approval policy. Any such approval must be reported to the committee at the next regularly scheduled meeting. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">46 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom802241_10"></A>PROPOSAL 1: ELECTION OF DIRECTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Constitution requires that each of our directors retire at each annual general meeting of our shareholders, and each retiring director is then eligible
for <FONT STYLE="white-space:nowrap">re-election.</FONT> The Board, acting on the recommendation of the Nominating and Corporate Governance Committee, has nominated each of Paul B. Bolno, M.D., MBA, Mark H.N. Corrigan, M.D., Christian Henry, Peter
Kolchinsky, Ph.D., Adrian Rawcliffe, Ken Takanashi, Aik Na Tan, Gregory&nbsp;L.&nbsp;Verdine, Ph.D. and Heidi L. Wagner, J.D. for election at the 2024 AGM. Voting on the election of each nominee will be done separately. If each such nominee is
elected, he or she will serve on our Board until our 2025 Annual General Meeting of Shareholders and until their successor has been elected and qualified. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the Singapore Companies Act and our Constitution, our Board must have at least one director who is ordinarily resident in Singapore. Ms.&nbsp;Tan
is our Singapore resident director. Due to the Singapore Companies Act requirement that we have at least one director who is ordinarily resident in Singapore in office at all times, the sole resident director cannot resign or step down unless there
is at least one other resident director. In the event that Ms.&nbsp;Tan is not elected at the 2024 AGM, she will continue in office after the 2024 AGM as a member of our Board until her qualifying successor (<I>i.e.</I>, a Singapore resident
director) is appointed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each of the nominees has indicated a willingness to continue to serve as director, if elected. We have no reason to believe that
any nominee will be unable or unwilling to serve as a director. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each nominee for director who receives the affirmative vote of a majority of the votes
cast by the holders of ordinary shares voting either in person or by proxy at the 2024 AGM will be elected (meaning the number of shares voted &#147;for&#148; a nominee must exceed the number of shares voted &#147;against&#148; such nominee). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>THE BOARD OF DIRECTORS RECOMMENDS A VOTE &#147;<U>FOR</U>&#148; THE ELECTION OF PAUL&nbsp;B.&nbsp;BOLNO, M.D., MBA, MARK H.N. CORRIGAN, M.D., CHRISTIAN
HENRY, PETER&nbsp;KOLCHINSKY, PH.D., ADRIAN RAWCLIFFE, KEN TAKANASHI, AIK NA TAN, GREGORY&nbsp;L.&nbsp;VERDINE, PH.D. AND HEIDI L. WAGNER, J.D. AS DIRECTORS, AND PROXIES SOLICITED BY THE BOARD WILL BE VOTED IN FAVOR THEREOF UNLESS A SHAREHOLDER HAS
INDICATED OTHERWISE ON THE PROXY CARD. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">47 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom802241_11"></A>PROPOSAL 2: INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM AND
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INDEPENDENT SINGAPORE AUDITOR AND </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AUDITOR REMUNERATION </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Audit Committee
has appointed KPMG LLP as our independent registered public accounting firm and independent Singapore auditor to audit our financial statements for the fiscal year ending December&nbsp;31, 2024. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the fiscal year ended December&nbsp;31, 2023, KPMG LLP was our independent registered public accounting firm and independent Singapore auditor of our
Singapore Statutory Financial Statements. Pursuant to Section&nbsp;205(2) and 205(4) of the Singapore Companies Act, any <FONT STYLE="white-space:nowrap">re-appointment</FONT> after the initial appointment of our independent Singapore auditor, or
its subsequent removal, requires the approval of our shareholders. The Board proposes that the shareholders approve the <FONT STYLE="white-space:nowrap">re-appointment</FONT> of KPMG LLP as our independent registered public accounting firm and
independent Singapore auditor of our Singapore Statutory Financial Statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We expect that representatives of KPMG LLP will be present at the 2024
AGM, will be able to make a statement if they so desire, and will be available to respond to appropriate questions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to Section&nbsp;205(16) of
the Singapore Companies Act, the remuneration of a company&#146;s auditor appointed by the company at a general meeting shall be fixed by the shareholders in a general meeting or the shareholders may authorize directors to fix the remuneration. Our
Board believes that it is appropriate for the Audit Committee, as part of its oversight responsibilities, to fix the auditor&#146;s remuneration. Our Board therefore also proposes that the shareholders authorize the Audit Committee to fix KPMG
LLP&#146;s remuneration for services rendered as our independent registered public accounting firm and independent Singapore auditor through the date of our 2025 Annual General Meeting of Shareholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In deciding to <FONT STYLE="white-space:nowrap">re-appoint</FONT> KPMG LLP, the Audit Committee reviewed auditor independence issues and existing commercial
relationships with KPMG LLP and concluded that KPMG LLP has no commercial relationship with the Company that would impair its independence for the fiscal year ending December&nbsp;31, 2024. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Principal Accountant Fees and Services </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our independent
registered public accounting firm is KPMG LLP, Boston, MA, Auditor Firm ID: 185. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table presents fees for professional audit services
rendered by KPMG LLP for the services described in the table. Fees disclosed below include fees actually billed or expected to be billed for services pertaining to the applicable fiscal year. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="66%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD ???? 1 VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Audit fees<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,338,799</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,209,625</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Audit-related fees<SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tax fees<SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">All other fees<SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Audit fees consisted of audit work performed in the preparation of financial statements, as well as work
generally only the independent registered public accounting firm and independent Singapore auditor can reasonably be expected to provide, such as statutory audits and the provision of consents in connection with the filing of registration statements
and related amendments, as well as other filings. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">There were no audit-related, tax or other fees in 2023 or 2022. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">48 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Policy on Audit Committee <FONT STYLE="white-space:nowrap">Pre-Approval</FONT> of Audit and Permissible <FONT
STYLE="white-space:nowrap">Non-Audit</FONT> Services of Independent Public Accounting Firm </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with our initial public offering, we adopted
a policy under which the Audit Committee must <FONT STYLE="white-space:nowrap">pre-approve</FONT> all audit and permissible <FONT STYLE="white-space:nowrap">non-audit</FONT> services to be provided by the independent registered public accounting
firm and independent Singapore auditor. As part of its review, the Audit Committee also considers whether the categories of <FONT STYLE="white-space:nowrap">pre-approved</FONT> services are consistent with the rules on accountant independence of the
SEC and the Public Company Accounting Oversight Board. The Audit Committee <FONT STYLE="white-space:nowrap">pre-approved</FONT> all services performed since the <FONT STYLE="white-space:nowrap">pre-approval</FONT> policy was adopted. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prior to engagement of an independent registered public accounting firm and independent Singapore auditor for the next year&#146;s audit, management will
submit an aggregate of services expected to be rendered during that year for each of four categories of services to the Audit Committee for approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1.
Audit services include audit work performed in the preparation of financial statements, as well as work that generally only an independent registered public accounting firm and independent Singapore auditor can reasonably be expected to provide,
including comfort letters, statutory audits, and attest services and consultation regarding financial accounting and/or reporting standards. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2.
Audit-related services are for assurance and related services that are traditionally performed by an independent registered public accounting firm and independent Singapore auditor, including due diligence related to mergers and acquisitions,
employee benefit plan audits, and special procedures required to meet certain regulatory requirements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">3. Tax services include all services performed by
an independent registered public accounting firm&#146;s tax personnel except those services specifically related to the audit of the financial statements, and include fees in the areas of tax compliance, tax planning, and tax advice. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">4. Other fees are those associated with services not captured in the other categories. We generally do not request such services from our independent
registered public accounting firm and independent Singapore auditor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prior to engagement, the Audit Committee
<FONT STYLE="white-space:nowrap">pre-approves</FONT> these services by category of service. During the year, circumstances may arise when it may become necessary to engage our independent registered public accounting firm and independent Singapore
auditor for additional services not contemplated in the original <FONT STYLE="white-space:nowrap">pre-approval.</FONT> In those instances, the Audit Committee requires specific <FONT STYLE="white-space:nowrap">pre-approval</FONT> before engaging our
independent registered public accounting firm and independent Singapore auditor. The Audit Committee may delegate <FONT STYLE="white-space:nowrap">pre-approval</FONT> authority to one or more of its members. The member to whom such authority is
delegated must report, for informational purposes only, any <FONT STYLE="white-space:nowrap">pre-approval</FONT> decisions to the Audit Committee at its next scheduled meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The affirmative vote of a majority of the votes cast by holders of ordinary shares voting in person or by proxy at the 2024 AGM is required to approve <FONT
STYLE="white-space:nowrap">the&nbsp;re-appointment&nbsp;of</FONT> KPMG LLP as our independent registered public accounting firm and our independent Singapore auditor and to authorize the Audit Committee to fix the auditor&#146;s remuneration
(meaning the number of shares voted &#147;for&#148; the proposal must exceed the number of shares voted &#147;against&#148; the proposal). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>THE BOARD
OF DIRECTORS RECOMMENDS A VOTE </B>&#147;<B><U>FOR</U></B>&#148;<B> THE APPROVAL OF THE <FONT STYLE="white-space:nowrap">RE-APPOINTMENT</FONT> OF KPMG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM AND INDEPENDENT SINGAPORE AUDITOR FOR THE
YEAR ENDING DECEMBER</B><B></B><B>&nbsp;31, 2024 AND THE AUTHORIZATION OF THE AUDIT COMMITTEE TO FIX KPMG LLP&#146;S REMUNERATION FOR SUCH SERVICES, AND PROXIES SOLICITED BY THE BOARD WILL BE VOTED IN FAVOR OF SUCH APPROVAL AND AUTHORIZATION UNLESS
A SHAREHOLDER INDICATES OTHERWISE ON THE PROXY CARD. </B> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">49 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom802241_12"></A>PROPOSAL 3:
<FONT STYLE="white-space:nowrap">NON-EMPLOYEE</FONT> DIRECTORS&#146; COMPENSATION </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the laws of Singapore, our shareholders must approve the
compensation we pay to our directors for services rendered in their capacity as directors. Directors who are also our employees are not eligible to receive compensation from us for services rendered in their capacity as directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director Compensation Policy</U></B>. At our 2023 AGM, our shareholders approved our 2023 <FONT
STYLE="white-space:nowrap">Non-Employee</FONT> Director Compensation Policy, under which our directors were compensated for their service as directors, including as members of the various committees of our Board on which they serve, for the Board
service period that commenced on the date of our 2023 AGM and runs through our 2024 AGM. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are now asking our shareholders to approve the terms of our
2024 <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director Compensation Policy, which would take effect on the date shareholder approval is obtained for this Proposal 3 and enable us to provide payment of the compensation described under
(A)&nbsp;Cash Compensation and (B)&nbsp;Equity Compensation below to our <FONT STYLE="white-space:nowrap">non-employee</FONT> directors for their service on our Board and its committees for the service period commencing on the date of our 2024 AGM
and running through the date on which our 2025 Annual General Meeting of Shareholders is held. The terms of our 2024 <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director Compensation Policy we are asking that you approve are described
below. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(A)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Cash Compensation</U>: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I><U>Board of Directors</U></I>: Annual cash compensation of $40,000 to each
<FONT STYLE="white-space:nowrap">non-employee</FONT> director, other than the Chair of the Board, and cash compensation of $75,000 to the <FONT STYLE="white-space:nowrap">non-employee</FONT> Chair of the Board. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I><U>Audit Committee</U></I>: Additional annual cash compensation of $20,000 to the Chair of the Audit Committee
and $10,000 to each member of the Audit Committee other than the Chair. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I><U>Compensation Committee</U></I>: Additional annual cash compensation of $15,000 to the Chair of the
Compensation Committee and $7,500 to each member of the Compensation Committee other than the Chair. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I><U>Nominating and Corporate Governance Committee</U></I>: Additional annual cash compensation of $15,000 to
the Chair of the Nominating and Corporate Governance Committee and $7,500 to each member of the Nominating and Corporate Governance Committee other than the Chair. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I><U>Research and Development Committee</U></I>: Additional annual cash compensation of $15,000 to the Chair of
the Research and Development Committee and $7,500 to each member of the Research and Development Committee other than the Chair. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I><U>Proration</U></I>: Additional pro rata cash compensation of the annual cash compensation amounts set forth
above shall be made, as applicable, to (i)&nbsp;any director who ceases to be a director, Chair of the Board or member or chair of any committee of the Board and (ii)&nbsp;any new <FONT STYLE="white-space:nowrap">non-employee</FONT> director who is
appointed by the Board, any <FONT STYLE="white-space:nowrap">non-employee</FONT> director who is appointed to the position of Chair of the Board or chair of any such committee of the Board or any <FONT STYLE="white-space:nowrap">non-employee</FONT>
director who is appointed to serve on any such committee of the Board, for their services rendered as a director and/or committee member, for the portion of the year in which such director so served. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(B)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Equity Compensation</U>: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I><U>Initial Equity Grant</U></I>: <FONT STYLE="white-space:nowrap">One-time</FONT> equity grant upon initial
appointment or election to the Board of (i)&nbsp;an option to purchase 64,460 ordinary shares, which shall vest as to 12.5% of the shares on a quarterly basis during the <FONT STYLE="white-space:nowrap">two-year</FONT> period following the grant
date; and (ii)&nbsp;a restricted share unit award of 32,230 ordinary shares, which shall vest as to 50% of the shares on the earlier of (x)&nbsp;the following year&#146;s annual general meeting of shareholders or (y)&nbsp;the following year&#146;s
anniversary of the grant date, in each case during the two-year period following the grant date. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">50 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I><U>Refresh Equity Grant</U></I>: Each <FONT STYLE="white-space:nowrap">non-employee</FONT> director whose
initial equity grant has an expiration date within twelve months following the 2024 AGM shall be granted (i)&nbsp;an option to purchase 64,460 ordinary shares, which shall vest as to 12.5% of the shares on a quarterly basis during the <FONT
STYLE="white-space:nowrap">two-year</FONT> period following the grant date; and (ii)&nbsp;a restricted share unit award of 32,230 ordinary shares, which shall vest as to 50% of the shares on the earlier of (x)&nbsp;the following year&#146;s annual
general meeting of shareholders or (y)&nbsp;the following year&#146;s anniversary of the grant date, in each case during the two-year period following the grant date. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I><U>Annual Equity Grant</U></I><I>:</I> Annual equity grant of (i)&nbsp;an option to purchase 32,230 ordinary
shares, which shall vest as to 100% of the shares on the earlier of the 2025 Annual General Meeting of Shareholders or the first anniversary of the grant date; and (ii)&nbsp;a restricted share unit award of 16,115 ordinary shares, which shall vest
as to 100% of the shares on the earlier of the 2025 Annual General Meeting of Shareholders or the first anniversary of the grant date. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I><U>Limitation on Equity Grants</U></I>: A <FONT STYLE="white-space:nowrap">non-employee</FONT> director shall
be eligible to receive only one type of option grant at the 2024 AGM, which shall be an initial equity grant, a refresh equity grant, or an annual equity grant, in each case as described above. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">*&#8195;&#8195;&#8195;&#8195;* &#8195;&#8195;&#8195;&#8195;* </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Singapore law requires that options granted to our directors who do not hold a salaried office or employment in Wave or its related corporations <FONT
STYLE="white-space:nowrap">(&#147;non-employee</FONT> directors&#148;) have a term of no more than five years. By contrast, our peer companies incorporated in the United States are able to grant options with significantly longer terms and, when
granting options to their <FONT STYLE="white-space:nowrap">non-employee</FONT> directors, generally grant options with <FONT STYLE="white-space:nowrap">10-year</FONT> terms. This significant difference in term of options may put us at a competitive
disadvantage with our peer companies in connection with the recruitment and retention of independent directors. In addition, certain of our long-standing <FONT STYLE="white-space:nowrap">non-employee</FONT> directors have been serving on our Board
for periods approaching or exceeding five years and, as a result, have had, or may have in the near future, their prior option grants expire. In order to address this disparity with our peer companies resulting from the impact of the five-year term
limitation on options for <FONT STYLE="white-space:nowrap">non-employee</FONT> directors under Singapore law, we are proposing to alter the mix of our equity grants to <FONT STYLE="white-space:nowrap">non-employee</FONT> directors to include both
options as well as restricted share units, and to make a refresh equity grant of options and restricted share units to any <FONT STYLE="white-space:nowrap">non-employee</FONT> director whose initial equity grant has an expiration date within twelve
months following the 2024 AGM, as described above. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We believe the authorizations requested in this Proposal 3 will benefit our shareholders by enabling
us to attract and retain qualified individuals to serve as members of our Board and to continue to provide advice to, and independent oversight of, management. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The affirmative vote of a majority of the votes cast by holders of ordinary shares voting in person or by proxy at the 2024 AGM is required to approve the <FONT
STYLE="white-space:nowrap">non-employee</FONT> directors&#146; compensation policy (meaning the number of shares voted &#147;for&#148; the proposal must exceed the number of shares voted &#147;against&#148; the proposal). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>THE BOARD OF DIRECTORS RECOMMENDS A VOTE &#147;<U>FOR</U>&#148; THE APPROVAL OF THE <FONT STYLE="white-space:nowrap">NON-EMPLOYEE</FONT> DIRECTORS&#146;
COMPENSATION AND PROXIES SOLICITED BY THE BOARD WILL BE VOTED IN FAVOR THEREOF UNLESS A SHAREHOLDER HAS INDICATED OTHERWISE ON THE PROXY CARD. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">51 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom802241_13"></A>PROPOSAL 4: APPROVAL OF AN AMENDMENT TO THE 2021 EQUITY
INCENTIVE PLAN, AS AMENDED </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Board is
requesting that our shareholders approve an amendment to the Wave Life Sciences Ltd. 2021 Equity Incentive Plan, as amended (the &#147;2021 Plan&#148;), to increase the total number of ordinary shares available for issuance by 5,000,000, as
recommended by the Compensation Committee and approved by our Board on June&nbsp;5, 2024, such amendment to be effective upon approval by our shareholders at the 2024 AGM. If this proposal is approved, the number of shares authorized for issuance of
awards under the 2021 Plan will be increased from 17,950,000 to an aggregate of 22,950,000 ordinary shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of June&nbsp;5, 2024, a total of 2,034,356
ordinary shares remained available for issuance under the 2021 Plan and options to purchase 20,411,077 ordinary shares and awards for 368,436 restricted share units, and 292,264 performance-based restricted share units were outstanding under both
our 2021 Plan and our 2014 Plan. The shares currently available for future issuance under the 2021 Plan represent less than <FONT STYLE="white-space:nowrap">one-half</FONT> of our projected needs for the next year, which provides limited
availability and flexibility for our equity usage as part of our broad-based equity program. We expect the increase in shares under the 2021 Plan that we are requesting to last at least through our 2025 Annual General Meeting of Shareholders. As of
June&nbsp;5, 2024, the Company&#146;s equity overhang, represented by (a)&nbsp;the sum of all outstanding share options and other awards, plus the number of shares available for issuance pursuant to future awards under the 2021 Plan, as a percentage
of (b)&nbsp;the sum of (i)&nbsp;the number of ordinary shares outstanding as of June&nbsp;5, 2024, plus (ii)&nbsp;the number of shares described in clause (a)&nbsp;above, was 15.87%. If the amendment to the 2021 Plan is approved by our shareholders,
the equity overhang would be 18.67%. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of June&nbsp;5, 2024, 13% of our outstanding share options were underwater, with such underwater options having a
weighted-average exercise price of $17.79 per share, a weighted average term of 4.23 years and individual option exercise prices ranging up to $50.00 per share, as compared to the $6.23 per share closing price of our ordinary shares as reported by
the Nasdaq Stock Market on June&nbsp;5, 2024. As of June&nbsp;5, 2024, all outstanding share options had a weighted-average exercise price of $5.75 per share and weighted average term of 7.61 years. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The purpose of the 2021 Plan is to assist the Company and its subsidiaries in attracting, motivating, retaining and rewarding high-quality executives and
other employees, officers, directors, and consultants who provide services to the Company or its subsidiaries, by enabling such persons to acquire or increase a proprietary interest in the Company to align the interests between such persons and the
Company&#146;s shareholders, and providing such persons with incentives to expend their maximum efforts in the creation of shareholder value. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Reasons
for an Amendment to the 2021 Plan </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The Board believes that the number of ordinary shares currently remaining available for issuance pursuant to
future awards under the 2021 Plan (as of June&nbsp;5, 2024) is not sufficient for the Company&#146;s future granting needs. As of June&nbsp;5, 2024, there were approximately 275 employees and consultants, and eight
<FONT STYLE="white-space:nowrap">non-employee</FONT> directors eligible to participate in the 2021 Plan. Our Board, the Compensation Committee and management believe that the effective use of share-based long-term incentive compensation is vital to
our ability to achieve strong performance in the future. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We believe that maintaining the broad-based equity program is essential to aligning shareholder and
employees&#146; interests while providing high motivation, retention, and potential upside value over the long term. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">In addition, our future success depends, in large part, upon our ability to maintain a competitive position in
attracting, retaining, and motivating key personnel. We believe that an increase in the number of ordinary shares available for issuance under our 2021 Plan is essential to permit us to continue to provide long-term, equity-based incentives to
present and future employees, directors, and consultants. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">52 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The 2021 Plan authorizes the Board or a committee of the Board to grant incentive share options, <FONT
STYLE="white-space:nowrap">non-qualified</FONT> share options, share appreciation rights and restricted share and share unit awards to eligible employees, <FONT STYLE="white-space:nowrap">non-employee</FONT> directors and consultants of the Company.
By its terms, the 2021 Plan may be amended by the Board provided that any amendment that the Board determines requires shareholder approval is subject to receiving such shareholder approval. Approval by our shareholders is required by the listing
rules of the Nasdaq Stock Market. In addition, shareholder approval is required in order to ensure favorable federal income tax treatment for grants of incentive share options under Section&nbsp;422 of the Code. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Promotion of Good Corporate Governance Practices </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
2021 Plan includes the following provisions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>No Liberal Share Recycling &#151;</I> ordinary shares that are withheld to satisfy any tax withholding
obligation related to any share award, for payment of the exercise price or purchase price of any share award, and ordinary shares repurchased by the Company on the open market with the proceeds of the exercise price of an option or share
appreciation right will not become available again for issuance under the 2021 Plan; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>No Discounted Share Options or Share Appreciation Rights</I><B> </B>&#151; share options and share
appreciation rights may not be granted with exercise prices lower than the fair market value of the underlying ordinary shares on the grant date except to replace equity awards due to a corporate transaction; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>No Repricing without Shareholder Approval</I><B> </B>&#151; we may not, without shareholder approval, reprice
the purchase price or the exercise price of any outstanding award; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>No Evergreen Provision</I> &#151; the number of authorized shares under the 2021 Plan, if amended following
the approval of this proposal, will be fixed at 22,950,000 ordinary shares. The 2021 Plan, does not include an &#147;evergreen&#148; feature that would cause the number of authorized shares to automatically increase in future years under the 2021
Plan; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>No Transferability</I><B> </B>&#151; awards generally may not be transferred, except by will or the laws of
descent and distribution, unless approved by the Compensation Committee; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Clawback Policy </I>&#151; awards will be subject to recoupment in accordance with any clawback policy that
the Company is required to adopt pursuant to the listing standards of any national securities exchange or association on which its securities are listed or as is otherwise required by the Dodd-Frank Wall Street Reform and Consumer Protection Act or
other applicable law, including the Company&#146;s Clawback Policy adopted in October 2023. In addition, the Company may impose other clawback, recovery or recoupment provisions allowing the Company to recover from a participant any compensation
received from any award (whether or not vested or settled) or cause a participant to forfeit any award (whether or not vested); and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>No Dividends or Dividend Equivalents </I>&#151; we may not pay dividends or dividend equivalents before the
vesting of the underlying award. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following is a brief summary of the 2021 Plan. This summary is qualified in its entirety by
reference to the text of the 2021 Plan, as amended, a copy of which is attached as <U>Appendix B</U> to this proxy statement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Summary of Material
Features of our 2021 Plan </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Eligibility. </B>The 2021 Plan, allows us, under the direction of our Compensation Committee, to make grants of incentive
share options, <FONT STYLE="white-space:nowrap">non-qualified</FONT> share options, share appreciation rights and restricted share and share unit awards to employees, consultants and directors who, in the opinion of the Compensation Committee, are
in a position to make a significant contribution to our long-term success. All employees, directors and consultants of the Company and its affiliates are eligible to participate in the 2021 Plan. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">53 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Shares Available for Issuance</B>. The 2021 Plan, if amended following the approval of this proposal,
provides for the issuance of up to 22,950,000 ordinary shares plus the number of ordinary shares underlying any awards under the 2014 Plan that are forfeited, canceled or otherwise terminated (other than by exercise or withheld by the Company to
satisfy any tax withholding obligation) on or after the date the 2021 Plan was initially approved by our shareholders. Generally, ordinary shares that are reserved for awards under the 2021 Plan, that lapse or are canceled (other than by exercise)
will be added back to the share reserve available for future awards. However, ordinary shares tendered in payment for an award, ordinary shares withheld for taxes, ordinary shares covered by a share-settled share appreciation right or other award
that was not issued upon the settlement of the award, and ordinary shares repurchased by the Company on the open market with the proceeds of the exercise price of an option or share appreciation right are not available again for future awards. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Share Options.</B> Share options granted under the 2021 Plan, may either be incentive share options, which are intended to satisfy the requirements of
Section&nbsp;422 of the Code, or <FONT STYLE="white-space:nowrap">non-qualified</FONT> share options, which are not intended to meet those requirements. Incentive share options may be granted to U.S. employees of the Company and its affiliates. <FONT
STYLE="white-space:nowrap">Non-qualified</FONT> share options may be granted to employees, directors and consultants of the Company and its affiliates. The exercise price of a share option may not be less than 100% of the fair market value of our
ordinary shares on the date of grant and the term of the option may not be longer than ten years, except for <FONT STYLE="white-space:nowrap">non-qualified</FONT> share options granted to <FONT STYLE="white-space:nowrap">non-employee</FONT>
directors and consultants which will have a maximum term of five years. If an incentive share option is granted to an individual who owns more than 10% of the combined voting power of all classes of our share capital, the exercise price may not be
less than 110% of the fair market value of our ordinary shares on the date of grant and the term of the option may not be longer than five years. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Award
agreements for share options include rules for exercise of the share options after termination of service. Share options may not be exercised unless they are vested, and no share option may be exercised after the end of the term set forth in the
award agreement. Generally, share options will be exercisable for three months after termination of service for any reason other than death or total and permanent disability, and for 12&nbsp;months after termination of service on account of death or
total and permanent disability but will not be exercisable if the termination of service was due to cause. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Restricted Shares.</B> Restricted shares
are ordinary shares that are subject to restrictions, including a prohibition against transfer and a substantial risk of forfeiture, until the end of a &#147;restricted period&#148; during which the recipient must satisfy certain vesting conditions.
If the recipient does not satisfy the vesting conditions by the end of the restricted period, the restricted shares are forfeited. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the restricted
period, the holder of restricted shares has the rights and privileges of a regular shareholder, except that the holder of such restricted shares is not entitled to receive dividends during the restricted period and the restrictions set forth in the
applicable award agreement apply. For example, the holder of restricted shares may vote and accrue dividends on the restricted shares; but he or she may not sell the shares until the restrictions are lifted and dividends will be forfeited if the
restricted shares are forfeited. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Restricted Share Units.</B> A restricted share unit is an award entitling the recipient to receive ordinary shares to
be delivered at the time such award vests pursuant to the terms and conditions established in the award agreement. The award agreement may provide the recipient with the right to receive dividends or other distributions declared and paid on an equal
number of outstanding ordinary shares, which we refer to as dividend equivalents. Dividend equivalents must be subject to the same restrictions on transfer and forfeitability as the restricted share units with respect to which they are paid. A
recipient will have no voting rights with respect to any restricted share units unless and until ordinary shares are&nbsp;issued. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Restricted awards may
be granted at the sole discretion of the Compensation Committee, with vesting conditions based on the attainment of written performance goals. The Compensation Committee shall determine the performance period and whether, with respect to a
performance period, the applicable performance goals have been met. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">54 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Share Appreciation Rights</B>. A share appreciation right is an award entitling the recipient, upon
exercise, to receive an amount payable in cash or ordinary shares equal to the number of ordinary shares subject to the share appreciation right that is being exercised multiplied by the excess of (a)&nbsp;the fair market value of an ordinary share
on the date the award is exercised, over (b)&nbsp;the exercise price. The exercise price may not be less than 100% of the fair market value on the date the share appreciation right is granted and may not be granted with a term in excess of
ten&nbsp;years. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Plan Administration.</B> In accordance with the terms of the 2021 Plan, our Board has authorized our Compensation Committee to
administer the 2021 Plan. The Compensation Committee may delegate part of its authority and powers under the 2021 Plan, to one or more of our directors and/or officers, but only the Compensation Committee can make awards to participants who are
subject to the reporting and other requirements of Section&nbsp;16 of the Exchange Act. In accordance with the provisions of the 2021 Plan, our Compensation Committee determines the terms of awards, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">which employees, directors and consultants will be granted awards; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number of ordinary shares subject to each award; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the vesting provisions of each award; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the termination or cancellation provisions applicable to awards; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">all other terms and conditions upon which each award may be granted in accordance with the 2021 Plan.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, our Compensation Committee may, in its discretion, amend any term or condition of an outstanding award provided
(i)&nbsp;such term or condition as amended is permitted by our 2021 Plan, and (ii)&nbsp;any such amendment shall be made only with the consent of the participant to whom such award was made, if the amendment is adverse to the participant; and
provided, further, that, without the prior approval of our shareholders, awards will not be repriced, replaced or regranted through cancellation or by lowering the exercise price of a previously granted award. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Share Dividends and Share Splits.</B> If our ordinary shares shall be subdivided or combined into a greater or smaller number of ordinary shares or if we
issue any ordinary shares as a share dividend, the number of ordinary shares deliverable upon exercise of an option issued or upon issuance of an award shall be appropriately increased or decreased proportionately, and appropriate adjustments shall
be made in the purchase price per share and performance goals applicable to performance awards, if any, to reflect such subdivision, combination or share dividend. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Corporate Transactions.</B> If we are acquired, our Board or Compensation Committee will with respect to share options and share appreciation rights:
(i)&nbsp;make appropriate provision for the continuation of the share option or share appreciation right by substituting on an equitable basis for the ordinary shares then subject to such share option or share appreciation right either the
consideration payable with respect to the outstanding ordinary shares in connection with the corporate transaction or securities of any successor or acquiring entity; (ii)&nbsp;cancel or arrange for the cancellation of the share options or share
appreciation rights, to the extent not vested or exercised prior to the effective time of the transaction, in exchange for a payment in cash or ordinary shares as determined by our Board, in an amount equal to the amount by which the then fair
market value of the ordinary shares subject to such vested share option or share appreciation right exceeds the exercise price; or (iii)&nbsp;after giving holders an opportunity to exercise to the extent vested their outstanding share options or
share appreciation rights, terminate any or all unexercised share options and share appreciation rights at such time as the Board deems appropriate. With respect to outstanding restricted awards, our Board or Compensation Committee shall make
appropriate provision for the continuation of such restricted awards on the same terms and conditions by substituting on an equitable basis for the ordinary shares then subject to such restricted awards either the consideration payable with respect
to the outstanding ordinary shares in connection with the transaction or securities of any successor or acquiring entity. In lieu of the foregoing, if we are acquired, our Board may </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">55 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
provide that, upon consummation of the acquisition, each outstanding restricted award shall be terminated in exchange for payment of an amount equal to the consideration payable upon consummation
of such transaction to a holder of the number of ordinary shares comprising such restricted award to the extent then vested. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Amendment and
Termination. </B>The 2021 Plan may be amended by our shareholders. It may also be amended by our Board, provided that any amendment approved by our Board which is of a scope that requires shareholder approval as required by (i)&nbsp;the rules of the
Nasdaq Stock Market, (ii)&nbsp;in order to ensure favorable federal income tax treatment for any incentive share options under Code Section&nbsp;422, or (iii)&nbsp;for any other reason, is subject to obtaining such shareholder approval. In addition,
other than in connection with share dividends, share splits, recapitalizations or reorganizations, the Compensation Committee may not without shareholder approval reduce the exercise price or cancel any outstanding option in exchange for a
replacement option having a lower exercise price. In addition, we may not take any other action that is considered a direct or indirect &#147;repricing&#148; for purposes of the shareholder approval rules of the applicable securities exchange or
inter-dealer quotation system on which the ordinary shares are listed, including any other action that is treated as a repricing under generally accepted accounting principles. However, no such action may adversely affect any rights under any
outstanding award without the holder&#146;s consent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Duration of 2021 Plan.</B> The 2021 Plan will expire by its terms on August&nbsp;10, 2031. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Federal Income Tax Considerations </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The material federal
income tax consequences of the issuance and exercise of share options and other awards under the 2021 Plan, based on the current provisions of the Code and regulations, are as follows. Changes to these laws could alter the tax consequences described
below. This summary assumes that all awards granted under the 2021 Plan are exempt from or comply with, the rules under Section&nbsp;409A of the Code related to nonqualified deferred compensation. This summary is not intended to be exhaustive and
does not discuss the income tax laws of any local, state or foreign jurisdiction in which a participant may reside. The information is based upon current federal income tax rules and therefore is subject to change when those rules change. Because
the tax consequences to any participant may depend on their particular situation, each participant should consult the participant&#146;s tax adviser regarding the federal, state, local and other tax consequences of the grant or exercise of an award
or the disposition of ordinary shares acquired under the 2021 Plan. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="23%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="75%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Incentive&nbsp;Share&nbsp;Options:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Incentive share options are intended to qualify for treatment under Section&nbsp;422 of the Code. An incentive share option does not result in taxable income to the optionee or deduction to us at the time it is granted or exercised,
provided that no disposition is made by the optionee of the ordinary shares acquired pursuant to the incentive share option within two years after the date of grant of the incentive share option nor within one year after the date of issuance of
ordinary shares to the optionee (referred to as the &#147;ISO holding period&#148;). However, the difference between the fair market value of the ordinary shares on the date of exercise and the incentive share option exercise price will be an item
of tax preference includible in &#147;alternative minimum taxable income&#148; of the optionee. Upon disposition of the ordinary shares after the expiration of the ISO holding period, the optionee will generally recognize long term capital gain or
loss based on the difference between the disposition proceeds and the incentive share option exercise price paid for the ordinary shares. If the ordinary shares are disposed of prior to the expiration of the ISO holding period, the optionee
generally will recognize taxable compensation, and we will have a corresponding deduction, in the year of the disposition, equal to the excess of the fair market value of the ordinary shares on the date of exercise of the incentive share option over
the incentive share option exercise price. Any additional gain realized on the disposition will normally constitute capital gain. If the amount realized upon such a disqualifying disposition is less than fair
market</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">56 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="23%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="75%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD ???? 1 VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">value of the ordinary shares on the date of exercise, the amount of compensation income will be limited to the excess of the amount realized over the optionee&#146;s adjusted basis in the ordinary shares.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B><FONT STYLE="white-space:nowrap">Non-Qualified&nbsp;Share</FONT> Options:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Options otherwise qualifying as incentive share options, to the extent the aggregate fair market value of ordinary shares with respect to which such options are first exercisable by an individual in any calendar year exceeds
$100,000, and share options designated as <FONT STYLE="white-space:nowrap">non-qualified</FONT> share options will be treated as options that are not incentive share options.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD ???? 1 VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">A <FONT STYLE="white-space:nowrap">non-qualified</FONT> share option ordinarily will not result in income to the optionee or deduction to us at the time of grant. The optionee will recognize compensation income at the time of
exercise of such <FONT STYLE="white-space:nowrap">non-qualified</FONT> share option in an amount equal to the excess of the then value of the ordinary shares over the option exercise price per share. Such compensation income of optionees may be
subject to withholding taxes, and a deduction may then be allowable to us in an amount equal to the optionee&#146;s compensation income.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD ???? 1 VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">An optionee&#146;s initial basis in ordinary shares so acquired will be the amount paid on exercise of the <FONT STYLE="white-space:nowrap">non-qualified</FONT> share option plus the amount of any corresponding compensation income.
Any gain or loss as a result of a subsequent disposition of the ordinary shares so acquired will be capital gain or loss.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Share Grants:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">With respect to share grants under our 2021 Plan that result in the issuance of ordinary shares that are either not restricted as to transferability or not subject to a substantial risk of forfeiture, the grantee must generally
recognize ordinary income equal to the fair market value of ordinary shares received. Thus, deferral of the time of issuance will generally result in the deferral of the time the grantee will be liable for income taxes with respect to such issuance.
We generally will be entitled to a deduction in an amount equal to the ordinary income recognized by the grantee.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD ???? 1 VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">With respect to share grants involving the issuance of ordinary shares that are restricted as to transferability and subject to a substantial risk of forfeiture, the grantee must generally recognize ordinary income equal to the fair
market value of the ordinary shares received at the first time the ordinary shares become transferable or are not subject to a substantial risk of forfeiture, whichever occurs earlier. A grantee may elect to be taxed at the time of receipt of
ordinary shares rather than upon lapse of restrictions on transferability or substantial risk of forfeiture, but if the grantee subsequently forfeits such ordinary shares, the grantee would not be entitled to any tax deduction, including as a
capital loss, for the value of the ordinary shares on which the grantee previously paid tax. The grantee must file such election with the Internal Revenue Service within 30 days of the receipt of the ordinary shares. We generally will be entitled to
a deduction in an amount equal to the ordinary income recognized by the grantee.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Restricted&nbsp;Share Units:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">The grantee recognizes no income until the issuance of the ordinary shares. At that time, the grantee must generally recognize ordinary income equal to the fair market value of the ordinary shares received. We generally will be
entitled to a deduction in an amount equal to the ordinary income recognized by the grantee.</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">57 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="23%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="75%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Share&nbsp;Appreciation Rights:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Generally, if a share appreciation right is granted with an exercise price equal to the fair market value of the underlying ordinary shares on the grant date, the grantee will recognize ordinary income equal to the fair market value
of the ordinary shares received upon such exercise. We generally will be entitled to a deduction in an amount equal to the ordinary income recognized by the grantee.</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Limitation on Our Deductions. </B>As a general rule, the Company will be entitled to a deduction in the same amount and at
the same time as the compensation income is received by a participant, except to the extent the deduction limits of Section&nbsp;162(m) of the Code apply. Section&nbsp;162(m) of the Code denies a deduction to any publicly held corporation for
compensation paid to any &#147;covered employee&#148; in a taxable year to the extent that compensation to such covered employee exceeds $1,000,000. It is possible that compensation attributable to a covered employee, including awards under the 2021
Plan, may cause this limitation to be exceeded in any particular year. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Plan Benefits </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Since the adoption of the 2021 Plan through June&nbsp;5, 2024, we have granted the following share options and restricted share unit awards under the 2021 Plan
to the individuals and groups listed below. In all cases, the securities underlying such share options and restricted share unit awards were our ordinary shares: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="59%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name and Position</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of&nbsp;Share<BR>Options</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Restricted&nbsp;Share<BR>Unit Awards</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Paul&nbsp;B.&nbsp;Bolno,&nbsp;M.D., MBA</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,559,600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Chandra Vargeese, Ph.D.</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">917,100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Kyle Moran, CFA</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">879,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>All current executive officers as a group</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,082,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>All current directors who are not executive officers as a group</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">964,467</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>All current employees who are not executive officers as a group</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,591,850</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">426,625</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Other than as discussed above in our director compensation policy in the section entitled &#147;Executive Officer and Director
Compensation,&#148; the amounts of future grants under the 2021 Plan, are not determinable as awards under the 2021 Plan, and will be granted at the sole discretion of the Compensation Committee, or other delegated persons and we cannot determine at
this time either the persons who will receive awards under the 2021 Plan, or the amount or types of any such awards. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On June&nbsp;5, 2024, the closing
market price per share of our ordinary shares was $6.23 as reported by the Nasdaq Stock Market. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Accordingly, our Board seeks shareholder approval of
Ordinary Resolution 4 as set out in the Notice. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The affirmative vote of a majority of the votes cast by holders of ordinary shares voting in person or by
proxy at the 2024 AGM is required to approve the amendment to the 2021 Plan (meaning the number of shares voted &#147;for&#148; the proposal must exceed the number of shares voted &#147;against&#148; the proposal). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>THE BOARD OF DIRECTORS RECOMMENDS A VOTE &#147;<U>FOR</U>&#148; THE AMENDMENT TO THE 2021 EQUITY INCENTIVE PLAN, AS AMENDED, TO INCREASE THE TOTAL NUMBER
OF ORDINARY SHARES AVAILABLE FOR ISSUANCE UNDER THE 2021 EQUITY INCENTIVE PLAN, AS AMENDED, BY 5,000,000 ORDINARY SHARES AND PROXIES SOLICITED BY THE BOARD WILL BE VOTED IN FAVOR THEREOF UNLESS A SHAREHOLDER HAS INDICATED OTHERWISE ON THE PROXY
CARD. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">58 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom802241_14"></A>PROPOSAL 5: ORDINARY SHARE ALLOTMENTS AND ISSUANCES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are incorporated in the Republic of Singapore. Under the laws of Singapore, our directors may issue ordinary shares and make offers or agreements or grant
options that might or would require the issuance of ordinary shares only with the prior approval of our shareholders. We are submitting this proposal to authorize our Board (or a committee thereof) to allot and issue our ordinary shares from time to
time, as set forth below, because we are required to do so under the laws of Singapore before we can issue any ordinary shares in connection with our equity compensation plans, possible future strategic transactions, or public and private equity
offerings. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Many of our peer companies are incorporated and listed in the United States, and are thus not subject to similar share issuance restrictions
mandated by the laws of Singapore. We are asking you to approve this proposal to allow us to continue to execute on our business and growth strategy in a timely and competitive manner. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If this proposal is approved, the authorization would be effective from the date of the 2024 AGM and continue until the earlier of (i)&nbsp;the conclusion of
our 2025 Annual General Meeting of Shareholders; or (ii)&nbsp;the expiration of the period within which our 2025 Annual General Meeting of Shareholders is required by the laws of Singapore to be held. Our 2025 Annual General Meeting of Shareholders
is required to be held no later than 15&nbsp;months after the date of the 2024 AGM or within six months after the 2024 financial year end, whichever is earlier.<B><I> </I></B>The laws of Singapore allow for an application to be made to the Singapore
Accounting and Corporate Regulatory Authority to extend the deadline for holding an annual general meeting for an additional sixty days, which may be granted in the discretion of that authority. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Board believes that it is advisable and in the best interests of our shareholders for our shareholders to authorize the directors to issue ordinary shares
and to make, enter into or grant offers, agreements or options that might or would require the issuance of ordinary shares. In the future, the directors may need to issue ordinary shares or make agreements that would require the allotment and
issuance of new ordinary shares. For example, we may issue ordinary shares: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in connection with strategic transactions and acquisitions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">pursuant to public and private offerings of our ordinary shares, as well as instruments (including debt
instruments) convertible into our ordinary shares; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in connection with our equity compensation plans and arrangements. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notwithstanding this general authorization to allot and issue our ordinary shares, we will be required to seek shareholder approval with respect to future
issuances of ordinary shares, where required under the Nasdaq Stock Market rules, such as if we were to propose an issuance of ordinary shares that would result in a change in control of the Company, which Nasdaq generally considers to occur where a
stockholder acquires 20% of a company&#146;s outstanding ordinary shares or voting power, or in connection with certain transactions involving the issuance of ordinary shares representing 20% or more of our outstanding ordinary shares. Furthermore,
our Board is bound by its fiduciary duties to our shareholders, which duties include requiring board members to act in good faith and in the best interests of the Company, to exercise due care, skill and diligence in the performance of their duties,
and to avoid conflicts of interest. Accordingly, in connection with any future issuances of equity securities, our Board will need to conclude that any such issuance is in the best interest of our shareholders, including, without limitation, taking
into account the dilutive impact of any such issuance on existing shareholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We believe the approval of this annually required proposal will provide
us with the continued ability to operate and raise equity capital through our next annual general meeting, at which time we would need to return to shareholders for additional approval. We have publicly stated that we believe our current cash and
cash equivalents will be sufficient to fund operations into the fourth quarter of 2025. We believe it is in the interests of all shareholders to ensure that we retain the ability to raise equity capital on reasonably short notice if advisable. This
proposal is consistent with U.S. capital markets practice and governance standards, and, if approved, will keep us on an equal footing with our peer companies who are incorporated and listed in the United States. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">59 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We expect that we will continue to issue ordinary shares and grant share options and other equity-based
awards in the future under circumstances similar to those in the past. As of the date of this proxy statement, other than issuances of ordinary shares or agreements that would require the issuance of new ordinary shares in connection with our equity
compensation plans and arrangements (including the amendments to the total number of ordinary shares available for issuance under 2021 Plan, if they are approved by shareholders), including any equity compensation plans and awards we have assumed or
may assume as a result of any acquisitions we may make, and our <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants, we have no specific plans, agreements or commitments to issue any ordinary shares for which approval of this proposal is
required. Nevertheless, our Board believes that it is advisable and in the best interests of our shareholders for our shareholders to provide this general authorization in order to avoid the delay and expense of obtaining shareholder approval at a
later date, and to provide us with greater flexibility to pursue strategic transactions and acquisitions and raise additional capital through public and private offerings of our ordinary shares, as well as instruments convertible into our ordinary
shares. Access to capital and the ability to raise equity capital at short notice have been important factors that have contributed to our ability to execute on our long-term growth strategy. Subject to receiving shareholder approval, we intend to
responsibly raise capital and issue shares in order to appropriately execute our business plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If this proposal is approved, our directors would be
authorized to allot and issue ordinary shares, during the period described above, subject to our Constitution, applicable Singapore laws and the Nasdaq Stock Market rules. The issuance of a large number of ordinary shares (or instruments convertible
into ordinary shares) could be dilutive to existing shareholders or reduce the trading price of our ordinary shares on the Nasdaq Global Market. If this proposal is not approved, we would not be permitted to issue ordinary shares (other than shares
issuable on exercise or settlement of outstanding options and other instruments convertible into or exercisable for ordinary shares or the like, which were previously granted). If we are unable to rely upon equity as a component of compensation, we
would have to review our compensation practices, and would likely have to substantially increase cash compensation to retain key personnel. Furthermore, if this proposal is not approved, we would be required to seek shareholder approval in
connection with specific issuances of shares on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">case-by-case</FONT></FONT> basis by convening general meetings from time to time, which we do not believe to be a workable
alternative. The delays we would experience in seeking and obtaining such approval could be harmful to the terms of any such share issuance and could negatively impact our ability to retain our employees. In addition, the <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">case-by-case</FONT></FONT> approval approach ignores market windows and other deal timing and competitive realities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Accordingly, our Board seeks shareholder approval of Ordinary Resolution 5 as set out in the Notice. The affirmative vote of a majority of the votes cast by
holders of ordinary shares voting in person or by proxy at the 2024 AGM is required to authorize the Board to allot and issue ordinary shares of the Company (meaning the number of shares voted &#147;for&#148; the proposal must exceed the number of
shares voted &#147;against&#148; the proposal). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>THE BOARD OF DIRECTORS RECOMMENDS A VOTE &#147;<U>FOR</U>&#148; THE AUTHORIZATION OF ORDINARY SHARE
ALLOTMENTS AND ISSUANCES AND PROXIES SOLICITED BY THE BOARD WILL BE VOTED IN FAVOR THEREOF UNLESS A SHAREHOLDER HAS INDICATED OTHERWISE ON THE PROXY CARD. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">60 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom802241_15"></A>PROPOSAL 6: <FONT STYLE="white-space:nowrap">NON-BINDING</FONT>
ADVISORY RESOLUTION ON APPROVAL OF EXECUTIVE </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>COMPENSATION AS DISCLOSED IN THIS PROXY STATEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are seeking your advisory vote (on a <FONT STYLE="white-space:nowrap">non-binding,</FONT> advisory basis only) as required by Section&nbsp;14A of the
Exchange Act on the approval of the compensation of our named executive officers as described in the compensation tables and related material contained in this proxy statement. Because your vote is advisory, it will not be binding on our
Compensation Committee or our Board. However, our Compensation Committee and our Board will review the voting results and take them into consideration when making future decisions regarding executive compensation. We have determined to hold an
advisory vote to approve the compensation of our named executive officers annually, and the next such advisory vote will occur at our 2025 Annual General Meeting of Shareholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our compensation philosophy is designed to align each executive&#146;s compensation with our short-term and long-term performance and to provide the
compensation and incentives needed to attract, motivate and retain key executives who are crucial to our long-term success. Our Compensation Committee and our Board believe that our compensation policies and procedures are effective in implementing
our compensation philosophy and in achieving its goals. Therefore, we are asking our shareholders to indicate their support for our named executive officer compensation as described in this proxy statement. This proposal, commonly known as a
&#147;say on pay&#148; proposal, gives our shareholders the opportunity to express their views on our named executive officers&#146; compensation. This vote is not intended to address any specific item of compensation, but rather the overall
compensation of our named executive officers and the compensation philosophy, policies and practices described in this proxy statement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In accordance
with the rules of the SEC, the following proposal is being submitted for a <FONT STYLE="white-space:nowrap">non-binding,</FONT> advisory shareholder vote at the 2024 AGM: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;RESOLVED, on a <FONT STYLE="white-space:nowrap">non-binding,</FONT> advisory basis only, that the compensation paid to the named executive officers of
the Company, as disclosed pursuant to the compensation disclosure rules of the U.S. Securities and Exchange Commission, including the compensation tables and the related material disclosed in this proxy statement, is hereby APPROVED.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This <FONT STYLE="white-space:nowrap">non-binding</FONT> advisory resolution is being proposed to shareholders as required pursuant to the requirements of
Section&nbsp;14A of the Exchange Act. The shareholders&#146; vote on this proposal is solely advisory and <FONT STYLE="white-space:nowrap">non-binding</FONT> in nature, will have no legal effect for purposes of Singapore law, and will not be
enforceable against our Company or our Board. For the avoidance of doubt, this is not an Ordinary Resolution. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The affirmative vote of a majority of the
votes cast by holders of ordinary shares voting in person or by proxy at the 2024 AGM is required to approve, on a <FONT STYLE="white-space:nowrap">non-binding,</FONT> advisory basis only, the compensation of our named executive officers, as
described in this proxy statement (meaning the number of shares voted &#147;for&#148; the proposal must exceed the number of shares voted &#147;against&#148; the proposal). Although the advisory resolution is
<FONT STYLE="white-space:nowrap">non-binding,</FONT> our Compensation Committee and our Board will review the voting results and take them into consideration when making future decisions regarding executive compensation. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>THE BOARD OF DIRECTORS RECOMMENDS A VOTE &#147;<U>FOR</U>&#148; THE APPROVAL (ON A <FONT STYLE="white-space:nowrap">NON-BINDING,</FONT> ADVISORY BASIS
ONLY) OF THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS AND PROXIES SOLICITED BY THE BOARD WILL BE VOTED IN FAVOR THEREOF UNLESS A SHAREHOLDER HAS INDICATED OTHERWISE ON THE PROXY CARD. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">61 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom802241_16"></A>CODE OF BUSINESS CONDUCT AND ETHICS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have adopted a code of business conduct and ethics that applies to all of our employees, including our principal executive officer and principal financial
and accounting officer. The text of the code of conduct and ethics is posted on our website at www.wavelifesciences.com. Disclosure regarding any amendments to, or waivers from, provisions of the code of conduct and ethics that apply to our
directors, principal executive officer or principal financial officer will be included in a Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> filed with the SEC within four business days following the date of the amendment or
waiver, unless website posting or the issuance of a press release of such amendments or waivers is then permitted by the rules of the Nasdaq Stock Market. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom802241_17"></A>OTHER MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Board knows of no other business which will be presented at the 2024 AGM. If any other business is properly brought before the 2024 AGM, proxies will be
voted in accordance with the judgment of the persons named therein. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom802241_18"></A>SHAREHOLDER PROPOSALS AND NOMINATIONS
FOR DIRECTOR </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To be considered for inclusion in the proxy statement relating to our 2025 Annual General Meeting of Shareholders, we must receive
shareholder proposals (other than for director nominations) no later than February&nbsp;20, 2025. To be considered for presentation at our 2025 Annual General Meeting of Shareholders, although not included in the proxy statement, proposals
(including director nominations that are not requested to be included in our proxy statement) must be received no later than May&nbsp;6, 2025. Shareholder proposals are also subject to the requirements of the Singapore Companies Act as described in
the paragraph below. In addition to satisfying the foregoing advance notice requirements, to comply with the universal proxy rules under the Exchange Act, stockholders who intend to solicit proxies in support of director nominees other than the
Company&#146;s nominees must follow the requirements set forth in Rule <FONT STYLE="white-space:nowrap">14a-19</FONT> as promulgated under the Exchange Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Proposals that are not received in a timely manner will not be voted on at our 2025 Annual General Meeting of Shareholders. If a proposal is received on time,
the proxies that management solicits for the meeting may still exercise discretionary voting authority on the proposal under circumstances consistent with the proxy rules of the SEC. All shareholder proposals should be marked for the attention of
General Counsel, Wave Life Sciences Ltd., 733 Concord Avenue, Cambridge, MA 02138. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, under Section&nbsp;183 of the Singapore Companies Act,
only registered shareholders representing not less than 5% of the total voting rights or registered shareholders representing not fewer than 100 registered shareholders having an average paid up sum of at least S$500 (Singapore dollars) each may, at
their expense, request that we include and give notice of their proposal for our 2025 Annual General Meeting of Shareholders. Subject to satisfaction of the requirements of Section&nbsp;183 of the Singapore Companies Act, any such requisition must
be signed by all the shareholders making the request and be deposited at our registered office in Singapore, 7 Straits View <FONT STYLE="white-space:nowrap">#12-00,</FONT> Marina One East Tower, Singapore 018936, at least six weeks prior to the date
of our 2025 Annual General Meeting of Shareholders in the case of a request requiring notice of a resolution, or at least one week prior to the date of our 2025 Annual General Meeting of Shareholders in the case of any other request. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Cambridge, Massachusetts </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>June&nbsp;21, 2024 </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">62 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><A NAME="rom802241_19"></A>Appendix A </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Wave Life Sciences Ltd. and its Subsidiaries </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Registration Number: 201218209G </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Singapore Statutory Financial Statements </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Year ended December&nbsp;31, 2023 </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>Wave Life Sciences Ltd. and its Subsidiaries </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>Singapore Statutory Financial Statements </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>Year ended December&nbsp;31, 2023 </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="index"></A>Index </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#appatoc802241_1">Directors&#146; Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#appatoc802241_2">Independent Auditors&#146; Report to the Members of Wave Life Sciences
 Ltd.</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#appatoc802241_3">Consolidated Financial Statements of Wave Life Sciences Ltd. and its Subsidiaries
</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-1</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#appatoc802241_4">Supplementary Financial Information of Wave Life Sciences Ltd. (Parent
 Company)</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-35</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="appatoc802241_1"></A>Directors&#146; Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The directors are pleased to submit this annual report to the members of Wave Life Sciences Ltd. (&#147;the Parent&#148;), together with these directors&#146;
statements, the audited financial statements for the financial year ended December&nbsp;31, 2023, and the auditors&#146; report thereon. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In our opinion:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">other than as discussed in the Investment in Subsidiaries paragraph in Note 2 to the supplementary financial
information, the consolidated financial statements of Wave Life Sciences Ltd. and its subsidiaries (together &#147;the Company&#148;) and the supplementary financial information of the Parent set out on pages
<FONT STYLE="white-space:nowrap">F-1</FONT> to <FONT STYLE="white-space:nowrap">F-47</FONT> are drawn up so as to give a true and fair view of the financial position of the Company and of the Parent as at December&nbsp;31, 2023, the financial
performance, changes in equity and cash flows of the Company for the year ended on that date in accordance with the provisions of the Singapore Companies Act 1967 and Generally Accepted Accounting Principles of the United States of America; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">at the date of this statement, there are reasonable grounds to believe that Wave Life Sciences Ltd. will be
able to pay its debts as and when they fall due. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The board of directors has, on the date of this statement, authorized these financial
statements for issue. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Directors </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The directors in
office at the date of this statement are as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="18%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="80%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Paul&nbsp;B.&nbsp;Bolno</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Chief Executive Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mark&nbsp;H.&nbsp;N.&nbsp;Corrigan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Christian O. Henry</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Peter Kolchinsky</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Aik Na Tan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adrian Rawcliffe</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ken Takanashi</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gregory&nbsp;L.&nbsp;Verdine</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Heidi L. Wagner</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">3</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Directors&#146; Interests </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">According to the register kept by Wave Life Sciences Ltd. for the purposes of Section&nbsp;164 of the Singapore Companies Act 1967 (&#147;the Act&#148;) and
the Wave Life Sciences Ltd. option ledger, particulars of interests of directors who held office at the end of the financial year (including those held by their spouses and infant children) in shares, debentures, warrants and share options of Wave
Life Sciences Ltd. or in related corporations (other than wholly-owned subsidiaries) are as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name of director and corporation in which interests are
held</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Holdings&nbsp;as&nbsp;of<BR>January&nbsp;1,&nbsp;2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Holdings&nbsp;as&nbsp;of<BR>December&nbsp;31,&nbsp;2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Paul B. Bolno</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Wave Life Sciences Ltd.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">- Ordinary shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">346,825</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">407,425</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">- Options to purchase ordinary shares at:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">- US$2.48 between March&nbsp;10, 2015 and March&nbsp;10, 2025</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">219,025</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">219,025</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">- US$18.79 between June&nbsp;16, 2016 and June&nbsp;16, 2026</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">236,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">236,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">- US$29.05 between January&nbsp;25, 2017 and January&nbsp;25, 2027</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">72,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">72,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">- US$40.05 between January&nbsp;23, 2018 and January&nbsp;23, 2028</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">109,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">109,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">- US$8.17 between March&nbsp;3, 2020 and March&nbsp;3, 2030</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">63,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">63,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">- US$10.48 between February&nbsp;1, 2021 and February&nbsp;1, 2031</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">200,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">200,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">- US$3.14 between January&nbsp;1, 2022 and January&nbsp;1, 2032</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">600,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">600,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">- US$2.83 between July&nbsp;25, 2022 and July&nbsp;25, 2032</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">180,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">180,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">- US$4.75 between February&nbsp;17, 2023 and February&nbsp;17, 2033</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">771,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">- Time-based restricted share units</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">90,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">- Performance-based restricted share units</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">92,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">92,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Mark H. N. Corrigan</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Wave Life Sciences Ltd.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">- Options to purchase ordinary shares at:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">- US$21.03 between September&nbsp;4, 2019 and September&nbsp;4, 2024</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">- US$9.13 between August&nbsp;18, 2020 and August&nbsp;18, 2025</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">- US$5.97 between August&nbsp;16, 2021 and August&nbsp;16, 2026</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">- US$3.50 between August&nbsp;15, 2022 and August&nbsp;15, 2027</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">- US$4.585 between August&nbsp;7, 2023 and August&nbsp;7, 2028</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">45,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Christian O. Henry</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Wave Life Sciences Ltd.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">- Options to purchase ordinary shares at:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">- US$46.70 between August&nbsp;13, 2018 and August&nbsp;13, 2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">- US$20.34 between August&nbsp;15, 2019 and August&nbsp;15, 2024</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">- US$9.13 between August&nbsp;18, 2020 and August&nbsp;18, 2025</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">- US$5.97 between August&nbsp;16, 2021 and August&nbsp;16, 2026</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">42,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">42,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">- US$3.50 between August&nbsp;15, 2022 and August&nbsp;15, 2027</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">- US$4.585 between August&nbsp;7, 2023 and August&nbsp;7, 2028</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">45,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Peter Kolchinsky</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Wave Life Sciences Ltd.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">- Options to purchase ordinary shares at:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">- US$46.70 between August&nbsp;13, 2018 and August&nbsp;13, 2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">- US$20.34 between August&nbsp;15, 2019 and August&nbsp;15, 2024</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">- US$9.13 between August&nbsp;18, 2020 and August&nbsp;18, 2025</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">- US$5.97 between August&nbsp;16, 2021 and August&nbsp;16, 2026</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">42,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">42,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">- US$3.50 between August&nbsp;15, 2022 and August&nbsp;15, 2027</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">- US$4.585 between August&nbsp;7, 2023 and August&nbsp;7, 2028</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">45,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">4</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name of director and corporation in which interests are
held</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Holdings&nbsp;as&nbsp;of<BR>January&nbsp;1,&nbsp;2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Holdings&nbsp;as&nbsp;of<BR>December&nbsp;31,&nbsp;2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Aik Na Tan</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Wave Life Sciences Ltd.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">- Options to purchase ordinary shares at:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">- US$9.13 between August&nbsp;18, 2020 and August&nbsp;18, 2025</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">- US$5.97 between August&nbsp;16, 2021 and August&nbsp;16, 2026</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">- US$3.50 between August&nbsp;15, 2022 and August&nbsp;15, 2027</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">- US$4.585 between August&nbsp;7, 2023 and August&nbsp;7, 2028</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">45,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Adrian Rawcliffe</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Wave Life Sciences Ltd.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">- Options to purchase ordinary shares at:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">- US$46.70 between August&nbsp;13, 2018 and August&nbsp;13, 2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">- US$20.34 between August&nbsp;15, 2019 and August&nbsp;15, 2024</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">- US$9.13 between August&nbsp;18, 2020 and August&nbsp;18, 2025</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">- US$5.97 between August&nbsp;16, 2021 and August&nbsp;16, 2026</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">42,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">42,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">- US$3.50 between August&nbsp;15, 2022 and August&nbsp;15, 2027</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">- US$4.585 between August&nbsp;7, 2023 and August&nbsp;7, 2028</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">45,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Ken Takanashi</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Wave Life Sciences Ltd.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">- Options to purchase ordinary shares at:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">- US$46.70 between August&nbsp;13, 2018 and August&nbsp;13, 2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">- US$20.34 between August&nbsp;15, 2019 and August&nbsp;15, 2024</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">- US$9.13 between August&nbsp;18, 2020 and August&nbsp;18, 2025</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">- US$5.97 between August&nbsp;16, 2021 and August&nbsp;16, 2026</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">42,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">42,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">- US$3.50 between August&nbsp;15, 2022 and August&nbsp;15, 2027</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">- US$4.585 between August&nbsp;7, 2023 and August&nbsp;7, 2028</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">45,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Gregory L. Verdine</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Wave Life Sciences Ltd.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">- Ordinary shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">- Options to purchase ordinary shares at:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">- US$2.48 between March&nbsp;10, 2015 and March&nbsp;10, 2025</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">266,402</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">266,402</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">- US$46.70 between August&nbsp;13, 2018 and August&nbsp;13, 2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">- US$20.34 between August&nbsp;15, 2019 and August&nbsp;15, 2024</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">- US$9.13 between August&nbsp;18, 2020 and August&nbsp;18, 2025</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">- US$5.97 between August&nbsp;16, 2021 and August&nbsp;16, 2026</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">42,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">42,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">- US$3.50 between August&nbsp;15, 2022 and August&nbsp;15, 2027</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">- US$4.37 between October&nbsp;27, 2022 and October&nbsp;27, 2027</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">163,467</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">163,467</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">- US$4.585 between August&nbsp;7, 2023 and August&nbsp;7, 2028</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">45,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Heidi L. Wagner</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Wave Life Sciences Ltd.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">- Options to purchase ordinary shares at:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">- US$21.03 between September&nbsp;4, 2019 and September&nbsp;4, 2024</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">- US$9.13 between August&nbsp;18, 2020 and August&nbsp;18, 2025</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">- US$5.97 between August&nbsp;16, 2021 and August&nbsp;16, 2026</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">- US$3.50 between August&nbsp;15, 2022 and August&nbsp;15, 2027</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">- US$4.585 between August&nbsp;7, 2023 and August&nbsp;7, 2028</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">45,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">5</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Except as disclosed in this statement, no director who held office at the end of the financial year had
interests in shares, debentures, warrants or share options of Wave Life Sciences Ltd., or of its related corporations, either at the beginning of the financial year, or date of appointment to this board of directors, if later, or at the end of the
financial year. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Except as disclosed in Note 7 to the consolidated financial statements, there were no unissued shares of Wave Life Sciences Ltd. or its
subsidiaries under options granted by Wave Life Sciences Ltd. or its subsidiaries as of the end of the financial year. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Auditors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">KPMG LLP were <FONT STYLE="white-space:nowrap">re-appointed</FONT> as auditors of Wave Life Sciences Ltd. on August&nbsp;1, 2023. The auditors, KPMG LLP, have
indicated their willingness to accept <FONT STYLE="white-space:nowrap">re-appointment.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On behalf of the board of directors, </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Adrian Rawcliffe</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Adrian Rawcliffe</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Director</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Paul B. Bolno, M.D.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Paul B. Bolno, M.D.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Director</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">6</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">


<IMG SRC="g802241g01l07.jpg" ALT="LOGO" STYLE="width:1.55882in;height:0.608806in;">
</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">KPMG LLP</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">12 Marina View <FONT
STYLE="white-space:nowrap">#15-01</FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Asia Square Tower 2</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Singapore 018961</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Telephone&#8195; +65 6213 3388<BR> <P STYLE="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">Fax&#8195;&#8195;&#8195;&#8199;&#8201; +65 6225 0984</P>
<P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">Internet&#8195;&#8195;&#8194;www.kpmg.com.sg</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="appatoc802241_2"></A>Independent auditors&#146; report </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Members of the Company </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Wave Life Sciences Ltd. and its
subsidiaries </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Report on the audit of the financial statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Qualified opinion </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have audited the accompanying
consolidated financial statements of Wave Life Sciences Ltd. and its subsidiaries (the &#147;Company&#148;) and the supplementary financial information of Wave Life Sciences Ltd. (the &#147;Parent&#148;), which comprise the balance sheets of the
Company and Parent as at December&nbsp;31, 2023, consolidated statements of operations and comprehensive loss, consolidated statements of series A preferred shares and shareholders&#146; equity, and consolidated statements of cash flows of the
Company for the year then ended, and notes to the financial statements, including a summary of significant accounting policies, as set out on pages <FONT STYLE="white-space:nowrap">F-1</FONT> to <FONT STYLE="white-space:nowrap">F-47</FONT>
(collectively, the &#147;financial statements&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In our opinion, except for the effects of the matter described in the &#147;Basis for qualified
opinion&#148; section of our report, the consolidated financial statements of the Company and the balance sheet of the Parent are properly drawn up in accordance with the provisions of the Singapore Companies Act 1967 (the &#147;Act&#148;) and
Generally Accepted Accounting Principles of the United States of America (&#147;U.S. GAAP&#148;) (the use of which is approved by the Accounting and Corporate Regulatory Authority of Singapore) so as to give a true and fair view of the financial
position of the Company and of the Parent as at December&nbsp;31, 2023 and of the financial performance, changes in equity and cash flows of the Company for the year ended on that date. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Basis for qualified opinion </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">U.S. GAAP requires that the
Parent prepare consolidated financial statements. The Act requires that a balance sheet of the parent company be presented with the consolidated financial statements. In order to comply with the Act&#146;s requirement to present a separate
standalone balance sheet of the Parent, the Parent did not consolidate the investments in subsidiaries and instead reported these investments and the balances with subsidiaries as separate lines on the Parent&#146;s standalone balance sheet. Our
audit opinion on the financial statements for the year ended December&nbsp;31, 2022 dated May&nbsp;24, 2023 also included a modification on the same matter. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We conducted our audit in accordance with Singapore Standards on Auditing (&#147;SSAs&#148;). Our responsibilities under those standards are further described
in the &#147;Auditors&#146; responsibilities for the audit of the financial statements&#148; section of our report. We are independent of the Company in accordance with the Accounting and Corporate Regulatory Authority Code of Professional Conduct
and Ethics for Public Accountants and Accounting Entities (&#147;ACRA Code&#148;) together with the ethical requirements that are relevant to our audit of the financial statements in Singapore, and we have fulfilled our other ethical
responsibilities in accordance with these requirements and the ACRA Code. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our qualified opinion. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Key audit matters </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Key audit matters are those matters that, in our professional judgement, were of most significance in our audit of the financial statements of the current
period. These matters were addressed in the context of our audit of the financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters. In addition to the matter described in the
&#147;<I>Basis for qualified opinion</I>&#148; section, we have determined the matter described below to be the key audit matter to be communicated in our report. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Evaluation of revenue recognition for certain research and development services</P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Refer to Note 5 Collaboration Agreements and the accounting policy note on revenue
recognition in the consolidated financial statements.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><I>The key audit matter</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><I>How the matter was addressed in our audit</I></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As discussed in Note 5 to the consolidated financial statements, the Company is party to a collaboration agreement with GlaxoSmithKline
(&#147;GSK&#148;) which has two performance obligations, including the promise to provide research and development (&#147;R&amp;D&#148;) services. The Company recognizes R&amp;D services revenue over time using an input method. This method measures
progress based on costs incurred in relation to the R&amp;D activities and the costs expected to be incurred in the future to satisfy each performance obligation. Amounts received by the Company before performance are recorded as deferred revenue.
For the year ended December&nbsp;31, 2023, the Company recognized over-time revenue under the GSK collaboration agreement of $66.3&nbsp;million. In addition, as of December&nbsp;31, 2023, a portion of the Company&#146;s current and long-term
deferred revenue relates to R&amp;D services.</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">We identified the evaluation of
revenue recognition for certain R&amp;D services as a key audit matter. Specifically, evaluating the estimate of total costs expected to be incurred in satisfying certain R&amp;D performance obligations was subjective and required significant
auditor judgment. The assessment of the nature of the work to be performed and the method for measuring progress, involved a high degree of auditor judgment.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">The following are the primary procedures we performed to address this key audit matter. For a selection of R&amp;D performance obligations, we read the underlying contract with the customer, evaluated the determination of the method
for measuring progress, and tested the Company&#146;s estimate of total contract costs to be incurred by (1)&nbsp;comparing the Company&#146;s initial estimates to actual costs incurred to assess the Company&#146;s ability to estimate accurately;
(2)&nbsp;inspecting underlying documentation and third-party evidence and comparing them to management&#146;s assumptions and inputs; (3)&nbsp;inquiring of R&amp;D personnel of the Company to evaluate factors related to the nature of the work to be
performed and their impact on the total contract costs to be incurred, including progress to date and the estimate of remaining contract costs; and (4)&nbsp;assessing the Company&#146;s history of estimating costs to be incurred in satisfying
R&amp;D performance obligations under similar contracts.</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The above key audit matter applies to both the consolidated financial statements and the supplementary balance sheet. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Other information </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Management is responsible for the
other information contained in the Singapore Statutory Financial Statements. Other information is defined as all information in the Singapore Statutory Financial Statements other than the financial statements and our auditors&#146; report thereon.
We have obtained all other information, which comprises the directors&#146; statement, prior to the date of this auditors&#146; report. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">8</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our opinion on the financial statements does not cover the other information and we do not express any form
of assurance conclusion thereon. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with our audit of the financial statements, our responsibility is to read the other information and, in
doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If, based on the work we have performed, we conclude
that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Responsibilities of management and directors for the financial statements </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Management is responsible for the preparation of financial statements that give a true and fair view in accordance with the provisions of the Act and U.S.
GAAP, and for devising and maintaining a system of internal accounting controls sufficient to provide a reasonable assurance that assets are safeguarded against loss from unauthorised use or disposition; and transactions are properly authorised and
that they are recorded as necessary to permit the preparation of true and fair financial statements and to maintain accountability of assets. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In
preparing the financial statements, management is responsible for assessing the Company&#146;s ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless
management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The directors are responsible
for overseeing the Company&#146;s financial reporting process. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Auditors&#146; responsibilities for the audit of the financial statements </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud
or error, and to issue an auditors&#146; report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SSAs will always detect a material misstatement when it
exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As part of an audit in accordance with SSAs, we exercise professional judgement and maintain professional skepticism throughout the audit. We also: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or
error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher
than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal controls. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Obtain an understanding of internal controls relevant to the audit in order to design audit procedures that are
appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company&#146;s internal controls. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and
related disclosures made by management. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Conclude on the appropriateness of management&#146;s use of the going concern basis of accounting and, based on
the audit evidence obtained, whether a material uncertainty exists related to events or </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">9</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
conditions that may cast significant doubt on the Company&#146;s ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in
our auditors&#146; report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditors&#146; report.
However, future events or conditions may cause the Company to cease to continue as a going concern. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Evaluate the overall presentation, structure and content of the financial statements, including the disclosures,
and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Obtain sufficient appropriate audit evidence regarding the financial information of the entities or business
activities within the Company to express an opinion on the consolidated financial statements. We are responsible for the direction, supervision and performance of the company audit. We remain solely responsible for our audit opinion.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We communicate with the directors regarding, among other matters, the planned scope and timing of the audit and significant audit
findings, including any significant deficiencies in internal controls that we identify during our audit. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We also provide the directors with a statement
that we have complied with relevant ethical requirements regarding independence, and communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">From the matters communicated with the directors, we determine those matters that were of most significance in the audit of the financial statements of the
current period and are therefore the key audit matters. We describe these matters in our auditors&#146; report unless the law or regulations preclude public disclosure about the matter or when, in extremely rare circumstances, we determine that a
matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Report on other legal and regulatory requirements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In our
opinion, the accounting and other records required by the Act to be kept by the Parent have been properly kept in accordance with the provisions of the Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The engagement partner on the audit resulting in this independent auditors&#146; report is Malcolm Ramsay. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ KPMG LLP </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>KPMG LLP </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Public Accountants and </I></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Chartered Accountants </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Singapore </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">May&nbsp;15, 2024 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">10</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>WAVE LIFE SCIENCES LTD. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="appatoc802241_3"></A>CONSOLIDATED BALANCE SHEETS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>(In thousands, except share amounts) </I></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,&nbsp;2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,&nbsp;2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">200,351</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">88,497</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts receivable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21,086</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,912</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,932</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,024</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,108</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">235,373</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">98,537</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Long-term assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment, net of accumulated depreciation of $42,709 and $37,846 as of
December&nbsp;31, 2023 and 2022, respectively</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13,084</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17,284</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22,637</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">26,843</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,699</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,660</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">156</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">62</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total long-term assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">39,576</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">47,849</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">274,949</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">146,386</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Liabilities, Series A preferred shares and shareholders&#146; equity (deficit)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,839</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,915</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expenses and other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,828</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17,552</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current portion of deferred revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">150,059</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">31,558</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current portion of operating lease liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,714</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,496</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">186,440</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">71,521</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Long-term liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred revenue, net of current portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,601</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">79,774</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease liability, net of current portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25,404</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">32,118</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">190</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total long-term liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">41,005</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">112,082</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">227,445</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">183,603</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series A preferred shares, no par value; 3,901,348 shares issued <BR>and outstanding at
December&nbsp;31, 2023 and 2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,874</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,874</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shareholders&#146; equity (deficit):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ordinary shares, no par value; 119,162,234 and 86,924,643 shares issued and outstanding at
December&nbsp;31, 2023 and 2022, respectively</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">935,367</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">802,833</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">129,237</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">119,442</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated other comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(124</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(29</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,024,850</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(967,337</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total shareholders&#146; equity (deficit)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">39,630</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(45,091</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities, Series A preferred shares and shareholders&#146; equity (deficit)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">274,949</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">146,386</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>The accompanying notes are an integral part of the consolidated financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">F-1</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>WAVE LIFE SCIENCES LTD. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>(In thousands, except share and per share amounts) </I></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="75%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>For&nbsp;the&nbsp;Year&nbsp;Ended&nbsp;December&nbsp;31,</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">113,305</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,649</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">130,009</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">115,856</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">51,292</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">50,513</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">181,301</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">166,369</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(67,996</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(162,720</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income, net:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dividend income and interest income, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,928</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,571</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (expense), net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,878</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other income, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,806</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,578</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss before income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(58,190</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(161,142</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax benefit (provision)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">677</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(681</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(57,513</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(161,823</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share attributable to ordinary shareholders&#151;basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0.54</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2.05</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average ordinary shares used in computing net loss per share attributable to ordinary
shareholders&#151;basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">106,097,268</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">78,855,810</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other comprehensive loss:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(57,513</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(161,823</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Foreign currency translation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(95</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(210</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(57,608</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(162,033</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>The accompanying notes are an integral part of the consolidated financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">F-2</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>Wave Life Sciences Ltd. and its Subsidiaries </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>Consolidated Financial Statements </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>Year ended December 31, 2023 </I></B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>WAVE LIFE SCIENCES LTD. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONSOLIDATED STATEMENTS OF SERIES A PREFERRED SHARES AND SHAREHOLDERS&#146; EQUITY (DEFICIT) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>(In thousands, except share amounts) </I></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="53%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD ???? 1 VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series A<BR>Preferred Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" ???? 1 VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Ordinary Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Additional</B><br><B><FONT STYLE="white-space:nowrap">Paid-In-</FONT><BR>Capital</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accumulated<BR>Other</B><br><B>Comprehensive<BR>Income&nbsp;(Loss)</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accumulated<BR>Deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B><br><B>Shareholders&#146;<BR>Equity&nbsp;(Deficit)</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD ???? 1 VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" ???? 1 VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Balance at December&nbsp;31, 2021</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,901,348</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,874</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">59,841,116</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">749,851</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">87,980</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">181</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(805,514</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">32,498</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD ???? 1 VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Issuance of ordinary shares, net of offering costs</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25,464,483</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">51,220</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">51,220</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Issuance of ordinary shares pursuant to the <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">at-the-market</FONT></FONT> equity program, net</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">458,092</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,167</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,167</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Issuance of <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants, net of offering
costs</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,268</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,268</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Share-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17,194</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17,194</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Vesting of RSUs</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">904,891</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Option exercises</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">90,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">223</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">223</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Issuance of ordinary shares under the ESPP</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">166,061</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">372</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">372</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Other comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(210</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(210</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(161,823</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(161,823</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD ???? 1 VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Balance at December&nbsp;31, 2022</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,901,348</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,874</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">86,924,643</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">802,833</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">119,442</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(29</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(967,337</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(45,091</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD ???? 1 VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Issuance of ordinary shares, net of offering costs</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">93,574</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">93,574</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Issuance of ordinary shares, pursuant to the GSK Collaboration Agreement</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,683,761</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">34,623</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">34,623</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Issuance of ordinary shares pursuant to the <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">at-the-market</FONT></FONT> equity program, net</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">751,688</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,080</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,080</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Share-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,795</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,795</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Vesting of RSUs</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">415,658</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Option exercises</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">160,571</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">509</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">509</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Issuance of ordinary shares under the ESPP</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">225,913</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">748</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">748</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Other comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(95</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(95</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(57,513</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(57,513</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD ???? 1 VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Balance at December&nbsp;31, 2023</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,901,348</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,874</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">119,162,234</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">935,367</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">129,237</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(124</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,024,850</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">39,630</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD ???? 1 VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom"></TD>
<TD ???? 1 VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>The accompanying notes are an integral part of the consolidated financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>WAVE LIFE SCIENCES LTD. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONSOLIDATED STATEMENTS OF CASH FLOWS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>(In thousands) </I></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="81%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>For&nbsp;the&nbsp;Year&nbsp;Ended&nbsp;December&nbsp;31,</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash flows from operating activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(57,513</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(161,823</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjustments to reconcile net loss to net cash used in operating activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Amortization of
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,206</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,540</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation of property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,574</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,795</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17,194</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss on disposal of property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Changes in operating assets and liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts receivable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(21,086</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,980</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,348</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2,010</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,394</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3,761</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,348</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expenses and other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(724</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,691</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">54,328</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3,245</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5,496</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4,308</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other <FONT STYLE="white-space:nowrap">non-current</FONT> liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(190</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">190</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(19,431</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(127,781</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash flows from investing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchases of property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,115</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,361</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from the sale of property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">106</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchase of short-term investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(75,044</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from the maturity of short-term investments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">75,044</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,115</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,255</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash flows from financing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from issuance of ordinary shares, net of offering costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">93,574</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">51,220</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from issuance <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants, net of
offering costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,268</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from issuance of ordinary shares pursuant to the GSK Collaboration Agreement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">34,623</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from issuance of ordinary shares pursuant to the <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">at-the-market</FONT></FONT> equity program, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,080</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,105</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from the exercise of share options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">509</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">223</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from the ESPP</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">748</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">372</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash provided by financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">132,534</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">67,188</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Effect of foreign exchange rates on cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(95</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(210</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net increase (decrease) in cash, cash equivalents and restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">111,893</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(62,058</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash, cash equivalents and restricted cash, beginning of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">92,157</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">154,215</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash, cash equivalents and restricted cash, end of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">204,050</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">92,157</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Supplemental disclosure of cash flow information:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Offering costs in accounts payable at period end</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">210</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increase in operating lease
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets and lease liabilities related to new lease</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,006</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>The accompanying notes are an integral part of the consolidated financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">F-4</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Wave Life Sciences Ltd. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1. THE COMPANY </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Organization </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Wave Life Sciences Ltd. (together with its subsidiaries, &#147;Wave&#148; or the &#147;Company&#148;) is a clinical-stage biotechnology company focused on
unlocking the broad potential of RNA medicines (also known as oligonucleotides), or those targeting ribonucleic acid &#147;RNA&#148;), to transform human health. Wave&#146;s RNA medicines platform, PRISM, combines multiple modalities, chemistry
innovation and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. The Company&#146;s toolkit of <FONT STYLE="white-space:nowrap">RNA-targeting</FONT> modalities includes RNA editing,
splicing, antisense silencing and RNA interference (&#147;RNAi&#148;), providing the Company with unique capabilities for designing and sustainably delivering candidates that optimally address disease biology. The Company&#146;s lead programs are in
rare and prevalent diseases, including <FONT STYLE="white-space:nowrap">alpha-1</FONT> antitrypsin deficiency (&#147;AATD&#148;), obesity, Duchenne muscular dystrophy (&#147;DMD&#148;), and Huntington&#146;s disease (&#147;HD&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company was incorporated in Singapore on July&nbsp;23, 2012 and has its principal U.S. office in Cambridge, Massachusetts. The Company was incorporated
with the purpose of combining two commonly held companies, Wave Life Sciences USA, Inc. (&#147;Wave USA&#148;), a Delaware corporation (formerly Ontorii, Inc.), and Wave Life Sciences Japan, Inc. (&#147;Wave Japan&#148;), a company organized under
the laws of Japan (formerly Chiralgen., Ltd.), which occurred on September&nbsp;13, 2012. On May&nbsp;31, 2016, Wave Life Sciences Ireland Limited (&#147;Wave Ireland&#148;) was formed as a wholly<B>-</B>owned subsidiary of Wave Life Sciences Ltd.
On April&nbsp;3, 2017, Wave Life Sciences UK Limited (&#147;Wave UK&#148;) was formed as a wholly<B>-</B>owned subsidiary of Wave Life Sciences Ltd. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
Company&#146;s primary activities have been developing and evolving PRISM to design, develop and commercialize RNA medicines, advancing the Company&#146;s differentiated portfolio, building the Company&#146;s research, development and manufacturing
capabilities, advancing programs into the clinic, furthering clinical development of such clinical-stage programs, building the Company&#146;s intellectual property, and assuring adequate capital to support these activities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Liquidity </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Since its inception, the Company has
not generated any product revenue and has incurred recurring operating losses. To date, the Company has primarily funded its operations through private placements of debt and equity securities, public and other registered offerings of its equity
securities and collaborations with third parties. Until the Company can generate significant revenue from product sales, if ever, the Company expects to continue to finance operations through a combination of public or private equity or debt
financings or other sources, which may include upfront and milestone payments from collaborations with third parties. Adequate additional financing may not be available to the Company on acceptable terms, or at all. The inability to raise capital as
and when needed would have a negative impact on the Company&#146;s financial condition and ability to pursue its business strategy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of
December&nbsp;31, 2023, the Company had cash and cash equivalents of $200.4&nbsp;million. The Company expects that its existing cash and cash equivalents will be sufficient to fund its operations for at least the next twelve months. The Company has
based this expectation on the best information available, however the Company may use its available capital resources sooner than it currently expects. In January 2024, the representatives of the underwriters in connection with the December 2023
Offering (as defined in Note 6) exercised their option to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">F-5</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
purchase an additional 3,000,000 ordinary shares as a part of the December 2023 Offering, for additional net proceeds of approximately $14.0&nbsp;million. If the Company&#146;s anticipated
operating results are not achieved in future periods, planned expenditures may need to be further reduced in order to extend the time period over which the then-available resources would be able to fund the Company&#146;s operations. In addition,
the Company may elect to raise additional funds before it needs them if the conditions for raising capital are favorable due to market conditions or strategic considerations, even if the Company expects it has sufficient funds for its current or
future operating plans. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Risks and Uncertainties </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company is subject to risks common to companies in the biotechnology industry including, but not limited to, new technological innovations, protection of
proprietary technology, maintaining internal manufacturing capabilities, dependence on key personnel, compliance with government regulations and the need to obtain additional financing. The Company&#146;s therapeutic programs will require
significant additional research and development efforts, including extensive preclinical and clinical testing and regulatory approval, prior to commercialization of any product candidates. These efforts require significant amounts of additional
capital, adequate personnel infrastructure and extensive compliance-reporting capabilities. There can be no assurance that the Company&#146;s research and development efforts will be successful, that adequate protection for the Company&#146;s
intellectual property will be obtained, that any products developed will obtain necessary government regulatory approval or that any approved products will be commercially viable. Even if the Company&#146;s product development efforts are
successful, it is uncertain when, if ever, the Company will generate significant revenue from product sales. The Company operates in an environment of rapid change in technology and substantial competition from pharmaceutical and biotechnology
companies. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Basis of Presentation </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company
has prepared the accompanying consolidated financial statements in conformity with generally accepted accounting principles in the United States (&#147;U.S. GAAP&#148;) and in U.S. dollars. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2. SIGNIFICANT ACCOUNTING POLICIES </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cash and Cash
Equivalents </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company considers all highly liquid securities with maturities of three months or less from the date of purchase to be cash
equivalents. The Company&#146;s cash and cash equivalents are comprised of funds held in checking and money market accounts. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Short Term Investments
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s short term investments consist of term deposits. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Principles of Consolidation </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s
consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Use of Estimates </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s consolidated
financial statements are prepared in accordance with U.S. GAAP. The preparation of the Company&#146;s financial statements and related disclosures requires the Company to make estimates and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">F-6</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
assumptions that affect the reported amount of assets, liabilities, revenue, costs and expenses and related disclosures. Management considers many factors in selecting appropriate financial
accounting policies and in developing the estimates and assumptions that are used in the preparation of the financial statements. Management must apply significant judgment in this process. The Company believes that its revenue recognition policy,
particularly (a)&nbsp;assessing the number of performance obligations; (b)&nbsp;determining the transaction price; (c)&nbsp;allocating the transaction price to the performance obligations in the contract; and (d)&nbsp;determining the pattern over
which performance obligations are satisfied, including estimates to complete performance obligations, and the assumptions and estimates used in the Company&#146;s analysis of contracts with contract research organizations (&#147;CROs&#148;) and
contract manufacturing organizations (&#147;CMOs&#148;) to estimate the contract expense, involve a greater degree of judgment, and therefore the Company considers them to be its critical accounting policies. The Company evaluates its estimates and
assumptions on an ongoing basis. The Company&#146;s actual results may differ from these estimates under different assumptions and conditions. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Segment Data </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company manages its operations
as a single segment for the purposes of assessing performance and making operating decisions. The Company&#146;s focus is on developing its proprietary RNA medicines platform, PRISM, to develop and commercialize a broad pipeline RNA medicines in a
variety of therapeutic areas. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Going Concern </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At each reporting period, the Company evaluates whether there are conditions or events that raise substantial doubt about the Company&#146;s ability to
continue as a going concern within one year after the date that the financial statements are issued. The Company is required to make certain additional disclosures if the Company concludes substantial doubt exists and it is not alleviated by the
Company&#146;s plans or when the Company&#146;s plans alleviate substantial doubt about the Company&#146;s ability to continue as a going concern. The Company&#146;s evaluation entails analyzing prospective operating budgets and forecasts for
expectations of the Company&#146;s cash needs and comparing those needs to the current cash and cash equivalent balance. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Foreign Currency
Translation </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The functional currency is the U.S. dollar for all of the Company&#146;s entities aside from Wave Japan, which has the Japanese Yen as
its functional currency. Assets and liabilities of Wave Japan are translated at period end exchange rates while revenues and expenses of Wave Japan are translated at average exchange rates for the period. Net unrealized gains and losses from foreign
currency translation are reflected as other comprehensive income (loss) within the consolidated statements of Series A preferred shares and shareholders&#146; equity (deficit) and the consolidated statements of operations and comprehensive loss.
Gains and losses on foreign currency transactions are included in the consolidated statements of operations and comprehensive loss within other income, net. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Fair Value of Financial Instruments </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company
is required to disclose information on all assets and liabilities reported at fair value that enables an assessment of the inputs used in determining the reported fair values. The fair value hierarchy is a hierarchy of inputs used in measuring fair
value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing the financial
instrument based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#146;s assumptions about the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">F-7</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
inputs that market participants would use in pricing the financial instrument and are developed based on the information available in the circumstances. The fair value hierarchy applies only to
the valuation inputs used in determining the reported fair value of the investments and is not a measure of the investment credit quality. The hierarchy defines three levels of valuation inputs: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Level 1&#151;Unadjusted quoted prices in active markets that are accessible at the measurement date of identical, unrestricted assets. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Level 2&#151;Quoted prices for similar assets, or inputs that are observable, either directly or indirectly, for substantially the full term
through corroboration with observable market data. Level&nbsp;2 includes investments valued at quoted prices adjusted for legal or contractual restrictions specific to the security. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Level 3&#151;Pricing inputs are unobservable for the asset, that is, inputs that reflect the reporting entity&#146;s own assumptions about the
assumptions market participants would use in pricing the asset. Level&nbsp;3 includes private investments that are supported by little or no market activity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cash, cash equivalents and restricted cash are Level&nbsp;1 assets which are comprised of funds held in checking and money market accounts. Short-term
investments are Level&nbsp;2 assets which are comprised of term deposits. Cash, cash equivalents and restricted cash were recorded at fair value as of December&nbsp;31, 2023 and 2022, totaling $204.1&nbsp;million and $92.2&nbsp;million,
respectively. There were no&nbsp;short-term investments as of December&nbsp;31, 2023 or 2022, as the $75.0&nbsp;million of term deposits that constitute the Company&#146;s short-term investments were all purchased and reached maturity during the
twelve months ended December&nbsp;31, 2022. The carrying amounts of accounts payable and accrued expenses approximate their fair values due to their short-term maturities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Concentration of Credit Risk </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cash, cash
equivalents, restricted cash and short-term investments are financial instruments that potentially subject the Company to concentration of credit risk. The Company uses several financial institutions to maintain its cash, cash equivalents,
restricted cash and short-term investments, all of which are high quality, accredited financial institutions and, accordingly, such funds are subject to minimal credit risk. The Company has not experienced any losses in such accounts and management
believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held. The Company has no financial instruments with
<FONT STYLE="white-space:nowrap">off-balance</FONT> sheet risk of loss. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Restricted Cash </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Restricted cash consists primarily of cash placed in separate restricted bank accounts as required under the terms of the Company&#146;s lease agreements for
its Cambridge, Massachusetts and Lexington, Massachusetts facilities (refer to Note 8). As of December&nbsp;31, 2023 and 2022, the Company had $3.7&nbsp;million of restricted cash, of which $2.7&nbsp;million related to the Lexington facility and
$1.0&nbsp;million related to the Cambridge facility. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Property and Equipment </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Property and equipment, which consists primarily of equipment, furniture, software and leasehold improvements, are stated at cost less accumulated
depreciation. Depreciation is calculated on a straight-line basis over the following estimated useful lives of the assets: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Equipment, Furniture and Software</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP><FONT STYLE="white-space:nowrap">3-7</FONT> years</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Leasehold Improvements</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Shorter of asset life or lease term</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">F-8</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Depreciation begins at the time the asset is placed in service. Maintenance and repairs are charged to
operations as incurred. Upon retirement or sale, the cost of the disposed asset and the related accumulated depreciation are removed from the accounts and any resulting gain or loss is reflected in the consolidated statements of operations and
comprehensive loss. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Impairment of Long-Lived Assets </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Long-lived assets consist of property and equipment. Long-lived assets are reviewed for impairment whenever events or other changes in circumstances indicate
that the carrying amount may not be recoverable. Certain factors may exist or events may occur that indicate that impairment exists including, but not limited to, the following: significant underperformance relative to historical or projected future
operating results; significant changes in the manner of use of the underlying assets; and significant adverse industry or market economic trends. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">When
performing the impairment assessment for long-lived assets, the Company compares the carrying value of such assets to the estimated undiscounted future net cash flows expected from the use of the assets and their eventual disposition. In the event
that the carrying value of the assets is determined to be unrecoverable, the Company would estimate the fair value of the assets and record an impairment charge for the excess of the carrying value over the fair value. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Revenue Recognition </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company recognizes
revenue in accordance with Accounting Standards Codification (&#147;ASC&#148;) Topic 606, Revenue from Contracts with Customers (&#147;ASC 606&#148;). This standard applies to all contracts with customers, except for contracts that are within the
scope of other standards, such as leases, insurance, and financial instruments. Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity
expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the entity performs the following five-step analysis: (i)&nbsp;identify the
contract(s) with a customer; (ii)&nbsp;identify the performance obligations in the contract; (iii)&nbsp;determine the transaction price; (iv)&nbsp;allocate the transaction price to the performance obligations in the contract; and (v)&nbsp;recognize
revenue when (or as) the entity satisfies a performance obligation. The Company only applies the five-step analysis to contracts when it is probable that the entity will collect the consideration to which it is entitled in exchange for the goods or
services it transfers to the customer. At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract, determines those that are performance
obligations, and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance
obligation is satisfied. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has entered into collaboration agreements for research, development, and commercial services, under which the
Company licenses certain rights to its product candidates to third parties. The terms of these arrangements typically include payment to the Company of one or more of the following: <FONT STYLE="white-space:nowrap">non-refundable,</FONT> upfront
license fees; reimbursement of certain costs; customer option exercise fees; development, regulatory and commercial milestone payments; and royalties on net sales of licensed products. Any variable consideration is allocated to a performance
obligation, and the cumulative revenue associated with this consideration is not recognized until it is deemed not to be at significant risk of reversal. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In determining the appropriate amount of revenue to be recognized as the Company fulfills its obligations under each of its agreements for which the
collaboration partner is also a customer, the Company performs the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">F-9</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
following steps: (i)&nbsp;identification of the promised goods or services in the contract; (ii)&nbsp;determination of whether the promised goods or services are performance obligations,
including whether they are distinct in the context of the contract; (iii)&nbsp;measurement of the transaction price, including the constraint on variable consideration; (iv)&nbsp;allocation of the transaction price to the performance obligations;
and (v)&nbsp;recognition of revenue when (or as) the Company satisfies each performance obligation. As part of the accounting for these arrangements, the Company must use significant judgment to determine: (a)&nbsp;the number of performance
obligations based on the determination under step (ii)&nbsp;above; (b) the transaction price under step (iii)&nbsp;above; and (c)&nbsp;the timing of satisfaction of performance obligations as a measure of progress in step (v)&nbsp;above. The Company
uses significant judgment to determine whether milestones or other variable consideration, except for royalties, should be included in the transaction price as described further below. The transaction price is allocated to the optional goods and
services the Company expects to provide. The Company uses estimates to determine the timing of satisfaction of performance obligations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Amounts received
prior to being recognized as revenue are recorded as deferred revenue. Amounts expected to be recognized as revenue within the 12 months following the balance sheet date are classified as current portion of deferred revenue in the accompanying
consolidated balance sheets. Amounts not expected to be recognized as revenue within the 12 months following the balance sheet date are classified as deferred revenue, net of current portion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Licenses of intellectual property: </I>In assessing whether a promise or performance obligation is distinct from the other promises, the Company considers
factors such as the research, development, manufacturing and commercialization capabilities of the customer and the availability of the associated expertise in the general marketplace. In addition, the Company considers whether the customer can
benefit from a promise for its intended purpose without the receipt of the remaining promise, whether the value of the promise is dependent on the unsatisfied promise, whether there are other vendors that could provide the remaining promise, and
whether it is separately identifiable from the remaining promise. For licenses that are combined with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined
performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if
necessary, adjusts the measure of performance and related revenue recognition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Research and development services</I>: If an arrangement is determined
to contain a promise or obligation for the Company to perform research and development services, the Company must determine whether these services are distinct from other promises in the arrangement. In assessing whether the services are distinct
from the other promises, the Company considers the capabilities of the customer to perform these same services. In addition, the Company considers whether the customer can benefit from a promise for its intended purpose without the receipt of the
remaining promise, whether the value of the promise is dependent on the unsatisfied promise, whether there are other vendors that could provide the remaining promise, and whether it is separately identifiable from the remaining promise. For research
and development services that are combined with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point
in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related
revenue recognition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Customer options: </I>If an arrangement is determined to contain customer options that allow the customer to acquire additional
goods or services, the goods and services underlying the customer options are not considered </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">F-10</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to be performance obligations at the outset of the arrangement, as they are contingent upon option exercise. The Company evaluates the customer options for material rights, that is, the option to
acquire additional goods or services for free or at a discount. If the customer options are determined to represent a material right, the material right is recognized as a separate performance obligation at the outset of the arrangement. The Company
allocates the transaction price to material rights based on the standalone selling price. Amounts allocated to any material right are not recognized as revenue until the option is exercised and the performance obligation is satisfied. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Milestone payments:</I> At the inception of each arrangement that includes milestone payments, the Company evaluates whether a significant reversal of
cumulative revenue provided in conjunction with achieving the milestones is probable, and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant reversal of cumulative
revenue would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being
achieved until those approvals are received. For other milestones, the Company evaluates factors such as the scientific, clinical, regulatory, commercial, and other risks that must be overcome to achieve the particular milestone in making this
assessment. There is considerable judgment involved in determining whether it is probable that a significant reversal of cumulative revenue would not occur. At the end of each subsequent reporting period, the Company reevaluates the probability of
achievement of all milestones subject to constraint and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative <FONT STYLE="white-space:nowrap">catch-up</FONT> basis, which would
affect revenues and earnings in the period of adjustment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Royalties:</I> For arrangements that include sales-based royalties, including milestone
payments based on a level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i)&nbsp;when the related sales occur, or (ii)&nbsp;when the performance
obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue resulting from any of its licensing arrangements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Contract costs</I>: The Company recognizes as an asset the incremental costs of obtaining a contract with a customer if the costs are expected to be
recovered. As a practical expedient, the Company recognizes the incremental costs of obtaining a contract as an expense when incurred if the amortization period of the asset that it otherwise would have recognized is one year or less. To date, the
Company has not incurred any incremental costs of obtaining a contract with a customer. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Research and Development Expenses </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Research and development expenses are expensed as incurred. External development costs are recognized based on an evaluation of the progress to completion of
specific tasks. Payments for these activities are based on the terms of the individual agreements, which may differ from the pattern of costs incurred, and are reflected in the accompanying consolidated balance sheets as prepaid or accrued expenses.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>License Agreements and Patent Costs </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Costs
associated with licenses of technology and patent costs are expensed as incurred and are generally included in research and development expense in the consolidated statements of operations and comprehensive loss. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Net Loss per Share </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Basic net loss per share is
computed using the weighted-average number of ordinary shares outstanding during the period. The outstanding <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants (as defined in Note 6) are included in the weighted-average
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">F-11</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
number of ordinary shares outstanding used in the calculation of basic net loss per share as the exercise price is negligible and the warrants are fully vested and exercisable. Diluted net loss
per share is computed using the sum of the weighted-average number of ordinary shares outstanding during the period and, if dilutive, the weighted-average number of potential ordinary shares, including the assumed exercise of share options and the
assumed vesting of RSUs (as defined in Note 7). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company applies the <FONT STYLE="white-space:nowrap">two-class</FONT> method to calculate its basic
and diluted net loss per share attributable to ordinary shareholders, as its Series A preferred shares are participating securities. The <FONT STYLE="white-space:nowrap">two-class</FONT> method is an earnings allocation formula that treats a
participating security as having rights to earnings that otherwise would have been available to ordinary shareholders. However, for the periods presented, the <FONT STYLE="white-space:nowrap">two-class</FONT> method does not impact the net loss per
ordinary share as the Company was in a net loss position for each of the periods presented and holders of Series A preferred shares do not participate in losses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s Series A preferred shares contractually entitle the holders of such shares to participate in dividends but do not contractually require the
holders of such shares to participate in losses of the Company. Accordingly, for periods in which the Company reports a net loss attributable to ordinary shareholders, diluted net loss per share attributable to ordinary shareholders is the same as
basic net loss per share attributable to ordinary shareholders, since dilutive ordinary shares are not assumed to have been issued if their effect is anti-dilutive. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Share-Based Compensation </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company measures and
recognizes share-based compensation expense, for both employee and director option awards, based on the grant date fair value of the awards. The Company calculates the fair value of awards based on the grant date fair value of the underlying
ordinary shares. The Company determines the fair value of share-based awards granted to <FONT STYLE="white-space:nowrap">non-employees</FONT> as either the fair value of the consideration received or the fair value of the equity instruments issued,
whichever is more reliably measurable. Equity instruments issued to <FONT STYLE="white-space:nowrap">non-employees</FONT> as consideration for goods or services received by the Company have been accounted for based on the fair value of the equity
instruments issued. The Company recognizes share-based compensation expense on a straight-line basis over the requisite service period of the awards, which is generally the vesting period. The Company accounts for forfeitures as they occur. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company classifies share-based compensation expense in its consolidated statements of operations and comprehensive loss in the same manner in which the
award recipient&#146;s compensation costs are classified or in which the award recipient&#146;s service payments are classified. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The fair value of each
share option grant was determined using the methods and assumptions discussed below. These inputs are generally subjective and require significant judgment and estimation by management. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Fair Value of Ordinary Shares </I>The fair value of the ordinary shares underlying the Company&#146;s
share-based awards is based on the closing price of the Company&#146;s ordinary shares as reported by the Nasdaq Global Market on the date of grant. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Expected Term </I>The expected term of share options represents the weighted-average period that the share
options are expected to remain outstanding. The Company estimated the expected term using the simplified method, which is an average of the contractual term of the option and the vesting period. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Expected Volatility </I>Since there was limited historical data for the Company&#146;s ordinary shares and
limited company-specific historical volatility through the third quarter of 2021, the Company determined the share price volatility for options granted based on an analysis of the volatility used by a
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">F-12</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
peer group of publicly traded companies. In evaluating similarity, the Company considers factors such as industry, stage of life cycle and size. Beginning in the fourth quarter of 2021, the
Company had sufficient historical volatility data for its ordinary shares and as such no longer relies on an analysis of the volatility from a peer group to calculate expected volatility. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Risk-free Interest Rate </I>The risk-free interest rate is based on the U.S. Treasury yield in effect at the
time of the grant for <FONT STYLE="white-space:nowrap">zero-coupon</FONT> U.S. Treasury notes with remaining terms similar to the expected term of the options. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Dividend Rate </I>The expected dividend was assumed to be zero as the Company has never paid dividends and has
no current plans to do so. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Income Taxes </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company accounts for income taxes using an asset and liability approach, which requires recognition of deferred tax assets and liabilities for the expected
future tax consequences of events that have been recognized in the consolidated financial statements but have not been reflected in taxable income. A valuation allowance is established to reduce deferred tax assets to their estimated realizable
value. Therefore, the Company provides a valuation allowance to the extent that it is more likely than not that all or a portion of the deferred tax assets will not be realized in the future. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company accounts for uncertainty in income taxes recognized in the financial statements by applying a <FONT STYLE="white-space:nowrap">two-step</FONT>
process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination by the tax authorities. If the tax position is deemed <FONT
STYLE="white-space:nowrap">more-likely-than-not</FONT> to be sustained, the tax position is then assessed to determine the amount of benefit to recognize in the financial statements. The amount of the benefit that may be recognized is the largest
amount that has a greater than 50% likelihood of being realized upon ultimate settlement. The provision for income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits, that are considered appropriate as well as the
related net interest and penalties. The Company recognizes interest and penalties related to uncertain tax positions in the income tax provision on the consolidated statements of operations and comprehensive loss. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has certain service arrangements in place between its U.S., Japan, U.K. and Singapore entities, which include transfer pricing assumptions. The
determination of the appropriate level of transfer pricing requires judgment based on transfer pricing analyses of comparable companies. The Company monitors the nature of its service arrangements for changes in its operations as well as economic
conditions. The Company also periodically reviews the transfer pricing analyses for changes in the composition in the pool of comparable companies as well as the related ongoing results of the comparable companies. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Leases </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company accounts for leases in
accordance with ASC Topic 842, <I>Leases</I> (&#147;ASC 842&#148;). At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present in the arrangement.
Most leases with a term greater than one year are recognized on the balance sheet as <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets and short-term and long-term lease liabilities, as applicable.
The Company typically only includes an initial lease term in its assessment of a lease arrangement. Options to renew a lease are not included in the Company&#146;s assessment unless there is reasonable certainty that the Company will renew the
lease. The Company monitors its plans to renew its leases on a quarterly basis. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">F-13</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain lease agreements include rental payments that are adjusted periodically for inflation or other
variables. In addition to rent, the leases may require the Company to pay additional amounts for taxes, insurance, maintenance, or other expenses, which are generally referred to as <FONT STYLE="white-space:nowrap">non-lease</FONT> components. Such
adjustments to rental payments and variable <FONT STYLE="white-space:nowrap">non-lease</FONT> components are treated as variable lease payments and recognized in the period in which the obligation for these payments are incurred. Variable lease
components and variable <FONT STYLE="white-space:nowrap">non-lease</FONT> components are not measured as part of the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> asset and lease liability. Only when
lease components and their associated <FONT STYLE="white-space:nowrap">non-lease</FONT> components are fixed are they accounted for as a single lease component and are recognized as part of a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">right-of-use</FONT></FONT> asset and lease liability. Total contract consideration is allocated to the combined fixed lease and <FONT STYLE="white-space:nowrap">non-lease</FONT> component. This policy election applies
consistently to all asset classes under lease agreements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Operating lease liabilities and their corresponding <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets are recorded based on the present value of lease payments over the expected remaining lease term. Certain adjustments to the
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> asset may be required for items such as incentives received. The interest rate implicit in lease contracts is typically not readily determinable. As a
result, the Company utilizes its incremental borrowing rate, which reflects the fixed rate at which the Company could borrow on a collateralized basis the amount of the lease payments in the same currency, for a similar term, in a similar economic
environment. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Recently Issued Accounting Pronouncements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In November 2023, the Financial Accounting Standards Board (the &#147;FASB&#148;) finalized Accounting Standards Update
<FONT STYLE="white-space:nowrap">No.&nbsp;2023-07,</FONT> Segment Reporting (Topic 280):<I>&nbsp;Improvements to Reportable Segment Disclosures</I><I></I>&nbsp;(&#147;ASU <FONT STYLE="white-space:nowrap">2023-07&#148;).</FONT> ASU <FONT
STYLE="white-space:nowrap">2023-07</FONT> requires enhanced disclosures about reportable segments and the chief operating decision maker. The new guidance is effective for fiscal years beginning after December&nbsp;15, 2023, and interim periods
within fiscal years beginning after December&nbsp;15, 2024. Early adoption is permitted. The Company is currently evaluating the potential impact that the adoption of ASU <FONT STYLE="white-space:nowrap">2023-07</FONT> may have on its consolidated
financial statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In December 2023, the FASB finalized Accounting Standards Update <FONT STYLE="white-space:nowrap">No.&nbsp;2023-09,</FONT> Income
Taxes (Topic 740): <I>Improvements to Income Tax Disclosures</I> (&#147;ASU <FONT STYLE="white-space:nowrap">2023-09&#148;).</FONT> ASU <FONT STYLE="white-space:nowrap">2023-09</FONT> requires a company&#146;s annual financial statements to include
consistent categories and greater disaggregation of information in the rate reconciliation, and income taxes paid disaggregated by jurisdiction. ASU <FONT STYLE="white-space:nowrap">2023-09</FONT> is effective for the Company&#146;s annual reporting
periods beginning after December&nbsp;15, 2025. Adoption is either with a prospective method or a fully retrospective method of transition. Early adoption is permitted. The Company is currently evaluating the effect that adoption of ASU <FONT
STYLE="white-space:nowrap">2023-09</FONT> will have on its consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">F-14</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3. PROPERTY AND EQUIPMENT, NET </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Property and equipment, net, consists of the following: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center">(in thousands)</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Furniture and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">26,072</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25,509</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Software</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">902</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">890</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Leasehold improvements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28,525</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28,413</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fixed assets in progress</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">294</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">318</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">55,793</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">55,130</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less accumulated depreciation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(42,709</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(37,846</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13,084</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17,284</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Substantially all of the Company&#146;s long-lived assets were located in the United States as of December&nbsp;31, 2023 and
2022. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Depreciation expense was $5.0&nbsp;million and $6.6&nbsp;million for the years ended December&nbsp;31, 2023 and 2022, respectively. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4. ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Accrued expenses and other current liabilities consist of the following: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center">(in thousands)</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,065</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,287</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expenses related to CROs and CMOs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,768</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,516</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expenses and other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">995</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,749</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total accrued expenses and other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,828</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17,552</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5. COLLABORATION AGREEMENTS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>GSK Collaboration and Equity Agreements </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On
December&nbsp;13, 2022, Wave USA and Wave UK entered into a Collaboration and License Agreement (the &#147;GSK Collaboration Agreement&#148;) with GlaxoSmithKline Intellectual Property (No. 3) (&#147;GSK&#148;). Pursuant to the GSK Collaboration
Agreement, Wave and GSK have agreed to collaborate on the research, development, and commercialization of oligonucleotide therapeutics, including an exclusive global license to <FONT STYLE="white-space:nowrap">WVE-006.</FONT> The discovery
collaboration component has an initial four-year research term and combines Wave&#146;s proprietary discovery and drug development platform, PRISM, with GSK&#146;s unique genetic insights and its global development and commercial capabilities. On
January&nbsp;27, 2023, the GSK Collaboration Agreement became effective, and GSK paid Wave an upfront payment of $120.0&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Simultaneously with
the execution of the GSK Collaboration Agreement, Wave entered into a Share Purchase Agreement (the &#147;SPA&#148;) on December&nbsp;13, 2022, with Glaxo Group Limited (&#147;GGL&#148;), an affiliate of GSK,
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">F-15</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
pursuant to which Wave agreed to sell 10,683,761 of its ordinary shares to GGL at a purchase price of $4.68 per share (the &#147;GSK Equity Investment&#148;). The GSK Equity Investment closed on
January&nbsp;26, 2023, following the completion of customary closing conditions. The ordinary shares purchased by GGL are subject to <FONT STYLE="white-space:nowrap">lock-up</FONT> and standstill restrictions and carry certain registration rights,
customary for transactions of this kind. The Company did not incur any material costs in connection with the issuance of the ordinary shares under the SPA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The GSK Collaboration Agreement has three components: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">An exclusive global license for GSK to <FONT STYLE="white-space:nowrap">WVE-006,</FONT> the Company&#146;s then
preclinical, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">A-to-I(G)</FONT></FONT> RNA editing candidate for <FONT
STYLE="white-space:nowrap">alpha-1</FONT> antitrypsin deficiency (&#147;AATD&#148;), with development and commercialization responsibilities transferring to GSK after the Company completes the <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">first-in-patient</FONT></FONT> study (the &#147;AATD Collaboration&#148;). The Company will be responsible for preclinical, regulatory, manufacturing, and clinical activities for
<FONT STYLE="white-space:nowrap">WVE-006</FONT> through the initial Phase 1/2 study, at the Company&#146;s sole cost. Thereafter, GSK will be responsible for advancing <FONT STYLE="white-space:nowrap">WVE-006</FONT> through pivotal studies,
registration, and global commercialization at GSK&#146;s sole cost; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A discovery research collaboration which enables GSK to advance up to eight programs leveraging PRISM and the
Company&#146;s oligonucleotide expertise and discovery capabilities (the &#147;Discovery Research Collaboration&#148;); and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A discovery collaboration which enables the Company to advance up to three programs leveraging targets informed
by GSK&#146;s novel genetic insights (&#147;Wave&#146;s Collaboration Programs&#148;). </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the GSK Collaboration Agreement, each
party grants to the other party certain licenses to the collaboration products to enable the other party to perform its obligations and exercise its rights under the GSK Collaboration Agreement, including license grants to enable each party to
conduct research, development and commercialization activities pursuant to the terms of the GSK Collaboration Agreement. The parties&#146; exclusivity obligations to each other are limited on a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">target-by-target</FONT></FONT> basis with regard to targets in the collaboration. GSK may terminate the GSK Collaboration Agreement for convenience, in its entirety or on a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">target-by-target</FONT></FONT> basis. Subject to certain exceptions, each party has the right to terminate the GSK Collaboration Agreement on a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">target-by-target</FONT></FONT> basis if the other party, or a related party, challenges the patentability, enforceability or validity of any patents within the licensed technology
that cover any product that is subject to the GSK Collaboration Agreement. In the event of any material breach of the GSK Collaboration Agreement by a party, subject to cure rights, the other party may terminate the GSK Collaboration Agreement in
its entirety if the breach relates to all targets or on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">target-by-target</FONT></FONT> basis if the breach relates to a specific target. In the event that GSK and its affiliates
cease development, manufacturing and commercialization activities with respect to compounds or products subject to the GSK Collaboration Agreement and directed to a particular target, the Company may terminate the GSK Collaboration Agreement with
respect to such target. Either party may terminate the GSK Collaboration Agreement for the other party&#146;s insolvency. In certain termination circumstances, the Company would receive a license from GSK to continue researching, developing and
manufacturing certain products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The GSK Collaboration Agreement, unless terminated earlier, will continue until the date on which: (i)&nbsp;with respect
to a validation target, the date on which such validation target is not advanced into a collaboration program; or (ii)&nbsp;with respect to a collaboration target, the royalty term has expired for all collaboration products directed to the
applicable collaboration target. The GSK Collaboration Agreement includes options to extend the research term for up to three additional years, which would increase the number of programs available to both parties. The Company will lead all
preclinical research for GSK and the Company&#146;s collaboration programs up to investigational new drug (&#147;IND&#148;)-enabling studies. The Company will lead <FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies, clinical development
and commercialization for the Company&#146;s collaboration programs. GSK collaboration programs will transfer to GSK for <FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies, clinical development and commercialization. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">F-16</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The GSK Collaboration Agreement is managed by a joint steering committee in which both parties are
represented equally. In addition, the AATD Collaboration is overseen by a joint development committee, a joint patent committee advises on intellectual property activities, and the Discovery Research Collaboration is overseen by a joint research
committee. Both parties are represented equally for these committees and report to the joint steering committee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company assessed this arrangement in
accordance with ASC 606 and concluded that the contract counterparty, GSK, is a customer for the AATD Collaboration prior to GSK exercising its option and, for the Discovery Research Collaboration programs during the target validation research term.
The Company identified the following material promises under the arrangement: (1)&nbsp;the exclusive global license for <FONT STYLE="white-space:nowrap">WVE-006;</FONT> (2) the research and development services for
<FONT STYLE="white-space:nowrap">WVE-006</FONT> through the Phase 1/2 study; (3)&nbsp;the discovery research services under the Discovery Research Collaboration to perform target validation programs; (4)&nbsp;research and development license for the
Discovery Research Collaboration; and (5)&nbsp;the research and development services for the GSK collaboration programs through completion of a candidate selection. The research and development services for
<FONT STYLE="white-space:nowrap">WVE-006</FONT> were determined to not be distinct from the exclusive global license and should therefore be combined into a single performance obligation for the AATD Collaboration. The research and development
services for the Discovery Research Collaboration were determined to not be distinct from the research and development license for the Discovery Research Collaboration and should therefore be combined into a single performance obligation. In
addition, the Company determined the standalone selling price for the option to advance up to eight programs from the Discovery Research Collaboration and determined it did not provide a material right to GSK. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based on these assessments, the Company identified two performance obligations in the GSK Collaboration Agreement: (1)&nbsp;AATD Collaboration consisting of
the research and development services through completion of the Phase 1/2 study and research and development license for <FONT STYLE="white-space:nowrap">WVE-006</FONT> and (2)&nbsp;Discovery Research Collaboration which consists of research and
development services for validating the targets and license for research and development license for targets. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At the outset of the arrangement, the
transaction price included fixed consideration of the $120.0&nbsp;million upfront, the $15.4&nbsp;million in premium related to the GSK Equity Investment and the fixed consideration related to the additional target validation research funding. The
Company allocated the estimated variable consideration relating to the target validation research to the Discovery Research Collaboration programs and the variable consideration relating to the developmental milestone to the AATD Collaboration and
then allocated the fixed consideration to the performance obligations on a relative standalone selling price basis. The Company determined that the GSK Collaboration Agreement did not contain a significant financing component. The program initiation
fees to advance up to eight programs from the Discovery Research Collaboration to preclinically develop the GSK collaboration programs and the additional potential milestone payments were excluded from the transaction price, as all milestone amounts
were fully constrained at the inception of the GSK Collaboration Agreement. The Company will reevaluate the transaction price at the end of each reporting period, and as uncertain events are resolved or other changes in circumstances occur, the
Company will adjust its estimate of the transaction price. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">F-17</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table summarizes the allocation of the total transaction price to the identified performance
obligation under the GSK Collaboration Agreement, and the amount of the transaction price unsatisfied as of December&nbsp;31, 2023 (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="68%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Transaction<BR>Price<BR>Allocated</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Transaction<BR>Price<BR>Unsatisfied&nbsp;<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Performance Obligations:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">AATD Collaboration</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">156,778</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">92,057</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Discovery Research Collaboration</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19,514</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17,948</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">176,292</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">110,005</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Unsatisfied transaction price will be recognized over the remaining research term. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company developed the estimated standalone selling price for the global license for <FONT STYLE="white-space:nowrap">WVE-006,</FONT> under the AATD
Collaboration, using a discounted cash flow model. For the performance obligation associated with the research and development services under the Discovery Research Collaboration and the research and development services for <FONT
STYLE="white-space:nowrap">WVE-006</FONT> under the AATD Collaboration, the Company determined the standalone selling price using estimates of the costs to perform the research and development services, including expected internal and external costs
for services and supplies, adjusted to reflect a profit margin. The total estimated cost of the research and development services reflected the nature of the services to be performed and the Company&#146;s best estimate of the length of time
required to perform the services. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Revenue associated with the AATD Collaboration performance obligation is being recognized as the research and
development services are provided using an input measure, according to the costs incurred and the total costs expected to be incurred to satisfy the performance obligation. The revenue associated with the Discovery Research Collaboration performance
obligation is being recognized as the research and development services are provided using an input measure, according to the costs incurred and the total costs expected to be incurred to satisfy the performance obligation. The amounts received that
have not yet been recognized as revenue are recorded in deferred revenue on the Company&#146;s consolidated balance sheet. Additional funding related to the Company&#146;s research activities under the Discovery Research Collaboration will be
recorded as accounts receivable when contractually enforceable and recorded as deferred revenue, or as revenue as the services are provided. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the
year ended December&nbsp;31, 2023, the Company achieved a developmental milestone which pertained to the initiation of dosing in healthy volunteers in the RestorAATion clinical trial program, triggering a $20.0&nbsp;million milestone payment to the
Company from GSK. As of December&nbsp;31, 2023, the $20.0&nbsp;million related to the achievement of the milestone is included in the current portion of accounts receivable and payment was received from GSK in the first quarter of 2024. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the year ended December&nbsp;31, 2023, the Company recognized revenue of $66.3&nbsp;million under the GSK Collaboration Agreement using the input
method described above, which includes the $8.3&nbsp;million of unconstrained revenue recognized for achievement of the developmental milestone mentioned above. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The aggregate amount of the transaction price allocated to the Company&#146;s unsatisfied and partially unsatisfied performance obligations and recorded in
deferred revenue on December&nbsp;31, 2023 is approximately $94.3&nbsp;million, of which approximately $78.7&nbsp;million is included in current liabilities and $15.6&nbsp;million is included in long-term liabilities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">F-18</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Takeda Collaboration and Equity Agreements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In February 2018, Wave USA and Wave UK entered into a global strategic collaboration (the &#147;Takeda Collaboration&#148;) with Takeda Pharmaceutical Company
Limited (&#147;Takeda&#148;), pursuant to which Wave USA, Wave UK and Takeda agreed to collaborate on the research, development and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System (&#147;CNS&#148;). The
Takeda Collaboration provides the Company with at least $230.0&nbsp;million in committed cash and Takeda with the option to <FONT STYLE="white-space:nowrap">co-develop</FONT> and <FONT STYLE="white-space:nowrap">co-commercialize</FONT> the
Company&#146;s CNS development programs in (1)&nbsp;Huntington&#146;s disease (&#147;HD&#148;); (2) amyotrophic lateral sclerosis (&#147;ALS&#148;) and frontotemporal dementia (&#147;FTD&#148;); and (3)&nbsp;the Company&#146;s discovery-stage
program targeting <I>ATXN3</I> for the treatment of spinocerebellar ataxia 3 (&#147;SCA3&#148;) (collectively, &#147;Category 1 Programs&#148;). In addition, the Takeda Collaboration provided Takeda the right to exclusively license multiple
preclinical programs for CNS disorders, including Alzheimer&#146;s disease and Parkinson&#146;s disease (collectively, &#147;Category 2 Programs&#148;). In April 2018, the Takeda Collaboration became effective and Takeda paid the Company
$110.0&nbsp;million as an upfront payment. Takeda also agreed to fund the Company&#146;s research and preclinical activities in the amount of $60.0&nbsp;million during the four-year research term and to reimburse the Company for any
collaboration-budgeted research and preclinical expenses incurred by Wave that exceed that amount. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Simultaneously with Wave USA and Wave UK&#146;s entry
into the collaboration and license agreement with Takeda (the &#147;Takeda Collaboration Agreement&#148;), the Company entered into a share purchase agreement with Takeda (the &#147;Takeda Equity Agreement,&#148; and together with the Takeda
Collaboration Agreement, the &#147;Takeda Agreements&#148;) pursuant to which it agreed to sell to Takeda 1,096,892 of its ordinary shares at a purchase price of $54.70 per share. In April 2018, the Company closed the Takeda Equity Agreement and
received aggregate cash proceeds of $60.0&nbsp;million. The Company did not incur any material costs in connection with the issuance of the shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">With
respect to Category 1 Programs, the Company will be responsible for researching and developing products and companion diagnostics for Category 1 Programs through completion of the first proof of mechanism study for such products. Takeda will have an
exclusive option for each target and all associated products and companion diagnostics for such target, which it may exercise at any time through completion of the proof of mechanism study. If Takeda exercises this option, the Company will receive
an <FONT STYLE="white-space:nowrap">opt-in</FONT> payment and will lead manufacturing and joint clinical <FONT STYLE="white-space:nowrap">co-development</FONT> activities and Takeda will lead joint
<FONT STYLE="white-space:nowrap">co-commercial</FONT> activities in the United States and all commercial activities outside of the United States. Global costs and potential profits will be shared 50:50 and the Company will be eligible to receive
development and commercial milestone payments. In addition to its 50% profit share, the Company is eligible to receive option exercise fees and development and commercial milestone payments for each of the Category 1 Programs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">With respect to Category 2 Programs, the Company granted Takeda the right to exclusively license multiple preclinical programs during a four-year research
term (subject to limited extension for programs that were initiated prior to the expiration of the research term, in accordance with the Takeda Collaboration Agreement) (&#147;Category 2 Research Term&#148;). During that term, the Takeda
Collaboration provided that the parties may collaborate on preclinical programs for up to six targets at any one time. The Company was responsible for researching and preclinically developing products and companion diagnostics directed to the agreed
upon targets through completion of Investigational IND enabling studies in the first major market country. Thereafter, Takeda would have an exclusive worldwide license to develop and commercialize products and companion diagnostics directed to such
targets, subject to the Company&#146;s retained rights to lead manufacturing activities for products directed to such targets. Takeda agreed to fund the Company&#146;s research and preclinical activities in the amount of $60.0&nbsp;million during
the research term and reimburse the Company for any collaboration-budgeted research and preclinical expenses incurred by the Company that exceeded that amount. The Company was also eligible to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">F-19</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
receive tiered high single-digit to <FONT STYLE="white-space:nowrap">mid-teen</FONT> royalties on Takeda&#146;s global commercial sales of products from each Category 2 Program. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the Takeda Collaboration Agreement, each party granted to the other party specific intellectual property licenses to enable the other party to perform
its obligations and exercise its rights under the Takeda Collaboration Agreement, including license grants to enable each party to conduct research, development and commercialization activities pursuant to the terms of the Takeda Collaboration
Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The term of the Takeda Collaboration Agreement commenced on April&nbsp;2, 2018 and, unless terminated earlier, will continue until the date on
which: (i)&nbsp;with respect to each Category 1 Program target for which Takeda does not exercise its option, the expiration or termination of the development program with respect to such target; (ii)&nbsp;with respect to each Category 1 Program
target for which Takeda exercises its option, the date on which neither party is researching, developing or manufacturing any products or companion diagnostics directed to such target; or (iii)&nbsp;with respect to each Category 2 Program target,
the date on which royalties are no longer payable with respect to products directed to such target. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Takeda may terminate the Takeda Collaboration
Agreement for convenience on 180 days&#146; notice, in its entirety or on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">target-by-target</FONT></FONT> basis. Subject to certain exceptions, each party has the right to terminate
the Takeda Collaboration Agreement on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">target-by-target</FONT></FONT> basis if the other party, or a third party related to such party, challenges the patentability, enforceability
or validity of any patents within the licensed technology that cover any product or companion diagnostic that is subject to the Takeda Collaboration Agreement. In the event of any material breach of the Takeda Collaboration Agreement by a party,
subject to cure rights, the other party may terminate the Takeda Collaboration Agreement in its entirety if the breach relates to all targets or on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">target-by-target</FONT></FONT>
basis if the breach relates to a specific target. In the event that Takeda and its affiliates cease development, manufacturing and commercialization activities with respect to compounds or products subject to the Takeda Collaboration Agreement and
directed to a particular target, the Company may terminate the Takeda Collaboration Agreement with respect to such target. Either party may terminate the Takeda Collaboration Agreement for the other party&#146;s insolvency. In certain termination
circumstances, the Company would receive a license from Takeda to continue researching, developing and manufacturing certain products, and companion diagnostics. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Takeda Collaboration is managed by a joint steering committee in which both parties are represented equally. The joint steering committee is tasked with
overseeing the scientific progression of each Category 1 Program and, prior to the Amendment (discussed below), the Category 2 Programs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company
assessed this arrangement in accordance with ASC 606 and concluded that the contract counterparty, Takeda, is a customer for Category 1 Programs prior to Takeda exercising its option, and for Category 2 Programs during the Category 2 Research Term.
The Company identified the following material promises under the arrangement: (1)&nbsp;the <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> royalty-free research and development license for each Category 1 Program; (2)&nbsp;the research and
development services for each Category 1 Program through completion of the first proof of mechanism study; (3)&nbsp;the exclusive option to license, <FONT STYLE="white-space:nowrap">co-develop</FONT> and
<FONT STYLE="white-space:nowrap">co-commercialize</FONT> each Category 1 Program; (4)&nbsp;the right to exclusively license the Category 2 Programs; and (5)&nbsp;the research and preclinical development services of the Category 2 Programs through
completion of <FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies. The research and development services for each Category 1 Program were determined to not be distinct from the research and development license and should therefore be
combined into a single performance obligation for each Category 1 Program. The research and preclinical development services for the Category 2 Programs were determined to not be distinct from the exclusive licenses for the Category 2 Programs and
therefore were combined into a single performance obligation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">F-20</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additionally, the Company determined that the exclusive option for each Category 1 Program was priced at a
discount and, as such, provide material rights to Takeda, representing three separate performance obligations. Based on these assessments, the Company identified seven performance obligations in the Takeda Collaboration Agreement: (1)&nbsp;research
and development services through completion of the first proof of mechanism and <FONT STYLE="white-space:nowrap">non-exclusive</FONT> research and development license for HD; (2)&nbsp;research and development services through completion of the first
proof of mechanism and <FONT STYLE="white-space:nowrap">non-exclusive</FONT> research and development license for ALS and FTD; (3)&nbsp;research and development services through completion of the first proof of mechanism and <FONT
STYLE="white-space:nowrap">non-exclusive</FONT> research and development license for SCA3; (4) the material right provided for the exclusive option to license, <FONT STYLE="white-space:nowrap">co-develop</FONT> and
<FONT STYLE="white-space:nowrap">co-commercialize</FONT> HD; (5)&nbsp;the material right provided for the exclusive option to license, <FONT STYLE="white-space:nowrap">co-develop</FONT> and <FONT STYLE="white-space:nowrap">co-commercialize</FONT>
ALS and FTD; (6)&nbsp;the material right provided for the exclusive option to license, <FONT STYLE="white-space:nowrap">co-develop</FONT> and <FONT STYLE="white-space:nowrap">co-commercialize</FONT> SCA3; and (7)&nbsp;the research and preclinical
development services and right to exclusively license the Category 2 Programs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At the outset of the arrangement, the transaction price included the
$110.0&nbsp;million upfront consideration received and the $60.0&nbsp;million of committed research and preclinical funding for the Category 2 Programs. The Company determined that the Takeda Collaboration Agreement did not contain a significant
financing component. The option exercise fees to license, <FONT STYLE="white-space:nowrap">co-develop</FONT> and <FONT STYLE="white-space:nowrap">co-commercialize</FONT> each Category 1 Program that may be received are excluded from the transaction
price until each customer option is exercised. The potential milestone payments were excluded from the transaction price, as all milestone amounts were fully constrained at the inception of the Takeda Collaboration Agreement. The Company will
reevaluate the transaction price at the end of each reporting period and, as uncertain events are resolved or other changes in circumstances occur, if necessary, will adjust its estimate of the transaction price. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company allocated the transaction price to the performance obligations on a relative standalone selling price basis. For the performance obligations
associated with the research and development services through completion of the first proof of mechanism and <FONT STYLE="white-space:nowrap">non-exclusive</FONT> research and development license for HD; the research and development services through
completion of the first proof of mechanism and <FONT STYLE="white-space:nowrap">non-exclusive</FONT> research and development license for ALS and FTD; the research and development services through completion of the first proof of mechanism and <FONT
STYLE="white-space:nowrap">non-exclusive</FONT> research and development license for SCA3; and the research and preclinical development services and right to exclusively license the Category 2 Programs, the Company determined the standalone selling
price using estimates of the costs to perform the research and development services, including expected internal and external costs for services and supplies, adjusted to reflect a profit margin. The total estimated cost of the research and
development services reflected the nature of the services to be performed and the Company&#146;s best estimate of the length of time required to perform the services. For the performance obligations associated with the material right provided for
the exclusive option to license, <FONT STYLE="white-space:nowrap">co-develop</FONT> and <FONT STYLE="white-space:nowrap">co-commercialize</FONT> HD; the material right provided for the exclusive option to license,
<FONT STYLE="white-space:nowrap">co-develop</FONT> and <FONT STYLE="white-space:nowrap">co-commercialize</FONT> ALS and FTD; and the material right provided for the exclusive option to license, <FONT STYLE="white-space:nowrap">co-develop</FONT> and <FONT
STYLE="white-space:nowrap">co-commercialize</FONT> SCA3, the Company estimated the standalone fair value of the option to license each Category 1 Program utilizing an adjusted market assessment approach, and determined that any standalone fair value
in excess of the amounts to be paid by Takeda associated with each option represented a material right. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Revenue associated with the research and
development services for each Category 1 Program performance obligation is being recognized as the research and development services are provided using an input method, according to the costs incurred on each Category 1 Program and the total costs
expected to be incurred to satisfy each Category 1 Program performance obligation. Prior to the Amendment described below, revenue associated with the research and preclinical development services for the Category 2 Programs performance obligation
was recognized as the research and preclinical development services that were provided using an input method, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">F-21</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
according to the costs incurred on Category 2 Programs and the total costs expected to be incurred to satisfy the performance obligation. The amount allocated to the material right for each
Category 1 Program option will be recognized on the date that Takeda exercises each respective option, or immediately as each option expires unexercised. The amounts received that have not yet been recognized as revenue are recorded in deferred
revenue on the Company&#146;s consolidated balance sheet. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On October&nbsp;15, 2021, Wave USA, Wave UK and Takeda entered into the Second Amendment to the
Takeda Collaboration Agreement (the &#147;Amendment&#148;), which discontinued the Category 2 component of the Takeda Collaboration. The Category 1 Programs under the Collaboration Agreement remain in effect and are unchanged by the Amendment.
Pursuant to the Amendment, Takeda agreed to pay the Company an additional $22.5&nbsp;million as full payment for reimbursable Category 2 Programs collaboration-budgeted research and preclinical expenses. The Company received this payment from Takeda
related to the Category 2 component and recognized the full amount as collaboration revenue in the year ended December&nbsp;31, 2021. During the year ended December&nbsp;31, 2021, in addition to the revenue recognized related to the Amendment, the
Company recognized another $18.5&nbsp;million of collaboration revenue related to services pertaining to the Category 1 Programs and Category 2 Programs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In May 2023, the Company announced its decision to discontinue clinical development of <FONT STYLE="white-space:nowrap">WVE-004</FONT> for C9orf72-associated
ALS and FTD (&#147;C9 for ALS/FTD&#148;), one of the Category 1 Programs. In July 2023, the joint steering committee that manages the Takeda Collaboration terminated C9 for ALS/FTD as a target under the collaboration (the &#147;C9 Target&#148;) and
consequently Takeda and the Company&#146;s rights and obligations under the Takeda Collaboration were terminated with respect to the C9 Target. As a result of the termination of the C9 for ALS/FTD Category 1 Program, the Company recognized
$28.0&nbsp;million in revenue during the three months ended September&nbsp;30, 2023, which represented the remainder of the deferred revenue for the C9 for ALS/FTD Category 1 Program as of June&nbsp;30, 2023. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In December 2023, the joint steering committee that manages the Takeda Collaboration, terminated SCA3 Program, another one of the Category 1 Programs, as a
target under the collaboration and consequently Takeda and the Company&#146;s rights and obligations under the Takeda Collaboration were terminated with respect to the SCA3 Category 1 Program. As a result of the termination of the SCA3 Category 1
Program, the Company recognized $9.9&nbsp;million in revenue during the three months ended December&nbsp;31, 2023, which represented the remainder of the deferred revenue for the SCA3 Category 1 Program as of September&nbsp;30, 2023. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the third quarter of 2023, the Company achieved a developmental milestone related to the HD Category 1 Program, which pertained to the positive results
from a <FONT STYLE="white-space:nowrap">non-clinical</FONT> study of <FONT STYLE="white-space:nowrap">WVE-003</FONT> in <FONT STYLE="white-space:nowrap">non-human</FONT> primates (&#147;NHPs&#148;). As a result of achieving the milestone, the
Company recognized $7.0&nbsp;million in revenue, which was not previously recorded in deferred revenue, as it was fully constrained at the inception of the Takeda Collaboration. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the years ended December&nbsp;31, 2023 and 2022, the Company recognized revenue of approximately $47.0&nbsp;million and $3.3&nbsp;million,
respectively, under the Takeda Collaboration Agreement in the Company&#146;s consolidated statements of operations and comprehensive loss. Through December&nbsp;31, 2023, the Company had recognized revenue of $128.2&nbsp;million under the Takeda
Collaboration Agreement as collaboration revenue in the Company&#146;s consolidated statements of operations and comprehensive loss. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The aggregate amount
of the transaction price allocated to the Company&#146;s unsatisfied and partially unsatisfied performance obligations and recorded in deferred revenue as of December&nbsp;31, 2023 and 2022, was $71.3&nbsp;million and $111.3&nbsp;million,
respectively. The deferred revenue included in current liabilities as of December&nbsp;31, 2023 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">F-22</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and 2022, was $71.3&nbsp;million and $31.6&nbsp;million, respectively. There was no&nbsp;deferred revenue included in long-term liabilities as of December&nbsp;31, 2023, the deferred revenue
included in long-term liabilities as of December&nbsp;31, 2022 was $79.8&nbsp;million. The decrease in the long-term portion of deferred revenue as of December&nbsp;31, 2023, was related to the expectation of the timing of the HD data that the
Company expects to report in the second quarter of 2024, which will form the basis for decision making for the advancement of this program. As a result, the deferred revenue related to this program was moved to short term as of December&nbsp;31,
2023. Additionally, the current portion of deferred revenue decreased from December&nbsp;31, 2022 to December&nbsp;31, 2023 due to revenue recognized during the year ended December&nbsp;31, 2023. The Company expects to recognize revenue for the
portion of the deferred revenue that relates to the research and development services for each remaining Category 1 Program as costs are incurred, over the remaining research term. The Company expects to recognize revenue for the portion of the
deferred revenue that relates to the material right for each remaining Category 1 Program option upon Takeda&#146;s exercise or termination of such option, or immediately as each option expires unexercised. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>6. SHARE CAPITAL </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following represents the
Company&#146;s financing transactions during the years ended December&nbsp;31, 2023 and 2022: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The Company entered into an open market sales agreement with Jefferies LLC in May 2019, as amended in March 2020
and March 2022, for its <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">at-the-market</FONT></FONT> equity program. During the year ended December&nbsp;31, 2022, the Company sold 458,092 ordinary shares under its <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">at-the-market</FONT></FONT> equity program for aggregate net proceeds of $1.2&nbsp;million after deducting commissions and offering expenses. During the year ended December&nbsp;31, 2023,
the Company sold 751,688 ordinary shares under its <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">at-the-market</FONT></FONT> equity program for aggregate net proceeds of $3.1&nbsp;million after deducting commissions and offering
expenses. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">On June&nbsp;16, 2022, the Company closed an underwritten offering (the &#147;June 2022 Offering&#148;) in which
the Company issued and sold 25,464,483 of the Company&#146;s ordinary shares at a price of $2.15 per share and <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants (the <FONT STYLE="white-space:nowrap">&#147;Pre-Funded</FONT> Warrants&#148;)
to purchase up to 7,093,656 of the Company&#146;s ordinary shares at an offering price of $2.1499 per <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrant, which represents the per share offering price for the ordinary shares less the $0.0001
per share exercise price for each <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrant. These <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants were recorded as a component of shareholders&#146; equity within additional <FONT
STYLE="white-space:nowrap">paid-in</FONT> capital. The gross proceeds to the Company from the June 2022 Offering were $70.0&nbsp;million before deducting underwriting discounts and commissions and other offering expenses. The net proceeds to the
Company from the June 2022 Offering were approximately $65.5&nbsp;million after deducting underwriting commissions and offering expenses. The <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants are exercisable at any time after their
original issuance and on or prior to the five-year anniversary of the original issuance date. A holder of <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants may not exercise the warrant if the holder, together with its affiliates, would
beneficially own more than 19.99% of the number of the Company&#146;s ordinary shares outstanding or more than 19.99% of the combined voting power of the Company&#146;s securities outstanding immediately after giving effect to such exercise, unless
and until shareholder approval is obtained. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">On December&nbsp;7, 2023, the Company entered into an underwriting agreement relating to the issuance and sale in
an underwritten offering of the Company&#146;s ordinary shares. On December&nbsp;11, 2023, the Company closed an underwritten public offering (the &#147;December 2023 Offering&#148;) in which the Company issued and sold 20,000,000 of the
Company&#146;s ordinary shares at a price of $5.00 per share. The gross proceeds to the Company from the December 2023 Offering were $100.0&nbsp;million before deducting underwriting discounts and commissions and other offering expenses. The net
proceeds to </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">F-23</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
the Company from the December 2023 Offering during the year ended December&nbsp;31, 2023 were approximately $93.6&nbsp;million after deducting underwriting discounts and offering expenses. On
January&nbsp;4, 2024, the Company closed on the sale of an additional 3,000,000 ordinary shares at a price of $5.00 per share after the underwriters exercised their option to purchase the additional shares in full, which increased the aggregate
number of ordinary shares sold in the December 2023 Offering to 23,000,000. The Company&#146;s aggregate gross proceeds from the December 2023 Offering were $115.0&nbsp;million, before deducting underwriting discounts and commissions and offering
expenses; $15.0&nbsp;million of which relates to the exercise of the underwriters&#146; option in January 2024. Subsequent to December&nbsp;31, 2023, the Company received $14.0&nbsp;million in net proceeds after deducting the underwriting discounts
and commissions and offering expenses related to the December 2023 Offering. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Features of the Series A Preferred Shares and
Ordinary Shares </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Series A preferred shares and ordinary shares have no par value and there is no concept of authorized share capital under
Singapore law. The Series A preferred shares are not redeemable and have no entitlement to dividends. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Voting </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The holders of Series A preferred shares are not entitled to vote on any of the matters proposed to shareholders, other than as specified in the Company&#146;s
Constitution. The holders of ordinary shares are entitled to one vote for each ordinary share held at all meetings of shareholders and written actions in lieu of meetings. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Dividends </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All dividends, if any, shall be
declared and paid pro rata according to the number of ordinary shares held by each member entitled to receive dividends. The Company&#146;s board of directors may deduct from any dividend all sums of money presently payable by the member to the
Company on account of calls. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Liquidation </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In
the event of a liquidation, dissolution or winding up of, or a return of capital by the Company, the ordinary shares will rank equally with the Series A preferred shares after the payment of the liquidation preference of an aggregate of
approximately $10&nbsp;thousand for Series A preferred shares. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>7. SHARE-BASED COMPENSATION </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Wave Life Sciences Ltd. 2021 Equity Incentive Plan was approved by the Company&#146;s shareholders and went into effect on August&nbsp;10, 2021 and was
amended effective as of August&nbsp;9, 2022 and August&nbsp;1, 2023 (as amended, the &#147;2021 Plan&#148;). The 2021 Plan serves as the successor to the Wave Life Sciences Ltd. 2014 Equity Incentive Plan, as amended (the &#147;2014 Plan&#148;),
such that outstanding awards granted under the 2014 Plan continue to be governed by the terms of the 2014 Plan, but no awards may be made under the 2014 Plan after August&nbsp;10, 2021. The aggregate number of ordinary shares authorized for issuance
of awards under the 2021 Plan was originally 5,450,000 ordinary shares, and was subsequently increased to 11,450,000 and 17,950,000 in August 2022 and August 2023, respectively, plus the number of ordinary shares underlying any awards under the 2014
Plan that are forfeited, cancelled or otherwise terminated (other than by exercise or withheld by the Company to satisfy any tax withholding obligation) on or after August&nbsp;10, 2021. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">F-24</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The 2021 Plan authorizes (and the 2014 Plan previously authorized) the board of directors or a committee of
the board of directors to, among other things, grant <FONT STYLE="white-space:nowrap">non-qualified</FONT> share options, restricted awards, which include restricted shares and restricted share units (&#147;RSUs&#148;), and performance awards to
eligible employees and directors of the Company. The Company accounts for grants to its board of directors as grants to employees. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of
December&nbsp;31, 2023, 8,101,005 ordinary shares remained available for future grant under the 2021 Plan. In accordance with Nasdaq Listing Rule 5635(c)(4), the board of directors or a committee of the board may also issue inducement grants outside
of the 2021 Plan, as an inducement material to an individual&#146;s entering into employment with the Company. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Options and RSUs </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Share option activity is summarized as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="52%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted-<BR>Average<BR>Exercise&nbsp;Price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted-<BR>Average<BR>Remaining<BR>Contractual<BR>Term&nbsp;(in&nbsp;years)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Aggregate<BR>Intrinsic&nbsp;Value<BR>(in&nbsp;thousands)<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding as of January&nbsp;1, 2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,682,054</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7.73</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,769,100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4.74</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercised</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(160,571</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Forfeited or cancelled</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,182,873</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7.51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding as of December&nbsp;31, 2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,107,710</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6.58</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6.98</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">34,682</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Options exercisable as of December&nbsp;31, 2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,560,153</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9.17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5.18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,418</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The aggregate intrinsic value of options is calculated as the difference between the exercise price of the
share options and the fair value of the Company&#146;s ordinary shares for those share options that had exercise prices lower than the fair value of the ordinary shares as of the end of the period. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Options generally vest over periods of one to four years, and options that are forfeited or cancelled are available to be granted again. The contractual life
of options is generally five or ten years from the grant date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The assumptions used in the Black-Scholes option pricing model to determine the fair value
of share options granted to employees during the period were as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="57%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For&nbsp;the&nbsp;Year&nbsp;Ended December&nbsp;31,</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk-free interest rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">3.46%&nbsp;&#150;&nbsp;4.71%</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">1.35%&nbsp;&#150;&nbsp;4.23%</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected term (in years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">3.0 &#150; 6.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">3.0 &#150; 6.1</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">87% &#150; 93%</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">63% &#150; 96%</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected dividend yield</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">0%</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">0%</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In October 2022, the compensation committee of the Company&#146;s board of directors granted Dr.&nbsp;Verdine, one of the
Company&#146;s founders and a member of the Company&#146;s board of directors, a <FONT STYLE="white-space:nowrap">non-qualified</FONT> share option for 163,467 ordinary shares (&#147;Verdine Scientific Advisory Grant&#148;) as form of payment under
Dr.&nbsp;Verdine&#146;s consulting agreement for scientific advisory services (as described in Note 13) for the service period of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">F-25</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
October&nbsp;1, 2022 through December&nbsp;31, 2024, the vesting of which is subject to Dr.&nbsp;Verdine&#146;s continued service under the consulting agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Verdine Scientific Advisory Grant was the only <FONT STYLE="white-space:nowrap">non-employee</FONT> grant made during the year ended December&nbsp;31,
2022, and there were no equity grants made to <FONT STYLE="white-space:nowrap">non-employees</FONT> during the year ended December&nbsp;31, 2023. The assumptions used in the Black-Scholes option pricing model to determine the fair value of the
Verdine Scientific Advisory Grant were as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="73%"></TD>

<TD VALIGN="bottom" WIDTH="23%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended<BR>December&nbsp;31,&nbsp;2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk-free interest rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4.29</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected term (in years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">99</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected dividend yield</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">RSU activity for the year ended December&nbsp;31, 2023 is summarized as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="67%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>RSUs</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Average&nbsp;Grant<BR>Date Fair<BR>Value&nbsp;(in<BR>dollars per<BR>share)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding as of January&nbsp;1, 2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">934,342</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10.94</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">208,875</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vested</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(415,658</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14.60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Forfeited</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(90,002</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7.61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">RSUs Outstanding at December&nbsp;31, 2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">637,557</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7.08</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">RSUs can be time-based or performance-based. Vesting of the performance-based RSUs is contingent on the occurrence of certain
regulatory or commercial milestones. In March 2021, the Compensation Committee approved an amendment and restatement of the Company&#146;s outstanding 2019 performance-based RSUs to add an additional milestone to the existing milestones. In 2021,
the Company also granted performance-based RSUs with the same terms to certain employees who did not receive the 2019 performance-based RSUs. The Company did not recognize expense in 2023 related to the performance-based RSUs as the remaining
milestones were not considered probable of achievement. In April 2022, the Company determined that a performance-based RSU milestone was achieved and consequently 50% of the outstanding performance-based RSUs vested, which resulted in the issuance
of 384,646 ordinary shares. During the year ended December&nbsp;31, 2022, the Company recorded share-based compensation expense of approximately $3.8&nbsp;million related to the performance-based RSUs, which represents all of the expense related to
the achievement of this performance-based RSU milestone. During the years ended December&nbsp;31, 2023 and 2022, the Company recognized share-based compensation expense of $1.0&nbsp;million and $10.3&nbsp;million, respectively, related to RSUs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">RSUs that are forfeited are available to be granted again. During the year ended December&nbsp;31, 2023, 208,875 time-based RSUs were granted to employees. Of
the RSUs outstanding at December&nbsp;31, 2023, 342,876 are time-based RSUs and 294,681 are performance-based RSUs. Time-based RSUs generally vest over periods of one to four years. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the years ended December&nbsp;31, 2023 and 2022, the Company recognized share-based compensation expense related to options of $8.5&nbsp;million and
$6.7&nbsp;million, respectively. The total intrinsic value of options </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">F-26</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
exercised was $0.3&nbsp;million and $0.4&nbsp;million for the years ended December&nbsp;31, 2023 and 2022, respectively. As of December&nbsp;31, 2023, the unrecognized compensation cost related
to outstanding options was $18.8&nbsp;million. The unrecognized compensation cost related to outstanding options is expected to be recognized over a weighted-average period of approximately 2.62 years. For the years ended December&nbsp;31, 2023 and
2022, the weighted-average grant date fair value per granted option was $3.45 and $2.06, respectively. The aggregate fair value of options that vested during the years ended December&nbsp;31, 2023 and 2022 was $8.4&nbsp;million and
$6.9&nbsp;million, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The unrecognized compensation costs related to outstanding time-based RSUs was $1.3&nbsp;million as of December&nbsp;31,
2023, and is expected to be recognized over a weighted-average period of approximately 2.93 years. The total fair value of RSUs vested during the years ended December&nbsp;31, 2023 and 2022 was $2.0&nbsp;million and $1.3&nbsp;million, respectively.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Employee Share Purchase Plan </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Wave Life
Sciences Ltd. Employee Share Purchase Plan, as amended (&#147;ESPP&#148;), allows full-time and certain part-time employees to purchase the Company&#146;s ordinary shares at a discount to fair market value. Eligible employees may enroll in a <FONT
STYLE="white-space:nowrap">six-month</FONT> offering period beginning every January 15<SUP STYLE="font-size:75%; vertical-align:top">th</SUP> and July 15<SUP STYLE="font-size:75%; vertical-align:top">th</SUP>. Shares are purchased at a price equal
to 85% of the lower of the fair market value of the Company&#146;s ordinary shares on the first business day or the last business day of an offering period. During the years ended December&nbsp;31, 2023 and 2022, 225,913 and 166,061 ordinary shares
were issued under the ESPP, respectively. The aggregate number of ordinary shares authorized for issuance under the ESPP was originally 1,000,000 and was subsequently increased to 3,000,000 in August 2023. As of December&nbsp;31, 2023, there were
2,490,500 ordinary shares available for issuance under the ESPP. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Share-Based Compensation Expense </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Share-based compensation expense for the years ended December&nbsp;31, 2023 and 2022 is classified as operating expenses in the consolidated statements of
operations and comprehensive loss as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>For&nbsp;the&nbsp;Year&nbsp;Ended&nbsp;December&nbsp;31,</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center">(in thousands)</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,617</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,467</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,178</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,727</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total share-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,795</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17,194</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Of the total share-based compensation expense recorded for the years ended December&nbsp;31, 2023 and 2022, $0.2&nbsp;million
and less than $0.1&nbsp;million, respectively, were related to <FONT STYLE="white-space:nowrap">non-employee</FONT> option grants, specifically the Verdine Scientific Advisory Grant, and all of the related expense is included in research and
development expenses on the consolidated statements of operations and comprehensive loss. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">F-27</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>8. LEASES </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Lease Arrangements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company enters into lease
arrangements for its facilities. A summary of the arrangements is as follows: </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Operating Leases </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Lexington </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On September&nbsp;26, 2016, and as amended on
December&nbsp;31, 2016, the Company entered into a 10 year and <FONT STYLE="white-space:nowrap">9-month</FONT> lease, which includes two successive five-year renewal options, for its facility in Lexington, Massachusetts, which the Company uses
primarily for its current good manufacturing practices (&#147;cGMP&#148;) manufacturing, as well as for additional laboratory and office space. As there is not reasonable certainty that the renewal options will be exercised, the lease liabilities
and the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets pertaining to the Lexington Lease do not account for the two successive five-year renewal options. Throughout the term of the lease, the
Company is responsible for paying certain costs and expenses, in addition to the rent, as specified in the lease, including a proportionate share of applicable taxes, operating expenses and utilities. As required under the terms of the lease
agreement, the Company has placed restricted cash of approximately $2.7&nbsp;million in a separate bank account as of December&nbsp;31, 2023 and 2022. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Cambridge </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In April 2015, the Company entered into a
lease agreement for an office and laboratory facility in Cambridge, Massachusetts (the &#147;Cambridge Lease&#148;), which commenced in October 2015 with a term of 7.5 years with a five-year renewal option to extend the lease. Throughout the term of
the lease, the Company is responsible for paying certain costs and expenses, in addition to the rent, as specified in the lease, including a proportionate share of applicable taxes, operating expenses and utilities. As required under the terms of
the lease agreement, the Company has placed restricted cash of $1.0&nbsp;million in a separate bank account as of December&nbsp;31, 2023 and 2022. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In
December 2020, the Company exercised its option under the Cambridge Lease to lease the additional office and laboratory space at the existing facility. The combined space constitutes the entire building. The lease for the additional space commenced
on October&nbsp;1, 2021, with a term of five years and is considered a separate lease from the Cambridge Lease. On the commencement date, the Company utilized the operating lease classification and recorded a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">right-of-use</FONT></FONT> asset and corresponding operating lease liability of $4.5&nbsp;million and began recognizing straight-line rent expense under ASC 842. Throughout the term of the lease, the Company is responsible
for paying certain costs and expenses, in addition to the rent, as specified in the lease, including a proportionate share of applicable taxes, operating expenses and utilities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In June 2022, the Company exercised the five-year renewal option under the Cambridge Lease to extend the lease term through March 2028 (the &#147;Cambridge
Lease Extension&#148;). Therefore, as required by ASC 842, the Company calculated an incremental borrowing rate of 10.53% and remeasured the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> asset and the
lease liabilities related to the Cambridge Lease Extension. As a result, an additional $12.0&nbsp;million of operating <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> asset and corresponding operating
lease liabilities were recorded relating to the Cambridge Lease Extension. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">F-28</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table contains a summary of the lease costs recognized under ASC 842 and other information
pertaining to the Company&#146;s operating leases for the years ended December&nbsp;31, 2023 and 2022: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="73%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>For&nbsp;the&nbsp;Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center">(in thousands)</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Lease cost</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease cost</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,365</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,458</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Variable lease cost</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,798</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,508</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total lease cost</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,163</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,966</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Other information</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating cash flows used for operating leases</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,655</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,226</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increase in operating
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,006</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease liabilities arising from obtaining <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,006</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average remaining lease term</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4 years</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5 years</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average discount rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9.2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9.2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Future minimum lease payments under the Company&#146;s <FONT STYLE="white-space:nowrap">non-cancelable</FONT> operating leases
as of December&nbsp;31, 2023, are as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="18%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;of&nbsp;December&nbsp;31,<BR>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">(in&nbsp;thousands)</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2024</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,311</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2025</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,591</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2026</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,584</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2027</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,987</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2028</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">886</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Thereafter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total lease payments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">38,359</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: imputed interest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(6,241</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">32,118</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>9. COMMITMENTS AND CONTINGENCIES </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Unasserted Claims </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the ordinary course of business, the
Company may be subject to legal proceedings, claims and litigation as the Company operates in an industry susceptible to patent and other legal claims. The Company accounts for estimated losses with respect to legal proceedings and claims when such
losses are probable and estimable. Legal costs associated with these matters are expensed when incurred. The Company is not currently a party to any material legal proceedings. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">F-29</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>10. NET LOSS PER ORDINARY SHARE </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Basic loss per share is computed by dividing net loss attributable to ordinary shareholders by the weighted-average number of ordinary shares outstanding: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="63%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center">(in&nbsp;thousands&nbsp;except&nbsp;share&nbsp;and&nbsp;per&nbsp;share&nbsp;data)</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Numerator:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss attributable to ordinary shareholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(57,513</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(161,823</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Denominator:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average ordinary shares outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">106,097,268</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">78,855,810</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per share, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0.54</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2.05</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2023 and 2022, there were 7,093,656 vested and exercisable
<FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants outstanding to purchase ordinary shares at an exercise price of $0.0001 per share. The <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants are included in the weighted-average
shares outstanding used in the calculation of basic net loss per share as the exercise price is negligible and the warrants are fully vested and exercisable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s potentially dilutive shares, which include outstanding share options to purchase ordinary shares and RSUs, are considered to be ordinary
share equivalents and are only included in the calculation of diluted net loss per share when their effect is dilutive. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following potential ordinary
shares, presented based on amounts outstanding at each period end, were excluded from the calculation of diluted net loss per share attributable to ordinary shareholders for the periods indicated because including them would have had an
anti-dilutive effect: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="69%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Options to purchase ordinary shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,107,710</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,682,054</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">RSUs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">637,557</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">934,342</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series A preferred shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,901,348</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,901,348</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>11. INCOME TAXES </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
components of loss before income taxes were as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="71%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center">(in thousands)</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Singapore</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(7,441</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(8,714</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Rest of world</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(50,749</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(152,428</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss before income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(58,190</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(161,142</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">F-30</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the years ended December&nbsp;31, 2023 and 2022, the Company recorded an income tax benefit of
$0.7&nbsp;million and an income tax provision of $0.7&nbsp;million, respectively. The income tax benefit for the year ended December&nbsp;31, 2023 was due to a change in estimate in connection with recent U.S. tax guidance relating to the
capitalization of research and development expenditures. The income tax provision for the year ended December&nbsp;31, 2022 was primarily due to the requirement under the Tax Cuts and Jobs Act of 2017 for taxpayers to capitalize and amortize
research and development expenditures over five or fifteen years pursuant to Section&nbsp;174 of the Internal Revenue Code of 1986, as amended (the &#147;Code&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The components of the benefit (provision) for income taxes were as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="71%"></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;2023&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;2022&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center">(in thousands)</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current benefit (provision) for income taxes:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Singapore</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Rest of world</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">677</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(681</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current benefit (provision) for income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">677</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(681</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred benefit for income taxes:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Singapore</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Rest of world</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total deferred benefit (provision) for income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total benefit (provision) for income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">677</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(681</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A reconciliation of the Singapore statutory income tax rate to the Company&#146;s effective income tax rate is as follows:
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;2023&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;2022&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Singapore statutory income tax rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Federal and state tax credits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Permanent differences</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Changes in reserves for uncertain tax positions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(2.8</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Foreign rate differential</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tax rate change</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Return to provision</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0.9</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0.1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in deferred tax asset valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(36.1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred tax adjustments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0.7</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(36.3</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Effective income tax rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0.4</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">F-31</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The components of the Company&#146;s deferred tax assets and liabilities as of December&nbsp;31, 2023 and
2022 are as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center">(in thousands)</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred tax assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net operating loss carryforwards</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">172,547</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">158,413</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Federal and state tax credits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,155</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">368</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,512</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,265</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">694</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">782</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,775</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,276</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,716</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,786</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Capitalized research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">41,239</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">36,643</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated depreciation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,508</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,807</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">237</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">357</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total deferred tax assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">253,383</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">233,697</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(247,193</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(226,273</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net deferred tax assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,190</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,424</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred tax liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(6,185</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(7,333</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated depreciation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(86</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(5</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total deferred tax liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(6,190</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(7,424</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net deferred tax assets (liabilities)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A roll-forward of the valuation allowance for the years ended December&nbsp;31, 2023 and 2022 is as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center">(in thousands)</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance at beginning of year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">226,273</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">238,170</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increase in valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20,969</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,134</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Decrease in valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(14,934</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Effect of foreign currency translation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(49</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(97</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance at end of year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">247,193</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">226,273</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2023, the Company had federal net operating loss carryforwards in the United States of
$302.2&nbsp;million, of which $301.4&nbsp;million may be available to offset future income tax liabilities indefinitely, while $0.8&nbsp;million of carryforwards that were in existence as of December&nbsp;31, 2017 may offset future income tax
liabilities up through 2037. As of December&nbsp;31, 2023, the Company had state net operating loss carryforwards of $54.7&nbsp;million that will begin to expire in 2038. As of December&nbsp;31, 2023 and 2022, the Company had U.S. federal research
and development tax credit carryforwards of approximately $6.1&nbsp;million and $0.2&nbsp;million, respectively, available to offset future U.S. federal income taxes and will begin to expire in 2042. As of December&nbsp;31, 2023 and 2022, the
Company had state research and development tax credit carryforwards of approximately $2.6&nbsp;million and $0.2&nbsp;million, respectively, available to offset future state income taxes and will begin to expire in 2037, and no longer had state
investment tax credit carryforwards. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">F-32</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2023 and 2022, the Company had net operating loss carryforwards in Japan of
$1.4&nbsp;million and $2.3&nbsp;million, respectively, which may be available to offset future income tax liabilities and begin to expire in 2024. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of
December&nbsp;31, 2023 and 2022, the Company had net operating loss carryforwards in Singapore of $122.0&nbsp;million and $111.2&nbsp;million, respectively, which may be available to offset future income tax liabilities and can be carried forward
indefinitely. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2023 and 2022, the Company had net operating loss carryforwards in the United Kingdom of $335.7&nbsp;million and
$314.5&nbsp;million, respectively, which may be available to offset future income tax liabilities and can be carried forward indefinitely. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company
has evaluated the positive and negative evidence bearing upon its ability to realize its deferred tax assets. As of December&nbsp;31, 2023, management has considered the Company&#146;s history of cumulative net losses incurred since inception and
its lack of commercialization of any products or generation of any revenue from product sales since inception and has concluded that it is more likely than not that the Company will not realize the benefits of the deferred tax assets in all
jurisdictions. Accordingly, a full valuation allowance has been established against those deferred tax assets as of December&nbsp;31, 2023. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The valuation
allowance increased by $20.9&nbsp;million in 2023. The increase in the valuation allowance for 2023 was primarily a result of operating losses generated with no corresponding financial statement benefit. The Company may release this valuation
allowance when management determines that it is <FONT STYLE="white-space:nowrap">more-likely-than-not</FONT> that the deferred tax assets will be realized. Any release of valuation allowance will be recorded as a tax benefit either increasing net
income or decreasing net loss. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s reserves related to taxes and its accounting for uncertain tax positions are based on a determination
of whether and how much of a tax benefit taken by the Company in its tax filings or positions is <FONT STYLE="white-space:nowrap">more-likely-than-not</FONT> to be realized following resolution of any potential contingencies present related to the
tax benefit. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A summary of activity in the Company&#146;s unrecognized tax benefits is as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center">(in thousands)</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unrecognized tax benefit at the beginning of the year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13,945</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19,864</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tax positions related to prior years</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">114</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(7,320</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tax positions related to the current year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,731</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,401</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unrecognized tax benefit at the end of the year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,790</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13,945</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2023 and 2022, the total amount of gross unrecognized tax benefits, which excludes interest and
penalties, was $15.8&nbsp;million and $13.9&nbsp;million, respectively. At December&nbsp;31, 2023, none of the net unrecognized tax benefits would affect the Company&#146;s annual effective tax rate if recognized. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company files income tax returns as prescribed by the tax laws of the jurisdictions in which it operates. In the normal course of business, the Company is
subject to examination by various tax authorities in the United States, Japan, Singapore and the United Kingdom. Tax years from 2020 to the present are still open to examination in the United States, from 2018 to the present in Japan, from 2019 to
the present in Singapore and from 2022 to the present in the United Kingdom. To the extent that the Company has tax attribute carryforwards, the tax years in which the attribute was generated may still be adjusted upon examination by the tax
authorities to the extent utilized in a future period. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">F-33</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2023 and 2022, $23.9&nbsp;million and $44.1&nbsp;million, respectively, of cash and
cash equivalents were held by the subsidiaries outside of Singapore. The Company does not provide for Singapore income tax or foreign withholding taxes on foreign unrepatriated earnings, as the Company intends to permanently reinvest undistributed
earnings in its foreign subsidiaries. If the Company decides to change this assertion in the future to repatriate any additional foreign earnings, the Company may be required to accrue and pay taxes. Because of the complexity of Singapore and
foreign tax rules applicable to the distribution of earnings from foreign subsidiaries to Singapore, the determination of the unrecognized deferred tax liability on these earnings is not practicable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Utilization of the net operating loss carryforwards and research and development tax credit carryforwards in the United States may be subject to a substantial
annual limitation under Section&nbsp;382 of the Code, due to ownership changes that have occurred previously or that could occur in the future. These ownership changes may limit the amount of carryforwards that can be utilized annually to offset
future taxable income. In general, an ownership change, as defined by Section&nbsp;382, results from transactions increasing the ownership of certain shareholders or public groups in the shares of a corporation by more than 50% over a three-year
period. In 2018, 2020 and 2022, the Company completed studies to assess whether an ownership change had occurred or whether there have been multiple ownership changes since its formation. The results of the 2018 and 2020 studies indicated that the
Company experienced ownership changes as defined by Section&nbsp;382 of the Code. Based on the results of the 2018 and 2020 studies, management had determined that the limitations will not have a material impact on the Company&#146;s ability to
utilize its net operating losses and research and development credit carryforwards to offset future tax liabilities. The results of the 2022 study indicated that the Company experienced an ownership change and will be limited in its ability to
utilize net operating losses and its research and development credit carryforwards in the 2022 tax year and going forward. Should one or more ownership changes occur in the future, the Company&#146;s ability to utilize its net operating losses and
research and development credit carryforwards may be further limited. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>12. EMPLOYEE BENEFIT PLANS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has a 401(k) retirement and savings plan (the &#147;401(k) Plan&#148;) covering employees of Wave USA. The 401(k) Plan allows employees to make
contributions up to the maximum allowable amount set by the Internal Revenue Service. Under the 401(k) Plan, the Company may make discretionary contributions as approved by the board of directors. The Company made contributions of $1.4&nbsp;million
and $1.1&nbsp;million in the years ended December&nbsp;31, 2023 and 2022, respectively. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>13. RELATED PARTIES </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company had the following related party transactions for the periods presented in the accompanying consolidated financial statements: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In 2012, the Company entered into a consulting agreement for scientific advisory services with
Dr.&nbsp;Gregory&nbsp;L. Verdine, one of the Company&#146;s founders and a member of the Company&#146;s board of directors. The consulting agreement does not have a specific term and may be terminated by either party upon 14 days&#146; prior written
notice. Pursuant to the consulting agreement, the Company pays Dr.&nbsp;Verdine approximately $13&nbsp;thousand per month, plus reimbursement for certain expenses. In October 2022, the compensation committee of the Company&#146;s board of directors
granted Dr.&nbsp;Verdine a <FONT STYLE="white-space:nowrap">non-qualified</FONT> share option for 163,467 ordinary shares in lieu of cash as payment under this consulting agreement for the service period of October&nbsp;1, 2022 through
December&nbsp;31, 2024, the monthly vesting of which is subject to Dr.&nbsp;Verdine&#146;s continued service under the consulting agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In April 2023, the Company engaged Shin Nippon Biomedical Laboratories Ltd. (&#147;SNBL&#148;), one of the
Company&#146;s shareholders, to provide approximately $2.8&nbsp;million in certain NHPs contract research services to the Company. During the year ended December&nbsp;31, 2023, the Company paid SNBL $1.4&nbsp;million for the aforementioned contract
research services. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">F-34</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="appatoc802241_4"></A>Supplementary Financial Information of Wave Life Sciences
Ltd. (Parent Company) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>WAVE LIFE SCIENCES LTD. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BALANCE SHEETS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>(In
thousands, except share amounts) </I></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="69%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,&nbsp;2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,&nbsp;2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">176,465</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">44,373</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Intercompany accounts receivable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,262</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">657</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">860</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,327</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">684</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">217</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">180,271</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">46,574</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Long-term assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Investment in subsidiary&#151;Wave USA</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Investment in subsidiary&#151;Wave UK</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Investment in subsidiary&#151;Wave Japan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,959</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,945</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total long-term assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,959</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,945</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">183,230</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">49,519</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Liabilities, Series A preferred shares and shareholders&#146; equity</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">993</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">733</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Intercompany accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,301</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,126</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expenses and other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">439</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">210</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,733</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,069</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,733</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,069</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series A preferred shares, no par value; 3,901,348 shares issued and outstanding at
December&nbsp;31, 2023 and 2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,874</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,874</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shareholders&#146; equity:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ordinary shares, no par value; 119,162,234 and 86,924,643 shares issued and outstanding at
December&nbsp;31, 2023 and 2022, respectively</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">935,366</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">802,833</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29,162</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28,221</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(798,905</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(791,478</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total shareholders&#146; equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">165,623</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">39,576</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities, Series A preferred shares and shareholders&#146; equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">183,230</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">49,519</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>The accompanying notes are an integral part of the supplementary financial information. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">F-35</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Wave Life Sciences Ltd. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Supplementary Financial Information </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1. DOMICILE AND ACTIVITIES </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Wave Life Sciences Ltd. (the
&#147;Parent&#148;), formerly Wave Life Sciences Pte. Ltd., registration number 201218209G, is a company incorporated in the Republic of Singapore on July&nbsp;23, 2012. The Parent&#146;s registered office is located at 7 Straits View <FONT
STYLE="white-space:nowrap">#12-00,</FONT> Marina One East Tower, Singapore 018936. The Parent was incorporated with the purpose of combining two commonly held companies, Wave Life Sciences USA, Inc. (&#147;Wave USA&#148;), a Delaware corporation
(formerly Ontorii, Inc.), and Wave Life Sciences (Japan) (&#147;Wave Japan&#148;), a company organized under the laws of Japan (formerly Chiralgen., Ltd.), which occurred on September&nbsp;13, 2012. On May&nbsp;31, 2016, Wave Life Sciences Ireland
Limited (&#147;Wave Ireland&#148;) was formed as a wholly-owned subsidiary of Wave Life Sciences Ltd. On April&nbsp;3, 2017, Wave Life Sciences UK Limited (&#147;Wave UK&#148;) was formed as a wholly-owned subsidiary of Wave Life Sciences Ltd. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On November&nbsp;5, 2015, the Parent converted from a Singapore private company limited by shares to a Singapore public company limited by shares. In
connection with this conversion, the Parent changed its name from &#147;Wave Life Sciences Pte. Ltd.&#148; to &#147;Wave Life Sciences Ltd.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Wave
Life Sciences Ltd. (together with its subsidiaries, &#147;Wave&#148; or the &#147;Company&#148;) is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines (also known as oligonucleotides), or those targeting
ribonucleic acid &#147;RNA&#148;), to transform human health. Wave&#146;s RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation and deep insights into human genetics to deliver scientific breakthroughs that treat both
rare and prevalent disorders. The Company&#146;s toolkit of <FONT STYLE="white-space:nowrap">RNA-targeting</FONT> modalities includes RNA editing, splicing, antisense silencing and RNA interference (&#147;RNAi&#148;), providing the Company with
unique capabilities for designing and sustainably delivering candidates that optimally address disease biology. The Company&#146;s lead programs are in rare and prevalent diseases, including <FONT STYLE="white-space:nowrap">alpha-1</FONT>
antitrypsin deficiency (&#147;AATD&#148;), obesity, Duchenne muscular dystrophy (&#147;DMD&#148;), and Huntington&#146;s disease (&#147;HD&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
Company&#146;s primary activities have been developing and evolving PRISM to design, develop and commercialize RNA medicines, advancing the Company&#146;s differentiated portfolio, building the Company&#146;s research, development and manufacturing
capabilities, advancing programs into the clinic, furthering clinical development of such clinical-stage programs, building the Company&#146;s intellectual property, and assuring adequate capital to support these activities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2. SIGNIFICANT ACCOUNTING POLICIES </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Basis of
preparation </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In order to comply with the requirements of the Singapore Companies Act, the Parent must present supplementary balance sheets
comprised solely from the standalone accounts of Wave Life Sciences Ltd., the Parent company. This supplementary financial information is presented on page <FONT STYLE="white-space:nowrap">F-35.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Parent applied to the Accounting and Corporate Regulatory Authority of Singapore (&#147;ACRA&#148;) for an exemption from preparing its 2023 Singapore
Statutory Financial Statements in accordance with Singapore Financial Reporting Standards. The Parent applied for this exemption because it is listed on the Nasdaq and therefore is required to prepare its audited annual consolidated financial
statements in accordance with the Generally Accepted Accounting Principles of the United States of America (&#147;U.S. GAAP&#148;) in order to maintain </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">F-36</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
its listing on Nasdaq. These U.S. GAAP annual consolidated financial statements (&#147;U.S. GAAP Consolidated Financials&#148;) were included in the Form
<FONT STYLE="white-space:nowrap">10-K,</FONT> which was filed with the Securities and Exchange Commission (&#147;SEC&#148;) on March&nbsp;6, 2024. The Parent received the exemption from ACRA and therefore the Singapore Statutory Financial Statements
were prepared in accordance with U.S. GAAP, except as noted in the paragraph entitled &#147;Investment in Subsidiaries.&#148; The U.S. GAAP Consolidated Financials are included in these Singapore Statutory Financial Statements on pages <FONT
STYLE="white-space:nowrap">F-1</FONT> to <FONT STYLE="white-space:nowrap">F-34.</FONT> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Functional and presentation currency </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This supplementary financial information is presented in U.S. dollars, which is the Parent&#146;s functional currency. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Investment in Subsidiaries </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the purposes of
the supplementary financial information provided as a part of the Singapore Statutory Financial Statements, the Parent did not consolidate its investments in subsidiaries and reported these investments as separate lines in the Parent&#146;s
standalone balance sheet. The Parent&#146;s investment in each subsidiary is accounted for by either increasing its initial investment in each subsidiary by that subsidiary&#146;s net income for each financial year or by decreasing its initial
investment in each subsidiary by that subsidiary&#146;s net loss for each financial year to the extent of the initial investment of the subsidiary. U.S. GAAP requires that a Parent&#146;s investments in subsidiaries be consolidated. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cash and Cash Equivalents </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Parent considers
all highly liquid securities with maturities of three months or less from the date of purchase to be cash equivalents. The Parent&#146;s cash and cash equivalents are comprised of funds held in checking and money market accounts. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Use of Estimates </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The preparation of financial
statements and related disclosures in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amount of assets, liabilities, revenue, costs and expenses and related disclosures at the date of the
financial statements and the supplementary financial information. Management considers many factors in selecting appropriate financial accounting policies and in developing the estimates and assumptions that are used in the preparation of the
financial statements and the supplemental information. Management must apply significant judgment in this process. The Company believes that its revenue recognition policy, particularly (a)&nbsp;assessing the number of performance obligations;
(b)&nbsp;determining the transaction price; (c)&nbsp;allocating the transaction price to the performance obligations in the contract; and (d)&nbsp;determining the pattern over which performance obligations are satisfied, including estimates to
complete performance obligations involve a greater degree of judgment, and therefore the Company considers them to be its critical accounting policies. The Company evaluates its estimates and assumptions on an ongoing basis. The Company&#146;s
actual results may differ from these estimates under different assumptions and conditions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Going Concern </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At each reporting period, the Parent evaluates whether there are conditions or events that raise substantial doubt about the Parent&#146;s ability to continue
as a going concern within one year after the date that the financial statements are issued. The Parent is required to make certain additional disclosures if the Parent concludes substantial doubt exists and it is not alleviated by the Parent&#146;s
plans or when the Company&#146;s plans alleviate </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">F-37</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
substantial doubt about the Parent&#146;s ability to continue as a going concern. The Parent&#146;s evaluation entails analyzing prospective operating budgets and forecasts for expectations of
the Parent&#146;s cash needs and comparing those needs to the current cash and cash equivalent balance. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Fair Value of Financial Instruments
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Parent is required to disclose information on all assets and liabilities reported at fair value that enables an assessment of the inputs used
in determining the reported fair values. The fair value hierarchy is a hierarchy of inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the observable inputs
be used when available. Observable inputs are inputs that market participants would use in pricing the financial instrument based on market data obtained from sources independent of the Parent. Unobservable inputs are inputs that reflect the
Parent&#146;s assumptions about the inputs that market participants would use in pricing the financial instrument and are developed based on the information available in the circumstances. The fair value hierarchy applies only to the valuation
inputs used in determining the reported fair value of the investments and is not a measure of the investment credit quality. The hierarchy defines three levels of valuation inputs: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Level 1&#151;Unadjusted quoted prices in active markets that are accessible at the measurement date of identical, unrestricted assets. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Level 2&#151;Quoted prices for similar assets, or inputs that are observable, either directly or indirectly, for substantially the full term
through corroboration with observable market data. Level&nbsp;2 includes investments valued at quoted prices adjusted for legal or contractual restrictions specific to the security. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Level 3&#151;Pricing inputs are unobservable for the asset, that is, inputs that reflect the reporting entity&#146;s own assumptions about the
assumptions market participants would use in pricing the asset. Level&nbsp;3 includes private investments that are supported by little or no market activity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents are Level&nbsp;1 assets which are comprised of funds held in checking and money market accounts. Short-term investments are
Level&nbsp;2 assets which are comprised of term deposits. Cash and cash equivalents were recorded at fair value as of December&nbsp;31, 2023 and 2022, totaling $176.5&nbsp;million and $44.4&nbsp;million, respectively. There were no short-term
investments as of December&nbsp;31, 2023 or 2022, as the $75.0&nbsp;million of term deposits that constitute the Parent&#146;s short-term investments were all purchased and reached maturity during the twelve months ended December&nbsp;31, 2022. The
carrying amounts of intercompany account receivables and payables, accounts payable and accrued expenses approximate their fair values due to their short-term maturities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Given their related party nature, intercompany accounts receivables and intercompany accounts payables were transacted based upon terms and amounts set forth
between the Parent and its subsidiaries. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Concentration of Credit Risk </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cash, cash equivalents and short-term investments are financial instruments that potentially subject the Parent to concentration of credit risk. The Parent
uses several financial institutions to maintain its cash, cash equivalents and short-term investments, all of which are high quality, accredited financial institutions and, accordingly, such funds are subject to minimal credit risk.&nbsp;The Parent
has not experienced any losses in such accounts and management believes that the Parent is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held. The Parent has no
financial instruments with <FONT STYLE="white-space:nowrap">off-balance</FONT> sheet risk of loss. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">F-38</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Share-Based Compensation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company measures and recognizes share-based compensation expense, for both employee and <FONT STYLE="white-space:nowrap">non-employee</FONT> director
option awards, based on the grant date fair value of the awards. The Parent calculates the fair value of restricted share unit awards based on the grant date fair value of the underlying ordinary shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company determines the fair value of share-based awards granted to <FONT STYLE="white-space:nowrap">non-employees</FONT> as either the fair value of the
consideration received or the fair value of the equity instruments issued, whichever is more reliably measurable. Equity instruments issued to <FONT STYLE="white-space:nowrap">non-employees</FONT> as consideration for goods or services received by
the Parent have been accounted for based on the fair value of the equity instruments issued. The Parent recognizes share-based compensation expense on a straight-line basis over the requisite service period of the awards, which is generally the
vesting period. The Parent accounts for forfeitures as they occur. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company classifies share-based compensation expense in its consolidated statements
of operations and comprehensive loss in the same manner in which the award recipient&#146;s compensation costs are classified or in which the award recipient&#146;s service payments are classified. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital presented on the Parent&#146;s supplementary balance sheets only reflects share-based
compensation expense for <FONT STYLE="white-space:nowrap">non-employee</FONT> option awards and share-based compensation expense for option awards granted to <FONT STYLE="white-space:nowrap">non-employee</FONT> directors, which are accounted for as
employee option awards. The remainder of the consolidated share-based compensation expense was recorded by the Parent&#146;s subsidiaries as the expense relates to option awards and restricted share units granted to employees of the subsidiaries.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The fair value of each share option grant was determined using the methods and assumptions discussed below. These inputs are generally subjective and
require significant judgment and estimation by management. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Fair Value of Ordinary Shares</I> The fair value of the ordinary shares underlying the Company&#146;s
share-based awards is based on the closing price of the Parent&#146;s ordinary shares as reported by the Nasdaq Global Market on the date of grant. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Expected Term</I> The expected term of share options represents the weighted-average period that the share
options are expected to remain outstanding. The Company estimated the expected term using the simplified method, which is an average of the contractual term of the option and the vesting period. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Expected Volatility </I>Since there was limited historical data for the Parent&#146;s ordinary shares and
limited company-specific historical volatility through the third quarter of 2021, the Company determined the share price volatility for options granted based on an analysis of the volatility used by a peer group of publicly traded companies. In
evaluating similarity, the Parent considers factors such as industry, stage of life cycle and size. Beginning in the fourth quarter of 2021, the Parent had sufficient historical volatility data for its ordinary shares and as such no longer relies on
an analysis of the volatility from a peer group to calculate expected volatility. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Risk-free Interest Rate</I> The risk-free interest rate is based on the U.S. Treasury yield in effect at the
time of the grant for <FONT STYLE="white-space:nowrap">zero-coupon</FONT> U.S. Treasury notes with remaining terms similar to the expected term of the options. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Dividend Rate</I> The expected dividend was assumed to be zero as the Parent has never paid dividends and has
no current plans to do so. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">F-39</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Income Taxes </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Parent accounts for income taxes using an asset and liability approach, which requires recognition of deferred tax assets and liabilities for the expected
future tax consequences of events that have been recognized in the consolidated financial statements but have not been reflected in taxable income. A valuation allowance is established to reduce deferred tax assets to their estimated realizable
value. Therefore, the Parent provides a valuation allowance to the extent that it is more likely than not that all or a portion of the deferred tax assets will not be realized in the future. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Parent accounts for uncertainty in income taxes recognized in the financial statements by applying a <FONT STYLE="white-space:nowrap">two-step</FONT>
process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination by the tax authorities. If the tax position is deemed <FONT
STYLE="white-space:nowrap">more-likely-than-not</FONT> to be sustained, the tax position is then assessed to determine the amount of benefit to recognize in the financial statements. The amount of the benefit that may be recognized is the largest
amount that has a greater than 50% likelihood of being realized upon ultimate settlement. The provision for income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits, that are considered appropriate as well as the
related net interest and penalties. The Parent recognizes interest and penalties related to uncertain tax positions in the income tax provision on the consolidated statements of operations and comprehensive loss. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has certain service arrangements in place between its U.S., Japan, U.K. and Singapore entities,&nbsp;which include transfer pricing
assumptions.&nbsp;The determination of the appropriate level of transfer pricing requires judgment based on transfer pricing analyses of comparable companies.&nbsp;The Parent monitors the nature of its service arrangements for changes in its
operations as well as economic conditions.&nbsp;The Parent also periodically reviews the transfer pricing analyses for changes in the composition in the pool of comparable companies as well as the related ongoing results of the comparable companies.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Unasserted Claims </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the ordinary course of
business, the Parent may be subject to legal proceedings, claims and litigation as the Parent operates in an industry susceptible to patent and other legal claims. The Parent accounts for estimated losses with respect to legal proceedings and claims
when such losses are probable and estimable. Legal costs associated with these matters are expensed when incurred. The Parent is not currently a party to any material legal proceedings. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3. INTERCOMPANY BALANCES </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The intercompany balances
presented on the Parent&#146;s balance sheets are the result of intercompany transactions between the Parent and its subsidiaries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of
December&nbsp;31, 2023, intercompany accounts receivables totaled $2.3&nbsp;million and related to amounts due from Wave USA and Wave UK related to the reimbursement of certain expenses that were paid for by the Parent on behalf of Wave USA and Wave
UK, as well as amounts due from Wave USA related to proceeds from the exercise of share options by Wave USA&#146;s employees. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31,
2022, intercompany accounts receivables totaled $0.7&nbsp;million and related to amounts due from Wave USA and Wave UK related to the reimbursement of certain expenses that were paid for by the Parent on behalf of Wave USA and Wave UK, as well as
amounts due from Wave USA related to proceeds from the exercise of share options by Wave USA&#146;s employees. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">F-40</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2023, the intercompany accounts payable totaled $8.3&nbsp;million and related to
amounts due to Wave USA under the intercompany management services agreement, amounts due to Wave UK related to GSK equity premium, as well as amounts due to Wave Japan related to the reimbursement of certain expenses that were paid for by Wave
Japan on behalf of the Parent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2022, the intercompany accounts payable totaled $1.1&nbsp;million and related to amounts due to
Wave USA under the intercompany management services agreement, as well as additional amounts due to Wave Japan related to the reimbursement of certain expenses that were paid for by Wave Japan on behalf of the Parent. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4. INCOME TAXES </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The components of the Parent&#146;s
deferred tax assets and liabilities as of December&nbsp;31, 2023 and 2022 are as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="56%"></TD>

<TD VALIGN="bottom" WIDTH="14%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="14%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,&nbsp;2023</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,&nbsp;2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center">(in thousands)</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred tax assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net operating loss carryforwards</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21,616</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">19,731</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Capitalized research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,917</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,917</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total deferred tax assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">36,533</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">34,648</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(36,533</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(34,648</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net deferred tax assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total deferred tax liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net deferred tax asset (liability)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2023 and 2022, the Parent had net operating loss carryforwards in Singapore of $122.0&nbsp;million and
$100.9&nbsp;million, respectively, which may be available to offset future income tax liabilities and can be carried forward indefinitely provided the Parent satisfies the shareholdings test for carry-forward losses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Parent has evaluated the positive and negative evidence bearing upon its ability to realize its deferred tax assets. As of December&nbsp;31, 2023,
management has considered the Parent&#146;s history of cumulative net losses incurred since inception and its lack of commercialization of any products or generation of any revenue from product sales since inception and has concluded that it is more
likely than not that the Parent will not realize the benefits of the deferred tax assets in Singapore. Accordingly, a full valuation allowance has been established against those deferred tax assets as of December&nbsp;31, 2023. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The valuation allowance increased by approximately $1.9&nbsp;million in 2023 and $1.6&nbsp;million in 2022 primarily as a result of operating losses generated
with no corresponding financial statement benefit. The Parent may release this valuation allowance when management determines that it is <FONT STYLE="white-space:nowrap">more-likely-than-not</FONT> that the deferred tax assets will be realized. Any
release of valuation allowance will be recorded as a tax benefit increasing net income. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Parent files income tax returns as prescribed by the tax laws
of the jurisdictions in which it operates. In the normal course of business, the Parent is subject to examination by various taxing authorities in Singapore. Tax years from 2018 to the present are still open to examination in Singapore. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">F-41</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2023 and 2022, $23.9&nbsp;million and $44.1&nbsp;million, respectively, of cash and
cash equivalents was held by the Parent&#146;s subsidiaries outside of Singapore. Additionally, as of December&nbsp;31, 2023 and December&nbsp;31, 2022 the Parent&#146;s subsidiaries held restricted cash of $3.7&nbsp;million, respectively, outside
of Singapore. The Parent does not provide for Singapore income tax or foreign withholding taxes on foreign unrepatriated earnings, as the Parent intends to permanently reinvest undistributed earnings in its foreign subsidiaries. If the Parent
decides to change this assertion in the future to repatriate any additional foreign earnings, the Parent may be required to accrue and pay taxes. Because of the complexity of Singapore and foreign tax rules applicable to the distribution of earnings
from foreign subsidiaries to Singapore, the determination of the unrecognized deferred tax liability on these earnings is not practicable. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5.
COLLABORATION AGREEMENTS </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>GSK Collaboration and Equity Agreements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December&nbsp;13, 2022, Wave USA and Wave UK entered into a Collaboration and License Agreement (the &#147;GSK Collaboration Agreement&#148;) with
GlaxoSmithKline Intellectual Property (&#147;GSK&#148;). Pursuant to the GSK Collaboration Agreement, Wave USA, Wave UK and GSK have agreed to collaborate on the research, development, and commercialization of oligonucleotide therapeutics, including
an exclusive global license to <FONT STYLE="white-space:nowrap">WVE-006.</FONT> The discovery collaboration component has an initial four-year research term and combines Wave USA, and Wave UK&#146;s proprietary discovery and drug development
platform, PRISM, with GSK&#146;s unique genetic insights and its global development and commercial capabilities. On January&nbsp;27, 2023, the GSK Collaboration Agreement became effective, and GSK paid Wave USA and Wave UK an upfront payment of
$120.0&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Simultaneously with the execution of the GSK Collaboration Agreement, the Parent entered into a Share Purchase Agreement (the
&#147;SPA&#148;) on December&nbsp;13, 2022, with Glaxo Group Limited (&#147;GGL&#148;), an affiliate of GSK, pursuant to which the Parent agreed to sell 10,683,761 of its ordinary shares to GGL at a purchase price of $4.68 per share (the &#147;GSK
Equity Investment&#148;). The GSK Equity Investment closed on January&nbsp;26, 2023, following the completion of customary closing conditions. The Parent received cash proceeds of $50.0&nbsp;million at closing of which $34.6&nbsp;million was
recorded as equity and $15.4&nbsp;million in intercompany payable related to the GSK Equity Investment. The ordinary shares purchased by GGL are subject to <FONT STYLE="white-space:nowrap">lock-up</FONT> and standstill restrictions and carry certain
registration rights, customary for transactions of this kind. The Parent did not incur any material costs in connection with the issuance of the ordinary shares under the SPA. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Takeda Collaboration and Equity Agreements </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In
February 2018, Wave USA and Wave UK entered into a global strategic collaboration, as amended in October 2021 (the &#147;Takeda Collaboration&#148;) with Takeda Pharmaceutical Company Limited (&#147;Takeda&#148;), pursuant to which Wave USA, Wave UK
and Takeda agreed to collaborate on the research, development and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System (&#147;CNS&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Simultaneously with Wave USA and Wave UK&#146;s entry into the collaboration and license agreement with Takeda (the &#147;Takeda Collaboration
Agreement&#148;), the Parent entered into a share purchase agreement with Takeda (the &#147;Takeda Equity Agreement,&#148; and together with the Takeda Collaboration Agreement, the &#147;Takeda Agreements&#148;) pursuant to which the Parent agreed
to sell to Takeda 1,096,892 of its ordinary shares at a purchase price of $54.70 per share. In April 2018, the Parent closed the Takeda Equity Agreement and received aggregate cash proceeds of $60.0&nbsp;million. The Parent did not incur any
material costs in connection with the issuance of shares. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">F-42</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>6. SHARE CAPITAL </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following represents the Parent&#146;s financing transactions during the years ended December&nbsp;31, 2023 and 2022: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The Parent entered into an open market sales agreement with Jefferies LLC in May 2019, as amended in March 2020
and March 2022, for its <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">at-the-market</FONT></FONT> equity program. During the year ended December&nbsp;31, 2022, the Parent sold 458,092 ordinary shares under its <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">at-the-market</FONT></FONT> equity program for aggregate net proceeds of $1.2&nbsp;million after deducting commissions and offering expenses. During the year ended December&nbsp;31, 2023,
the Parent sold 751,688 ordinary shares under its <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">at-the-market</FONT></FONT> equity program for aggregate net proceeds of $3.1&nbsp;million after deducting commissions and offering
expenses. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">On June&nbsp;16, 2022, the Parent closed an underwritten offering (the &#147;June 2022 Offering&#148;) in which
the Parent issued and sold 25,464,483 of the Parent&#146;s ordinary shares at a price of $2.15 per share and <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants (the <FONT STYLE="white-space:nowrap">&#147;Pre-Funded</FONT> Warrants&#148;) to
purchase up to 7,093,656 of the Parent&#146;s ordinary shares at an offering price of $2.1499 per <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrant, which represents the per share offering price for the ordinary shares less the $0.0001 per
share exercise price for each <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrant. These <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants were recorded as a component of shareholders&#146; equity within additional <FONT
STYLE="white-space:nowrap">paid-in</FONT> capital. The gross proceeds to the Parent from the June 2022 Offering were $70.0&nbsp;million before deducting underwriting discounts and commissions and other offering expenses. The net proceeds to the
Parent from the June 2022 Offering were approximately $65.5&nbsp;million after deducting underwriting discounts and commissions and other offering expenses. The <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants are exercisable at any time
after their original issuance and on or prior to the five-year anniversary of the original issuance date. A holder of <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants may not exercise the warrant if the holder, together with its
affiliates, would beneficially own more than 19.99% of the number of the Parent&#146;s ordinary shares outstanding or more than 19.99% of the combined voting power of the Parent&#146;s securities outstanding immediately after giving effect to such
exercise, unless and until shareholder approval is obtained. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">On December&nbsp;7, 2023, the Parent entered into an underwriting agreement relating to the issuance and sale in
an underwritten offering of the Parent&#146;s ordinary shares. On December&nbsp;11, 2023, the Parent closed an underwritten public offering (the &#147;December 2023 Offering&#148;) in which the Parent issued and sold 20,000,000 of the Parent&#146;s
ordinary shares at a price of $5.00 per share. The gross proceeds to the Parent from the December 2023 Offering were $100.0&nbsp;million before deducting underwriting discounts and commissions and other offering expenses. The net proceeds to the
Parent from the December 2023 Offering during the year ended December&nbsp;31, 2023 were approximately $93.6&nbsp;million after deducting underwriting discounts and offering expenses. On January&nbsp;4, 2024, the Parent closed on the sale of an
additional 3,000,000 ordinary shares at a price of $5.00 per share after the underwriters exercised their option to purchase the additional shares in full, which increased the aggregate number of ordinary shares sold in the December 2023 Offering to
23,000,000. The Parent&#146;s aggregate gross proceeds from the December 2023 Offering were $115.0&nbsp;million, before deducting underwriting discounts and commissions and offering expenses; $15.0&nbsp;million of which relates to the exercise of
the underwriters&#146; option in January 2024. Subsequent to December&nbsp;31, 2023, the Parent received $14.0&nbsp;million in net proceeds after deducting the underwriting discounts and commissions and offering expenses related to the December 2023
Offering. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">F-43</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Features of the Series A Preferred Shares and Ordinary Shares </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Series A preferred shares and ordinary shares have no par value and there is no concept of authorized share capital under Singapore law. The Series A
preferred shares are not redeemable and have no entitlement to dividends. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Voting </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The holders of Series A preferred shares are not entitled to vote on any of the matters proposed to shareholders, other than as specified in the Parent&#146;s
Constitution. The holders of ordinary shares are entitled to one vote for each ordinary share held at all meetings of shareholders and written actions in lieu of meetings. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Dividends </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All dividends, if any, shall be
declared and paid pro rata according to the number of ordinary shares held by each member entitled to receive dividends. The Parent&#146;s board of directors may deduct from any dividend all sums of money presently payable by the member to the
Parent on account of calls. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Liquidation </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In
the event of a liquidation, dissolution or winding up of, or a return of capital by the Parent, the ordinary shares will rank equally with the Series A preferred shares after the payment of the liquidation preference of an aggregate of approximately
$10&nbsp;thousand for Series A preferred shares. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>7. SHARE-BASED COMPENSATION </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Wave Life Sciences Ltd. 2021 Equity Incentive Plan was approved by the Parent&#146;s shareholders and went into effect on August&nbsp;10, 2021 and was
amended effective as of August&nbsp;9, 2022 and August&nbsp;1, 2023 (as amended, the &#147;2021 Plan&#148;). The 2021 Plan serves as the successor to the Wave Life Sciences Ltd. 2014 Equity Incentive Plan, as amended (the &#147;2014 Plan&#148;),
such that outstanding awards granted under the 2014 Plan continue to be governed by the terms of the 2014 Plan, but no awards may be made under the 2014 Plan after August&nbsp;10, 2021. The aggregate number of ordinary shares authorized for issuance
of awards under the 2021 Plan was originally 5,450,000 ordinary shares, and was subsequently increased to 11,450,000 and 17,950,000 in August 2022 and August 2023, respectively, plus the number of ordinary shares underlying any awards under the 2014
Plan that are forfeited, cancelled or otherwise terminated (other than by exercise or withheld by the Company to satisfy any tax withholding obligation) on or after August&nbsp;10, 2021. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The 2021 Plan authorizes (and the 2014 Plan previously authorized) the board of directors or a committee of the board of directors to, among other things,
grant <FONT STYLE="white-space:nowrap">non-qualified</FONT> share options, restricted awards, which include restricted shares and restricted share units (&#147;RSUs&#148;), and performance awards to eligible employees and directors of the Company.
The Parent accounts for grants to its board of directors as grants to employees. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2023, 8,101,005 ordinary shares remained
available for future grant under the 2021 Plan. In accordance with Nasdaq Listing Rule 5635(c)(4), the board of directors or a committee of the board may also issue inducement grants outside of the 2021 Plan, material to an individual&#146;s
entering into employment with the Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">F-44</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Options and RSUs </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Share option activity is summarized as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted-<BR>Average<BR>Exercise&nbsp;Price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted-<BR>Average<BR>Remaining<BR>Contractual<BR>Term&nbsp;(in&nbsp;years)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Aggregate<BR>Intrinsic&nbsp;Value<BR>(in&nbsp;thousands)<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding as of January&nbsp;1, 2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,682,054</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7.73</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted<SUP STYLE="font-size:75%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,769,100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4.74</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercised</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(160,571</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Forfeited or cancelled<SUP STYLE="font-size:75%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,182,873</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7.51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding as of December&nbsp;31, 2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,107,710</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6.58</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6.98</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">34,682</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Options exercisable as of December&nbsp;31, 2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,560,153</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9.17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5.18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,418</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The aggregate intrinsic value of options is calculated as the difference between the exercise price of the
share options and the fair value of the Parent&#146;s ordinary shares for those share options that had exercise prices lower than the fair value of the ordinary shares as of the end of the period. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes 360,000 options granted by the Parent to <FONT STYLE="white-space:nowrap">non-employee</FONT>
directors in 2023. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Includes the cancellation of 45,000 options granted by the Parent to
<FONT STYLE="white-space:nowrap">non-employee</FONT> directors based on the expiration of the five-year contractual life. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Options
generally vest over periods of one to four years, and options that are forfeited or cancelled are available to be granted again. The contractual life of options is generally five or ten years from the grant date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The assumptions used in the Black-Scholes option pricing model to determine the fair value of share options granted to employees during the period were as
follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="45%"></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For&nbsp;the&nbsp;Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;&#8195;&#8195;&#8195;2023&#8195;&#8195;&#8195;&#8195;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8195;&#8195;&#8195;&#8195;2022&#8195;&#8195;&#8195;&#8195;</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk-free interest rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">3.46%&nbsp;&#150;&nbsp;4.71%</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">1.35%&nbsp;&#150;&nbsp;4.23%</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected term (in years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">3.0&nbsp;&#150;&nbsp;6.1</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">3.0&nbsp;&#150;&nbsp;6.1</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">87%&nbsp;&#150;&nbsp;93%</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">63%&nbsp;&#150;&nbsp;96%</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected dividend yield</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">0%</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">0%</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In October 2022, the compensation committee of the Parent&#146;s board of directors granted Dr.&nbsp;Verdine, one of the
Company&#146;s founders and a member of the Parent&#146;s board of directors, a <FONT STYLE="white-space:nowrap">non-qualified</FONT> share option for 163,467 ordinary shares (&#147;Verdine Scientific Advisory Grant&#148;) as form of payment under
Dr.&nbsp;Verdine&#146;s consulting agreement for scientific advisory services (as described in Note 13) for the service period of October&nbsp;1, 2022 through December&nbsp;31, 2024, the vesting of which is subject to Dr.&nbsp;Verdine&#146;s
continued service under the consulting agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">F-45</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Verdine Scientific Advisory Grant was the only <FONT STYLE="white-space:nowrap">non-employee</FONT>
grant made during the year ended December&nbsp;31, 2022, and there were no equity grants made to <FONT STYLE="white-space:nowrap">non-employees</FONT> during the year ended December&nbsp;31, 2023. The assumptions used in the Black-Scholes option
pricing model to determine the fair value of the Verdine Scientific Advisory Grant were as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="73%"></TD>

<TD VALIGN="bottom" WIDTH="23%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended<BR>December&nbsp;31,&nbsp;2022</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk-free interest rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4.29</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected term (in years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">99</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected dividend yield</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">RSU activity for the year ended December&nbsp;31, 2023 is summarized as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="67%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>RSUs</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Average&nbsp;Grant<BR>Date Fair<BR>Value (in<BR>dollars per<BR>share)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding as of January&nbsp;1, 2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">934,342</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10.94</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">208,875</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vested</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(415,658</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14.60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Forfeited</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(90,002</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7.61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">RSUs Outstanding at December&nbsp;31, 2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">637,557</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7.08</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">RSUs can be time-based or performance-based. Vesting of the performance-based RSUs is contingent on the occurrence of certain
regulatory or commercial milestones. In March 2021, the Compensation Committee approved an amendment and restatement of the Company&#146;s outstanding 2019 performance-based RSUs to add an additional milestone to the existing milestones. In 2021,
the Company also granted performance-based RSUs with the same terms to certain employees who did not receive the 2019 performance-based RSUs. The Company did not recognize expense in 2023 related to the performance-based RSUs as the remaining
milestones were not considered probable of achievement. In April 2022, the Company determined that a performance-based RSU milestone was achieved and consequently 50% of the outstanding performance-based RSUs vested, which resulted in the issuance
of 384,646 ordinary shares. During the year ended December&nbsp;31, 2022, the Company recorded share-based compensation expense of approximately $3.8&nbsp;million related to the performance-based RSUs, which represents all of the expense related to
the achievement of this performance-based RSU milestone. During the years ended December&nbsp;31, 2023 and 2022, the Company recognized share-based compensation expense of $1.0&nbsp;million and $10.3&nbsp;million, respectively, related to RSUs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">RSUs that are forfeited are available to be granted again. During the year ended December&nbsp;31, 2023, 208,875 time-based RSUs were granted to employees. Of
the RSUs outstanding at December&nbsp;31, 2023, 342,876 are time-based RSUs and 294,681 are performance-based RSUs. Time-based RSUs generally vest over periods of one to four years. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the years ended December&nbsp;31, 2023 and 2022, the Company recognized share-based compensation expense related to options of $8.5&nbsp;million and
$6.7&nbsp;million, respectively. The total intrinsic value of options exercised was $0.3&nbsp;million and $0.4&nbsp;million for the years ended December&nbsp;31, 2023 and 2022, respectively. As of December&nbsp;31, 2023, the unrecognized
compensation cost related to outstanding options was $18.8&nbsp;million. The unrecognized compensation cost related to outstanding options is expected to be recognized over a weighted-average period of approximately 2.62 years. For the years ended
December&nbsp;31, 2023 and 2022, the weighted-</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">F-46</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
average grant date fair value per granted option was $3.45 and $2.06, respectively. The aggregate fair value of options that vested during the years ended December&nbsp;31, 2023 and 2022 was
$8.4&nbsp;million and $6.9&nbsp;million, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The unrecognized compensation costs related to outstanding time-based RSUs was $1.3&nbsp;million
as of December&nbsp;31, 2023, and is expected to be recognized over a weighted-average period of approximately 2.93 years. The total fair value of RSUs vested during the years ended December&nbsp;31, 2023 and 2022 was $2.0&nbsp;million and
$1.3&nbsp;million, respectively. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Employee Share Purchase Plan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Wave Life Sciences Ltd. Employee Share Purchase Plan, as amended (&#147;ESPP&#148;) allows full-time and certain part-time employees to purchase the
Parent&#146;s ordinary shares at a discount to fair market value. Eligible employees may enroll in a <FONT STYLE="white-space:nowrap">six-month</FONT> offering period beginning every January 15<SUP STYLE="font-size:75%; vertical-align:top">th</SUP>
and July 15<SUP STYLE="font-size:75%; vertical-align:top">th</SUP>. Shares are purchased at a price equal to 85% of the lower of the fair market value of the Parent&#146;s ordinary shares on the first business day or the last business day of an
offering period. During the years ended December&nbsp;31, 2023 and 2022, 225,913 and 166,061 ordinary shares were issued under the ESPP, respectively. The aggregate number of ordinary shares authorized for issuance under the ESPP was originally
1,000,000 and was subsequently increased to 3,000,000 in August 2023. As of December&nbsp;31, 2023, there were 2,490,500 ordinary shares available for issuance under the ESPP. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Share-Based Compensation Expense </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Share-based
compensation expense for the years ended December&nbsp;31, 2023 and 2022 is classified as operating expenses in the consolidated statements of operations and comprehensive loss as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="60%"></TD>

<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For the Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8194;&#8195;&#8195;2023&#8195;&#8195;&#8194;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&#8194;&#8195;&#8195;2022&#8195;&#8195;&#8194;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center">(in thousands)</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,617</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,467</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,178</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,727</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total share-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,795</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17,194</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Of the total share-based compensation expense recorded, the Parent recorded share-based compensation expense of $0.9 million
and $0.6 million for the years ended December&nbsp;31, 2023 and 2022, respectively, all of which is included in general and administrative expenses on the consolidated statements of operations and comprehensive loss. The Parent records the
share-based compensation expense related to options granted to <FONT STYLE="white-space:nowrap">non-employee</FONT> directors for their service as directors. The options granted to <FONT STYLE="white-space:nowrap">non-employee</FONT> directors are
treated as options granted to employees. The Parent&#146;s subsidiaries record share-based compensation expense related to options and RSUs granted to employees of the subsidiaries, as well as the October 2022
<FONT STYLE="white-space:nowrap">non-employee</FONT> grant to Dr. Verdine. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Of the total share-based compensation expense recorded for the years ended
December&nbsp;31, 2023 and 2022, $0.2&nbsp;million and less than $0.1&nbsp;million, respectively, were related to <FONT STYLE="white-space:nowrap">non-employee</FONT> option grants, specifically the Verdine Scientific Advisory Grant, and all of the
related expense is included in research and development expenses on the consolidated statements of operations and comprehensive loss. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">F-47</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><I><A NAME="rom802241_20"></A><U>Appendix B</U> </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><I><U>Proposed Effective Date: August</U><U></U><U>&nbsp;6, 2024</U> </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>WAVE LIFE SCIENCES LTD. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2021 EQUITY INCENTIVE PLAN, AS AMENDED </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1.&#8195;<U>Purpose; Eligibility</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.1&#8195;<U>General Purpose</U>. The name of this plan is the Wave Life Sciences Ltd. 2021 Equity Incentive Plan (the
&#147;<U>Plan</U>&#148;). The purposes of the Plan are to (i)&nbsp;provide eligible Employees, Consultants, and Directors with the opportunity to acquire a proprietary interest, or otherwise increase their proprietary interest, in the Company as an
incentive for them to remain in the service of Wave Life Sciences Ltd., a corporation formed in Singapore (the &#147;<U>Company</U>&#148;), and any Affiliate; and (ii)&nbsp;promote the success of the Company&#146;s business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.2&#8195;<U>Eligible Award Recipients</U>. The persons eligible to receive Awards are the Employees, Consultants, and Directors of the
Company and its Affiliates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.3&#8195;<U>Available Awards</U>. Awards that may be granted under the Plan include: (a)&nbsp;Incentive
Share Options; <FONT STYLE="white-space:nowrap">(b)&nbsp;Non-qualified</FONT> Share Options; (c)&nbsp;Share Appreciation Rights; (d)&nbsp;Restricted Awards and (e)&nbsp;Performance Awards. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2.&#8195;<U>Definitions</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Affiliate</U>&#148;&nbsp;means a corporation or other entity that, directly or through one or more intermediaries, controls, is
controlled by or is under common control with, the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Applicable Laws</U>&#148;&nbsp;means the requirements related to or
implicated by the administration of the Plan under (i)&nbsp;applicable laws of the Republic of Singapore, including but not limited to, the Singaporean Equity Remuneration Incentive Scheme and the Income Tax Act of Singapore; (ii)&nbsp;applicable
laws of the United States, including but not limited to, United States federal and state securities laws and the Code; (iii)&nbsp;applicable laws of Japan, including but not limited to, the Financial Instruments and Exchange Act of Japan;
(iv)&nbsp;any stock exchange or quotation system on which the Ordinary Shares are listed or quoted; and (v)&nbsp;the applicable laws of any foreign country or jurisdiction where Awards are granted under the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Award</U>&#148;&nbsp;means any right granted under the Plan, including an Incentive Share Option, a
<FONT STYLE="white-space:nowrap">Non-qualified</FONT> Share Option, a Share Appreciation Right, a Restricted Award or a Performance Award. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Award Agreement</U>&#148;&nbsp;means a written agreement, contract, certificate or other instrument or document evidencing the terms
and conditions of an individual Award granted under the Plan which may, in the discretion of the Company, be transmitted electronically to any Participant. Each Award Agreement shall be subject to the terms and conditions of the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Board</U>&#148;&nbsp;means the Board of Directors of the Company, as constituted at any time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Cause</U>&#148;&nbsp;means: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">With respect to any Employee or Consultant: (a)&nbsp;if the Employee or Consultant is a party to an employment or service agreement with the
Company or its Affiliates and such agreement provides for a definition of Cause, the definition contained therein; or (b)&nbsp;if no such agreement exists, or if such agreement does not define Cause: (i)&nbsp;the commission of, or plea of guilty or
no contest to, a felony or a crime involving fraud, embezzlement or any other act of moral turpitude or the commission of any other act involving willful </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
malfeasance or material fiduciary breach with respect to the Company or an Affiliate; (ii)&nbsp;conduct that results in or is reasonably likely to result in harm to the reputation or business of
the Company or any of its Affiliates; (iii)&nbsp;gross negligence or willful misconduct with respect to the Company or an Affiliate; (iv)&nbsp;material breach of any employment, consulting, advisory, nondisclosure,
<FONT STYLE="white-space:nowrap">non-solicitation,</FONT> <FONT STYLE="white-space:nowrap">non-competition</FONT> or similar agreement with the Company or its Affiliates; or (v)&nbsp;material violation of state or federal securities laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">With respect to any Director, a determination by a majority of the disinterested Board members that the Director has engaged in any of the
following: (a)&nbsp;gross misconduct or neglect; (b)&nbsp;false or fraudulent misrepresentation inducing the Director&#146;s appointment; or (c)&nbsp;willful conversion of corporate funds. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The Committee, in its absolute discretion, shall determine the effect of all matters and questions relating to whether a Participant has been
discharged for Cause. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">&#147;<U>Code</U>&#148;&nbsp;means the U.S. Internal Revenue Code of 1986, as it may be amended from time to time.
Any reference to a section of the Code shall be deemed to include a reference to any regulations promulgated thereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Committee</U>&#148;&nbsp;means a committee of one or more members of the Board appointed by the Board to administer the Plan in
accordance with <B><I>Section</I></B><B><I></I></B><B>&nbsp;3.3</B>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Company</U>&#148;&nbsp;means Wave Life Sciences Ltd., a
corporation formed in Singapore, and any successor thereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Consultant</U>&#148;&nbsp;means any individual who is engaged by the
Company or any Affiliate to render consulting or advisory services. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Continuous Service</U>&#148;&nbsp;means that the
Participant&#146;s service with the Company or an Affiliate, whether as an Employee, Consultant or Director, is not interrupted or terminated. The Participant&#146;s Continuous Service shall not be deemed to have terminated merely because of a
change in the capacity in which the Participant renders service to the Company or an Affiliate as an Employee, Consultant or Director or a change in the entity for which the Participant renders such service, <I>provided that</I> there is no
interruption or termination of the Participant&#146;s Continuous Service; <I>provided further that</I> if any Award is subject to Section&nbsp;409A of the Code, this sentence shall only be given effect to the extent consistent with Section&nbsp;409A
of the Code. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Corporate Transaction</U>&#148; has the meaning set forth in <B><I>Section</I></B><B><I></I></B><B>&nbsp;14.8</B>.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Director</U>&#148; means a member of the Board. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Disability</U>&#148;&nbsp;means that the Participant is unable to engage in any substantial gainful activity by reason of any
medically determinable physical or mental impairment; <I>provided, however,</I> for purposes of determining the term of an Incentive Share Option pursuant to <B><I>Section</I></B><B><I></I></B><B>&nbsp;6.10</B> hereof, the term Disability shall have
the meaning ascribed to it under Section&nbsp;22(e)(3) of the Code. The determination of whether an individual has a Disability shall be determined under procedures established by the Committee. Except in situations where the Committee is
determining Disability for purposes of the term of an Incentive Share Option pursuant to <B><I>Section</I></B><B><I></I></B><B>&nbsp;6.10</B> hereof within the meaning of Section&nbsp;22(e)(3) of the Code, the Committee may rely on any determination
that a Participant is disabled for purposes of benefits under any long-term disability plan maintained by the Company or any Affiliate in which a Participant participates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Disqualifying Disposition</U>&#148;&nbsp;has the meaning set forth in <B><I>Section</I></B><B><I></I></B><B>&nbsp;14.8</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Effective Date</U>&#148;&nbsp;shall mean August&nbsp;10, 2021. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Employee</U>&#148;&nbsp;means any person, including an Officer or Director,
employed by the Company or an Affiliate; <I>provided, that,</I><I></I>&nbsp;for purposes of determining eligibility to receive Incentive Share Options, an Employee shall mean an employee of the Company or a parent or subsidiary corporation within
the meaning of Section&nbsp;424 of the Code. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Exchange Act</U>&#148;&nbsp;means the U.S. Securities Exchange Act of 1934, as
amended. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Fair Market Value</U>&#148;&nbsp;means, as of any date, the value of an Ordinary Share as determined below. If an
Ordinary Share is listed on any established stock exchange or a national market system, including without limitation, the New York Stock Exchange or the NASDAQ Stock Market, the Fair Market Value shall be the closing price of an Ordinary Share (or
if no sales were reported the closing price on the date immediately preceding such date) as quoted on such exchange or system on the day of determination, as reported in the <I>Wall Street Journal</I>. In the absence of an established market for an
Ordinary Share, the Fair Market Value shall be determined in good faith by the Committee and such determination shall be conclusive and binding on all persons. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Grant Date</U>&#148;&nbsp;means the date on which the Committee adopts a resolution, or takes other appropriate action, expressly
granting an Award to a Participant that specifies the key terms and conditions of the Award or, if a later date is set forth in such resolution, then such date as is set forth in such resolution. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Incentive Share Option</U>&#148;&nbsp;means an Option intended to qualify as an incentive stock option within the meaning of
Section&nbsp;422 of the Code. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U><FONT STYLE="white-space:nowrap">Non-qualified</FONT> Share Option</U>&#148;&nbsp;means an Option
that by its terms does not qualify or is not intended to qualify as an Incentive Share Option. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Officer</U>&#148;&nbsp;means a
person who is an officer of the Company within the meaning of Section&nbsp;16 of the Exchange Act and the rules and regulations promulgated thereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Option</U>&#148;&nbsp;means an Incentive Share Option or a <FONT STYLE="white-space:nowrap">Non-qualified</FONT> Share Option granted
pursuant to the Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Optionholder</U>&#148;&nbsp;means a person to whom an Option is granted pursuant to the Plan or, if
applicable, such other person who holds an outstanding Option. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Option Exercise Price</U>&#148;&nbsp;means the price at which an
Ordinary Share may be purchased upon the exercise of an Option. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Ordinary Shares</U>&#148;&nbsp;means ordinary shares in the
capital of the Company, or such other securities of the Company as may be designated by the Committee from time to time in substitution thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Participant</U>&#148;&nbsp;means an eligible person to whom an Award is granted pursuant to the Plan or, if applicable, such other
person who holds an outstanding Award. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Performance Award</U>&#148; means a Restricted Award which vests based on the attainment
of written Performance Goals as set forth in <B><I>Section</I></B><B></B><B><I>&nbsp;7.2(g)</I></B><B>.</B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Performance
Goals</U>&#148; mean performance goals based on any criteria as determined by the Committee. Where applicable, the Performance Goals may be expressed in terms of a relative measure against a set of identified peer group companies, attaining a
specified level of the particular criterion or the attainment of a percentage increase or decrease in the particular criterion, and may be applied to one or more of the Company or an Affiliate of the Company, or a division or strategic business unit
of the Company, all as determined by the Committee. The Performance Goals may include a threshold level of performance below which no Performance </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Award will be issued or no vesting will occur, levels of performance at which Performance Awards will be issued or specified vesting will occur, and a maximum level of performance above which no
additional issuances will be made or at which full vesting will occur. Each of the foregoing Performance Goals shall be evaluated in an objectively determinable manner and in accordance with generally accepted accounting principles where applicable,
unless otherwise specified by the Committee, and shall be subject to certification by the Committee. The Committee shall have the authority to make equitable adjustments to the Performance Goals in recognition of unusual or <FONT
STYLE="white-space:nowrap">non-recurring</FONT> events affecting the Company or any Affiliate or the financial statements of the Company or any Affiliate, in response to changes in applicable laws or regulations, or to account for items of gain,
loss or expense determined to be extraordinary or unusual in nature or infrequent in occurrence or related to the disposal of a segment of a business or related to a change in accounting principles. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Permitted Transferee</U>&#148;&nbsp;means the following if prior approval is obtained from the Committee in its sole and absolute
discretion: (a)&nbsp;a member of the Optionholder&#146;s immediate family (child, stepchild, grandchild, parent, stepparent, grandparent, spouse, former spouse, sibling, niece, nephew,
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mother-in-law,</FONT></FONT> <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">father-in-law,</FONT></FONT> <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">son-in-law,</FONT></FONT> <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">daughter-in-law,</FONT></FONT> <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">brother-in-law,</FONT></FONT> or <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">sister-in-law,</FONT></FONT> including adoptive relationships), any person sharing the Optionholder&#146;s household (other than a tenant or employee), a trust in which these persons have
more than 50% of the beneficial interest, a foundation in which these persons (or the Optionholder) control the management of assets; and any other entity in which these persons (or the Optionholder) own more than 50% of the voting interests; and
(b)&nbsp;such other transferees as may be permitted by the Committee in its sole discretion and in compliance with Applicable Laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Plan</U>&#148;&nbsp;means Wave Life Sciences Ltd. 2021 Equity Incentive Plan, as amended and/or amended and restated from time to
time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Restricted Award</U>&#148;&nbsp;means any Award granted pursuant to
<B><I>Section</I></B><B><I></I></B><B>&nbsp;7.2(a)</B>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Restricted Period</U>&#148;&nbsp;has the meaning set forth in
<B><I>Section</I></B><B><I></I></B><B>&nbsp;7.2(a)</B>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Rule <FONT STYLE="white-space:nowrap">16b-3</FONT></U>&#148;&nbsp;means
Rule <FONT STYLE="white-space:nowrap">16b-3</FONT> promulgated under the Exchange Act or any successor to Rule <FONT STYLE="white-space:nowrap">16b-3,</FONT> as in effect from time to time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Securities Act</U>&#148;&nbsp;means the U.S. Securities Act of 1933, as amended. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Share Appreciation Right</U>&#148;&nbsp;means the right pursuant to an Award granted under
<B><I>Section</I></B><B><I></I></B><B>&nbsp;7.1</B> to receive, upon exercise, an amount payable in cash or Ordinary Shares equal to the number of Ordinary Shares subject to the Share Appreciation Right that is being exercised multiplied by the
excess of (a)&nbsp;the Fair Market Value of an Ordinary Share on the date the Award is exercised, over (b)&nbsp;the exercise price specified in the Share Appreciation Right Award Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Ten Percent Shareholder</U>&#148;&nbsp;means a person who owns (or is deemed to own pursuant to Section&nbsp;424(d) of the Code) more
than 10% of the total combined voting power of all classes of shares of the Company or of any of its Affiliates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">3.&#8195;<U>Administration</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.1&#8195;<U>Authority of Committee</U>. The Plan shall be administered by the Committee or, in the Board&#146;s sole discretion, by the Board.
Subject to the terms of the Plan, the Committee&#146;s charter and Applicable Laws, and in addition to other express powers and authorization conferred by the Plan, the Committee shall have the authority: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&#8195;to construe and interpret the Plan and apply its provisions; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&#8195;to promulgate, amend, and rescind rules and regulations relating to the administration of the Plan; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&#8195;to authorize any person to execute, on behalf of the Company, any instrument
required to carry out the purposes of the Plan; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d)&#8195;to determine when Awards are to be granted under the Plan and the applicable
Grant Date; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e)&#8195;from time to time to select, subject to the limitations set forth in this Plan, those Participants to whom Awards
shall be granted; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f)&#8195;to determine the number of Ordinary Shares to be made subject to each Award; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g)&#8195;to determine whether each Option is to be an Incentive Share Option or a <FONT STYLE="white-space:nowrap">Non-qualified</FONT> Share
Option; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h)&#8195;to prescribe the terms and conditions of each Award, including, without limitation, the exercise price and medium of
payment and vesting provisions, and to specify the provisions of the Award Agreement relating to such grant; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i)&#8195;to amend any
outstanding Awards, including for the purpose of modifying the time or manner of vesting, or the term of any outstanding Award; <I>provided, however</I>, that any such amendment shall be subject to the Participant&#146;s consent if required pursuant
to <B><I>Section</I></B><B><I></I></B><B>&nbsp;13.5;</B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(j)&#8195;to make decisions with respect to outstanding Awards that may become
necessary upon a change in corporate control or an event that triggers anti-dilution adjustments; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(k)&#8195;to interpret, administer,
reconcile any inconsistency in, correct any defect in and/or supply any omission in the Plan and any instrument or agreement relating to, or Award granted under, the Plan; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(l)&#8195;to exercise discretion to make any and all other determinations which it determines to be necessary or advisable for the
administration of the Plan; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(m)&#8195;to adopt <FONT STYLE="white-space:nowrap">sub-plans</FONT> that, when taken together with the
Plan, shall constitute the Plan for those certain tax residents identified in the applicable <FONT STYLE="white-space:nowrap">sub-plan.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The Committee also may modify the purchase price or the exercise price of any outstanding Award, <I>provided that</I> if the modification
affects a repricing, shareholder approval shall be required before the repricing is effective. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.2&#8195;<U>Committee Decisions
Final</U>. All decisions made by the Committee pursuant to the provisions of the Plan shall be final and binding on the Company and the Participants, unless such decisions are determined by a court having jurisdiction to be arbitrary and capricious.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.3&#8195;<U>Delegation</U>. The Committee, or if no Committee has been appointed, the Board, may delegate administration of the Plan to
a committee or committees of one or more members of the Board, and the term &#147;<U>Committee</U>&#148; shall apply to any person or persons to whom such authority has been delegated. The Committee shall have the power to delegate to a subcommittee
any of the administrative powers the Committee is authorized to exercise (and references in this Plan to the Board or the Committee shall thereafter be to the committee or subcommittee), subject, however, to Applicable Laws and such resolutions, not
inconsistent with the provisions of the Plan, as may be adopted from time to time by the Board. The Board may abolish the Committee at any time and revest in the Board the administration of the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.4&#8195;<U>Indemnification</U>. In addition to such other rights of indemnification as they may have as Directors or members of the
Committee, and to the extent allowed by Applicable Laws, the Committee shall be indemnified </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
by the Company against the reasonable expenses, including attorney&#146;s fees, actually incurred in connection with any action, suit or proceeding or in connection with any appeal therein, to
which the Committee may be party by reason of any action taken or failure to act under or in connection with the Plan or any Award granted under the Plan, and against all amounts paid by the Committee in settlement thereof (<I>provided, however</I>,
that the settlement has been approved by the Company, which approval shall not be unreasonably withheld) or paid by the Committee in satisfaction of a judgment in any such action, suit or proceeding, except in relation to matters as to which it
shall be adjudged in such action, suit or proceeding that such Committee did not act in good faith and in a manner which such person reasonably believed to be in the best interests of the Company, or in the case of a criminal proceeding, had no
reason to believe that the conduct complained of was unlawful; <I>provided, however</I>, that within 60 days after institution of any such action, suit or proceeding, such Committee shall, in writing, offer the Company the opportunity at its own
expense to handle and defend such action, suit or proceeding. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">4.&#8195;<U>Shares Subject to the Plan</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.1&#8195;Subject to adjustment in accordance with <B><I>Section</I></B><B><I></I></B><B>&nbsp;11</B>, a total of (i) 22,950,000 Ordinary
Shares shall be available for the grant of Awards under the Plan; plus (ii)&nbsp;the number of Ordinary Shares underlying any awards under the Company&#146;s 2014 Equity Incentive Plan, as amended, that are forfeited, canceled or otherwise
terminated (other than by exercise or withheld by the Company to satisfy any tax withholding obligation) on or after the Effective Date shall be added to the Ordinary Shares available for issuance under (i)&nbsp;hereof; provided that no more than
22,950,000 Ordinary Shares may be issued upon the exercise of Incentive Share Options. During the terms of the Awards, the Company shall keep available at all times the number of Ordinary Shares required to satisfy such Awards. Notwithstanding the
foregoing, to the extent permitted by Applicable Laws, Awards that provide for the delivery of Ordinary Shares subsequent to the applicable grant date may be granted in excess of the share limits set forth in this paragraph if such Awards provide
for the forfeiture of such Awards to the extent that insufficient Ordinary Shares remain at the time that the Ordinary Shares would otherwise be issued in respect of such Award. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.2&#8195;Ordinary Shares available for distribution under the Plan may consist, in whole or in part, of authorized and unissued shares,
treasury shares or shares reacquired by the Company in any manner. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.3&#8195;Any Ordinary Shares subject to an Award that is canceled,
forfeited or expires prior to exercise or realization, either in full or in part, shall again become available for issuance under the Plan. Notwithstanding anything to the contrary contained herein, Ordinary Shares subject to an Award under the Plan
shall not again be made available for issuance or delivery under the Plan if such Ordinary Shares are (a)&nbsp;Ordinary Shares tendered in payment of the exercise price of an Option; (b)&nbsp;Ordinary Shares delivered or withheld by the Company to
satisfy any tax withholding obligation; (c)&nbsp;Ordinary Shares covered by a share-settled Share Appreciation Right or other Awards that were not issued upon the settlement of the Award, or (d)&nbsp;Ordinary Shares repurchased by the Company on the
open market with the proceeds of the exercise price of an Option or Share Appreciation Right. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">5.&#8195;<U>Eligibility</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.1&#8195;<U>Eligibility for Specific Awards</U>. Incentive Share Options may be granted only to Employees who are tax residents of the United
States and shall not include Employees who are solely Officers and Directors. Awards other than Incentive Share Options may be granted to Employees, Consultants and Directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.2&#8195;<U>Ten Percent Shareholders</U>. A Ten Percent Shareholder shall not be granted an Incentive Share Option unless the Option Exercise
Price is at least 110% of the Fair Market Value of an Ordinary Share at the Grant Date and the Option is not exercisable after the expiration of five years from the Grant Date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">6.&#8195;<U>Option Provisions</U>. Each Option granted under the Plan shall be evidenced by an Award Agreement. Each Option so granted shall be subject to the
conditions set forth in this <B><I>Section</I></B><B>&nbsp;6</B>, and to such other conditions not </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
inconsistent with the Plan as may be reflected in the applicable Award Agreement. All Options shall be separately designated Incentive Share Options or
<FONT STYLE="white-space:nowrap">Non-qualified</FONT> Share Options at the time of grant, and, if certificates are issued, a separate certificate or certificates will be issued for Ordinary Shares purchased on exercise of each type of Option.
Notwithstanding the foregoing, the Company shall have no liability to any Participant or any other person if an Option designated as an Incentive Share Option fails to qualify as such at any time or if an Option is determined to constitute
&#147;nonqualified deferred compensation&#148; within the meaning of Section&nbsp;409A of the Code and the terms of such Option do not satisfy the requirements of Section&nbsp;409A of the Code. The provisions of separate Options need not be
identical, but each Option shall include (through incorporation of provisions hereof by reference in the Option or otherwise) the substance of each of the following provisions: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.1&#8195;<U>Term</U>. Subject to the provisions of <B><I>Section</I></B><B><I></I></B><B>&nbsp;5.2</B> regarding Ten Percent Shareholders, no
Incentive Share Option shall be exercisable after the expiration of 10 years from the Grant Date. The term of a <FONT STYLE="white-space:nowrap">Non-qualified</FONT> Share Option granted under the Plan shall be determined by the Committee;
<I>provided, however</I>, no <FONT STYLE="white-space:nowrap">Non-qualified</FONT> Share Option shall be exercisable after the expiration of 10 years from the Grant Date, and <FONT STYLE="white-space:nowrap">Non-qualified</FONT> Share Options
granted to persons who are not Employees (including Directors who are not Employees) shall not be exercisable after the expiration of five (5)&nbsp;years from the Grant Date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.2&#8195;<U>Exercise Price of An Incentive Share Option</U>. Subject to the provisions of <B><I>Section</I></B><B><I></I></B><B>&nbsp;5.2</B>
regarding Ten Percent Shareholders, the Option Exercise Price of each Incentive Share Option shall be not less than 100% of the Fair Market Value of an Ordinary Share subject to the Option on the Grant Date. Notwithstanding the foregoing, an
Incentive Share Option may be granted with an Option Exercise Price lower than that set forth in the preceding sentence if such Option is granted pursuant to an assumption or substitution for another option in a manner satisfying the provisions of
Section&nbsp;424(a) of the Code. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.3&#8195;<U>Exercise Price of a <FONT STYLE="white-space:nowrap">Non-qualified</FONT> Share Option</U>.
The Option Exercise Price of each <FONT STYLE="white-space:nowrap">Non-qualified</FONT> Share Option shall be not less than 100% of the Fair Market Value of an Ordinary Share subject to the Option on the Grant Date. Notwithstanding the foregoing, a <FONT
STYLE="white-space:nowrap">Non-qualified</FONT> Share Option may be granted with an Option Exercise Price lower than that set forth in the preceding sentence if such Option is granted pursuant to an assumption or substitution for another option in a
manner satisfying the provisions of Section&nbsp;409A of the Code. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.4&#8195;<U>Consideration</U>. The Option Exercise Price of an
Ordinary Share acquired pursuant to an Option shall be paid, to the extent permitted by Applicable Laws, either (a)&nbsp;in cash or by certified or bank check at the time the Option is exercised; or (b)&nbsp;in the discretion of the Committee, upon
such terms as the Committee shall approve, the Option Exercise Price may be paid: (i)&nbsp;by reduction in the number of Ordinary Shares otherwise deliverable upon exercise of such Option with a Fair Market Value equal to the aggregate Option
Exercise Price at the time of exercise; (ii)&nbsp;in accordance with a cashless exercise program established with a securities brokerage firm, or (iii)&nbsp;in any other form of legal consideration that may be acceptable to the Committee. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.5&#8195;<U>Transferability of An Incentive Share Option</U>. An Incentive Share Option shall not be transferable except by will or by the
laws of descent and distribution and shall be exercisable during the lifetime of the Optionholder only by the Optionholder. Notwithstanding the foregoing, the Optionholder may, by delivering written notice to the Company, in a form satisfactory to
the Company, designate a third party who, in the event of the death of the Optionholder, shall thereafter be entitled to exercise the Option. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.6&#8195;<U>Transferability of a <FONT STYLE="white-space:nowrap">Non-qualified</FONT> Share Option</U>. A
<FONT STYLE="white-space:nowrap">Non-qualified</FONT> Share Option may, in the sole discretion of the Committee, be transferable for no consideration to a Permitted Transferee, upon written approval by the Committee to the extent provided in the
Award Agreement. If the <FONT STYLE="white-space:nowrap">Non-qualified</FONT> Share Option does not provide for transferability, then the <FONT STYLE="white-space:nowrap">Non-qualified</FONT> Share Option shall not be transferable except by will or
by the laws of descent and distribution and shall be exercisable during the lifetime of the Optionholder only by the Optionholder. Notwithstanding the foregoing, the Optionholder may, by delivering written notice to the Company, in a form
satisfactory to the Company, designate a third party who, in the event of the death of the Optionholder, shall thereafter be entitled to exercise the Option. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.7&#8195;<U>Vesting of Options</U>. Each Option may, but need not, vest and therefore
become exercisable in periodic installments that may, but need not, be equal. The Option may be subject to such other terms and conditions on the time or times when it may be exercised (which may be based on performance or other criteria) as the
Committee may deem appropriate. The vesting provisions of individual Options may vary. No Option may be exercised for a fraction of an Ordinary Share. The Committee may, but shall not be required to, provide for an acceleration of vesting and
exercisability in the terms of any Award Agreement upon the occurrence of a specified event. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.8&#8195;<U>Termination of Continuous
Service</U>. Unless otherwise provided in an Award Agreement or in an employment agreement the terms of which have been approved by the Committee, in the event an Optionholder&#146;s Continuous Service terminates (other than upon the
Optionholder&#146;s death or Disability), the Optionholder may exercise his or her Option (to the extent that the Optionholder was entitled to exercise such Option as of the date of termination) but only within such period of time ending on the
earlier of (a)&nbsp;the date three months following the termination of the Optionholder&#146;s Continuous Service; or (b)&nbsp;the expiration of the term of the Option as set forth in the Award Agreement; <I>provided that</I>, if the termination of
Continuous Service is by the Company for Cause, all outstanding Options (whether or not vested) shall immediately terminate and cease to be exercisable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.9&#8195;<U>Extension of Termination Date</U>. An Optionholder&#146;s Award Agreement may also provide that if the exercise of the Option
following the termination of the Optionholder&#146;s Continuous Service for any reason would be prohibited at any time because the issuance of Ordinary Shares would violate the registration requirements under the Securities Act or any other
Applicable Laws, then the Option shall terminate on the earlier of (a)&nbsp;the expiration of the term of the Option in accordance with <B><I>Section</I></B><B><I></I></B><B>&nbsp;6.1</B>; or (b)&nbsp;the expiration of a period after termination of
the Participant&#146;s Continuous Service that is three months after the end of the period during which the exercise of the Option would be in violation of such registration or other securities law requirements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.10&#8195;<U>Disability of Optionholder</U>. Unless otherwise provided in an Award Agreement, in the event that an Optionholder&#146;s
Continuous Service terminates as a result of the Optionholder&#146;s Disability, the Optionholder may exercise his or her Option (to the extent that the Optionholder was entitled to exercise such Option as of the date of termination), but only
within such period of time ending on the earlier of (a)&nbsp;the date 12 months following such termination; or (b)&nbsp;the expiration of the term of the Option as set forth in the Award Agreement. If, after termination, the Optionholder does not
exercise his or her Option within the time specified herein or in the Award Agreement, the Option shall terminate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.11&#8195;<U>Death of
Optionholder</U>. Unless otherwise provided in an Award Agreement, in the event an Optionholder&#146;s Continuous Service terminates as a result of the Optionholder&#146;s death, then the Option may be exercised (to the extent the Optionholder was
entitled to exercise such Option as of the date of death) by the Optionholder&#146;s estate, by a person who acquired the right to exercise the Option by bequest or inheritance or by a person designated to exercise the Option upon the
Optionholder&#146;s death, but only within the period ending on the earlier of (a)&nbsp;the date 12 months following the date of death; or (b)&nbsp;the expiration of the term of such Option as set forth in the Award Agreement. If, after the
Optionholder&#146;s death, the Option is not exercised within the time specified herein or in the Award Agreement, the Option shall terminate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.12&#8195;<U>Incentive Share Option $100,000 Limitation</U>. To the extent that the aggregate Fair Market Value (determined at the time of
grant) of an Ordinary Share with respect to which Incentive Share Options are exercisable for the first time by any Optionholder during any calendar year (under all plans of the Company and its Affiliates) exceeds U.S. $100,000, the Options or
portions thereof which exceed such limit (according to the order in which they were granted in accordance with Section&nbsp;422(d) of the Code) shall be treated as <FONT STYLE="white-space:nowrap">Non-qualified</FONT> Share Options. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">7.&#8195;<U>Provisions of Awards Other Than Options</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.1&#8195;<U>Share Appreciation Rights</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&#8195;<U>General</U>.<B> </B>Each Share Appreciation Right granted under the Plan shall be evidenced by an Award Agreement. Each Share
Appreciation Right so granted shall be subject to the conditions set forth in this <B><I>Section</I></B><B></B><B>&nbsp;7.1</B>, and to such other conditions not inconsistent with the Plan as may be reflected in the applicable Award Agreement. Share
Appreciation Rights may be granted alone or in tandem with an Option granted under the Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&#8195;<U>Grant Requirements</U>. Any
Share Appreciation Right that relates to a <FONT STYLE="white-space:nowrap">Non-qualified</FONT> Share Option may be granted at the same time the Option is granted or at any time thereafter but before the exercise or expiration of the Option. Any
Share Appreciation Right that relates to an Incentive Share Option must be granted at the same time the Incentive Share Option is granted. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&#8195;<U>Term of Share Appreciation Rights</U>. The term of a Share Appreciation Right granted under the Plan shall be determined by the
Committee; <I>provided, however</I>, no Share Appreciation Right shall be exercisable later than the tenth anniversary of the Grant Date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d)&#8195;<U>Vesting of Share Appreciation Rights</U>. Each Share Appreciation Right may, but need not, vest and therefore become exercisable
in periodic installments that may, but need not, be equal. The Share Appreciation Right may be subject to such other terms and conditions on the time or times when it may be exercised as the Committee may deem appropriate. The vesting provisions of
individual Share Appreciation Rights may vary. No Share Appreciation Right may be exercised for a fraction of an Ordinary Share. The Committee may, but shall not be required to, provide for an acceleration of vesting and exercisability in the terms
of any Share Appreciation Right upon the occurrence of a specified event. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e)&#8195;<U>Exercise</U>. Upon exercise of a Share
Appreciation Right, the holder shall be entitled to receive from the Company an amount equal to the number of Ordinary Shares subject to the Share Appreciation Right that is being exercised multiplied by the excess of (i)&nbsp;the Fair Market Value
of an Ordinary Share on the date the Award is exercised, over (ii)&nbsp;the exercise price specified in the Share Appreciation Right or related Option. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f)&#8195;<U>Exercise Price</U>. The exercise price of a Share Appreciation Right shall be determined by the Committee, but shall not be less
than 100% of the Fair Market Value of one Ordinary Share on the Grant Date of such Share Appreciation Right. Notwithstanding the foregoing, a Share Appreciation Right may be granted with an exercise price lower than that set forth in the preceding
sentence if such Share Appreciation Right is granted pursuant to an assumption or substitution for another option in a manner satisfying the provisions of Section&nbsp;409A of the Code. A Share Appreciation Right granted simultaneously with or
subsequent to the grant of an Option and in conjunction therewith or in the alternative thereto shall have the same exercise price as the related Option, shall be transferable only upon the same terms and conditions as the related Option, and shall
be exercisable only to the same extent as the related Option; <I>provided, however</I>, that a Share Appreciation Right, by its terms, shall be exercisable only when the Fair Market Value per Ordinary Share subject to the Share Appreciation Right
and related Option exceeds the exercise price per share thereof and no Share Appreciation Rights may be granted in tandem with an Option unless the Committee determines that the requirements of <B><I>Section</I></B><B><I></I></B><B>&nbsp;7.1(b)</B>
are satisfied. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.2&#8195;<U>Restricted Awards</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&#8195;<U>General</U>. A Restricted Award is an Award of actual Ordinary Shares (&#147;<U>Restricted Share</U>&#148;) or hypothetical
Ordinary Share units (&#147;<U>Restricted Share Units</U>&#148;) having a value equal to the Fair Market Value of an identical number of Ordinary Shares, which may, but need not, provide that such Restricted Award may not be sold, assigned,
transferred or otherwise disposed of, pledged or hypothecated as collateral for a loan or as security for the performance of any obligation or for any other purpose for such period (the &#147;<U>Restricted Period</U>&#148;) as the Committee shall
determine. Each Restricted Award granted under the Plan shall be evidenced by an Award Agreement. Each Restricted Award so granted shall be subject to the conditions set forth in this <B><I>Section</I></B><B></B><B>&nbsp;7.2</B>, and to such other
conditions not inconsistent with the Plan as may be reflected in the applicable Award Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&#8195;<U>Restricted Share and Restricted Share Units</U>. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Each Participant granted Restricted Share shall execute and deliver to the Company an Award Agreement with
respect to the Restricted Share setting forth the restrictions and other terms and conditions applicable to such Restricted Share. If the Committee determines that the Restricted Share shall be held by the Company or in escrow rather than delivered
to the Participant pending the release of the applicable restrictions, the Committee may require the Participant to additionally execute and deliver to the Company (A)&nbsp;an escrow agreement satisfactory to the Committee, if applicable; and
(B)&nbsp;the appropriate blank share power with respect to the Restricted Share covered by such agreement. If a Participant fails to execute an agreement evidencing an Award of Restricted Share and, if applicable, an escrow agreement and Share
power, the Award shall be null and void. Subject to the restrictions set forth in the Award, the Participant generally shall have the rights and privileges of a shareholder as to such Restricted Share, including the right to vote such Restricted
Share and the right to receive dividends; provided however that dividends (other than share dividends to be issued pursuant to <B><I>Section</I></B><B><I></I></B><B>&nbsp;11</B>) may accrue but shall not be paid prior to the time, and only to the
extent that, the restrictions on the Ordinary Shares subject to the Restricted Share to which it relates lapses. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The terms and conditions of a grant of Restricted Share Units shall be reflected in an Award Agreement. No
Ordinary Shares shall be issued at the time a Restricted Share Unit is granted, and the Company will not be required to set aside a fund for the payment of any such Award. A Participant shall have no voting rights with respect to any Restricted
Share Units granted hereunder. At the discretion of the Committee, each Restricted Share Unit (representing one Ordinary Share) may be credited with cash paid by the Company in respect of one Ordinary Share (&#147;<U>Dividend Equivalents</U>&#148;).
Dividend Equivalents shall be paid only upon the vesting of a Restricted Share Unit and in accordance with Section&nbsp;409A of the Code if paid to a tax resident of the United States. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&#8195;<U>Restrictions</U>. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Restricted Share awarded to a Participant shall be subject to the following restrictions until the expiration
of the Restricted Period, and to such other terms and conditions as may be set forth in the applicable Award Agreement: (A)&nbsp;if an escrow arrangement is used, the Participant shall not be entitled to delivery of the share certificate;
(B)&nbsp;the shares shall be subject to the restrictions on transferability set forth in the Award Agreement; (C)&nbsp;the shares shall be subject to forfeiture to the extent provided in the applicable Award Agreement; and (D)&nbsp;to the extent
such shares are forfeited, the share certificates shall be returned to the Company, and all rights of the Participant to such shares and as a shareholder with respect to such shares shall terminate without further obligation on the part of the
Company. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Restricted Share Units awarded to any Participant shall be subject to (A)&nbsp;forfeiture until the expiration
of the Restricted Period, to the extent provided in the applicable Award Agreement, and to the extent such Restricted Share Units are forfeited, all rights of the Participant to such Restricted Share Units, including Dividend Equivalents, shall
terminate without further obligation on the part of the Company; and (B)&nbsp;such other terms and conditions as may be set forth in the applicable Award Agreement. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Committee shall have the authority to remove any or all of the restrictions on the Restricted Share,
Restricted Share Units whenever it may determine that, by reason of changes in Applicable Laws or other changes in circumstances arising after the date the Restricted Share or Restricted Share Units are granted, such action is appropriate.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d)&#8195;<U>Restricted Period</U>. With respect to Restricted Awards, the Restricted Period shall commence on the
Grant Date and end at the time or times set forth on a schedule established by the Committee in the applicable </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Award Agreement. No Restricted Award may be granted or settled for a fraction of an Ordinary Share. The Committee may, but shall not be required to, provide for an acceleration of vesting in the
terms of any Award Agreement upon the occurrence of a specified event. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e)&#8195;<U>Delivery of Restricted Shares; Settlement of
Restricted Share Units</U>. Upon the expiration of the Restricted Period with respect to any Restricted Shares, the restrictions set forth in <B><I>Section</I></B><B><I></I></B><B>&nbsp;7.2(c)</B> and the applicable Award Agreement shall be of no
further force or effect with respect to such shares, except as set forth in the applicable Award Agreement. If an escrow arrangement is used, upon such expiration, the Company shall deliver to the Participant, or his or her beneficiary, without
charge, the share certificate evidencing the Restricted Shares which have not then been forfeited and with respect to which the Restricted Period has expired (to the nearest full share) and any cash dividends or share dividends credited to the
Participant&#146;s account with respect to such Restricted Shares and the interest thereon, if any. Upon the expiration of the Restricted Period with respect to any outstanding Restricted Share Units unless payment is further deferred in compliance
with Applicable Laws including, but not limited to Section&nbsp;409A of the Code, the Company shall deliver to the Participant, or his or her beneficiary, without charge, one Ordinary Share for each outstanding vested Restricted Share Unit and cash
equal to any Dividend Equivalents credited with respect to each such vested Restricted Share Unit in accordance with <B><I>Section</I></B><B><I></I></B><B>&nbsp;7.2(b)(ii)</B> hereof and the interest thereon or, at the discretion of the Committee,
in Ordinary Shares having a Fair Market Value equal to such Dividend Equivalents and the interest thereon, if any; <I>provided, however</I>, that, if explicitly provided in the applicable Award Agreement, the Committee may, in its sole discretion,
elect to pay cash or part cash and part Ordinary Shares in lieu of delivering only Ordinary Shares for vested Restricted Share Units. If a cash payment is made in lieu of delivering Ordinary Shares, the amount of such payment shall be equal to the
Fair Market Value of an Ordinary Share as of the date on which the Restricted Period lapsed in the case of Restricted Share Units. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f)&#8195;<U>Share Restrictions</U>. Each certificate representing Restricted Share awarded under the Plan shall bear a legend in such form as
the Company deems appropriate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g)&#8195;<U> Performance Awards</U>. Restricted Awards may be granted at the sole discretion of the
Committee, with vesting conditions based on the attainment of written Performance Goals. The Committee shall determine the performance period and whether, with respect to a performance period, the applicable Performance Goals have been met with
respect to a given Participant and, if they have, to so certify and ascertain the amount of the applicable Performance Award. No Performance Awards will be issued for such performance period until such certification is made by the Committee. The
number Ordinary Shares issued in respect of a Performance Award to a given Participant may be less than the amount determined by the applicable Performance Goal formula, at the discretion of the Committee. The number of Ordinary Shares issued in
respect of a Performance Award determined by the Committee for a performance period shall be paid to the Participant at such time as determined by the Committee in its sole discretion after the end of such performance period and any dividends (other
than share dividends to be issued pursuant to <B><I>Section</I></B><B><I></I></B><B>&nbsp;11</B>) or Dividend Equivalents that accrue shall only be paid in respect of the number of Ordinary Shares earned in respect of a Performance Award. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">8.&#8195;<U>Securities Law Compliance</U>. Each Award Agreement shall provide that no Ordinary Shares shall be purchased or sold thereunder unless and until
(a)&nbsp;any then Applicable Laws have been fully complied with to the satisfaction of the Company and its counsel; and (b)&nbsp;if required to do so by the Company, the Participant has executed and delivered to the Company a letter of investment
intent in such form and containing such provisions as the Committee may require. The Company shall use reasonable efforts to seek to obtain from each regulatory commission or agency having jurisdiction over the Plan such authority as may be required
to grant Awards and to issue and sell Ordinary Shares upon exercise of the Awards; <I>provided, however</I>, that this undertaking shall not require the Company to register the Ordinary Shares, the Plan or any Award under the Securities Act with the
U.S Securities and Exchange Commission or with any state securities commission or stock exchange or under any other Applicable Laws. If, after reasonable efforts, the Company is unable to obtain from any such regulatory commission or agency the
authority which counsel for the Company deems necessary for the lawful issuance and sale of Ordinary Shares under the Plan, the Company shall be relieved from any liability for failure to issue and sell Ordinary Shares upon exercise of such Awards
unless and until such authority is obtained. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">9.&#8195;<U>Use of Proceeds from Shares</U>. Proceeds from the sale of Ordinary Shares pursuant to Awards,
or upon exercise thereof, shall constitute general funds of the Company. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">10.&#8195;<U>Miscellaneous</U>. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.1&#8195;<U>Acceleration of Exercisability and Vesting</U>. The Committee shall have the power to accelerate the time at which an Award may
first be exercised or the time during which an Award or any part thereof will vest in accordance with the Plan, notwithstanding the provisions in the Award stating the time at which it may first be exercised or the time during which it will vest.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.2&#8195;<U>Shareholder Rights</U>. Except as provided in the Plan or an Award Agreement, no Participant shall be deemed to be the
holder of, or to have any of the rights of a holder with respect to, any Ordinary Shares subject to such Award unless and until such Participant has satisfied all requirements for exercise of the Award pursuant to its terms and no adjustment shall
be made for dividends (ordinary or extraordinary, whether in cash, securities or other property) or distributions of other rights for which the record date is prior to the date such Ordinary Shares are issued, except as provided in
<B><I>Section</I></B><B><I></I></B><B>&nbsp;11</B> hereof. Any dividends or Dividend Equivalents shall in all events be subject to the same vesting and forfeiture restrictions as apply to the Award to which they relate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.3&#8195;<U>No Employment or Other Service Rights</U>. Nothing in the Plan or any instrument executed or Award granted pursuant thereto
shall confer upon any Participant any right to continue to serve the Company or an Affiliate in the capacity in effect at the time the Award was granted or shall affect the right of the Company or an Affiliate to terminate (a)&nbsp;the employment of
an Employee with or without notice and with or without Cause; or (b)&nbsp;the service of a Director pursuant to the Articles of Association of the Company or an Affiliate, and any applicable provisions of the corporate law of the state in which the
Company or the Affiliate is incorporated, as the case may be. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.4&#8195;<U>Transfer; Approved Leave of Absence</U>. For purposes of the
Plan, no termination of employment by an Employee shall be deemed to result from either (a)&nbsp;a transfer of employment to the Company from an Affiliate or from the Company to an Affiliate, or from one Affiliate to another; or (b)&nbsp;an approved
leave of absence for military service or sickness, or for any other purpose approved by the Company, if the Employee&#146;s right to reemployment is guaranteed either by a statute or by contract or under the policy pursuant to which the leave of
absence was granted or if the Committee otherwise so provides in writing, in either case, except to the extent inconsistent with Applicable Laws, including but not limited to Section&nbsp;409A of the Code if the applicable Award is subject thereto.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.5&#8195;<U>Withholding Obligations</U>. To the extent provided by the terms of an Award Agreement and subject to the discretion of the
Committee, the Participant may satisfy any foreign, federal, state or local tax withholding obligation relating to the exercise or acquisition of Ordinary Shares under an Award by any of the following means (in addition to the Company&#146;s right
to withhold from any compensation paid to the Participant by the Company) or by a combination of such means: (a)&nbsp;tendering a cash payment; (b)&nbsp;authorizing the Company to withhold Ordinary Shares from the Ordinary Shares otherwise issuable
to the Participant as a result of the exercise or acquisition of Ordinary Shares under the Award, <I>provided, however</I>, that no Ordinary Shares are withheld with a value exceeding the maximum amount of tax required to be withheld by Applicable
Laws; or (c)&nbsp;delivering to the Company previously owned and unencumbered Ordinary Shares of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">11.&#8195;<U>Adjustments Upon Changes in
Shares</U>. In the event of changes in the outstanding Ordinary Shares or in the capital structure of the Company by reason of any share or extraordinary cash dividend, share split, reverse share split, an extraordinary corporate transaction such as
any recapitalization, reorganization, merger, consolidation, combination, exchange, or other relevant change in capitalization occurring after the Grant Date of any Award, Awards granted under the Plan and any Award Agreements, the exercise price of
Options and Share Appreciation Rights, the maximum number of Ordinary Shares subject to all Awards stated in <B><I>Section</I></B><B><I></I></B><B>&nbsp;4</B> will be equitably adjusted or substituted, as to the number, price or kind of an Ordinary
Share or other consideration subject to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
such Awards to the extent necessary to preserve the economic intent of such Award. In the case of adjustments made pursuant to this <B><I>Section</I></B><B></B><B>&nbsp;11</B>, unless the
Committee specifically determines that such adjustment is in the best interests of the Company or its Affiliates, the Committee shall, in the case of Incentive Share Options, ensure that any adjustments under this
<B><I>Section</I></B><B></B><B>&nbsp;11</B> will not constitute a modification, extension or renewal of the Incentive Share Options within the meaning of Section&nbsp;424(h)(3) of the Code and in the case of
<FONT STYLE="white-space:nowrap">Non-qualified</FONT> Share Options, ensure that any adjustments under this <B><I>Section</I></B><B></B><B>&nbsp;11</B> will not constitute a modification of such <FONT STYLE="white-space:nowrap">Non-qualified</FONT>
Share Options within the meaning of Section&nbsp;409A of the Code. The Company shall give each Participant notice of an adjustment hereunder and, upon notice, such adjustment shall be conclusive and binding for all purposes. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">12.&#8195;<U>Effect of Corporate Transaction</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12.1&#8195;The obligations of the Company under the Plan and the Award Agreements shall be binding upon any successor corporation or
organization resulting from the merger, consolidation or other reorganization of the Company, or upon any successor corporation or organization succeeding to all or substantially all of the assets and business of the Company and its Affiliates,
taken as a whole (a &#147;Corporate Transaction&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12.2&#8195;In the event of a Corporate Transaction, the Board may take one or
more of the following actions with respect to Options and Share Appreciation Rights: (i)&nbsp;make appropriate provision for the continuation of the Option or Share Appreciation Right by substituting on an equitable basis for the Ordinary Shares
then subject to such Option or Share Appreciation Right either the consideration payable with respect to the outstanding Ordinary Shares in connection with the Corporate Transaction or securities of any successor or acquiring entity;
(ii)&nbsp;require that Participants surrender their outstanding Options or Share Appreciation Rights in exchange for a payment by the Company, in cash or Ordinary Shares as determined by the Board, in an amount equal to the amount by which the then
Fair Market Value of the Ordinary Shares subject to such vested Option or Share Appreciation Right exceeds the Exercise Price; or (iii)&nbsp;after giving Participants an opportunity to exercise to the extent vested their outstanding Options or Share
Appreciation Rights, terminate any or all unexercised Options and Share Appreciation Rights at such time as the Board deems appropriate. Such surrender or termination shall take place as of the date of the Corporate Transaction or such other date as
the Board may specify. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12.3&#8195;In the event of a Corporate Transaction with respect to outstanding Restricted Awards, the Board, shall
make appropriate provision for the continuation of such Restricted Awards on the same terms and conditions by substituting on an equitable basis for the Ordinary Shares then subject to such Restricted Awards either the consideration payable with
respect to the outstanding Ordinary Shares in connection with the Corporate Transaction or securities of any successor or acquiring entity. In lieu of the foregoing, in connection with any Corporate Transaction, the Board may provide that, upon
consummation of the Corporate Transaction, each outstanding Restricted Award shall be terminated in exchange for payment of an amount equal to the consideration payable upon consummation of such Corporate Transaction to a holder of the number of
Ordinary Shares comprising such Restricted Award to then extent then vested. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">13.&#8195;<U>Amendment of the Plan and Awards</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13.1&#8195;<U>Amendment of Plan</U>. The Board at any time, and from time to time, may amend or terminate the Plan. However, except as provided
in <B><I>Section</I></B><B><I></I></B><B>&nbsp;11</B> relating to adjustments upon changes in Ordinary Shares and <B><I>Section</I></B><B><I></I></B><B>&nbsp;13.3</B>, no amendment shall be effective unless approved by the shareholders of the
Company to the extent shareholder approval is necessary to satisfy any Applicable Laws. At the time of such amendment, the Board shall determine, upon advice from counsel, whether such amendment will be contingent on shareholder approval. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13.2&#8195;<U>Shareholder Approval</U>. The Board will, submit any amendment to the Plan for shareholder approval if required under Applicable
Laws. Other than as set forth in <I>Section</I><I></I><I>&nbsp;12</I> of the Plan, the Board may not without shareholder approval reduce the exercise price of a share option or share appreciation right or cancel any outstanding Share Option or Share
Appreciation Right Award in exchange for a replacement Award having a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
lower exercise price, any other Award or for cash. In addition, the Board shall not take any other action that is considered a direct or indirect &#147;repricing&#148; for purposes of the
shareholder approval rules of the applicable securities exchange or inter-dealer quotation system on which the Ordinary Shares are listed, including any other action that is treated as a repricing under generally accepted accounting principles. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13.3&#8195;<U>Contemplated Amendments</U>. It is expressly contemplated that the Board may amend the Plan in any respect the Board deems
necessary or advisable to provide eligible Employees, Consultants and Directors with the maximum benefits provided or to be provided under the provisions of the Code relating to Incentive Share Options or to the nonqualified deferred compensation
provisions of Section&nbsp;409A of the Code and/or to bring the Plan and/or Awards granted under it into compliance therewith. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13.4&#8195;<U>No Impairment of Rights</U>. Rights under any Award granted before amendment of the Plan shall not adversely affect the
Participant&#146;s material rights by any amendment of the Plan unless (a)&nbsp;the Company requests the consent of the Participant; and (b)&nbsp;the Participant consents in writing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13.5&#8195;<U>Amendment of Awards</U>. The Committee at any time, and from time to time, may amend the terms of any one or more Awards;
<I>provided, however</I>, that the Committee may not affect any amendment which would adversely affect the Participant&#146;s material rights under any Award unless (a)&nbsp;the Company requests the consent of the Participant; and (b)&nbsp;the
Participant consents in writing. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">14.&#8195;<U>General Provisions</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14.1&#8195;<U>Other Compensation Arrangements</U>. Nothing contained in this Plan shall prevent the Board from adopting other or additional
compensation arrangements, subject to shareholder approval if such approval is required; and such arrangements may be either generally applicable or applicable only in specific cases. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14.2&#8195;<U>Unfunded Plan</U>. The Plan shall be unfunded. Neither the Company, the Board nor the Committee shall be required to establish
any special or separate fund or to segregate any assets to assure the performance of its obligations under the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14.3&#8195;<U>Recapitalizations and Reorganizations</U>. Each Award Agreement shall contain provisions required to reflect the provisions of
<B><I>Sections </I></B><B>11</B> and <B>12</B>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14.4&#8195;<U>Delivery</U>. Upon exercise of a right granted under this Plan, the Company
shall issue Ordinary Shares or pay any amounts due within a reasonable period of time thereafter. Subject to any statutory or regulatory obligations the Company may otherwise have, for purposes of this Plan, 30 days shall be considered a reasonable
period of time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14.5&#8195;<U>No Fractional Shares</U>. No fractional Ordinary Shares shall be issued or delivered pursuant to the Plan.
The Committee shall determine whether cash, additional Awards or other securities or property shall be issued or paid in lieu of fractional Ordinary Shares or whether any fractional shares should be rounded, forfeited or otherwise eliminated. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14.6&#8195;<U>Other Provisions</U>. The Award Agreements authorized under the Plan may contain such other provisions not inconsistent with
this Plan, including, without limitation, restrictions upon the exercise of the Awards, as the Committee may deem advisable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14.7&#8195;<U>Section 409A</U>. The Plan is intended to comply with Section&nbsp;409A of the Code to the extent subject thereto, and,
accordingly, to the maximum extent permitted, the Plan shall be interpreted and administered to be in compliance therewith. Any payments described in the Plan that are due within the &#147;short-term deferral period&#148; as defined in
Section&nbsp;409A of the Code shall not be treated as deferred compensation unless Applicable Laws require otherwise. Notwithstanding anything to the contrary in the Plan, to the extent required to avoid
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
accelerated taxation and tax penalties under Section&nbsp;409A of the Code, amounts that would otherwise be payable and benefits that would otherwise be provided pursuant to the Plan during the 6
month period immediately following the Participant&#146;s termination of Continuous Service shall instead be paid on the first payroll date after the 6 month anniversary of the Participant&#146;s separation from service (or the Participant&#146;s
death, if earlier). Notwithstanding the foregoing, neither the Company nor the Committee shall have any obligation to take any action to prevent the assessment of any excise tax or penalty on any Participant under Section&nbsp;409A of the Code and
neither the Company nor the Committee will have any liability to any Participant for such tax or penalty. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14.8&#8195;<U>Disqualifying
Dispositions</U>. Any Participant who shall make a &#147;disposition&#148; (as defined in Section&nbsp;424 of the Code) of all or any portion of Ordinary Shares acquired upon exercise of an Incentive Share Option within two years from the Grant Date
of such Incentive Share Option or within one year after the issuance of the Ordinary Shares acquired upon exercise of such Incentive Share Option (a &#147;<U>Disqualifying Disposition</U>&#148;) shall be required if requested by the Company to
immediately advise the Company in writing as to the occurrence of the sale and the price realized upon the sale of such Ordinary Shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14.9&#8195;<U>Section 16</U>. It is the intent of the Company that the Plan satisfy, and be interpreted in a manner that satisfies, the
applicable requirements of Rule <FONT STYLE="white-space:nowrap">16b-3</FONT> as promulgated under Section&nbsp;16 of the Exchange Act so that Participants will be entitled to the benefit of Rule <FONT STYLE="white-space:nowrap">16b-3,</FONT> or any
other rule promulgated under Section&nbsp;16 of the Exchange Act, and will not be subject to short-swing liability under Section&nbsp;16 of the Exchange Act. Accordingly, if the operation of any provision of the Plan would conflict with the intent
expressed in this <B><I>Section</I></B><B></B><B>&nbsp;14.9</B> such provision to the extent possible shall be interpreted and/or deemed amended so as to avoid such conflict. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14.10&#8195;<U>Beneficiary Designation</U>. Each Participant under the Plan may from time to time name any beneficiary or beneficiaries by
whom any right under the Plan is to be exercised in case of such Participant&#146;s death. Each designation will revoke all prior designations by the same Participant, shall be in a form reasonably prescribed by the Committee and shall be effective
only when filed by the Participant in writing with the Company during the Participant&#146;s lifetime. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14.11&#8195;<U>Expenses</U>. The
costs of administering the Plan shall be paid by the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14.12&#8195;<U>Severability</U>. If any of the provisions of the Plan or
any Award Agreement is held to be invalid, illegal or unenforceable, whether in whole or in part, such provision shall be deemed modified to the extent, but only to the extent, of such invalidity, illegality or unenforceability and the remaining
provisions shall not be affected thereby. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14.13&#8195;<U>Plan Headings</U>. The headings in the Plan are for purposes of convenience only
and are not intended to define or limit the construction of the provisions hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14.14&#8195;<U><FONT STYLE="white-space:nowrap">Non-Uniform</FONT> Treatment</U>. The Committee&#146;s determinations under the Plan need not
be uniform and may be made by it selectively among persons who are eligible to receive, or actually receive, Awards. Without limiting the generality of the foregoing, the Committee shall be entitled to make
<FONT STYLE="white-space:nowrap">non-uniform</FONT> and selective determinations, amendments and adjustments, and to enter into <FONT STYLE="white-space:nowrap">non-uniform</FONT> and selective Award Agreements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">15.&#8195;<U>Effective Date and Termination or Suspension of Plan</U>. The Plan shall become effective as of the Effective Date and shall terminate at the
earliest of (a)&nbsp;such time as no Shares remain available for issuance under the Plan, (b)&nbsp;termination of the Plan by the Board, or (c)&nbsp;the tenth anniversary of the Effective Date. Awards outstanding upon expiration of the Plan shall
remain in effect until they have been exercised or terminated, or have expired. No grants of Incentive Stock Options may be made under the Plan on or after June&nbsp;15, 2031. The Board may suspend or terminate the Plan at any earlier date pursuant
to <B><I>Section</I></B><B><I></I></B><B>&nbsp;13.1</B> hereof. No Awards may be granted under the Plan while the Plan is suspended or after it is terminated. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">16.&#8195;<U>Choice of Law</U>. The applicable laws of the State of Delaware, United States of America shall
govern all questions concerning the construction, validity and interpretation of this Plan unless this Plan so specifies the interpretation of other Applicable Laws then, in such case, those Applicable Laws shall govern. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">17.&#8195;<U>Clawback</U>. Notwithstanding anything to the contrary contained in this Plan, the Company may recover from a Participant any compensation
received from any Award (whether or not vested or settled) or cause a Participant to forfeit any Award (whether or not vested) in the event that the Company&#146;s Clawback Policy then in effect is triggered. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g802241g19p19.jpg" ALT="LOGO">
 </P> <P STYLE="font-family:Times New Roman; font-size:0.5pt"><FONT COLOR="#FFFFFF">WAVE LIFE SCIENCES LTD. C/O 733 CONCORD AVENUE CAMBRIDGE, MA 02138 ATTN: LINDA ROCKETT VOTE BY MAIL or scan the QR Barcode above Mark,
sign and date your proxy card and return it in the postage-paid envelope we have provided or return it to Vote Processing, c/o Broadridge, 51 Mercedes Way, Edgewood, NY 11717. TO VOTE, MARK BLOCKS BELOW IN BLUE OR BLACK INK AS FOLLOWS: V53536-P15053
KEEP THIS PORTION FOR YOUR RECORDS THIS PROXY CARD IS VALID ONLY WHEN SIGNED AND DATED. DETACH AND RETURN THIS PORTION ONLY WAVE LIFE SCIENCES LTD. The Board of Directors recommends a vote FOR all of the director nominees listed in Proposal 1 and
FOR Proposals 2, 3, 4, 5, and 6. 1. The election of the nominees for director: For Against Abstain 1a. Paul B. Bolno, M.D., MBA ! ! ! 1b. Mark H. N. Corrigan, M.D. ! ! ! 1c. Christian Henry ! ! ! 1d. Peter Kolchinsky, Ph.D. ! ! ! 1e. Adrian
Rawcliffe ! ! ! 1f. Ken Takanashi ! ! ! 1g. Aik Na Tan ! ! ! 1h. Gregory L. Verdine, Ph.D. ! ! ! 1i. Heidi L. Wagner, J.D. ! ! ! 2. To approve the re-appointment of KPMG LLP to serve as our ! ! ! independent registered public accounting firm and
independent Singapore auditor for the year ending December 31, 2024, and to authorize the Audit Committee of the Board of Directors to fix KPMG LLP&#146;s remuneration for services provided through the date of our 2025 Annual General Meeting of
Shareholders For Against Abstain 3. to To approve non-employee our payment directors of for cash service and equity-based on the Board compensation of Directors ! ! ! and its committees, in the manner and on the basis set forth under &#147;Proposal
3: Non- Employee Directors&#146; Compensation&#148; in the proxy statement 4. To approve a proposed amendment to our 2021 Equity Incentive Plan, as amended, in the manner and on the basis as set forth under &#147;Proposal 4: Approval of an Amendment
to the 2021 Equity ! ! ! Incentive Plan, as amended&#148; in the proxy statement 5. To authorize the Board of Directors to allot and issue Ordinary ! ! ! Shares of Wave Life Sciences Ltd. 6. To approve, by a non-binding advisory vote, the
compensation of ! ! ! our named executive officers as disclosed in the proxy statement 7. To transact such other business as may properly come before the 2024 Annual General Meeting of Shareholders and all adjournments or postponements thereof Yes
No Please indicate if you plan to attend the 2024 Annual General Meeting. ! ! Please sign exactly as your name(s) appear(s) hereon. When signing as attorney, executor, administrator, or other fiduciary, please give full title as such. Joint owners
should each sign personally. All holders must sign. If a corporation or partnership, please sign in full corporate or partnership name by authorized officer. Signature [PLEASE SIGN WITHIN BOX] Date Signature (Joint Owners) Date </FONT></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g802241g20p20.jpg" ALT="LOGO">
 </P> <P STYLE="font-family:Times New Roman; font-size:0.5pt"><FONT COLOR="#FFFFFF">Wave Life Sciences Ltd. 2024 Annual General Meeting of Shareholders Tuesday, August 6, 2024, 11:30 a.m., Eastern Time Wave Life Sciences
Ltd. 733 Concord Avenue, Cambridge, MA 02138 Upon arrival, please present this admission ticket and photo identification at the registration desk. IMPORTANT NOTICE REGARDING THE AVAILABILITY OF PROXY MATERIALS FOR THE 2024 ANNUAL GENERAL MEETING OF
SHAREHOLDERS: The notice, proxy statement and our 2023 annual report to shareholders are available for viewing, printing and downloading at www.proxyvote.com Vote by Mail Whether or not you expect to attend the 2024 Annual General Meeting of
Shareholders, please mark, sign and date your proxy card and return it in the postage-paid envelope we have provided or return it to Vote Processing, c/o Broadridge, 51 Mercedes Way, Edgewood, NY 11717. YOUR PROXY CARD MUST BE RECEIVED AT THE
ADDRESS ABOVE NOT LESS THAN 48 HOURS BEFORE THE TIME APPOINTED FOR HOLDING THE 2024 ANNUAL GENERAL MEETING OF SHAREHOLDERS (OR WITHIN SUCH OTHER TIME AS MAY BE REQUIRED BY THE SINGAPORE COMPANIES ACT). V53537-P15053 Proxy - WAVE LIFE SCIENCES LTD.
(Incorporated in the Republic of Singapore; Company Registration Number 201218209G) 2024 Annual General Meeting of Shareholders August 6, 2024 This proxy is solicited by the Board of Directors Paul B. Bolno, M.D., MBA, and in his absence, Linda
Rockett, Esq., each with the power of substitution and each with the full power to act alone, are hereby authorized as Proxies to represent and vote the ordinary shares of Wave Life Sciences Ltd. owned by the undersigned, with all the powers which
the undersigned would possess if personally present, at the 2024 Annual General Meeting of Shareholders of Wave Life Sciences Ltd. to be held on August 6, 2024 or at any postponement or adjournment thereof. Shares represented by this proxy will be
voted by the Proxies as directed herein by the shareholder. If no such directions are indicated, the Proxies will have authority to vote FOR the director nominees listed in Proposal 1, FOR Proposal 2, FOR Proposal 3, FOR Proposal 4, FOR Proposal 5,
and FOR Proposal 6. In their discretion, the Proxies are authorized to vote upon such other business as may properly come before the 2024 Annual General Meeting of Shareholders or at any adjournment or postponement thereof. Continued and to be
signed on reverse side </FONT></P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g802241g00r01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g802241g00r01.jpg
M_]C_X  02D9)1@ ! 0$ 7@!>  #_[10:4&AO=&]S:&]P(#,N,  X0DE-! 0
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M    # !0 '( ;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E='5P
M 0    !";'1N96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+.$))
M300[      (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,    7
M     $-P=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP      $-R
M;D-B;V]L      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L
M      !%;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0
M     %)'0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6)
M;^            !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
M             $)L9"!5;G1&(U)L=                %)S;'15;G1&(U!X
M;$!7DDE         "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !0
M9U!S     %!G4$,     3&5F=%5N=$8C4FQT                5&]P(%5N
M=$8C4FQT                4V-L(%5N=$8C4')C0%D            08W)O
M<%=H96Y0<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P
M   ,8W)O<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M        "V-R;W!296-T5&]P;&]N9P      .$))30/M       0 %Y)(P !
M  ( 7DDC  $  CA"24T$)@      #@             _@   .$))300-
M   $    6CA"24T$&0      !    !XX0DE- _,       D           $
M.$))32<0       *  $          CA"24T#]       $@ U     0 M
M!@       3A"24T#]P      '   _____________________________P/H
M   X0DE-! @      !     !   "0    D      .$))300>       $
M #A"24T$&@     #00    8              #D   "]    !@!G #  , !R
M #  ,0    $                          0              O0   #D
M                     0                         0     0
M &YU;&P    "    !F)O=6YD<T]B:F,    !        4F-T,0    0
M5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P   #D
M    4F=H=&QO;F<   "]    !G-L:6-E<U9L3',    !3V)J8P    $
M  5S;&EC90   !(    '<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG
M          9O<FEG:6YE;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N
M97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y<&4     26UG(     9B
M;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG
M  !,969T;&]N9P          0G1O;6QO;F<    Y     %)G:'1L;VYG
MO0    -U<FQ415A4     0       &YU;&Q415A4     0       $US9V54
M15A4     0      !F%L=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA4
M34QB;V]L 0    AC96QL5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU
M;0    ]%4VQI8V5(;W)Z06QI9VX    '9&5F875L=     EV97)T06QI9VYE
M;G5M    #T53;&EC959E<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4
M>7!E96YU;0   !%%4VQI8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U
M='-E=&QO;F<         "FQE9G1/=71S971L;VYG          QB;W1T;VU/
M=71S971L;VYG          MR:6=H=$]U='-E=&QO;F<      #A"24T$*
M    #     (_\        #A"24T$%       !     $X0DE-! P     "A\
M   !    D    "L   &P  !(D   "@, &  !_]C_[0 ,061O8F5?0TT  ?_N
M  Y!9&]B90!D@     '_VP"$  P(" @)" P)"0P1"PH+$14/# P/%1@3$Q43
M$Q@1# P,# P,$0P,# P,# P,# P,# P,# P,# P,# P,# P,# P!#0L+#0X-
M$ X.$!0.#@X4% X.#@X4$0P,# P,$1$,# P,# P1# P,# P,# P,# P,# P,
M# P,# P,# P,# P,#/_  !$( "L D ,!(@ "$0$#$0'_W0 $  G_Q $_   !
M!0$! 0$! 0         #  $"! 4&!P@)"@L!  $% 0$! 0$!          $
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MW#@N:''[W!296RL;:VA@\&@ ?@II)*?_V0 X0DE-!"$      %<    ! 0
M  \ 00!D &\ 8@!E "  4 !H &\ = !O ', : !O '     4 $$ 9 !O &(
M90 @ %  : !O '0 ;P!S &@ ;P!P "  ,@ P #( ,0    $ .$))300B
M  %*34T *@    @ " $2  ,    !  $   $:  4    !    ;@$;  4    !
M    =@$H  ,    !  (   $Q  (    ?    ?@$R  (    4    G0$[  (
M   /    L8=I  0    !    P    .P   !>     0   %X    !061O8F4@
M4&AO=&]S:&]P(#(R+C$@*%=I;F1O=W,I #(P,C0Z,#8Z,C$@,#4Z,S<Z,C(
M3&EN9'-A>2!,979I;F4   .@ 0 #     ?__  "@ @ $     0   +V@ P $
M     0   #D         !@$#  ,    !  8   $:  4    !   !.@$;  4
M   !   !0@$H  ,    !  (   (!  0    !   !2@("  0    !
M      !(     0   $@    !.$))30/]       (          #_X0%217AI
M9@  34T *@    @ " $2  ,    !  $   $:  4    !    ;@$;  4    !
M    =@$H  ,    !  (   $Q  (    ?    ?@$R  (    4    G0$[  (
M   /    L8=I  0    !    P    .P   !>     0   %X    !061O8F4@
M4&AO=&]S:&]P(#(R+C$@*%=I;F1O=W,I #(P,C0Z,#8Z,C$@,#4Z,S<Z,C(
M3&EN9'-A>2!,979I;F4   .@ 0 #     ?__  "@ @ $     0   +V@ P $
M     0   #D         !@$#  ,    !  8   $:  4    !   !.@$;  4
M   !   !0@$H  ,    !  (   (!  0    !   !2@("  0    !
M      !(     0   $@    !_^(#H4E#0U]04D]&24Q%  $!   #D$%$0D4"
M$   <')T<D=205E865H@!\\ !@ #        86-S<$%04$P     ;F]N90
M                  $  /;6  $     TRU!1$)%
M                                           %8W!R=    ,     R
M9&5S8P   /0   !G=W1P=    5P    48FMP=    7     4:U120P   80
M  (,=&5X=     !#;W!Y<FEG:'0@,3DY.2!!9&]B92!3>7-T96US($EN8V]R
M<&]R871E9    &1E<V,         #41O="!'86EN(#(P)0
M
M                                6%E:(        /;6  $     TRU8
M65H@                     &-U<G8        !     !  (  P $  4 !A
M '\ H #% .P!%P%$ 74!J '> A8"4@*0 M #$P-9 Z$#[ 0Y!(@$V@4N!84%
MW@8Y!I8&]@=7![L((@B*"/0)80G0"D$*M LI"Z ,&@R5#1(-D@X3#I8/' ^C
M$"P0N!%%$=0291+X$XT4)!2]%5<5]!:2%S(7U!AX&1X9QAIO&QL;R!QV'2<=
MVAZ.'T0?_""U(7$B+B+M(ZTD<"4T)?DFP2>**%4I(BGP*L KDBQE+3HN$2[J
M+\0PH#%],EPS/30?-0,UZ3;0-[DXI#F0.GX[;3Q>/5$^13\[0#-!+$(F0R)$
M($4?1B!'(T@G22U*-$L\3$=-4TY@3V]0?U&14J53NE315>E7 E@>63I:6%MX
M7)E=O%[@8 9A+6)68X!DK&799PAH.&EI:IUKT6T';C]O>'"R<>YS*W1J=:IV
M['@O>71ZNGP!?4I^E7_A@2Z"?(/-A1Z&<8?%B1N*<HO+C26.@8_=D3R2FY/]
ME5^6PY@HF8^:]YQ@G<N?-Z"EHA2CA:3VIFFGWJE4JLNL1*V^KSFPMK(TL[2U
M-+:WN#JYO[M%O,V^5K_@P6S"^<2'QA?'J,D[RL[,8\WZSY+1*]+%U&'5_M><
MV3S:W=Q_WB/?R.%NXQ;DO^9IZ!3IP>MO[1_NT/""\C7SZO6@]U?Y$/K*_(7^
M0?__ /_A/U9H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O #P_>'!A8VME
M="!B96=I;CTB[[N_(B!I9#TB5S5-,$UP0V5H:4AZ<F53>DY48WIK8SED(C\^
M"CQX.GAM<&UE=&$@>&UL;G,Z>#TB861O8F4Z;G,Z;65T82\B('@Z>&UP=&L]
M(D%D;V)E(%A-4"!#;W)E(#8N,"UC,# U(#<Y+C$V-#4Y,"P@,C R,"\Q,B\P
M.2TQ,3HU-SHT-" @(" @(" @(CX*(" @/')D9CI21$8@>&UL;G,Z<F1F/2)H
M='1P.B\O=W=W+G<S+F]R9R\Q.3DY+S R+S(R+7)D9BUS>6YT87@M;G,C(CX*
M(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*(" @(" @(" @
M(" @>&UL;G,Z<&1F>#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]P9&9X+S$N,R\B
M"B @(" @(" @(" @('AM;&YS.GAM<#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87 O,2XP+R(*(" @(" @(" @(" @>&UL;G,Z<&1F/2)H='1P.B\O;G,N861O
M8F4N8V]M+W!D9B\Q+C,O(@H@(" @(" @(" @("!X;6QN<SID8STB:'1T<#HO
M+W!U<FPN;W)G+V1C+V5L96UE;G1S+S$N,2\B"B @(" @(" @(" @('AM;&YS
M.GAM<$U-/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O;6TO(@H@(" @
M(" @(" @("!X;6QN<SIS=$5V=#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O
M,2XP+W-4>7!E+U)E<V]U<F-E179E;G0C(@H@(" @(" @(" @("!X;6QN<SIS
M=%)E9CTB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E+U)E<V]U
M<F-E4F5F(R(*(" @(" @(" @(" @>&UL;G,Z<&AO=&]S:&]P/2)H='1P.B\O
M;G,N861O8F4N8V]M+W!H;W1O<VAO<"\Q+C O(CX*(" @(" @(" @/'!D9G@Z
M05!42U9%4CXQ,2XQ+C N,C(Q,SD@4')O(%!R;V1U8W1I;VXM,S(\+W!D9G@Z
M05!42U9%4CX*(" @(" @(" @/'AM<#I#<F5A=&5$871E/C(P,C0M,#8M,C!4
M,3DZ,#@Z-3(M,#0Z,# \+WAM<#I#<F5A=&5$871E/@H@(" @(" @(" \>&UP
M.D-R96%T;W)4;V]L/E1O;VQK:70@:'1T<#HO+W=W=RYA8W1I=F5P9&8N8V]M
M/"]X;7 Z0W)E871O<E1O;VP^"B @(" @(" @(#QX;7 Z36]D:69Y1&%T93XR
M,#(T+3 V+3(Q5# U.C,W.C(R*S U.C,P/"]X;7 Z36]D:69Y1&%T93X*(" @
M(" @(" @/'AM<#I-971A9&%T841A=&4^,C R-"TP-BTR,50P-3HS-SHR,BLP
M-3HS,#PO>&UP.DUE=&%D871A1&%T93X*(" @(" @(" @/'!D9CI0<F]D=6-E
M<CY4;V]L:VET(&AT=' Z+R]W=W<N86-T:79E<&1F+F-O;3PO<&1F.E!R;V1U
M8V5R/@H@(" @(" @(" \9&,Z8W)E871O<CX*(" @(" @(" @(" @/')D9CI3
M97$^"B @(" @(" @(" @(" @(#QR9&8Z;&D^3&EN9'-A>2!,979I;F4\+W)D
M9CIL:3X*(" @(" @(" @(" @/"]R9&8Z4V5Q/@H@(" @(" @(" \+V1C.F-R
M96%T;W(^"B @(" @(" @(#QD8SIF;W)M870^:6UA9V4O97!S9CPO9&,Z9F]R
M;6%T/@H@(" @(" @(" \>&UP34TZ26YS=&%N8V5)1#YX;7 N:6ED.F,Q,61D
M-C=E+6-C8SDM93DT8RUA.#DR+3!F860T9C4R,# Q.3PO>&UP34TZ26YS=&%N
M8V5)1#X*(" @(" @(" @/'AM<$U-.D1O8W5M96YT240^861O8F4Z9&]C:60Z
M<&AO=&]S:&]P.C8P,C5A.3@Y+34X,C(M-# T9"TX,&-F+3 X8S9F83<R,C,P
M.#PO>&UP34TZ1&]C=6UE;G1)1#X*(" @(" @(" @/'AM<$U-.D]R:6=I;F%L
M1&]C=6UE;G1)1#YX;7 N9&ED.F9D8S8P9C!D+3(R8V(M9#4T8BTY,SAC+60Y
M,C9A-C5A,# Y-CPO>&UP34TZ3W)I9VEN86Q$;V-U;65N=$E$/@H@(" @(" @
M(" \>&UP34TZ2&ES=&]R>3X*(" @(" @(" @(" @/')D9CI397$^"B @(" @
M(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@
M(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/G-A=F5D/"]S=$5V=#IA
M8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#II;G-T86YC94E$/GAM
M<"YI:60Z9F1C-C!F,&0M,C)C8BUD-31B+3DS.&,M9#DR-F$V-6$P,#DV/"]S
M=$5V=#II;G-T86YC94E$/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z=VAE
M;CXR,#(T+3 V+3(Q5# U.C,W.C$U*S U.C,P/"]S=$5V=#IW:&5N/@H@(" @
M(" @(" @(" @(" @(" \<W1%=G0Z<V]F='=A<F5!9V5N=#Y!9&]B92!0:&]T
M;W-H;W @,C(N,2 H5VEN9&]W<RD\+W-T179T.G-O9G1W87)E06=E;G0^"B @
M(" @(" @(" @(" @(" @(#QS=$5V=#IC:&%N9V5D/B\\+W-T179T.F-H86YG
M960^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \
M<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @
M(" @(" @/'-T179T.F%C=&EO;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@(" @
M(" @(" @(" @(" @(" \<W1%=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.F%D,S=B
M,C(W+3AC,#DM,6$T,"UB834S+69D9F8X9F$Q8S$R83PO<W1%=G0Z:6YS=&%N
M8V5)1#X*(" @(" @(" @(" @(" @(" @/'-T179T.G=H96X^,C R-"TP-BTR
M,50P-3HS-SHR,BLP-3HS,#PO<W1%=G0Z=VAE;CX*(" @(" @(" @(" @(" @
M(" @/'-T179T.G-O9G1W87)E06=E;G0^061O8F4@4&AO=&]S:&]P(#(R+C$@
M*%=I;F1O=W,I/"]S=$5V=#IS;V9T=V%R94%G96YT/@H@(" @(" @(" @(" @
M(" @(" \<W1%=G0Z8VAA;F=E9#XO/"]S=$5V=#IC:&%N9V5D/@H@(" @(" @
M(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z
M<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$5V
M=#IA8W1I;VX^8V]N=F5R=&5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @
M(" @(" @(#QS=$5V=#IP87)A;65T97)S/F9R;VT@87!P;&EC871I;VXO=FYD
M+F%D;V)E+G!H;W1O<VAO<"!T;R!I;6%G92]E<'-F/"]S=$5V=#IP87)A;65T
M97)S/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @
M/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @
M(" @(" @(#QS=$5V=#IA8W1I;VX^9&5R:79E9#PO<W1%=G0Z86-T:6]N/@H@
M(" @(" @(" @(" @(" @(" \<W1%=G0Z<&%R86UE=&5R<SYC;VYV97)T960@
M9G)O;2!A<'!L:6-A=&EO;B]V;F0N861O8F4N<&AO=&]S:&]P('1O(&EM86=E
M+V5P<V8\+W-T179T.G!A<F%M971E<G,^"B @(" @(" @(" @(" @(#PO<F1F
M.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E
M<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T.F%C=&EO;CYS879E
M9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z:6YS
M=&%N8V5)1#YX;7 N:6ED.F,Q,61D-C=E+6-C8SDM93DT8RUA.#DR+3!F860T
M9C4R,# Q.3PO<W1%=G0Z:6YS=&%N8V5)1#X*(" @(" @(" @(" @(" @(" @
M/'-T179T.G=H96X^,C R-"TP-BTR,50P-3HS-SHR,BLP-3HS,#PO<W1%=G0Z
M=VAE;CX*(" @(" @(" @(" @(" @(" @/'-T179T.G-O9G1W87)E06=E;G0^
M061O8F4@4&AO=&]S:&]P(#(R+C$@*%=I;F1O=W,I/"]S=$5V=#IS;V9T=V%R
M94%G96YT/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z8VAA;F=E9#XO/"]S
M=$5V=#IC:&%N9V5D/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @
M(" @(" @/"]R9&8Z4V5Q/@H@(" @(" @(" \+WAM<$U-.DAI<W1O<GD^"B @
M(" @(" @(#QX;7!-33I$97)I=F5D1G)O;2!R9&8Z<&%R<V54>7!E/2)297-O
M=7)C92(^"B @(" @(" @(" @(#QS=%)E9CII;G-T86YC94E$/GAM<"YI:60Z
M860S-V(R,C<M.&,P.2TQ830P+6)A-3,M9F1F9CAF83%C,3)A/"]S=%)E9CII
M;G-T86YC94E$/@H@(" @(" @(" @(" \<W12968Z9&]C=6UE;G1)1#YX;7 N
M9&ED.F9D8S8P9C!D+3(R8V(M9#4T8BTY,SAC+60Y,C9A-C5A,# Y-CPO<W12
M968Z9&]C=6UE;G1)1#X*(" @(" @(" @(" @/'-T4F5F.F]R:6=I;F%L1&]C
M=6UE;G1)1#YX;7 N9&ED.F9D8S8P9C!D+3(R8V(M9#4T8BTY,SAC+60Y,C9A
M-C5A,# Y-CPO<W12968Z;W)I9VEN86Q$;V-U;65N=$E$/@H@(" @(" @(" \
M+WAM<$U-.D1E<FEV961&<F]M/@H@(" @(" @(" \<&AO=&]S:&]P.D-O;&]R
M36]D93XQ/"]P:&]T;W-H;W Z0V]L;W)-;V1E/@H@(" @(" @(" \<&AO=&]S
M:&]P.DE#0U!R;V9I;&4^1&]T($=A:6X@,C E/"]P:&]T;W-H;W Z24-#4')O
M9FEL93X*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(#PO<F1F.E)$1CX*
M/"]X.GAM<&UE=&$^"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"CP_>'!A8VME="!E;F0](G<B/S[_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MP  +"  ] ,D! 1$ _\0 '  !  (# 0$!              8' @,% 00(_\0
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M)C?9U^MX#<N OH4:Z<R1^'_WTW/VU%2=D:K*E*5JD2&X[+KSZDH:;25*4KL
M.YJD+;%=XP9DNY7)"OY-M3VHD<_=EN@_>4/,5>"&4I&D]!VT.E5QF.!9!=[M
M(EVO.+S;&72%".VYI#8\PG55-.X;9!E&;+L#^8W6[6:(D*GOO.J4&W"3IL;.
MBK6C[;JU<:X,X3CX;5]F(FOI[*FJ\39]0D] ?H*LB-'9992AAM#;20.5*$Z
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g802241g00r41.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g802241g00r41.jpg
M_]C_X  02D9)1@ ! 0$ N@"Z  #_[1?T4&AO=&]S:&]P(#,N,  X0DE-! 0
M     "(< 5H  QLE1QP"   "   < E  #DQI;F1S87D@3&5V:6YE.$))300E
M       0'!L2UKZ=]).O'+!\>>UDOCA"24T$.@     !'@   !     !
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M;       0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O;
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M;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'0
M  !4;W @56YT1B-2;'0               !38VP@56YT1B-0<F- 60
M     !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL
M;VYG          QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I
M9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T
M !  NG;(  $  0"Z=L@  0 !.$))300F       .             #^    X
M0DE-! T       0   !:.$))3009       $    'CA"24T#\P      "0
M         0 X0DE-)Q        H  0         ".$))30/U      !( "]F
M9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H    &
M       ! #4    ! "T    &       !.$))30/X      !P  #_________
M____________________ ^@     _____________________________P/H
M     /____________________________\#Z     #_________________
M____________ ^@  #A"24T$"       $     $   )    "0      X0DE-
M!$0      !     "   "0    D      .$))300>       $     #A"24T$
M&@     #00    8              G,   2!    !@!G #  , !R #0 ,0
M  $                          0             $@0   G,
M             0                         0     0       &YU;&P
M   "    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO
M;F<          $QE9G1L;VYG          !"=&]M;&]N9P   G,     4F=H
M=&QO;F<   2!    !G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC
M90   !(    '<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG
M  9O<FEG:6YE;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D
M     %1Y<&5E;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/
M8FIC     0       %)C=#$    $     %1O<"!L;VYG          !,969T
M;&]N9P          0G1O;6QO;F<   )S     %)G:'1L;VYG   $@0    -U
M<FQ415A4     0       &YU;&Q415A4     0       $US9V5415A4
M 0      !F%L=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB;V]L
M 0    AC96QL5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0    ]%
M4VQI8V5(;W)Z06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M
M#T53;&EC959E<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E96YU
M;0   !%%4VQI8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E=&QO
M;F<         "FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S971L
M;VYG          MR:6=H=$]U='-E=&QO;F<      #A"24T$*       #
M  (_\        #A"24T$$0       0$ .$))3004       $    !CA"24T$
M#      -/0    $   "@    5P   >   *,@   -(0 8  '_V/_M  Q!9&]B
M95]#30 "_^X #D%D;V)E &2      ?_; (0 # @(" D(# D)#!$+"@L1%0\,
M# \5&!,3%1,3&!$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# $-"PL-#@T0#@X0% X.#A04#@X.#A01# P,# P1$0P,# P,#!$,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,_\  $0@ 5P"@ P$B  (1 0,1 ?_=  0
M"O_$ 3\   $% 0$! 0$!          ,  0($!08'" D*"P$  04! 0$! 0$
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MGPW-24D0[J*[@-TAS=6/;HYI\6.1$DE$7NUA?900S*C;PW(&C3Y6C_!/_P#
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M &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <    !0 00!D &\ 8@!E "
M4 !H &\ = !O ', : !O '  (  R #  ,@ T     0 X0DE-!"(      4I-
M30 J    "  ( 1(  P    $  0   1H !0    $   !N 1L !0    $   !V
M 2@  P    $  @   3$  @   !\   !^ 3(  @   !0   "= 3L  @    \
M  "QAVD !     $   #     [    +H    !    N@    %!9&]B92!0:&]T
M;W-H;W @,C4N," H5VEN9&]W<RD ,C R-#HP-CHR,2 P.3HR-#HQ.0!,:6YD
M<V%Y($QE=FEN90   Z !  ,    !__\  * "  0    !   $@: #  0    !
M   "<P         & 0,  P    $ !@   1H !0    $   $Z 1L !0    $
M  %" 2@  P    $  @   @$ !     $   %* @( !     $
M $@    !    2     $X0DE- _T       @          /_A 5)%>&EF  !-
M30 J    "  ( 1(  P    $  0   1H !0    $   !N 1L !0    $   !V
M 2@  P    $  @   3$  @   !\   !^ 3(  @   !0   "= 3L  @    \
M  "QAVD !     $   #     [    +H    !    N@    %!9&]B92!0:&]T
M;W-H;W @,C4N," H5VEN9&]W<RD ,C R-#HP-CHR,2 P.3HR-#HQ.0!,:6YD
M<V%Y($QE=FEN90   Z !  ,    !__\  * "  0    !   $@: #  0    !
M   "<P         & 0,  P    $ !@   1H !0    $   $Z 1L !0    $
M  %" 2@  P    $  @   @$ !     $   %* @( !     $
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M56)S=),7)$,E@O'_Q  9 0$  P$!                 0(#! 7_Q  N$0$
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M!\[/_5="3R7/.?=EP=K?S<R[,B#DL[9J&6>BJY\2CV<@QUT<SA+*7,A-.US
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M(Y)97U9$;WRNEMG)#FEH/):!8"P%EE8%L?1X/+ASX*FJE% V=D E<#9LK@7
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M(=YQ[5*HJKQ#O./:I5DZD5/X4WI^X*514_A3>G[@I4(4;;V-WTO1OJ1(ZB=
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MC2TI3JC;GRYIQSJ(=W^G\(_S.C_[F_%/I_"/\SH_^YOQ7"$5O*AE]5/P[O\
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MBK:VVM*=$:$1%5<1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$'QS0YI:X
M@Z$'G4<%-#!%''%&UK(_  '@J5$1J.47>\&1S-S'D<;N;E%B?*I0 T    :
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?,\W5-[?R0*KQ#O./:I5!)O9&9=VT7(US>7S*=$/_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g802241g00r42.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g802241g00r42.jpg
M_]C_X  02D9)1@ ! 0$ MP"W  #_[1;B4&AO=&]S:&]P(#,N,  X0DE-! 0
M     "(< 5H  QLE1QP"   "   < E  #DQI;F1S87D@3&5V:6YE.$))300E
M       0'!L2UKZ=]).O'+!\>>UDOCA"24T$.@     !'@   !     !
M   +<')I;G1/=71P=70    &     $-L<E-E;G5M     $-L<E,     4D="
M0P    !.;2 @5$585     @ 0P!) $4 ( !2 $< 0@       $EN=&5E;G5M
M     $EN=&4     04-L<@    ]P<FEN=%-I>'1E96Y":71B;V]L      MP
M<FEN=&5R3F%M951%6%0    & $$ 4 !$ "T ,@      #W!R:6YT4')O;V93
M971U<$]B:F,    , %  <@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F
M4V5T=7     !     $)L=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O
M9D--64LX0DE-!#L      BT    0     0      $G!R:6YT3W5T<'5T3W!T
M:6]N<P   !<     0W!T;F)O;VP      $-L8G)B;V]L      !29W--8F]O
M;       0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O;
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M;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'0
M  !4;W @56YT1B-2;'0               !38VP@56YT1B-0<F- 60
M     !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL
M;VYG          QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I
M9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T
M !  MQA1  $  0"W&%$  0 !.$))300F       .             #^    X
M0DE-! T       0   !:.$))3009       $    'CA"24T#\P      "0
M         0 X0DE-)Q        H  0         ".$))30/U      !( "]F
M9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H    &
M       ! #4    ! "T    &       !.$))30/X      !P  #_________
M____________________ ^@     _____________________________P/H
M     /____________________________\#Z     #_________________
M____________ ^@  #A"24T$"       $     $   )    "0      X0DE-
M!$0      !     "   "0    D      .$))300>       $     #A"24T$
M&@     #00    8              F@   1L    !@!G #  , !R #0 ,@
M  $                          0             $;    F@
M             0                         0     0       &YU;&P
M   "    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO
M;F<          $QE9G1L;VYG          !"=&]M;&]N9P   F@     4F=H
M=&QO;F<   1L    !G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC
M90   !(    '<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG
M  9O<FEG:6YE;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D
M     %1Y<&5E;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/
M8FIC     0       %)C=#$    $     %1O<"!L;VYG          !,969T
M;&]N9P          0G1O;6QO;F<   )H     %)G:'1L;VYG   $;     -U
M<FQ415A4     0       &YU;&Q415A4     0       $US9V5415A4
M 0      !F%L=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB;V]L
M 0    AC96QL5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0    ]%
M4VQI8V5(;W)Z06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M
M#T53;&EC959E<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E96YU
M;0   !%%4VQI8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E=&QO
M;F<         "FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S971L
M;VYG          MR:6=H=$]U='-E=&QO;F<      #A"24T$*       #
M  (_\        #A"24T$$0       0$ .$))3004       $    !CA"24T$
M#      ,+     $   "@    5P   >   *,@   ,$  8  '_V/_M  Q!9&]B
M95]#30 "_^X #D%D;V)E &2      ?_; (0 # @(" D(# D)#!$+"@L1%0\,
M# \5&!,3%1,3&!$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# $-"PL-#@T0#@X0% X.#A04#@X.#A01# P,# P1$0P,# P,#!$,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,_\  $0@ 5P"@ P$B  (1 0,1 ?_=  0
M"O_$ 3\   $% 0$! 0$!          ,  0($!08'" D*"P$  04! 0$! 0$
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MW2P"=!M:WO\ R@H9;J1M]3(-'AM<!/W@JP[Z)^"/1;N3X/\ _]/U1OT1\$@
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M &( 90 @ %  : !O '0 ;P!S &@ ;P!P    % !! &0 ;P!B &4 ( !0 &@
M;P!T &\ <P!H &\ <  @ #( ,  R #0    ! #A"24T$(@     !2DU- "H
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M*  #     0 "   " 0 $     0   4H" @ $     0              2
M  $   !(     3A"24T#_0      "           _^$!4D5X:68  $U- "H
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M*  #     0 "   " 0 $     0   4H" @ $     0              2
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M P$! 0             #!00&!P(!"/_$ $D0  $# P$$!0<)!0<$ @,   $
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MX;='>_(Y+C(YF]CB-.)6L+R,#+R&ZB,X.%>_)9)&Z+:5T5P-PB%U>&U3B"9
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MP(#ASP> QA;$L"TVBAM+)&4$.Z#\:B7N>< 8 RXD@ <AR'0L] 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 5)>MI[=9JMM-6NE$KF!XTLR,$D?\%7
M:Y1\JGWCA_#-_J<K4C=.)9:MYI7,-M_;VR=I/_**?M[9.TG_ )17($6WEPY?
M4W=>_;VR=I/_ "BG[>V3M)_Y17(43RX/4W=?_;VR=I/_ "BIJ';2T5M9#30/
MF,LK@QN8R!DKC2M=D_O+;/Q#/BHG3C":^(O,X=T1$6#N$1$!$1 1$0$1$!$1
M 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0%5W&TNJ8C'#5/B8]^N1K]4@?\
MZ>+A@>@<%:(IB9CK"MJ5O&+*@V8FI#S48B+XY9(VQ@:GL P0<\!P'#CR5NB)
M-IGE%:5IP(B*%T55]FD]E2J*J^S2>RI4$47UT_M#X!2J*+ZZ?VA\ I4(:3MC
M9KY>Z]T+*6V.M<>#%(7Z:C...'%C@SCG!;Q](6VVR%U/;J6&35KCB:QVJ4R'
M(&.+SQ=ZSS6F5T%VJ[Q<J>6M%12MD$I%+5[A[6-8=$&G.6N+CJ+\\1CER6R[
M+RU'S)"RXW"FKJR!H9430<&AP R#Q/$=)X9ZAR06Z+ L]VI+Q3NGH'2NB! U
M/A?&'<,Y&H#(](6>@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@+E'
MRJ_>.'\,W^IRZNN4?*I]XX?PS?ZG+33Y8>([&FHB+=YXB(@*UV3^\UL_$,^*
MJE:[)_>:V?B&?%)X6IW0[HB(N1ZHB(@(B("(B B(@(B("(B B(@(B("(B B'
M.#CGT95-60U#ZV"5\6J1ND !NJ,>=Q.3Q!QC_P#:FL94O;;[+E%6T5+'33U%
M0VGT%S]VQK&_PY''\SQ]2CLL,D,TP=&X-< 7/>P-<79.1PYCTJ=L(B\YB)A;
M(B*K01$0$1$!$1 5%M!>9*2BE\DCE$P+AK?"[2W2,YY<?0>2O5\<UKVEK@'-
M(P01D%6K,1.9A34K:U9BLX:Z;O4.KFZ)6",20QB LPZ1KP"7<>(QG]"MC7@P
MQ&1LAC9O&C =I&0/6O:6F)XA&G2U<[IR^%[6D N )Y E?5JE[IXX*U[([8VI
M<]HD,LK7/)XNR >CDT#U^A;-2P,IX&11ZM#>0<XN(]&2IM6(B)5T]2;6F)CC
M^_!5?9I/94JBJ_LTGLJ54;(HOKI_6/@%*HHOKI_:'P"E0AI6U$].^_LHZC9
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MG/#B.O8EB6VV4-LC?';:.GI&/.IS8(PP./+)PLM 1$0$1$!$1 1$0$1$!$1
M1$0$6!65KF:?)P#B9D<FMKA@.<!PX<>:A\LJ=Y58?!NXP[+R"&QD$  G^(XR
M3CD1A6BLRSG5K$X6J*O;4SBV.FD='&\'@^1I:-.<:M//..A9%!)++2M?4-TO
M)/1C(R<''1D8.%$QA,7B9PR$1%"XB(@(B("Y1\JOWCA_#-_J<NKKE'RJ?>.'
M\,W^IRTT^6'B.QIJ(BW>>(B("M=D_O+;/Q#/BJI6NR?WFMGXAGQ2>%J=T.Z(
MB+D>J(JB2_0QWN.VOIJIN\DW+:@M C=)N]YI''4?-&<@:>C.>""^Q?/8MSZ6
MJ9J>8F5#F@1O>&:RT<=7T>G&GHSE!;HB("(B B(@(B("PKK<Z6UT^]K)0P'Z
M+1Q<X]0"K;C?RZH-#98O+*WDXCZN+TN*]6JP"*H\MNDOEEP/'6[Z,?H:%I%(
MCK=SSJS>=NEU^_M'[88IKCM$0ZOUT-LYBG:</E'^H] ]"V.CI8*.!L-+$V*)
MO)K0IE64%]M]?7RT=+,YT\>K(,3VM=I.EVEQ&'8) .DG!*BUYGI[+Z>E%.L]
M9^5FBK+9?;?<ZN:FHIW/EBR3F)S0X!VDEI( < 1C(SQ5FJ-1$1 1$0$1$!$1
M 1$0$1$!$1 51<Z2JJ-PYVEQCJF.:(W$#1GB7 G!*MT4UG;U4O2+QB6G"U5N
MEH%*X%GVDZA_U7[T'KX^:#SZ\+8+%!)3T<C9(S$UTKW1Q$CS&$\!P5BBO;4F
MT8EGI^'KISNAJ>T4 ??6NEA#V&%H:74KIQG4[(&.16V+5]I(6RU\S_,<(Z=A
MD<^,N="W4?.8<\^?NK:!R'2IOVPKH1B]_P"_**J^S2>RI5%5?9I/94JR=**+
MZZ?VA\ I5%%]=/[0^ 4J$-(^465]/4VZ62I#:/3(U\)N+J,N?YI#@YH)=@!W
M#D,Y6VVK^[*3_:;REWO1_C_B]?2M4VQ=6F\4SK7HAKXXY&-<:B(:X3H+CI>#
M_%@?ET@X6P;.>3P;,6WR7)I64D99I?O,M#1C!'TN'2.:"U155BO3+JZHC\EJ
M*6:$,<Z.<#5I>"6G@3C(!X'B.E6J B(@(B("(B B(@(B("(B B(@\O8UX >T
M. ((R.D'(*QS048WF:>+][]/S1YW'/'\^*REK>UUDK;M-2OHZD1MCR'-<XC!
M_P 0QTJ].LXF<,M:9K7=%<RNS0TIBW9IXS'C&G3PYY^("FAB9#&(XF!C!R Y
M+7A/M'0- EI::OC:,:HW:7GO7J/:NE8X,N--54,G5+&<=X5O+M/'5G&OIQW1
MMG[QC_O#8D6+1W&CK1FDJ89?0UP)[EE+.8QRZ(M%HS B(H2(B("Y1\JGWCB_
M#-_J<NKKE'RJ?>.'\,W^IRTT^6'B.QIJ(BW>>(B("M=D_O-;/Q#/BJI66S3R
MR_V]S>8F:?U2>%J]T.[HJ/YSJ.MG<GSG4=;.Y<N'I[X>'V"8[1S787%VI[-W
M'&^%KMR-.,,)Y<?./7R/!?:*P34^T,UUFN#JATC0S1)"WS&Z0,-=_",C) YD
MKU\YU'6SN3YSJ.MG<F#?"\14?SG4=;.Y/G.HZV=R8-\+Q%#12.FIF/?C4>I3
M*%A$5+=[]'2S>2449K+@[@(6?P^EQZ%-:S:<0I?4KIQFTK*OK:>@IW3U<K8X
MV])Z?0.M:]KN.TF1%KM]J/-Y^MF'HZA_[Q610V&2HJ&UM^E%34CBR$?5Q>@#
MI6PC@,!7S%..LL=M];NZ5^/>?]_IBVVWTUMIQ#1Q"-G2>EQZR>E92HMLKW+8
MK9'4P11RN=*(\/SC!!/1ZEIG]I%?_D:7O=XJ(K:W5>=2FG]/#J"UNVV:YTUV
MK:ZHJ:2>64EL+C&[,49>#H S@# XD<2<$YQA:G_:17_Y&E[W>*?VD5_^1I>]
MWBGEV/44;AL_9ZVBN=;67*HIZF2;+62,8YKF,U$A@!. T9Z!Q/$Y6P+E_P#:
M17_Y*E[W>*?VD5_^1I>]WBGEV1ZBCJ"+E_\ :17_ .1I>]WBNFPO,D+'G@7-
M!436:\KTU*W[7M$15:"(B B(@(B("(B B(@+"K[@VD, W;I-[*V++<8:2<<5
MFK%FH*>0 ;MK/WK9B6 -U.!R">M37&>JE]V/I5\E],4\L,E&]L@P(VZQEV7Z
M1G_#D\?4K"W5?ED+W&,QR1O=&]A.<.'/CTK$;8Z=HG&]J")7[PY?Q#\Y#@<9
MR"%G45+'1PF.+4<N+W.<<ESCS)5[;<=&>G&KN^J>C7MHHS+>(]41+&1M+7MI
M3+DZCD$Y'+AU\UM"UFN;0-N$[#9:J:8$.#VM.'N)/3GEZ5LR7XA70CZK2BJ_
MLTGLJ5157V:3V5*LW2BB^NG]H? *511?73^T/@%*A#0/E'M3YJVEK*>V44H;
M&?**J2A94R!H<SAAW'@W4X8SG3CI6U[/-J';,V]E4'051I6!^&M:6.TC/ <!
M@]'):Q\HE(:V[6F&&"6IFW<CS!B/=O8UT9(.MP'T@S(&<MU#AS6U[.TIHK!;
MJ5VL.AIXXR'D$Y#0...'=P08VR]C^8:.2G%7+5:W:S)*Q@>YV.+G%H!<3UG)
M5RB("(B B(@(B("(B".IJ(:6!\U3*R&%@RY[W!H ])*Q[A=*"W;KYPK::FWI
MTQ[Z0,UGT9YK%VKM0O.S];0B.%\LL9$6]&0U^.!Y'&.M56UMJN=VI9*:&DI-
M+HWPME\I='(T'202=!\TD'4SITCB>@-K1>86N9"QKR"X- ) P"5Z0$1$!$1
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MQ5%OJPUL54TC2YNESCJ.KVN*QV3'+M\^L]*SU^_1EMJXRT.(>-3PP9;TG_\
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M0=3^Y4B^)@WRO/G2#J?W*>EJHZG5N]7F\\A:XK:Q\IOR2836TS*T1$55Q$1
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M]L;1E[9998W1MR\F!^G4&M<6!V,.=AS> SS07CJ6G<S0Z"(LR#I+!C(Z5,
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M8.]X>*;R3L'>\/%!*BBWDG8.]X>*;R3L'>\/%!*BBWDG8.]X>*;R3L'>\/%
8J_LTGLJ58\QDDB<P0N!(QDN'BLA$/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>g802241g01l07.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g802241g01l07.jpg
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M(" @(" @(" @(" @(" @(" @(" */#]X<&%C:V5T(&5N9#TB=R(_/O_; $,
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_
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M&/\ O>*2_I[>GY523@RVWR/JBMOLQ^\>[ /QL;4_GG.^"\/DC^V/HB$?!87
M%P MS;/^4[Z]/Q0+O\_;C\&"^O+I_% D?!N+@"X N ;?'!YYC,;D_P 7VU?X
MD;R_,^4<'?')=%Z$;N"1< 7 "W>S7^6LZC?ZGQO\O[]X,(?6GT?K$$BX-Q<
M7 " /AC_ +WBDOZ>WI^54DX,MM\CZHK;[,?O'NP#\;&U/YYSO@O#Y(_MCZ(A
M'P6%P!< +<VS_E.^O3\4"[_/VX_!@OKRZ?Q0).44:</VR2C#AYQG. % $8/.
M X\YSZ08SGQC'VYSX\8Q]N>#<_&<9QG.,XSC.,YQG&<>,XSC[,XSC/VXSC/]
M^. ?. +@&WH<<2F)-4*#2B$Y!1AQYYQ@2B222@Y&::::/(0%E%@"(9A@Q!"
M(<B%G&,9SP>>#Q]8_5MI'9>L2[8F^-:*9N>7;273>NRC1+K3KQ@DSRDJ^SK)
M?G&I$B!<_(E"I$Q.%9)(O,"F\ BDR=PE#H<$ C#SE!PTG.5TG*-)*KK%9Y/C
M^: %%W0K&\'8O:4"T@IED3LEM7G)(KK[5E7,#='HX1!6=<<R19U+;V\M(RQ]
MM,B3*3,YD]J1)FEL]Y]?W9:6E*5K,#I3W8)S>*6-NW;TQU#AJHZH>JOJ1T,4
MV/V P6E+JEK&E+D5J6G9D*:IJK?I\Z(L!;ZLI".2!,)<<B :F&TQ=H1ITKM(
MSRG&6R3+4B$J*8!SN<YR^%M7@DF\N+KS8"#O1LQ7.TE\/T[IO7&I-6J@0>ZS
M5S5550R.1D:2/$J#!D/$[=V)O1&2N;.V,A4NBTX66QKQDMJ84J=&G,4+ATPB
MXJFVWJVV\>5Z!K?1/IE0&U^B<?V6W1H:K[59&>-,-(T47;\49Y@W0RD=>T;X
M5)G]E&^IE"=H#*[NE=TN3P)$43@UO:6,M8<H-08R4.;:-QFTFUJZM8OUPKDL
M:U;CHT=G?PN3J[IVI=H2Q1Q"I4?+G2)WTXK@UH1%9'Z,K%!4<D3Y(<I\!_:>
M$+(J68!_A3>YX!P6W-M_D_\ =^Y8G971MT[]D.N".VM/H[$:N-GC N<*JO:@
M')^1QHIT3C4)2T<IK!S7AC2I(WO:8;;+XTLCL7G#6:E7L^':..I1OLBJVDXN
MFVZ>*?+2ZOOZF>)G7BS<[)BU0*:2U-QAN\>O@6-*:,\@ZR@3L5<Y;"#PDX,-
M(%)PY3 /P1@0BO!GM8S_ &<#JWEN[VE7CAI>)IV5]U ]25(K*7J-PH*HAW4Z
M5^N1QEU7.DA:+)L\FLV*--EC3(@*"2IEJTX)CZSN,M/1^$Z<^2)@G8"!64$0
MXG*3MW*KXNE=TO4"F^).UQHW6#L+8H!0-<,=8Q%YUV@4X>F5B$X&$.DQ?YS:
M1#S(UI[FN<%BES<TS8VEK%)JC(CA) #%C(\C&,=.Q;<7;;^)Y]$4)1]@>Y6_
M,D6C+2X/TDDKNVL$?8VE*<N='E[>%I+<U-+:B3A&>L<'%>I3HT:4@ SE"@XL
MHL(AC#C(URS-*G1;H=ZZJ-H"CZ6VQIZE[@V]E,*>;$GADP?!*96[.)2IF-F3
M="V5,_HU+G!:K42:,PT]Z:FX:$:D] \N0TBR4$D"''+:2DVTVEDDFTOMB\\?
ML#P_$\:[Z5ZBS_5JCM5Z!KRG):]0^=6K9ZZ))UY;BZQYS>6V(URC/$M<5OMH
M@N4:L4\P(0 ^8/*2YP+]V%@0UV+D]YMMK!*VVN>?;Q+'NK;64KM<ZPM+]4;+
MB[Y%=--79K+I];TTR-<R3"_+L+LJYG-@J&JU98R_H]81&'640X6S902SW)WD
MCLBK^!":72.RN2-K\_/?W*;26[.4D_B=)<E25OKHN^35SYNCN$Z:NH9:KUKI
MB I'65PL>6*4U[J57,/6%1IV0^$YZ*P[#?'Z(,CS*23BC"9%@<HF,R1.A1Y,
MH3IW/W Y%5"<\=,<9/#MKCR5'!H;=;IW[_AS'7>;T"H3VR1&'-];V&YH)%8S
M:)C&ARF3N,IJ.VH$_2!>C7L(UZ,U<WII,R/AB;Y@\^/NT<2NIP!+C/95*^Z;
MKH\@)7MRZX'[K&VY>Z-$^+IA6<G84=CTM-G(@DEU?*^>7!S;"FZ1A1E%-X99
M%7EH=(^^B1%ID[D%(@D:=N:43^D;4HZ-G/?C>JP?7CW*ON"YL#]D\RD+!J3.
MX%!7 QML_9)YAFJ%7JTW^^M\OV/E#;59LE19\A" R 1:0R:QU)X\X+2M\/6J
MC/4$C(1#@6>.2Q?;3OEU8TW9K.EVIG6C94(H".NBJP'VNXIJ3K)!(HF.621;
M-[.(;J=@+3$D:8/N*'>+LB]5)D9>,! %/%SS1AR O)8A,<9*\KMODL65I: :
M0ZQ?#X:533<C<1X:U>PC]&D!5E2AI2D2!S83'D92B.ZZ4N1@987-R='8E,5(
M7@A2B1RA]1C=W=S00>,(5C8+RE+:R2C=:+[O\=:9@6_:'VEWSV?78;/+%4'1
M*J(HI<$E,TDUN)RF,U\Q*1X )<M,]"<N13Q[(*(,E$N4I23EA@"VYK3-4?0M
MK0D'1""@N+>;_-"MV/L+Q*GYDB\=;U+O()([MK"Q-*,'N+'-X>%I+>V-Z4OS
MCW%*U:H(3$ \X]1IH0^<>>"[=)MY+%FJKL'3\VTFZ2)YKQKY!9I95EUUI^11
M43CM3Q*032:22PIZR(JZDDT8(Q%FUQ>UZS$GE[[8SF<C;C"D!!#@ZJP$H$B@
M98XD]Z:<J2<K=X*LZQK3 SA8[U:=E4H>4#"UZ"[A%+W$\"=.:^:ZVO%FDL9@
ML!"-?()/%F=A:D^,YQ[BMS<D:4H/D1IP XSG ZW."QWH]FGY+$T1NG[5I\ZD
MNL1P;]MY@R15U9W6Q]CKBP)Z3.L=J=M7LC,6=%2'I(::@=%#/'XBA6N^64Q4
MWJI>ZO"!A5/2?*)R<1R3>_-M:TEST\P5SH(J<W?;NCMG<21,(RX?6LKN;:YS
M2+"@'(T]AVW,GTBN&%2,OU@ YMSI,'F9M@P#P7\U7Y@\&""'!9HVVCW=G&.K
M279)6UY+N7K.FUOZW/BC*WI1I<OF(KKEJO8]5_+$FX-1#G\N@H[=G"X@6,Y#
M\T% HA\8<RP>/960XPDS&#23<<&=5LK_ ,I+P5UUU[>8_P!\6&/U=G\9#Y\^
MWJG5 /'_ "^9M;!GC_W]7_'_ !?]N#78?(_W/T0Z/PV&B\( ]V7VL[2";XQK
MSJ.W2-;7+O)RLELRZQF!D,=)78@BS2S,KFVIXZ=Z6?*=.>8LG[VVFLIV7R&G
MI,B-M+*"S=77/)?>NA?3TD6_-^QG:/>7M+GC<X-,-7.+'J#JG%W#./,$IR)*
M"+&F+9@.!FE#=9*O<ZWD<I6HS3$QTN-D:1.H&WHF](@&6T6ZHPU2N75^VG(%
MS[>5$N[(N^":T'7"P*M2?;5;Z@0=09@:M)' PS#?&I\YK@E##GZ5')ZKL:3.
MN"L@RG;4ZO(O)I8S!C;9_!LM[K+[+QI!6/<9?3)T\]1T3I#5<1D"D<B2QO5R
MEG)M-"G?HLV*6%V=["LSYI,%.<.7',+2^*#I.0,ER)L2:-TIR,Q8 S(WY[F,
M%^I.WCG)^WF9G)AAAQAAII@S331B,--,$(9AA@Q9$,PP8LY$,8Q9R(0A9R(0
MLYSG.<YSG@["5VD&XUGZ#[+U_M-3S5#GZ>5VGEZ1L8K 0OKG#75--(7((.YD
M/K?&Y#%7E46F;Y$H<6\*1^0^R\(FY2?\RG(-2'BLHJ:IW7+/ D1V6]J]\]I<
MDJB57S J8A+M4+')X\PF5 Q35D [-\J7M#BJ"_XF4^G1JD2!2T!$UX0'-Q9&
M%[A[Y:D1I0B1$(*%TV[K/E96-P7-=^U\?KH[&M:ZJ#^]174VJ9WMU.$^?VZ0
M-FVB!\UVUW3JR,?L0'EQ=1L[(DPE/J-(6LC.L2%!, %06_/SS.%81;XM)=L7
M]O'/C6UW1UMNIN'?6M6O^AKC#T4[TX51K?*PULQDZR/-9$NS)7N':Y,B0Y"U
MNA:M_<SX=="GZ,Z";T2QIQ[JI:E3&!$H%H.*4G*Z:W557CF\7IAXEDEI02KN
MV[K6=XPJ3X:8QM11Z%U9L.I CG&L;*PG3O#'ET3Y* >5(JFM)H(1O[?@LH[Z
MG&W-I/#@!AQ>15-PE>L7IKQ[->0 _0_PVW8;L1 !6#!GC75O2(I=/*_D<<E5
ME29HET.G59S%Z@DUB<J9T]>.);8\LTB85Q0BBUJE.L0#0NJ%0I;G!&I.'2]M
M%:2XY+7N3LZ[N@S8_67M5TY;MHE]/OS)'4=@;/GL];2MYERM WT,IB:2).4@
M*=8E'4S:D6W#.JY):PC,5#=R6R1A()QAK4# *SVJE"56G@L>=WDWHF%Z;=;*
M[41BYZYUNTDJNFK6N)YK66W798[QFLH@T)@-9-$ECL'B1@G*)L[VY*9+8$K=
M9$3'$ D>4YK= )<I,,!E&#.1@DJMMI76"3Q\41Z76-WY&)30-FM/6HD6B#G!
M"A=?%[.*4L?C/I$:C3PAK-.#C/C.0 7$9SC&<8&'.?. J'&7^J_]%,^_/7+\
M1IV+-'Z%7;;NH$5J/"Y.YYI:H9]-877:UP1G!4(E4A K@C]+)AE"H+3JF])+
MY4^MC8N3$N+8@1+PY4B&D9[*.*4F^+2\L<":/P[VK;+H#UYWWL';+DP8<9U8
M%LSJ839@/-5L:BF-:S91"F1U:%RU*VJW"-JED<LN>QIR5I6_+G')<UKLHTH3
MO[0C:2WY*KJDDGQ>??1].16_UV:$[K4QVY:H]A^TF*];V??:<;$RMMC[#+75
MYFL<?[?UBNR]T<;E+,LC36A9Q,#*TJ6<](A=G AM5MQ3:EP8E* <$3*<7L]V
M-_#6+57C3:Q>KR]CQW?#H=;.]W<# X!5+W#T;L\5OK#59C8[+5XY*2DF[IL/
M+9#/T+"A;E %T+J^&5Y)Y+/758YM($ 38TRH,N#Y*&= H$[.:A!VF\6^64:3
M?-]=27?:-KK;4\TJD76]UV'P& :<=>L#;7K<RUI[*UL8;)9(X?%5=L**O1+V
M..O0)3*V%*65=]Y! G3)?TSF4"1C5)')*]M7!$))2WY6Y2;I+2]<\%FEW+A>
MMFJ6'K9Z@ZH%.$.&@^K==9/L?<P#L!3+B9(^L+Q<\Y0.1P@^!+(T0M%$2SA8
M%@"2/HR@>HLH'D4F]Z;=W;I<*R0-QUH]5FXFKG:GI#N1MV;6:A'LY-K_ ),V
MI8Y*79ZE*:RY]JW>%JFIY6TN,::DK8XD)?KJHX"=U<Q)WAN& HP[!.%.6.'G
M_7<UE.,H.,;P2S6#2:6%-ZUF68_$:Z37WV#V!U_:V4$O@[=(EY&V,^4F6'('
M"-1U29#&RA24Z(IP;F1_.,>1-K^_+$2/*#&#42)U.]\O"<01BFRDH;TGR6%7
MC>CKAY$3.I;J2W&ZS;(O9_OO1J"[CAL2(0-@@KI ;7H%9&XP6WNDA=9>!6BO
MAUA#R4YK#<Q8HA0WQ_*?)21:#*XT(@!S%\F_#[M$[3:*=;K<:O.UGTOAYA#N
MGZ_7?:NIY/:[II36=+-\:M"SJRPW2V(TG)RG@VI']1#I?*6>2PE*\1=QBQ$S
M:)3'$;JA=521<;&5[BE4&MBA$I/DS;:_Y7@G@WJKUH#(M'H6W_[&K(G>\].H
M=;H136T4L?K;IF+/4Q>(8YM%.2-R4CJ@I5&62N5K6UY/KXF.*R@)%)@5!"@I
M88$HY084 ;QVL8)1:DVL'26>N;O,\)_JH7:'_P!<U:_\LRW_ .7\$_KPX2\%
M[AG&BUP5-,)5N#M))+1KIM<;_P!E)3%(,0[36--JY+1>L(,Z_P!< "@7.92Y
M,W2>3Q*SK8;,JBRA*4MGX6E$ED*2\C'.TZBDG@L<,V\?2EV'"Z\Q!M O9S<0
M\6%0=J=AI8;7:[SC(1:^4!@- TR)%@/D(6>5EP:6V^VYP(7O_K64J_./F?&
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g802241g19p19.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g802241g19p19.jpg
M_]C_X1RL17AI9@  34T *@    @ # $   ,    ! N8   $!  ,    ! \
M  $"  ,    #    G@$&  ,    !  (   $2  ,    !  $   $5  ,    !
M  ,   $:  4    !    I $;  4    !    K $H  ,    !  (   $Q  (
M   >    M $R  (    4    TH=I  0    !    Z    2  "  (  @ +<;
M   G$  MQL   "<0061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD ,C R
M-#HP-CHQ.2 P,#HS-#HS,P     $D   !P    0P,C(QH $  P    '__P
MH ( !     $   +FH , !     $   /           8! P #     0 &   !
M&@ %     0   6X!&P %     0   78!*  #     0 "   " 0 $     0
M 7X" @ $     0  &R8         2     $   !(     ?_8_^(,6$E#0U]0
M4D]&24Q%  $!   ,2$QI;F\"$   ;6YT<E)'0B!865H@!\X  @ )  8 ,0
M86-S<$U31E0     245#('-21T(               $  /;6  $     TRU(
M4" @
M       18W!R=    5     S9&5S8P   80   !L=W1P=    ?     48FMP
M=    @0    4<EA96@   A@    49UA96@   BP    48EA96@   D     4
M9&UN9    E0   !P9&UD9    L0   "(=G5E9    TP   "&=FEE=P   ]0
M   D;'5M:0   _@    4;65A<P  ! P    D=&5C:   !#     ,<E120P
M!#P   @,9U120P  !#P   @,8E120P  !#P   @,=&5X=     !#;W!Y<FEG
M:'0@*&,I(#$Y.3@@2&5W;&5T="U086-K87)D($-O;7!A;GD  &1E<V,
M    $G-21T(@245#-C$Y-C8M,BXQ               2<U)'0B!)14,V,3DV
M-BTR+C$
M             %A96B        #S40 !     1;,6%E:(
M      !865H@        ;Z(  #CU   #D%A96B        !BF0  MX4  !C:
M6%E:(        "2@   /A   ML]D97-C         !9)14,@:'1T<#HO+W=W
M=RYI96,N8V@              !9)14,@:'1T<#HO+W=W=RYI96,N8V@
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M"58 4    %<?YVUE87,          0                        */
M G-I9R      0U)4(&-U<G8        $      4 "@ / !0 &0 > ", *  M
M #( -P [ $  10!* $\ 5 !9 %X 8P!H &T <@!W 'P @0"& (L D "5 )H
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M# P,$0P,# P,# P,# P,# P,# P,# P,# P,# P,# S_P  1" "@ 'P# 2(
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MMWM_D[O5_P#!$E->RS+]:VI[J/3VO>&-+O5].-K7;3[?YS\]#_\ 6=_] _\
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M7#A"24T$.@      Y0   !     !       +<')I;G1/=71P=70    %
M %!S=%-B;V]L 0    !);G1E96YU;0    !);G1E     $-L<FT    /<')I
M;G13:7AT965N0FET8F]O;      +<')I;G1E<DYA;65415A4     0
M#W!R:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %, 90!T '4
M<       "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U:6QT:6Y0
M<F]O9@    EP<F]O9D--64L .$))300[      (M    $     $      !)P
M<FEN=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#;&)R8F]O
M;       4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O;
M3&)L<V)O;VP      $YG='9B;V]L      !%;6Q$8F]O;       26YT<F)O
M;VP      $)C:V=/8FIC     0       %)'0D,    #     %)D("!D;W5B
M0&_@            1W)N(&1O=6) ;^            !";" @9&]U8D!OX
M         $)R9%15;G1&(U)L=                $)L9"!5;G1&(U)L=
M             %)S;'15;G1&(U!X;$!RP           "G9E8W1O<D1A=&%B
M;V]L 0    !09U!S96YU;0    !09U!S     %!G4$,     3&5F=%5N=$8C
M4FQT                5&]P(%5N=$8C4FQT                4V-L(%5N
M=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN9V)O;VP     #F-R
M;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N9P
M   -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N9P
M    .$))30/M       0 2P    !  $!+     $  3A"24T$)@      #@
M           _@   .$))30/R       *  #_______\  #A"24T$#0
M!    '@X0DE-!!D       0    >.$))30/S       )           ! #A"
M24TG$       "@ !          $X0DE- _4      $@ +V9F  $ ;&9F  8
M      $ +V9F  $ H9F:  8       $ ,@    $ 6@    8       $ -0
M  $ +0    8       $X0DE- _@      '   /______________________
M______\#Z     #_____________________________ ^@     ________
M_____________________P/H     /____________________________\#
MZ   .$))300(       0     0   D    )      #A"24T$'@      !
M   X0DE-!!H      T$    &              /    "Y@    8 9P Q #D
M<  Q #D    !                          $              N8   /
M                      $                         $     $
M  !N=6QL     @    9B;W5N9'-/8FIC     0       %)C=#$    $
M %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<   /
M     %)G:'1L;VYG   "Y@    9S;&EC97-6;$QS     4]B:F,    !
M   %<VQI8V4    2    !W-L:6-E241L;VYG          =G<F]U<$E$;&]N
M9P         &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E
M;F5R871E9     !4>7!E96YU;0    I%4VQI8V54>7!E     $EM9R     &
M8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N9P
M    3&5F=&QO;F<          $)T;VUL;VYG   #P     !29VAT;&]N9P
M N8    #=7)L5$585     $       !N=6QL5$585     $       !-<V=E
M5$585     $       9A;'1486=415A4     0      #F-E;&Q497AT27-(
M5$U,8F]O; $    (8V5L;%1E>'1415A4     0      "6AO<GI!;&EG;F5N
M=6T    /15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N
M96YU;0    ]%4VQI8V5697)T06QI9VX    '9&5F875L=     MB9T-O;&]R
M5'EP965N=6T    115-L:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/
M=71S971L;VYG          IL969T3W5T<V5T;&]N9P         ,8F]T=&]M
M3W5T<V5T;&]N9P         +<FEG:'1/=71S971L;VYG       X0DE-!"@
M      P    "/_         X0DE-!!$       $! #A"24T$%       !
M  (X0DE-! P     &T(    !    ?    *    %T  #H@   &R8 &  !_]C_
MX@Q824-#7U!23T9)3$4  0$   Q(3&EN;P(0  !M;G1R4D="(%A96B 'S@ "
M  D !@ Q  !A8W-P35-&5     !)14,@<U)'0@               0  ]M8
M 0    #3+4A0("
M                 !%C<')T   !4    #-D97-C   !A    &QW='!T   !
M\    !1B:W!T   "!    !1R6%E:   "&    !1G6%E:   "+    !1B6%E:
M   "0    !1D;6YD   "5    '!D;61D   "Q    (AV=65D   #3    (9V
M:65W   #U    "1L=6UI   #^    !1M96%S   $#    "1T96-H   $,
M  QR5%)#   $/   " QG5%)#   $/   " QB5%)#   $/   " QT97AT
M $-O<'ER:6=H=" H8RD@,3DY."!(97=L971T+5!A8VMA<F0@0V]M<&%N>0
M9&5S8P         2<U)'0B!)14,V,3DV-BTR+C$              !)S4D="
M($E%0S8Q.38V+3(N,0
M                        6%E:(        /-1  $    !%LQ865H@
M                 %A96B        !OH@  ./4   .06%E:(        &*9
M  "WA0  &-I865H@        )*    ^$  "VSV1E<V,         %DE%0R!H
M='1P.B\O=W=W+FEE8RYC:               %DE%0R!H='1P.B\O=W=W+FEE
M8RYC:
M      !D97-C         "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O
M;&]U<B!S<&%C92 M('-21T(              "Y)14,@-C$Y-C8M,BXQ($1E
M9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(
M        9&5S8P         L4F5F97)E;F-E(%9I97=I;F<@0V]N9&ET:6]N
M(&EN($E%0S8Q.38V+3(N,0              +%)E9F5R96YC92!6:65W:6YG
M($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$
M         '9I97<      !.D_@ 47RX $,\4  /MS  $$PL  UR>     5A9
M6B       $P)5@!0    5Q_G;65A<P         !
M     H\    "<VEG(     !#4E0@8W5R=@        0     !0 *  \ %  9
M !X (P H "T ,@ W #L 0 !% $H 3P!4 %D 7@!C &@ ;0!R '< ? "! (8
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M]7:CVL<[?%3'RV/>8G7Z#_8_V)*8%N3&GI%WA!_O1*FW GU-D&(V C7\Z9*
M,=S7!S<2@%IEI#H()Y/\RK+"\M!L :[N&G</\XM8DIDHV&&.((; .KN!YN4E
M&R?3=$3!^EQ_:_DI*:H<[T,,^K3)<P%T>UWM=[<?^4[\Q%K<3EW OK(#60QO
MTV_2_G?ZW^#0_=Z&)ICSN9/[GT7?T3^7_HO^#1*Y^U7?S40R-O\ .?G?SW\G
M_1)*9/R:&!I>\-#Q+2=)X_\ ))CF8HB;6Z\:JKGEKS2[<:R6ET%KB8]GTF-;
M^9_*59E>/N<USSN<T>VMCW:SJ]VYJ2G3^UXW^D:F^VXAXM;]ZSPS&(CUK--0
M=D #V[3Q_)3O9B;S^DL $0"PGGXC=]%B2G1KR<>UVVNQKS$P#.BJ.R,[T:[6
MV8I89:^PN<&[MVQGI_2^E]'Z7\XEB-QADCTWO+PUP(<TP=6[W;C^=O5H?9/0
M$>GZ&X1]'9NW>W^3N]7_ ,$24U[+,OUK:GNH]/:]X8TN]7TXVM=M/M_G/ST/
M_P!9W_T#_P#12MW^C%GT?6])WAOV?]5LW*K_ .L[_P"@?_HI)3__UO26_P#+
M%G_A:O\ ZNU&N8'"R:6VRP"#'NU/Z-VX?106_P#+%G_A:O\ ZNU&N9N+_P!&
MY\LC1VV=3[?I-VN_EI*15X]?J@G#K9!D6#:8C5CAIN5M5:]]0+F8UDNT+2]I
M.G]:US?SD>M[W3O860=)(,CQ]J2F:C8)8X !T@C:[@^3E)1L$UN&W?((V\3I
M]%)35%;O0PQZ-4M<PEL^UD-=[J?WG-_,1:VD9=SO38T.:R+&GWNC=_.#^3^8
MA>B?0PV_9A-;F$U[_P":AKAOW?X7T_HHM=<9=S_1#-S6#UMTE\;M-GYGII*0
MYC7.-3C2][P"1L<0&N]O/M_Z>U5O0;L+1AV 3)&[SW<Q]'Z.U&SOLS&TLM:6
MPP[&,<!]$U^UL_2VJL7X6V3ZD:<O;&HVQ_9:DI*S%#SL&.]H G<YY$Z]_:?<
MB-P=IGT08,AILT,<2W9M]RJA^ ('Z1H;JUV\1J>Y_-^C^<I[*2UL49!9M!!'
MN!Y>/H[OWTE-ZFG9;/V>NL 0'L,F!P-NQB&*G_86L]"G<+ ?2G]&/TD[FF/I
M?G_\8HX=3*\C2JUNA]S]6R8*L?8\;T!C^F/1:X.#->0[U?\ JTE([VGU['^F
MR/0</5G]),_S>W_1_G(/_K._^@?_ **5J^BK])D;?TOI.KW?R?I;?\Y5?_6=
M_P#0/_T4DI__U_2 2.K6D DC&9H.3[[?%2R\JBIQKL%A+VCZ!(T]W!:YNQ,W
M_EBS_P +5_\ 5VILS!?D6BQKPV&P 1(D;O=_TTE(CE8;7 Q?N; CU'<?2!>/
M5V_G?GHHZE0Q@ 8^&C0&)(']9_\ U2&>F7:Q8T Z\'4QM.[7W?G)OV9=/\XR
M.>"==?=J[Z6J2DQZG0&[MC]!,0"=!N_>4V9=.2U[*VN>-A,<;@9$-=*K,Z7:
M'#]* V==H(,>#=5;Q\1E#RYKG.D!L.C0#X )*0BIOV?";]G=#',(9N,U0UPW
M/=/Z39]%%J8!F7O](M+FLFTF0^-VC6?F^FK"22E)( Q&"/TENG_"._O2^RMU
M_26ZZ?3<DI.D@?9&?Z2W_MQW_DDCB,/-ENO_  CA_%)2=!^UXOH^OZU?H@[3
M;N&V2=FW?.WZ?L4ZJA6TM#G.DS+R7'[RA?8JOLPQI?L#@^9]TA_K:N_K)*27
M_P Q9_5=^14O_6=_] __ $4KM_\ ,6?U7?D5+_UG?_0/_P!%)*?_T/1G 'JE
MX,@'%8"1S].Y3^Q&(];((T_/'9-E8V6<EU^,6'U*O1>'ES"V"YS7L>QMG^D=
M^:JGV'K4 &]LZ:BUX_\ 1;DE-S[&[;'K9!/B7CQ2.%KI;D >&\'_ *J53^P=
M9_TXXY]5WCS_ #*=F#UAKPYUP>T<L-SP#_:94UR2FT[$),>KD-D%HAXX^ERG
M&'+H-UXF2!O['\T;?BJUF)U5P 86U$&=PR+7:?N[7U[46NKJ=;BYM=1)T]]]
MK_NWUE)2;[#)_I%T'D;_ #W>'M_LI?88U^T7>8W:1]RCNZO_ */'_P"W'_\
MI)+=U?\ T6/_ -N/_P#2*2EAADP1;D1 _/'$0I,PPT^Y]]@B-KK-/C["QRI#
M!ZT!'KM\CZK_ /TFG&%U@.DVM(D2WUK-?$;O3_.24W_L]<1MMXC^<=QS_I$Q
MQZXU%NI_TKO_ $JJWV;J/[C/_8F__P @HOQ.J.:0S96[L\9%SH_LOKVI*;U=
M3&/! L!,@;GN<-=?HE[_ -U&6=73U2LAP94YP$2^^UP/\K8ZO:B[NK_Z/'_[
M<?\ ^DDE-B_^8L_JN_(J7_K._P#H'_Z*4W_M=[',]/&&X$3O>8D?\4B_8_\
M)WV'?_@?1WQ_)]/?M24__]DX0DE-!"$      %4    ! 0    \ 00!D &\
M8@!E "  4 !H &\ = !O ', : !O '     3 $$ 9 !O &( 90 @ %  : !O
M '0 ;P!S &@ ;P!P "  0P!3 #8    ! #A"24T$!@      !P (     0$
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M    !@(# 0             '" 8%! D#"@(!  L!   & P$! 0
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M=&9L?!MW Y[:\N.6J^Z,6+JZR)8U>1Z8J8YM]:(^6?\ 5]O1&NE?YCW\[/\
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M9?\ +JR>Z7^)?6/7>\OG-M^3Y,;6V[N3I[LC=W5^W>[=[_'WI?&Y?K00=_\
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M64T$BWBB6#W[KU:FO08]*_R7O@3\;M_?'?LWH#K?+]/[R^/'7&]>I:;*['W
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M'IS&] ='Y_+YW;&5:.3*3;DZLW?V--NEJ-1;+8>*KHV=&2E9?=; !7Y])3Y
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M?_*)AHCU-Q[]U[J10]B=?Y/<%'M/&[ZV=D-TY#!'=%!MJAW-A*O<%=MD5<E
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M^SBD:HUJ1HN#[]UZA].A0]^ZUU[W[KW7O?NO=?_2W^/?NO=>]^Z]TV9;,8C
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MHG%-3U.;RE#BJ>>I,<DHIX9J^>G26<Q1LVA26TJ3:P/OW6NDV>V.K5!)[*V
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MCV[V+D<=BL/D=]=D=-[!WENRMQ6#CEAPV-JL_G\%79.>CQ<4[K3Q-(4B5B%
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M>O=@]=[BWGA<54MEH</)-M[&8O(9['X^JG-0(;RI$[:[ F_OW6B2>/2%WO\
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ML J(H  '  ]^ZMXC_P 71CNC?C#\<OC'C-Q87XY]$]2]%XC=V4ILYNG%]3;
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M"9.9*&,5YBIO=6#C\_\ 5QZ'/Y9_&[MG?F[OGY03?#WO_LSY[?(+OCI'?O\
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M+?/3JGXU=S?!3LKXTY;<%+VQVO\ RR/EIA,](^<^771>Z_D'3?*SJ+;_ /,
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M!%AXGAS G3&Y7K_=E?0Y.,/_ +E&J#/5&6H591[JVIO7H3=A=$=9=9]B=O\
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M^@IW^29_WE+N7_TG_OO_ .UU[]U[P9/3^8_S]>_Z"G?Y)G_>4NY?_2?^^_\
M[77OW7O!D]/YC_/U[_H*=_DF?]Y2[E_])_[[_P#M=>_=>\&3T_F/\_7O^@IW
M^29_WE+N7_TG_OO_ .UU[]U[P9/3^8_S]>_Z"G?Y)G_>4NY?_2?^^_\ [77O
MW7O!D]/YC_/U[_H*=_DF?]Y2[E_])_[[_P#M=>_=>\&3T_F/\_7O^@IW^29_
MWE+N7_TG_OO_ .UU[]U[P9/3^8_S]>_Z"G?Y)G_>4NY?_2?^^_\ [77OW7O!
MD]/YC_/U[_H*=_DF?]Y2[E_])_[[_P#M=>_=>\&3T_F/\_7O^@IW^29_WE+N
M7_TG_OO_ .UU[]U[P9/3^8_S]>_Z"G?Y)G_>4NY?_2?^^_\ [77OW7O!D]/Y
MC_/U[_H*=_DF?]Y2[E_])_[[_P#M=>_=>\&3T_F/\_7O^@IW^29_WE+N7_TG
M_OO_ .UU[]U[P9/3^8_S]>_Z"G?Y)G_>4NY?_2?^^_\ [77OW7O!D]/YC_/U
M[_H*=_DF?]Y2[E_])_[[_P#M=>_=>\&3T_F/\_7O^@IW^29_WE+N7_TG_OO_
M .UU[]U[P9/3^8_S]>_Z"G?Y)G_>4NY?_2?^^_\ [77OW7O!D]/YC_/U[_H*
M=_DF?]Y2[E_])_[[_P#M=>_=>\&3T_F/\_7O^@IW^29_WE+N7_TG_OO_ .UU
M[]U[P9/3^8_S]>_Z"G?Y)G_>4NY?_2?^^_\ [77OW7O!D]/YC_/U[_H*=_DF
M?]Y2[E_])_[[_P#M=>_=>\&3T_F/\_7O^@IW^29_WE+N7_TG_OO_ .UU[]U[
MP9/3^8_S]>_Z"G?Y)G_>4NY?_2?^^_\ [77OW7O!D]/YC_/U[_H*=_DF?]Y2
M[E_])_[[_P#M=>_=>\&3T_F/\_7O^@IW^29_WE+N7_TG_OO_ .UU[]U[P9/3
M^8_S]>_Z"G?Y)G_>4NY?_2?^^_\ [77OW7O!D]/YC_/U[_H*=_DF?]Y2[E_]
M)_[[_P#M=>_=>\&3T_F/\_7O^@IW^29_WE+N7_TG_OO_ .UU[]U[P9/3^8_S
M]>_Z"G?Y)G_>4NY?_2?^^_\ [77OW7O!D]/YC_/U[_H*=_DF?]Y2[E_])_[[
M_P#M=>_=>\&3T_F/\_7O^@IW^29_WE+N7_TG_OO_ .UU[]U[P9/3^8_S]>_Z
M"G?Y)G_>4NY?_2?^^_\ [77OW7O!D]/YC_/U[_H*=_DF?]Y2[E_])_[[_P#M
M=>_=>\&3T_F/\_7O^@IW^29_WE+N7_TG_OO_ .UU[]U[P9/3^8_S]>_Z"G?Y
M)G_>4NY?_2?^^_\ [77OW7O!D]/YC_/U[_H*=_DF?]Y2[E_])_[[_P#M=>_=
M>\&3T_F/\_7O^@IW^29_WE+N7_TG_OO_ .UU[]U[P9/3^8_S]>_Z"G?Y)G_>
M4NY?_2?^^_\ [77OW7O!D]/YC_/U[_H*=_DF?]Y2[E_])_[[_P#M=>_=>\&3
MT_F/\_7O^@IW^29_WE+N7_TG_OO_ .UU[]U[P9/3^8_S]>_Z"G?Y)G_>4NY?
M_2?^^_\ [77OW7O!D]/YC_/U[_H*=_DF?]Y2[E_])_[[_P#M=>_=>\&3T_F/
M\_7O^@IW^29_WE+N7_TG_OO_ .UU[]U[P9/3^8_S]>_Z"G?Y)G_>4NY?_2?^
M^_\ [77OW7O!D]/YC_/U[_H*=_DF?]Y2[E_])_[[_P#M=>_=>\&3T_F/\_7O
M^@IW^29_WE+N7_TG_OO_ .UU[]U[P9/3^8_S]>_Z"G?Y)G_>4NY?_2?^^_\
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M_P!;O?NO=>_T5=7_ //M]A?^@?M[_P"MWOW7NO?Z*NK_ /GV^PO_ $#]O?\
MUN]^Z]U[_15U?_S[?87_ *!^WO\ ZW>_=>Z]_HJZO_Y]OL+_ - _;W_UN]^Z
M]U[_ $5=7_\ /M]A?^@?M[_ZW>_=>Z]_HJZO_P"?;["_] _;W_UN]^Z]U[_1
M5U?_ ,^WV%_Z!^WO_K=[]U[KW^BKJ_\ Y]OL+_T#]O?_ %N]^Z]U[_15U?\
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MW8=!@:Y?CQAXLAC&R$L$ZU-48VB9T*;KUO70<,]!-N#^3)T>>D_CIU%U]O\
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M>>!VWB]F9:KP<.^*_95'T:NRMR8IZW)39.IRCG[Z601UM$_L=>[*=0*_8O\
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MO=>]^Z]T#7R,_P"R>^]__$-=H?\ O$9SW[K8XCJHC_A,]_VY'^#O_AN]K?\
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M+A1[KPTT(/1!NX_Y;7\R/L3JN@Z<S'R7@[=V#7)U:<M@^S^[]^BICWOBL/\
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M -T]'[]TUTK??NO=>]^Z]U__T-_CW[KW7O?NO=:\G_"IW_MR9\I?_#EZ _\
M?]==^_=/0?VB]7N]4_\ ,KNMO_#!V=_[SN.]^Z:/$]+[W[K77O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW6NG_ ,*J?^W+GR"_
M\2-\<_\ W^>Q??O(].P?V@^P]7_[!_X\397_ (:6W/\ W3T?OW372M]^Z]U[
MW[KW7__1W^/?NO=>]^Z]UKR?\*G?^W)GRE_\.7H#_P!_UUW[]T]!_:+U>[U3
M_P RNZV_\,'9W_O.X[W[IH\3TOO?NM=>]^Z]U[W[KW7O?NO=%%[6^5@ZH[ W
MGLG(=7;MSE-M3:W06Z,?F,!5T>6K=Y)W;W76],5F&VUM7%PY'/R9G9-;'35K
M1U$<"9):H11.@CDF'NM@5-.C"===A;4[6V3MSL+9&2_BNU]U8\9#%5C034DX
M599:6KHZZBJ4CJJ#)XROIY::JIY562GJ87C<!E(]^ZUT];FS<.V=N;@W)41^
M:GV_@\KG*B(RK!Y8<505%?+'YG5DAUI3D:B"%O<CW[KW1 .O?YC.S]\T/3%;
M4]6;YVX_8GQR[![W[$QE5682OR_3&Y-@4>QZN3HW<%!23A\[VAN(;FKWQ]/3
MF%)Z7$FH'[=73:O=6*D5].E]A_GOTANGLCK78.SJG*;BB[/W1NW8>V\VF,R^
M.?-[WVGLO8?8==A-HX7(8J&NW=C\5L_>SUF:RE.R8W!+C:I:F75%*(O=:TFE
M>E,GR_V&?D6GQD.-R2]BMV'7;+:$M*:5,+2=!T?>D>]#5"A..-!4Q5JX@48J
M/O5J1YBGA]^Z]0TKY=-F\_F-@-D?('(=!9?8V?6O9NA:+:.[SDL9%M_>NX^Y
M-]97;&X=HXN)BU;2[DZOVK10[FK()E"9'$32FE<R4LZK[KU#2OET(^^^Z\SA
M>W=J=)[!V+#OG>>7VE5=C[H?*;KCV7AMH]>4>X\=M;^+K728+<$^X,]D<O6R
M+28Z"&-&2DE:HJ:8-!YO=>IBO02UW\PCXVXY()*C+;Y89#%;NW=@TI.M=YY"
M;<?6&QL-D<WN;N+ TU!B:FHR'5E%#BY*>/+!56JK7@@@222JIEF]UO2WITH*
M+YJ=/2[KH]E5[;CI=P5F]ZWK^HAI-M[@KJ#:FZ##E)MMX#L;,R8FAQ&P\[O#
M^!5R4,59-]HTE*P:J"O&S^IU[2WIU/Z[^9_1G:&Z-F[0VIDMT2Y;>V+IZRBE
MR.S<_CL1B,Q5Q;WJ:79.XL[4TBXC%;YJ*;K;/R)C3,\ACQ<C7M)3^;W6B"./
M2$[X^<&#Z'WQW1LG,];;GSLO5WQBJ_D'M?(8O*8F)>V=TT%7O*&KZ*V?05!^
M]3L!:';V/K(Y)%:E>ERIEX2BJF7W6PM0/MZB[Z^;@V)D=F3U_5M34[+R/3?5
MO=/86YXMYT'W^Q<#VMOO'=?XNCPVWH,)5KOJJP65R!JJ]HZR@!H8F:E6IG*4
M[>ZT!4T'1\_?NM=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U5G_ #3<5/O?;WPLZ1R&X]XX3K?Y"_//
MJ?J7NC$;'WCN78&6W[U?)U=W?O[)["K-W[+R>"WCB,!G=R;"Q;Y 8VOHYZRE
MIWI9)#3SSQR>ZLOXOLZ"[K?XW]9_"C^9'\?>N_C=)V-LCK;O[XN?*;-]L]>Y
M[N3MWM'9VZ=S].[X^-@ZXW=3XCMC>^]UV[NS;5#V+FJ/[W&O2/5T-<8*D2I#
M3^+W6_B5J_%4=7.^_=4Z][]U[JMK^:959JJ^/'777^-W5NW:&#[O^8'PTZ&[
M(KMB[FS.R=UY;J;MWY'=>;,[-VEB=Z;9K<9NO:?]\=GY*JQE178JKH\C'254
MH@GB9M8]U=.+?8>BMS?%7J+X-?S!?Y?%'\75[*ZVP'R#K?E#UYW7M*N[N[G[
M)V;V)MG970>:[*V3%E]L]K[]WSB<?F=H;RP$55CLCCXZ.NABEJ:<RM35$L1W
MUZI96KU>3[UU3KWOW7NJ^/YK/86_.JOY<_R_WYUEN[,[!WWA.F=PIMW>FW)X
MZ3<.V:K,34>#GS&WZ^2.4XO.4=%DY6HZR,">CJ-$T3++&C#W5E + 'AT1'Y"
M_"?H3X'[_P#@GVY\4:?MCJS?>X_G=T!TAO')5'R*^0G9&+WSU)VNNZL!O_9&
M]]L=L]G[\VON6@S\4,%4*FIHVR%+E*:&LIZB*H0NV^M@DU!].K]?>NJ=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW5-G
MQV_G/?'[M'I_.]X=TKM/H3:'^DOLCKW9VW,-V1/\A.V)8NH9=[5/9N=[:ZOZ
M@V)D]Q=(TNP]I;*DW+FI,C]WC<+MJJAR&0KJ6$^_=6*D4'GU8IT]\H.B^_MW
M=N;)Z>WRF^\WT3N7&;-[2EQ>WMUP;=VYNK,86DW+C\#3;PR6#H=I;FR,NW<A
M2U[)B:VN$5'64TTA5*B!I/=:((X] '\E/G[L;XW?)3XT?'+*;*W%O"O[WR]!
M!OK=^WZVB3&?'_;&\]Z;?Z>Z>WKV!CJB%JNKP/;7?N[L7L['-3NGAKJB2:4Z
M(M+^ZV%)!/3C1?S*?A9D]Q=K;3Q/<C9;<'2^"W!N??5#C.NNU:^/^[>U.TYN
MC]S;AV?DJ78\F)[)P>W^WZ2HVY6U>W)\K3TN6I*F"5T:FG\?NO:&QCCT$E5_
M-U^&6"K\IE=U]M[.AZORVT]@[VZBWOL5.S>U<[V1MG=72V[^_MPYO(]?[(ZH
MR&2V3B-G]8;)R&8EJ'JJ]3C:&LFJQ0/220^_=>T'I;=C_P T3XC; J,92XO=
M&\.VY*SY*](_%+)S]*==[O[*Q6VNV>_<3B-Q[&H\OGL%C),'5X]-JY^AR5;_
M  RHR%9#35L 6GDEF2,^ZT%)Z.]V'OW:?56P-\]H;]S$&W]C=;[/W-OW>>>J
M@YI<)M39^%K=P[BR]0L:O(8,;A\=-,X4$Z4-A?W[KP%33JFG9?\ /#ZOK]N_
M'/<_;/179?1]%VSN7Y/[3[EQ&X1EM\;R^-F7^.G4N"[[H#N;9_6&S=WYG>F-
M["Z2W3C-T_>8](:7!8:K^XK'*12E=TZWH/1L][_S3/A_M6F>JVQN_=7<]/1_
M(SI#XM9FKZ.Z_P!V]EX;!]L]_56WDV1CJO<^$QAVQDJ6#&;IH*^N&-K*^KBI
M:N 1P2SSPPR:ZT%)ZP;Z_FB?$[:%?DHH.T]EG']=]G9/K_OU]WU6^-B[AZFH
M<9TYW#W)+N&DVC7]=9',;V$V"Z9RCPQQ"BHIZ.EK)XJUY:5:2H]3K>@]&BZ
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MO=?_U-_CW[KW7O?NO=:\G_"IW_MR9\I?_#EZ _\ ?]==^_=/0?VB]7N]4_\
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M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=:Z?\
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MY_[IZ/W[IKI6^_=>Z][]U[K_U=_CW[KW7O?NO=:\G_"IW_MR9\I?_#EZ _\
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MWN;X][FW9U_09NAVWFMX[%HNW=E[2CWM@MM;CRE)0Y23&/4MC:BMIEJ5B%3
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M+&CCW6P:&O1$-@_RL^M]M=C=5=B=E?)[YP_)Q>E-UT?8/6NPODM\AJCL7KG
M]D8?%UV&VOV'5[;H-K[:DW)N[9]#E*DXRHRE36QT]5,:PQO6)'4)[JQ>HII
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MZ<9.DHL:M56UM#YJN)?+%&Z7D7GGW[KW7&IWCM*CRN)P57NG;M-F]P9/(X;
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M>]^Z]U[W[KW7O?NO=:Z?_"JG_MRY\@O_ !(WQS_]_GL7W[R/3L']H/L/5_\
ML'_CQ-E?^&EMS_W3T?OW372M]^Z]U[W[KW7_T]_CW[KW7O?NO=:\G_"IW_MR
M9\I?_#EZ _\ ?]==^_=/0?VB]7N]4_\ ,KNMO_#!V=_[SN.]^Z:/$]+[W[K7
M1?.X>GMT]I;VZ4R\.^Z#%=?]8[T&^MV=:9#:U5E:/L?<.+EQTVQLA69^AW/@
MJK%CK^MAJ<C0TKP5M%/F&HZNHB<T$4;^ZV#0'H<L5#DZ?&T4.9KJ7)Y6*G1*
M_(46/?%4E74@?N34^.DK\F]%$Y^D9J)BO^J/OW6NG'W[KW5;W?WQFV/W=V%N
ME:KN;"[1W1OK+8_"XW9>ZL!B,K%7R;<ZMW?LW)YG:^WZK<^!R&X]W[8QF_6R
M^WLL@D&W,Q1M-X:A'EC]^ZLIIY=0>\]A[-^4F)VS@.N?D^E&.FY-U[5IL=+E
M\/53;^[#VYLO:6YFRL'8FN',5>1Q&V<A]KG*Z@.0I8J7+UIF@6JA#1^Z\*CR
MP>B\[1^$F K,;TU!/WSTWC,-!U7G<KF<UUX,12Q[;S6T9_C5C\UN/XWTD>ZI
M:3861I'Z1JY-S;S2:O:HKLE.9:&G,R"#?5BW'!Z6&9^+'1^ GV/M[;/R)VMM
MB3LS9T&U.H<CL':N%KMZ1;UQW4!P>%WMA<_A=R5*S].;9W!UVV^_X-+!_"?[
MXPR5%37NDS0-KK568$4QT*W1O4_QW^(F?[,[ES'R5VSF<-N#9&4[#GR^ZM\T
MM+2[=V+N++8;<6^=SQK%O&?;=3UO4[\AEK\54_P[_<*F4FHH:UX'TM[K1):@
MITGLO\&NE-KT4M+E.Z\#UM7QTV]<QLO<VW*?:/7^[=I=:YCLSNWLO>SX#-_Q
M2(T4>5J^_A2Y_*TD5/1UT>/I'J8-4S#WNO6]1/ET)N"Z'Z<VUTKB?C/F.Q<!
MN>7&=F]=]F=AX^GJ/XQ%62X_?^$[9A&=V5F=V[@;8NQ]V?W4C'BC>'$TZRM)
M30!&\9UU6N:@=!?TU\>>J=K]=[^Z^ZW^8E1D-_-O"#9==OW%[[I\P)MU[BV-
MB*C:V"[!V!D=VY?8>\][Y?K:L6:18Z2D?)+5G)+ *V.*JB]U9B<$CHO#_""D
MQVP.W\!@?D!TMN%8NI\5MG96Y,WD\3!F,[M7*XC;FS,MD.W=SQYW)U#=-[?R
MF*K*?%;:"RTT]=0T[R9$2!XEWUO5D8/0P;3^*/5&Z*':':V%^2%#A=K]LY?$
M;CV)61[:BV+7IE9LGN%L7U9TK%GMT0UVS_CWN [@,\NP4@KGKLA%%5BM_<DC
M?W6B:56G4O=_Q%Z#VOD^N-A2]M8';F=[0R78.*V?6R[,Q52F6W5NKJ?O+8/8
M67P^=@RD%/ANS=V8'NJ-XJQJD5>1;!0TS)5H2D.NM:VZ;L9\/_CYO[ [4RG7
M7;R=?;;WEO#=5#AMGKA(^O\ "]I5=#V7V'N*MVK6;8@S>UMQYR38V!W%7XC!
MFC>FKL&M!%74C1J@0[ZWJ8<1TN,!\,.CNM&VC40]R[+CEZ>[&ZAW#FY-VTFU
M:UGW[MGLGLK=>#R6\*W*[A;)0=F[GVUV[-@J#+UD[YDB"GF\E2))(']UZI]/
M+IX[P^+W4/>G9^]<[F>_-GP4W9E!FNNZS;%7_=;<&Y(=Q;:ZRW7L/.]<83*5
MVXXHI.N4H=U_Q[<^RI,=.U7F:*"KEGIT+HVNM!J#AT*?R+Z0ZV[;W9\=,^W<
M&#ZSWCT)E=\;UZ6BI)-M52MO2KZSJ<!0YR/;U?D:6EW!@]J[0R]3/58P0R0S
MXZL,BO2RQTU7#[KP)%<=%MC^*_07:>S=A9W8'R.Q6-WUN;*]M[]ZA[PQ-1B,
M_7Y;>W;M#NO>NP=V]'0[GW3EJ2';/4-?V-45^-PN(=L56.]7]U%YJNKG?W6Z
ME:XQU@WGT#U)U/U1V)V1US\I:'K;JFAW"_\ I%W!LB"'-5^(-!WG1]H;6V[L
MK=.T]ZXG([:[ AWKN2NQ-7'/+6X_<#9\C(XR20*6]UJI)&,]#MWAUMMGM3>^
M=W+)WMM#JY.Q/CCN/H#=FRMY8K#R[IHL;O3.Y2JVWNC"M4[UP38S+P;@2> 0
M5-+7TF2CB9(6C<>3W[KP-!2GGTM>L^I]@;9W_G?E)OSM#8^^=T]BXK8.V\+N
MF@J$P76F RF*PK[*K*GK;'Y+>>Z,319KL!Q%3U%0E1/E9XXDH34S4Z)$ONM'
MTIT5OL'XQ]);6SO:_;F1^1&Q]J[7P/;&X>S-^G$X+;PWGU]GJK?6 [IS=-M+
M<&&W/3UNT^X-PY+:D^-JLC_#ZG*97;\D5']J\]/'4/OJU3@4Z7GR/^/&Q.X=
MUY+?M9WJG3>#WSM?IO.9JDJ\5'B=O=AOM+<];5[!Q?9&<W%N7'5=7@ZF'+5M
M$,#B6P$U6]4LM9)5RTU*L.NM G  Z#7</Q0^/\W8&X.L<3\C<EL7<:9#>&_.
MU(\+)!'GLWMOLR@PO773VRMY]GY;,UV4.5ZS[0VYA<QMJ')UM3DZRJH$@,3P
MU$[2[ZWJ:E:8Z&W'=![%PGQCS_QMV[\B-M8/(U&^J3$=@;I@K\9EZ:MW3N/<
M=)59CK^MVIN;=^=;9K[[@IVHOX1C:S'RP23R-01P,VGWKJM<UIU'ZTV7U1\7
M^O>[LUG/DU19/8==M[:FS-TY7!U^'I-U8GL?977 VGN;=LNX:3+[DW/5]T;S
MQ6-HYAB:1H*6CDQ\+4&,CGEJI:CW6S4D8ST$>WOA-M/:]'28;$?*C:6(K,YN
M3:?668H,;@,)C\=D&Z_R_4>XY=O[5VT>P'3!][[RK.J*2HW=DV:NFRLV1GF_
MAM.Z4QBWUO5YZ>C\?%[&=58;H#J[%=)[GVSO7K/'[;CH]N[QV>V.?!;JDIJR
MKASFX8)<5-44,U9EMQ)5SUCK)(SUCREV9RQ.NJFM<\>A\]^ZUT0KY^='=U=O
M[4^/F\_C[1;"W%VC\8?E'UY\D\-UYV3N7+;&VMVICMK;4["V'N/8$O8.&V[O
M&KV#ELAM_LFHK,?DWPV5ITKJ&*&>G\,SS1>ZLI&:\".@PZIZX^9?<7S.ZX^3
M?R6Z>Z9^.NS.B.B.Y^J]G;+Z][VS?R!W;V-NKO/=G4.<RNX,SF:GI_J'";,V
MMLO"]1QP0TR19&MR5=DF<M3PTP%1[KQ( (!KU:)[]U7KWOW7NB5?/;HGM#OO
MH_ XSI2HV:>V.JN]?CW\BMAX/L3(Y7!['WOG?C]W!M#M1>OMS;EP6*S^8VE0
M;WH]LS8Y<M3X[(MCIZB.=J6HC1XF]UL&E?LZ+=@.M_G'\BOE]\5.[OD+T9TA
M\9^MOB?%WAN:&@V9\B<Y\B-Z=J[P[@ZUFZJQ.WZ>G_T)=.X38FW-IXG*UV2K
MJZ:HRE175*TM/!3Q1F><;ZW50" :UZMF]ZZKU[W[KW12_G=\=L_\L_AY\B/C
MEM/<V)V=NSMKK+/;7VKN;/T-7DMOXG<SI%7[?FS]'CY(\A+@I,O10QUIIR:A
M*9W>)6D55/NMJ:$'HDN^.O\ ^8=\O=]?%3 ]X_''X[_&CKCHKY-=8_)G?F_=
MI?*?<?R W!N:;IZAW%/B>NMD;"?X[]10TC;SW3EZ8RYC(Y=%QF*@F(HZFJDC
M1/=6!"@T)K3JX[W[JG7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=:Z?_"JG_MRY\@O_$C?'/\ ]_GL7W[R/3L']H/L
M/5_^P?\ CQ-E?^&EMS_W3T?OW372M]^Z]U[W[KW7_]3?X]^Z]U[W[KW6O)_P
MJ=_[<F?*7_PY>@/_ '_77?OW3T']HO5[O5/_ #*[K;_PP=G?^\[CO?NFCQ/2
M^]^ZUU[W[KW7O?NO=>]^Z]U55N#JSXR]@=O?(3/9C.;OI\C2[PVYL+>._JS%
M[0VSAMD;DIJC#=E[FV_LK?F6&/W'B:['[7QM/)EJN(J(J"N6>FDF,<C0>ZWF
MGRZ!K'_"SXR5LFV:[$?)/JS?6_\ L[KW?FU.I*;,TG76*P&X9Z3857U[LK,]
M887:-12IB]P;3J\+(^9R-'3Y6ISZPU453"1"BP;KU?6>-,=<]N?"#XD57W-)
MNOY$]9[HWAV!UP<_O"&&EZZQB40V?LROV;!OOJ3:]-6TN*ZLVCC=J8W*0YVB
M7'U.,W"T=75UZ&HCFD776B21PQTJ-[?$GX?;YR6;SJ?)_!X;9G8D62[)R>!P
M&?ZZBF7%;EK.V=G[0J-C[BA RNQ.MJ2O[&RU%-0XY8J7-UE#*E1*=62BG]UJ
MI7RSTN-U_ SXRX7;VY=N[O[ V?L3</;$/\>R>8PVW]A[&Q=;6X/JC>77N8KL
M!@\M_%:?'[8K#O=LY6XC[R7'?>PD1)%3R21^]];U-Q\NG'Y<=??&_>>Y-DU?
M8?9FWZWMO=IZ\Z-V3C\5B-D;EFDW9L;LE^Q:QLMLZLS%#55&R*W<&":DW1B:
MJN3$K!'"M08YX89DUUH$CAPZ+[LCX\?&#/\ 8^5RU%W9\?EZ;:L[!@Z[V'DJ
M':N6GS&[]A[EGQ?=6%WH-W4F(S>X.GMJ9;9=;0IMZ7(5,>,IZ9UI<C'3P+;?
M6\T\Z].W8'QH^+M%6]"[8[&[TFW_ !]M8S=V_,!NK=&WMFY/:>[=I['Z6Z[Q
M79?9FY=QX>LVMAL8D&!V7M.7 9R*1Y\5,Z0QBKIZNH*ZZU4]V.EC3_$#XE25
MF9WIL_NS83U>P.N.K^V\7EJ'&;-W)E>O,=L+;&W=MTF_,E0X&NHJ+(]0;^P7
M4QDK=M5>.&*GRE/5UE"]/4I^UOK>IO3I*XCK_P".?<&R/C=MG8?R-V9_HR^(
M^T-V;?WEN+>&*V*V\]W[!W]L#K23$[QV;0U>-BQFR\/N"AW+0M1YZBIJ%J"2
MHCBH5$B@+KKV16HR>A3S7PBZDA3#+G/DI%%BL?529[:-%G\=U?44M!TCG,;N
M#8']WZ+(Y2G;)5U4TG:;1T.\14_?4^2JJ4IJ\ABFWU[4/X>GSKCHKX[].[MV
M/V]MCY(;>%#M3;W9=?EJS?57L7-X;,]:X_)TF8W56P9^ODQJ[7R^S,Q20OD=
MQQR/624"^&MUQI#)#KK18FH/7+=/Q8ZGH>X9>_,Y\CJ+&[XWUN"@WSL6?>%'
ML>IVW4[2V[7;MW95X_*8FNEQM)O:FV[M3>M908/-2O3UNVL9%324\IJ$FJ*G
MW7JFFFG0![Q^/7Q1@V1UGB,C\D:7=FQ^R:2I^/>T<9L:BZ]DW=OWKP=AU>X\
M9A]L[FP]=29#$[VVYNNJE@W)O;'"&IR,!1\@B5:)6C?5M3?P]"7MGIOXIXV.
MI[3[$^5&QMXY;8U?L'"9C>N5KNG]LT>QUP6[.KMP[9VJ]1A0:7:U558+HFGP
MM>RU8EJH(\@SL&BM![K53P"]!MN[H+XL]-;CVCUMO[>_9&;R65Z@VE0P=@;5
MV'MS';:ZVZVA[$Z6V=MC=DN]-O8H?W!J=Q5O7N&PSY/'-)(@GJ,C(M-%&)H-
M=:J221T*W3/075VR>JNV.E^T>YNJEK>V.W]K8NBQ&TY]GT;XC_05LKK+#8;9
M]?2U.,QU'N/>M!M_J:*JSE9)CXG59"2(Q$A7?6R34$#RZB;J^//P8R-'-2[G
M[UZTCGWYM[>$E!59?+=31Y*NV]O38>]^G**JQHKZ(5$N.VR-W9)\8P!CAK(Y
MEY05"^]=>4MP Z=MP=8?&KN3J3L+I?#=_P &RMMTWR5[.._-HUZ[&C.+W-NK
M=>]]J5'7T^U*U(AAL?1[I$^4VK.OB=,A0TU8Z5")+ ^^O5((-/+H/NW_ (>_
M'JIZCW?V)LOL;=NYZ#:U%VSLK=N8ZQVYUQV:9ZK=>YNX(^X\QN;;U0E%M;/]
M@;2I>T\K2')9&26JP<N/:\4LTE53U'NO!C4#H<)^I?CM\H.S&QU-GMWYC(]?
M?'/JNE2BW'L 1;=R.R^TMG=QXWKG>N,R&]-K1IFMST-)N+(54R4[%L574].E
M1'#+(\;:ZKD=WSZ*IV/\5/CGUQVW_".P-S=GY:JVIUO6Y3K[;NZ>I\+N[:G:
M^VI]S4D/9VT7R-++1[B[Q[=S&;[6I:+%5%?4P5. GRU.V/\ )+'5R>]]64M3
M Z1?77Q]^.V0RW6%3V#O*O6NEP/;O:NQ$S75ADZ.R?5N.W]V%NKM3K;=E##7
M8S(;H[>ZWQ6_7IZO,9CPYS;]>DAHIYI9*P5'NMEB3V]&/V;\*_C[W!T%U/V)
MU/OK<NQ]@5G5V-FQF1W#UKM:CKZO9V5P^]X=Q9O>&Q]U[<HH\1VC4X7>+0G*
M5]'_ !3"ST/"!Y*A']UHLP)!X]>V;\1?AAMJBJ]NP]S]?5N0I=N[C[4Q^6EK
M]B_WSINNLUD=EYS$]A;NS&4KLI5Y?([=QVS)*2/=(CQSU>/K*@5(D9!*/=;U
M-Z='?^(IZ^_T!;23JC<<FZ^NX<YV32[3SDF,QF)^YQM)VAO.E:"&GPRKC:JB
MQU9#+34]9&J??T\*5+*'E8>]=4-:YX]&5]^ZUU[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]UCD5GC=%D>%G1E66,1F2)F! =
M!*DL1=";C4K+<<@CCW[KW6MSC/YG7S*Z%SF_L=\C=M[*[=GZ)[\HOY>\>)ZZ
MI<%U[1_(KY.;JV;7_)W ]^[DW35UNZQT)L*@^*T.WJ&GVS%C\I/E]^[EJZ=)
M8Z.C@D&^KA0QQ]O5G_Q@^?>.^1W?>_>A<IU1FNEMS[8Z.Z<[\VM@NP=VX.M[
M$WQL#M3$4<F3W%'LS:5+G<#MW;VQMY5$NVZJ2KSYRDV5I)'_ (=%124M54ZZ
MJ10TZL+]^ZUU[W[KW6NW\J_YFWR,Z/\ G!WAT+B<IL6#JL=P_P LSH;JC,S;
M7CSNX-E]J_(GL"AW7VGMS=N.I:B&MRE!W!T+C]PTFUJDEI:3<>*CBCB)E7S>
MZL *<?7H]/P2_F7[7^<._P#L'8N'ZOR6Q3MSKO:/<VTLG%O7![_%=UCOO?O9
MG7FWL7VQ3[<H8*?I#OJERW5M;4938M=49&JH*.>)EK9Y8ZV&D]UYEI3/5G?O
MW5>O>_=>Z][]U[KWOW7NO>_=>ZUT_P#A53_VY<^07_B1OCG_ ._SV+[]Y'IV
M#^T'V'J__8/_ !XFRO\ PTMN?^Z>C]^Z:Z5OOW7NO>_=>Z__U=_CW[KW7O?N
MO=:\G_"IW_MR9\I?_#EZ _\ ?]==^_=/0?VB]7N]4_\ ,KNMO_#!V=_[SN.]
M^Z:/$]+[W[K77O?NO=>]^Z]U[W[KW55O;V,^&'8'<7<Y[>[KSV+W3C=R[$ZA
MW'@JJDH-EXG"5[; EW5C,4,C%LJGCW[B:?;W:?W$N:RLV4I]O_Q$T:5=&E3/
M!/[JXU8IPZ;NU/CMT_'\DL%M:@[HHNJIMZ[]QW>G8F";/5F*[0WYO.IK-V;.
MZQH^LLE-AJ;&;?QV!SN_JE5EQ%7_ !.&:2(3H^N.8>ZT":''16<)U7\!CV+N
M_JC*]Y;IW#U_OO?NVH:2&BI:/#;3H^^-B8W(;]H]V9/L1L'32Y=*+(]XTE3A
M(<1.VUZ6:BGI<TM0/VY-]6J_&G0X;JZH_E^9'"9ZBW'W9%O'>.\NZHLON.OS
M&7V=]WV!VW@L1V;0;OJ9MMY+ X?95?M#.[3[6SM-DHXXDVI'3E7@,-0CR2>Z
MUW4X8Z$GMS9WP5^179NP]K;H[JGQ><V+EATEM;J''9^;:6-PV_\ :^(SM/C,
M7!MK*X6"3 [DIJ#?:1*J"GCRKQ8RF/G6&.GE]UX:@#C'0*C87PCW/V)6]<Y[
MO7MM]P[@[D[1S_:>X\_'MC:>#[![QZ<WA5X'+8?-5N2V)CH\)!LZO[EE7'+@
M8*' UM'+&D]34S1J']U[N\AY=+'LOJSX?;AZ.[H[_I^S.T.V.F<OF<KD^Q=C
M]30X'=NXM[Y[;V\-U;IV7L#;F%;;R;O;<6T]V=DU\F*QE+/35&7@K:9*S[VF
M\9D]UX%J@4ST:#N+'?%7M/:VT<ONGMNCP.+V3M3+4VSLIB-PXS'_ ,.%7MKJ
M[MC'9H8FLQE5'E,S@<%C=MYJAHI:=X)8*N-):6>.H$1UUH5&:=!!\6]S?$.3
M)9K%[-W1O'+[[^<=!OG?>ZIMSP4W\4WK+UYCOX#O;=>4FV;C8L%UK/E\;N**
MLIL;--CU:"H22BI8_P!X>_=>.K]G02U/3/Q"WCT]LC>_9>>[BVCL3:_8M%O[
MI_MGLL;0QD/9NZ5V7M_8NW=[8K9>WZ2MS.;VKB=@]/T=5%3YS#XZ"IQ ;)5$
M,M,PGAWUNIK@"O2X[9I/A)VSN3X_]85O<W5N,ZZ^.>'[2V]E-F83+38"+*X:
M3IW,["I-M056#BHMI4>Q-O4E%59<M&_@BW#MK')2D3TCQ+KKPU"IIT!.0ZK_
M );&*Z]RV_)>[<SN'KWK[:51#NRFVG+CHHJ"'<^U-R[;R^[5V;1[5:NS&[=V
M8/;$M)GX\;0U62RV5QD4M="T]-I3?7NZM:9Z,/W-#\ /DKVB-T]E=D8K$;MV
M_%V1\8<A2;PA& HLC_!*?&[SRZ8:'?N%.-QF5VME\W2U6*W)1+%Y*YS1Q3S2
M_L+[KPU 8'4_=G6OPNW3A*#OE.]LE@NNNQ.P$7-UF%RV$.'WKN7#U+-B]J5\
M%?M+(9[:U-L7(X:NK*V&F7'U%-$M2^3E^T@_9UUX:AVTST6#=_6WQER/0NW,
MWT_N[=&S*^FWAVI\%>G]Z[NH:[=9SAK\CW7!V54XS 8#:S8J3,;QARVZ8,7D
ML]'2XHQ1TU09Z;SK-+[KV?3Y]&1IE^&G=Q^..[8^^\QB<5OOKW8O2>#ZXJ<I
MMW&)V?C-I9[8_8^W-D[QB?!U^4PV6BW"^-IZQ<=D:&GRZY%*!9*A*J%9/=:&
MI:XZ+_M?KSX!8;._(C9:Y_?W6U%M+&[]Z#[SW#DX-H2P]F=7;PW7N##/U7GL
MYMC^\V^8JS![TKJ^LVU69*+"[LGQJ3S4K5F%CF==];JU!T/AZJ^ NPVR&V,[
MVY@L/GY*;&)G)J2LVMME\_5]I]3=Z[>HM]4]/C-LQX_*5.\NO^T]RU]3FJ,S
M4<TU#]Q-(H@J$?W7JMQ\N@KPG47P1WIC:+O_ #_8^Z*[9_2':W9W3'6]=V72
M;:S.V*>+>6>.\>XMB8S:E%MMI=_[3W[D*B6H:7/TE9EL52T$DE-)24L4S2>Z
M]W<*>70H5&[/CWEOBWNSH7KRF[)R_5M-\BJ_XH4E/MO;G5.\,QO_ '9O+*KN
MW<U%24?:V-AZXDV-65>\*A8<O5Z \$"U5/([&%YM=:R"">/2QPO<?QWVO#LW
M>NV>Z9^GLB,!TYU'F<+VS$-P;UFV;T=/O;<6XNKLQM/(U\N[-O\ :#Q9^LH<
MQE*[[N5KTTU&)S/!//[KVEO3I.]E9WXF;G[*S78V7^2VXLU5]X470O7&S/[M
M8S#[GQ'5>6K=R4^_.FLOL7=F*V/6R[-HJC?6RFW)EX,S75>-J*J".3*Q"BAI
M88M]>S2FGI+87!? [#U]/F,U\EANC:IV#BZ>'96X,GCL944E+UOVEM[LFLWO
M@<GM;;FV>R\,V_N\MW8K/5?BK#0;JR]9B:>BCFHH<;11^ZWW4TTZ$"9>@^A]
MC=@_#K=OR'W_ +4VAA^I>O<]M)*Q-Y0]B[/V1O+.[AP8JZKMFH@R67[%WEOG
M?NWLO/5T "U5+B8FA:D2E629M=:J20:9Z#/(=2?##8&4V)\>*'/[L?\ O'UA
MMWN; [WH\QMN/!8[;6 J<KLGKS<&%RC8:'%;EGESN^YZ^AP])]TLD-$C-3R4
M=X)_=>[FSU8E\<,-L/ ]18"@ZVW]4]H[5J,SOG/Q=A557A<@=VYS=V_-R[OW
M=F*>MVSBL+MJHHIMV9VM6#^'TZ4<42K%'<)<^ZT:USQZ'3W[K77O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=,V/W#@<O-/3XK.8?)U%-4Y"CJ8,?DJ*MFIZO$S4]/E:6:*FJ)7BJ<;/5
MQ)4(P#0O*@< L ?=>Z>??NO=19*NDBJ::BEJZ:.LK$J)*6DDGB2IJHZ41FJ>
MF@9A+.E,)D\A4$)K%[7'OW7NL-1E<7255-0U>2H*6MK2%HZ.HK*>&JJR3I I
MJ>2199SJX] //OW7NG#W[KW37E,WAL'!)59K+XS$4L5+75TM3E*ZEQ\$5%C*
M62OR57)-5RPQ)2XZAA>:>0D)#$I=R%!/OW7NG".2.>..:&1)(I$62*6-E=)$
M=0R21NI*LC*0002"#[]U[K)[]U[J+'5TDM344455325E&E/+5TD<\;U-+'5^
M7[62H@5O+ E2('\98 /I:U['W[KW4KW[KW7O?NO=>]^Z]U&JZNEH*:>LKJFG
MHZ.FB>:IJZN:.GI:>%!>26>>9EBBC0"Y9B ![]U[KC+6T<%52T4U72PUE=YV
MHJ26HBCJ:Q:5%DJ32P.PEJ!31N&DT Z 038'W[KW6'*9;%X*@GRF:R>/P^,I
M#']UD<I64V/H*;S31TT/GJZN6&GA\M1,B+J8:G8*.2![]U[IOKMV;6QK9-,E
MN7 8]\*<6,RM=F<=2-B&SDI@P@R:SU,9H/XQ."E+Y='W#BT>H^_=>Z>A44YJ
M&I!/":I(EJ&IA*AJ%IY':*.=H=7D$+R1LH:VDLI%[@^_=>ZZIZFGJXEJ*2H@
MJH'+A)Z>9)H6,;M%(%DC9D8Q2(5:QX8$'D>_=>ZD>_=>Z@')8X25L)KZ%9L7
M#%49*(U4 DQU/-')+!/71^3520RQ0NRM(%5E1B#8'W[KW7#$YC%9['4F8P64
MQV:Q%?'Y:'*8FMILECJR(.T9EI*ZCDFIJB,2(5U(Y%P1]1[]U[IR]^Z]TWSY
M3&TT\U-49&@@J:>A?*5%/-5T\4\.,C=HGR,T4CJ\5"DB%3,P$8((O<>_=>ZS
MK5TSSBE2IIVJ33K5BG6:-IS2NYC2I$0;R&G:0%0]M)(M>_OW7NNZFJIJ.+SU
ME3!2PF6G@$M1-'!$9ZJ>*FI81)*R(9:FIF2.-;W>1PHN2![]U[J1[]U[KWOW
M7NO>_=>Z][]U[KWOW7NJ1]]_+_MCM8?)F+I/^4]A/D_\<MC=N]D]>]B;SWSW
M?T!US5=S]@_'W(+LOL_*474&]MM;A;<D6W]Q[+DPV"KL]744N5;$Q/:CH_MY
MSOJ^D"E6H>K-?C9G>D^U.KMB?)/I38V%VK@OD5UGUAV/391-E879^\LUM7*;
M,Q=9L6@WNF,@^YER6U]LUL5#'335%0F/6,P0MXU%]=5-0:'RZ,'[]UKKWOW7
MNJBNUODYV?NSY ][]9_&'^6KMOY5KT1O/JS!]P]M;Z[EZ9Z0H)^\<;LC;7;F
MQ<1MRAWAM/>.Z]X5'5^T-[8:KAS\\5&F-R%<8,=Y6@GE3W5@!0$M2O1N_A+V
M=U9WWT5B_D-UGTU#TA7=Q[DWME.U-G5>W=I8;>%-W+LC>>X.KNTJ;?>5V:U1
MB=[;BPN^-DU]!_'$J:M,I34T51%*T,B6]UH@@T/'HW7OW6NO>_=>Z][]U[KW
MOW7NO>_=>ZUT_P#A53_VY<^07_B1OCG_ ._SV+[]Y'IV#^T'V'J__8/_ !XF
MRO\ PTMN?^Z>C]^Z:Z5OOW7NO>_=>Z__UM_CW[KW7O?NO=:\G_"IW_MR9\I?
M_#EZ _\ ?]==^_=/0?VB]7N]4_\ ,KNMO_#!V=_[SN.]^Z:/$]+[W[K77O?N
MO=>]^Z]U[W[KW5,O?NY/C/FNQ/F3N2NQ'<=9NCI?#08/Y(Q[?['P6R=L3X'=
M&PNHZ7;76&:R.9K$H<-L[OC;.1QE3D'DFI(J#'[:J:^>HHO)&N0]U:AP/7I!
M;\[;^*N^,_VE\@=P[&^1V'[$ZVRGQOH]G8.@W-M^@:'<G=61ZWV7MS?_ $AB
M\QE'P%'C]I9/:T--E:FO6/ R4>-J<C#2SQ9):FLWU:AP,4Z&+JWKSXWY+"=D
M85-H;ZAZ\Q/Q\W!+M?';H[GPV9WCV?U%'1T>Q]R]DTG6\V4_OU@:3LBFZTH#
M%F,KXXL@!&Q2DGDGA]^ZJ2<9\^D[EZ+XN;6Z]WIVE)LWL_<S[5Z+Z,BP-)O_
M +/V[MS'[;ZB^5VZ*+%[)ZAQV[<WF*/;VT-C;$R^$CGKZG)S2KCZ9G?[NJ10
MJ:Z\*UI\^E]\?=G_ !LWAO\ Z=W*];W90=O9+";T[)Z^V_W'5XG<>[-W]79+
M?%)V5E]Q9R&/!9@0;$PO<NZI9\%E,A+C\O\ =I#]G4MC9*&-O=:))KZ=-6[=
MQ_RT]S0=F+O+MF3)X?MP;[?<6U<EE=]14V5I<]V;@H]XXG9^#CPM/G*NGW_V
M/U!(E!!0_<2YIJ/(?PGRP"4I[JW<*8Z6.TL5\"MS]>;%ZMEWK6[LVIUOOG,]
MMX7&[OHMP;;RF<W%U!@<W23;DS$M+M/9^0WG1]5TV$J*85C"?QY7 B"IFGKZ
M!T3W5>ZIXUZ!S"X?^67MG&;/JL5WUNG:6T\(M3MKJK%Y7>V],!M_&9V-TV?1
M]J=?KNK!T]5N*78$76E/B*?<8FR.W\(F!CAD,;+)Y?=;.KS'0@[:W?\ !CX_
M[<ZQ[-VIV!VAN6?!83LO?.S:>D&_-W;V[:V_D:[;W5_8N;_NSD,'!D]]XZES
M--19+720H%%.:ZFU4>K5[KU&)(KU!SF.^%NV-N9/;VZ.\.Q]G8KJS<FZ*/:T
MV*W/GMP8KI(Y7^]NP\QT]UYOBGV)D(:/);XVMDJBGCV;55.0W#3T8@7'P0&C
MIY(O=:H?3KEOS;7PKV5LOI#"T.WMV_Z+^P)]S;)ILZN4WIMC =4;-Z$RG;';
M^YY-YU&7Q;YK;=9M/>4V1PL6+KXH,A4Y&6*@-I(2/>^K#42<YZ6\V!^"7:;=
MCTTNZMQ&IV#L'LK=O:<-4_8VUJWKG;6>WCV1N3>$^]8\IA,9-L_<=#N/<N9K
M*?%UXARD=-!',E,]-$CGV>O=PIT%F]\-_+7W1N7.5N_NT\ENG.;TV?%E-S;%
MRISF?RF^ML=G4O7-33XJDV%3;,J]RS9O+[GR&W]W4U'@:>FS>/RN5@R%.M/1
MU2(WL]>[\=+G*4WPVWEMK9'4\?86XLV,)31[DP._-G5,]1W'O/*][4.3P&YL
M748K:FP3D=W3[\V5N*HBW'64] ]704_[]6]'5TRU<6NJY^+I8[.W+\%>W,?L
M_P"-75':L.:J=F[SK]];1VWUYN'.UN:VY+0U6?FGJ16T]%71T^P)*#.UV-II
MJHMCIJ-_%!*SQJZ>ZV*C-.D'&G\O/!=F;<WW3]AY'"[RV#44G7:M7T>YZS&;
MHV[U-2?W>_A593[GV?DZ'<.P.N-P?'*IK*K<.,:.EQ.>PU0\V2BDD,;^Z]W?
M/IBRN&^$)K>T]_;>[7WWBNQ=R]CXK.N\^Y<]UIN_K+>.]<YFZS(1X&+<>RJ*
MNVC2Y[[_ "<E=-G*2M6DH*L0K-24L],OOW7NZ@%,=(+;]/\ RV,1VGV90;@W
M)F-I8:BVYA.K,'4]C;[W'BM@U^Q.T=G[@H<C2[*I-QI1Y;&]9TJ;G*P;AK9G
MPD==D*5<;7(AAC][ZV=9&1T(&WH/C#7[!W-!C<[\EIX-N_*O8M'B.[:?^]=9
MV]FNU_E/M/8NVDW)C4JMI09C ]?YG:W;E)CJJHEQ$&*3%-]_2FR05(]U[->
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MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K73_X54_\
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M5N^DR]2\XS5(D&69SZJ@@ #W6ZGUZ4L'1/3U/N.LW;'UWMD[FR&6DSU9G)J
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MK?*+4SRU,8I<A&M)(%J&T#W7J'TZ453\V/C%1K+]SVA%#64L=$U=A7VGOO\
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M((X])'"?+3X[[DW1MC9>![,QF5W3O7<63VSLO"T>*W)+5[OK,+0Y_(Y?*[7
MPOBW!LS%TVU<B*C<-(TV!AEHY(FK!*-'OW7J'TZ3FZ/FE\?]N5_\%I=UUNYM
MQ3[CRFTL?A]N[;W+7KD,YBL=OBIJI*;+#$+A9ML4V8Z^R.'J\]'/)A<=F8UH
MZNJ@F)4>Z]0^G35MKYZ?%;.[;Z^SN2[=VQM"O[%VQ-N;$[6W943X?<E%%1;7
MBW=DJ+*8VKIHIJ.JAP[M)2%PL>66-FH&J5L??NMZ6].G?._+OK?&;MZVV]0F
M:JPG8O45;WC%OK.??;+VEA>NUW3U[L[!Y#(9/<V*HJ>');BS79%%X:*H>EJ(
MX$>215NBM[JM.H6T/F]\>]W9#LV(;TI-OX7K*FVSEZW<NYXZK 8O,;5W/CMH
MU5'O/'QY:FHZ^GVDF0WK0T@KZF*&FG\JU$3O2NLQ]UL@CCTJ8_ECT4*!]P9#
M?F+PNTGR'7^&H=QYV#,X."KRO9F>S>W-F&:BS&)H*W'X#=&4PI3%9B=5Q.56
M3735#QC6WNM4/"F>GK87R:Z)[.R./Q.Q>QL1GLGELUE,!BL?'2YBBK,GD,-A
MZO<%>]!3Y/&T4M9BDP]#-/'7QAJ&=8R(IG;T^_=;((XCI-[O^6W2VU-V5NP5
MW-#F-YX;>6W=G;DPE.LN.CP$N6JMGOGLC49W-18[;U?%L+;>^L;FL[3T=745
MF-Q53'431)&ZL?=>H:5\NFJ#YS?$:IVY1;OB[\V"-KY&BWU74F>EKZFGQDD7
M6N,I,WO6%JNHHXHH,CAL)7T]<*20K555%/%44\<L,B.WNO4/IT(&)^2?16:W
MKNSKJA[/VP-\[$VFV^=Z;7R%1/A\MM7:L-%A\CD,IGZ;+T]"<7_ Z+<6/DR<
M,Q2HQ:U]-]W' 9X@_NO4-*^70?X'YK_''<>26FQG9>!&.?;^X,\E;DES.#R'
MCVM1TV8S:R[;SF&QV;IZ.+;U=3UU+5R1+#D89U^T,U[^_=>H?3J!N+YM=&1]
M7[^[)ZSW-1=S?Z/MX['Z]S&V]A335N7I]Z=C[LV_LW9^.R*"CEEQ6*RN5W+3
MR#)R1-1&D669'D6-A[]UO2:TZ==U_+KK'!;EZPVYM]JC?A[/?#/0Y+;%7C31
MX7';DSVW<#MW+95<A54=0V/S<F;FEIVA20M'CYQ8,$#>ZKTS[H^;_1^T\GG,
M9D:O='GVYW*_064IH]F[KDR]3V6\/7$]+!MS"PX2:OW1M%$[0Q@KL_1+)B<8
MT@%1,EQ[]UL GATM>K?E5TEVS6S;;V[O?"KV'A^O\)V+O+K8U\%;NO9>(RN*
MPN4K:7+PXPU=%55^W'W#1TV2CHY:@T=14PI+I,T0?W7B"./3MU]\FNANU:BJ
MI>N^S=O;LGQ^TFWSETQ1KG3 [87-9K;W\0W'-+1Q0[<F.9VYD(!2US4]8S44
MY$16)R/=>((X],Z?+OXVOM%-]MVYMB#:,M%M+)09RL&3H:.JH-_;<R>[MB5E
M&*S'P3UE-O7;F(GJ\2\2.N2C""G\C2Q*_NO4-:>?7NL/E'U?VGOO=O6V+J<O
M@]Y;9S>2Q=)A-TX/,;>K=R46)VQL?=.0R>)AR^/HC%58^@W_ $/W>*J/%F:)
M6$M12Q0O&[>Z]0@5\NI6Z_D]U+L+?F=Z_P!\9FLVOE,-%LUX*VMQE774&:;>
M-'NK):L8F%CR>23'[5QFTIZK.5]53TV-Q-++%-45"1L67W7J&E?+H.<Q\\OC
MAMW;&?W#EMZ??U6U=OX?<^=P>QL3G^P:O^#YO*[=QM%/@*S;.'JL;NR6&#=V
M-KJJ#'2U%11XZK2JFC2G/D/NO4/IT+.\?DGT;U_NZ38^\NQL-@-QP3[7HJRG
MK8,H<=C<KO>K:CV9@,MN"#'S;>Q&YMV21N^-Q=5519"NIXWGAA>%'D'NO4-*
M^72,J?FK\6:6MP./E[DVV]3N2NW7CL8*:ESM; D^Q]]5G6>\I<O5T>(GI-NX
M_:V^<?-CZ^KR$E+2TLB%Y)%B(<^ZWI;TZ;*KYX?$&DILG6R=\[*FI<+D,[C,
MS-0/E<FN)JMNC!G(/DQCL;5-04,YW/CEH:J4)2Y1ZZ!:.2H:5 ?=:H?3I1]P
M_*SJ7IFBR/\ '\I6Y'<N+VCL_L*LV/B\7DVW=3[!WCV+@>LJ#=%1AYJ*.JIX
MUW'G/''12*N2K):6>"FIYIXVC'NO $\.G#&?*SX\YC.[;VWC>TL!4Y;=]/@)
M=M1+#EHZ3+U6Z:J@I<+@J7*2XZ/%?WMJ'R<#RX9IURU+#)YIZ:.(,X]UZA].
M@QS_ ,[.E<)49>CIZG(9VMAWQLS96UJ;"(E>^\UW9N78FRJK<]"\.J+ [5VU
MO3?28BJK<NU!!+DZ.6FIVEF:)']UO2WIT(^[OEO\;=B;CWYM'=O<.T,+N7K#
M;_\ >K?V%GJ:J:NVSM^*/"5%=DZ^*DI)]4&%HMR8ZIR(B,CXRCKZ>HJUA@FC
MD;W6J'TZ2.\/FWT+LW>&S=LUNYGK<3NO<.[=JU6_,=0Y"JV/MW.[2VUA=T5=
M/7[ABHWQ^0H#09V%:BOH9*F@QDMTK9J=N/?NMZ3Z=+G>OR>Z5V)N3<6U<_O_
M &SC\SL4[:G[%I\CDSCX]DXW=^"W1N';,^4JYZ8T,N5S^/VC6246,CE.0JXH
MVDCB95&KW5>H6U/EM\>-[;GV_LS;G9%'4[IW-59;'XW!5V!W7@\A#F,)F-U[
M>R&W\Y#GL#C?[K;F7-;%S--%C,F:/(5,N,J1##)XGM[KW1CO?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M:Z?_  JI_P"W+GR"_P#$C?'/_P!_GL7W[R/3L']H/L/5_P#L'_CQ-E?^&EMS
M_P!T]'[]TUTK??NO=>]^Z]U__]3?X]^Z]U[W[KW6O)_PJ=_[<F?*7_PY>@/_
M '_77?OW3T']HO5[O5/_ #*[K;_PP=G?^\[CO?NFCQ/2^]^ZUT4CY';F^-VT
M=T;&RW>29"+-56Q^U]MX//P8K=-7BMD]=;LJ.O=M]K;NW+N'#T[X3K[;]/-D
M\#1U.<KYZ1J6.L(CE$35)7W6Q7-.B,52_P MG=4XV3C$WWN*#&Y&ES-/L/9^
M)WQ58O&8[>E9M;9% M96X;&K!CMJ]\YG)XF?'/E<C&N0KIA6T$E+(]3*?=;[
MOBZ7E'OGX)["[.J>T*',]BY?LEL[O_<[9FEVQN[=U3VOB8LQG,]O/,[>IJ?;
M=;CL[UOU)GMOUSO6X=*.BPU52->5WK%-9[KW<P^70:?(G*_'6+)]EOL*OWY6
M]LY[)'L#<';.*W-DLEN;8"T6$Z_W#LW>76&%@R-+B:Q:K9V2^TQ%3CHFJ9EI
MJBFJ4JY:BTGNMBII7AT<GI[K'XDMUAFI]J55+NS8>QMJ]A]?;\W-N#*YN7$9
M+&]@;)ZVS?;LF?;*3PT4O\<PFWL5+E/&B18^I2IIT6GD6HA7W522>)Z(CL3-
M?&+M';?17V_5?9<&5RF?SGQ\PM34=LXZDW?U3M2L[&ZZ&&HI*O9Q_@^7VMV-
MM#.;*WBB$U$F5QE%B(,BTTU%XX]]6[EKZ="9L5?AOMN/>/6V*VQW;LNNV;VY
ME:?:_5FUAV'GZS?V_>F>Q]QXK.]T=18G%8N6KW5N;)/!4G>-3BS-'%0R>+(+
M=8W/NO'\N@]VUV%\/-L8SNG'RMDY]L_('O'9NS-YYW;^Y]P8_:?6?6O3O7TF
M Z<W[E-\PSYO$82JR&"Z8.1BHZ^M@R6X*Z>3STT@=H9-=:S^SH9>M=V_"^EJ
M\ALOI/)[\BWEF.NZ#XMXJCK=I;WW/M?KJKW56[\W<NRMQ8^O7&;/J-Z+ECEL
M_E,?D,@^36B@,$#4]-)%3M[KQ#<3TEI]A?R_^F(J#H#+U_:--0]3;:VMLZL6
M@HNS8NO=N;ZV/M+K;%5'>IR=!CFVCC^XMH8'=NV:G+;HCF>6BDR\$DKM4R3D
M>Z]W-GH3*[/_  FZZZU[5ZZQU/V-OJAS_4M1V[V)@L<W8VX][[LVIM+8=/VM
M!EOXUG*JAJ*K=.XL1DX9DIX*N.JFJZL)*D4:N8M];[J@GUZB[GV?\+,+O7*=
MH9G [EP^\=_["P_R,W52;LW!O/;VW]OX7L3=>V]GU&[\Y4N^0Q^UL\9,D*.I
MQU&WVT<=+))4PQ$K5G76JMP\^FJGW7_+^WOO3KW&4L.\H-X;<S&.H\!+D]D]
MB10XO:?8NX,A)2U.XJS=NW:O;U+U/W=6]Z)C_NZAE@R\.9IH%D1J=?MO=>HU
M/EUS[;VSU;\<NU_C1AY=M=K]G[AR.:ZZV'L.G&<,NT-NXBA[5PVU-A0;HQU#
M232T&W>LZGL=,M%7+25$_P#N$@A:2..64-[KV37IRWM\>OB#)\@LK0YK=VZ]
MG[LV9MOLGO/LW'U.ZMPT&'W5U;NZGW'!OC"5^YX\O!+CMBX7,=@UN0R="'64
MQ99(BWV24\=/[KVIJ= YM6'X#]78[:N\-S;F[*IMR;&J\MNK;N_L_LG=5+5]
M8;;[&W#O7>6VNG\3MRJP&;QVQ]K=Q8#*5,.(VC%1K)N.ACI-%.*AJ%?>^MY/
MITL<+C_@C@8^R]L[-Q_<6/W[N:>?!4N+AVQVIE^R,KDMH;KQ=74T'56V\KCY
MZW>4O1N[=DP)D:BCAK&Q'VI2KJ7CD4O[/7N_'2BQ>\?AE%6[SWK1;L[![)QW
M9N4[HZAGJ?M\[5XC??96[MJ8W=?9U!US/5Q8B*3/9C:^V,9MN"?!B#'15>-%
M$\QR#5,C:ZUW8Z9:7+?!7>@P^]MRX3=FR1N_9,B[KBRU-N>.HP?6NY-C[$EP
MM#WS4R8ZK?J_56-0TN( K86.=204=9,\TP/L];H_2MR&)^%NZ]F[F[YQ<G:&
MVY-Y=KP56'I]HX?>FRNWJ/N3L?:V*DR9ZTVY%A,?V/1;D[QZWS=#59*DAUP9
M3#S15;0Q/&9H_=5R*CI;]=;E^&6U]KU_9W3K[II]G]&93']>TV5Z^PW8N5Q6
M1R?<.Y=J;H3J_:F/I,?7/OF7+[SW/A(JRCH(JC^'Y&6.DJ)('BJHH_=;[B<\
M3T'^=R/\O_);^P>]\K'N5-Y=S]P=+?)+;L&,D[(\F\.X]K!/CSLZ.GV=@*F9
MJ7+;:J/\BW'A)Z*"CCJ/+79*)G2>=?=>[OAZ1>VMZ_R_LPF%[*K\)V#U3D=O
M]6X7!9K(=@X+<^)2+JSKZGW=MC9/66],]G(\YM.=-XT&PZ[+8C&PUQRF3EH8
MJI76K**V\];H_2V7M+X;5G6_8^Q^N)^P:N'=.U,9C-R8_#Q;ZQ1RU?U+T97Y
M*/JZNW]G<=D,)@]T4'4_5+4N6BBJ&K(+^0M]Y(L@]UZC8/0'8R/XEUN6ZDWF
M*GM+;77.!ZQZ\D3XUX; ]M97>&5WI5T%=6=<Y#?&#:EJ]Z[FRNTMJY.>HQ>9
M?Q+/BX5\\U13B-??NO=V?6O1O-^["^&NS]EQ]K9K!;@W-MSY!46T]E8:+:$?
M8V^*[LJFWIN!.TMLXG;VVMMG(5LBYNOH#7F5884^U1DD=8R4.NM58XKT5;IO
M+_$ZOI.X=G[E[3W5N?,]O;_H<WMO$X;-U:TNW=K](SY;*?'_ &WL(1UV1I]N
M4VYL#L:ORV P63J95KZ6EGIY81$@A??6S44QPZ7<&Z_Y>V)ZMW=E*7=>\J?K
M/.]=].]<4-7%FM[P4V*V7M/"Y_M#9V!V$C30UM8>O,-ALIN/-5+)7-34T%1#
M532T\1HDUUJK5IY]/6]-F?!?;,8Z[R,.3;:6VL+TA1;K-;N;=^-V'2[=SN*[
MIK=A9.HRHIZBDS^5W)MW=FYA(*1A%/$T$1F@J*>A1-];JQR.G+JS<'PH7<.)
MP6+7MRJW]NSMG955N[/]F;?[<HMU4_<>P]R;FCZXA[;S^XL7CJ3$[AR>6:JH
M,335#)!D:>G@@1&A2'WKJIU>?2&J>K/AANK<5;\;</-D-L_WC[LV57[KVPN+
MW?GMI5&Z^H=]3Y6BIU[!>GP$6R^SNYVZ%GI*UCE*RIR-!B:R)87>=:B3?5NX
M9^72NCW[U)V%B=PY'M.+L*O[7^+G<'=N)ZWS^ZX*#%[TW_ ^],_M*MDQDE%L
MY-DXOK_?^Y\)4;=Q].\$HBQF)HZF66)B'776J$</,=(_9FROA%D>JNJ^RMT=
M?9W:D/?,'8V-?K2?-Y+?U3GL1D-TY;>/9^=W1(T-744V!P^]::??V:W#%)0/
MC<_5R9*2J6JJ")O=>:M3UPK\Y\#<J:O<6>WOWYNK,C8]309A:R7N/*;BKL>V
MW]I["VIW7GL)B,2LE5NO>FVMZ[=H-J[DJ8//F$FI9*0234]5+#[KV?E_+KG/
MG_@;UQ_&>S,1NWM'9^Y-M;1WCM':_9,.)[!W!6])9_L>+)T&1Z)VCBZC#Y;&
M8WMBIW5D9LI3[%JJ*LR!R\<7^2Z(Z6%=];%1C%.E#W5NKX1[D[#VZG=\/8&[
M<OUHLW6._P#<.=;(R[/V*VT.I=]=H8/>G<;XVLI<3AYJO%5F<@Q^2IX5,V?J
M#331B2GIOM]=:750TZ?MLT?P<V5L';F\*?(;[W(G;/86\,U65N;S786\>QLE
MOC9]!V/M#M7<6]*$U55E<-2=;8W>6>BW!.\4&/Q,91B%T4OO>>M]_36<-\ 9
M>AL9V#CMO[]W!U%OWL3;V-VA4;>QG<6;R.^=P=+[<WEB<'G=I4.+67<%5M#&
M;0VQFJR/*HL.,R&/HVK%EF1Z>2376JM6E<]1-T[X^#O6VX:W/U64[-WKO[;K
M[T[FI,/M6?=NZLQV;3[RV[FOD7/NO%8W;;P[=GVU0T.%K:C%N3BL9C:PM#^W
M-4 R^Z\-1Q7I&4M+_+XVSM&"AGJ>V-F5.PJRCR&.ER\V^<%NV;LS=F&Z73&8
M#;.4K(X<;N[M[K6#";+=:?&2U<^,J(A+,TQFR3R[SULZZ]*K$=X?%_I':%=O
M#X[9WLO.[;V)/OCL_=6U\%C-R28;OZLCDZXZLW?NBKWOO#;61K=XUFW=P[^H
MJV08>?7D=P-(SB0AO>NO:6;)ZF;-SWP;Z7["QF^*"#>5+G-C3[AVKL^NJ8>T
MMQU?3NS\ICFR?8^RLYMN;!HG4O66PZRJ%36TF5)@H9W1P4$$21>ZUW:?Z/3_
M +AV9\*MH=E=B;#GC[#BW=M.AR&]Y,3B7WM2[:V+%+CL_P!L;EZZZNS#PT&U
M<55;TPNX\EF\CM_'U3O54DQ!6-(*:*'W7NZ@].D<=P?RZLGO6GS>,J-QK)N3
MK?;^S-Q[LH,)OI=@Y?K'(; Z]V3AXMW;\R>)DP>(Q'7VW]][;$V2@R%%/@Z_
M/1-/4++-4!-YZWWTZ6W9/<?Q'[&V9A-YTVV<[V_@4WEUQ\7,UA,%_>N7*TVU
M>Q-Q[%[ V_5_W/Q<-9EMY;?W!3X#!Y6!:>FEFRN'F(#>&2=#KJM#6G29VATE
M_+][/ILQC=M9[=^_J>7:F7SN\Z&IWMOZJAWAU-L9.OZ&AV+NR3)5%'3UW5.*
M3%86+%X=I(*.L6EJ01.IR6OW6ZL./25W0OP!RG32=B5^2[<[2P_7.WZ7.T&W
ML=D]_P"X=_9';E!MSLK>F'ZDIL29*.BRT6'V_L/.Q4M)+,M30C&:/O8Y&5I=
M];S6F.HVVMW_ !SH>R\WVN<QVUU;O/KK;F)Z'V9L#%;3WAF=X93JKJGO?>&\
M>Q,SMN&JAS,V_L1N2HV754.Z,GCJ3R;3Q%-64+5*3RI,?=>->&.G+(/\-\EV
M+W7V7NN;?G<N*K-S5F]0<?B-_93;^*EW&_6W3FXZ3JS9&(Q24F^L)FY<#08O
M,9C$-6_Q;[YZ'QSJ\I.NM=V!TB,OO'X$[+V]4[YZQR/8/8^^.IJ7"[6V[C=I
M9;.29O%X6+[KK':&_P!JFBP5?@L+M'9.V^RJW"T6=RE,M!4PM]O7?>5,,#1[
MZL*G%!3H4=X9KXE_$C =S[9V!LC>6^ZR7$1=>YWKR+&Y[<NRMU=A[UQ^TL5N
M;;<^]<ECZM:WLK.[.R.+RFYZ,9*:MFPU*)1 9HRGO7515B.@BZ7QGQ6AVU0X
MGO'_ $D[IWCN#L^?=V"C[ DWJ-]?W7^,/=^9P> R^9VG3-/3[>Z6ZUK>H8ZR
MIER%;5PM@ZJ.DR,DZS"!]]7;5Y<.C7= [E^&N\::EZ-Z=R&<W)0[IR![?H<!
M3X[/?9[6P'6F\=F;KVG4U&YZ3'TD6*V=+G,CB:S;M)7UT\V3H*PB%9:59EBU
MTV0PST,.V_A1T)MC-4^?I,/NJOR..S^-SN!.9WYN[*4NV8<%E*7+;<VUMV@G
MRWV6+VGMRKI%^TH4C,:H660R ^_=>J?7IZW3\2>F]WYS<VY,I0;B@S>Y=T0[
MT^_Q&ZLWBI=O[M6+KV&JW!M=:.JCBPV1R8ZMPC5)5621Z5FT@SU!E]UZI]>N
M]N_$CI7:>-[-P.W\'D\7MGMK;V3V]N_;M%F:NFI)$SV#H=N[FS&,R<!CW+C<
M_NG%XFC%?5)7ZIIJ2*8!9@TC>ZUU(Z^^*_5?6>>V_N+;*[J3(;8QO8%)ATJ]
MTY*6A@R?:V<H]Q]D;FDQ\+4U)/GMW9?&TTLNM31TK0@T=/3%I"_NMDD\>@QJ
M?Y?'QRR K1F:#?6:3,9%]R[CAK^PMS)2[EWY$V8;#]BYFCH*RAHY-Y[5.=G.
M'GACAIL6ZPR4\$<E/ \?NMZF]>A8P?QBZRP-?@<]32;OJMWX#.9W<T6]\AN_
M,56Z<CN#=6%VGMO=&5RU7YDHJN?<& V504E0HITB6)'\21M(['W5>FS>?Q+Z
MAW[NK.;WW)#NNIW3N+/X[*Y/,TV[<O0U+8&BVO%LZMZXIOM98HZ/K+<F"$R9
M7#Q*L&0FJ99Y29BLB>ZV"1PZ@/\ ##X^#97^CZBVED,5MF+$[CPV.I<5NC<=
M%/A:/<VV]K;5K#A:I,D9L?-0XG9.+%"4-J.2C5X@I+ZO=>J:UKGK-V+\/.CN
MUMT9_=6]\'F<I4;KQD-+N?$0[CRF-V[GL[C]K9/96W]_UN&QTU-31=B;3VSE
MYZ;$YBG\-5CV$$\)6HI*.6G]UX$CAU%P_P *?CG@J'?.-Q^QZA*+LG^/'>\4
MVYMS57]X7W1M'K79.X9:UZC*R.9<SANI\2]05*^2N:LJS_E-?62S^Z]4^O4_
M$_$?J/;^W\UMS;L>Y=OTV4VYN[9=%6XG-+2Y';FRMYUFW:O)[1P4WV;P?P2B
M7:U)3T(K8JR>BI \$4HB<K[]UKIZK/C)U7D,EU/7UE-N6HIND=J8S:/6^%EW
M;GFQ6&HL3D-JU]'D,@&K#D-RY@'96-C>?)U%8'6GUE3,S2GW7JG/2&G^#_0;
M2Q/18O=>'AH?N,I@:'$[TS]+0;7W]45OWB]O;<I6JY4QG;=,B1TT6=&JI6DB
M6$W34&]UNI]>H%)\"OCE0+M,46#W=3/M67!&6I3L/>;U^[J/;FZ</OS$X??6
M2FS$N0W1A(=^X.GS3TD\O@FKS*9%:*>:*3W6]3>O3YO[X7]%]C9'>V0SV(S5
M,.P,_3;NW%08/-286@FW@-M'9&9W13I1PK40Y?=FQ@N(RP,C4U;2Q12-$*N&
M*I3W6@Q'#J3#\-^BX*7(8E<)GVVO48C=6"Q&S6W;N ;6V?B=][?Q>W-[46SL
M='6I)@J?=%+B(JBI1)61:]YJJ(135$[R>Z]4^O4OMWXF]4=U[@S&[-]T62S^
M>J]I1[4P<&7R^9GVIMH4O\4J:')TVU,9DL)29*L@S&02MU5,LDB5%-$].].X
M9V]UX$C@>D]U%\-NN^M<'ADW#EMR=E[[I.P(>U,UV)N+*Y.FRVX=^TF?[!W!
MC<Q58ZFR4M##38R;LS*0Q4Y,BM \:RM*8HRONO$U^SHWOOW6NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NM=/
M_A53_P!N7/D%_P")&^.?_O\ /8OOWD>G8/[0?8>K_P#8/_'B;*_\-+;G_NGH
M_?NFNE;[]U[KWOW7NO_5W^/?NO=>]^Z]UKR?\*G?^W)GRE_\.7H#_P!_UUW[
M]T]!_:+U>[U3_P RNZV_\,'9W_O.X[W[IH\3TOO?NM= 5VC\=^N.Y=Y;%W;V
M'0UV?I]A87=V%HMIRY*MI=I9ZGWCF=A9ROBWCAZ&>FAW=BX:[KNA88S(_<XJ
M<W:>FE98RGNM@D<.FBE^)O0%!MW+[3H-@K0X'.;1RW7]?1T>X]VTKC8.=SW]
MY<OL>BK(<['6XS:&0RM_+C::2*D:F=Z8Q_;.T1]UKJ-MOX??&W:%;15^V^JL
M)BI,1M_)[1V[34]?GFQ>S]H9K&9;$YC:&Q\-+EI,3LC:>4I,]5M/C,3#1T,M
M1-]PT1G5)%]UNI]>H.U/A?\ &784M-5;*ZDVU@*S')0KAY$ES592XD8JK@R.
M*IZ/'U67>EBQU%E*9*@4J!(6E+L1JD<M[KU3Z]3^L_BKU5UQTNW1J463W!L_
M*;;W5M[>,&1S&6HZ;>7^D#<NY-Y=AY#(X?$U]%B*&IWGN;>&2FJS2Q1.U/4B
ME+FGBCC7W7B237J;C?B?\<<'N>3>.!Z@V;M_/29/9F9,^WJ"3 T$>5Z]6FCV
M=D:?!XB>CP5+5X6&BIXU>.F0RQ4T*2ZTAC5?=>J?7J;N+XR=(;HFBK<GL>.'
M+4M=NS)8_<&$SVZ-M;GQ%?OO=%3O'>=7@]S;=S6+SV$EW/N"LFEK325$/GBF
MD@:].[1'W6NDG5?"CXLUDE()^F-KBAI:FJKGP,$F8I-J9*OJ<5N/"1Y#/;1I
M<G#MC<F0QF)W?E*>@GKZ2IEQL==,*5H=7OW6ZGUZ>JOXG= 9#;53M'); CR6
MW<C5]>UF;QV2W#NNO7<C]4D-UY!NF>KSDU3N:@VK/''-34U>]13B>"&5D:2&
M)T]UKI3YKX^]-;BJ=PUF;V!ALG/NRIS=7N-JMJ^1,O/N0=?KG6K(?O!"Z9->
MK-OB5 H0C&1BP#2:_=>Z15/\._CC3R/(>MZ>L5]Q5F[&ILMN+=V:H1N"JV!7
M=54^0BH,OGZVBIS@^M<G48/%1QQK%A\9*T%$L"<>_=>Z46>^,_2&ZWV,VZMB
MP;H7K;9TNPME0;CR^X<W1X3:]4N%CR%$E'DLM4TM;5Y>GV[1P5U94I-6UU-
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M8,6>VQEZ_!93<&*RV>W17Q[HK]L[>I-K[?J=V3U&;DJMT28?$4%.M/\ ?R5
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MU1_[[_GU[_9(_P":_P#][N=S?^F\?B+_ ->/?NO:H_\ ??\ /KW^R1_S7_\
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M=51S/35,3QR!7)1U*FQ!'OW7M4?^^_Y]/O\ LD/\U_\ [W>;J_\ 3>/Q _\
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M%_Z&&WO_ *X^_=>Z]_I5ZO\ ^?D;"_\ 0PV]_P#7'W[KW7O]*O5__/R-A?\
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M""L2D,D=X8($L@UU4U).,]&#_P!*O5__ #\C87_H8;>_^N/OW6NO?Z5>K_\
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>KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>g802241g20p20.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g802241g20p20.jpg
M_]C_X2(#17AI9@  34T *@    @ !P$2  ,    !  $   $:  4    !
M8@$;  4    !    :@$H  ,    !  (   $Q  (    >    <@$R  (    4
M    D(=I  0    !    I    -  +<;    G$  MQL   "<0061O8F4@4&AO
M=&]S:&]P($-3-B H5VEN9&]W<RD ,C R-#HP-CHQ.2 P,#HP,#HS-0   Z !
M  ,    !__\  * "  0    !   "YJ #  0    !   #P          & 0,
M P    $ !@   1H !0    $   $> 1L !0    $   $F 2@  P    $  @
M @$ !     $   $N @( !     $  "#-         $@    !    2     '_
MV/_B#%A)0T-?4%)/1DE,10 ! 0  #$A,:6YO A   &UN=')21T(@6%E:( ?.
M  ( "0 & #$  &%C<W!-4T94     $E%0R!S4D="                  #V
MU@ !     -,M2% @(
M                    $6-P<G0   %0    ,V1E<V,   &$    ;'=T<'0
M  'P    %&)K<'0   ($    %')865H   (8    %&=865H   (L    %&)8
M65H   )     %&1M;F0   )4    <&1M9&0   +$    B'9U960   -,
MAG9I97<   /4    )&QU;6D   /X    %&UE87,   0,    )'1E8V@   0P
M    #')44D,   0\   (#&=44D,   0\   (#&)44D,   0\   (#'1E>'0
M    0V]P>7)I9VAT("AC*2 Q.3DX($AE=VQE='0M4&%C:V%R9"!#;VUP86YY
M  !D97-C         !)S4D="($E%0S8Q.38V+3(N,0              $G-2
M1T(@245#-C$Y-C8M,BXQ
M                          !865H@        \U$  0    $6S%A96B
M                    6%E:(        &^B   X]0   Y!865H@
M8ID  +>%   8VEA96B         DH   #X0  +;/9&5S8P         6245#
M(&AT=' Z+R]W=W<N:65C+F-H               6245#(&AT=' Z+R]W=W<N
M:65C+F-H
M         &1E<V,         +DE%0R V,3DV-BTR+C$@1&5F875L="!21T(@
M8V]L;W5R('-P86-E("T@<U)'0@              +DE%0R V,3DV-BTR+C$@
M1&5F875L="!21T(@8V]L;W5R('-P86-E("T@<U)'0@
M          !D97-C         "Q2969E<F5N8V4@5FEE=VEN9R!#;VYD:71I
M;VX@:6X@245#-C$Y-C8M,BXQ               L4F5F97)E;F-E(%9I97=I
M;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0
M            =FEE=P      $Z3^ !1?+@ 0SQ0  ^W,  03"P #7)X    !
M6%E:(       3 E6 %    !7'^=M96%S          $
M       "CP    )S:6<@     $-25"!C=7)V        !      %  H #P 4
M !D '@ C "@ +0 R #< .P!  $4 2@!/ %0 60!> &, : !M '( =P!\ ($
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M# P,# P1$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P,_\
M$0@ H !\ P$B  (1 0,1 ?_=  0 "/_$ 3\   $% 0$! 0$!          ,
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M /_4]'R7Y%N9]FH;2-E6]S[FE\A[BSTVM:6;?YOW^Y-]GZE,SBSS_-.\-O\
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MUN])2XQ^I"(.((B/T3OS?H_X7\U1.)U(D'U,=H&FUM;@.=W[Y41]6^BAY?\
M9I)),%[R-3N^@7[-O\E7\>BK&I912W956-K&R3 ';W)*:+L;J5;'O+\=X#2=
MKZW$>)'T_P _\]6?M8_9WVW9IZ/K>G/\GU-FY%O_ )BS^J[\BI?^L[_Z!_\
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M_+5N]K'9^2VQQ8PXC0YXB0"Z[<[W!S?;_55,=/Z<+2'9Y,$6&LU8HEH:+/\
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M_P!N/_\ 222FXJ5G5\*NQU3O5WM.TQ3:X3J/I,J<W\U/NZO_ */'_P"W'_\
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M %, 90!T '4 <       "G!R;V]F4V5T=7     !     $)L=&YE;G5M
M#&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[      (M    $
M  $      !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L
M  !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L      !#;G1#
M8F]O;       3&)L<V)O;VP      $YG='9B;V]L      !%;6Q$8F]O;
M    26YT<F)O;VP      $)C:V=/8FIC     0       %)'0D,    #
M %)D("!D;W5B0&_@            1W)N(&1O=6) ;^            !";" @
M9&]U8D!OX            $)R9%15;G1&(U)L=                $)L9"!5
M;G1&(U)L=                %)S;'15;G1&(U!X;$!RP           "G9E
M8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S     %!G4$,
M3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M    4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN9V)O
M;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T
M;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T
M5&]P;&]N9P      .$))30/M       0 2P    !  $!+     $  3A"24T$
M)@      #@             _@   .$))300-       $    >#A"24T$&0
M    !    !XX0DE- _,       D           $ .$))32<0       *  $
M         3A"24T#]0      2  O9F8  0!L9F8 !@       0 O9F8  0"A
MF9H !@       0 R     0!:    !@       0 U     0 M    !@
M 3A"24T#^       <   _____________________________P/H     /__
M__________________________\#Z     #_________________________
M____ ^@     _____________________________P/H   X0DE-! @
M !     !   "0    D      .$))300>       $     #A"24T$&@     #
MFP    8              \    +F    ,P!7 $$ 5@!% "  3 !) $8 10 @
M %, 0P!) $4 3@!# $4 4P @ $P 5 !$ %\ 4 !2 %@ 60!? $< 5  R #
M7P!0 #$ -0 P #4 ,P!? #( -  @ $8 20!. $$ 3  Q "T ,@    $
M                     0             "Y@   \
M     0                         0     0       &YU;&P    "
M!F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M     $QE9G1L;VYG          !"=&]M;&]N9P   \      4F=H=&QO;F<
M  +F    !G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC90   !(
M   '<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG          9O<FEG
M:6YE;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y
M<&5E;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC
M 0       %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M        0G1O;6QO;F<   /      %)G:'1L;VYG   "Y@    -U<FQ415A4
M     0       &YU;&Q415A4     0       $US9V5415A4     0
M!F%L=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB;V]L 0    AC
M96QL5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(
M;W)Z06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M    #T53;&EC
M959E<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%
M4VQI8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E=&QO;F<
M    "FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S971L;VYG
M      MR:6=H=$]U='-E=&QO;F<      #A"24T$*       #     (_\
M     #A"24T$$0       0$ .$))3004       $     CA"24T$#      @
MZ0    $   !\    H    70  .B    @S0 8  '_V/_B#%A)0T-?4%)/1DE,
M10 ! 0  #$A,:6YO A   &UN=')21T(@6%E:( ?.  ( "0 & #$  &%C<W!-
M4T94     $E%0R!S4D="                  #VU@ !     -,M2% @(
M
M$6-P<G0   %0    ,V1E<V,   &$    ;'=T<'0   'P    %&)K<'0   ($
M    %')865H   (8    %&=865H   (L    %&)865H   )     %&1M;F0
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M
M      !865H@        \U$  0    $6S%A96B
M6%E:(        &^B   X]0   Y!865H@        8ID  +>%   8VEA96B
M       DH   #X0  +;/9&5S8P         6245#(&AT=' Z+R]W=W<N:65C
M+F-H               6245#(&AT=' Z+R]W=W<N:65C+F-H
M                                                 &1E<V,
M    +DE%0R V,3DV-BTR+C$@1&5F875L="!21T(@8V]L;W5R('-P86-E("T@
M<U)'0@              +DE%0R V,3DV-BTR+C$@1&5F875L="!21T(@8V]L
M;W5R('-P86-E("T@<U)'0@                            !D97-C
M     "Q2969E<F5N8V4@5FEE=VEN9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M
M,BXQ               L4F5F97)E;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN
M($E%0S8Q.38V+3(N,0                                  =FEE=P
M    $Z3^ !1?+@ 0SQ0  ^W,  03"P #7)X    !6%E:(       3 E6 %
M  !7'^=M96%S          $                        "CP    )S:6<@
M     $-25"!C=7)V        !      %  H #P 4 !D '@ C "@ +0 R #<
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M.RT[:SNJ.^@\)SQE/*0\XSTB/6$]H3W@/B ^8#Z@/N _(3]A/Z(_XD C0&1
MID#G02E!:D&L0>Y",$)R0K5"]T,Z0WU#P$0#1$=$BD3.11)%546:1=Y&(D9G
M1JM&\$<U1WM'P$@%2$M(D4C721U)8TFI2?!*-TI]2L1+#$M32YI+XDPJ3'),
MNDT"34I-DTW<3B5.;DZW3P!/24^33]U0)U!Q4+M1!E%049M1YE(Q4GQ2QU,3
M4U]3JE/V5$)4CU3;52A5=57"5@]67%:I5O=71%>25^!8+UA]6,M9&EEI6;A:
M!UI66J9:]5M%6Y5;Y5PU7(9<UETG77A=R5X:7FQ>O5\/7V%?LV %8%=@JF#\
M84]AHF'U8DEBG&+P8T-CEV/K9$!DE&3I93UEDF7G9CUFDF;H9SUGDV?I:#]H
MEFCL:4-IFFGQ:DAJGVKW:T]KIVO_;%=LKVT(;6!MN6X2;FMNQ&\>;WAOT7 K
M<(9PX'$Z<95Q\')+<J9S 7-=<[AT%'1P=,QU*'6%=>%V/G:;=OAW5G>S>!%X
M;GC,>2IYB7GG>D9ZI7L$>V-[PGPA?(%\X7U!?:%^ 7YB?L)_(W^$?^6 1X"H
M@0J!:X'-@C""DH+T@U>#NH0=A("$XX5'A:N&#H9RAM>'.X>?B 2(:8C.B3.)
MF8G^BF2*RHLPBY:+_(QCC,J-,8V8C?^.9H[.CS:/GI &D&Z0UI$_D:B2$9)Z
MDN.339.VE""4BI3TE5^5R98TEI^7"I=UE^"83)BXF229D)G\FFB:U9M"FZ^<
M')R)G/>=9)W2GD">KI\=GXN?^J!IH-BA1Z&VHB:BEJ,&HW:CYJ16I,>E.*6I
MIAJFBZ;]IVZGX*A2J,2I-ZFIJARJCZL"JW6KZ:Q<K-"M1*VXKBVNH:\6KXNP
M +!UL.JQ8+'6LDNRPK,XLZZT);2<M1.UBK8!MGFV\+=HM^"X6;C1N4JYPKH[
MNK6[+KNGO"&\F[T5O8^^"KZ$OO^_>K_UP'# [,%GP>/"7\+;PUC#U,11Q,[%
M2\7(QD;&P\=!Q[_(/<B\R3K)N<HXRK?+-LNVS#7,M<TUS;7.-LZVSS?/N- Y
MT+K1/-&^TC_2P=-$T\;42=3+U4[5T=95UMC77-?@V&38Z-ELV?':=MK[VX#<
M!=R*W1#=EMX<WJ+?*=^OX#;@O>%$X<SB4^+;XV/CZ^1SY/SEA.8-YI;G'^>I
MZ#+HO.E&Z=#J6^KEZW#K^^R&[1'MG.XH[K3O0._,\%CPY?%R\?_RC/,9\Z?T
M-/3"]5#UWO9M]OOWBO@9^*CY./G'^E?ZY_MW_ ?\F/TI_;K^2_[<_VW____M
M  Q!9&]B95]#30 !_^X #D%D;V)E &2      ?_; (0 # @(" D(# D)#!$+
M"@L1%0\,# \5&!,3%1,3&!$,# P,# P1# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# $-"PL-#@T0#@X0% X.#A04#@X.#A01# P,# P1$0P,# P,#!$,
M# P,# P,# P,# P,# P,# P,# P,# P,# P,_\  $0@ H !\ P$B  (1 0,1
M ?_=  0 "/_$ 3\   $% 0$! 0$!          ,  0($!08'" D*"P$  04!
M 0$! 0$          0 " P0%!@<("0H+$  !! $# @0"!0<&" 4###,!  (1
M P0A$C$%05%A$R)Q@3(&%)&AL4(C)!52P6(S-'*"T4,')9)3\.'Q8W,U%J*R
M@R9$DU1D1<*C=#87TE7B9?*SA,/3=>/S1B>4I(6TE<34Y/2EM<75Y?569G:&
MEJ:VQM;F]C='5V=WAY>GM\?7Y_<1  (" 0($! ,$!08'!P8%-0$  A$#(3$2
M!$%187$B$P4R@9$4H;%"(\%2T? S)&+A<H*20U,58W,T\24&%J*R@P<F-<+2
M1)-4HQ=D154V=&7B\K.$P]-UX_-&E*2%M)7$U.3TI;7%U>7U5F9VAI:FML;6
MYO8G-T=79W>'EZ>WQ__:  P# 0 "$0,1 #\ ]522224I))))2DDEG,^L'27M
M+VW^T$ DL>!)W;>6?R$E.BDL?(^L-;+/U84W40 ;'6NK(L(<_P!'9Z%GYC/]
M)_UI1?\ 6)K22&TN87!M;Q:Z#(>[]([[/LI_F_SW_0_S$E.TDL5OUA=8UPKJ
MI?:-HKJ%QW.<XN8QNWT-[6NV?SFS]]6&?6'I)8USKPUQ:"YH:\QI,'V?Z_VT
ME.DDJV'U##S@XXM@L# "[0B)W!OTPW]QRLI*4DDDDI22222G_]#U5))))2DD
MDDE*0+69I<XTVUM:?HA]9<1I^\VVM'5"[,Q['N8X93'4N,EE-P!@AOM>RO9<
MUWYNQ)22Y^35[K,FBJMQAI>P@R9+6[C<UKO\U1^T^]Q.91LB0V!+9^@[=ZON
M^@_\Q5W9&-$N.:6SM(--NDASMVWT=VQFW^=^@E]IQ0(+LQVYO_<>TQK /]']
MK_;_ )B2FTR]Q>!]KH>'.(#0-3(EM;3ZOTO[*FVO.@AUU9TT(J(U_P"WG*CZ
M^.TFS]=/IG5OHV.W;QVVTN^AN_ZTD+<8L+=V?HWDUW@Z'=,FH>Y)3J5BP, M
M<'/[N:"T?YI=9_U:D@XV2S)87L98P [2+6.K,P'?1M:QVWW?21DE*22224I)
M)))3_]'U5))))2E68<FTO+;&L#7N:!LG1NG.Y657Q7- MD@?I7]_-)32?U05
MN>UUEP]-VQSOL=^V02WVV;/3>W3Z;7;%5=^Q[/TKJ*WNM>XEQP7ESG-]SGOE
MF[_M1[7V_P YZC_26G?COO:ZNR^NRISMVRRMKQ .YK>=KMCOHJB[IK-0,7%+
M2WT8%54>FS9Z//\ @]U;+/1_P>Q)2%S.B -#L:H@LAG^3WGV!SH8W;6?SVO=
MZ7]M)O[%(>1CUCV2\' >TECMM1$/K;ZOTV[F,_,1/V722''#Q2X-@;JJ01R-
MK8W>U*SI=+VM#L/&=L#6M)JID-:US0V';V[6S[$E([!T,G;=35+CZQW8+P"Y
MX;;ZF[9[K7_G_P#"_H?YS]&DUG175OL;C5;-AW?J#@2TQ4:]A9O?])OZ/;]!
M%_9U>]I^QXPV L:X5TDAI+O:SZ/LW6/ML3MZ=6U@9]CQH#2WVUTAL.++'L#/
MW-[??^^DIGCY.-CO.)C?H(>X&MF)8QF[Z3GZ-;7[_P#2?X1.WK%;P"VVX@]Q
MAWF/ZT,]G]M KZ52TR,+%:!)(%5 DZ;?HJWC8'V=GZL['Q'/ ]054L$D$[=V
MQPW;6N24V:OM%M;;&W ->)&ZHM,'Q8]S7-4\=]KC:RPAQK?M#@(D%C+-=7?O
MJ3' ,:'V!S@/<[02?':H8Q!MR8,_I1_Y[I24G22224__TO54DDDE,7.:QI<\
MAK1R28"$6X5CBXBI[M))VD]H4LB@7U^F7.8"=2V-?Y)WM>U _9M(=N:YS3.[
MVA@X._;_ #?[R2DOHX,3LJCX-3>E@Z^RK34Z-51W2[2'-#JP-0T[6R6DGV.]
MFW^5]%/^S;H+8J#2#    .D>ST_H._/_ *E:2FUZ?3Q,MIT!)T;P.2J;<6XN
MTOPW,WR ,?79+MS=WV@^_;M_2>G^9_-J7[.R!(;Z6V7%LC@'0-]K?W?I).Z9
M:Y@UK!/TF0"W7^<:UQ9NV;OYM)3/$QVL8?MEF->[2'5U"H"!#]S76Y'TGHXK
MP")#:2(G0-X\54_9N2/=NK<]OT20-?Y3W-9]/Z.UWYB8]+N#G1Z>PC0$"03I
MVJ_<]G_?$E-O9T^)VTQ\&]D_I8$ [*H/&C=56_9ECBYSW,!<)T:T^Z23[WLW
M;%)G2JMI%CMQ.X"&L@ _N-+/8DIL"C")VBNHGF &SHBL8RL;6-#6^#1 _!5V
M8%3'BQKG!X(]P#02!^8[:P>Q6DE*22224__3]53?!,Y[&_2<&Z$ZF-!REZE?
M[[?O'AN_ZE)31=T[)>[>_)!>>2&$ G^JVW:D.EO:US670UT  AY( W>W=ZVY
M7?5K/Y[=8[CO]'_.2]6K]]NL=QWT"2F@[IUU;-S'FUS2T,9[A[03H=]Q8[Z6
M[?\ R$'[#F>X-86B0UIWDG:UK]I_GO*NO]__  CUJ^K5SO;]X[':D;:QR]ND
MSJ.WTO\ -24Y0Q<XM:TU%I);+]\[0T>UL>M[O<YV[]]+[#F^U^T^I],G>="2
M/T/NMV?R_5_ZVM;U:^-[?#D>&[_J4PMK/#VZQ&H[_1_SDE.4W#S)/Z-XWEVY
MQL,@/',>K_@W?N?^!)'%Z@'']$7-C:!NV^W]W^=_Z:U?5JYWM\>1W.W_ *I+
MU:OWVZ3W';0I*<VO RG%K7ES1[@YQ<XZ.#7GVB[_ $K?]:T0=*L[W[CJ1(?]
M([=SOY_]UOT5>]6L<O;I,ZCM]+_-2]6OC>W[QX;O^I24TCTRR &7;8:6B0XZ
M$[N]OT_^$5C%Q[,<.8;-]7^#:09:))]UCG/=9RBBVH\/;K$:CO\ 1_SDO5JY
MWM\>1X[?^J24S24/5J'+VZ3.H[?2_P U2D1/9)3_ /_4]'R7Y%N9]FH;2-E6
M]S[FE\A[BSTVM:6;?YOW^Y-]GZE,SBSS_-.\-O\ I?W5-O\ RQ9_X79_U=JN
M)*: Q^H]CB2(_P $[L/;_A?S4WV?J(TG$T@?S3NQEO\ A?WE+)Z)TK*L?;?C
M-=;;'J6"6N= ]-NY]9:[V-^A^XED=$Z3E6-MR,5EEC&"MKW#4-:2YC9_DN<D
MICZ&>1]+$@R/YIVLF3_A?WDC3GF27XG<N/IN[_3G]+^=^<J'4\7IN#;B^A16
MR]@_0$T6W-8&D; S[//H?I-G_'?S:S:\;$9=7ZF/C!M)JVN^R9C7!D->TLL=
MO]!]=5UO[^R_]7M_2>KZ:4]#Z6?(]^)).GZ-VI V?Z7]WVIQC]1['$TB(J=^
M;]'_  OYBYZLL8:1LQME36W4O;A9@@-L?9N92USO2VN:ZSZ:7H8Q8]UE=(]1
MUC=U>'FF+7,-C76;7_1;Z_NL_P"MU^E9_-I3T/V;J,1.) T_FG< [O\ 2_O)
M?9NHGOB&9_P3NYEW^%7-G%Q7EN^O&#-CB0[$S02QHW7^EN>WU/8=WI_\6K-Q
MH&07O937:RQ]U).%DE["_9F-+GUN_2V;A0[*V>GL_P# TE.W]GZB=9Q#,F?2
M=^</=_A?SDWH=1!$NQ >1^B=V&S_ $O]E<VS'PFN:QU6.*_;NH;A9K0 WW'9
M[O38YN[^;]%=(.B](LK'ZLTM=6RMLS/IL/JUL$G<UN])2XQ^I"(.((B/T3OS
M?H_X7\U1.)U(D'U,=H&FUM;@.=W[Y41]6^BAY?\ 9I)),%[R-3N^@7[-O\E7
M\>BK&I912W956-K&R3 ';W)*:+L;J5;'O+\=X#2=KZW$>)'T_P _\]6?M8_9
MWVW9IZ/K>G/\GU-FY%O_ )BS^J[\BI?^L[_Z!_\ HI)3_]7TEO\ RQ9_X79_
MU=JN+/M&[J.0T\'$:."?SKNS/?\ YBJ%GMB+099J6Y9X:?SM^_\ G+$E.VDL
M?:\&IS19+6R"]F2[5KG/W/W/^C[?T=;_ %+?^M*#*GUM? L8ZQP+G;<LZ0'-
MVM;8[;]'9[+$E.CD.ZDV]GV:NFR@@!XL>YCP9]SF[:[F.]GYB$S(ZR7MWX=+
M:W.AQ&07.:TF-^S[.UCO9[G,]55-CP!(M+7- AK<L& 6DR2__-_])^JGVW5A
MX)M< "T>W+))'N#A^EL_Z+TE),MG6,JME3\:IK(8]Y9E6UN#QM?#'TT,=LKN
M_P"WJ_\ !_X-5:^F=2 VVUV.;8XL>1U'(<YC'D.]6N:JF.]+\QFW?_PJ(:G;
MW!IM&H ,9DQ.]LN]3\W<]2_2 N##:T%@8/9EQIM;+O=]/]']-OZ3_A4E(VX'
M56WMRSCL-^\O>P9V0*YAKF.8ST?3V^HZQCL=U7I?X173;UPMTQ\9CH>?YY[A
MHP>@W^8JW>I?_..]GIU?Z157,=MEOJ1,,+FY>A(]V^OU-[]SG_SG[F_>EMLT
M -TC4&,S; [$;_I[O^@DIM^MUS2<3&[ D9#_ "]W]$5VLV&MIL:&6$ O:#N
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MN >WTL9OM?'L<ZO$;9Z3]WO=O24IV7TSUB#@DN]CK';L?VFS])[OUG?['/\
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M %  : !O '0 ;P!S &@ ;P!P    $P!! &0 ;P!B &4 ( !0 &@ ;P!T &\
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MQ &B    !@(# 0             '" 8%! D#"@(!  L!   & P$! 0
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MGZ>W9FMM=4=I=-;'PGQ[H.LL92G:>W<Q@MQ8&K@W!B.RH:?'UF)DBCI:>G*
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M]D%^3O\ WMQ^=G_H'?";_P"Y1]^Z]J'\ _GU[_9!?D[_ -[<?G9_Z!WPF_\
MN4??NO:A_ /Y]>_V07Y._P#>W'YV?^@=\)O_ +E'W[KVH?P#^?7O]D%^3O\
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M]D%^3O\ WMQ^=G_H'?";_P"Y1]^Z]J'\ _GU[_9!?D[_ -[<?G9_Z!WPF_\
MN4??NO:A_ /Y] K7;1^3OQ5^;_\ +VV;EOGM\C_D5U[\CNP?D9L3LKK_ +FV
MO\;*7;T^.V/\7>RNU=I9+#5G5G1/7.Z<9FL5N[:$+N_\1DIYX',;0BQ9M];P
MRL=(%.KK??NF^O>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO_2W^/?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=5>_'K_MZ]_,K_\ %=OY<W_6SY@^]>O5S\"?GU:%[WU3KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NJO?F3_V7Y_)]_\ $[_+3_X!;O?W[JZ_"_Y?
MX>K0O?NJ=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=?_3W^/?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=5>_'K_MZ]_,K_\ %=OY<W_6SY@^]>O5S\"?GU:%[WU3KWOW7NO>
M_=>Z][]U[HBW\R7Y2;W^&/P][!^1/76W-J[LW=M+>WQ_VQCL#O5\NFVZJD[;
M^175'3N=J*UL%5463%3C-O[^JJJDT2!?O(8O('CUHWNK*-3 =5-TG\Z_OC&5
M'\T/;FZ>D^MJG?/QU[8W7UI\!<'MUMWI%\AZW'_*3(_"S$XGL62NS-1,^X<5
MW[7[=7++AA1HN+S.J-$\8F?5>K^'\-/]6*]%T[&_GY_*G9?47Q(['.U_A;M_
M</;7P&["^7^\=C=@97M7"U7>/:/7G>6U^HX?BU\4ZS$[FR^37L_LVFSLL^W(
M:S';HFEJ8;2P_;K).F^M% -7&HZ/#O[^99\X=U8+YK_(SXR=$_'>L^+W\OC/
M[AVCVSL3N[=?8F#^1G=F[.G.K]K=M_); ; RNUJ2HZ_Z;J^M,5N9\)B#F:'<
MPS^<QL_E_AM.Z./=:TC -:GAT ^4_G@=X[B^>F-^/G2^T/CIO7KG>O8GPNVQ
MU'T[N!NQ-O?+GL_J[Y;_ !GVOWWN;Y"X2HI-P9;KRDVA\;8=S&KW-BZG&1)/
MB,?4#^+450U.9O=;T46I!K_FZ%+;7\RSYL=3UO\ ,GWK\MJGX:S=-_RR<9)@
M>P1TYL'N[;>^NZ^RMW=$;&[CZIH]@5&]>VMW87:%%F<SO_'[:FQU;3Y2IK,E
M4*T%7"E@^L]:HIH #7I/[N_FZ?,_:/\ +XW)V54_''J&L_F-]-_-CK'X4=T_
M&.BRFZ)=@9'L+L7>.SJG;%-UO7-N:/<6GL[JOL+"3[>K:JMJJ1<Q6NI%7'3M
M$^^MA 6H#BE>N?9/\W[Y';VZC_F _('XDX#XXU75'PKZ:^.?R@VR_<."[*S.
M?[<Z8[;^*^YNZ]X[*K?[D;^V_2;![=VOV!@OX,K2I74=$M/54M93"JC,B^ZU
MI  )KFO5I&UNY_DEL3X%]@_([Y!2=&;A[@VOT?V/WIBZ#J';?8&U^L?X-B.O
M<AO_ &;MW*8[>.\=X;LJ*^D@IDI<K50UT:53!I*>&GU"-?=:(&J@K2O52'4?
M\][L7*=2]%]C]Q]*[1P&?P7P_P#GA\B/FOUKM=\Q!NO9NY?BAU)\>^[^JZ3I
MULON;(8QMG?(;J[O>@S>(GRLU:CTM;"B5EZ2J=_=;*4U>E>C#X?YQ_S'-D[F
M^*VV_D7UK\0=I#^8=M_>6V?C;E>N*GMK>$?QL^0J=1;G[JZVZ[^2>/R^X,#+
MW/LO/;5V[/1Y'/;/FVX]+EZ22)*0TDT-:/=>HOE7Y] UUG_,[^?G^BG?O;G;
MF"^&]3B=K?S/.M?Y9^.PG7FSN[<743;A7YB[4^-O;7;V1S&Y>T<PBX#(8#.3
M5NW\3'1?<T%6B/5U-;&#3M[KS!12E>'1BNI_G;\U^^^K.X/G'U]L#XR;<^"^
MR\/\KJWJ[9^Z:OL_-?)[M7$_':@[4VKM[L.OS6.K\#UCL#&;][8Z[1AMZ:@R
M%73;<F:5LF*HI'[]U[2!VFNKI=?R>?GAV?\ S >C<MW!V9V#\;MVUTN"ZARP
MVI\?.J?D%UN_5N;WWU]3[TW'L??>4[TS>9I-_9+%S92GAI<GMWQXYDAE+%R\
M>GW7G720*'HC/QQ_G0_)3N/YC]B= S[,^,>\-K[5WY_,*VMN7:'74W9N.[P^
M-^ROAU7[@Q75O=O>HS.<W!M/</7G?VY<91X*G2@@P=139+)0O U7&M0D'O/K
M92@'KTS?&?\ G@]V]E?#.@^1N<I_C-WCW+W'O/X?]$]$_'7I?9'R!Z3BV;\D
MOESD*_';>V1W=VQW/E-X[=S>T\ J?=U>8VK1SP10XRK2[^:EE]^Z]I&* \*]
M&RP/\S[=O3O1'\POL?Y.=U?!WN3L;X.;:H)<_P!6_#S_ $MX[<FT^SZX;EVQ
MC.H^S\#VAF\_E1EM[=KT%#@=N5]$U,N2E>?530NBK[]UHJ*J #GUZ +??\XK
MY(]?? C ]I]B;0^-O3/S!Z]_F!; ^ 7R_P =O_\ OYE_CMT3N+=&Z:=,EVW1
MP87>>-WKFNOCUEN/!;CHG;,!)8*V51/((M9]UL("U*XI7KEL'^:=\]N_L;_+
M[V9TUUS\2=K=D?,;=7SVQD7:?8-/W/N?H;L38?P[@P\^P>Y.D\+@=P[1[&Q?
M7OR$ILG]U0-G7GK,?0Z9Q#5JT8F]UX*O<36@_P O4X_SJ.YYL9M6EK>DNL]F
M=@;3Z?\ YP$/R1V?D-P;HWAB-G_(_P#E;X_K$+B^O=XXT;9.X^I^PZS?HK9)
M:C&QY)*&:.&.1)H)'G]UX)FA^7\^FOK/^>?OI^K^INR.[.H=G;:R>TOA'\Y/
MD;\T>K]L2YH;[V+V5\3,!\:MY;'VSU@<MN"KPXV=WWL+Y#8W-X&?(S5R3T.3
MI"*Y?MJIG]UHK2OIT;OX=_-GY+]C?)7 ]&?*O?\ _+_Z^[#WETE_IF7X?=1[
ME[=SWRBZOQ^XZ? [BV;3;AW;NJHINONSZ'%[5KZA-P5N)P^)AI\BD9I/N:8^
M5O=>( %16O7#Y.?)G^87UG_,*^+WQ7ZOJ?AD>I/EO#W%N/9&X]^]?]WYCL?8
M&U_C=M/K'<O:%#NI-O=L[<VQNK.[UDWU/#@9Z2/&P8P1QM5Q5EG#>Z\ I4DU
MQT3OJK^?8O:%/\.^N<9C.KG^3G>/\R?>?Q'[CZK3;G;])A]A]%[9[*^0NTXN
MP-I[OK:0;2RO8#;=ZUVY5O V6JJ9YLG5!:5"@A@]UO1Q/E3H??Y1/\S/N;^8
M'NWLU.S=W?&#'1;/I^RXINC>I^KOD/A^UNO*O9_?.ZNJ]NY/>O;'8.X,GT[O
MC%YW ;1EJ9:?;\*5,-751ZBD:2)[]UIU"C%>E=_,)_FH;J^'/R?Z6ZIV?L':
M.\.HMI83K_MWY_\ 8&X*K*Q93H3X^=V=X;:^-/4F[]H+C<E2T%1G'[-SM=F,
MQ%70U(@VMM^LG2(:O/![KRK4'UZ0/9/\U3O;851\N>A_]''5$OS&ZT_F+?&_
MX=?&W:%2F]3U[V#U9\PCLK>_2';6^GARJ9R*NPW3?]]Z[< QM0E"M?LNI"&&
M,RQP>ZT%KFF.E%\>OYL.^^X_E;\@^J\[UELG;G0.5VS\F\K\ .VJ3,U]7D/D
M+D_@MOBAZ<^5U+N4?Q&;&2T]+V7F(*W;AQ<4!GVY!432F1U#CW7M(QG/2D_E
MY_S)^X/E[VMT+L'?FQ.MMN8KM7^4W\9OGWG<AM%-T0Y#']H=V]J=C[$S^SL3
M#F<WEJ9-@XW%[+@GHUF,N12HE<25$R%=/NO$#3J'KU&ZK_FI;HW]_,ZWM\4,
MAL/:5#\4Z[>?;/QBZ.[RI)<N=W;S^:OQHZ_V!VS\@^M,[%49,X"GVGCMF;YK
MJ/#RPTL=1-FMGY>$R36T4WNME:*#7/5<OQY_GT_*7M?9WR[W5D>O?C+NJKZ(
M^&'S_P#D[%MG8F&[JVID^D=U?$+?6ZMF=:;*[ER._L_)MWNG"]V+@UJI*W85
M9!/@C%)%6Q0">GF/NK&/*@>9IU9YT%_,5[<[9Q7\QRNSFQ.N<;/\-NH?C[V!
MU_'BGW,(MTYOMOX);%^5&?QV\6J\G4/_  O%[UW5+CJ-Z(4\IQ:)Y-4X,K^Z
MJ5II^?\ GZ+%U!_,"_F5]S]N?RZ]G8BF^#6V-H_/_P"(6/\ F325.0ZZ[\S>
MY>K=G;3VC\?<[V?L*I-/W-A\3NW<F:KNZI%P&11*"EHHJ1164U207DUGK9"@
MD$&HZ&/H+^8W\L>XOEGB?@7E^A]G;5^0_1/:7:68^<N])<+OF/IO;GQ/Q2--
M\;>SNC:^NS,1SF\OE>NY\2F(H:C)9*; ?W?W*^1HE%/2J^^M$ "OD>A^^4/R
MV^2P^8G77P)^&&T^D3W)F/CWN7Y6]I]J_)*3?5=UEU]U#B]^4O5>TL%M[9'6
MU=@MT[\W]OW?\]1&VO+XFBPN,Q\M2YK))8J;W[K0 IJ:M.JMNW?YYO?FWL5\
M:-L+@_C#\;NRMP]Q_/;XU_*[<_<>W>_OD%U5UWWG\'Z[KC$_P_J/'=(2[*[$
MWALWMIM\?Q&CKZZE@;%496&H62:(M/[JZQUJ2#3'\^K+OYH/SC[4^%G4_P 5
M=R=?YWXV;3ROR ^36P.AMY=N?)B;<^'Z%ZEVWNCJ_L_?65[(W'+C-Y;'R%!B
M:7*;"IZ.+[W+TT48KP)'+@ ^ZJBZB1U39O\ _P"%"OROH<#\<=R[<Z5^,^P,
MYVY\.=N?(?!]'=Q5G<J=D?*?M'+?*S>?QSPO4'Q5S&+3!U6)B[FVSM>EW?LF
MKSNVLG53X[+THJZ9(/)6)KJWAX)\ZTZL@[5_F$_.3=6=^=>^?A]TU\:-Q]&_
MRX\UD=D]L;>[LW?V)C.VOD+VCL#J7:/=_<W7_4V?VE2C9?4*;-VIO"GP^,R^
M<H=R4F9SZDM'1T-ZA=]5 ' UJ>@Q[A_G#]]8+>/QWVCTMTSUQO1OYH71O0/9
MG\K'+[QK\IMZ@BW;O&#:&4[_ -M?+J&DW5+DL9B^G^O-\4>\Z*? 04W\:HX9
ML)3//E"DGOW7M(S\CT*G8'\QGY>[)^7N9_EV4_1FQ\S\H>P.W^N]U?&OL=-O
M;[BZ$SWP*R% ,SWA\@>Q)TW&TN.[ Z&J=LY7:U;@4S5!+E]S9[;ST$$U%/4L
M/=: %*^70A?S>_YB?='\O+;_ ,9-T=0=8['[2H>QNV]UTO<&)W;_ 'B_C6,Z
M.ZIZLW9W)VWGNO1M_*XR([VP>P=EY&NI_O4JJ0I2N&A:X(]UM%U5Z3/7G\TK
M>6\OYH???Q=R&W^J<1\+NHOCSV=V+B?D!]]N%]W9[L#H9/C_ %_=S/7+DYMF
MR=<;*H^_:6DDFAI14+6T$I$TB$JGNO%**#Y]%8ZN_F[?-;O#XJ?++M? =5?'
M#IKNCHCJ;;WS^ZMV/VM0=E;FVUW)_+5[3ZN[,[&Z9SD7]T]]87,X?O3,576U
M3B\U5QRU.$Q504+4&JHCC7W6]*A@#P_U?+I@[D_FU?-OI#8G\OFH[/W5\$.L
MMP_./I;M[Y U/8^<Z7^5V^NMNN-M[?V9T;NOK'K--A=<]D9;L;<6\<D_:M9#
MELV*FGQ8CH%>*E@9A')[K80$M0&@^SH0]\?S>/DMM+^:+7_!K%;8^,.[\/A?
MDM\3^@_]%-.>S,-\H-^; [RZ"VGV]W)\H-AU$>X=P[(3K?X\29NLK,GBZW%+
M))AJ-EDR=/5F):CW6M'9JH:]1^R/YQ_R5Q_P]Z\W_P!-]*]2]G_+SMWY8?.#
MJKKCI\S[QQNS,]T9\#=]]ZY'M[?@8Y_^\ W(_4/3=/1TI%3]O+N[<5 JTQBD
M%&?=:"@D^G1]^JOYAO\ IQ^9WQBZ<ZPQFU<S\>?DO_+=W)\Z]M;\F&4&^Q6P
M]H=,[3VO@/'%D3@:3#S;9[/EEKH9*>2MCR$ 3R1K&Z/[K16BD_.G07?"?^89
MW)\F/FO\G/CWV>?CMTBG2&[.T]M87XJ[AI.U\1\U*G9FS-X8K;W7WR&J<ANE
M\/UAV%T[VOA9)LI'/M/'U]!B(LACH6R]7++(![K9 "BE:]7+>_=4Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NJO?F3_V7Y_)]_\ $[_+3_X!;O?W[JZ_"_Y?X>K0
MO?NJ=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=?_4W^/?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=5>_'K_MZ]_,K_\ %=OY<W_6SY@^]>O5S\"?GU:%[WU3KWOW7NO>_=>Z
M][]U[HM/R\^+>Q?F=T%NKX[]DYO=NWMG[MW'U9N?(9;8U=C,;N:GKNI.VMC=
MQ;?AHJS,8G.8^.DK]Q[!I*>M5Z9VDH99D1HY&61/=;4Z34=$YH_Y/GQDA[EZ
M>[OR&YNVLYN?I3YB?*CYJ[5Q>4W#MU]NU_8WRPW&F]MV[4W!04VTZ:HR/7NQ
M-_45!G=LTJS15M!D\;!)-55 \BR>ZL7)%/E3I3_%?^57T!\2=X_&O>^QMV]I
M;JR_Q:^)F\_A_P!>IO[*[3R]-6[#WQVIMWMK*[LS_P##=GX>ID[!@S>VXZ."
MLHY*.E&.GFC>F=V$B^ZT6+5KZ])?N?\ E#]'=O[N^0E?0]U?)[I_JCYA9C%[
M@^7_ ,<>G.QMN;6Z:^1.<H\1C=MY[+;@3([%SO8O75?V;M/#4F'WE+LC<.V'
MW5C:=8Z\R2M),_NO!L4TCHI'S!Z._EB]!=\S4'</R [@Z9[Q[^^0GQ,^9G36
MT^JMD[GWC6=9;J^$NR]C?&G8M7UCMGK+I3?5)M?K'-;'6/;.YX<VLU-4X_-5
M<234T#+X?=;%6'#ATG?D=L/^4#OKY'=^_&CO+Y@91-Y?)_YJ_&'NKY#]*5>6
MI'ZBW+VGU)UOL[9G4WQ7[&WW%UM5; VQA.QCU_A\O5[/R^XJ;=.:R$$4=-(E
M/*E,WL=>&H#4!TQ[4Z'_ )+=/\QM_?&_I#OBMZ3[:SOR3^).ZLY\<=B8W(;/
MZK;Y4?R^=ZR=Y;4H]F;@WAUC/LJM[3W/M_+4]%O'$8K/5.1RV#I::2*&GJH?
MNO?NO5:E3U$[IV#_ "??AQG_ .91\2NR_D%W7U-N?^:#3Y#*=I]?87K#L_=G
M]V3V#L;=4.8H?C%5[0Z W7MW(S?:;LRF>J</#-N1L-+4,\M/34@$(]CKW<P'
MIU:)OCO7X3[K^(O<?56:[Y%)TWM_/3_RWNS=Y8^FS(W+L_N#>]!MCHR+K^=F
MVG5+3[^7)]DXJ#[C["7&TU95J\Y6*.4)[K6=0/GQZK8Z4^-G\GOLWYK87K/K
MSM+L?MCO+HOX9=B?RNNY.L)MG]@R]1]H]>=2[/PG5'8V)[OWW2]1X;K?*]S[
M8VA''AJZ7';CQ\\U+,D IG2GIEA]CJQ+4)/ GH2NA.JOY>72WSGZ0Z!W9\Y>
M^_D%\COC!@-V]>?$'HCY([GBRFS>C9LSU[!D]R8/KK=VW^G^O]O]K]SXKI;,
M+1QON;<F[-W8O:<I5!&OEG;W6C7373CI%;6J/Y2.Z^A/DQM_9'S4W3N#8'37
M\Q/"_P QON+<^W'FS6?V]W)G?EEC>T]LXW8E+2]3U;]F]';@[OVNVVL96;9H
M<\M?+#44-/E9*^)WC]CKQ#$J*9IT\8+9?\MWK3XQ_(#YC[#_ )A/<?7W\LWL
MFN^0.1[<Z2Q^YMMY'XW;3W[W^VY^N.U,/M[8^Y>E\U\B>J\Y-V3V%5Y.'8&,
MR5#2T>[JB)X</'&S4DONO9';I%>K#?AKTMM7X2_&"EGK/F#W%WO\<=B]*[ R
M/7FY.^H^HZ7'=2]$]5];Z<;4X?+=8]2=7Y/(X:;9%'3U==5YW^)US"D1A)&3
M(K^ZT34\,]5O8;J_^5+L/IGXL_/:+Y@;XHNB]U_)'Y<[HZ@[?R&5J*7:_9.4
M_FA;@WCB>V.BMV8BFZVH,G0]=#?3)6X^'*4>/J]NY?;%-4Y&LO35)D]UO.1Y
M]-66Z+_EP]"_&/=_P*^47\PCN_L'IOIKLOXB?%+KS'=F5NS]A[[^(G?U+MC'
M]I?%R;J'MWHWHKK3=6W^R9=N5>+R]-N#(Y#*T%+2T*0U<T5,:VGE]UZIK4*!
M_J^9Z]V#\1/Y=>YMZ;^V9\I_G?WS\@-V[[^8'P4^+O>6WNY7Z[I:;MWM;I7
M[L[D^)'Q)WYC.LOCYU]MK-[8W%_I9_O+EIZ>)9<[6Q0BOR:%)Z=O=>K7(4</
M]7GTN%^!/\JO8'8WRNWAU]VKFNB]K_$GN_X7_*_Y0]2;)R-/@.I.E>V/B#MK
M*][=>[YK<=FME9":G7L_JC=5.=X?PRMJCE\?0TH5Z:OBD9O=>U-]I/21QGQ#
M^ +[!^"W=_1GS][^Z7V+V1\E/DMD/@)O?JN?K:2E3-_S&<7FMZ[^^/?76&[
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M919".*H@BEDIF/NJL:Y(%>DH/Y9'\LS^91M[OKY>;A2;Y48SY^;4Q#;5[EW
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M.B*?(G ?RG?GQ\QOD)T%O/Y2[K@^2?;7Q['\O/<'7& _C.T,-MW<W1G:-?\
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MVG7_ ,R2F^8E7E\Q\(_BKNKJ'MM<U@<YLB/"=5=V[JZRWW_I9WMU#G.L=O\
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M^(?1?6WQ\BWQM3-Y?/1X#9?9W9.R=K)EYZ7=%3BEDS=/5)*\8GC8[ZT&6N,
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MK5=.[IZNW72=8X"AVIELWA:/9*9[/5V0J**F+,_JDD;73@*J?*M#]G0I=K_
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MS'Q@SV*R]-F-Y;OZ/V9M3=:4%"'Q]!2U.+BT+/%+(8(]=6+C20 ./^3HW_\
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M2&U=]_&G-_-[MCJ#L_JCX\;!WMW/NKK+;6ZNOL/2[4JZ;.S8Z!*092-I*8/
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MN.FK:2+(5T=1+14,M3#'65D5&(S5RTM*[B>HCI1,GD9%(34-5KCW[KW6?RQ
M:C+&%*E]6M;: 0"U[VT@D<_3GW[KW0(]T?(CK;H7;5%O'?IWC/M:II<GEJ[.
M[)Z\WQV+B]M[7P-'%DMQ;UW96;'P.>@VSL_;^-F6HJJ^K:*)8=3)KT/I]UL
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M.47O'("K6(M[]U[INR>Y\/C*3-5/W#9.IP.#FW#6X7!1MFMQ2XV.GJ:F%J'
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M0.K7??NJ=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW57OS)_[+\_D^_\ B=_EI_\
M +=[^_=77X7_ "_P]6A>_=4Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z_]#?X]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U5[\>O^WKW\RO_P 5V_ES?];/F#[UZ]7/P)^?
M5H7O?5.O>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NB!
M_P PC';DS^ROCQM/#[GQ.!P.\OF)\=MM;_Q.<P%5N#%;[V95;LEK:S9&3I:/
M<VUY?X9E<GCZ66=/+*E0E/X9(WBDD4^ZLM,X\NBEU?\ ,"[YQ75>$[SI<5T;
MF*?O;J3Y3[]ZRZU2CW)0YGJG/?'.H\6WL3VGO&'<,TN],-5,5PV\*B#%X.7;
M&YJNGI*=*I)+>_=6TBM/3H]'>O>F\_BWU_U#V-VOF=FYO9%%O"/;GR1WKC=M
M9';&/P&&SVU-T#;>[ML45=N[+0[?H8^S*?"8B2"OJJXU$64 61)M%_=4 K7H
MAFX/EOWPV4H>N)NL,%_I?[<'7\6\L6-A[U[8P^ S>.^*F,[VW'LENILQVA@:
M."OFR65@PT0I*ND8TE!6Y">GJ:D*L?NKA1Z]+O<?\P7N'9F:3!]@;,ZWZSR_
M7^X^L^Z/D?@MWU66J<CU!\']Y];;-J-T[V>HQ&9--F-[;$[IW-D<)59.G6;"
M_8;8R,Q@U*"GNM4'E_J/63:?RA^0&]M\X?";2Q_5&S=Y=T;QZ+Q\V5W'4;ZW
M=1['ZX[&Z?\ E%V[MZMI=G1;UI<#E=\4>T>K,*QCI7Q%-6RY&I-7<T\(3W7J
M"F:]!UO#^85\C1U#NKL?;M9\9MG9GI7H#:':^_,/OMMVUV$[6W1N'Y!]G]$Y
M#%[,K*+<F$R>S-J4/^BBHEAFD3,57\?SN/QTGHBDEJ_=;""M,YZME[R[%J^L
M>C^Z^S]OQX;*YGJ_J_L7>U#09:JECP\V:V9L[*[DH\=G)Z)ONJ2AFGHHUJ2E
MI4A<LO-O?NJ 5('5:%/\R_D[Y=F;%I<]\:MT;U[53X1[FP6_=OX/=M1L+9.V
M?E?4]E4FZ\*^$CW^]?O?,;4I.MILMM.H_B6+7<6-JA]S#2^ S3^ZMI'SIG^7
M4"O^8/R#PV.[ J.OZ/IN@VKTKU1WAWON^'=;[^W'G]_5>POEGW1UA6[+QF2J
M]W3?W&Q6XMI]=5=8,@_\57$Y::&F@I#01>%?=;TCS_U8Z6U;W7V]L7<O?.6W
MIO;"=FXO;/S3["VYUGMVIQN6V,W7.U]H?!7<_?&*VQ5UVW-V:=Z4D^3HJ>.1
M,G3>%DJ*JL\1D:D%'[K5!BGI_EZ;:;Y@_)C$8#8&V]UU/24W87>>)^$67VKN
M[#;9W12;(ZEE^6&7[$P&[*#-X*NWK59'L*DV=DNN&@VQ4_?X-L[D<S2TM4E.
M8]51[KVD9IP%?Y=#CUY\MLQ#\7.[>Y.Y=R]?TF4ZB[D[RZ9IMX=:[3W1NC:N
MX\AL/N#*]1==5F/V-'N6ISN5W1N7-_PZBK\13Y:.)<[+-2QU44*B9?=:(R!T
M6[:'S/\ E5V++'USMN/IK:V^]J;N^8NU]^[KWSMRMKZIYOC-ANH<YM:F7KS8
MW:.=PN RVYZCM2.AS\2;FR:X^&G-13D32BEA]U;2O'RQ_/I,[P^7/:W=*==9
M89[I?KG85#\D?Y9^V<IL*;<6X!V7NG*]_GI7NFOR.W=UTV5Q="<69=Y)AL/B
M),14KN"EP^7DGGALL,7NO:1G\^A-_F*_(#L_ X3Y,=6;-W9U!UQMGKOX;2]R
M;HS?965SV'W!O,;_ -W;OZZBQ6S<]ALWAAL:CVG3[8D>7,F+*2OF\OBZ44\2
M,SR^ZTH&":\>N6XOF)\BO+69[8$/368I=T_(ON_XE=9]*5=#N&N[,P^_>K-G
M=B9#;&\]^9VCW'215%1G=P]=_?9C;L&*I%QVS\S29"/)/) _W7NO4'G7KVU?
MY@V^>Q=X4-#LN@ZV?9O?F3ZRH_B1E7BS&2R6<H]IU]-2_-#([S:'<-%0;ABZ
M3A-2]-_"5IA"*1_O#^![KVD?LX](>7Y+=Z=@;1ZSPW;[;#7_ $N[ ^$WRBV[
M%TTNY</EMH1;G^6G2>V\[U<E1ELY7S=@4N:QFY:/[.O'\*,U2]31S4TD,L3+
M[KU!FGSZ?<+\_NR<3@>KNP.P\[U--LWY*=,]J=F;#Q/6>TMS[YW7T=N':>Y]
ME;6V-LS=-#%O+'S]OU>X<]V!C]L9$01;7DI-] 8]/V*G72>Z]I&?ETB\Q\U^
M_-^]<=A; _BW2_7>\MC[,_F _P"D/>O8%-44.,RR?%.+96W:'"0XK97:65QW
M76Y:]>SHLIN*J@W#GH\!0XLS112FJ,5%[K>D5^6.GKHOOSNO*XOX]]2=1Y+K
MC!9;L?';3P.9["[!EWUVC-0XG9G\OGXY]RXK*8S;AWKMRCRV8S6[]^QT=<8:
MC&T\N*#5I1Z^1Y)?=>(&2?\ 5GK)5?/_ +XS^VX^QMN0]&[.PNR\)_+^;=VQ
M-W0;ES66[%R_S+W)M"BW14;'W)1[DP!P%!MG'[@J*#:,<E!DVSV<H:E*IX$B
M,:>ZUI'^'^71@/G-\S<O\:*BE38L^-SN>V-MG;O;':.R,GM(28U^J]Q=FX+K
M'&UV7[0R>^]I8CKQLUF*O(T^-^UQNZ,I55M&77'-3P2K-[K2@'CT^?'7=_?V
M?VQ\[77?&V.R-Z;.^2_?6U^A<-E]L1[:P^T8L3M/;>5V%L#<M1C,^[YG!TN9
MRT)GJB**LDCGFE:3]R/Q>Z\:=OV=%;PW\R'MSL4T5-U[ANFZ,][X'KKK#XKY
M3-G=F5CJOEIA<KC<;\LMD[^Q&.RE'D,QM/H6EW*:QACOLYV39^X(WJ)&2(Q^
MZWI&?EU+Q'\R'M#<U5MU\3MWJ^AQ_8FS=O\ 1O7U'DGSIW!-_,3H<WC*?M[I
M_+0IFHZ6':76^WLW)6?82"FRM2=NY8?=*$4)[KVD>7^H=1J[^8_W!@$K&S.V
MNIZL[+VMOWH'L2EQLFX5RE+_ #&(LID%Z8ZCQ%+)F9(I]G=H8#!"K_AZ&IRL
M#;BQ(%59GU^Z]I%>/_%=#U\CODQWEUUOQ.N]E;HZ P=9M;X;=Q_)S=>?WWC-
MQU]'N7=?2&YME87.;1P-!1;QP;8/8=2,S6KFLI)-65VWM=&WAJ"[H/=> %*Y
MX]!SM[YF?(3L3<V!P&,@ZQZSH^Y?D.>D.L<IN7:FX,XO6F*VS\>\=WSNFI[$
ME?>F#I]V=O[NKLA-M_ ;<IEPU+#'CI\C-/4NIQP]U[2!^SI);:_F"]X;I[-Z
M-ZCI:;HF*O[N3M#;*]GXVMS>9ZVVCOCHSL?M7K8Y*H9LWCZJMVA\N\KLVG/6
M$?G^[,^#W+3%\FU#3RR^ZWI%"<_ZO\W33#_,][*;9L/=-1L[KVFZFHL(_0^=
MHI6S\>Y8OGXG6]1N27J2DE;(>1,#3=PTPZU- ]$U<^Y)D=:SQ^@^ZUI'#S_R
M="MC_F#WW%N;'9/,5?2\FW*;YB[=^"F?ZYH\!NBEWM/ORMVIB?XYVWA<S5;M
M?534V[*^3/TFTY<8'FZZB&1?*I4/^W[KU!_*O1?NE_F=\OJ?8'Q]V7AJ!/E'
MV7%TIL7N;L7,8;85/25_;E#V9WMV'UZNW:;*P=@8?;73YZZVIL6LJ*S-U$6;
MI:JN:EA>EIO6M1[K95<GRZL:[6[C[$G^1?4WQTZNS>R-D2[QV!V+VIG>P=];
M=K=X4V;H>M-T[*VQD>M.NL#CMV[0AR>\4J-V?=YN>:L8X3')"133/5:Z;W50
M!0D]$;K?Y@_?F.ZKP7=L5!TKE<=W;UC\NMW=6]624FYZ+/\ 4FX?C9%EYL#2
M]F[GAW%.^],!65&(&)WM+38O!3;8W#74U+3K5@D/[K>D5IGH6H_E#\EMD]ZS
M=?[^JNE]U;+VS\F>HOCQEJK;.WMS;6W1NB/OSJNG[*P^Z8DR6Z]P8W:E9UED
MJZ#&_8 9,;DH?)5F;&3:*<>Z]04J/3JT[W[JG7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U5[\R?^R_/Y/O_B=_EI_\
M MWO[]U=?A?\O\/5H7OW5.O>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO_T=_CW[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW57OQZ_[>O?S*__ !7;^7-_UL^8/O7KU<_ GY]6
MA>]]4Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z:<M
M@<%GUQZYW"XG-+B,M09[$KEL=1Y%<9G<7(9L9FL>*R&8466QTK%H*F/3-"QN
MC ^_=>Z#VGZ&Z0I<UO3<E/T]UC%G^R(9:?L#,KL3;'\1WM3U%7'7U,&ZJLXP
MS9V&KR$*5$R5)D6:=%D<,X#>_=;J<"O2UW;L[:._]O9':.^]J[<WKM3+BF7+
M;8W;@\9N3;V4%%6T^1HQD<+F:6MQM:*3(4<,\7EB;QS1(ZV95(]UKATE=Z=*
M]/=CTF5H-_\ 5G7F\Z3.93$9S,P[FV=M_-#*YK 4$F*P>8R#5^/G>KRF'Q4S
MTM+4.6E@I7:)&6-F4^ZV"1P/4S)]2]59J3,39CK/K[+3;AZ^;J7/RY+9FW*Z
M3.=5.V09^L\Q)58V5\GU\S9:J)PTQ?'$U,I\/[CW]UZI]>G.EV!L.AKZ7*T6
MR=I4F4H7Q,E%DJ;;>&@KZ.3 87*;;P3TM9%1I4T[X7;N<K:"D*,#3459/!'I
MBED5O=:Z*]WK\)^N>]JW9&.RW]W-N==;72JCR6Q\)U7UDV0R45;NRAWID8]M
M=@5FW)MY=;KN'-4 _BS8:HIY*Z.1V5H:HBI7W5@Q'0JCXY=<T/6'=O5NVX,G
MMG%]^Y/N#<._<S05\E9GY]U=V+E%W;N2DK,N*^..MIER2QT$31M34E/2T\"1
M^*)4]^ZU4U!Z=.OOCWTKUCMW$;;V?U=U[AZ3$5NW,VLV.V/M7%SUFZMK86#;
M^'WE5+C,11P'==)C*<1QUR(L\2LRHRJ2/?NO5)\^EA_HTZX\.5I_]'^R?!G<
M5DL%FX/[J8+PYG"9G,93<.8P^5C^PT9#%97/YRMKJFGF#PSUE9/,ZM)+(S>Z
MU4^O6";JSK*ISNX-T5/7NR:G<>[!C!NC.U&U\+/E=Q'"X'-;5Q#9NNEHGJ,G
M)C=K[CR&-@:9G:/'UL].I$,KH?=;J?7I'=J]&[8[$V!GMEXG'[+VK59G;VW-
MI)E:[J_86^\8FU=K9F/,X?:63VCNW#UN"S.TJ.8S""@D5(Z1YVEIC#-9Q[KP
M.:]-_5?QOZVZQZ<JNDY,3CMZ[3S]7NW*[YI]S[>VR,7O;-[^S60W#O&KR6TL
M1A\9L['XO*Y3*2B+&4=!!04E,(X(H@B"_NO$DFO2[VYU'U5L^BH,=M3K786V
MZ'%T^;I<=383:. QD5%3[F3'Q[EBIUHZ"+QKN-<32_Q"W-;]M%YM?C6WNO5)
M\^FRIZ)Z2K-Q;7W=5]0=8U.Z-D8["8C9NX9]B;8ES&T\7MF;[C;5!MO(/C&J
M<)2[<G);'I3-&M$6;PZ-37]UZI]>IV^^G.I.TJK"UO9?6'7_ &%5[<^\&!J-
M[;/V_NB7#KD?M_OX\<^;Q]::6*M:DA:5$LKO#&Q!:-"ONO5(X'K+!U'U72]A
M57;5-UOL6G[2KJ(XVL[%AVI@XM[55"U+2T#TU1N=*$9F6.2@H8*=M4Q+4]/%
M$;I&BK[KU32E<=8,3TQT]@!L]<%U1UKA5Z]7=B[!7$[%VOC5V.N_9)9=]+M
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MOOW7NO>2/_CHG_)2_P#%??NO=>\D?_'1/^2E_P"*^_=>Z]Y(_P#CHG_)2_\
M%??NO=>\D?\ QT3_ )*7_BOOW7NO>2/_ (Z)_P E+_Q7W[KW7O)'_P =$_Y*
M7_BOOW7NO>2/_CHG_)2_\5]^Z]U[R1_\=$_Y*7_BOOW7NO>2/_CHG_)2_P#%
M??NO=>\D?_'1/^2E_P"*^_=>Z]Y(_P#CHG_)2_\ %??NO=>\D?\ QT3_ )*7
M_BOOW7NO>2/_ (Z)_P E+_Q7W[KW7O)'_P =$_Y*7_BOOW7NO>2/_CHG_)2_
M\5]^Z]U[R1_\=$_Y*7_BOOW7NO>2/_CHG_)2_P#%??NO=>\D?_'1/^2E_P"*
M^_=>Z]Y(_P#CHG_)2_\ %??NO=>\D?\ QT3_ )*7_BOOW7NO>2/_ (Z)_P E
M+_Q7W[KW7O)'_P =$_Y*7_BOOW7NO>2/_CHG_)2_\5]^Z]U[R1_\=$_Y*7_B
MOOW7NO>2/_CHG_)2_P#%??NO=>\D?_'1/^2E_P"*^_=>Z]Y(_P#CHG_)2_\
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M_E4?]X*]!_\ H,5'_P!</?NO:W_B/7O^&6?Y5'_>"O0?_H,5'_UP]^Z]K?\
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MNO:W_B/7O^&6?Y5'_>"O0?\ Z#%1_P#7#W[KVM_XCU[_ (99_E4?]X*]!_\
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M]^Z]K?\ B/7O^&6?Y5'_ '@KT'_Z#%1_]</?NO:W_B/7O^&6?Y5'_>"O0?\
MZ#%1_P#7#W[KVM_XCU[_ (99_E4?]X*]!_\ H,5'_P!</?NO:W_B/7O^&6?Y
M5'_>"O0?_H,5'_UP]^Z]K?\ B/7O^&6?Y5'_ '@KT'_Z#%1_]</?NO:W_B/7
MO^&6?Y5'_>"O0?\ Z#%1_P#7#W[KVM_XCU[_ (99_E4?]X*]!_\ H,5'_P!<
M/?NO:W_B/7O^&6?Y5'_>"O0?_H,5'_UP]^Z]K?\ B/7O^&6?Y5'_ '@KT'_Z
M#%1_]</?NO:W_B/7O^&6?Y5'_>"O0?\ Z#%1_P#7#W[KVM_XCU[_ (99_E4?
M]X*]!_\ H,5'_P!</?NO:W_B/7O^&6?Y5'_>"O0?_H,5'_UP]^Z]K?\ B/7O
M^&6?Y5'_ '@KT'_Z#%1_]</?NO:W_B/7O^&6?Y5'_>"O0?\ Z#%1_P#7#W[K
MVM_XCU[_ (99_E4?]X*]!_\ H,5'_P!</?NO:W_B/7O^&6?Y5'_>"O0?_H,5
M'_UP]^Z]K?\ B/7O^&6?Y5'_ '@KT'_Z#%1_]</?NO:W_B/7O^&6?Y5'_>"O
M0?\ Z#%1_P#7#W[KVM_XCU[_ (99_E4?]X*]!_\ H,5'_P!</?NO:W_B/0H]
M+?RP_P"7Y\=.S-O]R](?$OIOK;M3:=-G*/;&_-N;:$.X]OT^Y<548+<"8>OJ
M*BH?'G,86KEI:AH@K2T\C(Q*DCW[KQ9CQ/1[O?NJ]>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=?_4W^/?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW6-9HGDDA2
M6-I80AFB5U:2(2AC&9$!+() ITW O8V]^Z]UZ*6*=!)#)'-&Q8"2)UD0E&*.
M R$J2KJ0?Z$6]^Z]UD]^Z]TR;BW-MO9^)FS^[=P83:^"IJC'4E1FMQ9:@PF)
M@J\OD:3#XFEFR.3J*:CBJ,IEZ^"EIT9PT]3-'$@9W53[KW3W[]U[K'++%"AD
MFDCBC! +RNL: DV +,0H))L/?NO=>::)'CC>6-9);^*-G57DTB[>-20SZ1];
M7M[]U[J-D,ECL11SY'*U]%C,?3!&J:[(54%%1TZO(D2&>JJ9(H(@\LBJ-3"[
M,!]3[]U[J!A-S[;W-_%_[M[AP>X/[OYS(;8SW\$RU!EOX)N3$^+^*;>R_P!A
M45'\-SF-\Z?<4DVBHAUKK07'OW7NGSW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U__]7?X]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=:VG\Y+=_:GP;^1NR?G'T/MW=^=W9\J
MOB?W)_+4J*+:E#59*FI?DON:ID[%_E_[RS>.I66GAAQG9^1W3B:K*3:#34>2
M2'6VJ-5]U=<X/18.J/D!\E?A3W3UI\#^K^U,_A\Q\;_D[\2_AETG_+[K^@</
MN"+Y1_"G+]<=?0=X?/[*]T4VUY=[XO-5.X,_N[=LFX*#.TVR]G5.U?X-F\96
M5>0UM[K9R"VG\^@LV/\ +7Y8?&/KWNKK"F^57=.YLE1?SG?D]T]\M.X>QGZ'
MV_O_ .*G2-7)V?NGX_;PH\KV_P!.Y?J[JG:GRVJ<3@JF@W-N;%93K_'TE8,?
M@*?%_<4_AU]O5J E2$Q3H[/ST[-[S[A_X3H57:G?.5Z\W?W3F7^*NY=R;VZ0
MPF6[#Z^W#_=SYP=-3;:[7VUM;#8ZCKMTQU>U,/0[BR&*QU-#2SUGW--1!:4P
MM[]Y=54#70C&?\'0(U/\T_Y:=)=4[J^84W;V[OEU\,?CQ\[^W/CA6]CT/0^Q
M]G5_RIZD[:^.> JNCMV42;=VMM&""7H#YVU])UP^X-KT=!BMQXS+2K415%;0
M23G?7J MI( Z-C_,YZ0[:[4_DY?'KX\_,+>-=O[N'M_NW^71U?\ )G>6'QV,
MV[KW7VI\FNG,#VK68FAV!CL+A\=A]JU>XJR*B-+3PQM34432 LSEO=:4T8E1
MU6ET9-V]\@?G[_+([T[HQF[,-NKX(?(C/?RG\E!EY<R:;>G;G1GPW^6._/EC
MW9BJ6E::+-X3L7-;>V+28FMT/%7R0ND)+J;:].KD@*P'GTC>W_YEGR-[M^/O
MS<P3[ER/>_4&XO@_LKY)[7V5\C^CNB^Q]U=2=J8[YT[3ZJR_3>_MB=3]1[8Z
MZP>>Q.QLK1U&7Z_W!/OC<NU\A24U9/F0\[PK[K8454\,_P"3J_W^4)0+0?\
M#H(7&5&,^\_G!_->O/W&,J<;_$&J3UH3DX?N::G_ (A3U17TU*>2.73Z7:W&
M^FWIV4].K@_?NJ=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7_];?X]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7K?G\GW[KW7O?NO=%[[U^+_ %#\DLCU15=Q8S<>
MZ<1T]O\ Q/:&V]CQ[XWAA.NL_O;;=?C<UL_+]D["P6:QVU^T(MD[DP])EL/2
M9ZFKZ.@RE/'4QQ"5=7OW7J]&$]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U__7W^/?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7__0W^/?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO= UWGW'0]%;/P^^\W@ZO+;9J.Q.M=D;GR-+D,?01[.Q/9&]L+
ML.'>V2%?)&:S"[>S.X:1ZV*#5.*9GD4$1M[]UX=%UC^=^U)]P?*' TO6V]ZR
M3XY]E=4]782:GJ,%Y.[\[VCGMM]?QU'7-%/7P5*8[;'<&:JMI5TM:(5.5Q<Y
MC+1&-F]U;3PZ?.E/G5T7VGLC.;CSV^-F[(W!LG;N]]W=AX"HW%)6XW:VU]A[
M]W%U]G\_#NFKQ6'Q>?QN*S6W_!7M1^1L=5SQTU0L<TD:O[KQ4CK#NSY[=$8E
MNLL7M'(YK?NY>Z<7WU)UIC<3MS<-!12[C^/&R:[>N_=J;]K<GBJ:LZTS5)!1
MBF-/EJ6&JCGD&J$ 7]^Z]I.>G?J_YR?'KL;IQ>WG[!V_BZ+#[1ZKW'OG%TDF
M6S4VW:_M[#X^OV9B,-]KAHZ[?B;FRE8^.PU1AZ:KCS-=!)3THDJ(Y(4]UXJ0
M:4Z$7;WRE^/>[MU];;&VMVOM7<>[^WMGU^_^O-O8.HJ<ID\_LK%'(Q9/<[T]
M%2S'#8?'5V)J:*>:O^U6+(PM1M:JM#[]UJASCAUGRWR;Z&P7:J](Y;LS;]'V
M@WVL3[6<9"22GR5?MZNW=C=O5F6AHI,%1;MRNT\9/E*/#S5296KQT35,-.\/
MK]^Z]0TK3'4?%_*?X\YGI?+_ "+H.VMI'HG!QU=1DNV*NKFQNQXZ"BJH**;+
M4^>R5/24>0P;U-5&L-=3M+1U&L&*5QS[]UZA!H>/2>K/F?\ &/'[(B[#J^V<
M/'MN?>F8ZZBC7$[GFW0V^MO4$V8S^U3L.'!R;Z7-83!4[9*K@.-#4^+ K9--
M(1,?=;TFM*=..S/E;TOV%W7/T/LO/U^X]W+TKLWO^AS6+PF3J]@YSK7?F4R&
M+VWEMO[ZBIVV[FI*PT G"T\[J8)T*,S"58_=:((%3TY5WRC^/>,VO1[VR/;6
MSZ#:=?@^RMRTV>K*YZ;'M@^GL]2;5[-R,DLT*&GAV9NC(4^-K!($=<A414ZA
MII$1O=>H>%.L^RODST/V'14E=M'LO 9,5<6_)#03C(8C.X]^KS@O](5)G-N9
MNBQVX-NY+:";GQLE=25]-35,,5?3R&/1,C-[KQ!'$=/FYN].I=G]:8;N'/[W
MQ5+USN6DVO6;7W%21U^7&ZUWLM&^SZ7:F)PU'7YS=&5W.M?#]A14%-45E5Y
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M>ZU0TK3'39@_EQ\==RT'567P/9F.RF$[NF,/5N?I<-N=]O;L,FX?[IXZ6GW
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M=Q8;&;DB&3BAK113U$#-#+&DH2/W7B:M6G0-[C^%7>6^8=W;4W1O[J>@Z_\
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M7+TE-705L_WWW%+54]1"CGW6]63T/76?3W8_7WQM[2Q?3=?T[L[Y =F5F_\
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MY^N=M5E*<CLK:FW(Y\K6XNFQ6+I,S-N,8NC5_-#KRZ]05I3/0Y]1]D=G[#^
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M.%I,?MBGRM#%B,WBMF)CZ_(5^0H^RO[RU'VNM8X5Q^^MT'IC'1[>WU[CV/\
M&7I#:>VNY^PI^Q=Z=L?'S86\.YY]N;2RV_'PG9G96!I.QLK38==HOM#!U/\
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M'2Q4D-37U%234Q_:,K^Z\%^*OETY[9^96:SW0WQJ[F/6#5.0[ZW=N3;55LC
MY[^(Y7'G =<]U[[I:+:L];C\73[DW)N*LZF@QE#2U!Q\+U.44M,HC]?NO:<D
M5X= 36?-CY'9'XD4ORIV'@_BAO"DDW?MG'9/9^,[([*K9=KT&],[LK9L.Q]U
MY2'9,5;M_MWKC=V[)8-R8ZJQ\+0_9M"8::=F6/W6](K3/1D/DC\@NTOCIT1U
MMNO<-+TM#V=O/M'J?J?<6:W#NC<6VNC]G9'L3<D6$R.[*S,UU#_>%\!B82?M
MX)S2R5-5)%$T\0;7[]UH"I('1<L5_,%WSONA^,QVC)\5MD_Z;=L]N[GKMZ=G
M]SY=>L]W475'<>T.HZ*3H/<..V_BZC?^/[4AW&^?V[45,=)++BGIM5.3,7&N
MMZ>/'H7/G5\Q=U_%6NZIH-KX_IV1M\X;N/=&1R'<V_LIL3&5=/U%MG!YZFV%
MLZ7%87,397L'L6LSJ46+B*/HDC9EIZIB(O>^M*M:](K'?/+<]?W9O_;>?Q75
M'5'7'474_7_:^^]F=D[GSM/\I,EB=V=(Y[N;<]-M;JNAH4I'K^OZ;%&AK:<R
MU+/-15QU1F!4;W6].!Z]+F?Y(?)?;?QY[5^478?4?5.U-CX7H'.]R]>=;IO[
M=-?V7C\A2;?.Y<)MWMS*_P!T*?9^(67$6?,28EZY<34"2&)Z^-/N7]UJ@J!7
M->@YW3\[>P^M-E;%W-G\?\>^YHLO2=Q[YWKN/X[]F9K<FSL)U=TE5]93[XGV
M]65N'K),]O;";6WKD<I4T<DM+ D6*T:]4MT]U[3QX]*+Y(?.S,]7;NW-L_K_
M  G6LM'@=Z_&3K&J[0[5WAD]K=;87?7R&K=TYR>+,9+'8JIBFQ.T.M,'C<B7
MBJHS5UNY*"#5&NN0^Z\%KUSS_P I/DW3Y3=QV#UQT/VMA>F/CKU3W?V6NW.Q
M=VX^J[1K.Q*7LO*U>)^/>9_NOFMN5N+BPO7+/AJK-2PQ9>KJXX99*"&]6/=>
MTCSJ,]&9WS\BL#@_C/'\C=H8ZHW-0;IV)LW<W5^ K5JL95;NS_:J8*@ZGVS6
M_:TF4K,3)NK<VZ\9132)!4/2"H9]#Z-)]UJF:=%$ROR[^46XMF?&C=?6G6_1
M&+R/<N^)^@.R=G]E[O[!CR_4OR,VI!VE'V?A(ZK;.UJB'<NR-JY_JBNQ]'/)
M%CZ[(K-%5F.")A&==6TC-3T-/RR[F^2?3(Z9J.J=K]'[DI.R^Q=B=.9D=A9_
M?N'J,+OCL3*C&8G/8S^[>"RD>1VIB#%(]13R^"LGU*$DCL2=]: !KT'N\?Y@
M6!Z_VQWA1[F_T71]R].=V=;],T/5O^DVAQF<W]+O>#HY)MT8/!9"D.Z:>ADK
MNV*O^'TZT=4U5%CDO*&E?Q>ZWIK2G"G0@_&SY*[U[P[=[RVOE<C\?*#:W6'8
M/:_7V*V3M/L#*[@[ZI'ZT[%EV+3;I[!VI445%CMO8+<T-!-5Q+&',7W-*@DE
M#L_OW6B* <>L^]_F##L_Y;[ ^/(VK05VP<Y2T>U=_P#:[[C^UEV!WCV!B<SN
MOHOJ]]LOC'&53L79VQ-PU$]>M7&N-JSAZ9HW;*Q%/=:IBO03=7?-+N;,#JC?
MG9O5?7>-Z2[\[JWSTCL/-[&WIN3*;WV%NC#[M[$VKUZ>R<)F]JX_$Y7$]AUV
MP?LY*W%52G#Y/(TT;T]12M-60>ZL5 J <CI/[:^<_>NV^N^N.Q.Z^F>O6PW?
M70_8G<O3M;U+O?<^6@QNY=C=/5G>-)U'V=3[KVCB*G'Y'<VP\77R46<Q9K:9
MZK%U4,M'3WI9*CW7BHJ0#P/058#^9MV=ENGH]TR[8^.S9^M[B^-O5]'VWC^T
M=PU'Q;I/]F!VQ_>K+09#?<N!BK9-Y]0"/^'9K%Q2:&JLAC9&GIFJWI8/=>TY
MZ,SM_P"6?9N;[WZVZ06AZ(%3D.I=L=IYW/KOO-)!WY1YJ@W%5;BC^&D9H),7
MV-C>O&PM,V7J,KD*.:!,G3O+3P4SQ5DWNM4P3T)OPV^0N[_DOL;<'8NXZ?JK
M"T#9Q,9CMB['W1N3/]A]6Y2FA=MQ]9=_8S<6W-M-M3MK:-1)!%D*"& 11RL^
M@R0"&IJ/=>84QTVT_P M:FH^8;?'0;)B'6\N-KMEXWMQ,K5S35_R1PFSJ;N#
M<742X&'$R8Z#%XOI#)4^8_BCY%97R"U-#]J# TK>Z]3%>B8=/?S3MW[ZVGG:
MVJZYZD[(WOE-K]*97KW:_1/<4.>H,1V%\A.S*[K/KGHKNW,[AQ%'+UUOJ"6C
MES60JUIJI$P6.R<ZT:R4D$5;[K92A\Z=#;NCYL=M]);ER&P?D'UOUGB]P[8K
M.EM[[DW?L3>NZZW8-;\>^U>RI.G]U[_PJYO9M/FJ+=G2N_:_%_QO$UH6"KPN
M0CR%+5%ON*2E]UK37(ZB=[?._=^S^T9^M.O:+H?;6*C[<R73<7;G?W9=?M/K
MT[NVCT+5]X;\HI?X+CI989<*,IA<,@>I0M629 Z6-$T3>Z\%J*]#;\M_E)NG
MXN]9=/\ 8U#UU1]KQ;L[9V'L[LB@VOG:JFJMO=<9';6Z-V]G=E[%IAB,E)O.
M;K[:VU*S,1XN1J)LAC:6;3.LPCCD]UY0"2*](_<OS#WOFNP)NF^D]A[,W?O_
M '/VIE=G]=[HSN\LBO5R=:[:^/G4'>^Y>Y-W9;;6!R^0FQA'<.+PV&QF+%0V
M7K*RFD:KI*4U$]/[KVG%3T&&\?F+\I:3$4>/VYU/TG@^S-G_ "*V=\6^Y=J;
MZWOO2IP=+O+M'(;%?J_M'K+<6V-MS5FX>KMR;/WW1Y>2GRE!B\M!*TM P$E,
M\[ZZWI'KY='-W/V[NC8^^OC!UQN';V!R&=[OR>[-N[PRN%RN0AQ&V,SLSJ+<
M?8>1J=N4U=CFK<SC*_,;=:C@%2U+*E-*)6NZF,[ZK3B>BH;E^;G8N$[-^4F*
MQ>V.H-U[>^-L&[*:BZ6V_OO*5ORS[1KMM]1[$[(ASNV^OOX>E!3[/JZ[>WVS
MRPID*I:2C>6".IG=*4^\^K:<#Y]-V;^;':.)ZS^.^X*:N^)V:J_D9O+=&$V]
MWGC.TMYO\2\!38JBBK-J;7R_8<FU4S([+[%R'W&'Q%#/#14\^2H:F+R?>+!C
MJCW7M(J>/1@/F=W/WAT!T\O;'56U^J=U_P!W<CM^CWM@NP<_N_!B=-V;GVSL
MW$':V3VW@LP0U#E]Q&HJ35TX\E- $0!Y-2>ZT ":$]!)NOYYTG3\'R:VKW95
M]-;<[4^./1NR^R:3$#LJ':^*[<W=NC8.^-US8#9F.W;##N.GP2YS:<>+I*@)
M75-1+,Y,2R((C[KVFM*<#TM]^?,F?9?R"Z/ZC_N/2UFSMZ8W:5-W+O\ ?.5"
MS=2;Z[J?)XOXX[-@P-)B*Q\W4=D[EVCG*2NFJIL<N(5,=(1-_$4$?NO4P>@V
MV9_, SNX,GV!M?/=1TVV]W[-^8>U^B,/CCNNJKL9O/HG???F6Z+VC\@,)DSM
MRD+3C/;;RM#E<*(W7&9[&2T3U;))!/)[K>GAGRZ&7Y:_+)_CH-B83:FTJ#L3
M?>ZMT[(GSNWJO<+;=I-F=/9/M#8O7>]^S,QD(,9F95FQE3OFFI<'CVAC.=S$
MB4R2Q11U513^ZT!6O05;!^<NX]Y?-+/_ !;FVKUK",-N/L?;N6VACNQ9:[Y"
M]?;=V'MO%[DV_P![=E]<'#1X_#=*]P?QRAHMO54=69VGR= P:H,U7%CO>?7M
M/;7I7=O_ #IV5TQNCY5[3WG6]=[:RW072.U^V]B8_=_9.(VKE.V:O<.U^S<W
M)@:#&Y:&&IIX*3)[ BHA4T@KV>2K/[:O&$?W7@M=/S/2(W)\Q/D#48SN+L/K
M/H/:&XNKOC+04"=QTNX.P,EA>QM\;JQ_7&W.S^T=J=*XJ#;-7A6J.L<!N6&E
MCJ,_44,6?SD4U#$*.&+[]_=;TC%3D]+3<'S3J<?T3\C>[<)LG%YS'],=F;<V
M?M&D&XJZBI=^[6W7@.F-RX+=E54SX 5FW9ZS$]N+)]FU/.R?:J&8-(PC]UK3
MD#H$L!_,3W]5]L=^;+_T5;.[)H.LJ;Y7S[>V3TKO++;M[KP\OQ?R?\+Q4/;^
MTGP'VFT8N^ZI)(-L/"TDCUPCIHX:TR/)#[K97 ST:WJ+O[<N[OC!G_D%FLAT
MGV&U'MG>N]MNR_'S>6XMU[#SN%VWAJG)4F$&X=R[>P^9IMS09"AJ,?D(Y*".
M2FJ(K/!%,)*:/W52*&G1%]C?S.=\;LZ0W3O44?Q=R>[,/D_AW0_WRVKW/F,K
MT-LRK^6V4Q]-)MKM'<DFWH\MMO>'3^*JX\AE*9&:.NQ^4Q=1KHFJW@A]U;1F
MF:9_ET..*^8_8![=V=U]N#=WQ!H=NT'2^Q>X^PMR8_LO=62R/9&(W76=Q2YJ
MI^,> I<945&_\#M'!=4FHGJY&E>:2>5!$@A#2:ZUIQY]3MC?,+O*I7H?L3L[
MH[:>T^DOE1D*;#=2_P $WYDLWVIL3,;IV;G=\=1T7<>$.VHMM1GM3%804DK8
M:MJUVWF:VEI*@UD#S5U/OKQ49 .1T!.P_P"97V1NKH;?'9-5M_XVSYO%X+XI
M[BPV\-L]OYS*]%;+F^478.&V/4=>=U[QFVW!6[1[+Z7I,FN7SE%3B83XNJHY
MG%!]PBGW6RN:9Z/3ENS.Z9/B[_I6V15_'??/95#MROW95U> W9NO*]';@Q&$
MGR-;DUVGNO$T%=GJIZG"T/B@F:%XDKBVL-&MC[JM!6AKT#?47S1S0A^/2?)N
M7HWJA_D3T?NKO/;F9Q_8U5BMN8VCH)>F)=N[ CJNP:';S[AW7+C.T:J:NE@:
M)%7'*T<!25S%[K97C3R/05=5?S!]^=U=@?'O;6WJ+XX=>87MKJ? ]MY =C]K
MY?\ O-NS'9_NC>G65)MSI.@H,+04F\<K)@]G+DHIG8QRS9.EA$?C;S-[K96@
M/'HR7R*[6^3VP>UNEMF]0[9Z&S6U>Y=QUFQJ3*=D;A["Q6?V_N?#;$[ [(RN
M0J*';&WLKCLG@I\!L;[6FC6:"H%94:W;QI9O=5 %"3T'&V?G;E\E\CNJ.F<_
MUICL-LOL:C^1N%R79,.ZYJA=K]E]1_(C<72766UJK$U&#I(9Z'N7&[%SM93U
M'W2RT>2IH*$1S_<+,/=;*XKT#^\_YDN\EW#VI@MG;4Z6V?@=M_*;K?H#KCMC
MN[L_([<ZYW7L[=73&[NP<]VOFJO%8-X\7CAO[KW,[:PM+#62KDO#%5O-#Y5@
M.NMZ1CCPZM7V;DLAF=H;5R^6K-MY#*97;F$R61K]FUT^3VA75U=C::JJJS:N
M2J56HR&W*F>5GHIY 'EIF1CR?>^J=*3W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7_]#?X]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=!?D.
M[NFL5LG-=E9#MCKBEZ\VYG<GM;/;XDWKMS^Z>'W1A=RR[,R^V<EGUR+8NDW%
MB]X0OB:BA>454.34TK1B<&/W[K=#6E,] OW1V!\;>]>M<O\ 'JL^0?5./K/E
M/U3N;;.PEH=[;'S.8W9MS?N*RVU:?<>R,'5Y62GWC2RU$DZTHB6:GJYZ>2(%
MBC@>ZV 0:TX=!OV+MWKW>GR&V=4]&_+'KKJ_Y8=>;!W#U5N+9\B[)[/FWEUK
M5IB]TU.VM[=0R;KVWN:FRNR\W2TF<QM;CZ['5>.2JG2I6HHJYHC[KV:9&.@S
MVM\<]J[>FV-7_'WYM8;%=X[7ZC[1S/978FX*/K+MFN[5V-WSV3FM^;E[HW)L
M.AS>UL-MXT_=&$R=5@,Q0K%@J44U3B9J>MI*9(*?W6Z^JXZ#>?HWX54E9MKJ
MS:/RXZ\P7;^Q]B_%[:W2>6K-Q]8[D[9V!G_C_N/?7:F+[$QL5354]=G6[;H>
MTZY-Q0B&#$5V'KI8%5::I\:ZQU[NXTQT9?=V]OA/V9O_ *V^4FY>_.@MS[3Z
M?H-V=6[:J\UN3K?/[,H>P^T:_KO?&&R^%W-DZVICQF_*/"=;^3'K0N)Y\?53
M3@^.,-[WUJC#%#TDL1\*^B]Q5>9[VQG:N-W-MCL7??R$[#W[NK$5F'79G9W0
M?R)V&NV-_P#3>XMV;3SN-CS/7^*FP>+S>,RYK7EQV0PT4B60RAO=>J>'0*X/
M96QZ_K39V^\I_,_V;N[K+H/![CZU^/794M-U13XO9/:&\MBU^RME]C]C;GBW
M3)M7NON38_5NY9J?;J-38K'5$E=+D:G'5L\L;QZZWY_#GH;NL]E?$KXBYO9V
M_MF?)C8/7W3G<_4>V>OJ#:&YNP-B3;/[NWMLIZ-<#\@,/O3(Y2FFSW9^4VWE
MYZ/=64HWGCW0U70U>08U5-!))OKQJU<9Z,YL;J?K7IWX[=<?&K>&>PV8V52[
M!P?0%,-T28K; W_!-MB7;?\ =^GQM+445,V5W'B*:<+0T)\I0/XA921[JN:U
MZ*UE.HZ[KWX_=J]-;^^>.!Q_0^&V!/\ 'V@W'NS;/76#[$ZLH,[3[>Q^%PF]
MNT'W/0X7<&^*?K;*QXF@>?#8O)57\2ILA+]S6%)9O=;XD=N>D-5_ SX>;YBV
M-7]%=JX_:VU^QNG*/J'%8S#=E5_<6$[6ZUZF[*Z^[0V7CMH#?F_-TTTF-ZBR
MNS*ZD$>*62".@W#715*W$#1>Z]5O,9ZCX7HKK).Y*+:OQD^;G7.S^Q>JNT/D
MIN#;W33XGKWM";K/#]V8#9B=G=9[<V%2;SVQE,'0;#[(P%3N&DCT/!AY<O)C
MZFD:G2(>_=;J:5(QT-:=)=";H^,6YOB5M#Y#8W)UVYML5';V[^QCO#9&[NS-
MPQ[M[3RN\MT=Y[DIJ.HI*"HQN\^Q,+EX?X@E/3XBGD@FI*3Q1T:PQ>ZU4UK3
MH(-S]!_&GK?L&K[0WC\P-N;4QG<'R*ZN^3?5>$WGNSKJEQ&-VQL_)5&_MP]>
M=:Y?*Y*FK<OUEV/W#OO+;QKJQ))EILCGPL;"!*8#W7A6E .IU9T/UY\7WZEI
M>V?FAM[8W1756].S-Y?&K8O8U!L/:!P>^-V8;=-!@ANOLO<&>6?LW"]1XGL'
M+)@:!:?$RR+5TYR=1D9:>%S[K=:UHN>LNW/C5UWV'UG\D-R;E^5VSM];B[]/
M0/:79_:>P=O;$V-LG!;0Z5J,5G-E;J;9U-N+<-+1'=V+V36C)[BRN4J&KJ2%
M4@:&DQE-!#[K5<B@Z'7Y$_Z*_D-F]C]%;3^1O6^S>^.O.TNKN^-N;8+;;["S
M3U77E12;]Q]'N'KA-SX#,U>!SVW*E:@O%5T53'2SQ5<,H70S>Z\*C)&.BW4W
MQCV9M7L[J#KS;_RZZ@E^1.UJ#O7<.Y-D=F=;]>[]S6]:GO?LC9W=>[MQ[(ZA
M&_=LUW5E+@:O8NG$08T55-38IY9I%GJ!/62^.>MUP30TZ&CY$[ ^)WRBW)D9
MNQ.Z^M:S#?';8G=FQ^VMJINK8=4=BKW!A\!@I]S[KRE=73UG6.YMBS[0>;&5
MSK3RTM>';4DL M[K0U#@#GH,MA?&_9-3)O+Y$5_RJZI[FZ0["Z@V9M7O_>F\
M=E;0S'][,%T]TYN?J#LO=-)WS@.PL-3=;4&Z,=45==N$>&I7&5,56@FB264+
M[KU3PIGH4L)\6=^[G^/&^>B<O\K)>S>C]^]#9GJSJW/R=<[3J=[83;>XL*N.
MV=O'/]B8?/\ ]W^V9,-M:2&%95Q.+BS,7[]1))+(TK>Z]JS6F>DWL_IOJC<=
M/\>=]=A?(7HCL;;.;C[MV#UO#UIM+8/6?5??.*^0&Q\-!D-J;:QV(WUNRDW;
MFX=O==Y.N5L1732U]']RS1".E9Q[KQ)S0'H.J#XA=;8_J'J[XU47RUVEN+NK
M;_R9'=M'N??V+V'O+.]E[RZ6BQK/U]FNH*?=>!.2QO5_3=1MO!5--CIZ:LQF
M.Q^/K9RDLI:3W6ZFM:8ITN:_XV9OL'<FY\5M;YD[7P'^E+HKK[J3NS;O4W7N
MR*/<V9VUT]N+L[9.X<[U3//O3<J]-T^3GWCD=O58&/S0PN0HB*2:GJXR$]UJ
MM.*]"3VYTK\;>T-C?%#9.:[+VSM_X_[/[!V8O5>Q\+V ,%B^W-W;-V9FZ3I+
M:&U.P,5N_%;GR5=LJHQ+9^@H\56U%9D:G!QO+Y(8)P_NO G.,])[KSX2=:[.
MWCF/]&?:.5AV?M;Y9XGY,5'6GWZ[VJ=H]JU?367V=O[ YK=NX\YGMZ'_ $DC
M>E+NJICR$[5--63&2 "GK+#W7BQ\_3H3/E'6=&9C)=*[2[2[[V+U#N';/='6
M7<^UL)N+=.T,1F=Y3["W$QH<+!C-Q9*CJVP^<RM0M$]7 C%)V6-#Y&53[KPK
MF@Z+OV/U)\2,_D/DUU3N7Y!]5X?MKL/M3"?(O=M9D:SK7_2)U%B.ML1TSNRI
MH*@9&K7)8K;.+V[U139&>KKW@:BHLDU1Z8EB<^Z\-0H0,="/TQU_M#X[[F[0
M[;R?R-Z3R747:E3W!\C,?45>R]D;3S]%M#L#>>*[!R^ZJONVGWU/%O/K#:4F
MZ8(HJUL=#3"GKZ$RU%Q"9?=>-3BAKT6G>?2'P-W+@]Q=N;J^6VUZ3LGN[Y&#
MM[8G?M;W71XG%T';'4VY]M5?6V(VALJLWK#UON*GZ-V]M;#;?6"JI*J84*RB
MHD1ZZ75[K?=PICH;MG_%;$;!WSTOU[VG\G</N#;6U>S>WNY_CQT)%MG9G7.;
MW%ONKW'O;>\^?R=14;@SVY^U(^DL9VA.:2FQE/C<=3.*2OR5/430P.ONM5P2
M!GIAV%\&AN;8N)V3OSY2S]QX_I'ISL+XS]3ILO:6V=FX?JO-[CZZJ>HMU;RW
MABL)N3<LF\>X<+LBM_AJQU]528_'QU-44QT4]5Y8_=;+?+CTS0_!'K#<F(W'
M@>D._MMT-'U]V[\<=S[GVE3[:V;V-USL[Y!?&?:T>(W=+O#K[$[@P5-@]P]K
M]>Y3;K;BQ+5./K::HQ]'DU?R5#:_=:U'SZ=MTX[JSL_/?$G:.\?FO\?LOM6F
MJ^E.WNN=@=>[6ZRP.<[8WIL3-9J79F_.F-T4F^]RU^SM@[VRZPT<E/A*>MFJ
MZ*DK,?296.GK*N(ZZWD5P>I?3.\OCMU9V?WAWOVC\W^B>PNP=RXW875V^<W@
MZSK[J79>W,=UMDMZTN"I]X8K%[SW!2YG?Z9?(Y6DJ<OE:YI*6GH?L:6&BA@G
MCDWUH@F@ QT'^V/BK\.LCM?9?8^%^2^$RW;==\HMN?(3$?(&#M?QXG>'>N^.
MU<Q@:>''=84^_H.J:B;LS$P9/K>BHJ.A\M70H]-2^2MIU9?=;J>%,=8<?\$]
MB;0V3NG']B?,*AQ\O0O66Q]A;$WIMG =9=72_'1-E=A8GO/K[L;LC^+Y/=>.
MW+ONAS&*Q4BSYO[##U.':LC3'HN6K99O=>K\NATZCZ'Z][WH^YNTNP?D!M+Y
M:Y'N+K67XXY#<O7^(VQMOKC8W6>/CR%9F]C;4V[MW<.\YJ/<N9W'N*7+YBNR
M>7KZ^2<4*0BEI:6"+W[K1-*"E.@'P?QIZKS.!Z4ZCV'\T.J]^?(/XI9#M[>7
M;>Y^PMK=9]NYWL_>G8VV,[LOMKL3N/K#%;RVHV(W'#N#<?W,TZ5,<.-G5**9
M#"PB&NMU/$@T/1RJ-NI_E/B.F-R=>=[;,WU2_'SM?;'8>6W#U;7;;S>W<]G<
M7UONW;38.L_AF4RM)M[$YG&;\.0C6&HE9($B5'>)RYWUK*^71,^FOBOTOA<1
M3YWXW?-; 5&>VM\K]];FZ)W125FP^Q-M;!P78'5^T-H9KX;Y#"T>Y:,]H['I
M-D[!@J<4L^1I]SX^FQU ]-6+!CK3:ZV2?-<4Z'.#X_=;;6ZNW7N#LKY-X_-9
MS:?R?V?\H/D7WKN6NV3M_#0;TZCR.R\_%LS/4LN3_N]U/L+:NQ-K8;#TM!/5
MM48K$1QU$T\]3-+4S;ZU4UP/+I6?+E-E5>[OCEFQ\J>K?CAVEM#>&ZL_U?)V
M-2;5W-C=^IO#8F9ZLR>-I]J9K>VQ*[*"&;?E&]-4T=<H6N:G@99/N51O=>'G
MC'038;:>U.O_ )'=\?P/YD_'W#=G[ZI,UV%NK9^8ZRV#D>U>M]T0]([ V]DM
MS_WAK>R8LUC.O<70;+I=QRX7(T96.@K&C>M\+15 UUOR&,==U_Q(K<AUAVKU
MI1_*;KF#(?*O*=E]O][5+],]?Y':N^]D;SV9M3K_ #69ZUZRFWI_ -GX_#XJ
M#'5=3N&K;<G\2S5=]YEFK&J(XQOK5>&.'0G;GIOC/W]\5,MTML3Y,;)KNO-C
MT73VT\OV5B>R-F;^K=OILW<^SLIM%=VY^HR\V/ER^\Y-L04ZU-7(CU[U32PZ
MW9;^Z]D&I&>D5WKU+\4SV%\E\%W-WEU5M7L'YB]4;2V-@MO]@U?6U)N?8N,Q
M&UMY=88/=&QZ7=%7%D\E+DL[NN>2E\@2*3)P&&$LY<>_=>&J@I7'0==C_$3X
M>;T[#[GZXWUWW%'\JN]MQ;0WIMPXSM&KVQOW8%1UQA,5/\<Y<+U)@MX4."W"
MG4:]=KE<7/E\;439.:&NFF=TFG ]UNK4K3'46KZ8^,7:>!ZN[;VQ\S]C32?$
M_P"3>YN_>S.TMJ[EZXK]JYK;G87:^?[IW7TIV;&,[58';FP\SOS(4&3Q57+-
M][0UV&I:FDD9FG\WNO9&*<1T,_R&^+WQG^4FPMX=WQ]J[EVOC=Y[5ZPS&?[J
MZR[FWM2[2K^O.A=^GM'#R/C]N[UI=C5.*QCPY9&J5@U4KULU3<U<$,D?NM D
M8IT&VUNG>CMK_*#8]1/\N]AM/)V]OKY*];=&5B;$VYW?EM[]\;*R^*J,?F^P
M/[PTG8N\^NZS%9?(U>,P<^+BK*N&FI8*JKKJ/%0P)[K>:?#T(^[NHOC'W9V_
M\N-C5'<?6>YNX.[NF\'U1G-@B7KW<V_>G:+:>T=ZX.IS^(P=3456X$KE@[;@
MK:J"HCCCIF-,6TK4J6]UJK #TZ0O8/QQPF,VWWO3XKYQ4'4G1/9<^SMC_*BA
MR.-ZPFJ,9OMMG[&ZJW?+M/LS.96@I.D]]=U[*_@=!E(,C1YJ5,A70Y#%QT>0
MK#/-[K8/#MSUG[=^-76>+S78VS,G\IL!U5\?=]YOK?N+M_X^Y&AV=#F#C^HM
MN[9H:N+:>_JS.X[=&Q.M]X;;Z@Q/\>B>AR,T=/BZR3'UF.^XG=/=>!_HYZB=
M1]5?';/]DGM+XU_+/KJM[5R6\_E--DL]L>;K3=W]^*;Y!5N9[*I=B;IH,1E(
MZC>T'1^ZZ>CS>)5ZEZBGAH*N*00Q5U6??NM&OF.A"V;UMU%U#UK\I4[3^3G7
M,^;^062[%W=W+OV&KV-U+L;:M33X+ =&;ES&&V0^Z,I@MK3;:KJ6@I,]D<A6
MU==6;BG R%29'IZ>+W7LDB@Z"_$? *I&VJ[KG/?)K;FX^V\1LCX@8K;GCZEV
MOC]MX3KCXI;Y_O)L6MW=TDF^*V7>3]@;GQ5?3Y/+U>1@58U-)BQ0Q0S0R^Z]
MJ\Z8Z%KJG9/QYI]]]EYW>?<_0G;'86"ZZZKZ%[#QV#Q/7^TL1UN^%W%VOMZA
MQ-!MRFW)N3)==3]@5?:TN$FQ)KPLM92^&,>6=X5]UXUQTD,%\7*?8$6Q=N=G
M_,;^\'3/P\QTN\^N-E;DP?7>T\_U[3R;9W5LGJ#>'>G8YR1J=VXOJ?:4V4I]
MO5#4&W8:^LHEK\G)DJRB$R^Z]6O!<GH+MI_#_H3=?6='MCX__)_KLX+?&R_C
M;UO_ +B<)U[O_9W87=GPPW'M_>M#V36[0H=QX['9_>>?V)M,8G=6)IY4^YPE
M/2SR.AH89/?NMU(X@]6$;(VI#E^D<WU=6]@[(W77T^+WQUQN;=/6>UL+L_;V
M&R\[Y;'9#&TVR,;N#<V/VUE=L15Z0U-#+622"HB9I0A<HONJGC6G15=@XCX>
MPX_JK?\ )\BNFNT]G_#GX]Q?'_.Y&NSW6NX]N8D[ER'56.Q&_MSUU/7Y&EVA
MF\E5]3BDI AC@J6K)TC=C$![]ULZLX.>@>^._P ;^I:'=72>[?CI\O\ I3L3
M&=?]?P=(1T=5L+KKM*3<U#LKM#.=XUQZ[SV WWAO[F[DQ6$[%6CJ&H8LE%2T
M1HJHQ*R)K]ULDYJ.CE]R;X^/-9OWXW[CWA\A>N-FY/979N[=T;'P=5O':"OV
M-EQM+>_0^=V_1K59,5<HV_N+L+P5+4BO)!EH(Z.72\A3W[K0!SCHJ.1^+G2'
M<6XN\.KNO?F'!3=QTVS^V<--3=>9C8.2[)Z(W]NKY69OY0[6[2I\%3UU96TN
MY.F>R]R45%3P5T II?MHTK )*AT;W7JF@J,=(/=_0GQABWY%UKLGYC]-;1[-
MVEV%T9F</U5OO%=<]BIA)/CST9OKJJ;;V<ZVKMV[:S&1I<Y@-XU>8K*N2:G:
MAR$ D#$:P==;JW$@TZM0ZIWCM#,8:'9F&[-ZZ[%W;U_MW9%)OC_1_5;?I8L9
M)N+:]#G=LY*JV;@\YGGV3BMX;?FCR6(I99GCEQTL<D$DT.F0[ZJ?LZ8LW\G?
MCCMS$[6SV;[YZ?QV$WQEMQ8'9F7G[&VE_#=UYK9^<.V-W8K;E:F6>GS-?M7<
MH_AV2BIVD>@KO\GG$<OH]^Z]0^G0Y>_=:Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO__1W^/?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T OR?W?V/LCH/L[-]
M.;:R6[NWI]N2[<ZKPF,I?NR_8N\*FGVGLS*94&&HCI=K[<W!FJ?)9BI='CI,
M325,[*5C(/NMCC\NJ=-N?&WY%](0Y+X^X;K+#[:VSN#M[X2=_=6[@V909[NS
MKO"]K=?]Y[!V=\F-Z]C/1[7Z;R*9??5)BL5V'6TAJ*0UDE3FJYJ^*I6H3W[J
M]0<GY]#;@O@9O6/NC+]7U>^I!U/7; Z7[1[;WLO4:4$O:':%%\Q^[ODIEMK=
M8Y:EW9#M7IS&XC>$U)+)CJ>AS=50XNOA>&:&OE;)2^ZUJ%*TSTC]A8')U?4O
MQX^->2^._8]-\JNO_F=M;M+L+>%1L#<5-M3;.6V]WID^Q.X_E>O>>2Q='L?=
M.%[JZX_B]%2I2Y:ISN8DW7_!YZ-3%D(Z3W6SQ)J*4Z"' =!=L[*ZSIOD!M#H
MK?W^ECHCX-[&VV.M:3:U=A=U=V=:[AW]\P)^ZOC13ZY,=)E=YT6*K]N;GV[C
M9UJ13;EI<8/$L>2F,GNO5!-"<$_YNC,[3ZIWRE-U6B]9;RG@I/Y.65ZIG%7M
M3)X6=-\U$?6HINLJ]:ZDBGPF\JQ*&;_<3.$J8C$^J,&-K>Z]49S^+I ]([TR
MN!Z1^!N:[#S/9/8<71W:W7&,WL:3XE]O;"S73--4?"KLS8%/MK)[+I-J9C<>
M[(J;>^2@H)\Y14TE-25E8E)*8N/?NM<2U/\ #\^C%]4==;EIOB?\YJC']/[G
MZ\V[W=NOY+;^Z<Z4K\94T6[H-K[QZUQ^%#2[$$;5&RLUVWV#B\QN5=O^*.JI
M9-P 5,,-;+40)[KQ.5ST%&Q=E=D=$U7P"[1^2&+W1W-LSK;HK=6R7S6TNC*R
MFR?QD[*W7UQU+2[=W/N;K+94^\MYUIKMN;0W#M.?-T=#*V!ERP@G2FI*ZIF3
MW7B0=5.BL;R^.7R.WQM3<64Z9Z\W)U/M;?T7\S+>6Q^K]W]7OE&J>G^V&^/]
M*O3V4V]E:["1]"[E^3F2P.Y<_A898Y*G#U65$E7CGF2MHTUU:H''Y=6'?)78
MVZ^PNC/@Q0]%8'>NS7PWR"^,>Z,-)N;8N0WAN;J/9F&VGG&EK^Q]JY;(Q5M/
M5[?P\RXS*O75B24=;.6DE,J^K?55H"U?3HLU+UKVWU7W?B.VN^-O[R[MZ_Z_
M^<?:>\=X;FVOU#E:9:2KWK\1.C]F=1_(?'=1;9&Z:O<NW>LLEALQM>?+8P9"
MMQ-1D9:T1I%%624WNMX(H/3_ "]1-MUE#UU\D-F?)/)=*=K]:]#;T^3ORLWC
MM.1.E]]Y'*8O';J^.O46S,EV-G^O]F[;SN]NO*7Y!]J[%SV:H:?+XS'UM8TB
MUE5#%5Y(QM[K7E2HK3I78K%S;ZJ=F=2X'I/L7)=J[+_F6[\[X&^<QUSO38NU
M^G>MC\D-T]H9[L$=E[@P.'V_EQVUTIF)\#18O$5M=69E-QF*HA6GAK7@]Z=;
M^=<4Z+UM?H#MW8_6E#W_ +3Z*W\>V^A?@_LK;HZZI=KU^#W/W9UON'L?Y?5'
M=OQH@+MCI,KO&+#UVW=S[=QTXJ!3;EI<6?$L>1E9_=;J.!."?\W2NVI1]E?'
MKK?M#,+U[V%MCM[L+X@?%/&_'+L:K^/6^.\J*6AZSZ"VWA<K\4]S["QF,ER'
M669D[8Q64K*O#Y.3$T]6=SFICF>KI*H4WNM'-*'%>C^_+W"=C=H_ +,X^MZ\
MR5?VCN?:/2>2S_76VL--E\A0[E_OQUQG-U87'XBFDR4TL.WJBGJ2RK)-XH:8
ML78)J]^ZJI ;Y=%E^2W2/R.WEO[^9;E>KL]E=D[;WG\6NN]NTF&DZ6B[ ?O'
M,X[JKO"BR.W-EYRKS6(D3*1KF:7%O!20UDD-341-;5)XSKK8([:^O0F_'.KW
M=M/Y?]T;6RVZMU;,VYO+/[!S^$ZAR/QTWG4XK=(QWQ$Z&P,^\Z;Y'#'+M.AB
MQ67VG78R3&2RK**W%R4_$CJAWUX\!_J\^NNZ<_@NXOF_U)TYN+96YME;#Z"[
M*V-W34[\JNGNT*J7O3Y!/L'<5'U5MS8_8.W]J2;-Q_7'56W=Q557NK/U^45)
MLLU%M^,+&,JOOW7AA2?,]%/ZSR%9TSMCIS<59\6NY:O,?#+XM?(#9/R3VCAN
ME]P9W+=J[_WIV-UY-M+KS9%=187(TG<<G8_8F"R&^1DL8V3PV*H:LY*NJ::6
MHD4^ZWQKD9/6;*]/=R;Y^)FZJ'9?7>#[WHN]NR_DOWE\V=B42;OZ:Q.XNULY
ML:D39G3/7NTNT.O<=F.PNEZ3(Q8VCR-<8Z:IW9+@(JE_(F6R%+'[KU17C3A3
MHVFZ!\BJC^6QT5U9M#KC-;8^0W;_ %1T9T9D=OU=36R4G4W]Y]J8;&=H;@W_
M +HQ>!K*S9]%M'8&.S&K(QXRIEH\V]) D$DKI?W5<:CG'10J7XD=EY^MVC\2
M]S=4U?3NR.M_DIN/N[XS;HZQ2KWUU]\<-I;T^-':^6V#D=C[TI]H[ HMN;DZ
M'^3F'JJ>#'^"D8XO<%#1I)+25CE_=6J!4UZ2>Q>C>^N]=^8[L3-=(;LZ1[\V
M+\@?G-VGL3<>X]MY;'[5V7WWM7&?%K8^ S]!NGP2'.=&?(JEVEN;'T4J3S1Y
MO9V7G#&2II6$?NMU Q6HH.A8^,F]-S=5;LV#\F.T?CIWYUUMGM#I;Y0X:39=
M-U#O?>/8>P^S\C\W>S>W:'JC<VU=IX/+9^DJ-V8/=Y?;>8J(H<-G12F05,35
M5(L_J]:(KV@C_4.@JG^,?R[[%ZMZEZRVYTUM_%9WXG?%':M;U?D>P-W5W7=1
ML3YK;Y>C[,PVZ]BY:EV#OK;F[Y>I,#M7';7RM9355$E+4[ERM)!421//-%[K
MU14FO$_RZL2^(_;^*R/:G=V,W-L?M+K?>_?&_-B]QX#;&\.I>R<32Q8RM^*W
M15'N&DR.]9=I)L:EK]M;JVKE\/+%49&*H>KQK(B,7BU^ZJ1@9Z+SV_6=I]'9
M_P"<>1P>U-S1_(7M?>VUNP^A>R:?XX;A[_VCWGUWMSK?;^,V-\9ZFHVF)HMD
M5>V=Y[;RN/J*;,U>&BI%S?\ ':4SFKK98?=;&=/ITT;BINQ:/>G\R?KFFRF\
MJ<]HXOO+<6QNA?\ 9:MW;AH^Q\MG?A]U=BZ/=>"[ZBQ4VS,E%D]Q8.LQL.%9
MF>IJZ9J3U2 (?9_+K>.S_5Y]%M[5Z-[=Z\Z[[#^-NV^E^RZ_K+K[^7]VUDOC
M;N?!['SF]\5M':_8787Q4RS_ !NKXH*%ZNKWUT?N7KO*U6!V\3-59?9_VE/"
M->.G UUL$8).:_ZCT.'R6V3W_P#)':76V1Z?WYE.S,W0=)?/?:^Z-W9KXN9_
M8.(WMC=TTW4=-%T74;4WO5[?J=AY;LC!T]3B\/N1C612U5(:P4U9$DT)WGUZ
MT"!7\O/IA[$V+\A]WY>O^272_P =*F7 ?%'!_''$_%>AW]N3?.S^\L?LGJ3'
MXS>'R9VIC]@9C8>?K]VY'NG:&[*S9&J',T4N:KMM0QO(8UCGJ?=:QP)Z/+\+
M]VXK;V^ODWU1F<)OC;N]=P_*3O3MC#TV:ZQ[#PF S>Q-UU.ULW@MST&]LAM6
MEV36QY:@R\1CB7(FK:5)HC&):>=(_=:;R^SHF.W^LN\]@=M=WXC8'5?8V)P7
MSQ^6W=6P>X=U4.T$CQVR\;MG.8?(8;Y#YG)5[0?8;8WM\:,+G-H8_(QQNM3G
MZ3;Z(Y:4-'[JQ((&> Z@?$/;>^.C^R_C-M64[T^/6SI?BOT)U;3=:57QBWOO
M3%[DBVAWS\EXL7UA)V'C<:V,Z;DV/MS<V(9GR#1HE%DX*AM,:EQ[/7F(-?6O
M3K\<L1V#/\#_ )7=#YJIWKF]Y8KH[Y0X;!= 5_QNWIL;,;.KMP[J[R_@V!QF
M^\ICEPO;^1W,F6HDHUQS.TT9BJ45EJE8^SUXD:@?\O0@_*_X\Y;N7LG:6T,]
MU=N_<6P-QXW^7IA-QY/$8*O5,"=B]J?*3<&3S]%FJ>FD7"9_I_*97"YQ*KZX
M>L>AJ' #J&]UH$4_;_DZ![;NR>[,GG=_;T^0GQ][#[!/4GS6^.-1WS38_9]9
M4X_OK"=2_%>#8&,^1W5&TZ"DCE[:Z^V]V5G]N;T?#T5'55U+DL174<%+-78F
M*.7W6\8H?+H^O0>[N\NX-M_+[$C,5--A:O<N5QOQM[ER?3NY>B\IE8-V=98V
MJ-7D-MY](MP9D=7;WK6QB9PX^E:O6AX25XBY]U4T%.B1;>P4&Y^H/@QTIL[X
ML=I[+[3^,&.W15]TTN4ZCR&V<9UI@\/T/V)LGN/:M'V1)CDVSV15_*'>V:IX
MZ!=M5V9.Z!6#-UNAJ4R)[JWF37'1[/B]U!O3$_![;'67R/SU?O\ QF?^.>SM
MIYW9F,ZTJ^M=T[5V?/TOA-L;EZVEQ.U\UDMQ9'<].J5<'E@--D$J'$,4:.B>
M_=5)[JCUZ(IA-O\ R([ VSTKUIUQ4[YJNMND/F%TNG0GR6WS\=JS:V\9NJL9
MT-VQ0YZC[(ZCS.,Z]:O@ZG^XH]J?WP_AFWL?EILC&D=)]U15$U5[JV*DGT]>
MN,_2/R1W+B^P_CEN7K&F[HPG;GSG[?[>[WRV_,,O3O57;70.P^MNKGQ.T<E&
MFW>R:(T/:/8%=A,1!3+!4Q9C'8',,[I'',4]UZHP0?+H$MX='_,;=76>/V9F
MMG96IW7T1\2?D7\=>X,9)L&LW;B?D3U+LCO'I[([;Z_ZI[$RV'PIH][]N_'>
MB!V_N)<4]:^Y*>H=Z**:E,J>Z\"/Y]&:K'WS5[T_F$[(ILWOQ,1W'@.U=T]>
M]$S?&;L&:?LN'<?PPZGQ>$W9C^]JK$)B*7)9&NPE1BWP545R RE)+1RC[E3'
M[]U[';_J\^@H[(^,?RWRW7.WL)G:W,]VR2?RX*W9W]RL1UA1]/S%L3VA\5=R
M=B="Y#<<>XLC1U.ZNYNOMJ9;"P8VODH8)/!/'*5@:9XO?GUX$5/V_P"?I2_+
M#^%]Y'=_9O27QT[<IMH]<_%3#[([!SE5T5O?8N8W)5M\D.A=\]?]/;?ZVSFV
ML-OO>N2Z%V]L'=6:JQB\564.#&4^RIIGJ*VI@C\>O#T)\_7H;^TNSNN-X=F?
M(+.572';7>^R.^/A_L+K79>Q:/H+M)HNWL]M/L7Y$8W=?7E=5;FV5B\/LQ*6
M;>.->>LW%/BJ"GHJY*]9C3HTR^ZT. H?/H/OB[MGM?I7Y19O8/9VXMT86JW#
MT;\0-HYS!/TQOK?FWN^-\;"^-.?V;O'+X_Y*0T+X+:Z8;=5&(*F6OD6226D3
MR,C5ZAO=;)!&/GT$W270.\=M==56+^5%5VWA:BE^)OP:W5TSW'UET9EX<YT:
M_1^^:O.X3JK<_7-!A.R,5O7LOI'N+.T^:J'RF&K8,EMVOD6HH:>*AKGD]UXG
M./GY]'1WIN/M3L+^7G6[G[KV/6_Q3&[IVUF>Q<-BMFYGKO*]C]%]>?(/!Y#=
M&]I>LLGE<EG^L:OM#I/;U1G:S;E95UE7C$KI:.8F0,J>ZUP;'19.P\":OI7Y
M@_'-/CWV'NOY%=\?)S>/8?4^\<)M#<F9VAV(=][]P6Z.@/DM0]^8[&5FQ-G8
M+X\[-.'@G%=F*/)X+^YPI:6GD^YQBUGNM^8-<4Z4W5_4O;VU_FS#V?O#9>X:
MKI*K^;/RFEV?BZ7KVLQN?Z^W]OWHO:FW=L]W9;=M,F1R>[NF.P\/B-QX)E^U
MH<?09S)XZ>>KG2",0^ZT::<<:=*?Y%_&C</:?RZW%T;6[&W?G/CU\J,)M_Y$
M=H;T.+:IZPVEV)\<MC9/JW!;1W!(\$E!/NG>>Z,UUSN3%T\CI+/'L>N=5/@6
M2/W6@: GSZ2GQJVOWCO?N#XV=_=I]0=@[6W7NSNSNFAWQ4;MVYDJ?.;:VQTG
M\8:[XY;1W%NH5,"G;.%[4W[@=P;BPIDT+74FYJ9T+B5"?=;P PZZV1TEWM+@
M_P"7YC-F8W<73^Z-E=T?.K,[BW?F^JGW71[!P.[J[O X-]P[<R-9@J7%P;[_
M (W0R8ZJFJ(Q/Y(] D$WOW7JCNK\N@([0^.';6?ZU[%V3OWJ3=7<,NX]M?,S
M:>^Y1U;78["]I8_L7^99T[NJIB.UZ(Y"''XKL7K&"NRD-+#43>?$4\U7'(40
MNONMU'^K[.CW?$[97;&S?E[W3L_L3:^]JO!]/_'[JSJSKGNK.8R2;;';'64_
M;'=>\.L:*AWA_#L=#G>R.MMEY2#!;P@*>=:^D@R+,Z96,CW6FII%/7HKT^V]
M_;:V#WAT-\?^M^VNVOC3U=6]5]P[+Q6Z.I,WU_V9UUN[8/RSV?V?V+\==CY7
M?>,VA7_(*FJMN83,[AP54*>IR-'*D-%497+39.A:'W6\$@DBO^QTLNW*'-]X
M=G;Z[^P'1/:O8/Q\VUVM\*9-U[<RFP=S;9W+W3M7II._LSN_*[6ZAW=C,'OC
M?NWNG=]]N[8SAQ]7C$.9KMN5D6-AK*BFB27W6AC%<YZ,)W6VY/D3OKX>[R^-
M]=NO8PP'=W;U1FNT=R]![N^VVO3K\>NQ]O5M9FME]BXW8.0^PW'DLA38JERL
MWCA>KM%"TQ]/OW6A@-7H*L1T1W[E_@?\[>I8:/+U_<F^^Z?EA6XNJFPJ=8/W
M%C-Q;YJLJJ[?I*FMDQ^!Q?:NT_)AZ*K-8U&?NA.]0J%W7W6ZC4I\NE]U_58C
MN3Y9_&CL#H[I;L+J#9'2/Q[[)V7VOF=Z=.YSH^EQ^W]U1['I.M/BW38G-X;"
MR;ER.P-PX.HS4M%C$K-N[<2A'@J_)D8DF]UXX!J?/H$>ONDN^I-O?RI<=LNF
MSW36XNMNH.\J'?>X\]U,V[*78/\ %^OMHX^EVMNG Y&OP$&VLGN'*1J:=IIT
MD=Z%XU1]3:?=>)'?T$W4NVNX^D>UOCCEM[[BWOUM.NP_E3L_>>_U^*V\NP<?
MV+F<_P#S 'WM1[>DPFTJ;*1]32;^VU-)FZ&LGDDIQCJ[[F-G2F,GOWV=;)%#
M3_#\NAEZ#Z;[9VG\SMN]@]C[:W5F.L<IWM_,/7JBGH^N)]L2]+;OWYV'%N!-
MV[WW=!FY9M[=;=[[ V]6-A9ZF@I:6BR\-,@:K>MHGI/=:)!&.-!T8'OS8&[L
MS\E>Y=PXG8VXLOB,K_+;[-V%CL]C\!55F.R>\,CO_)5]'L>CR$4#156XZ^GE
M$\= K&61&#!3>_OW6A333SKT1O8_6_?G1U?FNTNK^I.S*#?W>FTOCQ\/MS4N
M*V=EJ%\#-6_#_P"/=#U%\@]Q?;T2"';?QQ[..[\5N+*5'E.-@JFI50- VCW5
MB0<5P*GI_P!N==;D^,F4^+&!VG7[TZ"V)UU5_P P7KF#<L7QEWCWBN;VQF?E
MOUYG=E8++8;:6)DJ-G5W;6U\%4;B@S\T:0Y(">= Y8^_=>)KJ)^7G\NKZQSS
M_7W[IOKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z__2W^/?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=5G_S'OE1
MO/H? ]=;'Z@[&V!USW!O*7=O:E/D>Q#M:7"97J_X^TN'WEV#L*&FW1EL7!%G
M^YJO(XO96.JXBT^.ES\E?"#+1J#[JRBM<=1L5\EMX;G[TZ5[!S>^]W[*^)'R
M$V9TSFOC%G]G;0V3G.NM_P"Y^Q=NU^3R?7?R+W/E<'N/>W7786YZ[-XI=H''
M56(V_7>$4?WU3EJ@47OW7J8/J.E!VM\A.U>LOGYUSLZMW%C%^+65Z.P&+[$P
M=3@,;]_M?N#M3LO=>$ZD[&&ZXXCFJ?;E3)U[5[;R%-,XQT-1F:*H8HX)/NO
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M;2Y7L[&[.I-W9C<.'SN[*BKRD2[D\\E''7_LQ_:1Z?=>TCM^?3U\B^TOE/\
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M8>QMA[4KZNAH*'<^\]VX#:^WJVNRD4D^-HJ3-9S(4.-J*O(PPN\$:2EYE0E
M0#[]UJAZ"S_9P_B1_P!Y2_'/_P!'=UG_ /9/[]UNA].A0E[4ZP@Z_';,W8^P
MX>K&Q4.>'9<N[]O1]?G!U#I%!F1O)\B-N'%3R2*J5'W/A9F #$D>_=:Z"_\
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MM7D]G[8PV+V]7U.X8 $KI):=VJT%I2XX]^ZU4G).>B\P_P L;^6Q3PQ4]/\
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M_P#1@,)_<C^ /5L931_8_;F0ZM&KGW[JM>@"_P"&R_Y;O_>OKX0_^DH]#_\
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M^KU[P9/X?YCKW_04[_),_P"\I=S?^D_]]_\ VNO?J]>\&3^'^8Z]_P!!3O\
M),_[REW-_P"D_P#??_VNO?J]>\&3^'^8Z]_T%._R3/\ O*7<W_I/_??_ -KK
MWZO7O!D_A_F.O?\ 04[_ "3/^\I=S?\ I/\ WW_]KKWZO7O!D_A_F.O?]!3O
M\DS_ +REW-_Z3_WW_P#:Z]^KU[P9/X?YCKW_ $%._P DS_O*7<W_ *3_ -]_
M_:Z]^KU[P9/X?YCKW_04[_),_P"\I=S?^D_]]_\ VNO?J]>\&3^'^8Z]_P!!
M3O\ ),_[REW-_P"D_P#??_VNO?J]>\&3^'^8Z]_T%._R3/\ O*7<W_I/_??_
M -KKWZO7O!D_A_F.O?\ 04[_ "3/^\I=S?\ I/\ WW_]KKWZO7O!D_A_F.O?
M]!3O\DS_ +REW-_Z3_WW_P#:Z]^KU[P9/X?YCKW_ $%._P DS_O*7<W_ *3_
M -]__:Z]^KU[P9/X?YCKW_04[_),_P"\I=S?^D_]]_\ VNO?J]>\&3^'^8Z]
M_P!!3O\ ),_[REW-_P"D_P#??_VNO?J]>\&3^'^8Z]_T%._R3/\ O*7<W_I/
M_??_ -KKWZO7O!D_A_F.O?\ 04[_ "3/^\I=S?\ I/\ WW_]KKWZO7O!D_A_
MF.O?]!3O\DS_ +REW-_Z3_WW_P#:Z]^KU[P9/X?YCKW_ $%._P DS_O*7<W_
M *3_ -]__:Z]^KU[P9/X?YCKW_04[_),_P"\I=S?^D_]]_\ VNO?J]>\&3^'
M^8Z]_P!!3O\ ),_[REW-_P"D_P#??_VNO?J]>\&3^'^8Z]_T%._R3/\ O*7<
MW_I/_??_ -KKWZO7O!D_A_F.O?\ 04[_ "3/^\I=S?\ I/\ WW_]KKWZO7O!
MD_A_F.O?]!3O\DS_ +REW-_Z3_WW_P#:Z]^KU[P9/X?YCKW_ $%._P DS_O*
M7<W_ *3_ -]__:Z]^KU[P9/X?YCKW_04[_),_P"\I=S?^D_]]_\ VNO?J]>\
M&3^'^8Z]_P!!3O\ ),_[REW-_P"D_P#??_VNO?J]>\&3^'^8Z]_T%._R3/\
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M_P DS_O*7<W_ *3_ -]__:Z]^KU[P9/X?YCKW_04[_),_P"\I=S?^D_]]_\
MVNO?J]>\&3^'^8Z]_P!!3O\ ),_[REW-_P"D_P#??_VNO?J]>\&3^'^8Z]_T
M%._R3/\ O*7<W_I/_??_ -KKWZO7O!D_A_F.O?\ 04[_ "3/^\I=S?\ I/\
MWW_]KKWZO7O!D_A_F.O?]!3O\DS_ +REW-_Z3_WW_P#:Z]^KU[P9/X?YCKW_
M $%._P DS_O*7<W_ *3_ -]__:Z]^KU[P9/X?YCKW_04[_),_P"\I=S?^D_]
M]_\ VNO?J]>\&3^'^8Z]_P!!3O\ ),_[REW-_P"D_P#??_VNO?J]>\&3^'^8
MZ]_T%._R3/\ O*7<W_I/_??_ -KKWZO7O!D_A_F.O?\ 04[_ "3/^\I=S?\
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M+_T#]O?_ %N]^Z]4]>_T5]8?\^XV%_Z!^WO_ *W>_=>J>O?Z*^L/^?<;"_\
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M *W>_=>J>O?Z*^L/^?<;"_\ 0/V]_P#6[W[KU3U[_17UA_S[C87_ *!^WO\
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M+_T#]O?_ %N]^Z]4]>_T5]8?\^XV%_Z!^WO_ *W>_=>J>O?Z*^L/^?<;"_\
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M *W>_=>J>O?Z*^L/^?<;"_\ 0/V]_P#6[W[KU3U[_17UA_S[C87_ *!^WO\
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MWN#Y>?(7^4'\PNUS@:3NO>_\IS^9E7[DJ\5@J>DP>7W%UEV)B]EX_?,.VZN
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ME.C)$Q0^ZU4@4KT&GQX_EB?R_OB=O?>_8_QS^)O3O4V\^Q-N979NZ\QMC;A
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M;JVFZ"WU4[NK-X]//L_#U?7NY:K?F8JMP;PGS.V*VFJ,7729[.5DE7.7C/\
ME!#KI95(]UZIX]$6SO\ )$_E]+U7C^DNJ.H*'H/J_(_(7HKY!=M[8ZP6G?\
MT]U'QYS==N+K_J_MC*[U@W=E\QU33YBL$C8RGFI6IXT,='+3+++K]UO4223D
MTZMR]^ZKU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
MKI_\*J?^W+?R"_\ $C?'+_W^FQ?>CT[#_:#[#U?_ +!_X\79?_AI;<_]T]'[
MWTT>/2M]^Z]U[W[KW7__T]_CW[KW7O?NO=:\G_"IW_MR7\I__#DZ _\ ?]]=
M>_>1Z=A_M%ZO=ZI_YE=UM_X8.S__ 'GL=[]TV>)Z7WOW6NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZH/_G';W[*
MWY\C_P"5Q_+VV]W!V%T#U'\YN[>X8/D%V/U9N.KV)O\ W%L'HKK:BWQ2]);9
M[!QP.6VFW;>6RJTE9+0M35DL$"Q+,8I)X)_=7488^8Z>^\<1\?OY&?1459\)
MNCMP;A[5^:'R2Z&^-/474_8GR#[IW7USEN^^Q)\_A-I[EW1N;M3=G:&9V+M>
M@PZ5]?GI\5&*C+O1P126E=:F'W7A5R:^0Z+EWG_.;^7OPGV-\Z.N?EET3\<M
MT_+CXC= ]'?*[9$W0V\NR:'X^]W=(=M]Z[?Z2S5-*N^<57=A]<[ZV1G,C- (
MIVR5-DI629?! A$FNMZ0Q&FM.D_O_P#FG_S;MD]E?+SHFJ^-7P,H^SOC5\3Z
M#^8,^XI^U.\\GL2A^.34^Y*FMZ.R6/I=L4&<W=\B:F;;U134V=IY\+M-31S3
MR0:9((FWU[2A\S_J_P!7SZ&;(_S6?F=WWW)\+NA?A+T%\=8]U?,S^6KL_P"?
MT&\ODMO[L6BVKTO%G,SB*;*X#<N"ZXV]49S?N,B7.46,HUH)\?525]:*F5XZ
M6!TD]UK2 3J.*GH,?^'KN^=__%OX^[SVFGPZ^/OR?WEWW\BOCAVOU/W?1?*;
MO>KSO8GQPS1VSN2?XP=1_%C8>Y>W.UMHUN4EII\KEZQJ"BVM3U21S/7RE#+[
MK84$D&M/RZD;6_G6_*WN_KS^61C_ (_?&KI"H[Z_F [M^;G3>X,=V?V#V-M_
MK/J;LCX>5D^(RF_Z.:AV6=[;DZSK/X)D<K48BJI,9GS3^"@62.I\DZ^Z]I%6
MKP'2@ZJ_G0?(U]L]#9?O?H+J/ 18W^:KV'_*<^:.ZMA;LW94[3V-VK3-B<9U
M%W!U3#FX9:^FZKW;N;-04.3.?F:;'O)%>5?*?'[K13_!7JS[X!_+W?OS/IOE
M'V'7[$VYM+I+KKY6]N?'SXZ[DQF0R60S?;FSNC<N-A[S[4RQJ/\ <7!B,YV7
MC,K28I*72PIZ!_,NH*[^ZJ0!3UZTKMS;P['RG<OR:@Z_WE\V^H/EIO[^>UV=
M\>/CG\^\Q\BNS,)\!.HL'#VK19T?'OM';#]J9G Y+-5NWXLE!1[=DV,U'DAD
M:.G3(BGAFI#[IT@#2?+3U>-\S_Y]W;W2?R<^2?6'1_7'2.YMD_#;<VU]C[]V
M'V%@_DQEN]_E'OFMVI@]\[RVM\><OT_UUN_JOJJHVW@\V*3'S;RFK?XUDXB!
M'34I^X7W50E5KFO0W=[?S8OF;DNX/FI3_"_XW]&;TZ-_EP_'KKGNOY*'Y#;[
MWOUYV[V5G^V.BJ[Y X3KGI^BVSBLS@ME9?9&P8HY<Q-N."ICJ<C')CXOMW_R
MA/=:"CSK7H(=G_/E<U\EXOEIM3X08?LKY6;L_P"$W?4_SFAR'6^^^RJS?6^8
M=V=H9#<^+^)VU-DU*9';4FT%WD7KX,U!B*C=<K,($@JB8Z4^ZV5(!'EJI_J_
MU?ET6?Y$_P V?Y\]N_R8^ZOEKTUWK\(\#V1M3N'J/:?968^,U1W7A^V_CALO
M?.<Z[V]5]<YGKCOS9>7K,=WY2=H;@DP>2J<I!C<5+M4U.2Q:_?K!$NNK*JZP
M*'JS;L#YX?S)ML?,'XS?R^-N=#_#K,?(CMOXHO\ (_M?L>7M#N2?H[JN#9O>
M/]R^PCAJ2;8^)["WQB,AL/[>FP<;Q8^K_O1DHC5LN.@EDDWTW0<<TZ C=/\
M.O[;V)\U=M]<BO\ B!WQ\8MW_-O:?PS9?COB?E9F^S^MZ_LS<<FS]B[LWG\A
M]S]>XOX@;EWE@,\T)W5L?"9.7*XP.\-)55LL,A7W5M *U%:_ET1W=/RS^;F\
M>@/^%!;_ ,P/8OQR^1WQT^.=7F-B9[HO;O:7<^W,=AMYT6 ZIR.T^K.M,WMK
M9W7&Y9NE,CMG-5&6S.XI\EB-U_WA1((J5Z=WJU]UXZ<::_ZAU:)N/Y^?,[L#
MO/=OP_\ Y<?1GQEFS'Q ^+_Q\[B^063^3^^.S\=@*NJ[IV-/NCK3H;I>#85%
M598YB7:.$9Y=TYVHEH::1UBEI&9#)-[K5 /BX]!9M+^=!\G/EQEOY?VTO@O\
M>>DZ7<'SV^*O>W=D6;^3._\ ?-#M;H??7Q^W[#L'?N*W)2];[<J<[V1M6AW)
MCZW&42T"8JLRD]325+R4%.DZCW6RH4D-7'^K_+U9Q_*V^:6[_GG\1-O=X]C[
M!P76O:.*["[;Z>[0VKM+*UV<V5#OWIKL//\ 7^>R>RLIE8X<O4;7S<F%2KID
MJT^XIO,T#/-XQ/)[JA%#UJ$]$_)/O_XY?%?^8_'VCW[V+N;IG^8-M7^;GL[X
M\;GSNY]Z5N;^/'S8^*U7VXNT>J-N[RJLHS;:QW?W32?Q#!-%50RQY_:9@ITU
MS%O>NG M64?/_+UL,? KY\=B3[BZ/^'F3VKB<[A^NOY('Q*^:4O:&?W1N')[
M[W5OW<V)AV77[?W++D15I5T%7%@#63Y"6>2ODJI'>0R>0E-]589/I7H"NN_Y
MROS1^0NS_P"53M_H+X[_ !Q7NW^9ET'\I.RVJ^S^P.Q<5U7TIG.@:W'-09G(
M0[=PF3W;O+:E9BI9/NL73M39&:LGA2*KAB268^Z\%7)8X_U?ZO\ /TE?CI_.
MS^;O8V1^!_8W;7QI^-FTOCS\I?F!G?Y>.\4V3V-V/N#MZ+Y&[:JM_8K*]O[(
MI\K@,=M##=$-GMCSTD.'R3Y#<+""25JI$DA'OW7BHX9K_J_U>71'OAO\Y?FQ
M\ OAG\I?D]MCHKH7?7P:Z3_FB?*[&_(&7<W9&]8/DGNK"=B?*.CVEEMY=-X?
M'89>OMNXKKO);HIHI:+-5-?79Z?[B2):&.)'J=>75M(8@"NK_9/1O_DG_P *
M#^V>L?DC\B<#U3U-U'O7I;XJ=V4'26X^GZS;OR7W)\N_DA68F':DW:.[^CLW
MU]UUE_CWL"FV:-UL<7A]T9&>OST&*J9I9,8LD"MOK0CQ4CJR#ISYT_,7Y ?S
M)OD]\2.OND>B\+\<_AEV5UG0=V]X[PWSO;^_VY-D]Q_'B@[)V)M/K'KW%X0T
M3=HP[WR*S9:KRM93X>AV_$81'+D9%T^ZK04!Z!#^?;UM\*L?\?LMW[\FIN[=
MV]U)LZLZ,^%73_4_>7<VR<_O+Y/;YJZ__18>J>K^KMWX&DW9VP^ZZ^F:?(55
M#E/ML/1E7@DC012>ZVA-:#AT2G*]'=T?)_Y3?RP_Y7W\Q;L3L;=N%V3_ "F=
MU?)'OG%;2[1WEL>;L#Y5X?=&R>I,7N#>6]>N=Q;9S>]\]T[#43UE%525DD%1
MF"]?(LIG<GW7@:"HX_\ %=%IWWO3YC_*_P#X3$[4^0V6^9O<77%9\?NGOE#2
M]LUVS%BINS/E95=(]OYSJWHRLW1W1)7)N[;.V,=C-FFJW-'1"HK=X32A*NL1
M/,9_=;:BLP ZL2_F>[&^%,?\N#H[Y(?,C)]Z;X['QWQ>ZZZH^*W5G7/>_=FU
M]U=D_*'LC8N'EZV/7/7W6N\\%4]A]WY'=1A?^(5U/EFIL93SS3PO#%*&UUH5
M5F X=!-_,6Z'^?6WO^$_.QZWM_YE]J=5=L?&OX8U^\/E%BNO9*8=D=Z=EXW;
MNTFZ^V=N[O):]-S83"=>UZU,6ZSC5FJ-Z5"Z9ZQ8?(]1OKU14XST'?\ ,]GK
M]X9_^3ILG=&QNY/G;LW=_P 8-[YG>?\ +GZ8[<[*ZN[1[%S&(Z6V;GL1\I<]
MO/96X-NKGL)UUEJ 8LP[BS%"QK\KY<8:RL>IISKTZVN-9!I3J-L3$?"??W\A
M?XR_)+^8[\A>Y/D]2]#;#[?VQ@\5MWO/Y%]6[US'?V]-]9"AV?\ &^IVGB-W
M[)WSVK\@NDLA@J78^WZK<E+53(E%5Y;PICYC/%O[>O9#D#A_J_U>OY],FT^J
MODAV=A_^$^?\KO\ F+;K[=S&([>Z=^8O=?RWV57=G[XVKO3M&HZ=VG#N3X[=
M.=K[ZV3GMM;XRLW4FW]\T/\ 'J7^(@5^5Q4+5(=X _O77J@:B./17-GY[LKN
MOK;X+]7_ "KVM\VOEK_+L^.?R]_F@?$WNRFZ.E[Y[&["WGNOJ_>U)@?@])WA
M'T7EZ+N/>&W-LX:IGQ&#KZ>HE@CRT$:Y!](C,F^O#%2#G_9Z5?QV[N^2ORYZ
M"_DO?R_.S_D;WYU#UI\GOD!_,DVEW3V$V_Y]L?(_L;I[X)[YR%/U;\;<MW!A
MJR7++G<_C*O^!Y^JH*M:VOH\.H%1.QE,ONO4 U'S'1^/CGT7_+J[6WA_,5_E
M<]=_#7YG?%3=>^OBM493LC _);LS>.\^O=W;.@WQN3:'67=?6=/NKY%]WU^,
MW+%OB(9C'944V+J9TH8I9E,L94^Z\2V&+?ZO]7Y]6B_R1/D;V#\KOY5WPX[I
M[7RM7N#LK*=<Y+9>]MRUY:2NW5G^I=Z[IZGJ]V5U4ZI]_D-T+LI:^IJ  )ZB
MH=["]O?NJN-+$'CU:K[]U7KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NM=/\ X54_]N6_D%_XD;XY?^_TV+[T>G8?
M[0?8>K_]@_\ 'B[+_P##2VY_[IZ/WOIH\>E;[]U[KWOW7NO_U-_CW[KW7O?N
MO=:\G_"IW_MR7\I__#DZ _\ ?]]=>_>1Z=A_M%ZO=ZI_YE=UM_X8.S__ 'GL
M=[]TV>)Z7WOW6NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z)S\UO@G\?/GSUI@NN.^<1N:&?9&\<3V1U5V9UQNO*
M]>]O]-]E8 O_  7?_5O8."=,KMC<F/\ (;&TU++93+#(8XRGNM@TZ*K6_P H
M#K+?W0O9G07R1^5_SB^6&,WWN[K3?^S^PN\>Z]O2]H_'S?O4#U\_7V^OCUN;
MKKKOK^EZ]WEBZVN^YJ\@])72Y29 *L30O+#)[K>KY#I'U7\C;XN[QZG^577_
M 'CV]\J/D3OWYEX'K#9O=OR.[<[2P%?WI/L#IS=^(WQU[UWL;)[:V'MK8/7V
MRL3N'#)/4T>,V_"<I)([UKU#B%HO=>#$$$=&GWS_ "X^@.PNW_DAW9G\EV8N
M[OE)\/(_A!V32XW=E'0X.DZ<1=THU?M.D7!/78??<B;NJ!_$9:FIAC*1F.G1
MO*9?=>#4I]O57_87\FK>N7^=?Q$K>J^RN].B?B]\3/Y7<?Q+ZT^0O3O<^VMM
M?(?:W9.UNQ,10[9Q&1Q^8VOG,'O'#Y[J:*I7)RY# U>+FJ7\D<=)5P4LJ^ZW
MJP<"M>C0X/\ D??&/K[;/QCQ/1W</RLZ WC\8\+V[M>@[EZM[8PT7<';NU>_
M]VIOWNS#]S;NWAL?=T>XJOL'>L8R;Y7'4N)S&*J4C&+JJ*."G2'W6M7R'0C=
M'?R>_B=\?,O\.,QL/+]V5$_P8WY\KNPNCX]U=EON59<Q\QDR,?:]-OZJKL+_
M !/>U%1)DY/X1)4U"UU/(3+4U-7*\LC^Z]J-"/7HF'\PG^6KN?"_"?Y:_$[X
M3_&W<WR*W%_,=^4'9/R$[)WKV9\A=C["V]\7N[>R,ILO<]#WI15&X\?#NBLV
M-L'=FR:"NH,#MJER.9C:F>-2RSDK[K8:N2> ZN0^'OQKVC\._BYT/\8-C%)M
MN])]:;9V-'DEA:GDW%F,;0I)NC=U9$\L[KD]X[HGK,K5EG<M4UDA))-_?NJD
MU)/1+]W_ ,FCX?;V^-_RJ^+^9JNX5V/\N/E9NKYH[VW+0[_IZ;L38/?NZMR[
M5W8^Z.GMS_W>DBV32X/+[0IOL*=Z6M6.&6HCE:9)W!]UO4<?+J5VK_*>V)OG
MM_?'=G6'RS^;?Q3WAW-A=FXGY%I\9>WMI[&Q7?\ D-BX/';9P>^MYT>X.M-X
M-M/L\[;Q4&/J-P[1?;>2FI%(+B0B4>Z]J\J=5=?S9/Y<?>7=/R([LW!\5_A!
MVWNO</R8^.6W.G>P>]]J?S#L%T5\<^T,O'AMP[)P4GS6^/%;)C^T>RL/T+AF
MH<AC/[OU&1.Z(V./KXUA$JS>ZLI !J17YCJSCIS^5!U]UUMOK#<%3W%W3MKY
M$;,_E>=4?RP<EW#U%O#'[/EQ>PNMYJ3<([-Z[QN1VMF(=O\ 9L>^$EJZ#(U2
M5=/!3:(GHW_<,GNM%\G&*UZ8*/\ DH_%K(_'[YC]'=I;][_[NW#\\\WLK<_R
M3^0?8N]ML0=X;IW)U9+BZGJ'+X3(;&V-LSK_ &M)U5686FFQ$5'MY(&="*Q*
MJ-F3W[K6H@@CHPW47\O'K3J[O;IWY.9OMOY ]T]\].?%[</Q-H^Q^Y-[[=W#
ME][]=[F[(I^T,AG=_0X'96UZ++;ZASU)'3PU]+'11?8(L<L$LBK,/=:)J*=%
M)V__ "(?BSMVLV7B:+NOY??Z'.H_E#M_Y=]"_'!>Y<32](=(=OX7L>J[3K*C
M:6WJ'8M-G]S8+.[KR-69*;=.3S\F/IZVI7&RT,M1/-)[K>HYQT(W9?\ )M^-
M_9N\?G)FZ[L_Y'[:V)_,,V)/MCY%=';4[ VQ3]15N^)X-I4)[TVGB,YL'/;B
MV[V[#C=F4M,D_P#$Y\,8IJ@/CG\HT>ZU7ACK+W__ "?.C>Z>PX^VMD=[?+/X
MK=EYKH_;WQM[8WC\7^VL1L;(]Z]+;5HFQVWML=I4NYME;WQ%7GL%02RP4.X\
M538K<5)#,T<=:(TA2+W6PQ].A:ZF_E@?%/HGM+XJ]H]0X/=NQ)/AQ\>M]_&C
MIG8^*W-]QL6#K[L7+8;.;ER.Z:/*X_([BW'O.KRV(-2^2DR:/4U%7/-5)43-
M')'[K5<4Z&7X>?#_ *J^$/4^5Z;Z>KMZ9':>8[2[3[=JJC?>;HL_FUW/V]O3
M*;YW-30UU!B,) N&I,MEI(Z*)H6FCIU7RRS2EY7]UXFO1.MW_P E7X6[^^$?
M9GP&WC!VCG^E^S>\MZ_(NISE;O'%_P"DS9_:F]^PJOL>LSNQ=TP[7BH,*F*R
M>0J**D2:@JBV+J)H*IJDS32/[K>K-:=0^S/Y,'QO[ W5TSN[ ]O?*GIG)]5?
M%#:_P>W1)TMV_2;*J._/B[L]8CA>L>Z<JVTLEFL@%G65Y,O@JG YHBJE5*N,
M>'P^Z]J.33/0B=&?RF_BY\>\]\&MP[ R/;+UG\O?KCO'JWH2#/[UH<G1U.V/
MD 8CO?\ O_''MRCEW+7420A<8T+T45*+:XY2D93W6J\<=,6S_P"3Y\4MD]??
M&SK7$YCN6?;WQ7^:&X/G9UE-D-\XN;*U'=&X]P[WW)5X_=5;!M2F7,;"@K=_
M5B1T$<=-5-"D:S54K>9IO=;U<<=%WJ?^$^'PZK*O(X2K[@^8E9T?O+Y%YOY3
M=Q?%ZM[T@J/C[W=V]E-[2;\H<IV#L[^YT>4I\3A,J*:%*/"9#$1U]/CJ-L@:
MRIITJ??NO:SZ#HPV_/Y3O7F<[W[,[RZC^57S:^*0[XWOM;LGY!=5?&?NG";'
MZM[BW]M9,)2MO+)XS/;!W?N;86Y]X8?;E%CMQUVT,KMZHSM! %J6:4M,?=:K
M\AT:SI+X?=4=!=Z_+'Y#;'J]Y3[]^96\.NM[=M4^X,Y2Y';E'E^L-B0]>;;C
MV7BH,50RX.BEP<.NK6:>LDFJ#<.D:I&ONO5P!T5OYD_RDNB/FM\C>J_E9O3N
M;Y7=3=T])[#R/7_5FY>@.YH.O(]CX_.5F=J-QYW;5+6;3W(,'O#<U'GY*'(9
M.D:"IJ:&GIHF/^3QL/=;5M/D.F#MS^4!U/VWLOXYT-9\H?F[M;N_XS;+["ZS
MV?\ ,';W>>.J?E1O+K7MB*2G[$V1VSV!NC8VXL!V'B<["8FIY:O#"MQ%32PU
M&/FI9A(\GNO:L\!T/F?_ )<?QFRG\OW)?RT,#A]S=?\ QCK^H)>E8*#9.>CI
MMYXO:]3)]W792BW+G\=N&*IW3E,L\M=5UE;2U8JZRHEDFC?R,I]UJN:]%\^2
M_P#)F^.'R=[&^,W;6<[B^6?5W87Q$ZEINGNA]S=*]TTVRJ_9>&CHY<7D-U4#
M5NS]P+1]A9_#2)0Y#+THIIZJE@@1A>"$I[\^MAB*X!Z,;NWX$=>]C?!'=7\O
M_M+MWY%]K=<[WZ[W!UKNSMWLOLZGWG\C-PXC<.9K,U-E,SV9F=MU%)EL_CI*
MM::EFJ<9+"E'3Q0O%(JG5[K5<UH.@N^17\J_IGOJK^-N[]M]O_)#XV=U_%'K
MVNZDZB^0/QW[#PFUNTX>L,Q@L3M_/;%W@^[=G;WV7O7 9BFPL%0RU^'DFI:]
M344LD#N^OW7J\<=%RW+_ " OAEF=C_$[9&WNS/EMUI_LFF2['W=U#O#KWO*/
M&[[J>V>VMUQ;TW[WIO;<N;VAN";<O<>:SRNZYC1!]I!+]O3Q100TT<'NMAB"
M30=#+OO^4?U=V!U)T+LC-_*'YLU?<?Q@[%WYV5T/\S<UWAC-W?+?8.3[-2OQ
M^^=NQ=B[PV-G=N9W8^X=LUPPTV*R.#JH?X73P1J5>%9/?NO:CG H>O5?\H_K
M';_QKZ7^+?0/RC^;'Q/V)U'5=@UV9W)\>N[,1MWLGO')]L5<N4[%W#WCO3=>
MP]Y5F[MWY_.UE5D(<M2ICJW%UE7(:%Z>-((H?=>U9K3I1]C?R@OA#V!\5.A?
MB)C]C;KZLV)\5J_&[@^,V_NGM^;@V%W?T3O;'S5-9-V!U_VK13U&X*7>.<RE
M=/792HK/O(<ID)?NJJ*6=(I(_=>U&M>B^S?RH^P.AMM?*_NOXY_)GO+Y'?/K
MOKXRO\7MD]Q_.7M7!UVUME;2?+/48&LJ5ZAZ9V])$-BSY.IR\+C%9"JKJ^,Q
M.T:U4\H]UO4"144'5C7PE^+&T/A'\3.@/B?L6NJ,OMWHOK; ['CSU7"E-5[F
MS%+$];NC==721,T-'5;KW16UF1DA0E(7JBBDA0??NJDUZ-)[]UKKWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NM=/_
M (54_P#;EOY!?^)&^.7_ +_38OO1Z=A_M!]AZO\ ]@_\>+LO_P -+;G_ +IZ
M/WOIH\>E;[]U[KWOW7NO_]7?X]^Z]U[W[KW6O)_PJ=_[<E_*?_PY.@/_ '_?
M77OWD>G8?[1>KW>J?^97=;?^&#L__P!Y['>_=-GB>E][]UKKWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[HOOR:ZR[I[>ZMJ
M-C=#_(S,?%C>F2W)M>HR';VVNN-C]G[JH-F4&8IZO>&WMJX/L>GR6S<3N#=>
M%BDH:?+UE!DABC,:B.EEE1+>ZV"!Q%>M7O;_ /-#^:_6OP@^?[[6[_H/DO5=
M?_S">K_@3\&OG1OOK7:&/EW;4]L[GVCM'?>ZMP;;V=B]O]=]G?Z J_-5D>-R
MM)11X[.U\:&?STZM#[]U:@J.CO=';B^>&[OD=\\/Y5E?\_=ZT^[>AL;\3N]N
MIOFKDNC^D-R=\S=+]Q19.H[<ZESFV/[K87II=R19;;4U)@=RO@*NHQ]'DVDD
MIJB6G@T>Z]C!T^72'^%'\S[L;IWXQ?S-NW/D?W'GOFET7\,_DOENDOB5\@*;
M96V=J]G_ "[W'+B\-BJ+I3;>/Z^P6,VAV!NN/N#.T.U<3G,1C/!E)JUYVU0P
MMXO=:(R,=&&_DH_(CYY]QY_^8%UO_,#[%V9OKMSX[_(_9NR:3$]?;:VCA-G]
M:4V\NG=I]F9?K/ Y7:^#P]1NZ@V/E=TMBQDLC)75E2]&TAJ)%<'W[KS4Q0=(
M'^=)\U?F]UYV)U3\4_Y:FY,'AODEBNCN\_G7W(V5V;MW?;U?QY^/6+6FP_5]
M/B-QXG-TM#DOD!V#5282BK8HJ>KAFH"D%3"\NKW[K:@4J1CHS>^?YRG0FR/C
MY\ N^L9UAW9W+%_,4_@N#Z.V5T7MW;F[-S#L+,=?S;PBV1G8-R[JV;!CZF+.
M4TF"GJ6<T]!6QR35K4U'#/41>ZT%J3GI U/\]/X_[3^,G;OR%[:Z'^276^Y?
MCO\ *O:OP\[[^/G]VME;R[?Z^[8WCE,'182IQ\>U=\5NT=_;4KJ'<-/5T]5A
M,G5SUJ:DIH)I/&)?=>"U-*]=Y'^>+U'L'KSYP;I[\^,7R?Z$W_\ !'9?5W:O
M971V\L9U7E^Q]V=2]TY6'$]<;WV-6[3[.S/7]9)6U4NC)X^KS5+48B=6AF+2
MHZI[KVGY]'8RGSTZQQORRVE\.H]D=HY?L[>GP^W+\T,)7X;"8"LV[4=>[9WC
MB]D3[.C=MS09R?L?)9?+1&EHXJ)Z)T_75HY56]UJG^'HC\W\VD;]R/<_QNWM
M\?.[_AS\@\U\5?D+W5T*=_[V^.N_:_<%%U1L]ZC<"Y!.A^W^WI>J>T-F3YFB
MKI,#N:&CG5(Y!J>2)HC[K87ATN_@Q\O-Q[/_ )'O1WS@^0&XMQ]I[FV3\%W^
M0?9V?S6163=.^J[9_7V5WCEA5Y8TDP.6S@Q?@%0\4EI'#N&]1/NO4JP'KU5-
MM+Y9][T'7'Q-^67\P?\ G;P?!7L/YF8G;7?72?Q*V#\=.HLST-A>F\CE]KY>
M'K/*93=NP-Z]@[WS.4VEN2A@KLQ6;BQM505>3(IQ,M)Y']U:@X!>'5H7?_\
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MW[KW7O?NO=>]^Z]U[W[KW6NG_P *J?\ MRW\@O\ Q(WQR_\ ?Z;%]Z/3L/\
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MHRE3O.M23*;(W5NFMK(LZ%\-7!4,IH86 )]UXM6IZ>.V?Y+F[^RJ#YCT5/\
M(/;N);Y2_P Q[X]?.W'2S=<Y&L&S<-TA-L*2IZWK53>%.<UDLZ-F$1Y)#310
M>47IVYMKK5>EM\O_ .3M5?+;L;^9'NS+=YT^T<%\\OB'TG\;L)C:'9,V1RO6
M&Y>D]RYK>&&WIDZV7<E+3;KP>2SU93?<8V*/'S-3)+&*E699!OKP/#H-]O\
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MR,W@=X;(WCCJ&KD@BR*X'>>V**JEHWE@^\IDD@\L)D\J;ZHK%6##CT27I?\
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MWQ?ZRQ!V?\:=O[VWONG8&^=R8FNAHHGKZQ-KY+"S11U+&\-=)(\7NG"P%!3
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MH]C;JAWUA-L+DME;%P6ZZG:>_P#>[EL5M'=U500T^ R3R*,EC9*M)9/=>%:
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M;<IT7WDU9D]R25E5M:HJJ+_**IJ]9M$WNJCBI\@>DO\ S .O?D-V?_%?C?\
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M3J6J[1QV8V3NVES>SW[KHL+7[#Q^1PPQ$E?-E:F+/TRUE/3I-+CY2R5 C9&
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MT(R.T,KN_9VX]C56Z=N5,4-5AMW8;"[JQ^*S4VU=RX^HCJ\;624\25E+(LJ
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ML?Y!=HU.=W?F,O/N[I;;.\%VMNC:'3VVJG)9W,9W?^0S?<NZ]UY9LMDF9:+
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M?9V\,)U3V/MC!92FV+\'L-U+!N;9U?D=MX7='PJ[!W#V305.^*;$;AQF1SF
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MP[J[RZWZOS79V3VG@^@(X8]X-L_,MMZJV]CMQ2U*03[B5(WIXJ"6+(OOK6G
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M_(SI7Y0YO^\D'9G16V.Q-H[7AQ>:^RVKGL3V-#B8JD[XP!I)DW+6;1EQLLV
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MQP2QU&L];T@X^SJ#M;YL?,FOVGM'";DVGMW:^:[Z[2^-/7W5'>V^^HMP]<[
MVWD.\L+V3NGL?!XOK[)=BYS,=IU/6>$Z[ACVU7_Q/$T.?JMR8^*J=):>=*G?
M7M*_LZ,I_+8K\_7XCYIG=63VQFMR4'\P?Y)X?,939LE>NW*V?##96,IIJ/&9
M3(YFMV[6_P /I85R&,:MK!09(5$*3R(JL?=:?\/V=!AV5\WN^MB]F;PZLBQ/
M5]5G>G?D?)NGN!VQN>FEQG\OV?![!S>/WYCJ)=Q4AINQZNM[,CQ<>1E>3$&H
MVSEF:F72/'[KU!2OR_GT3_Y*?+#NG?G7GR!WIUEN7;/3>],CTI@-\]2=X[:V
M]FI]YT?2J_S ,QU+L'&24^1WA'M^OHM][ P9S3UD<$,A_CI5&,00#W6P!CTK
M_DZ,TW9'?O3/>/S'[-P>8ZWK>KMO_,?X@[&W]M*NVUN&IW9OYNW>G/B=U1O/
M.;?S1W5%CNN3M*LWG19/$4/@S"5_V]1#531^:.2+77L$*/.A_P O0F?.KYO[
ME^.NYQ%U;EZ/=U;U+0]6;N[SZUBZNR.>QE!L[MWM3$]<[8EWQW8=\8'!=1UF
M=I/XK4X6EBQ6<RM3+CGJ9:1Z%0LN^M*M>/2#^)/_ &6+-^[,W^2_S4/2]1-(
MG_;P_KZW[;R,G[?Z4X]"^E;#CWKK;?#^S_!T U!G?D]NW<>/HLEW1MW?>Z,1
M_.R[*V'UQF-U[3R=)B.I^OL5\;.YY*G 4>"Q>[:B7=M#MS"U\QQ&-GJZ!/OC
MY*BH=&TKOKV!_O/0@[S^>?ROIQM[JS8FSJ'>7=^T-G?+'=V[JW8G2.Z>PL%W
M#FOC'\C:OX];3V/@ML479.%K>IZ3MVLIDR&6RE37YA=NM5111)-$34#W7M*Y
M-<8Z-SW1WA\A*OM;X==+=:UG6_1FXODGUAWAOO>]1VI@I^R-V=?YCJS;/5&;
MHMI;6VMA-W[-P^\,I2YC?L]+F&-?'"M#2R3P,&"'W[JH HQ/ET4C;7S_ /DK
MW+U-O+MW8L?2O6$7QZ^&6R/E-V=MS>&&W'N/$=Q;FSL_=;9?;VRMU#<N FV+
MTK+BNC*_[#<[TN6KOOLDA>GDBQD\61]U;2 0,Y/3W4_S(^T*#,=<TN1P77>
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M^?.GM&?LSL7K;J'?*3]?=@[$^8_7&Q.T4Z<R6V,/U?W+\;>G=R;IR^6V/O\
MS&_Y&[QRFU]W[8RF+RL=-A\;B(*ZF_R>N9\=5PU?NK!12IZ6/=>\_DA0_P H
M_IK?NV_D--MOO+);(^'&2W#W=!L^.JRN=_OYOOJ7&9N5L3+NJ*"GR6>IMS+'
MD:C[J1*U#4JL4/W2F#W7@!K(IC/2(Z8[8[FZ@[/[=SF(J]@UW4F_?YM.\^AM
MP[+R&+SK;QKU[-V=UY1S]A4.]Y=P28[ U>UM^T,OVF 3$U%/5XB5Q+6+5/&T
M&NMD @>NGH;O@-\N_DE\F]P8C<V_NJ\GC.F.TNFW[@VMNQ.M\OL;"=:YRJW'
M@Z;;?4<&[,UNS-+W++G=DYXUTN:HZ'%K2Y'$5R/ D-32Q0;ZTP X'/0'=NXJ
MLP/RG[R[E^&-+OC$Y#XY="_)_=ORJWV^XMY[HZX[B[XW7UN^;Z4^/6/PNZ\]
MF=M[HWKUCG*1-TY(XNC%/LZEDH,.K1_QFJHHO=;' !O,])KI#;'2NP\WUE@<
MYVCNK)=,_(_^61GODC\MJO<W=&^FI=P9S!;@Z2KJ/Y%YG=#[H3<FV\UV'0]A
M[FI<C4XBMQ]/D*&BBA,304$,<7NO$G-!D''6+8W;.Z?C?\=DHZ,[]^/VR_FE
M\H\\OQ@VWV92]F[ER?Q*^+DFTL#4;HW9N!LKB-Q5_76\=Z8O:.;W5M/9.3K(
MHL-N#>6-Q7BB:EKZ*G]UZE3\P.E)\.?E=@NJ_P"2]MKNG9><W;V9F>O-L=C=
M:]=0Y=MV=C[]W=V=%VQNGKOJ/:=><M'-O'?VX,EGLCAJ>H:%*FLJT9VBCD<"
M/W[K3+WTZ#GJ#Y-;W^+?2/RCZ*ZKSV>[(WYU+N/X^]C]#;G^4&([DPR[YVQ\
MK.UMI=>]MUL]-V!AMI]CY[9_7_R+KMXR4[TDL]/C,?E,5C(YDC@C3W[K>FI%
M>C85'R%^6D?8LGQHH-V].U_8E%\L</TCDNZ*_K?/8W&OU;O'X<;S^4=-N?'=
M9TN_<C3CLC:.:VW_  1()<J<5DZ715NM/(SP#76J+2M,4_R]0>N/G!W36SY[
M"]BP]44F2V-\3OEOVAN/,XG'Y[&XC*]C_%KY*;IZ&FW+21Y3<,S8?8&XL9MI
M,K5XV22>IQTM8(?OG1%=_=>TCR]1_/I#K_,0[)JMT?$JKP=7BMS8WL#)_#OK
M?Y$;7Q?3^>Q^Q]B]A?*[9.VMWPQTO>68W_'3P;KQV*WIB,MC=O4.'S!&+K(8
MJ^HCEKZ6H@WU[2.[Y=(+:.^MT[$_E*?%^/![VS?6.W-^]M]7=3=L]R83/P;>
MW!U+T_V9\F*W:&_MZXG>&46HI]H9*7&Y)<3#G)+-@WR@KXWBEIHY4]UL_&?/
MI0[Y[ZV/_+XS/RJZQZ=^,.6V;O3"=:](=F;&W'E.UL[VGM7MC&=D=WXWXXX3
M=69VKD-WUV\L-F=G;SW:U;DZ4M!59ZBC4-D4G96@]UZFJA)QTO=H_(KYU;ZW
MIU5T:])M'J3.[SW!\C8#W)VUT9N/#9[>.PNIME])[EV9O?:_0X[1B.%J:S>'
M9];MW,PY#-)!-'B9*V@*B>)(_=:HM">@\Q/\Q7Y2]E5?6]7U/TE6;IRN&Z5^
M)?:'9?6>SNM<WO'']BYOY'9W=N.WCB,#VY5;WV_B>GMK]<;;V17U]!D<IC\I
M]Y7_ .3U)C2G85'NMZ0*U/KT-2_*GN^;96_<ON3L/8NVMV]E_*OMOXY?$W8?
M5_1VY.W]]Y?$]'=H=K;<W#N+)X6I[)VU1[DSN>V/L&7+Y*JFDQ&WMJT5!)+-
M-5-41QK[K5!4?9TG?@9WWG/D_P!ZX7O7<V'HMO;CW[\ >F*C<&%Q,\[8FESF
M#^2GR<VQEIJ*CEK<C_#5K:_"23?:M4UCT>O[9JJI\7GD]UYA04^?1/?A)W=V
M+L_XBXKXT4^^]S;G[-^24^$W;\>]V;GS&=W+NG$8#Y,=V]GX#O2.DK*FLDW!
M4XCXO5FWLWG(*DU$XH<9DL1"Y5-"#W6V J?3I[^+GRR^2FU.I/C-TUT7LG>_
M<M+T]\<_A]F-QXW-;'S_ &!N;N''=[;GWIMYXMP=ZY#?V*QG5YZXZVV))73Y
MW*T.57)9M9HY_'% 5J?=>*BI)^?0R2_,_P"6W;=-WC5[ V?GMN]39W:GS>VO
MM/M%>GLQ@\?\=LG\=JSL+9?779.1W_FM]'&=LYGL7<>PZS[C!TN.Q<F%JZJB
M]<D-+5O5>ZU113\NDMU[\G_D+M':W1^%Q.1ZQW=W'VGU_P#RI]E;K[OWKMG=
M$^3W%1?(N/O=MY;GW'M_&;YBQ^5SFS\)MF6KP\=/)11UV6JYS62&"9%IM=;H
M,_GT,^TOEW\F=];^Z[^+M+G>I=K]JU7?WRMZNWCWM6;/RN5P6?V?\6\%L+<M
M#6[1Z@;=F-2@[![)I>T<4E922[@J:3&4F*RU53B8-3QTV^M%0,^5.CB_ ?O7
M?GR7^(W37=O9\>PX]_[VQ>XVW2>KCE&Z[J,IM[>^YMJ/6[-;-9#*Y5MOU\6"
M6>G-14S2%).7/OW6F #$#AT<#W[JO6NG_P *J?\ MRW\@O\ Q(WQR_\ ?Z;%
M]Z/3L/\ :#[#U?\ [!_X\79?_AI;<_\ =/1^]]-'CTK??NO=>]^Z]U__TM_C
MW[KW7O?NO=:\G_"IW_MR7\I__#DZ _\ ?]]=>_>1Z=A_M%ZO=ZI_YE=UM_X8
M.S__ 'GL=[]TV>)Z7WOW6N@L[9Z2ZH[UP6*VWVWL;";YP^"W#C]V8.GR\<ZS
MX7<F,CJ:>DS.(R-%/29+&5OV5=44LK031_<4=3-3RZX)I8W]UL$C@>@9FZ^^
M&?5&;V=T!%L'JK:&8[HZOW/TUM'K#";/IX(]T=,[47<.YMT[*&%PF-DH<9UK
MA9M]U[RK4BFQD=5F/"K>:JCC?W6ZL<])W?W4GP PG>76V3[*V[\=L)W]DYM@
M_P"BS'[MR6U,3O;-97KW(T]!UAF]K;6R60IILWNG9U?3Q4&#RT5)-DJ(::*E
MG1&\)]UX%J&E:=.W7WQ[^%?9V([ [0ZZZVZQW?MGY!G/TG8&7Q-(]=M3L&6F
MWC4S;L-;A))?X *RLW[@Y9\I+#2PS5N3@::H:6:[GW7JL,5X="9N;XP= ;T[
M%R';.[NJ]K;E["RFTLEL:MW%FZ>IR4DFV,S@<IM;+8^/'U53+B*:;);7S=;C
M)JJ*G2KDQU7-3-*8)7C;W6JFE*XZ*)WG\)NLZOLO =][JR?2W5O4'1:]6=EY
M;)X?J4XOLN@V[\8_M]X[9Q&7[/J=ZU>V:+9FVJK;<%0,A%ME-P8_#0U&,I*^
M"FJ97'NK!L4\^CG[<ZBZ,J\)U[DML=?[$FV_MBJW7O?K:;'X/'G&X6J[;HMP
M3;RS^WHA#X*5]]4&]LD:UT4?=1Y&8.")&!]U6I]>@9?XO_"CK;:AZ"EZNZXV
MQM'Y![IBQV/ZXF2LCQ^[=U;-V_E-\8N@VE0RUDAV_5[(V_L^IR>+BQ3428=,
M?Y:,0M$I'NMZF.:]0-I_'?XJ=<=^=7;>ZW7$]:[WZUVEW-VSM_I'8U:NVL!N
M&3N#*;-V=O\ [OWGMK'QQ/O'<HJ\2F/3)5\LS"IR]7-()*F99D]UXDD9Z,!N
M'H?IC=FZ-Z[VW+UCLO.;O['ZI3HO?NY,E@:&IS&[NG8Z[<F3CZUS]=)$9\EL
MY,AO#*3"BD)A$E?,;7<^_=5J>D]7?%OXZ9+;%1LROZ6Z[J]J573&*^.T^!FV
MUCWQK=&X$2_P/JY:?Q:8MGX9IV>DI$TI32$/'I8 CW6ZGUZ?(.ANF*';F6VP
M.N]K-M[-9;8>Y-P4=?1"O7-Y_JRDV;2=?[ASU9D9*FKR^;VC3==X,4E;522U
M$9Q5.Q<M&#[]UZI]>@(K=K_!;Y3TFS/D?GL!U%VAB\G7X_KK9?8V[<='%A=V
M5M#O\T6T<#1KN6+'XO?"P=DP^7:[R0UL?\2F6IQ#ZZA99/=;JPQT-6U=I_'[
M;_9F<I]G8WK/&]N[;PFXMP[DQV$GP2;\P.W.]M\UN]MQ9S-XJFG.;Q6$[3["
MV;4Y"2JGBC@RF2QDSJSR4\FGW6LT^73?M7I7XZ9?/U/=FS-D[ R^7[!W1MKM
MX[]P I,I0;DWCB-E978VW.RL95T5148:;<$FPMPU6.&6I%$]9CYPDDLJ*FGW
M7JGA7IMWQ\0_C-V/1XRAWGTOLC,18;>V\>QL5,N.?&Y"@WGV)DI,QV#FZ;*X
MB>@RD<F_,I*9\U")OMLK(%-5'+H6WNO!B.!Z#WY2?&7HKN+=75O:?R&R6SHN
ML.E=K=K8"OV_OB/'8G;=55=OR==86DS<N]JK,X:?:%1B8MK28Y%A8?Q&+,R4
M[L$/CE]UL,14#B>G?M/H+X5;FS&S*#MGKGI*7)]1=<5&7VIB=PT6!Q%/M?IK
M8.0P<M3!5X<24&.JNH]GY>#'3-05\4V"H:N.GE\22)&P]UX%LT)Z>=M=<?%+
MY'[.WWVYA.O.ONQ=H_+_ *IV]LSLC=63V88_].73N.QNZL7M;;^[X<_BZ')Y
M[9\&'WKEEH8:J+Q-39*1XP4F#'W6C4&AZ8>\-A?";9N9ZI[5[_IND^OLSUN<
M9MGJC>V_-Q8/K^?'4V J(-Q8C:.,R=9EL&F>PV"JL0N2@Q-0:JCI)(&JEA1E
M:3W[K8+9ITJ>ROCW\7M[]:5=!V3L'8>0ZIQNX-W=TY1:R8XS:1S&Z)L_NK?F
M]<S4XZNH:+(4&Z&W%DJO+_<O+19"*KF-2DD;L#[K0+5P<]+W.=8=,=N;;ZP?
M.;+V/OG:6Q-S;#[:ZB\V*QN2P6U]T;.A^]ZYWQLM8HS18ZNV]3U0DQE33!1!
M&X,9 (]^Z]G/4*/X[]%0Y#<65BZFV'%D]W=N;?[[W/7Q[=QZ5>?[HVIB]O83
M;79V5G6$25N\\'B=IXVGIJYR9HHJ*(*1I'OW7JGK(?CYT<^XZK=TG5&PY]RU
M^7WOGJ[,U&V\;45E=F.RMM8#9O8&0K'G@D6JGWEM3:N.QV1,@85='1112!D0
M#W[KU3Z])_JSXJ_'?I-L._5G4VU-FMMRLW%6;9..IZJ;^ZQW9BMOX/<%%M;^
M(558-M8;(X;:F,I#04/V]#'3T$$<<2I&H'NO%B>)ZXU'3WQIW?UENKXFML[K
M'-=8X7 8O!;NZ/H1B9<=MO!;@GGSVWX<IMC'U"UVVER%9125^,G*T\OGI_N*
M9P\0=?=>J0:^?2BCZ6Z2GQ\DJ;!V968^7LK%=V3U38^EKDJNV-M)BXL7V755
MKF:2MWGC?[O4ELC([U.NE5F<L+^_=>J>D;T%U#\8\"*[O3X[;0V5C:/O'%TF
M[)=X;'$\."W=B-QU4^ZXLSB<?'/_  7'TFX<EEI<E.U%34PK:NH>HF#RNSGW
M7B3P)ZBK\._BA5;[WEV1_H+ZPK=^;OJ-V#=NX)<#15M;45V_]L3[7W_(()3+
M28;(;_VOE'I\])2Q4\V:BE#5IG;2WOW7M1I2N.GC?O1?QGBVAN3)]C=8]:-L
MO"=)5G5FYJG<6WL;/B,=T-MP+N&IV;6_<02)#LS"MBUK5@ T024ZRI9T4CW7
MJGUZ#_;/Q ^%F[NGJ?;^U>F.M,SU1V1D-G]P05V,HIGGW7N.GVUC*+9W:XW@
ME2NZZS>YVE%34\.X#6_Q:2AM$U0T9*GW6]35XYZ$_<?3O0.W=A[W3<FR]IX?
M8LW4&(Z[WY65,4E)"_3?6>,W'/@]O9?+13)DO[O[.QV?RDM,?-KIONIG5@S$
M^_=:J:]!90_&'XY[GZ-BH.C=A=,08#>W3N8VQL;<>X-B#LG9N9Z\[5R>.[$R
MR;@Q%7G,+E-[;<W_ )H4^6R7FR<-7D:DK4O4>8!_?NMZC7)Z#CX\_&7HWXP[
MIQFV=ZYCK7)]W=T]F97N+86'PNUI]HXJASG5W3>.ZEJ9NM,!E]P;PW!593:W
M5>6FAS&?RF5R&<RSYFJDJ:CPR04U/[KQ8GAPZ%/>O1'PT[(WKANG=X; ZUS/
M8&SQNKO_  FTD@DQNZ,+2]H[XKI-];ZIYL3/09%,1V'OZGF;,1F8TF5KH@U5
M%*T:%?=:#$<#TN=R_$_XV;R[6H>\-U=*[ S_ &OC<EM/.T6]<I@J>KRD&Y-A
MR*^R=V".6]"^\=I1H(,=F&A;)T=(/MXIU@_;]^Z]4TI7'0DY#K#KO*]C;9[>
MR6R]MUW:&S-K;HV3M3?M5BJ6;=6WMH[VK]NY3=NW,3F'C-918C<61VEC)JN%
M&"32441(]/OW6N@"W-\=/A?C>O\ J#XL;CZ_Z<VQL>++9.+H+J'SXK9]3!GM
MNX?/;FSB].XVAK\1N&#,XG;-1E*NN_@C">/%2U9G_P E>>_NM@MDCI\WC\+_
M (G[_P ?L;#[P^/O5F;PG6VT:[K_ &7@9]J8Z# 8?8&2IX*:LV$^"HXZ?$Y3
M9$OVD,HQ%9#48Y*F&.H6$3QI(ONO:F%<]/\ O+XM?'GL''56*WAU%LW-4M;O
MZD[2J7DQQI*]^PZ/;>+V8F[ERN/EI,I%FJC9V&IL14RI,OW>*C-).)*=WC;W
M7JD>?08=L_"#ISL7J_H?H_ ;<VAUYTQT7W!L;L[&=68+8^(EV1DL-L>#<QH]
MAT. BGQN/VOCFRFX$K:>II8V>@J*2-H8PP5D]UL,02?/I6YGX=_%3/=<[/Z3
MR_2^P:C86Q:G)YS9>UUI)*2KP%=E7K8MRYO%Y:DJZ?<L=?N=L[51YJK^Z,N7
M%=.E<\XJ)0_NM:CQKTD>R>O?@IUWO[JC</:M+T1U[OC&[<H.L>E:/=VY<!LQ
M:3 XZFGVIA\!UWM&OS&+PR382CW9)C*&:@HON<?#DC3021+/H;W6QJ-:5Z?7
M^#'Q)DZRI>GGZ*V4W7U%NV3?M)B#'D_XC3[VFQ']W)MUQ;I_B/\ >U=P3;8_
MW$O5_?>9L0!0%C2 0^_=>U-6M<](K;?6O\O_ +IW?V?G]FMT7V=O2FV,.L>S
MZS:>_L7NG*[6V1-AJ?:,N#KH<)N6L.Q(*_";1CQT]33)0U%5%B_#+*_VQ5/=
M>JP ].G3:F2^ U'\<Y\?M+=GQMG^,&U-VXL9+(4.^=D97K*A[ Q>[L-O;%S9
M_<[YNKQU7OI][B@RBS5M5)DJO(R0U#-)+(C-[KQU5S6O2NSFV^A]T?&7NFJZ
MVWMUML;JCNG9'<&\=P]T;2R6VJO8D$_8F S9WKW-7;@I\K2[:R:4KS39*OKI
M:V*!S3NTLR ,R^ZUFHKQZ2'17PQ^)FS.BH]B;2ZVZFWQL3M'JCKO:>]\_0;=
MP61VMW)LW;VT:+&;;K!203Y?!?W.KJ263(X^AH)3C*>:NEJ:<>6:2:3W6RS5
MK7H:MB?'?I3K3'[=QNRNN\%AX-IXC?.!V]/)][ELGC</V9E<'F^P,?'FLU5Y
M',30;ORVV<=/7B6=S/)10EC^VMO=:J3Y]![2?"#XG4/7F3ZLI>B]DQ[*R^Z<
M;OBNHC3U\N7;>>$IEH,#NNFW;-72;OQ^X=O8M11XZLIZ^*?'T-Z:G:*G)C/N
MMZFK6N>EM@_CC\>-MT?]W=N]1=;X2BBZEDZ6;#8G;F)H85Z;K\ADJZHV%)0T
MT,8_NCD,K7UD\L#+XYZF:5VU2,Y/NM5/KTS4_P 0_C%2[\P?9L'1W72[YVS!
MLZ+;V??;]-+-A*GKW"IMK8^9Q='-Y,;1;GVIMB-<70Y:.%<G3XQ%HTG%,HB'
MNO:C2E<=!?WQ\&^J^VNE,U\?]I[<V#UGUSV-B>M.LNX*7&;%I<A7[F^/G7.9
MS6<INJ-N6R./QFWVFDSM;24E;5TV3I\9292N:*C:>6.6+W6PQ!KT(WR7^,FT
M_D[BNH]M[TJ*+^ZG6?=&U^W<GMNNP%-F\?O&/:VV]X82BVU-YJRB?!-'7[GA
MR%/D8-=125./C,2AB)$]UH&E>E]L3HCISK&EV+1[ ZXVIM2#K/;>Z-H[$.)Q
MD4$^VMO;XS&'W%O7'X^K;75?[_#<. H\AE99'>?(UT"U%0\DUW/NO5)\^@LH
M_@_\4,9M'>^P</TGM7![,[%S>&W#NO;6WYLW@,34Y7;V3K<S@Y<32X?+4*;6
MIL5E<G4SP4V*^RIHY*B0B/\ <:_NMZFXUZ?V^*OQFJ=W];;PI>HMAT>[^C\'
M@-I]=9#!4*X6IV7MK;CU%?M/;,='A)Z&EGP6W)\A/4XNBK(IJ>AFJ99J=(WF
MD9O=:U-0BN#TN,'T;T_ME-A1[?ZVVAATZMR^\,_URN/PM)3+LO-=@)G8][Y3
M;HCC'\,K=TIN?("M>.QG%9+JOK/OW7JGUZ#WK+XG]2]-[_PV].LJ/,;-PFU^
ML-Q=6;1ZJP>5FH^J=J8O>G9M5VQO7.X7:"@P0;DW-N=J6-YC(T5'04$-+1Q4
M\/D5_=>J3QZ=\3\5/CA@^R<YV_B^ENO:?LK<60W!ELGNYMNT=3DOXKN_&-AM
MYY/'+5I/283(;WQKF+.344=/)FAS6F=@#[]U[4:4KCJ;3_&?H2FZ+J_C*G5>
MTY>@JW Y/:\_5-9125^T1MW+5M3D:G#4]!735#4=!3UM4TE)'"Z"@*1BE\(B
MB">Z]4UK7/3G3?'_ *5I*&GQL/6FTVI*;LO%]S(M1C(ZR9^V\-'0QXWLJJJZ
MLSU=;O>F&,@/\3F=ZMWB#N[-<GW7JGUZ;NMOCGT1TGN+>N]>L.MMK]?9K?4M
M17;OKL!%-C:"L:;)U^?KY8L4*G^"82*MS>3JJ^K%%!3)45D\E1,'E=G/NO$D
M\3TBNM_A?\6.K-^Q]L=8=1[<VCO.7+[WW3'G-NY'/T]%/GNT*S(9;?VXOX+'
MFGVW497>F1S%155U6:5I:F>8RLQ>S#W7JFE/+IL7X$_#1-E=I=<)\;NJDV'W
M57X7(=H;33;5.F#W8^VMQ#=VVZ&JH5814.#VWNHODL?C:04^/H:Z66>"&.6:
M5G]U[4<9Z%WJ+HGJGH?&9[#]4[47:N/W/G9-S9^+^,[ASDN4STU)34,V2J:S
M<>6S%9]Q+34D:MID56*ZB-1)/NO$D\>D7NSK_P"+W2?4>WI=X;3ZVZ_Z8Z'W
M-1=E;93(XNBQ^S^N-UQYK(U&/W=C*81&FQF5AW!NNIEBG5=:558SK9R"/=>J
M2?GTHLQU[T!WKD9]R9G;'7O9F3VI-FNM:S,34N+SU3AI]O[ZVGN[.;*KZJ/R
MM#)@^Q>O,/D):*4WI<IBX)=*RQ@^_=>R.E..H.KAO&;L$;"VN-[S[JHM\S;J
M_A--_&Y=X8[K[(]44&Y'K]'G;,4G6N7JL''-?6N-G> '0Q'OW7JGA7'0;;Z^
M('QA[,Q.!P._>C^O=SX7;.?W_N7#8K)8.%J"GRO:^4KLWVB)Z:%HHLCB^QLQ
MD9:K.T%2)J#+5!62JAE9$*^Z]J(X'KDOQ"^,*;YV]V4.B^M_[Z[3H]E4>V\V
M=MT;'#-UM218[KW)T./93BH=Q;'Q<"4>)RO@_B6/H5%-!.D \?OW7M1X5Z$O
M#=2=7[>ZX/3V'Z^V?1]4MA\MMZ7KG^[^-GV54X'/25LN;PM7MNIIYL568G+O
MDJC[FGEB>*<3.'4AB#[K53Q\^@>V5\)OB;U[AM_;>VKT'UU28;M';B[,W_09
M'"KN*+<^RHS6/!LC(-N27+2KLFDER-1)!AXFCQL$LSO' KL2?=;U'!KTK^O/
MCIT)U(^S:78?7FVMNUVS(]\G952\E7D\]B(M_38*HW^<9E\Y6Y'-NFXI<#C?
MOB9G#BE@4V5$ ]UXDGB>@VWM\>?AAUWC]H=G;RZWZMV/0?&+:4N9VMNH4R;<
M3K?86U\H=W%9Y<3/1R5.R\!G:5LE%1UBU-!35H:>.)9BS'W6ZMZ\>A+W7\;>
MA.P-GTVRMS]7[3RVTH=^93M?'XV.B?'B@[$W%G<SNC.[WQ5=BYJ+)8S<6?S6
MY<C-6U-/-%)5KD*F.4O%/*C^ZT"1D'I0["Z/Z=ZKGH:GK3K'8VP),7LS%]=X
MQ=G[:Q6W8,=L3"YO.[EQ&T:"EQ5-2TU%M_&Y_<^1K(:6-%BCJ*V9P 7:_NO$
MD\3TR;>^-G0.TZWJ7);:Z?Z^PF0Z'QN^,/TQ78[;6-IJOK#%]F"D'8./V34)
M")<!2;S&/@_B*4Y1:KPIY+Z1;W7JDUZ!#LGI+X+]/MT'N7?O6_6FQZC8NZ-G
M=/\ Q_J,?@J^AR-+G<YN!LYLWKC;F/VK$:_/8R/<%#+E8,940U6/H'IYZ]HX
M5BFG7W6ZL:T/0U8#XT="[6[+WCW!MSJS:>%[%[ @R<&]=PX^B>G&Y6SB8Z//
M5V4PZ3# U&7W!'B*5<A7?:BLKUIT%1+(% ]^ZU4TI7'3/M'XD?&G8F-V]B=I
M]*[#P^/VED]EY?;$$6'2H.!K^N,GNK+]>2XJ>M>IJ**+8E=OC+-AHD<0XR.O
MECIECB(0>Z]4GSZ0O>?Q*VOV'ME</L':70^"KJWMRJ[HW">R^H\GO_#YCL#(
MXHXFOWLM/M?L#K/-T6[ZFGCBCJZD9!XLICEFQU5&U-4R%?=;#4]>A3^-71&V
M?C'T1UCT+L^MJLEM_K/;,&!I,E6TM!CY\E4O45.2RN2&+Q,%+B,-3U^7KIYH
M:&CBBHZ&)UIX$6*-%'NM$U)/0X^_=:ZUT_\ A53_ -N6_D%_XD;XY?\ O]-B
M^]'IV'^T'V'J_P#V#_QXNR__  TMN?\ NGH_>^FCQZ5OOW7NO>_=>Z__T]_C
MW[KW7O?NO=:\G_"IW_MR7\I__#DZ _\ ?]]=>_>1Z=A_M%ZO=ZI_YE=UM_X8
M.S__ 'GL=[]TV>)Z7WOW6NJY/G%O?+X'M#XI;,W=VQN[H3XT;^SO;4?<W;6T
M,^_7[P[RVUL_%93IKKO<O;Z20'JO:V]ZJ7.53UJST,F2R.%H\8M4OWIIZKW5
MEX'&>BA_"ZBW;V3\OOC[W1V!OKN;=&>_V2OY)X3;>?W8FY=D479G4NU_F%1[
M3Z+[-WSU^^+P6!H]W=H]/5>*SU9$M'2)6U'VV0%-$P5(_=6;"D8I7_)T*7R,
MW;M+XX_,"J[;Z>['V3O+N?NC/_%OJSO7X<;GQL>XNP^R]MS[V?;'7W9G0^16
MOHMP[!W/UKMW.Y;+5RU"5^QZJBQD\U<,+5F?,^_=:&5H1CHM7QDW9O\ ^,VT
M/B=OB@WKW;V/LW?L'\Q>3L'J3!X>?<&)R>V>IL_W'VWUS0=3]>R8ZC3"[]IZ
MG;XQV+J6E6MW&F0,5;+4L:4T^O3K9R3P\N@ZV;W5W?V[6XWKK9/R![BVKU]V
MEV]_+_J:[<FR>YLKWQNS:>+[RPOR<J^Z^O,;WMF.HMHXG;VX:K$]:;?BS6,P
MK92EV9DY6DI*JFEJ4BCWUN@XT\CTH>QNP_D'NS</S:PFXNW:' 2[&@^</76X
MOC[O#MC-UNYMQ_%_:7QRWA'TQF]A?&W*]9S5>7S>X:R7;VZTW[!NB;^-+6YB
M@JIS:EQM'KUSUX =N/3I=9[>7??QVV#O'KW:/=G>F>PU?\+?A;VWN??.3V[+
MV3O;J*BSW=M%U)\E>S>J,'3[:JZ#$2;=Z*AK-PC;\=%5T6+K<6*RGI%7SQ5'
MNM8-#0<3U!R/8/8Q[.RU'\>]_P"[?E#L;J'M[<^4^*W8&[\U5=I#*]V97^7%
M\P=Q[QZDPG9<<S+VULC!;NH=KS??RUM0V-R^>J<*:QFA2FI/=>^9QC_*.BSU
MG<6Z-O[@W)V-T9\D>X^Z]Z1?RT^B,OV;V%N*FJ=SYSJ6N[,^8/7^,^1.>CW-
M0;!W.O6F^-I=?5&?RN3V@</7S;#7"PSKAZ>-!3S>ZM3@"!QZ.CUCD.^-Y=J?
M$?KBO^5.;SO3VY>Z_E5O&BK.B^YJKN*;<?5W56R>I<[L;J3L_P"14^P]KYK=
MO]W^T<GF3)41**[(X(T^-JZZI<59;W5<48TST9[^75V;N'=&6^0/7^\^S\GW
MUO'8N<V=N#,][[=[#J=_=(=@1]@G>-704NP<.V.H:'HO?.W:?!:=T==TKUE+
MMQ*G&2054\=:"N^JL.&*=$,V/VEV5V=A^O,/NOO[NW*_(7NRN^7VQOF_\<Z'
M*93&X?X\];8#KOMKPY[;VV<9AYZGHA^IM[X;9V-V?FEJ8)M^TN=>5ILM]XE7
M2>ZO2GD*"E.CF;8^/V5["_DY=:]/;3R&\<IO6?XA=/[TZYJ=Q9FOR6Z*?MC9
MVT=H=M]84OW^8*UM'#ANR-O8V&E@;1]C30I"@41J![JI/>:\*]5\Y_LK,;MV
MU2_S#^OL%E:6N_F;4F_OASL25<1FL7O2BP_9VW-K;)^%U'N3&S4D-3MZ/8/8
M^U]VY&HJZF&"*E&YJEY9$$R,/=>IFGIT,$O9.Y*KY$;;^-O0&\NV^E<1B=Y=
MF_!1-LY3L[,YG-[8VMU]\-]Z+L#O#$?'NGZTKMJ]3;!H^R]J;?R6V-[5NY8*
M_<MY8XJ2:FR$=/%[K>--2*_\7TDZ_P"6/R1[<V#U[VIN/=6[NK>H=^=Y[:^+
MW;.0J-Y9#XY8O8FZ_C]T_P!COVQ52=G0;+WMFNM,3W!\T(YMG+N6.DIJ>HQ>
MV:"EBKZ%,JLLONO4 )'^K_53HQORQJ.R)/Y+V\,CWIO?9O:F]Z;KSK[,[M[$
MV#-5;AVENG XWN3:&4Q6[8LD=N;<_C)78]-2U64R,6+H:.>JCJ*J*&&F*!?=
M>6GB#TZS_-#MG&]\XWY$[)ZO[CJ]X=*Y7^6;\R,]E)NFMV4F6P<O9^P]R]=4
M="B;KV>*^9-QP8G*5=#+CXZN]7CJZ9'@D20,/=:44H?.HZ _;6[_ )&8SY";
M(Z<VSW9!UM'U;MOX,8SH#;_=/>&Y=KT7>'5^Z=I8BO[[RU?UWD^M=VU/R5W3
MN:MAS^WGJH,Y05VT<IC<7)%'CH9)ZBNUUO%":>O1Q?YAM=L;K#<FP/DCC.]>
MM.I?D5U+U9W93==;*[IPAWEUOWYU]FJ;:N1W_P!1C:L$E/O"AW?N/-X#!PX[
M+;,E?<T$DHA?'9NBFDQ<V^M+YBF.@"RO?6Z]U[H^3.ZNQ^T.X/C=W-LGH;![
MV^)OQ'KLTVP<;68#<OP_??U7G5VW_",='\A-^[>[IEW1B<K1@9"+;-5L^B@:
MDIC,S5WNMT&*"HKQ_/I*=3]O?)7L'Y0;$Q4O?..VKFMO;K^,M-C-@]H]JY#:
ML/;?QHW'\9]A;V[)W'MKH6DZ@%#VEOOL+?F;W5,FYDW )]N9;;<5!(*"E@JJ
M?(>Z\0 .'2#VUVI\O.KOCEU/VYL_N+NWNGNKO_X&_)?LW,;>WYBX]VXVA[0Z
MSR?4V?V=NGKGK>GV_34&W]W;0V7OC-Q4^ IXO#NQL?30STM57GS-[K=%)(H*
M ]+;NGM6APVV/C7@.A/F)OG>_P >NS,MW'D>T/DCO7Y35VS:[%=K8+J/86>Z
MBZ]W+WQ!UQO;&=3-GZ7)9C<D>U:G$X>AR6;QJXV98J:1\15:ZT :FJY^SH;.
MI^SNV-L?,'H7:O=/>=)WKNKM3I_8^ R6T>C^Q*N@VUTYV!@^@Y=X]@;R["Z'
MAVYB8=S]*=L9B@DRN#["JOL*O%9O+X_ _8)3/%,-]:(&DX\^ECUSV'U9M#^8
MU\^=B[\W_MS8&Z>V]K_"O!;&QV5W+2;/W7O>HR.P^U<! NPGJ:FARF=R5+DB
MU/')CC-)2U91;I(4!]UXUTJ>JU_C1NN/K?H/XI]3;U^2'<O1_0^V.GOF'69S
M>6.WQE?[\UGS&V!VPE!1]&]AU^7QV7SE%EMD;%R.2S.%V#/%1#=5>&5J;)+3
M?;/[JQR20,U'5S_\NW=V%K/AW\2]CU.6A'86(^('QLWINC:U;1/@MT8O$;VV
M''3X3.Y[:D\4%7M=MPY/;>2 HI8XVI9Z6:#0OBL/=4;XF/E7JM#,9&KZ4WM\
MO=MXCN[M[8..W]_,XZI'R6W-+O+-9;<W3'QC[,Z+VCE,)V7MI\NU0G5FQ-_]
MFT-#LVIWK%":;#8..8I4TKXDU%+[JW'3CRZ-UT[N[>6^/B-\[\;'N[=_=W6.
MU,[\B=C_ !L[/WG#4Y/<7:?6-#U%BIIX:;<$='1S=H[>VQVOD=Q;:P^Z(Y*A
M]PX_%12_<5+@UE3[K1P5]>JT-D]^=P;&^->WYOC5W]W-VKAH_P"7E\9MS_(&
MLSN,J\A/\:=_9'L;I78F;SN%HX.NMQ5'2>_8.B\GOG)979PPU0^ I]K4V9DQ
M+2K(<CKJU 34CSZM&Z;R._*WX4?*RJW9VCLWN[:D5%WPO4>6VCV[D?D'5XWK
MF/K2)_[B;I[@DV=LO(=B9O"[S.82GK&AJJY<3-1TU153U4$C^]]5/Q#'5>S;
M_P#E)\9_CKA\3TWV-VWV)F<]_*BZ9[DGH]UXV3<;;%WSMK=W4/7N\M]=;X:B
MVK7T^R)<#U)O/*9"3 4>-KJ43X.FJAC*NI6K%;KJQH2?]-TZU^YN\,/G=F[O
MZ[[0P_R%W-M7:?\ ,+S/Q%RNR.SZSY9UE!D\7\4.L<GB]C;R[2;8^SH]^YFM
M[@6:KPM'/35-4,;714$]1))&((?=>IQJ/3Y>?0\?!7<&S=Q_.;,5?7G?G9/R
M2VVO\NSHW(Y;?_8]1/N#(8[>VX^Y^RLEN/&2[K;#XN.@W)EY8EJLQM%CKV?4
M1QTJ4N.AE2D7W6FPM"*&O3#B>[>V9.\-IUB]W]J5'RFR?\PC<O3>^/B!5"27
MK_;WQ%IMU9ZCAW#3];_PK'?;['Q'QYI,7OVB[/73_$MR58QK5LJ5"XE-]>H*
M<,4X_/I5_"+=G>6,W)\$MQ;Y[M[A[8J/EE\>N^-S=QXWLN0U&VL;NCK_ "G7
M>X=AYO9VW*/$8J@ZTRF-Q>[*S#S00>.#+T066IAFKHA5#W7F [A3@>@O^8TG
MR [\[B[V[:Z.^/FX.VF^$];UWAOC+O2'>^R\'AL#W_U7GZ3N#Y'5>-V?N=J#
M>>1R&[MM'&=<5%1B4J*?*4;Y*A!(9W7W6A0 5.3TJ^S?FW631?(IL/VYV'M2
M7MG?W\N;?'Q4P?\  :ZCW?5]&]Y5'0N+WON'KW 38&HK:O:G\2?<L.[*LK4P
M[?G%4*Z6D!BO[K87A^?2?ZU[E["R?R4Z H<U\E^X8^_]_P#RM^;O7_?/Q@?*
MTE;UKM'8>QNK_D34]'X!MK5&WDHNN-N8:EVIM#+;:S\513S;WJ*^6JDK,E$P
M6EUUZF#C%!U[%_*K>W<G6O3VPMB_*RIZV[%QW\MC>F:[[[)WK138W;'6GR$P
M'87Q8V3DZ?NS<%7AJ*/K7M2;*-N[#2ZA'EL##E*C,0T$RPTVOW7M(!)IBO2G
M^-.=VWV!\POA_P!VYO=';.SYMT?$WY3=/;0P.].\MP]@;3[#WOU%\B=IXC,1
M;6WMDJ7#8WO3 [HVY%5;EV[F?MXZS<>V*"@R[TZ&DD\6^O'X6%//H+_DMO[M
M;I'YK?-'M3#[WVA0=IMMGXAXGXP=$[NZK;?NZOEEUY40QXS<?3/7N=R%3-N"
MAV_4=PY',-5T^S88I=N9B>+/Y\S8_P 47OW6Q0JHIZ]7]X3>>T=S3[II=N[G
MP.=J-CY^;:F\XL1EJ'(MM7<]/B,5GZG;NX?M)Y1B,Y38/.T57+2SZ)XZ>KAD
M90LB$^Z:ZUQNQ]W;*^:^U?F9\@?C5EMA0T^*^%W8/QR^-W2W7\FW8>[>VOC^
MG:. WK\B^U=R=:8A*7>V!VYV)6;:.&Z^V]4119";'2U&2:"*?<<5+!KIT=I4
M'C7H<\S\M?B[U7V]\A/E3U?A]I;\Z$?IGX6]/;,HMH8#&[=VAVS\QWW/VA+T
MSL/:VY\SC*+9^#W3L#K?<>W:'-Y6<T\.Q<:84R;TPQDD%-OK5"0%/'/[.D#E
M^L]TK\/=O]6;;V]@_E/T+V)6_+GY&?-?<7Q@SW7&X^H=T]S[IS>?["J/C3LS
M";G[-VQ5TO1</8.[ZNIR+TT+5&9QNUXJ6> 56=JXC[K8/=7@<4KT;*A[-[AV
MI_)CZ=[&ZPPF^]A]C8SXI?&R.H9-HXS=G8FQ=F28_K?;W9O8V#V3AJC<U%E]
MP[1ZKERVY<50,E5-Y*:".IHC,):(>ZJ0-9'E7HN>0W;OW>79U#T3T'\ON_MX
M_&'<_P BOC+M-N^<%N@;TW3'FMU]+_)/>/>?2>Q/D%+A<FV?V])AMD[*S=9E
M*>LJ*K:N7S<U!3U$#-%2T6NM^52!6G1]?GIVO1=?83H_JRIR/8.UAV]O3.8A
M.V,7W1E_C]L[9T>Q=AYO<C46_P#NO"[.[ S]'G]YR1QT^WL'1XN:KW+EHC&7
M2&&</OJJCCT43^7]N3(;^^377/<_;_8/8$?=W>W\LCXQ;MJMF[FS6XMK[;W5
ME\)OCMC%=B9#!]89>EQ%!2Y?:K/B*[)4D-'2S8JLW'-42T=(<B8Q[JS<" ,5
MZF=[?)S?E-\Y^OMN=<9?L#;%5MSY;]$?'?>VQL[V=F*Z#?/7.^NM<QN_>N^M
MN?%W%[#R%#%U.(\_1PIV7ELW0K'G\//34C 4[4M=[KP TFOIT!_7V5^7U?TY
M\;LKM/Y%]^;P[K^57Q3^1?8&1&ZJFDEPE'W!TCG^N>SNH*7;6VY,#0X?KRFS
MM/5U6S<M31""+-82O>2I26NB6J'NO&F<"@/1\_CUWGOSO;XC?)#YC8?<>XX=
MM]U8OLWL7XQ8'*)-AZG874VS^MX]K]>RR8'(1I/MW=&YMR;8K]PY..:6334Y
M%5!6.-%7W52!4#JL[9OR5[P3H_![MZ2^3_?G=+;I^ O0G:'ROWED]JOV+N/X
M]=B[F[,Z4P.\.Q]G[2AV?-3["[6EZ3W!V%G)]@I2)3TL6UZ3*G'%M1R7NKD"
MN0./0D=F]T[BVEA^^VZS^7&ZNP_B[TOO7K/=>V=P[E[[K=K[Q[XW)D>D.U=P
M=L_&CH?Y98[&[GK]Z[AV368G:>[<91K'DX,GN'(S[3K*ZBI6=:'W7@.%5S]G
M^3I([W[&DZU["^6^^=L=N_(?IC)]Q_+#^5=FM_0;IJ<Q4=F;!^/_ '!M?J7
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MQ1PH(XHTBC4L0D:*B LQ9B%4!069B3_4GW[KW7:(D8(C1$#.SL$4*&=V+.Y
M N[L;D_4GW[KW77CC\GF\:>4H(S+I7R&,,6$>NVK0&)-KVO[]U[KG[]U[KH
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MTE(RO7XN'))>>DDO#.A*L+$^_=>!IT))AA,7VYBB,&CQ^$QJ8O&!I$?C(T:
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M3X7?.4H9ZRFR^)VQ2TAJ,QE\MMR?&U*Y6EAIFJ,3]K.:Q(!#*4]UK2:TIGI
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M?=4!%1T ?9/\JGY.;CZ:R>\.J^@-L]3_ #EW7WSN[M79GR$R'\TGY'[T[/\
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ME%MS:VS7Z1VUA.\-Q4.W-D9#*#<?86VNV-RQ4\^8Q]5F1M?:NX6P-!D::HR
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ME=V_!SHWO39._NC-C;BSN8Z2J:?I/?V;J]J;&[FZAQV>FH(-TT-5+#FX7?\
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MW7NO>_=>ZUT_^%5/_;EOY!?^)&^.7_O]-B^]'IV'^T'V'J__ &#_ ,>+LO\
M\-+;G_NGH_>^FCQZ5OOW7NO>_=>Z_]7?X]^Z]U[W[KW6O)_PJ=_[<E_*?_PY
M.@/_ '_?77OWD>G8?[1>KW>J?^97=;?^&#L__P!Y['>_=-GB>E][]UKI"9_L
M[8.U]\; ZVW!NC&8K?7::;LDZ]VS5-*,CNM-BXNES6[FQ:I$\3C XJMBGGUL
MED<6N>/?NO=+OW[KW3-7[BV_BLI@L'E,[A\=FMT5%=2;9Q%?DZ*DR>XJK%XZ
M?+Y.FP=!431U66GQV*I9:F=($D:&GC:1P$4D>Z]TD>I.V-C]X=?X/L_K?*3Y
MG9NXY<W!B<E4XS)8>>HDV[N#*[7RH?'9>EHLA3B#,X6HC!DC42*@=;HRD^ZV
M00:'CTI]S[GQ&S\--G\Z^03&T]7BJ&5L7A,WN&M%1FLM0X3'A,5M['97*RPM
MD,C$)94@:*FA+33-'#')(ONM=*#W[KW27WOO' ==[+W?V!NNKDH-K;&VOG]X
M[EKH:2JKY:+ ;9Q57FLQ5Q4-#%45M;)38ZBD=8H8WED(THI8@'W7N/3+L/M'
M9O9=.*K:%7E:VG;;>S-V)4UNVMRX6BGP>_\ "G<&V*FAR.9Q-!C<K+4XL:ZB
M&DFGFH'(CJEAD95/NO4IT(7OW7NO>_=>Z3N4W=MG#5LN*R.;H(LU'MW+[M7;
M\4PK-R5.VL!+14^9S>/VY1"HSF3Q^.J\G302/3T\H%14PQ?YR6-6]U[J;@LS
M0;CPF'W#BFJFQ>>Q6/S.-:OQN2P]<U!E*2&NHVK,1F*2@R^*JC3SKY*:J@AJ
M8'NDL:.K*/=>Z=??NO=>]^Z]T'F^NU^O^N-O=B;EW7N;'TE'U3L#)=H[]H:.
M3^*[@V_L3%X[/Y.7<-3MO&"JSKT=73;6R(I-%.QK):.6.$.\;*/=; )I0=+7
M%Y*DS.,QV7Q\AFH,K0TF2HI6CDB:6DKJ>.JII&BE5)8B\,JDJP#+>Q /OW6N
MIWOW7NBSY;YC?&G ]VO\=<SVKB,9V]%FMG[8J-MUN*W+3XVCW9V'@:[<^P=G
M5V]),(-BT&\][8'&3U.)P\V33)9&-/\ )X)"5!]UO2:5ICHS'OW6NO>_=>Z8
M\/N/%9ZIW#28UJYI]KYP[=S K,/F,5$F47$XK-E<?496@HJ?.4/\/S5.?O*%
MJFC,IDA\OFAFCC]U[I\]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=!MO[M[KK
MK3;/9.[-V;GQ]+C>HMDU'8G8E)CW;,Y_;.SH,?F\G'F:[;>)6LS@@R-)MNO-
M&!3EJQJ.980[1L![K8!- .A"I:F*LIJ>KIV+P54$53"Q5D+13QK+&Q5@&4E&
M!L0"/?NM=9_?NO=)W;^ZL-NA\_'AWR+MMG<5=M7+_P 0P6=P@3,XV"CJ:I,>
M^;QN.3-XX15\?CKJ(U%#,Q98YF9'"^Z]THO?NO=(/>O96T.OLCUYBMU9&:@K
M>T]^0=:[*BAQ]?7+D]WU.UMU;SAQT\M%3SQXV%MO[+R,WW%08J<-"(R^N2-6
M]UNA->E%N'<FW=HXBIW!NO/87;.!HGI(ZS-[@RE#AL3229"MI\;01U.1R,]-
M1P/6Y&LBIX0S@RS2HBW9E!]UKCT]>_=>Z][]U[KWOW7NF6MW)MW&YK";;R&>
MPU!N'<L>5FVY@:S)T5-F<_#@H:>HS<N%QDTZ5N4CP]/5Q/5- CBG25#)I#"_
MNO=/7OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z#?J/MG8W>/7
MNW^TNM\I/F=E[H_BW\&R55C,EAIZG^"9O);=R.O&Y>EHLC3>'+8B>,>2)=80
M,MU92?=;((-#QZ$CW[K7317[@P.*R.#P^3S>)QV7W/5UE!MK%UV1HZ3([AK<
M=C:O,Y"CPE%431U.5JJ'#T$]7-' LCQ4T+RL B,P]U[I(]3]K;([LV)B>R>N
MLG/F-H9NMW'C\=D*G&9'#S35>T]SYG9^<C;'Y:EHZ^$4N?P%5$K/&%E5 Z%D
M96/NMD$&AZ$7W[K77O?NO=(+JWLS9_<O7>SNU.O\C-E]E;\P5%N3;.3J<?7X
MF>MQ&0C\E+42XW*4])D:)Y$^L<T22+^0/?NMD4-#QZ7OOW6ND\^Z,.FZH-EL
M^0_C]3MZKW1$@P><;$G#T62HL34/)N1<<=MPY 5N0B"4+U:UTL9:5(6BCD=?
M=>Z4/OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7N@Y[8[7V1TEL/+]E=C9.?#[/P=9MV@R61IL9DLQ-#4[J
MW-A]H81%Q^)I:ROF%3GL]31,R1L(E<NY5%9A[K8!)H.A&]^ZUU[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=!SU)VMLCO#KK:_:W7&3GS.R-Y44]?M_)U6,R.'GJZ6
MFKZO&3/)C,O2T61I"M90R+IEB1B%N!8@GW6R"#0\>I':79VR>F.N]X]J]C9E
M-O[(V)@JW<6X\JU/4UDE/0427\5'04,517Y/)5LS)!2TE/')4553+'#$CR.J
MGW6@*X'2AVOGDW3MK ;ECQ6=P4>X,-C,U'A=T8J?!;EQ*9.CAK5QN?PM5_E6
M(S-$LWCJ::3]R"961N5/OW7NGWW[KW7O?NO=!!V5WSU/U-M;>V\-Y[PQT&)Z
MXR.T,3OF'#B7<>:VODM^93 XG:='FL!@8\AFJ"?-3[FH9(ED@4FEG6?_ #-W
M]^ZV 3@="_[]UKKWOW7NO>_=>ZUT_P#A53_VY;^07_B1OCE_[_38OO1Z=A_M
M!]AZO_V#_P >+LO_ ,-+;G_NGH_>^FCQZ5OOW7NO>_=>Z__6W^/?NO=>]^Z]
MUKR?\*G?^W)?RG_\.3H#_P!_WUU[]Y'IV'^T7J]WJG_F5W6W_A@[/_\ >>QW
MOW39XGI?>_=:ZK$^<&W=^U_R,^)6Y]E[5W=FXMI]6?.\UF:VW@\SDJ3;^:S7
M0^(I-H4^1R.*@=<5D,_F:?[?'(\D<M54KHAU.+#W5UI0U^72#^#W5._>I.T?
MCV)3WB^([,_EV;-W1W[7=FY[?^ZX,_\ )';>7ZCQU/N#>5=O6IR$>![?J<'N
M+-P5U/":*>KI:<++ 4H(1#[KS4-?MZ$_YD=7;6S/RR_EO]R[IV7N3.X[K3NS
ML7;3[MP4&\LG2;(S78_5.?Q6P*C<&.VE-*,?A,YV%08ZCER=;3'&4TCQQUL\
M5/,0_NO+\+#HD'QSZ<[\ZDV_\1=S=98+M[ ]L=@8W^8#MWM*CWG+O&;9M-)+
ME>X>Q>A<+O?:V?\ -L[8>V<#V)+0C;<L='0_Y)5R1)),M;4&?WIULD&M>&.@
MSZ4VK\F:?X_]D[IP_8O:R;WJ]N_#'$=S=/X;9GRMQO:$7R2'R#Z\R?>'9F8W
MEVSDJ@IE:S;DN:Q6?H-EL^W:[ 4\-7(PQWV2>]9ZV::A7AGJTOX3=9YS&=@?
M,;M??Z=GS[VW7\K.X-K[5J.P\]O6;$8[I;;]?A&V/A^M=K9RM&VL/L2:L:KK
MH*K'4BFMJ:J=FGD0(D>^J,?A ].BB_S+\'F<MO;O6+?>!^2^Y=KY3X ]E8'X
MCXOH&D[(R=-/\H,G0]N46_\ &Q8WK9G0]SY_:-;M:GVVVXT&%FQ@RD*-I?(H
M_NK)Y4(XYZ06[=F]H5_7/R!P/8&_NWNG]GX'KC^774[1AKMB]W;UZEW%FMO=
M:9D[_P"I\OLKK"*GWI3=;[QS\-/C=WG:M1BJZEF-,U5,P0TM1KKV,4'KT)G3
M5?/N/O[J7<'RXZM[QZMQN8Z5^)&4^&G6$LO=VX=@=0]B14^X:7MS8^]<ULIZ
MG"5G;F-WC38N:HK]]B*>;9\E"I2F:/<%+#OK1X8^=>B[Y#J[NS;'Q6^/VZ-U
MT?:-5A^T_D+W;G_F[4=H9'Y,[FS\N"H*[O6F^/F,W-M[J_,KVAMCI3;NY6V_
M2?;8*&#%04$>/GR,510_=S-KJV"2/ECH5<'T=N?9G:/Q1[-[#RV_.XNZY_Y>
M7R;ZEZ^^0V%V;V]M:7)]C15^U]\=7[7S>&KZFIRVT-V)U34YB*AK]WI39'/9
M#'&66:3,>"-?=:K@CY]!?OF@[7FV/K[]QWRMR?83?R]_C@OP3GZW/>4NX,9\
MJTZWW&.S/[QU&TIEHZ#Y)MVH-O35E7O@B@;;B,LTGV2[B0[ZWBN*<<]"GO/J
MGY$S9/Y$]Z;L?NO)?([K3M;^7_'U<^S,UV-)UYBIY]E_&_%?)#_13L+$U$&T
M=S;!W;6[AW33[G26AKJ26GAD,PBDI \7NM5%%'EGJZ'KSM;K_M>'>-1U[N2F
MW-3[ ["W=U3NVHI*7(4\&)[ V'7+B]X[;\U?1TD==4[?RC&EJ):8S4ZU,<D0
MD+QR*ONFZ=5)?)SIK;V-^0O\Q+<V$Z]W\>U._/Y865PO76Z-OX7L'<./WMG=
MKXGO3 [VVKA)Z:++[$BWKC8\GLXTN'GBCKZD52RT4$P>M8^Z<!PN< ](3MKJ
MKNCI/9'<G7W05'WM)M#<?QT^$&\M]R5.5[IWSE<ED8>^<]M'Y4YC:N2Q.6EW
MM3=IYGX^8F!LWBMJ5%#EJFFA2>CITR3T[R>Z\"#0FE<]'_\ Y>6V=Q;:Z%R*
MY7L*'?NV<WV9O3.]8T5'M/MO:N)ZYZ]J3C*.AZVV_P#Z<9).R<]MS!;AH,E4
MT%;6V@6DKDI:0?:4L!/NJMQZ+7A_B]O_ +A^<_S&RV\-V[LV=\?J3NSX6=H#
M8L?7>.BH>[MV=(]5;'WEMFJI>SL_%52'96W>QMNXDY:@Q%,)IZK"_:R5D44]
M5!)[K=0%7UST73%]8[WP/7/0O8'>-)\A\MU%VK\G_DWF_G*E;F>[<UO63;N+
MWAWO2?%?'9_;6 K9MZ8#XW;6KZG'QS4&$IH:"6!L1/DUJ,9][*??EU8TJ:4K
M3'08[NQ/REJ^LM@1;*H/E9'AL)N+Y09S==&1V%'VED_Y3#]J8T8GK-ZK=L]-
MN"?YC;BQF/HY^M!-5C?-#M.CR$-9+#7U;1SZZ]BOE_L]&'^3D??&0P'9)2GW
MG4="UWSYQ-1OR#,8WO:OQ ^.51\+>N9]BC'X7J2HH>P8NAT[X-"-PPX$+34]
M7]T:^$TRY=?>^M"GYT_R]-.-VQV/UOO'^7EG-R=@=B_+7>U'B,!M@=:U&P_D
MEL:BH]D;O[4S51C_ )";5W3E7APV(WMTQUWFZ&AW51=H2S5.Y]M8*.19<=D:
MG1D_=:\FIP_+_5^SJRCYV;NW'L_XU;SJ=N=;5_9O\>R6TMG;BH:6OWW14&T-
MF[LW1BL)NSLO<\754T7:V7VAU[A*N7)Y.@VTKY:LI8'B7Q0M-40^ZJO$=59]
M']7=Q]DR_&#JWL^A[]'1F#^:7S1^WI:>#NGJS;^?^/>W.OMT9;X_T>YAE-SU
M_84/3&0W/54M7MZDW'F:EZMZ2C@#FE5*/WKJYH-1%*T'2^^ >U_DA5_)/([H
M[B[$RFV>U,.G?T/RBZXRNR_D+5CLXY3L^:EZ-R6-W5O.OD^.N&VOL':-'13;
M8J=DIKKL17STGCC6&M(WUYJ4QP\O]7'HU_\ ,6SV5DP'3'6$_6-7NCK_ +/[
M!R5)OOLJ6#N_,;=ZM?;VVZRNVI39+:GQVSNV>S-PYWL/-U?\.PI.1H,/1Y"-
M9ZF<5*T,4WNJKY]$('8/R:V!U/M+<W<>WOE#7;U[1_E#Y/KO 8C#;6[&S^\<
MI\OMNINC,3[0RNV]IIE)]E=Z9O$9BC-)DLI]I+524TZG(O)2S,-=7P3CR;K/
MF^F,AB4^<&7R'7_9Y^0WR"_E#=3XK ;FAQ78>X<AOO<NT>I.TME=K82CK'CR
MNT/]*.!S%1M73BJR./-5,]0E134TXFK6??6J_#Z:NA-[=ZC[,Z6QG='7W34'
MR/JNI,[LCX';^[73;FY.TMV[]R^W9.[^R=J_,.KZAW V1J\[1=N;FZ7VYA)\
M_08*>GR4]"DU100QY6JIFE]UH=U*TKG_ &.@Q;K/?'9F2;KSK-?D?CO@;NSY
MV_'ZBZ^QM+ENYMH9FJZR3H#L*M^1V-Q^6S<N-[=VW\8=P=FPXND3[NHH\<^3
MDR*XQXZ">D9_=6X<::J=9_D559.IV/W#U[VKMSM6+,;^^>'<.U.FNT]S[9^0
MV?V;\>>E*+J78D6X>T]OT?6L8%3183:T60H^O\.TM/BLIO.II_#<0UKK[K0X
MBGIUWN?8?;U3\L>N]J[:[*WQL'K#![7^%])\&NRMS[=^4?8-;4];[?I:6J[V
MH,M4[4R-)L?*]C;_ */&OBMU'M-%R<F*R5-73R&"G*K[KV-)]<UZR[3VWG,C
M\I?CW4[IV?\ )BN^3.*_F$?(+<_?^5JZ'M7-=&8;HT[!^4U!T%EILOFDDZVI
M^K:38^7VIC]DRX=8JFGS$E1'6+%5R9,/[KW '(I3H]G\UWJFA[B^"?<>UZ_9
M&X>Q(,97=:;UFVKM6#<E?GZO';*[2V;N/<=7C</M.HAS^=J,5M2@KZH4=,L]
M1/X;0Q23B)??NJIAAT13Y"4N_,IO/OG(;3H?DU4_)&OR_0-7_+#RVQ(NRHNJ
M:3K&79G6I%Y' Z[P]/3;\.YINVX^PA%45&VGI597@_AZ#W5A3'"GG_J_P=6Z
M_+38^^>P/CQV9A.KL]F-M]GXS$T.]^MLK@JF>DR!W[UQF\9O_:>':6FGIY'Q
MFYLWMJ'%U\+,T51CZR:*5)(W>-O=4'$5X=5.5<O9'8>VOCUW[\CL!\BL%\7?
MDMVWW-W5W_U0^'[%QF\^H\/E.M]M[:^'?7'<6R]@(W9^"Z^V[A=JU%1N'&T$
M$>/BWSDJ27+QM'Y)??NK@<0*5'33L+JO>3]L?RS^Y.X-B]NUU?M#=_SDV!TS
MO'M2G[+R^_=C;"WOF*NI^(.'^1O\%JJZHPFYL]UUC5IZNNSD0E*Q04^7G_BI
M96]U[%''V?[/0F?RM]K]WQ;]SVZNV-^;CH=ZKU%#AODCU+N39OR&I\KEOD37
M[OH\A4=D9O=_:==6=5_?X>''YK&8V'9!.+R6W*['2Q!,?1XY1[KST\NCF_)7
ML#+]2?)+XL]AY?']H5G40V?\B]B;PFV!MW>&\\1#V!NX=-Y/JBCW5M39U-DZ
MF2HS@VCFZ+$9"IHWIJ6OG%,9X'K4$ONJC((\^J5'J-TUM%T]M3Y!TOS2&ZQ_
M*3Q6Y]H;%VE7]U56\]M?*O(]QYNCV75;JQ.QJZISF*^05-E9:.@P>3SW^XJ*
M6GK8YJD(OJUTYZTIQZ';NO%?(HQ=H)\D:;Y%Y;Y/Q?%+X[4_P6K>BO[]2;7I
M/DZG6]>G<%1BZOJ[P]3X[?J_(B*&?<D^[F3&3;#-,L)?#IE(Q[K0IY4I7/0M
M)U?W!!V+F.\YXN]/]+F,_FA=8[1I*NBS':-5L['_ !UW)M/IC:/;^%VALG*U
M=1MP?'K-5\^;R4E5)1/#%7WKON(ZBFB:'W6L4IY4ZLH^9V"3<WQB[<PDO9FZ
MNGH*[!X[[CL/9VV=V[RR^#IJ;<6&JZFFJ]K[!FI-[9K:VXH*=L9G8<354&0.
M$K:LP5E%(%JX=]47B.JAH^Q^W=D=>1;NR73??/7.%[%_EN][=1=0]9]74'?&
M_P"CR'R"V)V3V(^T?[H8G+4$F_\ 8VY>Y=D56/W#LZ;==/B\K3XBI6AJ:J.?
M'S(GNG/.F,'Y=#5TWCLI3?(KK2E^9-#W95/1=+?#2/X;U/B[HR77=!OZEV3/
M#W?%O&IV$DVVX.ZQVA#%)FJC?!#2[<-%]NYI5RP'NM'@=/SKTD/A+T]V9U#F
M?@'N&DP?=>"R78G^SG[?^2%'N5M[SX"EVX-V;\[$ZIPVZ-K9?7M?K_';?W-4
MJFUWIJ3'2?:U4D$<DRU<_EUZ=>8@ZORZ.M\^J7/U,'QV_O!3;]K_ (OQ]SU#
M?*Z@ZNCWE-NR?8QZZWJ-@R[BIM@D;NK.G*3M?^$/NR''AY6I? :E'Q:Y(>]]
M57S]>B ;'ZFS&2WI\'.W.WME=P9CJOJSY\_(O"_&G<.^8.U,EV%U[\>NQ-B;
MLPGQRJ.R,9-+)V'CMK9;L^AI*7$U^\*9ZK&[;GQ4&;FIXY)E/NK?Q <:=.GQ
MWZ8[NZKI/B=O+8&$[<P/:N_MS?S!]N=JT>[JG>LFRJ;%5N;^0'8O2.%WKM3*
MF;:6RMFX7L./$OMN:*CHS]O6.D4LW\0J#4>Z\2#J],=%VV)U_P#)_,?%[O.N
MQO9_<V&["W'U3\9=F]W=7;*VC\J</W-0_)3+]V[#D[C[=3?W:U7DJ7&[OI]O
MS9_'U<>Q2V%FPD=)7QLF/AQH776\:A@4_+K90V+LC;76VS]N[#V=15..VOM3
M%TV&P=%69?,Y^KI\?2+HACJLWN+(97.Y6HMR\]74SSR,2SNQ)/O?37'/6N%\
M2^MNZ(^O>E-A=);8^4.Q^WH_AQ\H]D?,S!]R'L?95+0[TK]O&A^-6,@K=WRT
M76V)WY!V%523[3JMHS12X_:!J35R0T[4ZMKIUB,DTI7'0Q8;<^_.\*6JPU3O
M#Y;='[*VO_*PVOL#LSM]^M.YO+LGY#X_LG;]+O;"1[5R.)I\YOWL[;5%@*F+
M<4V'1\C+AJ]_L\I$\HJH-]>X>E:]-25?R*SW0>Z(]E; [HZHI*;^75\R]H;-
MP'6+=W0;<R/8V*[TVYB^LNW^J\=O:JK=_;?W/V9MIZC/[/QN>C_O5A\=*],H
MFHXTGJ?=>Q7\QT+_ 'KU)V_TGM;YD]?_ !OA[PFV=F=A_"O?$J/G.W-\Y"J&
M8[F[#V_\P,OUMEZ'+3[VE["W%TIMNAJ\UC]M5D66FG;[JACCRE9$\VNM @Z:
MT\_]CH!]U[.W;M/XR=9;SINQMW=W46W_ )!=E[YZ1^*VVNM_F-@>O^TMN2X+
M;%!BN@,7NNK@G[>VINC:N[<1ELIL#<FY)9-HT=3EI*2:CDQU+%6X_?7O,X\O
MET=CI9]P[<_F+=MTE+B^Q.V\7V3M?/;BW;O[=>'[)VK7_%.IQ]!U[)@NBLA7
M96II.BNT^N-VS/-5;7J=J0S9K%5E-D162Y&":;(Q^ZT?A'4G^:%F=TUNU^NN
MLL1UOGLWB-Z4/;&:3LO'47?FXH-G]B[2V9''UALK";0^/.<VSN3)]E]C9K<,
MTFWJW,9/'87&38::19)<@U%"?=>3B>@3Z;D[5PORF^(&[-\4?;G<G:'8OQNZ
M;P7<VQM\[<[3VKE_B7EX^B\C7;T[3H-VP#$_'_<FV=[;S@?&;OV[D//N6'=%
M735&/J9Q"N-@]UX\"/GT=#YZ[3W?OK;?QKVCMENR5PN=^8G15-V=_HRR6Z<-
MD)^K(:C<5;N^@W5E]HS4V3Q_7V6CI8:3-,\L--+1SM%(ZB0'W[K2TS7TZ)AT
M=TWV7U/V+UAOS"T?R,W!EL#\O_F9TXN'W-NO?.5Q]1\2=H;%^0&5Z&ZREI]X
MYBGVNG7='N7:&V8]J9_+R&;[VIA+9*5:N02ZZL2*$8X#]O16^MY_D5N"E[X[
M2VOMW?G3V$Q'Q^ZN^7.7VT<;\C<?L_9_R@Z:[]W7O[L'I;-;P[NSU1E>P.RJ
M[J'%2;9W2N)H\3MG(Q5<!DI9HHJ.:#?6S3&>KEO@95;AW9\>,-W?NO\ OA1Y
MOY0;CW-\F(ML[TS-7ELGL/9_;]<N?ZKZ^CI:HB/;O]S>HQ@:&LQT"I#!E8JM
M](>1_?NFVXT].JM,159[<GR6[>DVM-\E\S\D=O?S4L#A^N<S19#LNOZ=P7Q>
MQFWOCS7=_P"W)ZYZR3J+&].TO7]=GER^*J3'ECO2KI7I83.^.D'NKT[1PI3I
M:9OJG=>WMJ8CL3L>#Y%9?J3M#YZ?(:7Y@4Z9OMS,[[I_CYM7L#Y)8_XSX/';
M:Q%6^>P/QCV_N"LV]-F:?;U.DM?A:BGFJC58G[XCW7JCRI6F/\O0%U%3DJ7>
M7Q9VO\BIOE.WQ"SG:O\ ,3J.LMI&H[MGWE7?&G";<ZSFZ+G[LVWM)S\@,MM#
M"YF?+R;2_B\$^;QU%58(5XBDMI]UO^*E-6.FO>NU_F]E]B_%#;O>F[.R.O\
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MTP7QQ9*FJJ-B*BEGC3W7B"*$CI4'MWJ<;VR'6A[/Z\'8^(QDN:RO7YWKMO\
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MDNH=YY*OP'1VU-N]5XNE@WEV+A*+$4&*>JFFQ8,\KTZQ+14_NO%A2@].C?\
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MOW7NO>_=>Z][]U[K73_X54_]N6_D%_XD;XY?^_TV+[T>G8?[0?8>K_\ 8/\
MQXNR_P#PTMN?^Z>C][Z:/'I6^_=>Z][]U[K_U=_CW[KW7O?NO=:\G_"IW_MR
M7\I__#DZ _\ ?]]=>_>1Z=A_M%ZO=ZI_YE=UM_X8.S__ 'GL=[]TV>)Z7WOW
M6NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NM=
M/_A53_VY;^07_B1OCE_[_38OO1Z=A_M!]AZO_P!@_P#'B[+_ /#2VY_[IZ/W
MOIH\>E;[]U[KWOW7NO_6W^/?NO=>]^Z]UKR?\*G?^W)?RG_\.3H#_P!_WUU[
M]Y'IV'^T7J]WJG_F5W6W_A@[/_\ >>QWOW39XGI?>_=:Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZUT_^%5/_;EOY!?^)&^.
M7_O]-B^]'IV'^T'V'J__ &#_ ,>+LO\ \-+;G_NGH_>^FCQZ5OOW7NO>_=>Z
M_]??X]^Z]U[W[KW6O)_PJ=_[<E_*?_PY.@/_ '_?77OWD>G8?[1>KW>J?^97
M=;?^&#L__P!Y['>_=-GB>E][]UKKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[K73_X54_]N6_D%_XD;XY?^_TV+[T>G8?[0?8>
MK_\ 8/\ QXNR_P#PTMN?^Z>C][Z:/'I6^_=>Z][]U[K_T-_CW[KW7O?NO=:\
MG_"IW_MR7\I__#DZ _\ ?]]=>_>1Z=A_M%ZO=ZI_YE=UM_X8.S__ 'GL=[]T
MV>)Z7WOW6NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NM=/_A53_VY;^07_B1OCE_[_38OO1Z=A_M!]AZO_P!@_P#'B[+_ /#2
MVY_[IZ/WOIH\>E;[]U[KWOW7NO_1W^/?NO=>]^Z]UKR?\*G?^W)?RG_\.3H#
M_P!_WUU[]Y'IV'^T7J]WJG_F5W6W_A@[/_\ >>QWOW39XGI?>_=:Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZUT_^%5/_;EO
MY!?^)&^.7_O]-B^]'IV'^T'V'J__ &#_ ,>+LO\ \-+;G_NGH_>^FCQZ5OOW
M7NO>_=>Z_]+?X]^Z]U[W[KW6O)_PJ=_[<E_*?_PY.@/_ '_?77OWD>G8?[1>
MKW>J?^97=;?^&#L__P!Y['>_=-GB>E][]UKKWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K73_X54_]N6_D%_XD;XY?^_TV+[T>
MG8?[0?8>K_\ 8/\ QXNR_P#PTMN?^Z>C][Z:/'I6^_=>Z][]U[K_T]_CW[KW
M7O?NO=:\G_"IW_MR7\I__#DZ _\ ?]]=>_>1Z=A_M%ZO=ZI_YE=UM_X8.S__
M 'GL=[]TV>)Z7WOW6NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NM=/_A53_VY;^07_B1OCE_[_38OO1Z=A_M!]AZO_P!@_P#'
MB[+_ /#2VY_[IZ/WOIH\>E;[]U[KWOW7NO_4W^/?NO=>]^Z]UKR?\*G?^W)?
MRG_\.3H#_P!_WUU[]Y'IV'^T7J]WJG_F5W6W_A@[/_\ >>QWOW39XGI?>_=:
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZUT_
M^%5/_;EOY!?^)&^.7_O]-B^]'IV'^T'V'J__ &#_ ,>+LO\ \-+;G_NGH_>^
MFCQZ5OOW7NO>_=>Z_]7?X]^Z]U[W[KW6O)_PJ=_[<E_*?_PY.@/_ '_?77OW
MD>G8?[1>KW>J?^97=;?^&#L__P!Y['>_=-GB>E][]UKKWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K73_X54_]N6_D%_XD;XY?
M^_TV+[T>G8?[0?8>K_\ 8/\ QXNR_P#PTMN?^Z>C][Z:/'I6^_=>Z][]U[K_
MUM_CW[KW7O?NO=:\G_"IW_MR7\I__#DZ _\ ?]]=>_>1Z=A_M%ZO=ZI_YE=U
MM_X8.S__ 'GL=[]TV>)Z7WOW6NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NM=/_A53_VY;^07_B1OCE_[_38OO1Z=A_M!]AZO
M_P!@_P#'B[+_ /#2VY_[IZ/WOIH\>E;[]U[KWOW7NO_7W^/?NO=>]^Z]UKR?
M\*G?^W)?RG_\.3H#_P!_WUU[]Y'IV'^T7J]WJG_F5W6W_A@[/_\ >>QWOW39
MXGI?>_=:Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[ILS69QFW<-EMP9JKCQ^&P6,K\SEJ^5
M9&BHL9C*66MKZN58DDE:.FI8'=@JLQ"\ GCW[KW5.'PV^;'SA^5VT]H_.+<N
MQ_B-\=OY;>\<;OS?^,Q79.[.RLA\J:7H';>*W1+MGN[=>Z\8*3H[9C[E.%IL
MU4;>E@K(\7M^I8RY=JJ,QGW5J+PSJZ7NS?YTWPCWILCM;L&GJ>]=K[;ZR^/6
MZ_EMAYNQ?CSVMUO4]W_%[9D-)/G>^?C]3;WV[@V[3Z]IHLC2OYJ0QU2P5E-4
M/ E-40S/[K14BG2+[ _G;?&[%?'#Y>=X]6=<=^]B[L^)_3FT^\:GIS<_4._N
MF]V]C]6=F8_)U'6'<VU#V%MNAK)_CYG*G#U;Y;>$%%5P;>Q]#4U=73!4B2?W
M6])K0GIIQ'\WOKK#?WC[@[ER.X.I^I]H?R\NLOF?OOH'<'QZ[/A[]Z^Q^\>X
M=V=;UF^LAO>3-C:6?V5DI<%X,9@:?"PYIX*<Y9YS2U$<">Z\5I^WH:,#_. ^
M'6>VMV?NAI.Z]MMU%V?\<^LMX;7WUT7V+L'>T:_+;>-%LCXY]BXW:N\</A<I
MD.K>U<M5N^.RRH/V*:8RQ1NHC;W6BI''I==D?S._C#UC6]UX+*_Z5MQ[UZ3[
M\V'\7JGKO8756ZM[;][-[Y[)ZKQ_=6U.NNGMN8&FJJG?.6GZWKI,I5RJ:>DQ
MU)154]7+#3P--[]UX"M,]([/_P WGX;878_16],=6]T[WK/D!5=J0;7ZVZ]^
M/_;>\.Y-HT_06<&U_D-DNUNJ<5M:3>G6E!T-N@_PW<_\4I89J:M_;IXZDD7]
MUL*2:>?4K^63\O.Q?D?_ "P^A/F3WXE-N#?F\^K-Y]C[TBZBV#N&I.:I=O[I
MWG#00;%ZWPS[GW5ELOD=N8.F2EQE(M57UU8XCBB,LBQ#W7F%&(!Z2E3_ #F?
MAO@MC[ZWAV#1?(/JG,]6]K=(]0]F=3=D_'GLW;O=>QL_\D9*].C<UF.L4PU=
MN*LVEV6<74KC:['I6^2>GEIVC6JC>!?=>TFO4V/^<7\/9NK]O=@TU'\@JS=F
MY?D1N/XI4'QSH/CKVKD?E+#WULS;=/OO>NPZ_HB@V_4[RI)]G=;UD&Y,E6&,
MT%-AJB&4SF2:*%_=>TYI4=0/Y</SNWI\H?AEW5\J]]XC,;]I=F?(+YA8#8FW
MNJNM,[3;[W5U-TQVIN_!=;X7#];UTJ;CR?9.7VGA:>$T,T=)6U&1D$4D,4NH
M#W7B*$#H)?CQ_/&Z1[8^'_0_R9[&Z1^0'76__D?OK>O7O3'QBV5UONSNSN;N
M;-[%H*_<^Y\MT;M_9V!ILMVAU]M'9%(:W.[HCHJ' XFJ@J*2>H6:.,3>ZV4(
M)%>CC;L^:&T.T?Y>O>OS)^).Z\;NM=L_'WO_ 'QU[6;DVYF,<^%[-ZGV?O)Y
M-J=A[$W&NVMRX'.;2WYMIJ#-8;(+05D$L$D3F.X?W[JH&0.BC?$W^=9\6>Q?
MCO@=Y=^[XW-UAV%L;X2]9?+?MS<&^.D.TNK=A]B[(KMM[.Q?9/:/QY3<F!>I
M[-V#C>V]R)@*:+$&NJY\C64E/2)5BHIY9O=;*FM!T?3XJ?-;I[Y>+V3C-A8O
MM+8/8G3>8V]ANVNE^]NL=U].=R]=/O3"'<VP\GN;8.\**CR4& WYML-6XBOA
M,]+5)%/%K6IIJF"'W6B*=$GW?_-OZ=[(^/':/=_QRW-N_:'7G7_:72VP]O\
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M_'V%_P"AAM[_ .N/OW7J'KW^E3K#_GX^PO\ T,-O?_7'W[KU#U[_ $J=8?\
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M $,-O?\ UQ]^Z]0]>_TJ=8?\_'V%_P"AAM[_ .N/OW7J'KW^E3K#_GX^PO\
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M_'V%_P"AAM[_ .N/OW7J'KW^E3K#_GX^PO\ T,-O?_7'W[KU#U[_ $J=8?\
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M $,-O?\ UQ]^Z]0]>_TJ=8?\_'V%_P"AAM[_ .N/OW7J'KW^E3K#_GX^PO\
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MKWC2?Q?R'7O^@6+^29_WBUN;_P!* [[_ /MB^_4Z]XTG\7\AU[_H%B_DF?\
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M?R'7O^@6+^29_P!XM;F_]* [[_\ MB^_4Z]XTG\7\AU[_H%B_DF?]XM;F_\
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M8OY)G_>+6YO_ $H#OO\ ^V+[]3KWC2?Q?R'7O^@6+^29_P!XM;F_]* [[_\
MMB^_4Z]XTG\7\AU[_H%B_DF?]XM;F_\ 2@.^_P#[8OOU.O>-)_%_(=>_Z!8O
MY)G_ 'BUN;_TH#OO_P"V+[]3KWC2?Q?R'7O^@6+^29_WBUN;_P!* [[_ /MB
M^_4Z]XTG\7\AU[_H%B_DF?\ >+6YO_2@.^__ +8OOU.O>-)_%_(=>_Z!8OY)
MG_>+6YO_ $H#OO\ ^V+[]3KWC2?Q?R'7O^@6+^29_P!XM;F_]* [[_\ MB^_
M4Z]XTG\7\AU[_H%B_DF?]XM;F_\ 2@.^_P#[8OOU.O>-)_%_(=>_Z!8OY)G_
M 'BUN;_TH#OO_P"V+[]3KWC2?Q?R'7O^@6+^29_WBUN;_P!* [[_ /MB^_4Z
M]XTG\7\AU[_H%B_DF?\ >+6YO_2@.^__ +8OOU.O>-)_%_(=>_Z!8OY)G_>+
M6YO_ $H#OO\ ^V+[]3KWC2?Q?R'7O^@6+^29_P!XM;F_]* [[_\ MB^_4Z]X
MTG\7\AU[_H%B_DF?]XM;F_\ 2@.^_P#[8OOU.O>-)_%_(=>_Z!8OY)G_ 'BU
MN;_TH#OO_P"V+[]3KWC2?Q?R'7O^@6+^29_WBUN;_P!* [[_ /MB^_4Z]XTG
M\7\AU[_H%B_DF?\ >+6YO_2@.^__ +8OOU.O>-)_%_(=>_Z!8OY)G_>+6YO_
M $H#OO\ ^V+[]3KWC2?Q?R'7O^@6+^29_P!XM;F_]* [[_\ MB^_4Z]XTG\7
M\AU[_H%B_DF?]XM;F_\ 2@.^_P#[8OOU.O>-)_%_(=>_Z!8OY)G_ 'BUN;_T
MH#OO_P"V+[]3KWC2?Q?R'7O^@6+^29_WBUN;_P!* [[_ /MB^_4Z]XTG\7\A
MU[_H%B_DF?\ >+6YO_2@.^__ +8OOU.O>-)_%_(=>_Z!8OY)G_>+6YO_ $H#
MOO\ ^V+[]3KWC2?Q?R'7O^@6+^29_P!XM;F_]* [[_\ MB^_4Z]XTG\7\AU[
M_H%B_DF?]XM;F_\ 2@.^_P#[8OOU.O>-)_%_(=>_Z!8OY)G_ 'BUN;_TH#OO
M_P"V+[]3KWC2?Q?R'7O^@6+^29_WBUN;_P!* [[_ /MB^_4Z]XTG\7\AU[_H
M%B_DF?\ >+6YO_2@.^__ +8OOU.O>-)_%_(=>_Z!8OY)G_>+6YO_ $H#OO\
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0U[W[KW7O?NO=>]^Z]U__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
